cyclosporine profile

ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3'-ketolactose : A keto-disaccharide that is beta-D-galactosyl-(1->4)-beta-D-glucose in which the hydroxy group at position 3 of the galactosyl moiety has been oxidised to the corresponding ketone. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

cyclosporin A : A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

cyclosporine is involved in 2 pathway(s), involving a total of 0 unique proteins and 27 unique compounds

ID Source	ID
PubMed CID	5284373
CHEMBL ID	160
CHEBI ID	4031
CHEBI ID	92233
SCHEMBL ID	4442
SCHEMBL ID	3491
MeSH ID	M0025279
PubMed CID	123134263
MeSH ID	M0025279
PubMed CID	57339177
CHEBI ID	27571
MeSH ID	M0025279
PubMed CID	5280754
CHEMBL ID	386389
CHEBI ID	91802
SCHEMBL ID	3490
SCHEMBL ID	20475023
MeSH ID	M0025279
PubMed CID	2909
MeSH ID	M0025279

Synonym
MLS002207033
MLS001333756 ,
BRD-K13533483-001-03-0
gtpl1024
cyclosporin a & ifn.alpha.
csa & ifn.alpha.
zyclorin
modusik-a
neurostat
ciclomulsion
sigmasporin
pulminiq
de-076
st-603
olo-400
cyclokat
mitogard
papilock
smr000058578
cb-01-09 mmx
ath-002
sang-2000
vekacia
cipol-n
MLS000028376
ol-27400
nova-22007
consupren s
ciclosporin dt
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,2
BSPBIO_000450
cyclosporin a, from tolypocladium inflatum, >=95% (hplc), solid
neoral
PRESTWICK_731
CHEBI:4031 ,
ciclosporine
ciclosporina
(r-[r,r-(e)])-cyclic(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl-3-hydroxy-n,4-dimethyl-l-2-amino-6-octenoyl-l-alpha-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl)
ciclosporinum
cas-59865-13-3
NCGC00016890-01
PRESTWICK3_000435
BPBIO1_000496
nsc-290193
PRESTWICK2_000435
ramihyphin a
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methyl-hex-4-enyl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,3
sang-35
cyclo[[(e)-(2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-l-2-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl-l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl]
sandimmune
neoplanta
CSA ,
cipol n
sandimmun neoral
sigmasporin microoral
sdz-oxl 400
gengraf
sangcya
equoral
consupren
sandimmun
cyclosporin
ol 27-400
s-neoral
cyclosporine [usan]
s 7481f1
ciclosporine [inn-french]
ciclosporinum [inn-latin]
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,
sang 35
(r-(r,r-(e)))-cyclic(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl-3-hydroxy-n,4-dimethyl-l-2-amino-6-octenoyl-l-alpha-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl)
cyclo(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl-((3r,4r,6e)-6,7-didehydro-3-hydroxy-n,4-dimethyl-l-2-aminooctanoyl-l-2-aminobutanoyl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methylleucyl)
hsdb 6881
drg-0275
cyclo(((e)-(2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl)-l-2-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl-l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl)
ccris 1590
ciclosporina [inn-spanish]
nsc 290193
ciclosporin
cyclosporin a, from tolypocladium inflatum, bioreagent, for molecular biology, >=95%
DB00091
1CYN
1C5F
CYA ,
NCGC00164258-01
NCGC00164258-02
MLS002153454
cyclosporin a, >=98.5% (tlc)
HMS2089A09
antibiotic s-7481f1
zinograf me
CHEMBL160
sdz-oxl-400
ciclosporin a
ol-27-400
atopica
cyclosporine microemulsion
HMS1569G12
30-ethyl-33-((e)-1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,28-octamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r,2r,4e)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,
bdbm50022815
30-ethyl-33-(1-hydroxy-2-methyl-hex-4-enyl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31undecaaza-cyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-undecaone
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methyl-pent-3-enyl]-3,6,9,18,24-pentaisobutyl-21-isopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32
A832514
NCGC00164258-03
HMS2096G12
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17
dtxcid00365
dtxsid0020365 ,
NCGC00255232-01
tox21_301849
C2408
tox21_110667
HMS2230M14
AKOS015969287
AKOS015994720
imusporin
83hn0gtj6d ,
optimmune
debio088
ciclosporin [inn]
arpimune me
cyclosporine [usan:usp]
ciclosporina germed
papilock mini
abrammune
cicloral (antibiotic)
seciera
unii-83hn0gtj6d
sandimmune neoral
cyclosporine [vandf]
cyclosporine [usp-rs]
cequa
cyclosporine [orange book]
(r-(r,r-(e)))-cyclic(l-alanyl-d-alanyl-n-methyl-l-leucyl-n-methyl-l-leucyl-n-methyl-l-valyl-3-hydroxy-n,4-dimethyl-l-2-amino-6-octenoyl-l-.alpha.-aminobutyryl-n-methylglycyl-n-methyl-l-leucyl-l-valyl-n-methyl-l-leucyl)
ikervis
verkazia
cyclosporine [usp monograph]
cyclosporine [iarc]
vevye
ciclosporin [who-ip]
cyclosporine [usp impurity]
ciclosporin [jan]
cyclosporine [hsdb]
cyclosporin a [mi]
ciclosporin [ep monograph]
cyclosporine [green book]
ciclosporinum [who-ip latin]
ciclosporin [who-dd]
ciclosporin [mart.]
2WFJ
2Z6W
BRD-K03222093-001-01-8
CCG-208184
HY-B0579
SCHEMBL4442
SCHEMBL3491
tox21_110667_1
NCGC00093704-12
KS-1257
PMATZTZNYRCHOR-CGLBZJNRSA-N
Q-200913
4JJM
ciclosporin, european pharmacopoeia (ep) reference standard
SR-01000780563-3
sr-01000780563
cyclosporin a, vetranal(tm), analytical standard
CHEBI:92233
cyclosporine, united states pharmacopeia (usp) reference standard
cyclosporine, pharmaceutical secondary standard; certified reference material
ciclosporin for system suitability, european pharmacopoeia (ep) reference standard
SBI-0050230.P003
HMS3713G12
(3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-((1r,2r,e)-1-hydroxy-2-methylhex-4-en-1-yl)-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29
Q367700
ciclosporin;
cyclosporine manufacturer
104250-72-8
EX-A4110
SDCCGSBI-0050230.P004
M01532
cyclospori
BC164336
BP-28432
59865-13-3
cyclosporine
3'-dehydro-beta-d-galactosyl-beta-d-glucopyranoside
3-KETOLACTOSE ,
3'-ketolactose
4-o-beta-d-xylo-hexopyranosyl-3-ulose-beta-d-glucopyranose
CHEBI:27571
Q27103202
beta-d-glucopyranose, 4-o-beta-d-xylo-hexopyranos-3-ulos-1-yl-
DTXSID001236468
142696-68-2
LS-15525
BRD-A64290322-001-01-6
BRD-A69815203-001-04-3
SPECTRUM5_001628
LOPAC0_000242
EU-0100242
restasis (tn)
neoral (tn)
cyclosporine (usp)
ciclosporin (jp17)
sandimmune (tn)
gengraf (tn)
D00184
BSPBIO_003186
helv chim acta 60: 1568 (1977)
IDI1_000871
nsc290193 ,
BSPBIO_001596
C05086
NCGC00093704-03
NCGC00093704-02
NCGC00093704-05
SPECTRUM1502202
NCGC00093704-01
NCGC00093704-06
NCGC00093704-04
NCGC00093704-07
LMPK14000003
HMS1989P18
C 3662 ,
HMS2092F06
NCGC00093704-08
CHEMBL386389
HMS1791P18
HMS502L13
(3r,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17
HMS1921L20
A840608
-2,5,8,11,14,17,20,23,26,29,32-undecone
30-ethyl-33-[(4e)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane
STK177328
NCGC00093704-09
NCGC00093704-10
HMS3260B06
3c152
nsc-758194
nsc758194
pharmakon1600-01502202
bdbm86672
cas_2909
nsc_2909
CCG-39214
LP00242
AKOS015895103
SCHEMBL3490
NCGC00260927-01
tox21_500242
AB00052450_02
bdbm172718
us9090657, cyclosporine a, 1
CHEBI:91802
SR-01000075490-1
SR-01000075490-6
SR-01000075490-7
SR-01000075490-3
sr-01000075490
np444
NCGC00093704-17
SCHEMBL20475023
PMATZTZNYRCHOR-IMVLJIQESA-N
HMS3676G21
HMS3412G21
BRD-A69815203-001-05-0
NCGC00093704-35
NCGC00093704-43
HMS3267I20
83602-39-5
KBIO1_000871
DIVK1C_000871
restasis
SPECTRUM_000300
c62h111n11o12
cyclosporin a
KBIO2_005916
KBIOGR_001898
KBIO2_003348
KBIO3_002686
KBIO2_000780
KBIOSS_000780
SPECTRUM2_001484
SPBIO_001467
SPECTRUM3_001593
SPECTRUM4_001279
NINDS_000871
FT-0603156
FT-0603155
NCGC00093704-11
HMS3372A06
HB0220
AKOS024456385
mfcd00274558
5-(n-methyl-d-valine)-cyclosporin a
HMS3651O16
HMS3654L18
SY012000
FT-0701261
cyclosporine;ciclosporin

Role	Description
antifungal agent	An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce.
antirheumatic drug	A drug used to treat rheumatoid arthritis.
dermatologic drug	A drug used to treat or prevent skin disorders or for the routine care of skin.
immunosuppressive agent	An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response.
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
carcinogenic agent	A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
anti-asthmatic drug	A drug used to treat asthma.
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor	Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16).
anticoronaviral agent	Any antiviral agent which inhibits the activity of coronaviruses.
geroprotector	Any compound that supports healthy aging, slows the biological aging process, or extends lifespan.
mouse metabolite	Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
homodetic cyclic peptide	A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages.
keto-disaccharide	Any disaccharide that contains a keto group within its structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Drug induction of bile acid pathway	0	25
Primary focal segmental glomerulosclerosis (FSGS)	0	2

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	2.8184	0.0447	17.8581	100.0000	AID485341
glp-1 receptor, partial	Homo sapiens (human)	Potency	2.5119	0.0184	6.8060	14.1254	AID624417
hypoxia-inducible factor 1 alpha subunit	Homo sapiens (human)	Potency	12.7687	3.1890	29.8841	59.4836	AID1224846
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	6.4624	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
ATAD5 protein, partial	Homo sapiens (human)	Potency	8.1961	0.0041	10.8903	31.5287	AID504467
USP1 protein, partial	Homo sapiens (human)	Potency	354.8130	0.0316	37.5844	354.8130	AID743255
TDP1 protein	Homo sapiens (human)	Potency	4.0414	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	5.1202	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	12.8375	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	11.5646	0.0006	57.9133	22,387.1992	AID1259378
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	16.7639	0.0010	22.6508	76.6163	AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	3.4671	0.0123	7.9835	43.2770	AID1645841
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	4.4668	0.2818	9.7212	35.4813	AID2326
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	11.3801	0.0002	14.3764	60.0339	AID720691
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	14.2866	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	6.2784	0.0008	17.5051	59.3239	AID1159527; AID1159531; AID588544
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	12.5656	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	17.8497	0.3758	27.4851	61.6524	AID743217; AID743220
pregnane X nuclear receptor	Homo sapiens (human)	Potency	12.3071	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	14.0094	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	0.8709	0.0010	8.3798	61.1304	AID1645840
67.9K protein	Vaccinia virus	Potency	1.6193	0.0001	8.4406	100.0000	AID720579; AID720580
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	18.3676	0.0010	24.5048	61.6448	AID588535; AID743212
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	8.1780	0.0010	19.4141	70.9645	AID588536; AID588537; AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	10.3636	0.0237	23.2282	63.5986	AID588541; AID743222; AID743223; AID743241
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	11.2809	0.0017	23.8393	78.1014	AID743083
activating transcription factor 6	Homo sapiens (human)	Potency	9.5205	0.1434	27.6121	59.8106	AID1159516
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	4.4668	0.0126	2.4518	25.0177	AID485313
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	11.4366	0.0041	9.9848	25.9290	AID504444; AID720524
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	17.2545	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	6.4119	0.0006	27.2152	1,122.0200	AID651741; AID743202; AID743219
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	89.1251	0.0501	27.0736	89.1251	AID588590
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	2.5119	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	2.5119	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	2.5119	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	0.6310	0.0046	11.3741	33.4983	AID624297
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	26.6032	0.0015	57.7890	15,848.9004	AID1259244
Rap guanine nucleotide exchange factor 3	Homo sapiens (human)	Potency	2.5119	6.3096	60.2008	112.2020	AID720707
Cellular tumor antigen p53	Homo sapiens (human)	Potency	23.0745	0.0023	19.5956	74.0614	AID651631
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	10.0663	0.0032	45.4673	12,589.2998	AID1705; AID2517
Chain A, Ferritin light chain	Equus caballus (horse)	Potency	29.5263	5.6234	17.2929	31.6228	AID2323; AID485281
Chain A, Cruzipain	Trypanosoma cruzi	Potency	8.7169	0.0020	14.6779	39.8107	AID1476
endonuclease IV	Escherichia coli	Potency	10.0000	0.7079	12.4324	31.6228	AID1708
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	11.9538	0.1000	20.8793	79.4328	AID488772; AID488773; AID588453; AID588456
ATAD5 protein, partial	Homo sapiens (human)	Potency	6.1564	0.0041	10.8903	31.5287	AID493106; AID493107
Fumarate hydratase	Homo sapiens (human)	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
USP1 protein, partial	Homo sapiens (human)	Potency	32.1220	0.0316	37.5844	354.8130	AID504865
PPM1D protein	Homo sapiens (human)	Potency	2.3362	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	11.2952	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	8.9125	0.1800	13.5574	39.8107	AID1460
DNA polymerase III, partial	Bacillus subtilis	Potency	15.0030	1.0621	14.1528	26.6795	AID485295
nonstructural protein 1	Influenza A virus (A/WSN/1933(H1N1))	Potency	1.4125	0.2818	9.7212	35.4813	AID2326
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	2.3815	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224821
polyprotein	Zika virus	Potency	35.4813	0.0030	8.7949	48.0869	AID1347053
67.9K protein	Vaccinia virus	Potency	19.0623	0.0001	8.4406	100.0000	AID720579; AID720580
glucocerebrosidase	Homo sapiens (human)	Potency	17.7828	0.0126	8.1569	44.6684	AID2101
arylsulfatase A	Homo sapiens (human)	Potency	0.4256	1.0691	13.9551	37.9330	AID720538
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	79.4328	0.0355	20.9770	89.1251	AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)	Homo sapiens (human)	Potency	1.6482	0.0165	25.3078	41.3999	AID504836; AID602332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	12.5893	0.5406	17.6392	96.1227	AID2364; AID2528
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	3.7933	23.9341	23.9341	23.9341	AID1967
chromobox protein homolog 1	Homo sapiens (human)	Potency	63.0957	0.0060	26.1688	89.1251	AID488953
DNA polymerase beta	Homo sapiens (human)	Potency	12.5893	0.0224	21.0102	89.1251	AID485314
ubiquitin carboxyl-terminal hydrolase 2 isoform a	Homo sapiens (human)	Potency	10.0000	0.6561	9.4520	25.1189	AID927
serine/threonine-protein kinase mTOR isoform 1	Homo sapiens (human)	Potency	7.5222	0.0037	8.6189	23.2809	AID2667; AID2668
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	13.4591	0.4256	12.0591	28.1838	AID504536
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	14.1254	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	8.0714	0.0046	11.3741	33.4983	AID463097; AID504364
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	10.6213	0.0316	22.3146	100.0000	AID588579
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	14.1254	0.1259	12.2344	35.4813	AID1458
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	28.1838	0.2512	15.8432	39.8107	AID504327
lamin isoform A-delta10	Homo sapiens (human)	Potency	7.0795	0.8913	12.0676	28.1838	AID1487
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	1.0000	0.0158	12.3113	615.5000	AID1461
Interferon beta	Homo sapiens (human)	Potency	2.3362	0.0033	9.1582	39.8107	AID1347411
D(1A) dopamine receptor	Sus scrofa (pig)	Potency	4.6451	0.0037	8.1081	23.2809	AID2667
Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)	Potency	10.0000	1.5849	13.0043	25.1189	AID927
Ataxin-2	Homo sapiens (human)	Potency	4.4668	0.0119	12.2221	68.7989	AID588378
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	0.0095	0.0601	10.7453	37.9330	AID485368
Fumarate hydratase	Homo sapiens (human)	Potency	0.4176	0.0030	8.7949	48.0869	AID1347053
EWS/FLI fusion protein	Homo sapiens (human)	Potency	17.6277	0.0013	10.1577	42.8575	AID1259252; AID1259253
polyprotein	Zika virus	Potency	0.4176	0.0030	8.7949	48.0869	AID1347053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	11.8158	0.6315	4.4531	9.3000	AID1473740; AID1766762
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.6000	0.4000	2.7500	8.6000	AID1209456
Bile salt export pump	Rattus norvegicus (Norway rat)	Ki	0.3000	0.3000	3.1000	6.1000	AID679145
Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)	IC50 (µMol)	37.0000	0.5500	3.7083	6.1000	AID699544
Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)	Ki	36.0000	0.5300	4.1157	8.4800	AID699544
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	3.5000	0.1100	7.1903	10.0000	AID1209455; AID1443980; AID1443986; AID1449628; AID1473738; AID1674183; AID681139; AID681155
Bile salt export pump	Homo sapiens (human)	Ki	9.5000	7.0000	8.2500	9.5000	AID680941
Transthyretin	Homo sapiens (human)	Ki	0.0026	0.0018	0.0022	0.0026	AID496160
Sarcoplasmic/endoplasmic reticulum calcium ATPase 1	Oryctolagus cuniculus (rabbit)	IC50 (µMol)	62.0000	0.0002	2.8167	9.0000	AID1605061
Interleukin-2	Mus musculus (house mouse)	IC50 (µMol)	0.0050	0.0050	0.0090	0.0130	AID91889
Cytochrome P450 1A2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0001	1.7740	10.0000	AID496042
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	IC50 (µMol)	0.7000	0.0640	4.0126	10.0000	AID150754; AID681128
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	Ki	3.5000	3.5000	5.6067	6.9300	AID681138
ATP-dependent translocase ABCB1	Homo sapiens (human)	IC50 (µMol)	3.0464	0.0002	2.3185	10.0000	AID1057951; AID1206429; AID1303196; AID1335815; AID1447884; AID1501264; AID150619; AID150752; AID150755; AID1532102; AID1553598; AID1625585; AID1635780; AID1708432; AID1723059; AID1758181; AID1766766; AID310120; AID310122; AID326367; AID326368; AID326369; AID364884; AID365465; AID395103; AID416864; AID580942; AID598251; AID672543; AID680138; AID680506; AID681122; AID681126; AID681127; AID681131; AID681358; AID681579; AID681580; AID681581; AID681582; AID768684
ATP-dependent translocase ABCB1	Homo sapiens (human)	Ki	1.7183	0.0200	2.3594	8.5900	AID679909; AID680137; AID681142; AID681143; AID681356; AID681611
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	3.7340	0.0001	1.7536	10.0000	AID1209609; AID1209610; AID496039; AID54923
Cytochrome P450 3A4	Homo sapiens (human)	Ki	6.0550	0.0001	1.4162	9.9000	AID1209608; AID1874023
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	5.8200	0.0002	2.4585	9.9600	AID1804171
Cytochrome P450 2D6	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0000	2.0151	10.0000	AID496043
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	38.8000	0.0000	2.8005	10.0000	AID496041
Peptidylglycine alpha-amidating monooxygenase	Rattus norvegicus (Norway rat)	Ki	0.0060	0.0060	0.0060	0.0060	AID157232
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	9.3400	0.0002	1.8742	10.0000	AID416864
UDP-glucuronosyltransferase 2B7	Homo sapiens (human)	IC50 (µMol)	211.8333	0.1000	2.5000	4.9000	AID1802994
UDP-glucuronosyltransferase 1-6	Homo sapiens (human)	IC50 (µMol)	211.8333	4.9000	4.9000	4.9000	AID1802994
Cytochrome P450 3A5	Homo sapiens (human)	IC50 (µMol)	2.0600	0.0033	0.7073	6.2000	AID1209609
Cytochrome P450 3A5	Homo sapiens (human)	Ki	7.6000	0.0220	2.6040	7.6000	AID1209608
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	IC50 (µMol)	4.8000	0.2000	4.7130	10.0000	AID150753; AID681119
ATP-dependent translocase ABCB1	Mus musculus (house mouse)	Ki	3.6500	2.1000	4.3150	7.4800	AID681137
Substance-K receptor	Homo sapiens (human)	IC50 (µMol)	4.1390	0.0001	3.1210	9.5530	AID625227
Substance-K receptor	Homo sapiens (human)	Ki	1.3800	0.0001	1.9242	9.7930	AID625227
fMet-Leu-Phe receptor	Homo sapiens (human)	IC50 (µMol)	10.0000	0.0200	4.0067	10.0000	AID72183
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	IC50 (µMol)	211.8333	0.3000	3.2580	7.3000	AID1802994
UDP-glucuronosyltransferase 1A4	Homo sapiens (human)	IC50 (µMol)	211.8333	4.7200	4.8100	4.9000	AID1802994
Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)	IC50 (µMol)	0.0088	0.0088	0.0095	0.0103	AID528323
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	9.3400	0.0002	1.2704	10.0000	AID416864
Cytochrome P450 3A7	Homo sapiens (human)	IC50 (µMol)	2.0600	0.0140	2.7580	6.2000	AID1209609
Cytochrome P450 3A7	Homo sapiens (human)	Ki	7.6000	0.0220	5.0740	7.6000	AID1209608
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	7.0000	0.0000	2.3983	10.0000	AID496040
Multidrug resistance-associated protein 1	Homo sapiens (human)	IC50 (µMol)	3.5082	0.0015	3.7110	9.6600	AID1057950; AID1447886; AID1501265; AID1532103; AID1625586; AID1708433; AID1723060; AID1766765; AID365463; AID768683
Multidrug resistance-associated protein 1	Homo sapiens (human)	Ki	5.0000	0.0700	2.2020	8.1000	AID679985
UDP-glucuronosyltransferase 2B10	Homo sapiens (human)	IC50 (µMol)	211.8333	4.9000	4.9000	4.9000	AID1802994
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	IC50 (µMol)	9.3400	0.0000	1.8194	10.0000	AID416864
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	IC50 (µMol)	0.0252	0.0020	0.1438	1.5490	AID1265701; AID1271174; AID427507; AID495176; AID497686; AID528322; AID54723; AID54724; AID54725; AID594598; AID625946; AID95464
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	Ki	0.0645	0.0003	0.0473	0.2310	AID1426805; AID1895180; AID238355; AID496160; AID580952; AID580955; AID581778; AID770489
Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)	Ki	0.0200	0.0000	0.8837	5.4000	AID69108
Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)	Ki	0.0060	0.0060	0.0060	0.0060	AID157232
Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)	IC50 (µMol)	50.0000	0.0005	0.7427	10.0000	AID55740
Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)	IC50 (µMol)	0.0160	0.0160	5.1287	8.0000	AID223386
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)	IC50 (µMol)	0.1830	0.0148	0.0989	0.1830	AID45446
Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)	IC50 (µMol)	0.0036	0.0036	0.0036	0.0036	AID1300181
Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)	Ki	0.0129	0.0026	0.0129	0.0340	AID1296457; AID1300180; AID580951; AID580956
Ileal sodium/bile acid cotransporter	Homo sapiens (human)	Ki	24.0000	3.3000	6.4000	10.0000	AID681332
Sodium/bile acid cotransporter	Homo sapiens (human)	IC50 (µMol)	1.0000	1.0000	5.9267	9.6000	AID681378
Canalicular multispecific organic anion transporter 1	Rattus norvegicus (Norway rat)	Ki	5.9800	0.8400	4.9682	10.0000	AID679044; AID681175
Reverse transcriptase/RNaseH	Human immunodeficiency virus 1	IC50 (µMol)	0.4550	0.0001	1.0768	10.0000	AID197947
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	17.9940	2.4100	6.3433	10.0000	AID1327018; AID1327025; AID1473739; AID1766763; AID365464
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	Ki	11.2700	4.7000	6.4050	8.1100	AID678981; AID681596; AID682121
Cytochrome P450 3A43	Homo sapiens (human)	IC50 (µMol)	2.0600	0.0140	2.7580	6.2000	AID1209609
Cytochrome P450 3A43	Homo sapiens (human)	Ki	7.6000	0.0220	5.0740	7.6000	AID1209608
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Mus musculus (house mouse)	IC50 (µMol)	0.5700	0.5700	0.9360	1.3020	AID1272185
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	1.3000	0.1047	2.7195	7.0795	AID699543
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Ki	1.2000	0.0800	2.4688	9.8000	AID699543
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	IC50 (µMol)	24.6546	0.0040	1.9666	10.0000	AID1766764; AID1873213; AID364887
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	Ki	0.5000	0.5000	0.9000	1.3000	AID679625
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	IC50 (µMol)	0.9500	0.0500	2.3797	9.7000	AID1218863; AID1218864; AID1218865; AID1707622; AID699542
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Ki	0.4845	0.0440	1.3630	5.0000	AID1218867; AID678796; AID680769; AID699542
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-dependent translocase ABCB1	Homo sapiens (human)	EC50 (µMol)	25.7799	0.0160	0.6786	3.1000	AID1062339; AID1228907; AID1228910; AID1525922; AID317949; AID321879; AID407205; AID679129
Cytochrome P450 3A4	Homo sapiens (human)	Kd	0.0130	0.0130	0.4565	0.9000	AID1296459
Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)	Kd	0.0098	0.0010	0.0053	0.0098	AID339501
Multidrug resistance-associated protein 1	Homo sapiens (human)	EC50 (µMol)	1.7000	1.7000	4.3028	9.8000	AID1525921
Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)	Kd	0.6225	0.0022	0.4297	6.4200	AID1323837; AID1362385; AID1426804; AID339500; AID497687; AID54727; AID594599; AID625944; AID719606; AID719607; AID719608
Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)	Kd	0.0215	0.0130	0.0215	0.0300	AID1296459; AID1566287
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)	EC50 (µMol)	1.7500	0.0054	0.4220	3.2000	AID1525919
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
scavenger receptor class B member 1 isoform 1	Mus musculus (house mouse)	AbsAC40_uM	35.0000	0.3120	9.4047	34.6000	AID602191
ATP-dependent translocase ABCB1	Homo sapiens (human)	Activity	9.0333	0.0200	1.6700	4.5000	AID386358; AID386359; AID386360
ATP-dependent translocase ABCB1	Homo sapiens (human)	Km	4.1233	0.0140	3.7172	10.0000	AID679238; AID679263; AID681164
fMet-Leu-Phe receptor	Homo sapiens (human)	IC20 (µMol)	3.6000	3.6000	3.6000	3.6000	AID72182
Non-lysosomal glucosylceramidase	Mus musculus (house mouse)	Activity	11.0000	1.2000	1.2000	1.2000	AID386360
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
transport across blood-brain barrier	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
associative learning	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Rap protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
intracellular signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of GTPase activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of protein export from nucleus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of stress fiber assembly	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
establishment of endothelial barrier	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cellular response to cAMP	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
signal transduction	Transthyretin	Homo sapiens (human)
purine nucleobase metabolic process	Transthyretin	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
porphyrin-containing compound metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
toxin biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
post-embryonic development	Cytochrome P450 1A2	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
regulation of gene expression	Cytochrome P450 1A2	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
dibenzo-p-dioxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
lung development	Cytochrome P450 1A2	Homo sapiens (human)
methylation	Cytochrome P450 1A2	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 1A2	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
cellular respiration	Cytochrome P450 1A2	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 1A2	Homo sapiens (human)
hydrogen peroxide biosynthetic process	Cytochrome P450 1A2	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 1A2	Homo sapiens (human)
cellular response to cadmium ion	Cytochrome P450 1A2	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 1A2	Homo sapiens (human)
G2/M transition of mitotic cell cycle	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic metabolic process	ATP-dependent translocase ABCB1	Homo sapiens (human)
response to xenobiotic stimulus	ATP-dependent translocase ABCB1	Homo sapiens (human)
phospholipid translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
terpenoid transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of response to osmotic stress	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
transepithelial transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
stem cell proliferation	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide translocation	ATP-dependent translocase ABCB1	Homo sapiens (human)
export across plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
positive regulation of anion channel activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	ATP-dependent translocase ABCB1	Homo sapiens (human)
regulation of chloride transport	ATP-dependent translocase ABCB1	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
coumarin metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
isoquinoline alkaloid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2D6	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2D6	Homo sapiens (human)
negative regulation of cellular organofluorine metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
arachidonic acid metabolic process	Cytochrome P450 2D6	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
androgen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A5	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A5	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A5	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A5	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A5	Homo sapiens (human)
muscle contraction	Substance-K receptor	Homo sapiens (human)
tachykinin receptor signaling pathway	Substance-K receptor	Homo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmission	Substance-K receptor	Homo sapiens (human)
intestine smooth muscle contraction	Substance-K receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Substance-K receptor	Homo sapiens (human)
operant conditioning	Substance-K receptor	Homo sapiens (human)
positive regulation of vascular permeability	Substance-K receptor	Homo sapiens (human)
positive regulation of monoatomic ion transport	Substance-K receptor	Homo sapiens (human)
positive regulation of smooth muscle contraction	Substance-K receptor	Homo sapiens (human)
response to electrical stimulus	Substance-K receptor	Homo sapiens (human)
prolactin secretion	Substance-K receptor	Homo sapiens (human)
positive regulation of uterine smooth muscle contraction	Substance-K receptor	Homo sapiens (human)
positive regulation of flagellated sperm motility	Substance-K receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	fMet-Leu-Phe receptor	Homo sapiens (human)
chemotaxis	fMet-Leu-Phe receptor	Homo sapiens (human)
signal transduction	fMet-Leu-Phe receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	fMet-Leu-Phe receptor	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	fMet-Leu-Phe receptor	Homo sapiens (human)
nitric oxide mediated signal transduction	fMet-Leu-Phe receptor	Homo sapiens (human)
complement receptor mediated signaling pathway	fMet-Leu-Phe receptor	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	fMet-Leu-Phe receptor	Homo sapiens (human)
inflammatory response	fMet-Leu-Phe receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	fMet-Leu-Phe receptor	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
acute-phase response	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to nutrient	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
animal organ regeneration	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to lipopolysaccharide	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to starvation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
negative regulation of steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
biphenyl catabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to ethanol	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to glucocorticoid stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to estradiol stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
heme catabolic process	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
vitamin D3 metabolic process	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
regulation of post-translational protein modification	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation of multicellular organism growth	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation by host of viral process	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
positive regulation by host of viral genome replication	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein stabilization	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
bone development	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
chaperone-mediated protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A7	Homo sapiens (human)
steroid biosynthetic process	Cytochrome P450 3A7	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A7	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A7	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
leukotriene metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
response to xenobiotic stimulus	Multidrug resistance-associated protein 1	Homo sapiens (human)
cobalamin transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid biosynthetic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to oxidative stress	Multidrug resistance-associated protein 1	Homo sapiens (human)
heme catabolic process	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
phospholipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
positive regulation of inflammatory response	Multidrug resistance-associated protein 1	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cell chemotaxis	Multidrug resistance-associated protein 1	Homo sapiens (human)
transepithelial transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
cyclic nucleotide transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid translocation	Multidrug resistance-associated protein 1	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
cellular response to amyloid-beta	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 1	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein phosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein kinase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
apoptotic process	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
viral release from host cell	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neuron differentiation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
neutrophil chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
leukocyte chemotaxis	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
activation of protein kinase B activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of stress-activated MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
lipid droplet organization	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cellular response to oxidative stress	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein dephosphorylation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
endothelial cell activation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of MAPK cascade	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of viral genome replication	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of protein secretion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cell adhesion molecule production	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of protein K48-linked ubiquitination	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
platelet aggregation	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
negative regulation of viral life cycle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
regulation of apoptotic signaling pathway	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein peptidyl-prolyl isomerization	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
heart morphogenesis	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
protein folding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
'de novo' protein folding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
protein maturation by protein folding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
positive regulation of protein binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
regulation of protein localization	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
negative regulation of activin receptor signaling pathway	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
protein refolding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
T cell activation	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
regulation of immune response	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
ventricular cardiac muscle tissue morphogenesis	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activity	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
heart trabecula formation	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
calcium ion transmembrane transport	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
supramolecular fiber organization	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
regulation of amyloid precursor protein catabolic process	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
amyloid fibril formation	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
branching involved in blood vessel morphogenesis	Calcineurin subunit B type 1	Homo sapiens (human)
epithelial to mesenchymal transition	Calcineurin subunit B type 1	Homo sapiens (human)
protein import into nucleus	Calcineurin subunit B type 1	Homo sapiens (human)
heart development	Calcineurin subunit B type 1	Homo sapiens (human)
myelination in peripheral nervous system	Calcineurin subunit B type 1	Homo sapiens (human)
calcineurin-NFAT signaling cascade	Calcineurin subunit B type 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Calcineurin subunit B type 1	Homo sapiens (human)
lung epithelial cell differentiation	Calcineurin subunit B type 1	Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascade	Calcineurin subunit B type 1	Homo sapiens (human)
regulation of synaptic vesicle cycle	Calcineurin subunit B type 1	Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalization	Calcineurin subunit B type 1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Calcineurin subunit B type 1	Homo sapiens (human)
positive regulation of calcium ion import across plasma membrane	Calcineurin subunit B type 1	Homo sapiens (human)
negative regulation of calcium ion import across plasma membrane	Calcineurin subunit B type 1	Homo sapiens (human)
calcineurin-mediated signaling	Calcineurin subunit B type 1	Homo sapiens (human)
protein dephosphorylation	Calcineurin subunit B type 1	Homo sapiens (human)
'de novo' protein folding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
smooth muscle contraction	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
negative regulation of heart rate	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
neuronal action potential propagation	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
calcium-mediated signaling	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
protein maturation by protein folding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
response to vitamin E	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
insulin secretion involved in cellular response to glucose stimulus	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
protein refolding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
T cell proliferation	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
response to hydrogen peroxide	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
positive regulation of axon regeneration	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
negative regulation of calcium-mediated signaling	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
negative regulation of release of sequestered calcium ion into cytosol	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
positive regulation of sequestering of calcium ion	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
regulation of cytosolic calcium ion concentration	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
transmembrane transporter activity	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein domain specific binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
hormone activity	Transthyretin	Homo sapiens (human)
protein binding	Transthyretin	Homo sapiens (human)
identical protein binding	Transthyretin	Homo sapiens (human)
thyroid hormone binding	Transthyretin	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 1A2	Homo sapiens (human)
iron ion binding	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	Cytochrome P450 1A2	Homo sapiens (human)
electron transfer activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 1A2	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 1A2	Homo sapiens (human)
enzyme binding	Cytochrome P450 1A2	Homo sapiens (human)
heme binding	Cytochrome P450 1A2	Homo sapiens (human)
demethylase activity	Cytochrome P450 1A2	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 1A2	Homo sapiens (human)
aromatase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 1A2	Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activity	Cytochrome P450 1A2	Homo sapiens (human)
protein binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
efflux transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATP hydrolysis activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ubiquitin protein ligase binding	ATP-dependent translocase ABCB1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylcholine floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
phosphatidylethanolamine flippase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
ceramide floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
floppase activity	ATP-dependent translocase ABCB1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
monooxygenase activity	Cytochrome P450 2D6	Homo sapiens (human)
iron ion binding	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2D6	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2D6	Homo sapiens (human)
heme binding	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 2D6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A5	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A5	Homo sapiens (human)
protein binding	Cytochrome P450 3A5	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A5	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A5	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A5	Homo sapiens (human)
heme binding	Cytochrome P450 3A5	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A5	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A5	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A5	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-dependent translocase ABCB1	Mus musculus (house mouse)
tachykinin receptor activity	Substance-K receptor	Homo sapiens (human)
protein binding	Substance-K receptor	Homo sapiens (human)
substance K receptor activity	Substance-K receptor	Homo sapiens (human)
G protein-coupled receptor binding	fMet-Leu-Phe receptor	Homo sapiens (human)
G protein-coupled receptor activity	fMet-Leu-Phe receptor	Homo sapiens (human)
N-formyl peptide receptor activity	fMet-Leu-Phe receptor	Homo sapiens (human)
scavenger receptor binding	fMet-Leu-Phe receptor	Homo sapiens (human)
protein binding	fMet-Leu-Phe receptor	Homo sapiens (human)
RAGE receptor binding	fMet-Leu-Phe receptor	Homo sapiens (human)
complement receptor activity	fMet-Leu-Phe receptor	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
collagen binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
RNA polymerase binding	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A7	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A7	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A7	Homo sapiens (human)
heme binding	Cytochrome P450 3A7	Homo sapiens (human)
all-trans retinoic acid 18-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A7	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A7	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type vitamin B12 transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled lipid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
sphingolipid transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
carboxylic acid transmembrane transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
UDP-glycosyltransferase activity	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
integrin binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
virion binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
unfolded protein binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
heparan sulfate binding	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
transforming growth factor beta receptor binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
macrolide binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
FK506 binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
channel regulator activity	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
signaling receptor inhibitor activity	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
type I transforming growth factor beta receptor binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
transmembrane transporter binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
I-SMAD binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
activin receptor binding	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
calcium-dependent protein serine/threonine phosphatase activity	Calcineurin subunit B type 1	Homo sapiens (human)
calcium ion binding	Calcineurin subunit B type 1	Homo sapiens (human)
protein binding	Calcineurin subunit B type 1	Homo sapiens (human)
calmodulin binding	Calcineurin subunit B type 1	Homo sapiens (human)
cyclosporin A binding	Calcineurin subunit B type 1	Homo sapiens (human)
phosphatase binding	Calcineurin subunit B type 1	Homo sapiens (human)
protein domain specific binding	Calcineurin subunit B type 1	Homo sapiens (human)
calcium-dependent protein serine/threonine phosphatase regulator activity	Calcineurin subunit B type 1	Homo sapiens (human)
ryanodine-sensitive calcium-release channel activity	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
signaling receptor binding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
FK506 binding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
channel regulator activity	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
calcium channel inhibitor activity	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
cyclic nucleotide binding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
transmembrane transporter binding	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
dihydroorotase activity	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
protein binding	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
dihydroorotate dehydrogenase (quinone) activity	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
dihydroorotate dehydrogenase activity	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
RNA binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
ATP binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
GTP binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
FK506 binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
protein-macromolecule adaptor activity	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
heat shock protein binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
copper-dependent protein binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
nuclear glucocorticoid receptor binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
tau protein binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
phosphoprotein binding	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
protein serine/threonine phosphatase activity	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
calcium ion binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
calmodulin binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
cyclosporin A binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
myosin phosphatase activity	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
enzyme binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
calmodulin-dependent protein phosphatase activity	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
protein-containing complex binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
protein dimerization activity	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
ATPase binding	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
peptidyl-prolyl cis-trans isomerase activity	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
transcription factor binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cyclosporin A binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nuclear estrogen receptor binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
Hsp70 protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
heat shock protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
Hsp90 protein binding	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
protein binding	Ileal sodium/bile acid cotransporter	Homo sapiens (human)
bile acid:sodium symporter activity	Ileal sodium/bile acid cotransporter	Homo sapiens (human)
virus receptor activity	Sodium/bile acid cotransporter	Homo sapiens (human)
protein binding	Sodium/bile acid cotransporter	Homo sapiens (human)
bile acid:sodium symporter activity	Sodium/bile acid cotransporter	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A43	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A43	Homo sapiens (human)
heme binding	Cytochrome P450 3A43	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A43	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A43	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A43	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
urate transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
biotin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
efflux transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATP hydrolysis activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
riboflavin transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
identical protein binding	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
protein homodimerization activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
sphingolipid transporter activity	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
endopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Notch binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
interleukin-6 receptor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
integrin binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
protein binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
peptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metallopeptidase activity	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
SH3 domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytokine binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
PDZ domain binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
tumor necrosis factor binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metal ion binding	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic process	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
apical plasma membrane	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
apical plasma membrane	Solute carrier organic anion transporter family member 2B1	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cortical actin cytoskeleton	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
microvillus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
endomembrane system	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
lamellipodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
filopodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular exosome	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular region	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
azurophil granule lumen	Transthyretin	Homo sapiens (human)
extracellular exosome	Transthyretin	Homo sapiens (human)
extracellular space	Transthyretin	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 1A2	Homo sapiens (human)
cytoplasm	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cell surface	ATP-dependent translocase ABCB1	Homo sapiens (human)
membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
extracellular exosome	ATP-dependent translocase ABCB1	Homo sapiens (human)
external side of apical plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mitochondrion	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2D6	Homo sapiens (human)
cytoplasm	Cytochrome P450 2D6	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2D6	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
intracellular membrane-bounded organelle	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1-6	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Cytochrome P450 3A5	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A5	Homo sapiens (human)
plasma membrane	ATP-dependent translocase ABCB1	Mus musculus (house mouse)
plasma membrane	Substance-K receptor	Homo sapiens (human)
sperm flagellum	Substance-K receptor	Homo sapiens (human)
sperm head	Substance-K receptor	Homo sapiens (human)
sperm midpiece	Substance-K receptor	Homo sapiens (human)
sperm midpiece	Substance-K receptor	Homo sapiens (human)
plasma membrane	Substance-K receptor	Homo sapiens (human)
cytoplasm	fMet-Leu-Phe receptor	Homo sapiens (human)
plasma membrane	fMet-Leu-Phe receptor	Homo sapiens (human)
membrane	fMet-Leu-Phe receptor	Homo sapiens (human)
secretory granule membrane	fMet-Leu-Phe receptor	Homo sapiens (human)
azurophil granule membrane	fMet-Leu-Phe receptor	Homo sapiens (human)
ficolin-1-rich granule membrane	fMet-Leu-Phe receptor	Homo sapiens (human)
plasma membrane	fMet-Leu-Phe receptor	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
plasma membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
perinuclear region of cytoplasm	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum chaperone complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cytochrome complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A4	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum lumen	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
smooth endoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
melanosome	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
perinuclear region of cytoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum chaperone complex	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
intracellular membrane-bounded organelle	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase B	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A7	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basal plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
lateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
extracellular exosome	Multidrug resistance-associated protein 1	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 1	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B10	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
extracellular region	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular space	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
focal adhesion	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
vesicle	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
secretory granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
ficolin-1-rich granule lumen	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
terminal cisterna	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
sarcoplasmic reticulum	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
Z disc	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
cytoplasmic side of membrane	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
ryanodine receptor complex	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
sarcoplasmic reticulum membrane	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase FKBP1A	Homo sapiens (human)
nucleoplasm	Calcineurin subunit B type 1	Homo sapiens (human)
cytosol	Calcineurin subunit B type 1	Homo sapiens (human)
calcineurin complex	Calcineurin subunit B type 1	Homo sapiens (human)
protein serine/threonine phosphatase complex	Calcineurin subunit B type 1	Homo sapiens (human)
sarcolemma	Calcineurin subunit B type 1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Calcineurin subunit B type 1	Homo sapiens (human)
hippocampal mossy fiber to CA3 synapse	Calcineurin subunit B type 1	Homo sapiens (human)
parallel fiber to Purkinje cell synapse	Calcineurin subunit B type 1	Homo sapiens (human)
postsynapse	Calcineurin subunit B type 1	Homo sapiens (human)
glutamatergic synapse	Calcineurin subunit B type 1	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
membrane	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
Z disc	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
sarcoplasmic reticulum membrane	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
calcium channel complex	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
sarcoplasmic reticulum membrane	Peptidyl-prolyl cis-trans isomerase FKBP1B	Homo sapiens (human)
nucleoplasm	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
mitochondrion	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
cytosol	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	Dihydroorotate dehydrogenase (quinone), mitochondrial	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
mitochondrion	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
microtubule	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
neuronal cell body	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
axonal growth cone	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
perinuclear region of cytoplasm	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
extracellular exosome	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
protein-containing complex	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase FKBP4	Homo sapiens (human)
cytoplasmic side of plasma membrane	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
mitochondrion	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
cytosol	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
plasma membrane	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
calcineurin complex	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
protein serine/threonine phosphatase complex	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
extrinsic component of plasma membrane	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
Z disc	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
slit diaphragm	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
sarcolemma	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
dendritic spine	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
glutamatergic synapse	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
cytosol	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform	Homo sapiens (human)
nucleus	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nucleoplasm	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
nucleolus	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytosol	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
cytoplasm	Peptidyl-prolyl cis-trans isomerase D	Homo sapiens (human)
plasma membrane	Ileal sodium/bile acid cotransporter	Homo sapiens (human)
microvillus	Ileal sodium/bile acid cotransporter	Homo sapiens (human)
apical plasma membrane	Ileal sodium/bile acid cotransporter	Homo sapiens (human)
plasma membrane	Sodium/bile acid cotransporter	Homo sapiens (human)
basolateral plasma membrane	Sodium/bile acid cotransporter	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A43	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Mus musculus (house mouse)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
nucleoplasm	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
brush border membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
mitochondrial membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
membrane raft	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
external side of apical plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
focal adhesion	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
ruffle membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
Golgi membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
endoplasmic reticulum lumen	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytosol	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cell surface	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
actin cytoskeleton	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
apical plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
membrane raft	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
plasma membrane	Disintegrin and metalloproteinase domain-containing protein 17	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1423)

Assay ID	Title	Year	Journal	Article
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2008	Proteins, Mar, Volume: 70, Issue:4	Crystal structure of human cyclophilin D in complex with its inhibitor, cyclosporin A at 0.96-A resolution.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347155	Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150	Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID91889	The compound was evaluated in vitro for the immunosuppressive activity in interleukin-2 by interleukin-2 reporter gene assay (IL2-RGA)	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID657444	Immunosuppressive activity in anti-CD3/anti-CD8 co-stimulated Balb/c mouse lymph node cells assessed as inhibition of cell proliferation after 72 hrs by ELISA	2012	Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9	Design, synthesis, and biological evaluation of chalcone oxime derivatives as potential immunosuppressive agents.
AID91898	Compound was evaluated for in vitro immunosuppressive activity in the interleukin-2 reporter gene assay (IL2-RG)	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain.
AID1323951	Antiinflammatory activity in Balb/C mouse model of contact hypersensitivity assessed as inhibition of DNFB-stimulated ear swelling at 100 mg/kg, ip bid administered at 0 and 8 hrs measured 24 hrs post DNFB stimulation	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity.
AID1338616	Cytotoxicity against mouse HT22 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID416850	Antifungal activity against Trichophyton mentagrophytes DUMC160.03 by CLSI protocol	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID1289139	AUC in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1723060	Inhibition of human ABCC1 expressed in MDCK2 cells preincubated for 30 mins followed by calcein AM addition and measured every 60 secs for 60 mins by fluorescence assay
AID1874118	Inhibition of NFATC activity in HEK293T cells preincubated for 2 hrs followed by ionomycin/phorbol 12-myristate 13-acetate stimulation and measured after 4 hrs by luciferase reporter assay
AID444051	Total clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1756341	Inhibition of glutamate-induced oxidative stress in human SH-SY5Y cells assessed as superoxide radical formation at 0.05 to 0.5 uM measured after 4 hrs by DHE staining based fluorescence spectrophotometry (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1358239	Inhibition of P-gp in human MCF7/ADR cells assessed as cell viability after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell.
AID1289124	AUC in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1289183	Ratio of volume of distribution at steady state in blood to plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID681302	TP_TRANSPORTER: inhibition of CFDA efflux (CFDA: 1 uM, CsA: 20 uM) in HL60/Adr cells	2002	International journal of molecular medicine, Nov, Volume: 10, Issue:5	Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates.
AID679909	TP_TRANSPORTER: inhibition of Verapamil stimulated ATP hydrolysis in membranes from MDR1-expressing Sf9 cells	1994	Molecular pharmacology, Apr, Volume: 45, Issue:4	Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein.
AID558952	Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral replication at 8 uM after 24 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID581932	Cytotoxicity against CRFK	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1292977	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID393839	Inhibition of fetal calf serum-induced proliferation of human foreskin fibroblast assessed as [3H]thymidine incorporation after 4 days by scintillation counting	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID1756552	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation incubated for 48 hrs by MTT assay	2021	Journal of natural products, 02-26, Volume: 84, Issue:2	Hypothemycin-Type Resorcylic Acid Lactones with Immunosuppressive Activities from a
AID1061931	Inhibition of MDR-1 (unknown origin) expressed in human Caco2 cells using Calcein-AM at 50 uM preincubated for 30 mins by fluorescence based PDSP assay relative to control	2014	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1	Fluorescent probes of the isoxazole-dihydropyridine scaffold: MDR-1 binding and homology model.
AID183445	T cell-decreasing effect in spleen cells of WKAH rat which were injected into foot-pad of LEW rat.	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID1813132	Selectivity index, ratio of IC50 for cytotoxicity against mouse L929 cells to EC50 for inhibition of P-gp in human LCC6MDR cells assessed as reversal of paclitaxel resistance	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers.
AID15680	Partition coefficient (logP)	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID196259	Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 3 mg/kg	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID672896	Cytotoxicity against BALB/c mouse lymph node cells after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis, biological evaluation and molecular modeling of novel 1,3,4-oxadiazole derivatives based on Vanillic acid as potential immunosuppressive agents.
AID681122	TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID681139	TP_TRANSPORTER: increase in dihydrofluorescein intracellular accumulation (dihydrofluorescein: 1 uM) in SK-E2 cells (expressing BSEP)	2003	Pharmaceutical research, Apr, Volume: 20, Issue:4	Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID1289140	AUC in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1895180	Binding affinity to CypA (unknown origin) assessed as inhibition constant by isomer specific proteolysis assay	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID357957	Inhibition of PHA-induced human T cell proliferation after 24 hrs by MTT assay	2001	Journal of natural products, Oct, Volume: 64, Issue:10	Synthetic secofriedelane and friedelane derivatives as inhibitors of human lymphocyte proliferation and growth of human cancer cell lines in vitro.
AID496034	Intrinsic clearance in human liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1293020	Volume of distribution at steady state in healthy subject (8 subjects) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID69108	Compound was tested for its ability to inhibit FK506 binding protein 12 rotamase activity	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Immunophilins: beyond immunosuppression.
AID566105	Immunosuppressive activity in peripheral blood lymphocytes isolated from two individuals assessed as proliferation using [methyl-3H]thymidine by mixed lymphocyte reaction assay	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Discovery of 7-N-piperazinylthiazolo[5,4-d]pyrimidine analogues as a novel class of immunosuppressive agents with in vivo biological activity.
AID528325	Antiviral activity against HCV after 72 hrs by stable luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1221957	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID644404	Cytotoxicity against lymph node T cell after 24 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
AID496038	Half life in human liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1062339	Modulation of p-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
AID664605	Noncompetitive inhibition of P-gp assessed as reduction in P-gp-associated ATPase activity by Pgp-GloTM Assay	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Relationship between structure and P-glycoprotein inhibitory activity of dimeric peptides related to the Dmt-Tic pharmacophore.
AID681132	TP_TRANSPORTER: ATP hydrolysis in MDR1-expressing Sf9 cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID581768	Antiproliferative activity against mouse PBMC with MLR assessed as inhibition of [3H]thymidine incorporation after 18 hrs	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID428049	Cytotoxicity against rat H42E cells assessed as intracellular ATP level	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID1533104	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 1.56 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID396920	Immunosuppressive activity in human T cell assessed as inhibition of mitogenesis
AID432794	Antifungal activity against Candida kefyr ATCC 46764 after 14 to 18 hrs	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID679137	TP_TRANSPORTER: transcellular transport in mdr1b-expressing LLC-PK1 cells	2007	Neuropharmacology, Feb, Volume: 52, Issue:2	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID90140	Ratio of effect of compound on DOX accumulation (antiPgp activity) to its intrinsic cellular toxicity;	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID679348	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCK cells	1999	Pharmaceutical research, Apr, Volume: 16, Issue:4	Grapefruit juice activates P-glycoprotein-mediated drug transport.
AID680428	TP_TRANSPORTER: inhibition of MTX uptake (MTX: 1 uM, CsA: 10 uM) in membrane vesicles from MRP3-expressing HEK293 cells	2001	Cancer research, Oct-01, Volume: 61, Issue:19	Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.
AID596408	Inhibition of serine palmitoyltransferase in mouse spleen cells	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1293018	Clearance in healthy subject (8 subjects) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID132511	Compound was tested in vivo for immunosuppressive activity in the serum free mixed lymphocyte reaction	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Isolation and synthesis of a novel immunosuppressive 17alpha-substituted dammarane from the flour of the Palmyrah palm (Borassus flabellifer).
AID1226783	AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID150758	P-gp activity was measured by a direct transport assay, using polarized LLC-PK1 epithelial cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID496039	Inhibition of human recombinant CYP3A4 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID420711	Selectivity index, CC50 for splenocytes to IC50 for concanavalin A-induced splenocyte proliferation	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Hirtellanines A and B, a pair of isomeric isoflavonoid derivatives from Campylotropis hirtella and their immunosuppressive activities.
AID1327019	Inhibition of human ABCB1 expressed in mouse NH3T3 cells assessed as inhibition of calcein-AM efflux at 2.5 uM measured after 30 mins by flow cytometry	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.
AID1221964	Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1769569	Cytotoxicity against BALB/c mouse splenocyte assessed as reduction in cell viability measured after 72 hrs by CCK-8 assay	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Efophylins A and B, Two
AID330503	Activation of human P-gp ATPase in human Caco-2 cells at 100 uM	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
AID1142395	Cytotoxicity against hCMEC/D3 cells at 0.1 to 50 uM after 4 hrs by Alamar Blue assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding?
AID1293033	Clearance in iv dosed renal transplant patient plasma	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID496165	Cytotoxicity against human PBMC assessed as inhibition of cell proliferation at 0.3 uM after 18 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1331005	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant at 1:1 compound to protein ratio measured after 60 secs in presence of 20-fold excess of (3S,6S,9S,15S,18S,21S	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID679044	TP_TRANSPORTER: inhibition of BMG uptake in membrane vesicles from Mrp2-expressing HEK cells	1999	Hepatology (Baltimore, Md.), Aug, Volume: 30, Issue:2	Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2.
AID1426813	Immunosuppressive activity in human PBMC assessed as inhibition of anti-human CD3-induced T-cell proliferation after 4 days by CellTrace violet cell proliferation dye based FACS analysis	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.
AID1226789	Half life in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID356719	Antiinflammatory activity in human PMNC assessed as inhibition of proliferation	2001	Journal of natural products, Jul, Volume: 64, Issue:7	Monoterpene glycosides and triterpene acids from Eriobotrya deflexa.
AID428054	Immunosuppressive activity in LPS-activated B lymphocyte assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID1525920	Inhibition of BCRP in human MCF7/MX100 cells assessed as reversal of topotecan resistance after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID581778	Inhibition of human recombinant cyclophilin-associted cis-trans propyl isomerase activity	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID396921	Immunosuppressive activity in guinea pig T cell assessed as inhibition of mitogenesis
AID711680	Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin-induced cytotoxicity at 5 uM after 8 hrs by CCK-8 assay	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux.
AID1331007	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant at 1:1 compound to protein ratio measured after 240 secs in presence of 20-fold excess of (3S,6S,9S,15S,18S,21	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID1591788	Selectivity index, ratio of CC50 for BALB/c mouse splenocytes to IC50 for immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents.
AID1388389	Oral bioavailability in Wistar hyperlipidemia rat at 7 mg/kg	2018	Bioorganic & medicinal chemistry, 06-01, Volume: 26, Issue:10	Improving oral bioavailability of cyclic peptides by N-methylation.
AID681596	TP_TRANSPORTER: inhibition of Vinblastine transepithelial transport (basal to apical) in MRP2-expressing MDCK cells	2002	Pharmaceutical research, Jun, Volume: 19, Issue:6	Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa?
AID196258	Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 100 mg/kg; Toxic	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID1771418	Anti-aplastic anaemia in immune-mediated bone marrow failure BALB/c mouse model assessed as increase in spleen index at 10 mg/kg, po administered for 14 days
AID1062340	Cytotoxicity against mouse L929 cells assessed as growth inhibition after 3 days by MTS assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
AID681142	TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in MDR1-expressing LLC-PK1 cells	2002	Molecular pharmacology, May, Volume: 61, Issue:5	Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID681479	TP_TRANSPORTER: Western in vivo, liver of SD rat	2001	Research communications in molecular pathology and pharmacology, Jul, Volume: 109, Issue:1-2	In vivo induction of hepatic p-glycoprotein by cyclosporine in the rat.
AID1293015	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M21 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID150619	Inhibitory activity against Human MDR1 P-Glycoprotein ABC Transporter using leukemia CEM cells	2002	Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21	Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
AID1289158	Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 1.8 +/- 0.3 hrs during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID681669	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 1 uM, CsA: 20 uM) in Bsep-expressing LLC-PK1 cells	2000	Molecular pharmacology, Jan, Volume: 57, Issue:1	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
AID1169139	Oral bioavailability in rat	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID321881	Apparent permeability from basolateral to apical side of human Caco-2 cell membrane	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
AID1758185	Antiproliferative activity against human MCF7/ADR cells assessed as inhibition rate at 10 uM incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID1765690	Inhibition of human NFAT-1 in human Jurkat cells assessed as decrease of PMA/ionomycin-induced IL-2 concentration at 15 uM measured after 44 hrs by western blot assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Vomifoliol isolated from mangrove plant Ceriops tagal inhibits the NFAT signaling pathway with CN as the target enzyme in vitro.
AID1525919	Inhibition of BCRP (unknown origin) transfected in HEK293/R2 cells assessed as reversal of topotecan resistance after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID581929	Cytotoxicity against human embryonic lung cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID496158	Inhibition of calcineurin phosphatase activity of CyPA at 0.12 uM	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID322363	Inhibition of human wild type Pgp expressed in MDCK2 cells assessed as calcein-AM accumulation at 10 uM after 40 mins	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
AID1293000	Cmax in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po administered through solution by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID324585	Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID185516	Mean survival time of rats after skin allograft (intraperitoneal administration) at 3 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID1293028	Oral bioavailability in blood of renal transplant patient	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1209608	Competitive inhibition of recombinant CYP3A4 (unknown origin) expressed in supersomes	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1226796	Apparent permeability from apical to basolateral side in low-efflux MDCK cells expressing low levels of endogenous P-glycoprotein at 2 mM incubated for 2 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID1226786	AUC (0 to infinity) in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1380078	Antifungal activity against Cryptococcus neoformans H99 serotype A after 72 hrs by microdilution method	2018	Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13	Emerging New Targets for the Treatment of Resistant Fungal Infections.
AID581942	Antiviral activity against Herpes simplex virus 2 Lyons infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1226787	Clearance in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID1292980	Clearance in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID588999	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MDR3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID240399	Inhibition of T-cell proliferation	2004	Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17	Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives.
AID420710	Immunosuppressive activity in splenocytes assessed as inhibition of concanavalin A-induced proliferation after 48 hrs by [3H]thymidine incorporation assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Hirtellanines A and B, a pair of isomeric isoflavonoid derivatives from Campylotropis hirtella and their immunosuppressive activities.
AID680904	TP_TRANSPORTER: correlation between intestinal P-gp content and oral clearance in vivo, kidney transplant recipients	1997	Clinical pharmacology and therapeutics, Sep, Volume: 62, Issue:3	Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
AID681138	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells	2002	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1	Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID1591787	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation by measuring [3H]-thymidine uptake preincubated before LPS stimulation for 48 hrs followed by [3H]-thymidine addition for 8 hrs by beta-sc	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents.
AID432788	Effect on drug distribution assessed as fluconazole level in plasma of transplant patient within 11 days of testing by gas-liquid chromatography	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID770484	Inhibition of NFAT activation in PMA/ionomycin-stimulated human Jurkat T cells incubated for 30 mins prior to PMA/ionomycin stimulation measured after 5 hrs by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147.
AID1708434	Inhibition of ABCB1 (unknown origin) expressed in human A2780 ADR cells assessed as reduction in calcein AM efflux at 10 uM preincubated for 30 mins followed by calcein AM addition and measured at 60 secs interval for 1 hr by fluorescence assay relative t	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
AID1449628	Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method	2012	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12	Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1364652	Selectivity index, ratio of CC50 for cytotoxic activity against BALB/c mouse T-lymphocytes to IC50 for inhibition of ConA-induced cell proliferation of BALB/c mouse T-lymphocytes	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Absolute Configuration of Periplosides C and F and Isolation of Minor Spiro-orthoester Group-Containing Pregnane-type Steroidal Glycosides from Periploca sepium and Their T-Lymphocyte Proliferation Inhibitory Activities.
AID365465	Inhibition of P-gp in human A2780 cells	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins.
AID1292994	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M17 at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1335815	Inhibition of ABCB1 in human A2780/ADR cells assessed as reduction in calcien-AM efflux preincubated for 30 mins followed by calcien-AM addition measured immediately at 60 sec time interval for 60 mins by fluorescence assay	2016	European journal of medicinal chemistry, Nov-29, Volume: 124	Phenyltetrazolyl-phenylamides: Substituent impact on modulation capability and selectivity toward the efflux protein ABCG2 and investigation of interaction with the transporter.
AID357931	Immunosuppressant activity in mouse T cells assessed as inhibition of concanavalin A-induced cell proliferation	2001	Journal of natural products, Sep, Volume: 64, Issue:9	Immunomodulatory constituents from an Ascomycete, Eupenicillium crustaceum, and revised absolute structure of macrophorin D.
AID1474098	Ratio of drug concentration at steady state in human at 20 to 600 mg/kg, po after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1869235	Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in LPS-induced mouse B-lymphocytes proliferation incubated for 8 hrs by beta scintillation counting based [3H]thymidine incorporation assay	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Dolabrane-Type Diterpenoids with Immunosuppressive Activity from
AID558943	Antiviral activity against Yellow fever virus infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID404304	Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control	2008	Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11	Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID444052	Hepatic clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1675571	Antiproliferative activity against Con A-induced BALB/c mouse T cell after 48 hrs by CCK8 assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents.
AID95447	In vitro inhibition of Jurkat cell proliferation.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Aromatic quinolinecarboxamides as selective, orally active antibody production inhibitors for prevention of acute xenograft rejection.
AID496036	Cytotoxicity against human Huh7ET cells assessed as lactate dehydrogenase release up to 10 uM after 72 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1289173	Ratio of oral bioavailability in blood of healthy human subjects (8 subjects) at 10 mg/kg measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1293007	Tmax in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po administered through capsule by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID558961	Antiviral activity against Yellow fever virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after => 20 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID185527	Mean survival time of rats after skin allograft (oral administration) at 3 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID1533103	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 3.12 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID685500	HARVARD: Cytotoxicity in HepG2 cell line	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1265702	Antiviral activity against EV71 infected in RD cells after 24 hrs by luciferase assay	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
AID719606	Binding affinity to human cyclophilin A by fluorescence polarization assay	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Ranking high affinity ligands of low solubility by NMR spectroscopy.
AID1869234	Selectivity index, ratio of CC50 for cytotoxicity in BALB/c mouse splenocytes to IC50 for immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse T-lymphocytes proliferation	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Dolabrane-Type Diterpenoids with Immunosuppressive Activity from
AID680691	TP_TRANSPORTER: increase in Vinblastine intracellular accumulation of Cyclosporin A at a concentration of 20uM in LLC-GA5-COL150 cells	2004	British journal of pharmacology, Dec, Volume: 143, Issue:7	Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
AID1338178	Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as potentiation of paclitaxel-induced cytotoxicity at 1 uM measured after 5 days by Cell Titer 96 Aqueous assay relative to paclitaxel alone	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Extending the structure-activity relationship study of marine natural ningalin B analogues as P-glycoprotein inhibitors.
AID234689	Relative IC50 is the ratio of IC50 of the compound/IC50 CsA	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID245962	In vitro concentration of compound required to reduced spleen cell viability to 50% in BALB/c mice	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID573112	Cytotoxicity against human Huh5-2 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID496033	Intrinsic clearance in CD1 mouse liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID648433	Immunosuppressant activity in human CD4+ T cells assessed as Con A-induced intracellular IL4 level at 90 uM after 72 hrs by flow cytometry (Rvb = 4.2+/-0.9%)	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID714416	Cytotoxicity against mouse L929 cells after 72 hrs	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID681378	TP_TRANSPORTER: inhibition of Taurocholate uptake in NTCP-expressing HeLa cells	1999	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 291, Issue:3	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.
AID1289185	Ratio of oral bioavailability in blood to plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during low fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1296465	Cytotoxicity against CD1 mouse pancreatic acinar cells at 0.1 to 10 uM after 30 mins by propidium iodide staining based confocal microscopic analysis	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis.
AID581936	Cytotoxicity against human Huh 5.2 cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID182789	Decrease in number of T cells in peripheral blood after administration for 4 days in rat	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720.
AID1426806	Antiviral activity against HCV genotype 1b Con1 infected in human HuH7 cells after 72 hrs by luciferase reporter gene assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.
AID496028	Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 3 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID581951	Antiviral activity against HPV-16 infected in Caski cells assessed as inhibition of viral replication after 7 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1289143	Mean residence time in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1300181	Inhibition of human recombinant cyclophilin D using Suc-AAPF-MCA as substrate preincubated for 1 hr followed by substrate addition measured per millisec for 2 mins by real time fluorescence analysis	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Aβ-Mediated Mitochondrial Dysfunction.
AID625946	Inhibition of PPIase activity of human recombinant cyclophilin-A using succinyl-Ala-Ala-Pro-Phe-4-nitroanilide as substrate by protease coupled assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Oligopeptide cyclophilin inhibitors: a reassessment.
AID1370782	Inhibition of LPS-induced B lymphocytes (unknown origin) proliferation	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Spiroorthoester group-containing pregnane glycosides from the root barks of Periploca chrysantha and their inhibitory activities against the proliferation of B and T lymphocytes.
AID19468	Partition coefficient (logP)	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID19255	Partition coefficient (logP)	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID682148	TP_TRANSPORTER: transepithelial transport of SN-38(Lactone form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells	2003	Pharmaceutical research, Jun, Volume: 20, Issue:6	Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
AID680304	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.5 uM, Cyclosporin A: 10 uM) in MDR1-expressing NIH-3T3 cells	2004	Biochemical and biophysical research communications, Mar-19, Volume: 315, Issue:4	Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
AID161617	Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 25 mg/kg dose (for eotaxin)	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
AID326367	Inhibition of human Pgp in A2780 cells after 30 mins by Hoechst 33342 assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
AID1209612	Inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes preincubated for 15 mins before substrate addition by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1756553	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation incubated for 48 hrs by MTT assay	2021	Journal of natural products, 02-26, Volume: 84, Issue:2	Hypothemycin-Type Resorcylic Acid Lactones with Immunosuppressive Activities from a
AID681119	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1142019	Reversal of Pgp-1-mediated multidrug resistance in human HEK293 cells assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to paclitaxel alone-treated contr	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.
AID685502	HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID496019	Antiinflammatory activity in human Jurkat cells assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1206431	Inhibition of MRP1 in human A2780adr cells at 10 uM pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
AID1271174	Inhibition of Cyclophilin A peptidyl-prolyl cis-trans isomerase activity (unknown origin) using Succ-Ala-Leu-Pro-Phe-p-nitroaniline as substrate by ITC analysis	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID1895178	Ratio of drug level in brain to plasma in ICR mouse plasma at 1 uM preincubated for 10 mins followed by compound addition measured after 60 mins by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID581782	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent cytotoxic T cells at 10 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID523609	Antiviral activity against HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID1178328	Immunosuppressive activity in lymphocytes (unknown origin) by mixed lymphocyte reaction assay	2014	Journal of medicinal chemistry, Sep-11, Volume: 57, Issue:17	From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
AID681126	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1209611	Inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1699059	Inhibition of calcineurin in mouse lung macrophages assessed as reduction in LPS-induced IL6 production at 10 uM pre-incubated 4 hrs before LPS stimulation for 8 hrs by ELISA	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	A Peptidyl Inhibitor that Blocks Calcineurin-NFAT Interaction and Prevents Acute Lung Injury.
AID680941	TP_TRANSPORTER: inhibition of Taurochenodeoxycholate uptake(CsA 30uM, 30 % of control) in membrane vesicles prepared from High Five cells infected with the ABCB11 baculovirus	2002	Gastroenterology, Nov, Volume: 123, Issue:5	The human bile salt export pump: characterization of substrate specificity and identification of inhibitors.
AID1224296	Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as dead undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 6.77%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID581772	Immunosuppressive activity in human Jurkat cells assessed as inhibition of PHA-phorbol myristate acetate induced beta-galactosidase activity at 0.003 uM	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID90133	Concentration that reduces difference in reversal of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1756337	Inhibition of salsolinol-induced apoptosis in human SH-SY5Y cells assessed as appearance of necrotic cells along with late apoptotic cells at 0.5 uM measured after 24 hrs by AO/PIstaining based fluorescence microscopy	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID210271	In vitro inhibitory activity against human T-cell proliferation.	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant.
AID680137	TP_TRANSPORTER: inhibition of Calcein-AM efflux in CEM/VLB100 cells	1999	Biochemical and biophysical research communications, Apr-13, Volume: 257, Issue:2	PSC833, cyclosporin A, and dexniguldipine effects on cellular calcein retention and inhibition of the multidrug resistance pump in human leukemic lymphoblasts.
AID1292987	Oral bioavailability in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID324545	Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1140185	Inhibition of p-gp in doxorubicin-resistant human Saos2 cells assessed as increase in intracellular doxorubicin retention at 5 uM after 2 hrs by flow cytometric analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID427507	Inhibition of peptidyl-prolyl isomerase activity of Cyclophilin A	2009	Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17	Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach.
AID1142011	Reversal of Pgp-1-mediated multidrug resistance in human SW620 cells assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to paclitaxel alone-treated contro	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.
AID326369	Inhibition of Pgp by daunorubicin accumulation assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
AID177347	In vivo immunosuppressive activity was evaluated by inducing arthritis in lewis rats and measuring the primary lesions after 16 days	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant.
AID1292992	Slow half life in pre-kidney transplant end stage renal disease patient (8 patients) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID416852	Antifungal activity against Trichophyton mentagrophytes DUMC160.03 infected in human skin at 2 fold MIC administered 30 mins post infection followed by once in every 2 days for 7 days by scanning electron microscopy relative to control	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1895158	Effective permeability in PBS buffer assessed as mass retention measured after 18 hrs by PAMPA based LC-MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1289144	Volume of distribution in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1331006	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant at 1:1 compound to protein ratio measured after 120 secs in presence of 20-fold excess of (3S,6S,9S,15S,18S,21	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID1869232	Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in ConA-induced mouse T-lymphocytes proliferation incubated for 8 hrs by beta scintillation counting based [3H]thymidine incorporation assay	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Dolabrane-Type Diterpenoids with Immunosuppressive Activity from
AID1155564	Cardioprotective effect in New Zealand rabbit ischemia/reperfusion-induced left anterior descending coronary artery ligation myocardial infarction model assessed as ratio of area at risk to infarct area at 10 mg/kg, iv administered as bolus dose 5 min pri	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo.
AID357932	Immunosuppressant activity in mouse B cells assessed as inhibition of LPS-induced cell proliferation	2001	Journal of natural products, Sep, Volume: 64, Issue:9	Immunomodulatory constituents from an Ascomycete, Eupenicillium crustaceum, and revised absolute structure of macrophorin D.
AID1292993	Volume of distribution at steady state in pre-kidney transplant end stage renal disease patient (8 patients) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID581938	Antiviral activity against Herpes simplex virus 1 F infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID678716	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1292983	Slow half life in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1869236	Selectivity index, ratio of CC50 for cytotoxicity in BALB/c mouse splenocytes to IC50 for immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in LPS-induced mouse B-lymphocytes proliferation	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Dolabrane-Type Diterpenoids with Immunosuppressive Activity from
AID680103	TP_TRANSPORTER: increase in plasma concentration in PGP(-/-) mouse	1999	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 27, Issue:5	Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
AID1289178	Ratio of clearance in blood to plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID644405	Immunosuppressive activity in lymph node T cell assessed as inhibition of ConA-stimulated cell proliferation after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
AID1707622	Inhibition of OATP1B1 (unknown origin) mediated [3H]-estrone sulfate uptake expressed in human HepG2 cells
AID321887	Inhibition of human Pgp in adriamycin resistant MCF7 cells assessed as fold increase in accumulation of doxorubicin at 20 uM relative to control	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
AID1293037	Volume of distribution at steady state in healthy volunteer (5 volunteers) blood at 2.1 mg/kg, iv administered as infusion over 2 hrs by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID248495	In vivo inhibitory activity against proliferation of normal human peripheral blood T lymphocytes	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
AID1292998	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M21 at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID310122	Inhibition of P-glycoprotein by Hoechst assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	New functional assay of P-glycoprotein activity using Hoechst 33342.
AID1426805	Inhibition of full length recombinant human N-terminal His8-tagged Cyclophilin A (1 to 169 residues) expressed in Escherichia coli BL21(DE3) using Suc-Ala-Ala-Pro-Phe-para-nitroanilide as substrate after 5 mins by spectrophotometric method	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.
AID1271125	Binding affinity to Cyclophilin A (unknown origin) by surface plasmon resonance analysis	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID1224300	Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as dead undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 14.7%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1756285	Neuroprotective activity against salsolinol-induced neurotoxicity in human SH-SY5Y cells assessed as cell viability at 0.5 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis (Rvb = 70.49 +/-0.51%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1330996	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as inhibition of recombinant human His6-tagged calcineurin alpha phosphatase actvity using RII phosphopeptide as substrate by measuring amou	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID680138	TP_TRANSPORTER: inhibition of Calcein-AM efflux (Calcein-AM: 0.25 uM) in CEM/VLB100 cells	2000	Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13	Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.
AID596406	Immunosuppressive activity in F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as increase of skin graft survival time at 1 mg/kg, ip	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID648448	Inhibition of CD4 expression in human CD4+ T cells	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID1140177	Increase in doxorubicin uptake in P-gp-deficient human Me30966 cells at 5 uM after 3 hrs by flow cytometric analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID678717	Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1657640	Immunosuppressive activity in BALB/c mouse T cells assessed as reduction in ConA-induced cell proliferation	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Resorcylic Acid Lactones from an
AID648432	Immunosuppressant activity in human PBMC assessed as reduction in Con A-induced extracellular IL4 level at 90 uM after 72 hrs by ELISA relative to untreated control	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID1308443	Passive membrane permeability by PAMPA method	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Passive Membrane Permeability of Macrocycles Can Be Controlled by Exocyclic Amide Bonds.
AID669781	Inhibition of human recombinant MDR1 expressed in mouse L5178Y cells assessed as inhibition of rhodamine-123 efflux at 10'-4 M preincubated for 10 mins measured after 20 mins by FACS analysis	2012	ACS medicinal chemistry letters, Mar-08, Volume: 3, Issue:3	Ligand Promiscuity between the Efflux Pumps Human P-Glycoprotein and S. aureus NorA.
AID1303196	Inhibition of ABCB1 in human A2780/ADR cells incubated for 30 mins measured up to 3600 secs with time intervals of 60 secs by calcein accumulation assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID711678	Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin uptake at 5 uM after 8 hrs by flow cytometry analysis	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux.
AID524792	Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID598252	Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 at 0.1 mM after 20 mins by FACS analysis relative to 5 mM sodium orthovanadate	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID1271161	Cytotoxicity against HCV infected human Huh7.5 cells assessed as cell death by MTT assay in presence of IFN-alpha	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID358658	Modulation of P-gp in human CAKI1 cells assessed as increase in DINIB-induced cytotoxicity at 0.4 to 6.3 ug/mL	2001	Journal of natural products, Dec, Volume: 64, Issue:12	Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
AID680764	TP_TRANSPORTER: inhibition of E1S uptake (E1S: 0.004 uM, CsA: 10 uM) in Xenopus laevis oocytes	2003	The Journal of pharmacy and pharmacology, Jul, Volume: 55, Issue:7	Contribution of organic anion transporting polypeptide OATP-C to hepatic elimination of the opioid pentapeptide analogue [D-Ala2, D-Leu5]-enkephalin.
AID558941	Antiviral activity against West Nile virus infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1331000	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant in presence of 20-fold excess of (3S,6S,9S,15S,18S,21S,24S,27S,30R,33S)-15-ethyl-18-((1R,2R,E)-1-hydroxy-2-met	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID496010	Cytotoxicity against human Jurkat cells at 0.416 uM after 18 hrs	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID142318	In vitro inhibitory activity against murine antibody response to T-cell independent B-cell antigen TNP-LPS (type I)	1998	Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18	Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations.
AID416849	Antifungal activity against Trichophyton mentagrophytes DUMC112.02 by CLSI protocol	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID1756318	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 0.05 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID135186	Inhibition of paw edema formation in mouse after an ip dose of 5 mg/kg; Thickness of paw = 2.42+/-0.12 mm	1997	Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13	A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1414439	Inhibition of P-gp in human LCC6MDR cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring fold reduction in paclitaxel IC50 at 1 uM after 5 days by MTS assay relative to paclitaxel alone	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with "Click Chemistry".
AID648436	Inhibition of ConA-induced phospho-JAK1 expression in human PBMC at 90 uM after 72 hrs by flow cytometry	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID210937	Compound tested for inhibition of concanavalin A stimulated thymocytes in Tolypocladium inflatum gams	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Synthesis, conformation, and immunosuppressive activity of a conformationally restricted cyclosporine lactam analogue.
AID1293008	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M17 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1868238	Cytotoxicity against HUVEC assessed as reduction in cell viability at 10 uM incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay
AID470250	Inhibition of 0.2 ug/ml PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake at 5 uM after 3 days by scintillation counting	2009	Journal of natural products, Sep, Volume: 72, Issue:9	Oxygenated lignans from the fruits of Schisandra arisanensis.
AID54724	In vitro binding affinity against cyclophilin A by ELISA	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID1224295	Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as live undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 23.4%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1303209	Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID496032	Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 3 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID13302	Dissociation constant against binding to human cyclophilin A	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Design of a Gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: new insights for the development of novel anti-HIV-1 drugs.
AID1293019	Clearance in healthy subject (8 subjects) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1289174	Ratio of clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID247665	Inhibitory activity against KB/MDR cell line after 72 hr of drug exposure	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID581947	Antiviral activity against Vaccinia virus infected in human embryonic lung cells assessed as reduction in viral yield measured after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID457181	Permeability by PAMPA assay	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm.
AID1289117	Oral bioavailability in blood of healthy human subjects (8 subjects) at 10 mg/kg measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID399512	Immunosuppressive activity in BALB/c mouse splenic B lymphocytes assessed as inhibition of LPS-induced cell proliferation after 72 hrs by MTT assay	2004	Journal of natural products, Jan, Volume: 67, Issue:1	Immunomodulatory constituents from an Ascomycete, Chaetomium seminudum.
AID1362388	Unbound fraction in cell culture medium/buffer dialysis at 2 uM at pH 7.4 by LC/MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
AID54923	Inhibition of human cytochrome P450 3A4	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID150751	Inhibition of P-glycoprotein using ATPase in MDR1 membranes	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID581766	Antiproliferative activity against CD4+ human PBMC assessed as inhibition of [3H]thymidine incorporation at 0.83 uM after 18 hrs	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID573106	Cytotoxicity against human Huh-9-13 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID396925	Immunosuppressive activity in human lymphocytes by mixed lymphocyte reaction assay
AID558954	Cytotoxicity against african green monkey Vero cells at =< 10 uM after 48 hrs by MTT assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1224297	Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as dead divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 14.7%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1708432	Inhibition of ABCB1 (unknown origin) expressed in human A2780 ADR cells assessed as reduction in calcein AM efflux preincubated for 30 mins followed by calcein AM addition and measured at 60 secs interval for 1 hr by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
AID596405	Toxicity in ip dosed F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as concentration required for cause death	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID699543	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID19254	Partition coefficient of compound was measured in heptane/water system	1993	Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24	Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID330505	Apparent permeability from apical to basolateral side of human Caco-2 cell membrane	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
AID685503	HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID581943	Antiviral activity against VZV OKA infected in human embryonic lung cells assessed as inhibition of	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1364834	Inhibition of mTOR signaling pathway in (unknown origin) in sub-genomic replicon 2A cells assessed as reduction in phosphorylated rps6 protein levels up to 400 nM after 72 hrs by Western blot analysis	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
AID1639216	Cytotoxicity against BALB/c mouse lymph node cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Phloroglucinols with Immunosuppressive Activities from the Fruits of Eucalyptus globulus.
AID1289179	Ratio of volume of distribution at steady state in blood to plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1503633	Inhibition of TSPO in mouse HT22 cells assessed as recovery of ATP production at 5 uM preincubated for 10 mins followed by amyloid beta (1 to 42) stimulation and measured after 7 hrs by luciferase based assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
AID324582	Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID555954	Antiviral activity against BILN 2061-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID573109	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-9-13 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1300184	Effect on mouse brain cortical mitochondrial swelling at 5 uM incubated for 5 mins by spectrophotometric analysis	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Aβ-Mediated Mitochondrial Dysfunction.
AID470251	Inhibition of 5 ug/ml PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake at 5 uM after 3 days by scintillation counting	2009	Journal of natural products, Sep, Volume: 72, Issue:9	Oxygenated lignans from the fruits of Schisandra arisanensis.
AID1895170	Clearance in ICR mouse at 20 mg/kg, po measured after 0.25 to 24 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID95464	Immunosuppressive activity was measured by inhibition of the IL-2 production in Jurkat cells.	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs.
AID496022	Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 5 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID581923	Cytotoxicity against MDCK cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1289176	Ratio of MRT in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1403366	Inhibition of amyloid beta (1 to 42)-induced mPTP opening in mouse HT22 cells assessed as reduction in mitochondrial membrane potential loss by measuring green to red fluorescence ratio at 5 uM preincubated for 10 mins followed by amyloid beta (1 to 42) a	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease.
AID157232	The compound was tested for inhibition of Peptidyl-propyl isomerase (PPIase).	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	Cyclosporin analogs modified in the 3,7,8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive.
AID364884	Inhibition of P-gp in human adriamycin-resistant A2780 cells by Hoechst 33342 assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID1756333	Inhibition of salsolinol-induced mitochondrial depolarization in human SH-SY5Y cells assessed as recovery of mitochondrial membrane potential measured after 24 hrs by JC-1 staining based flow cytometry	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID681580	TP_TRANSPORTER: inhibition of JC-1 efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID711674	Toxicity in adriamycin-resistant human A2780 cells at 5 uM after 1 hr by CCK-8 assay	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux.
AID1293005	Tmax in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po administered through capsule by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID358646	Modulation of P-gp in human HCT15 cells assessed as increase in DINIB-induced cytotoxicity at 0.4 to 6.3 ug/mL	2001	Journal of natural products, Dec, Volume: 64, Issue:12	Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
AID1166177	Reduction in concanavalin A-induced IL2 production in Balb/c mouse at 3 mg/kg, po dosed 2 hrs before concanavalin A challenge by ELISA method	2015	Journal of medicinal chemistry, Jan-08, Volume: 58, Issue:1	Optimized protein kinase Cθ (PKCθ) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.
AID714414	Cytotoxicity against human MDA435/LCC6MDR cells expressing MDR after 72 hrs	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID1292981	Mean residence time in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1292988	Mean absorption time in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID150752	Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1289121	Volume of distribution at steady state in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1756330	Inhibition of salsolinol-induced apoptosis in human SH-SY5Y cells assessed as reduction in caspase 3/7 activity at 0.05 to 0.5 uM incubated for 24 hrs using Ac-DEVD-AMC as substrate by fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID481442	Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1771417	Anti-aplastic anaemia in immune-mediated bone marrow failure BALB/c mouse model assessed as prevention of food intake decrease at 10 mg/kg, po administered for 14 days
AID185524	Mean survival time of rats after skin allograft (oral administration) at 1 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID161616	Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 25 mg/kg dose (for IL-8)	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
AID1289171	Ratio of volume of distribution at steady state in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID679096	TP_TRANSPORTER: transepithelial transport of Cyclosporin at a concentration of 0.1 uM in MDR1-expressing MDCK cells	2003	Pharmaceutical research, Aug, Volume: 20, Issue:8	Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID445148	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
AID1214583	Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux at 50 uM	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1289131	AUC in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1603083	Anti-inflammatory activity in dinitrofluorobenzene-induced Balb/c mouse delayed-type hypersensitivity model assessed as auricular swelling at 100 mg/kg, po administered twice per day prior to and during dinitrofluorobenzene challenge (Rvb = 96.9 +/- 8.39%	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
AID1603085	Anti-inflammatory activity in dinitrofluorobenzene-induced Balb/c mouse delayed-type hypersensitivity model assessed as thymus index at 100 mg/kg, po administered twice per day prior to and during dinitrofluorobenzene challenge (Rvb = 20.9 +/- 4.4 No_unit	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
AID386358	Inhibition of cross-linking of human Pgp TM3T199R/TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot	2007	The Journal of biological chemistry, Nov-02, Volume: 282, Issue:44	Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
AID496024	Inhibition of human MDR1-mediated permeability from apical to basolateral side of transfected MDCK2 cells at 3 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID242724	In vitro inhibitory activity against recombinant p56 lck tyrosine kinase expressed as a His-tagged protein in insect cells'' NA denotes not active	2004	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 14, Issue:24	Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
AID1292976	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID588981	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OATP1B1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID394930	Effect on cancavalin-A-induced proliferation in mouse splenocytes at 0.1 ug/ml assessed as proliferation rate by MTT assay	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID90144	Potency relative to progesterone in reducing the difference in reversing of [3H]VBL accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID496030	Inhibition of human MDR1-mediated permeability in transfected MDCK2 cells assessed as efflux ratio of permeability form apical to basolateral over basolateral to apical side at 5 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1292991	Fast half life in pre-kidney transplant end stage renal disease patient (8 patients) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1381513	Inhibition of allograft rejection in Balb/c mouse heterotopic cardiac transplantation model using C57BL/6 as cardiac donor assessed as long-term graft survival rate by measuring cardiac allograft function by daily palpitation at 40 mg/kg administered via	2018	Journal of medicinal chemistry, 08-09, Volume: 61, Issue:15	Discovery of a Potent, Orally Bioavailable PI4KIIIβ Inhibitor (UCB9608) Able To Significantly Prolong Allogeneic Organ Engraftment in Vivo.
AID140315	Compound was tested for the immunomodulatory activity in vitro expressed as stimulation index by lymphocyte transformation test at 1.0 ug/mL	1998	Bioorganic & medicinal chemistry letters, Feb-17, Volume: 8, Issue:4	Immunosuppressant activity in human beta-casein fragment analogs.
AID161464	Bronchoalveolar lavages was collected after 48 hr (for eosinophil influx, eos) at 25 mg/kg dose	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
AID1293030	Drug metabolism in cadaveric renal transplant recipient (21 recipients) blood assessed as ratio of metabolite M1 AUCt at steady state to parent compound AUCt at steady state at 8 mg/kg/day, po	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID679985	TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicle from MRP1-expressing HeLa cells	1994	The Journal of biological chemistry, Nov-11, Volume: 269, Issue:45	The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.
AID140793	Compound was tested for Cytotoxic activity by lymphocyte viability assay.	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Immunosuppressive cyclolignans.
AID247607	Inhibitory activity against KB cell line after 72 h of drug exposure	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID581921	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID558953	Antiviral activity against West Nile virus infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1591786	Selectivity index, ratio of CC50 for BALB/c mouse splenocytes to IC50 for immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents.
AID1206430	Inhibition of ABCB1 in human A2780adr cells at 10 uM pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
AID105436	Growth inhibitory activity on MDA-435/LCC6-MDRI (Pgp-negative) human breast cancer cells.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1292996	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M18 at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID679926	TP_TRANSPORTER: inhibition of Rhodamine 123 transepithelial transport (basal to apical)(R123: 13 uM, CsA: 5 uM) in HCT8-cells	1998	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 286, Issue:3	Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
AID248381	Compound was tested for the inhibition of Trypanosoma cruzi epimastigote growth after 72 hours of treatment	2004	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18	In vitro anti-parasitic activity of Cyclosporin A analogs on Trypanosoma cruzi.
AID581926	Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1142396	Activity at P-gp in hCMEC/D3 cells at 0.1 to 50 uM after 15 mins by calcein-AM assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Shuttle-cargo fusion molecules of transport peptides and the hD2/3 receptor antagonist fallypride: a feasible approach to preserve ligand-receptor binding?
AID1289118	Clearance in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1756320	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 5 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1289129	Volume of distribution at steady state in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID376750	Antiproliferative activity against human PBMC	2005	Journal of natural products, Jan, Volume: 68, Issue:1	Furocoumarin glycosides from the leaves of Ficus ruficaulis Merr. var. antaoensis.
AID1675572	Selectivity index, ratio of CC50 for cytotoxicity against BALB/c mouse T cell to IC50 for antiproliferative activity against Con A-induced BALB/c mouse T cell	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents.
AID681483	TP_TRANSPORTER: Western in vivo, intestine of SD rat	1996	The American journal of physiology, May, Volume: 270, Issue:5 Pt 2	Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.
AID105424	Effect on reversal of [3H]- VBL accumulation in MDA-435/LCC6 (Pgp-negative) cells.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID330506	Ratio of permeability from apical to basolateral over basolateral to apical side of human Caco-2 cell membrane	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
AID161622	Resistance evaluated in an ascaris-induced nonhuman primate model of asthma after 10 min at 25 mg/kg dose	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
AID432793	Effect on posaconazole-mediated antifungal activity against Candida kefyr ATCC 46764 at 200 ng/ml by MVista microbiological assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID1771416	Anti-aplastic anaemia in immune-mediated bone marrow failure BALB/c mouse model assessed as slowing down the weight loss at 10 mg/kg, po administered for 14 days
AID407205	Inhibition of P-glycoprotein-mediated [3H]vinblastine transport in human Caco-2 cells	2008	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13	Effect of some P-glycoprotein modulators on Rhodamine-123 absorption in guinea-pig ileum.
AID1296457	Inhibition of Cyclophilin D (unknown origin) activity preincubated for 15 mins followed Suc-AAPF-pNA substrate addition by chymotrypsin coupled based spectrophotometry assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1533107	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 0.19 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID581940	Antiviral activity against Herpes simplex virus 2 G infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID364887	Inhibition of ABCG2 in human mitoxantrone-resistant MCF7 cells by Hoechst 33342 assay	2008	Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17	Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2).
AID1895163	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco2 cells measured at 0.5 to 2 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1322434	Inhibition of P-gp in doxorubicin-resistant human K562R cells assessed as rhodamine influx by measuring mean fluorescence intensity at 10 uM incubated for 20 mins by flow cytometry (Rvb = 1.8 No_unit)	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.
AID94960	In vitro inhibitory activity against Jurkat cell proliferation	1998	Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18	Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1272185	Inhibition of PI3K-gamma in mouse lymph node cells assessed as inhibition of ConA-stimulated T cell proliferation	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	(E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: Design, synthesis, molecular docking and biological evaluation.
AID1293023	Ratio of drug level in erythrocytes to plasma in pre-kidney transplant end stage renal disease patient (8 patients)	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID528326	Cytotoxicity against human HuH7 cells assessed as release of lactate dehydrogenase	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID1895160	Permeability across apical to basal side in human Caco-2 cells assessed as drug recovery measured at 0.5 to 2 hrs by LC-MS analysis relative to control	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID624640	Drug glucuronidation reaction catalyzed by human recombinant UGT2B7	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID679353	TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 1 uM, CsA:10uM) in membrane vesicles from MRP7-expressing HEK293 cells	2003	Molecular pharmacology, Feb, Volume: 63, Issue:2	Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10).
AID648439	Inhibition of JAK1-mediated GATA3 phosphorylation in PMA-stimulated human PBMC at 90 uM after 30 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID310121	Inhibition of P-glycoprotein expressed in MDCK-MDR1 cells by calcein AM assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	New functional assay of P-glycoprotein activity using Hoechst 33342.
AID528323	Binding affinity to cyclophilin B by ELISA	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID252957	Ratio of concentration that reduced cell viability to inhibitory concentration for ConA-induced T cell proliferation	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID1594833	Immunosuppressant activity in human T lymphocytes assessed as inhibition of anti-human CD3 and anti-human CD28 monoclonal antibody-induced T lymphocyte proliferation incubated for 72 hrs by FACS analysis	2019	Journal of natural products, 06-28, Volume: 82, Issue:6	Sesquiterpene Lactones from Artemisia argyi: Absolute Configuration and Immunosuppressant Activity.
AID321883	Ratio of apparent permeability from apical to basolateral over basolateral to apical side of human Caco-2 cell membrane	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
AID524795	Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID581928	Antiviral activity against VSV infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID102700	In vitro efficacy on humoral immune response by Mishell-Dutton assay (MD).	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.
AID386357	Inhibition of cross-linking of human Pgp TM1 L65R/TM6 L339C/TM7 F728 mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot	2007	The Journal of biological chemistry, Nov-02, Volume: 282, Issue:44	Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
AID1605063	Inhibition of Porcine cardiac microsomes SERCA preincubated for 10 mins followed by addition of ATP and measured after 10 mins by colorimetric method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID95450	Inhibition of production of IL-2 secretion in Jurkat cells	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID1065395	Oral bioavailability in patient transplanted with kidney and bone marrow	2014	Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2	Macrocyclic drugs and clinical candidates: what can medicinal chemists learn from their properties?
AID1228909	Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vincristine resistance measured as cell survival after 5 days by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID770486	Inhibition of calcineurin phosphatase activity (unknown origin) assessed as R2 phosphopeptide dephosphorylation after 30 mins by malachite green staining assay in presence of calmodulin and CypA	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147.
AID365463	Inhibition of human MRP1 in human 2008 cells	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins.
AID1209761	Inhibition of ABCB11-mediated taurocholate total uptake in sandwich-cultured human adult hepatocytes at 40 uM	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID1289126	Clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1293031	Ratio of drug level in blood to plasma in patient with normal hematocrit level	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1221961	Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1142023	Reversal of Pgp-1-mediated multidrug resistance in human HEK293 cells overexpressing human ABCB1 assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to pac	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.
AID1322437	Inhibition of P-gp in doxorubicin-resistant human K562R cells assessed as rhodamine efflux by measuring ratio of mean fluorescence intensity in presence and absence of compound at 10 uM incubated for 1 hr by flow cytometry	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.
AID196256	Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 10 mg/kg	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID581925	Antiviral activity against Parainfluenza 3 infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID680769	TP_TRANSPORTER: inhibition of Cerivastatin uptake in OATP2-expressing MDCKII cells	2003	The Journal of pharmacology and experimental therapeutics, Feb, Volume: 304, Issue:2	Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.
AID408608	Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.01 uM	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID1895172	Half life in ICR mouse at 20 mg/kg, po measured after 0.25 to 24 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID558940	Cytotoxicity against human Huh7.5 cells assessed as cell viability at =< 40 uM after 48 hrs by MTT assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID581770	Cytotoxicity against human PBMC at 0.83 uM by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID679342	TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse	1995	The Journal of clinical investigation, Oct, Volume: 96, Issue:4	Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
AID1756345	Inhibition of glutamate-induced apoptosis in human SH-SY5Y cells assessed as caspase 3/7 activity at 0.5 uM incubated for 1 hr using Ac-DEVD-AMC as substrate by fluorescence analysis (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1209610	Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1474100	Ratio of drug concentration at steady state in human at 20 to 600 mg/kg, po after 24 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID105431	Potency relative to progesterone in reversing of DOX accumulation in MDA-435/LCC6 (Pgp-negative) cells.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1586220	Cytotoxicity against BALB/c mouse splenocytes after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Design and Synthesis of Marine Phidianidine Derivatives as Potential Immunosuppressive Agents.
AID1708435	Inhibition of ABCC1 (unknown origin) expressed in human NCI-H69AR cells assessed as reduction in calcein AM efflux at 10 uM preincubated for 30 mins followed by calcein AM addition and measured at 60 secs interval for 1 hr by fluorescence assay relative t	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
AID680065	TP_TRANSPORTER: inhibition of Daunomycin efflux (Daunomycin: 10 uM, CyclosporinA: 2 uM) in K562/R7 cells	2003	Bioorganic & medicinal chemistry, Nov-17, Volume: 11, Issue:23	Modified jatrophane diterpenes as modulators of multidrug resistance from Euphorbia dendroides L.
AID497687	Binding affinity to human cyclophilin 18 assessed as reduction in calcineurin activity	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Augmented photoswitching modulates immune signaling.
AID182934	In vivo immunosuppressive effect of compound was determined on host versus graft reaction (HvGR) using popliteal lymph node gain assay in rat	1998	Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1	Synthesis and biological evaluation of 2,2-disubstituted 2-aminoethanols: analogues of FTY720.
AID1209609	Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1756325	Inhibition of Salsolinol-induced oxidative stress in human SH-SY5Y cells assessed as superoxide radical formation at 0.05 to 0.5 uM measured after 24 hrs by DHE staining based fluorescence spectrophotometry (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1140181	Increase in doxorubicin retention in wild type human Saos2 cells at 5 uM after 2 hrs by flow cytometric analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID680741	TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.5 uM, CsA: 10uM) in OATP-C-expressing HeLa cells	2003	The Journal of pharmacology and experimental therapeutics, Jan, Volume: 304, Issue:1	Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation.
AID1289115	AUC in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1265701	Inhibition of CypA (unknown origin) assessed as peptidyl-prolyl cis-trans isomerase activity using N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide as substrate by spectrophotometry	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1370781	Cytotoxicity against lymphocytes (unknown origin) assessed as decrease in cell viability	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Spiroorthoester group-containing pregnane glycosides from the root barks of Periploca chrysantha and their inhibitory activities against the proliferation of B and T lymphocytes.
AID416864	Inhibition of human MDR1-dependent accumulation of calcein-AM expressed in MDCK2 cells	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro.
AID596407	Immunosuppressive activity in F344 rat lateral thorax transplanted with dorsal skin of LEW rat assessed as increase of skin graft survival time at 3 mg/kg, ip	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID1289116	AUC in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID428052	Cytotoxicity against rat H42E cells assessed as release of alpha-glutathione S transferase	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID594599	Binding affinity to Cyclophilin A	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro.
AID1443992	Total Cmax in human administered as single dose	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID581779	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T-helper cells at 10 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID598251	Inhibition of human ABCB1-mediated rhodamine 123 efflux in mouse L5178 cells expressing human MDR1 after 20 mins by FACS analysis	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields.
AID681143	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells	2002	Molecular pharmacology, May, Volume: 61, Issue:5	Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein.
AID1364651	Cytotoxic activity against BALB/c mouse T-lymphocytes assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Absolute Configuration of Periplosides C and F and Isolation of Minor Spiro-orthoester Group-Containing Pregnane-type Steroidal Glycosides from Periploca sepium and Their T-Lymphocyte Proliferation Inhibitory Activities.
AID558957	Antiviral activity against Dengue virus 1 infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after =< 6 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID209953	Immunosuppressive activity was evaluated by the inhibition of human T-lymphocyte proliferation	1998	Bioorganic & medicinal chemistry letters, Jan-20, Volume: 8, Issue:2	Synthesis and immunosuppressive activity of ruthenium complexes.
AID1289154	Elimination half life in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID394913	Effect on humoral immune response in sheep red blood cells-immunized CBA mouse spleen assessed as number of antibody forming unit per 10'6 viable cells at 10 ug, ip by local hemolysis assay	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1625586	Inhibition of ABCC1 in human H69AR cells preincubated for 30 mins before calcein AM addition by calcein AM assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID90145	To estimate the extent of resistance conferred by Pgp, the ratio of IC50 in MDA-435/LCC6-MDR1 and MDA-435/LCC6 cells (relative resistance of Pgp-positive cells) was used	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID680496	TP_TRANSPORTER: inhibition of IAAP photoaffinity labelling (IAAP: 0.02 uM, CsA: 100-fold molar excess) in plasma membranes from CEM/VLB1.0 cells	1997	Biochemical pharmacology, Jan-10, Volume: 53, Issue:1	Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.
AID72182	Inhibitory activity against Human formylpeptide receptor (FPR) of human leukemia HL-60 cells	2002	Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21	Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor.
AID1675570	Cytotoxicity against BALB/c mouse T cell assessed as reduction in cell viability after 48 hrs by CCK8 assay	2020	Journal of natural products, 09-25, Volume: 83, Issue:9	Synthesis and Biological Evaluation of Celastrol Derivatives as Potential Immunosuppressive Agents.
AID683399	Inhibition of P-gp over expressed in human multidrug-resistant KBVIN cells assessed as intracellular accumulation of doxorubicin at 10uM after 3 hrs by fluorescence microplate reader analysis relative to control	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Antitumor agents. 293. Nontoxic dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate (DDB) analogues chemosensitize multidrug-resistant cancer cells to clinical anticancer drugs.
AID161615	Bronchoalveolar lavages was collected after 6 hr in an ascaris-induced nonhuman primate model of asthma at 25 mg/kg dose (for IL-5)	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
AID1296459	Binding affinity to Cyclophilin D (unknown origin) by isothermal titration calorimetry	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis.
AID1680747	Induction of PTK2 degradation in human A549 cells at 10 uM incubated for 18 hrs by protein capillary electrophoresis method	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions.
AID596404	Immunosuppressive activity in BALB/c/C57BL/6 mouse T cells assessed as inhibition of alloantigen-induced cell proliferation after 96 hrs by measuring [3H]thymidine uptake by mixed lymphocyte reaction assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
AID555953	Antiviral activity against R479-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID409956	Inhibition of mouse brain MAOB	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID679097	TP_TRANSPORTER: transepithelial transport of Cyclosporin at a concentration of 0.1 uM in Caco-2 cells	2003	Pharmaceutical research, Aug, Volume: 20, Issue:8	Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium.
AID482109	Inhibition of P-gp-mediated paclitaxel-resistance in P-glycoprotein-expressing human LCC-6 cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 1 uM after 5 days by MTS assay relative to control	2010	Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14	Design and syntheses of permethyl ningalin B analogues: potent multidrug resistance (MDR) reversal agents of cancer cells.
AID95298	The compound was tested in vitro for inhibition of IL-2 release stimulated with PMA/ionomycin by Jurkat cells.	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	Cyclosporin analogs modified in the 3,7,8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive.
AID135324	Evaluated for the delayed type hypersensitivity (DTH) response to methylated BSA (mBSA) in sensitive mice after peroral administration of 50 mg/kg	1990	Journal of medicinal chemistry, Aug, Volume: 33, Issue:8	Methylsulfamic acid esters. A new chemical class of oral antiarthritic agents.
AID105434	Ability of compound to inhibit MDA-435/LCC6-MDR cell growth relative to progesterone.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1293003	Cmax in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po administered through capsule by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID728305	Antioxidant activity in rat brain mitochondria assessed as inhibition of Ca2+/phosphate induced mitochondrial swelling by spectrophotometry	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity.
AID1362218	Inhibition of Inhibition of F1F0-ATP synthase subunit C in SV129 mouse liver mitochondria assessed as reduction of Ca2+ induced mPTP opening by measuring reduction in mitochondrial swelling at 1 uM measured after 10 mins relative to control
AID681356	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) in MDR1-expressing MDCK cells	2002	Pharmaceutical research, Jun, Volume: 19, Issue:6	Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
AID1221963	Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1508554	Inhibition of ATP synthase in mouse HT22 cells assessed as ATP production at 5 uM after 7 hrs by luciferase based assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity.
AID1533109	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 0.048 uM preincubated for 1 hr followed	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1289156	Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 1.8 +/- 0.3 hrs during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1403367	Toxicity in mouse HT22 cells assessed as ATP production level at 5 uM after 7 hrs by luciferase based assay relative to control	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease.
AID699544	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID324576	Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID648435	Inhibition of Con-A-induced phospho-STAT6 expression in human PBMC at 90 uM after 72 hrs by flow cytometry (Rvb = 10.52+/-1.9%)	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID432796	Antifungal activity against Candida kefyr ATCC 46764 at 1.5 ug/ml after 14 to 18 hrs	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID678722	Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1370784	Inhibition of ConA-induced T lymphocytes (unknown origin) proliferation	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Spiroorthoester group-containing pregnane glycosides from the root barks of Periploca chrysantha and their inhibitory activities against the proliferation of B and T lymphocytes.
AID90143	Potency relative to progesterone in reducing the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1508555	Cytotoxicity against mouse HT22 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity.
AID1209760	Inhibition of ABCB11-mediated taurocholate efflux in sandwich-cultured human adult hepatocytes at 40 uM	2013	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 41, Issue:2	Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.
AID386356	Inhibition of cross-linking of human Pgp TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot	2007	The Journal of biological chemistry, Nov-02, Volume: 282, Issue:44	Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
AID573107	Cytotoxicity against human Huh-Mono cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1327027	Inhibition of ABCC2 (unknown origin) expressed in MDCK2 cells assessed as inhibition of calcein-AM efflux at 25 uM measured after 30 mins in presence of ABCB1 inhibitor GF120918 and ABCC1 inhibitor MK-571 by flow cytometry	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.
AID679891	TP_TRANSPORTER: inhibition of imatinib mesilate uptake (imatinib mesilate: 10 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells	2003	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 307, Issue:2	Interaction of imatinib mesilate with human P-glycoprotein.
AID1766763	Inhibition of sulfasalazine-stimulated MRP2 ATPase activity (unknown origin) in presence of GSH	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID1062341	Cytotoxicity against human MDA435/LCC6MDR cells assessed as growth inhibition after 3 days by MTS assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
AID679746	TP_TRANSPORTER: increase in Colchicine intracellular accumulation (Colchicine: 0.0175 uM, CsA: 50 uM) in CEM/VBL600 cells	1999	Pflugers Archiv : European journal of physiology, Apr, Volume: 437, Issue:5	P-glycoprotein inhibition by glibenclamide and related compounds.
AID1289150	Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 8.4 +/- 0.9 hrs during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID102701	In vitro efficacy to suppress lymphocyte proliferation as measured by the incorporation of a labeled precursor ([3H]- thymidine) into DNA in Mixed Lymphocyte reaction (MLR).	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.
AID395103	Inhibition of P-glycoprotein-mediated multidrug resistance in adriamycin-resistant human A2780/ADR cells by calcein AM assay	2009	Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6	Synthesis and biological evaluation of a small molecule library of 3rd generation multidrug resistance modulators.
AID1895171	Apparent volume of distribution in ICR mouse at 20 mg/kg, po measured after 0.25 to 24 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1289125	AUC in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1426804	Inhibition of Cy5-labeled cyclosporin A binding to full length recombinant human N-terminal His8-tagged Cyclophilin A (1 to 169 residues) expressed in Escherichia coli BL21(DE3) after 2 hrs by TR-FRET assay	2017	Journal of medicinal chemistry, 02-09, Volume: 60, Issue:3	Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A.
AID1503634	Cytotoxicity against mouse HT22 cells as cell viability at 5 uM after 24 hrs by MTT assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
AID581948	Antiviral activity against HPV-16 infected in Caski cells assessed as inhibition of viral replication after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID393837	Inhibition of IL2-induced proliferation of human T cells assessed as [3H]thymidine incorporation after 72 hrs by scintillation counting	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID444057	Fraction escaping hepatic elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1525918	Cytotoxicity against human L929 cells assessed as reduction in cell viability	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID1447886	Inhibition of ABCC1 in human H69AR cells assessed as reduction in calcein AM levels preincubated for 30 mins followed by calcein AM addition measured immediately at 60 sec time interval for 60 mins by fluorescence assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1292975	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M1 at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID558959	Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after => 20 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1895166	Oral bioavailability in Wistar-Han rat relative to control	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID54725	In vitro binding affinity against cyclophilin A by rotamase assay	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID1676557	Inhibition of calcineurin phosphatase activity in alpha-TC2 cell extract	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Antifungal polybrominated proxyphylline derivative induces Candida albicans calcineurin stress response in Galleria mellonella.
AID1218864	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate	2012	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8	The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID386359	Inhibition of cross-linking of human Pgp TM5 I306R/TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot	2007	The Journal of biological chemistry, Nov-02, Volume: 282, Issue:44	Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
AID150364	MDR-reversal property tested in vitro on P388/VCR-20 cells, resistance was induced by vincristine	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID1209616	Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated at 0.25 to 10 uM for 15 mins before substrate addition by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID680113	TP_TRANSPORTER: transepithelial transport of propranolol in Caco2 cells	2004	Journal of controlled release : official journal of the Controlled Release Society, Mar-24, Volume: 95, Issue:3	The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability.
AID55740	In vitro inhibitory activity against human dihydroorotate dehydrogenase (DHODH)	1998	Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18	Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations.
AID679460	TP_TRANSPORTER: transcellular transport in MDR1-expressing MDCKII cells	2007	Neuropharmacology, Feb, Volume: 52, Issue:2	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID581937	Antiviral activity against Herpes simplex virus 1 KOS infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1221958	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1769570	Inhibition of CNB (unknown origin) using p-NPP as substrate preincubated for 10 mins followed by substrate addition by spectrophotometry analysis	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Efophylins A and B, Two
AID624622	Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID715592	Cardioprotective activity in New Zealand White rabbit ischemia/reperfusion model assessed as reduction of infarct to risk area ratio at 10 mg/kg administered bolus 10 mins before coronary occlusion	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	Discovery of 6-[4-(6-nitroxyhexanoyl)piperazin-1-yl)]-9H-purine, as pharmacological post-conditioning agent.
AID558955	Antiviral activity against Dengue virus 1 infected in african green monkey Vero cells assessed as decrease in viral RNA synthesis after 24 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID681557	TP_TRANSPORTER: transepithelial transport of SN-38(Carboxylate form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells	2003	Pharmaceutical research, Jun, Volume: 20, Issue:6	Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
AID1756319	Cytotoxicity against human SH-SY5Y cells assessed as cell viability at 0.5 uM measured after 24 hrs by calcein-AM staining based fluorescence analysis	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1322436	Inhibition of P-gp in doxorubicin-resistant human K562R cells assessed as rhodamine efflux by measuring mean fluorescence intensity at 10 uM incubated for 1 hr by flow cytometry (Rvb = 0.47 No_unit)	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.
AID1226784	Cmax in Wistar-Han rat at 10 mg/kg, po after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID1327024	Inhibition of ABCC2 (unknown origin) expressed in human Flp-InTM-293 cells assessed as inhibition of calcein-AM efflux at 25 uM measured after 30 mins in presence of ABCB1 inhibitor GF120918 and ABCC1 inhibitor MK-571 by flow cytometry	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.
AID1224318	Immunosuppressive activity in C57BL/6J mouse KLH-induced delayed-type hypersensitivity model assessed as alleviation of footpad swelling at 16 nmol administered on day 7 and 8 post-sensitization measured on day 9	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1221956	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID567809	Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of anti-CD3/anti-CD28-stimulated cell proliferation after 72 hrs by MTT assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis, biological evaluation of chrysin derivatives as potential immunosuppressive agents.
AID1676555	Inhibition of calcineurin phosphatase activity in human Jurkat cells by Western blot analysis	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Antifungal polybrominated proxyphylline derivative induces Candida albicans calcineurin stress response in Galleria mellonella.
AID496020	Plasma protein binding in human after 30 min by ultrafiltration	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1209456	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID682121	TP_TRANSPORTER: inhibition of BMG uptake in membrane vesicles from MRP2-expressing HEK cells	1999	Hepatology (Baltimore, Md.), Aug, Volume: 30, Issue:2	Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2.
AID711679	Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin-induced cytotoxicity at 5 uM after 1 hr by CCK-8 assay	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux.
AID1224307	Antiinflammatory activity in LLO118 TCR transgenic mouse Th17 cells assessed as inhibition of IL-17 production at 10 to 100 nM for 2 days by flow cytometric analysis	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1199782	Potentiation of doxorubicin-induced cytotoxicity against doxorubicin-resistant human K562/R7 cells assessed as doxorubicin IC50 at 1 uM after 72 hrs by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells.
AID555955	Antiviral activity against VX 950-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1289147	Distribution half life in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID284363	Inhibition of LPS-induced BALB/c mouse B cell proliferation	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Discovery and synthesis of new immunosuppressive alkaloids from the stem of Fissistigma oldhamii (Hemsl.) Merr.
AID1169076	Oral bioavailability in Wistar rat at 10 mg/kg measured over 8 hrs by LC-MS method	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed.
AID1765685	Inhibition of human NFAT-1 in human Jurkat cells assessed as decrease of PMA/ionomycin-induced NFAT dephosphorylation at 15 uM measured after 44 hrs by western blot assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Vomifoliol isolated from mangrove plant Ceriops tagal inhibits the NFAT signaling pathway with CN as the target enzyme in vitro.
AID338965	Inhibition of PHA-stimulated human PBMC proliferation assessed as [3H]thymidine uptake after 3 days by scintillation counting	2002	Journal of natural products, Apr, Volume: 65, Issue:4	Immunomodulatory proanthocyanidins from Ecdysanthera utilis.
AID681385	TP_TRANSPORTER: RT-PCR in HK-2 cell	2002	Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2	Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID695337	Inhibition of human P-gp overexpressed in doxorubicin resistant A2780adr cells at 10 uM preincubated for 30 mins prior to calcein AM addition measured every 60 secs up to 90 mins by calcein AM accumulation assay	2012	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21	4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
AID714200	Inhibition of P-gp-mediated paclitaxel resistance in human LCC6MDR cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 1 uM after 5 days by MTS assay relative to parental cells	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID321879	Inhibition of human Pgp mediated [3H]vinblastine transport in human Caco-2 cells	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
AID588995	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, BSEP	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID50622	In Vitro neurotrophic effect was measured in cultured chick DRG sensory neurons.	1998	Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26	Immunophilins: beyond immunosuppression.
AID458866	Immunosuppressive activity in lymphocytes by mixed lymphocyte reaction assay	2010	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3	Synthesis, immunosuppressive activity and structure-activity relationship study of a new series of 4-N-piperazinyl-thieno[2,3-d]pyrimidine analogues.
AID1508556	Inhibition of mPTP opening in mouse HT22 cells assessed as protection against amyloid beta (1 to 42)-induced toxicity by measuring cell viability at 5 uM preincubated for 10 mins followed by amyloid beta (1 to 42) addition measured after 24 hrs by MTT ass	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity.
AID243422	log (1/Km) value for human liver microsome cytochrome P450 3A4	2005	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18	Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID679128	TP_TRANSPORTER: transcellular transport in MDR1-expressing LLC-PK1 cells	2007	Neuropharmacology, Feb, Volume: 52, Issue:2	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID1289170	Ratio of clearance in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID699542	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1265703	Cytotoxicity against human RD cells after 24 hrs by WST-1 assay	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
AID558944	Antiviral activity against Western equine encephalomyelitis virus infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID580952	Inhibition of Cyclophilin 18 PPIase activity	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands.
AID496779	Inhibition of hexose-6-phosphate dehydrogenase-induced cell differentiation in mouse C2C12 cells assessed as myosin heavy chain fluorescence at 0.1 ug/ml for 3 days	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Carbon metabolism-mediated myogenic differentiation.
AID581945	Antiviral activity against Human cytomegalovirus Davis infected in human embryonic lung cells assessed as reduction in viral yield	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID523610	Antiviral activity against cyclosporine A-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID496160	Inhibition of calcineurin phosphatase activity of CyPA	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1766764	Inhibition of sulfasalazine-stimulated BCRP ATP ase activity (unknown origin)	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID324441	Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1271126	Binding affinity to Cyclophilin B (unknown origin) by surface plasmon resonance analysis	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID481441	Aqueous diffusivity at 37C	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1532162	1,9-decadiene/aqueous buffer solution partition coefficient, log D of the compound in PBS at pH 7.4 by shake flask method	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID481446	Effective permeability across human jejunum	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1874013	Antiviral activity against Hepatitis B virus infected in human HepG2 cells expressing NTCP assessed as inhibition of viral entry by measuring intracellular HBV DNA at 1 uM preincubated with compound for 2 hrs followed by viral infection and measured after	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1140175	Increase in doxorubicin uptake in wild type human Saos2 cells at 5 uM after 3 hrs by flow cytometric analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID1207634	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	2012	Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10	Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1533100	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 25 uM preincubated for 1 hr followed by	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1214607	Inhibition of P-gp in human Caco2 cells assessed as reduction in digoxin efflux	2013	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4	Characterization of efflux transporters involved in distribution and disposition of apixaban.
AID1292986	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1292990	Mean residence time in pre-kidney transplant end stage renal disease patient (8 patients) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1293021	Volume of distribution at steady state in healthy subject (8 subjects) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID681358	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	2000	Drug metabolism and disposition: the biological fate of chemicals, Jun, Volume: 28, Issue:6	Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
AID700073	Immunosuppressant activity in mouse splenocytes by mixed-leukocyte reaction assay	2012	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21	Part II. Development of novel colchicine-derived immunosuppressants with improved pharmacokinetic properties.
AID185388	Mean survival time of rats after skin allograft (intraperitoneal administration) at 1 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID679276	TP_TRANSPORTER: transepithelial transport (apical to basal) of Cyclosporin A at a concentration of 35.7 nM in MDR1-expressing LLC-PK1 cells	2001	Pharmaceutical research, Dec, Volume: 18, Issue:12	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
AID1228907	Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing paclitaxel resistance measured as cell survival after 5 days by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID580955	Inhibition of fluorescein labeled cyclosporin binding to Cyp18 by fluorescence polarization competition assay	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands.
AID226865	Inhibitory concentration against Con A stimulated thymocytes	1986	Journal of medicinal chemistry, Jun, Volume: 29, Issue:6	Synthesis and antimitogenic activities of four analogues of cyclosporin A modified in the 1-position.
AID558948	Antiviral activity against West Nile virus infected in human Huh7.5 cells at 20 uM after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1293009	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M17 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID573105	Cytotoxicity against human HuH6 cells after 3 days by MTT assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID580951	Inhibition of Cyclophilin 40 PPIase activity	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands.
AID1289164	Oral bioavailability in pre-renal transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID307316	Inhibition of Jurkat cell activation assessed as blocking of T-cell antigen receptor-induced IL-2 expression at 10 uM by luciferase assay	2007	Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11	The structure-activity relationship of the series of non-peptide small antagonists for p56lck SH2 domain.
AID1293022	AUC (0 to infinity) in healthy subject (8 subjects) plasma at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID185386	Mean survival time of rats after skin allograft (intraperitoneal administration) at 100 mg/kg; toxic - animals died	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID132693	Inhibitory activity against the production of interleukin 4 (IL-4)	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	Peptidic immunosuppressants from the fungus Trichoderma polysporum.
AID680483	TP_TRANSPORTER: inhibition of Levofloxacin transepithelial transport (basal to apical) (Levofloxacin: 100 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells	1997	The Journal of pharmacology and experimental therapeutics, Aug, Volume: 282, Issue:2	Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
AID1358241	Inhibition of P-gp in human MCF7/ADR cells assessed as assessed as potentiation of doxorubicin-induced antiproliferative activity by measuring doxorubicin antiproliferative activity at 20 uM after 2 days by MTT assay (Rvb = 5.3 +/- 1.1%)	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell.
AID142578	The compound was tested for inhibition of murine splenocyte proliferation by [3H]thymidine incorporation	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Analogues of the marine immunosuppressant microcolin A: preparation and biological activity.
AID1289145	Volume of distribution at steady state in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1362387	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by cell-titer glo assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
AID1289184	Ratio of MRT in blood to plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1330997	Inhibition of recombinant 6His-tagged human calcineurin-alpha expressed in Escherichia coli BL21(DE3/pLysS) assessed as inhibition of calcineurin phosphatase activity by measuring amount of free phosphate at 10 uM preincubated for 20 mins followed by addi	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID1293002	Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po administered through capsule by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID45446	Compound was evaluated for its inhibitory activity in a calcineurin inhibition assay	2003	Journal of medicinal chemistry, Feb-27, Volume: 46, Issue:5	Synthesis and biological evaluation of novel cyclosporin a analogues: potential soft drugs for the treatment of autoimmune diseases.
AID408612	Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.08 uM	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID678796	TP_TRANSPORTER: inhibition of Phalloidin uptake (Phalloidin: 1 uM) in OATP-C-expressing HEK293 cells	2003	Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 368, Issue:5	Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins.
AID185391	Mean survival time of rats after skin allograft (intraperitoneal administration) at 30 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID681666	TP_TRANSPORTER: inhibition of Taurochenodeoxycholate-stimulated ATPase activity (CsA: 30 uM) in membrane vesicles from Bsep-expressing Sf9 cells	2001	Hepatology (Baltimore, Md.), May, Volume: 33, Issue:5	Characterization of the mouse bile salt export pump overexpressed in the baculovirus system.
AID581924	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1322439	Inhibition of P-gp in doxorubicin-resistant human K562R cells assessed as rhodamine efflux by measuring ratio of mean fluorescence intensity in presence and absence of compound at 5 uM incubated for 1 hr by flow cytometry	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.
AID768683	Inhibition of MRP1 (unknown origin) expressed in human 2008 cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID415385	Antiviral activity against SIV in human CEM cells assessed as inhibition of virus-induced cytopathogenicity	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
AID1209457	Unbound Cmax in human plasma	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID555951	Antiviral activity against cyclosporine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID106877	In vitro T-cell immunosuppressive activity in the mouse mixed lymphocyte reaction (MLR)	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Aromatic quinolinecarboxamides as selective, orally active antibody production inhibitors for prevention of acute xenograft rejection.
AID1292985	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1272186	Selectivity index, ratio of CC50 for mouse lymph node cells to IC50 for Inhibition of PI3Kgamma-mediated ConA-stimulated T cell proliferation in mouse lymph node cells	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	(E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: Design, synthesis, molecular docking and biological evaluation.
AID581767	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as IgM level at 10 mg/kg, po administered once daily for 28 days by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID681579	TP_TRANSPORTER: inhibition of Tetramethylrosamine efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID94997	Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 0.1 uM	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.
AID1293035	Clearance in post-renal transplant patient (41 patients) blood at 9 mg/kg/day, iv	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1766766	Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin)	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID678714	Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID624629	Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID154221	Percent of cell viability of P388/VCR-20 murine leukemia cells remaining after inoculation with the modulator alone	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID1895182	Potency index, ratio of cyclosporin O Ki to test compound Ki for binding affinity to CypA (unknown origin)	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID1895162	Permeability across basal to apical side in human Caco-2 cells assessed as drug recovery measured at 0.5 to 2 hrs by LC-MS analysis relative to control	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID678982	TP_TRANSPORTER: inhibition of EGCG in MRP2-expressing MDCKII cells	2003	Biochemical and biophysical research communications, Oct-10, Volume: 310, Issue:1	Involvement of multidrug resistance-associated proteins in regulating cellular levels of (-)-epigallocatechin-3-gallate and its methyl metabolites.
AID1293001	Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po administered through solution by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1327020	Inhibition of human ABCC1 expressed in hamster BHK21 cells assessed as inhibition of calcein-AM efflux at 25 uM measured after 30 mins by flow cytometry	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.
AID105429	Ability of compound to inhibit MDA-435/LCC6 cell growth relative to progesterone.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1873213	Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells mediated pheophorbide A efflux and measured after 90 mins by FACSflow cytometry	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1289141	Oral bioavailability in plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1289128	Volume of distribution in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID681095	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux (R123: 10 uM, CsA: 20 uM) in HL60/Adr cells	2002	International journal of molecular medicine, Nov, Volume: 10, Issue:5	Dehydrothyrsiferol does not modulate multidrug resistance-associated protein 1 resistance: a functional screening system for MRP1 substrates.
AID428060	Immunosuppressive activity in BALB/c mouse skin allografted C57BL/6 mouse assessed as survival of allograft skin at 1 mg/kg, ip administered daily	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID1303210	Therapeutic ratio of GI50 for human A2780/ADR cells overexpressing ABCB1 to IC50 for ABCB1 in human A2780/ADR cells	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1289119	Mean residence time in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID680478	TP_TRANSPORTER: inhibition of MRK-1 uptake (vinblastine: 10 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells	2003	The Journal of pharmacology and experimental therapeutics, Mar, Volume: 304, Issue:3	Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
AID697853	Inhibition of horse BChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID580956	Inhibition of fluorescein labeled cyclosporin binding to Cyp40 by fluorescence polarization competition assay	2010	ACS medicinal chemistry letters, Dec-09, Volume: 1, Issue:9	Facile synthesis of a fluorescent cyclosporin a analogue to study cyclophilin 40 and cyclophilin 18 ligands.
AID496026	Inhibition of human MDR1-mediated permeability from basolateral to apical side of transfected MDCK2 cells at 5 uM after 1 to 2 hrs by HPLC analysis	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID324578	Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1774725	Antiinflammatory activity against mBSA-induced delayed type hypersensitivity in BALB/c mouse assessed as decrease in paw thickness at 100 mg/kg, po administered for 7 days followed by mBSA challenge and measured after 24 hrs by vernier caliper method	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-
AID394915	Effect on delayed type hypersensitivity in sheep red blood cells-immunized CBA mouse assessed as foot-pad edema at 10 ug, ip	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID241041	Inhibition of Peptidyl-prolyl cis-trans isomerase Trypanosoma cruzi cyclophilin (CL Brener strain, p19)	2004	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18	In vitro anti-parasitic activity of Cyclosporin A analogs on Trypanosoma cruzi.
AID1474096	AUC in human at 20 to 600 mg/kg, po after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1515525	Immunosuppressive activity in human Jurkat cells assessed as reduction in PHA + PMA-induced IL-2 production after 48 hrs by ELISA	2019	Bioorganic & medicinal chemistry, 01-15, Volume: 27, Issue:2	Leucoflavonine, a new bioactive racemic flavoalkaloid from the leaves of Leucosceptrum canum.
AID177348	In vivo immunosuppressive activity was evaluated by inducing arthritis in lewis rats and measuring the secondary lesions after 16 days	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant.
AID681337	TP_TRANSPORTER: Western blot, HK-2 cells	2002	Toxicology and applied pharmacology, Sep-01, Volume: 183, Issue:2	Influence of different chemicals on MDR-1 P-glycoprotein expression and activity in the HK-2 proximal tubular cell line.
AID1289138	Mean absorption time in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID573110	Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH6 cells assessed as reduction in replicon RNA after 4days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1766765	Inhibition of NEM-GS-stimulated MRP1 ATPase activity (unknown origin) in presence of GSH	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID678981	TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicles from MRP2-expressing LLC PK1 cells	1999	Molecular pharmacology, Dec, Volume: 56, Issue:6	Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
AID496785	Inhibition of serum withdrawal-induced cell differentiation in mouse C2C12 cells assessed as myosin heavy chain expression	2010	Nature chemical biology, Mar, Volume: 6, Issue:3	Carbon metabolism-mediated myogenic differentiation.
AID672897	Immunosuppressive activity in BALB/c mouse T cells assessed as inhibition of ConA-induced T cell proliferation incubated 24 hrs post ConA-induction for 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis, biological evaluation and molecular modeling of novel 1,3,4-oxadiazole derivatives based on Vanillic acid as potential immunosuppressive agents.
AID1591785	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-stimulated T-cell proliferation by measuring [3H]-thymidine uptake preincubated before concanavalin A stimulation for 48 hrs followed by [3H]-thymidine additio	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents.
AID1176909	Immunosupressive activity in OVA323-339 peptide-stimulated OT-2 T cell receptor transgenic mouse splenocytes assessed as inhibition of T cell proliferation after 3 days by MTT assay	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Antiproliferative glabretal-type triterpenoids from the root bark of Dictamnus dasycarpus.
AID132340	Compound was evaluated for in vitro immunosuppressive activity in the mouse mixed lymphocyte reaction (MLR-M)	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain.
AID1224298	Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as live divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 40.6%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1293025	Oral bioavailability in healthy subject (8 subjects) plasma at 10 mg/kg by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID524794	Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1630030	Immunomodulatory activity in albino OFA rat assessed as inhibition of SRBC specific B cell antibody response measured as reduction in plaque formation in spleen at 6 mg/kg qd treated for 4 consecutive days starting on the day of immunization measured post	2016	ACS medicinal chemistry letters, Aug-11, Volume: 7, Issue:8	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.
AID1362385	Inhibition of Cy5-labeled cyclosporin A binding to full length recombinant human N-terminal His8-tagged Cyclophilin A (1 to 169 residues) expressed in Escherichia coli BL21(DE3) after 30 mins by TR-FRET assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1209607	Competitive inhibition of CYP3A4 in human liver microsomes	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID657641	Immunosuppressive activity in BALB/c mouse lymph node cells assessed as inhibition of concanavalin A-stimulated cell proliferation at 1 uM administered 24 hrs post concanavalin A stimulation and measured 72 hrs after compound dosing by MTT assay	2012	Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10	Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
AID1889492	Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of concanavalin A induced T-cell proliferation by [3H]-thymidine incorporation based beta scintillation counter analysis	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID681137	TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells	2002	The Journal of pharmacology and experimental therapeutics, Oct, Volume: 303, Issue:1	Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
AID1708433	Inhibition of ABCC1 (unknown origin) expressed in human NCI-H69AR cells assessed as reduction in calcein AM efflux preincubated for 30 mins followed by calcein AM addition and measured at 60 secs interval for 1 hr by fluorescence assay	2021	European journal of medicinal chemistry, Feb-15, Volume: 212	Rational drug design of 6-substituted 4-anilino-2-phenylpyrimidines for exploration of novel ABCG2 binding site.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1221960	Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID679263	TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells	1996	British journal of pharmacology, Aug, Volume: 118, Issue:7	Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.
AID408610	Immunosuppressive activity against human PBMC assessed as inhibition of allogenic mixed lymphocyte reaction at 0.06 uM	2008	Journal of medicinal chemistry, May-22, Volume: 51, Issue:10	Aminoacyl-tRNA synthetase inhibitors as potent and synergistic immunosuppressants.
AID1218867	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells assessed as protein-mediated pitavastatin uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8	The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID1895157	Permeability in PBS buffer measured after 18 hrs by PAMPA based LC-MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID432789	Effect on drug distribution assessed as fluconazole level in plasma of transplant patient within 3 days of testing by gas-liquid chromatography	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID1209455	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	2012	Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1	In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1177610	Immunosuppressive activity in mouse T cells assessed as inhibition of ConA-induced cell proliferation at 100 uM	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Diterpenoids with Immunosuppressive Activities from Cinnamomum cassia.
AID681559	TP_TRANSPORTER: transepithelial transport of CPT-11(Carboxylate form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells	2003	Pharmaceutical research, Jun, Volume: 20, Issue:6	Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
AID648441	Inhibition of PMA-induced GATA3 expression in human PBMC at 90 uM after 15 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID558950	Antiviral activity against West Nile virus infected in CyPA-deficient human Huh7.5 cells assessed as decrease in viral replication at 8 uM after 24 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1533102	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 6.25 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1289167	Oral bioavailability in pediatric heart transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID648438	Inhibition of PMA-induced JAK1 phosphorylation in human PBMC at 90 uM after 15 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID1289149	Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 2.8 +/- 0.7 hrs during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1265705	Cytotoxicity against ICR mouse B spleen cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
AID1889494	Selectivity index, ratio of CC50 for BALB/c mouse Splenocyte to IC50 for Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of concanavalin A-induced T-cell proliferation	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID681464	TP_TRANSPORTER: increase in Glibenclamide intracellular accumulation (Glibenclamide: 0.525 uM, CsA: 50 uM) in CC531mdr+ cells	1999	Pflugers Archiv : European journal of physiology, Apr, Volume: 437, Issue:5	P-glycoprotein inhibition by glibenclamide and related compounds.
AID1226797	Intrinsic clearance in human liver microsomes	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID1533106	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 0.39 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1330995	Inhibition of recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) up to 1000 nM	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID91645	The compound was tested for inhibition of human splenocyte proliferation by [3H]thymidine incorporation	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Analogues of the marine immunosuppressant microcolin A: preparation and biological activity.
AID1289180	Ratio of MRT in blood to plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1853444	Inhibition of ConA-induced proliferation of BALB/c mouse splenocyte at 1 uM incubated for 48 hrs by CCK-8 assay relative to control	2021	RSC medicinal chemistry, Nov-17, Volume: 12, Issue:11	Synthesis and biological evaluation of bergenin derivatives as new immunosuppressants.
AID223386	50% inhibitory concentration of competitive binding against hCyp-18 PPIase activity using uncoupled assay	2000	Journal of medicinal chemistry, May-04, Volume: 43, Issue:9	Design of a Gag pentapeptide analogue that binds human cyclophilin A more efficiently than the entire capsid protein: new insights for the development of novel anti-HIV-1 drugs.
AID496163	Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3/CD28 antibody-induced IL-2 production treated for 1 hr before anti-CD3/CD28 antibody challenge measured after 6 hrs by immunosuppression assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1533105	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 0.78 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1533110	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 0.024 uM preincubated for 1 hr followed	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID679145	TP_TRANSPORTER: inhibition of Taurocholate uptake in membrane vesicles from Bsep-expressing Sf9 cells	2000	Gastroenterology, Feb, Volume: 118, Issue:2	Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1289166	Oral bioavailability in pediatric renal transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID428055	Immunosuppressive activity in concanavalin A-activated T cell assessed as inhibition of lymphoproliferation after 3 days by beta-scintillation counting	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID1218863	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate	2012	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8	The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID1293027	Oral bioavailability in blood of cadaveric renal transplant recipient (41 recipients) with good kidney function at 14 mg/kg	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID183454	Immunosuppressive activity against LEW rats transfected with spleen cells of WKAH rat in Popliteal Lymph Node Gain Assay.	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID555952	Antiviral activity against 2'-C-methyl-2'-fluoro-cytidine-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1895161	Permeability across basal to apical side in human Caco-2 cells measured at 0.5 to 2 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID284362	Inhibition of ConA-induced BALB/c mouse T cell proliferation	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Discovery and synthesis of new immunosuppressive alkaloids from the stem of Fissistigma oldhamii (Hemsl.) Merr.
AID1289157	Cmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 6.8 +/- 1.1 hrs during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1292982	Fast half life in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1293017	Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M17 at 10 mg/kg, po measured at 4 to 14 hrs by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID321882	Apparent permeability from apical to basolateral side of human Caco-2 cell membrane	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1296461	Inhibition of taurolithocholate acid 3-sulfate-induced necrosis in CD1 mouse pancreatic acinar cells at 0.1 to 10 uM after 30 mins by propidium iodide staining based confocal microscopic analysis	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	Small Molecule Inhibitors of Cyclophilin D To Protect Mitochondrial Function as a Potential Treatment for Acute Pancreatitis.
AID1209617	Inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes at 0.25 to 10 uM after 7.5 mins by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1289142	Clearance in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID679908	TP_TRANSPORTER: inhibition of Vinblastine binding (Vinblastine: 0.2 uM, CsA: 300-fold molar excess) in plasma membranes from CEM/VLB1.0 cells	1997	Biochemical pharmacology, Jan-10, Volume: 53, Issue:1	Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.
AID1224294	Induction of apoptosis in pMel-1 TCR transgenic C57BL/6 mouse gp100 (25 to 33)-activated CD8-positive T cells assessed as live divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 55.2%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID246433	Effective concentration required for the lysis of Trypanosoma cruzi trypomastigotes in blood stream after 24 hours of treatment	2004	Bioorganic & medicinal chemistry letters, Sep-20, Volume: 14, Issue:18	In vitro anti-parasitic activity of Cyclosporin A analogs on Trypanosoma cruzi.
AID496035	Half life in CD1 mouse liver microsomes at 1 uM after 5 to 30 mins by MS analysis in presence of NADPH	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID394916	Effect on delayed type hypersensitivity in sheep red blood cells-immunized CBA mouse assessed as foot-pad edema at 100 ug, ip	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID1224306	Antiinflammatory activity in LLO118 TCR transgenic mouse Th1 cells assessed as inhibition of IFN-gamma production at 100 nM for 2 days by flow cytometric analysis	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID150754	Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID183610	Lymphocyte-decreasing effect against F344 rats.	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID706966	Immunosuppressive activity in ICR mouse B cells assessed as inhibition of LPS-stimulated cell proliferation after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.
AID290715	Inhibition of fMLP-OMe-induced chemotaxis in human neutrophils	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	2-Phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole derivatives: new potent inhibitors of fMLP-induced neutrophil chemotaxis.
AID1265704	Cytotoxicity against ICR mouse T spleen cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 25, Issue:24	Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition.
AID1889495	Selectivity index, ratio of CC50 for BALB/c mouse Splenocyte to IC50 for Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of LPS-induced B-cell proliferation	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID1756338	Neuroprotective activity against glutamate-induced neurotoxicity in human SH-SY5Y cells assessed as cell death at 0.5 uM measured after 24 hrs by PI staining based assay (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1293016	Cmax in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M17 at 4 mg/kg, iv measured at 2 to 10 hrs by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID581949	Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1292979	Mean absorption time in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID444055	Fraction absorbed in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID581934	Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1895169	Cmax in ICR mouse at 20 mg/kg, po measured after 0.25 to 24 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID581927	Cytotoxicity against human HeLa cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID234691	Relative IC50 is the ratio of IC50 of the compound/IC50 CsA (MLR)	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID1289137	Volume of distribution at steady state in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID185387	Mean survival time of rats after skin allograft (intraperitoneal administration) at 10 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID122891	Compound was evaluated for IL 4 production inhibition from mice splenocytes stimulated by anti-CD3 mAb	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID437035	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A-induced cell proliferation at 1 uM after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity.
AID678741	TP_TRANSPORTER: inhibition of Vinblastine efflux (Vinblastine: 0.002 uM, CsA: 1 uM) in P388/S and P388/ADR cells	2000	Clinical and experimental pharmacology & physiology, Aug, Volume: 27, Issue:8	Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID594598	Inhibition of PPIase activity of Cyclophilin A by Spectrophotometry	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro.
AID1603084	Anti-inflammatory activity in dinitrofluorobenzene-induced Balb/c mouse delayed-type hypersensitivity model assessed as spleen index at 100 mg/kg, po administered twice per day prior to and during dinitrofluorobenzene challenge (Rvb = 49.1 +/- 6.56 No_uni	2019	Bioorganic & medicinal chemistry, 04-15, Volume: 27, Issue:8	Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
AID1292999	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M21 at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID324389	Induction of light chain 3-GFP level in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID1674184	Toxicity in po dosed human assessed as maximum daily dose	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID680812	TP_TRANSPORTER: increase in Vincristine intracellular accumulation (Vincristine: 1 uM, CsA: 10 uM) in MRP2-expressing LLC PK1 cells	1999	Molecular pharmacology, Dec, Volume: 56, Issue:6	Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.
AID90135	Concentration that reduces the difference in reversal of DOX accumulation between MDA-435/LCC6 and MDA-435/LCC6-MDRI cells by 50%.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID681128	TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID558956	Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after =< 6 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID284361	Cytotoxicity against BALB/c mouse spleen cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Discovery and synthesis of new immunosuppressive alkaloids from the stem of Fissistigma oldhamii (Hemsl.) Merr.
AID1289169	Drug absorption in healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by Loo-Riegelman method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1362389	Unbound fraction in human plasma at 2 uM at pH 7.4 by LC/MS/MS analysis	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
AID496042	Inhibition of human recombinant CYP1A2 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID210270	In vitro inhibitory activity against human T-cell production of lymphokine IL-2	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant.
AID1289132	AUC in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID428050	Cytotoxicity against rat H42E cells assessed as alteration in mitochondrial function by MTT assay	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID714413	Inhibition of P-gp-mediated paclitaxel resistance in human LCC6MDR cells assessed as fold decrease in paclitaxel IC50 for cytotoxic activity at 0.5 uM after 5 days by MTS assay relative to parental cells	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID1657641	Immunosuppressive activity in BALB/c mouse B cells assessed as reduction in LPS-induced cell proliferation	2020	Journal of natural products, 05-22, Volume: 83, Issue:5	Resorcylic Acid Lactones from an
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID624628	Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1323837	Inhibition of fluorescent cyclosporin A binding to human CypA by TR-FRET assay	2016	Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21	Design and synthesis of peptide-based macrocyclic cyclophilin inhibitors.
AID1221965	Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID150753	Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID415388	Antiviral activity against SIV in human CEM cells assessed as inhibition of virus-induced cytopathogenicity at 10 uM	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Discovery of dual inhibitors targeting both HIV-1 capsid and human cyclophilin A to inhibit the assembly and uncoating of the viral capsid.
AID1289127	Mean residence time in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID573111	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-Mono cells assessed as reduction in replicon RNA after 4 days by RT-qPCR analysis	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID581941	Antiviral activity against Herpes simplex virus 2 196 infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID324584	Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID528324	Immunosuppressive activity against human Jurkat cells assessed as inhibition of phytohemagglutinin-M/phorbol myristate acetate-induced IL2 production	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID1338615	Inhibition of TSPO in mouse HT22 cells assessed as protection against amyloid beta (1 to 42)-induced mitochondrial membrane potential loss by measuring recovery of ATP production at 5 uM preincubated for 10 mins followed by amyloid beta (1 to 42) addition	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID1322047	Cytotoxicity against human Jurkat T cells assessed as cell survival at 10 uM measured after 3 days by MTT assay	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Discovery and structure-activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents.
AID1765691	Cytotoxicity against human Jurkat cells assessed as inhibition of PMA/ionomycin-induced proliferation at 15 uM measured after 48 hrs by MTT assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Vomifoliol isolated from mangrove plant Ceriops tagal inhibits the NFAT signaling pathway with CN as the target enzyme in vitro.
AID1271127	Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability at 1 to 10 uM	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID50896	Relative immunosuppressive activity tested against inhibition of concanavalin A stimulated thymocytes	1990	Journal of medicinal chemistry, Mar, Volume: 33, Issue:3	Synthesis, conformation, and immunosuppressive activities of three analogues of cyclosporin A modified in the 1-position.
AID770463	Cellular uptake in human Jurkat T cells assessed as displacemnet of [O-(2-acetamido)-D-serine]8-cyclosporine N-{(5-aminopentyl)-[2,3,6,7-tetrahydro-11-oxo-1H,5H,11Hbenzopyrano(6,7,8-ij)quinolizine-10-carboxyl amide] from intracellular compartments after 9	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147.
AID621444	Immunosuppressive activity in human Jurkat T cells assessed as inhibition of PMA-induced IL-2 production at 10 uM after 13 hrs by ELISA relative to control	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and biological evaluation of α,β-unsaturated lactones as potent immunosuppressive agents.
AID681751	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 50 uM, CsA; 10 uM) in Xenopus laevis oocytes	1997	The Journal of biological chemistry, Nov-28, Volume: 272, Issue:48	Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney.
AID1447884	Inhibition of ABCB1 in human A2780adr cells assessed as reduction in calcein AM levels preincubated for 30 mins followed by calcein AM addition measured immediately at 60 sec time interval for 60 mins by fluorescence assay	2017	Journal of medicinal chemistry, 05-25, Volume: 60, Issue:10	4-Anilino-2-pyridylquinazolines and -pyrimidines as Highly Potent and Nontoxic Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID496018	Inhibition of calcineurin phosphatase activity of human recombinant CyPA at 5 uM after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1062342	Cytotoxicity against human MDA435/LCC6 cells assessed as growth inhibition after 3 days by MTS assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1221966	Ratio of plasma AUC in po dosed mdr1 knock out mouse to plasma AUC in po dosed wild type mouse	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID399511	Immunosuppressive activity in BALB/c mouse splenic T lymphocytes assessed as inhibition of Con A-induced cell proliferation after 72 hrs by MTT assay	2004	Journal of natural products, Jan, Volume: 67, Issue:1	Immunomodulatory constituents from an Ascomycete, Chaetomium seminudum.
AID770489	Inhibition of CypA PPIase activity (unknown origin) using Glt-(Ala)n-Pro-Phe-4-nitroanilides as substrate	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147.
AID209948	Tested for inhibitory activity against T lymphocyte proliferation induced by PHA at 10e-7 M; showed potent suppressive effect	1998	Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3	Immunomodulatory activity of thunberginol A and related compounds isolated from Hydrangeae Dulcis Folium on splenocyte proliferation activated by mitogens.
AID1639218	Stimulation index, ratio of CC50 for BALB/c mouse lymph node cells to IC50 for immunosuppressive activity in BALB/c mouse lymph node cells assessed as inhibition of concanavalin A stimulated T-cell proliferation	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Phloroglucinols with Immunosuppressive Activities from the Fruits of Eucalyptus globulus.
AID1407627	Blockade of amyloid beta (1 to 42)-induced cypD-mediated mPTP opening in mouse HT22 cells assessed as green to red fluorescence ratio at 5 uM preincubated for 10 mins followed by amyloid beta (1 to 42) addition measured at 1 hr time interval for 3 hrs by	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease.
AID681131	TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1209653	Efflux ratio of permeability from apical to basolateral over basolateral to apical side in MDCK1 cells expressing MDR1 at 25 uM after 2 hrs by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
AID185523	Mean survival time of rats after skin allograft (oral administration) at 10 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID1407630	Cytotoxicity against mouse HT22 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Pyrazinyl ureas revisited: 1-(3-(Benzyloxy)pyrazin-2-yl)-3-(3,4-dichlorophenyl)urea, a new blocker of Aβ-induced mPTP opening for Alzheimer's disease.
AID105432	Potency relative to progesterone in reversing of [3H]- VBL accumulation in MDA-435/LCC6 (Pgp-negative) cells.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1209605	Apparent oral intrinsic clearance in renal transplant patient	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID581952	Antiviral activity against HPV-18 infected in human HeLa cells assessed as inhibition of viral replication after 7 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID317951	Ratio of permeability from apical to basolateral side over basolateral to apical side in human Caco-2 cells	2008	Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5	Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.
AID1303208	Cytotoxicity against human A2780/ADR cells overexpressing ABCB1 assessed as reduction in cell viability after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2).
AID1533101	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 12.5 uM preincubated for 1 hr followed b	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID680506	TP_TRANSPORTER: inhibition of Doxorubicin transepithelial transport (basal to apical) (Digoxin: 0.8 uM) in MDR1-expressing LLC-PK1 cells	1998	Japanese journal of cancer research : Gann, Nov, Volume: 89, Issue:11	Inhibitory effects of a cyclosporin derivative, SDZ PSC 833, on transport of doxorubicin and vinblastine via human P-glycoprotein.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1228910	Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing doxorubicin resistance measured as cell survival after 5 days by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID680620	TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.1 uM, CsA: 30 uM) in Oatp1-expressing LLC-PK1 cells	2002	Pharmaceutical research, Feb, Volume: 19, Issue:2	Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
AID678712	Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1292995	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M17 at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID681127	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID558951	Antiviral activity against West Nile virus infected in human Huh7.5 cells assessed as decrease in viral replication at 4 uM after 24 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1322435	Inhibition of P-gp in doxorubicin-resistant human K562R cells assessed as rhodamine influx by measuring ratio of rhodamine mean fluorescence intensity in presence and absence of compound at 10 uM incubated for 20 mins by flow cytometry	2016	Journal of medicinal chemistry, 12-08, Volume: 59, Issue:23	Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors.
AID339501	Binding affinity to human Cyclophilin B	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Simultaneous identification of multiple receptors of natural product using an optimized cDNA phage display cloning.
AID1271163	Cytotoxicity against HCV infected human Huh7.5 cells assessed as cell death by MTT assay in presence of ribavirin	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID394931	Effect on cancavalin-A-induced proliferation in mouse splenocytes at 10 ug/ml assessed as proliferation rate by MTT assay	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID652504	Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in concanavalin-A-induced IFN-gamma production at 1 uM after 48 hrs by ELISA	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	Synthetic N-alkylated iminosugars as new potential immunosuppressive agents.
AID595710	Modulation of BCRP in human HCT116 cells assessed as intracellular accumulation of mitoxantrone at 10 uM after 30 mins by flow-cytometry	2011	Journal of medicinal chemistry, May-12, Volume: 54, Issue:9	Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID235867	Non cytotoxic IM activity index which is the ratio of IC50 of LcV to IC50 of MLR	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Immunosuppressive cyclolignans.
AID1169073	Apparent permeability in RRCK cells at 8 uM at pH 7.4 incubated for 2 hrs by LC-MS/MS method	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	Cyclic Penta- and Hexaleucine Peptides without N-Methylation Are Orally Absorbed.
AID1330998	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) by fluorescence analysis	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID140778	Effect of compound on IL-2 production from alloantigen-stimulated mouse spleen cells	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID1289136	Volume of distribution in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1553598	Inhibition of ABCB1 in human A2780/ADR cells preincubated for 30 mins followed by calcein AM addition and measured at 60 secs time interval by fluorescence assay	2019	Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9	Identification of Thienopyrimidine Scaffold as an Inhibitor of the ABC Transport Protein ABCC1 (MRP1) and Related Transporters Using a Combined Virtual Screening Approach.
AID248433	In vitro concentration of compound required to inhibit LPS-induced B cell proliferation to 50% in BALB/c mice	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID762654	Antiviral activity against HIV1 3B infected in human MT4 cells coinfected with HTLV1 assessed as reduction in virus-induced cytopathogenicity after 4 days by MTT assay	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Cyclophilin inhibitors as antiviral agents.
AID1756293	Neuroprotective activity against salsolinol-induced neurotoxicity in human SH-SY5Y cells assessed as cell death at 0.5 uM measured after 24 hrs by PI staining based analysis (Rvb = 100%)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID1474097	Drug concentration at steady state in human at 20 to 600 mg/kg, po after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1271162	Cytotoxicity against HCV infected human Huh7.5 cells assessed as cell death by MTT assay in presence of telaprevir	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID317949	Inhibition of human P-glycoprotein mediated [3H]vinblastine transport in human Caco-2 cells	2008	Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5	Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1331003	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant at 1:1 compound to protein ratio measured after 30 secs in presence of 20-fold excess of (3S,6S,9S,15S,18S,21S	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID259532	Reduction of HIV1 virion infectivity in the replication-deffective one-round infection assay	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Structure-based design, synthesis, and biological evaluation of novel inhibitors of human cyclophilin A.
AID581777	Antiviral activity against HIV-1 3B infected in human MT4 cells assessed as inhibition of virus induced cytopathic effect by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID245888	Maximum intracellular vinblastine accumulation of the KB/MDR cells caused by the compound in 1 h	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID484670	Immunosuppressive activity in BALB/c mouse assessed as CD3 antibody-induced IL2 production at 15 mg/kg, po relative to control	2010	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12	New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
AID1185179	Toxicity against mouse HT22 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: design, synthesis, and molecular docking study.
AID678715	Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1358240	Inhibition of P-gp in human MCF7/ADR cells assessed as increase in intracellular accumulation of doxorubicin at 20 uM after 2 days by fluorescence assay relative to doxorubicin alone	2018	European journal of medicinal chemistry, May-10, Volume: 151	Synthesis and biological evaluation of 2,5-disubstituted furan derivatives as P-glycoprotein inhibitors for Doxorubicin resistance in MCF-7/ADR cell.
AID774653	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei 427 after 3 days by Alamar Blue assay	2013	Journal of medicinal chemistry, Oct-24, Volume: 56, Issue:20	Approaches to protozoan drug discovery: phenotypic screening.
AID1869233	Cytotoxicity in BALB/c mouse Splenocyte assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2022	Journal of natural products, 06-24, Volume: 85, Issue:6	Dolabrane-Type Diterpenoids with Immunosuppressive Activity from
AID1185178	Inhibition of beta-amyloid peptide-induced mitochondrial permeability transition pore opening in mouse HT22 cells assessed as increase in green/red fluorescence ratio at 5 uM pre-incubated for 10 mins before Abeta peptide addition by JC-1 assay	2014	European journal of medicinal chemistry, Sep-12, Volume: 84	Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: design, synthesis, and molecular docking study.
AID420709	Cytotoxicity against splenocytes after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Hirtellanines A and B, a pair of isomeric isoflavonoid derivatives from Campylotropis hirtella and their immunosuppressive activities.
AID1300180	Binding affinity to human recombinant cyclophilin D by surface plasmon resonance analysis	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Aβ-Mediated Mitochondrial Dysfunction.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID558947	Antiviral activity against West Nile virus infected in human Huh7.5 cells at 8 uM after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1895165	Permeability across apical to basal side in human Caco-2 cells assessed as drug recovery preincubated with verapamil for 30 mins followed by compound addition measured at 0.5 to 2 hrs by LC-MS analysis relative to control	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID581771	Cytotoxicity against human MT4 cells at 0.83 uM by MTT assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID681481	TP_TRANSPORTER: Western in vivo, liver of SD rat	1996	The American journal of physiology, May, Volume: 270, Issue:5 Pt 2	Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.
AID1289153	Distribution half life in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1635780	Inhibition of ABCB1 in human A2780/ADR cells assessed as reduction in calcein AM efflux pre-incubated for 30 mins before calcein AM addition and measured for 60 mins by microplate reader analysis relative to control	2016	Journal of medicinal chemistry, 07-14, Volume: 59, Issue:13	Synthesis and Investigation of Tetrahydro-β-carboline Derivatives as Inhibitors of the Breast Cancer Resistance Protein (ABCG2).
AID94168	Percent of cell viability of KB-A1 human epidermoid carcinoma remaining after inoculation with the modulator alone	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID679625	TP_TRANSPORTER: inhibition of ATPase in membrane vesicle from BCRP-expressing Sf9 cells	2001	Biochemical and biophysical research communications, Jul-06, Volume: 285, Issue:1	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
AID1605062	Inhibition of Porcine cerebellar microsomes SERCA preincubated for 10 mins followed by addition of ATP and measured after 10 mins by colorimetric method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID734049	Inhibition of mPTP in mouse HT22 cells assessed as reduction in amyloid beta-induced mitochondrial membrane damage at 10 uM incubated for 10 mins prior to amyloid beta-challenge measured every 1 hr for 3 hrs by JC-1 based fluorometric analysis	2013	European journal of medicinal chemistry, Apr, Volume: 62	Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction.
AID679112	TP_TRANSPORTER: transepithelial transport in Caco-2 cells	2003	Pharmaceutical research, Jul, Volume: 20, Issue:7	The effects of pluronics block copolymers and Cremophor EL on intestinal lipoprotein processing and the potential link with P-glycoprotein in Caco-2 cells.
AID1331004	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as dissociation rate constant at 1:1 compound to protein ratio measured after 600 secs in presence of 20-fold excess of (3S,6S,9S,15S,18S,21	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID428053	Immunosuppressive activity in mouse splenocytes assessed as inhibition of allogenic mixed lymphocyte reaction	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID1226788	Volume of distribution at steady state in Wistar-Han rat at 10 mg/kg, iv after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID524793	Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID330504	Apparent permeability from basolateral to apical side of human Caco-2 cell membrane	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
AID284365	Selectivity index, ratio of CC50 for BALB/c mouse T cells to IC50 for BALB/c mouse B cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Discovery and synthesis of new immunosuppressive alkaloids from the stem of Fissistigma oldhamii (Hemsl.) Merr.
AID1300185	Inhibition of cyclophilin D in mouse brain cortical mitochondria assessed as suppression of calcium-induced mitochondrial swelling at 5 uM incubated for 5 mins by spectrophotometric analysis	2016	ACS medicinal chemistry letters, Mar-10, Volume: 7, Issue:3	Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing Aβ-Mediated Mitochondrial Dysfunction.
AID90142	Ratio of effect of compound on VBL accumulation (antiPgp activity) to its intrinsic cellular toxicity;	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID681332	TP_TRANSPORTER: inhibition of Taurocholate uptake in ASBT-expressing COS cells	1998	The American journal of physiology, 01, Volume: 274, Issue:1	Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
AID696918	Inhibition of MDR1 in human HCT15 cells assessed as calcein-AM efflux at 10 uM by fluorescence assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes.
AID581930	Antiviral activity against SARS coronavirus infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID657445	Cytotoxicity against Balb/c mouse lymph node cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9	Design, synthesis, and biological evaluation of chalcone oxime derivatives as potential immunosuppressive agents.
AID1293013	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M18 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID681550	TP_TRANSPORTER: inhibition of Taurocholate uptake (Taurocholate: 2.5 uM, CsA: 100 uM) in Ntcp-expressing CHO cells	1998	The American journal of physiology, 02, Volume: 274, Issue:2	Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells.
AID324493	Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 2.1 uM after 24 hrs by high throughput fluorescence microscopy relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID681474	TP_TRANSPORTER: increase in Colchicine intracellular accumulation (Colchicine: 0.035 uM, CsA: 50 uM) in CC531mdr+ cells	1999	Pflugers Archiv : European journal of physiology, Apr, Volume: 437, Issue:5	P-glycoprotein inhibition by glibenclamide and related compounds.
AID1566286	Inhibition of PPIase activity human recombinant cypD K133I mutant expressed in Escherichia coli BL21(DE3) cells using Suc-Ala-Ala-Cis-Pro-Phe-pNA as substrate by chymotrypsin-coupled assay	2019	Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23	Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies.
AID54727	Binding affinity towards cyclophilin A by fluorescence	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Structure-activity studies of ground- and transition-state analogue inhibitors of cyclophilin.
AID1155554	Inhibition of calcium-induced mPTP opening in C57/bl6 mouse liver mitochondria assessed as increase in calcium retention capacity at 1 uM by fluorimetry	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo.
AID581944	Antiviral activity against Human cytomegalovirus AD169 infected in human embryonic lung cells assessed as reduction in viral yield	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID621445	Immunosuppressive activity in human Jurkat T cells assessed as inhibition of PMA-induced IL-2 production at 1 uM after 13 hrs by ELISA relative to control	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and biological evaluation of α,β-unsaturated lactones as potent immunosuppressive agents.
AID407204	Inhibition of P-glycoprotein-mediated rhodamine 123 absorption in guinea-pig ileum	2008	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13	Effect of some P-glycoprotein modulators on Rhodamine-123 absorption in guinea-pig ileum.
AID432787	Effect on drug distribution assessed as posaconazole level in plasma of transplant patient by MVista microbiological assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID1289161	Clearance in plasma of pre-renal transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID54723	Compound was evaluated for in vitro binding affinity to cyclophilin A (CyP-A)	1994	Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22	Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain.
AID1895168	AUCinfinity in ICR mouse at 20 mg/kg, po measured after 0.25 to 24 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID588987	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OATP2B1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID592683	Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1625585	Inhibition of ABCB1 in human A2780adr cells preincubated for 30 mins before calcein AM addition by calcein AM assay	2016	Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11	Synthesis and Biological Evaluation of 4-Anilino-quinazolines and -quinolines as Inhibitors of Breast Cancer Resistance Protein (ABCG2).
AID1525922	Inhibition of P-gp (unknown origin) expressed in human LCC6MDR cells assessed as reversal of paclitaxel resistance after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID173625	In vivo immunosuppressive activity was evaluated by surgically implanting the hearts from Brown Norway rats into the peritoneal cavity of histoincompatible Lewis rats and rejection was assessed	1995	Journal of medicinal chemistry, Apr-14, Volume: 38, Issue:8	The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant.
AID594600	Cytotoxicity against human SKHEP1 cells at 20 uM after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro.
AID567808	Cytotoxicity against BALB/c mouse T cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis, biological evaluation of chrysin derivatives as potential immunosuppressive agents.
AID1605061	Inhibition of rabbit SERCA1a preincubated for 10 mins followed by addition of ATP and measured after 10 mins by colorimetric method	2020	Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5	Sarco/Endoplasmic Reticulum Calcium ATPase Inhibitors: Beyond Anticancer Perspective.
AID1224301	Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as dead divided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 3.04%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID416851	Toxicity to human skin assessed as damage of skin integrity at 2 fold MIC administered 30 mins post inoculation followed by once in every 2 days for 7 days by scanning electron microscopy	2007	Antimicrobial agents and chemotherapy, Oct, Volume: 51, Issue:10	Targeting the calcineurin pathway enhances ergosterol biosynthesis inhibitors against Trichophyton mentagrophytes in vitro and in a human skin infection model.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID105423	Effect on reversal of DOX accumulation in MDA-435/LCC6 (Pgp-negative) cells.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID322362	Inhibition of human multidrug resistant gene Pgp expressed in MDCK2 cells assessed as calcein-AM accumulation at 10 uM after 40 mins	2008	Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1	Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein.
AID728308	Antioxidant activity in rat liver mitochondria assessed as inhibition of Ca2+/phosphate induced mitochondrial swelling at 50 uM by spectrophotometry	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of new bifunctional sigma-1 selective ligands with antioxidant activity.
AID1438355	Inhibition of cyclophilin D in mouse HT22 cells assessed as reduction in amyloid beta (1 to 42) induced mitochondrial permeability transition pore opening by measuring increase in green to red fluorescence ratio at 5 uM pretreated for 10 mins followed by	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Discovery of 1-(3-(benzyloxy)pyridin-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea: A new modulator for amyloid beta-induced mitochondrial dysfunction.
AID1566287	Binding affinity to CypD (unknown origin) assessed as dissociation constant by SPR analysis	2019	Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23	Discovery of novel Cyclophilin D inhibitors starting from three dimensional fragments with millimolar potencies.
AID1707624	Effect on pGL3-NFAT -Luc signalling transfected in human Jurkat cells assessed as decrease in PMA and ionomycin induced luciferase activity at 2 uM incubated for 48 hrs by microplate reader analysis
AID581919	Antiviral activity against Coxsackie B3 infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1289172	Ratio of MRT in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1443986	Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell membrane vesicles assessed as reduction in ATP or AMP-dependent [3H]-taurocholic acid uptake in to vesicles preincubated for 5 mins followed by ATP/AMP addition measured after	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID558949	Antiviral activity against West Nile virus infected in CyPA-deficient human Huh7.5 cells assessed as decrease in viral replication at 4 uM after 24 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1140179	Inhibition of p-gp in doxorubicin-resistant human Saos2 cells assessed as increase in doxorubicin uptake at 5 uM after 3 hrs by flow cytometric analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID1209618	Inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes preincubated at 0.25 to 10 uM for 15 mins before substrate addition by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1289151	Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 2.8 +/- 0.7 hrs during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1322037	Immunosuppressive activity in human PMA/ionomycin stimulated Jurkat T cells assessed as suppression of IL2 production at 1 uM pretreated with cells followed by PMA/ionomycin stimulation measured after 13 hrs by ELISA	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Discovery and structure-activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents.
AID393840	Inhibition of allogenic cells-stimulated proliferation in human T cells by mixed lymphocyte reaction method	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID555950	Antiviral activity against compound-resistant HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication after 3 days by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID496156	Selectivity index, ratio of CC50 for human Huh7ET cells to EC50 for Hepatitis C virus infected in human Huh7ET cells	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1293012	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M18 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID394929	Effect on cancavalin-A-induced proliferation in mouse splenocytes at 1 ug/ml assessed as proliferation rate by MTT assay	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID386360	Inhibition of cross-linking of human Pgp TM6 F343R/TM6 L339C/TM7 F728C mutant expressed in HEK293 cells assessed as drug level causing 50% inhibition of cross linking by immunoblot	2007	The Journal of biological chemistry, Nov-02, Volume: 282, Issue:44	Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites.
AID132859	The compound was evaluated in vitro for the immunosuppressive activity in mouse mixed lymphocyte reaction (MLR_M)	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID1228904	Cytotoxicity against mouse L929 cells after 3 days by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID1289165	Oral bioavailability in 3 month post-renal transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID432795	Antifungal activity against Candida kefyr ATCC 46764 at 0.5 ug/ml after 14 to 18 hrs	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID365464	Inhibition of human MRP2 expressed in dog MDCK2 cells	2008	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 18, Issue:17	A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins.
AID681164	TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells	2001	Pharmaceutical research, Dec, Volume: 18, Issue:12	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein.
AID1155559	Inhibition of calcium-induced mPTP opening in C57/bl6 mouse liver mitochondria assessed as increase in calcium retention capacity at 0.1 to 5 uM by fluorimetry	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Cinnamic anilides as new mitochondrial permeability transition pore inhibitors endowed with ischemia-reperfusion injury protective effect in vivo.
AID697852	Inhibition of electric eel AChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1271165	Toxicity in NOD/SCID mouse assessed as body weight change at 50 mg/kg, ip measured up to 14 days	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID324577	Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID680107	TP_TRANSPORTER: increase in brain concentration in PGP(-/-) mouse	1999	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 27, Issue:5	Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
AID1444842	Antiviral activity against HBV infected in human HepaRG cells assessed as reduction in viral infection after 16 hrs	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496013	Antiviral activity against Hepatitis C virus infected in human Huh7ET cells assessed as inhibition of viral replication after 72 hrs by luciferase reporter gene assay	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID581946	Antiviral activity against HBV infected in human hepAD38 cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1292989	Clearance in pre-kidney transplant end stage renal disease patient (8 patients) blood at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1271128	Inhibition of calcium-dependent calcineurin phosphatase activity in ionomycin-stimulated BALB/c mouse splenocytes assessed as reduction in dephosphorylation of R2 phosphopeptide at 1 to 10 uM preincubated for 20 hrs followed by ionomycin stimulation measu	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID122892	Compound was evaluated for IL 5 production inhibitio from mice splenocytes stimulated by anti-CD3 mAb	1999	Journal of medicinal chemistry, Feb-25, Volume: 42, Issue:4	New N-(pyridin-4-yl)-(indol-3-yl)acetamides and propanamides as antiallergic agents.
AID1293014	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M21 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID680908	TP_TRANSPORTER: cell accumulation of doxorubicin in the presence of Cyclosporin A at a concentration of 1uM in K562/ADR cells	2004	European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3	Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.
AID680098	TP_TRANSPORTER: increase in saquinavir intracellular accumulation of Cyclosporin A at a concentration of 20uM in LLC-GA5-COL150 cells	2004	British journal of pharmacology, Dec, Volume: 143, Issue:7	Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux.
AID1289155	Clearance in blood of pre-renal transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID437038	Cytotoxicity against BALB/c mouse splenocytes at 1 uM after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity.
AID1765687	Inhibition of human calcineurin activity in PMA/ionomycin-induced human Jurkat cells at 15 uM measured after 44 hrs by Malachite green dye based fast green assay	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Vomifoliol isolated from mangrove plant Ceriops tagal inhibits the NFAT signaling pathway with CN as the target enzyme in vitro.
AID1292997	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M18 at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID558962	Inhibition of West Nile virus protease up to 100 uM	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID330502	Inhibition of human P-gp mediated [3H]vinblastine transport activity in human Caco-2 cells	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
AID1209615	Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation at 0.25 to 10 uM after 7.5 mins by LC-MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID1271131	Activation of calcium-dependent calcineurin phosphatase activity in ionomycin-stimulated BALB/c mouse assessed as production of IL-2 at 1 to 10 uM after 24 hrs by ELISA	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID317950	Activation of human P-glycoprotein ATPase in Caco-2 cells assessed as ATP depletion at 100 uM	2008	Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5	Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.
AID719608	Competitive binding affinity to biotinylated human recombinant T cell cyclophilin A expressed in Escherichia coli by spectrophotometric analysis	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Ranking high affinity ligands of low solubility by NMR spectroscopy.
AID496041	Inhibition of human recombinant CYP2C9 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID150755	Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID94996	Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 0.01 uM	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.
AID588996	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MRP2	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID679129	TP_TRANSPORTER: reversal of Vinblastine accumulation (Vinblastine: 0.005 uM) in MDA435/LCC6 MDR1 cells	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1532161	Thermodynamic aqueous solubility of compound in pH 7.4 PBS by UPLC-MS analysis	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
AID592682	Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	QSAR-based permeability model for drug-like compounds.
AID710863	Antiproliferative activity against concanavalin A-stimulated BALB/c mouse splenocytes after 72 hrs by AlamarBlue assay	2012	Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24	Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1503632	Inhibition of TSPO in mouse HT22 cells assessed as reduction in amyloid beta (1 to 42) (unknown origin) induced mitochondrial permeability transition pore formation by measuring increase in green to red fluorescence ratio at 5 uM pretreated for 10 mins fo	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of thienopyrrolotriazine derivatives to protect mitochondrial function against Aβ-induced neurotoxicity.
AID558958	Antiviral activity against Yellow fever virus infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after =< 6 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID246154	Concentration that causes 50% of maximum vinblastine accumulation in KB/MDR cells in 1 h	2004	Journal of medicinal chemistry, Oct-21, Volume: 47, Issue:22	Increased anti-P-glycoprotein activity of baicalein by alkylation on the A ring.
AID496043	Inhibition of human recombinant CYP2D6 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1370783	Selectivity index, ratio of CC50 for lymphocytes (unknown origin) to IC50 for LPS-induced B lymphocytes (unknown origin) proliferation	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Spiroorthoester group-containing pregnane glycosides from the root barks of Periploca chrysantha and their inhibitory activities against the proliferation of B and T lymphocytes.
AID679238	TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells	1993	The Journal of biological chemistry, Mar-25, Volume: 268, Issue:9	Human P-glycoprotein transports cyclosporin A and FK506.
AID1409701	Cytoprotective activity against H2O2-induced necrosis in human HL60 cells assessed as increase in cell viability at 0.3 to 3 uM incubated for 1 hr followed by H2O2 stimulation measured after 3 hrs by Alamar blue assay	2018	ACS medicinal chemistry letters, Mar-08, Volume: 9, Issue:3	Indolylmaleimide Derivative IM-17 Shows Cardioprotective Effects in Ischemia-Reperfusion Injury.
AID444050	Fraction unbound in human plasma	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1443991	Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625944	Binding affinity to human recombinant cyclophilin-A by isothermal titration calorimetry assay	2011	European journal of medicinal chemistry, Nov, Volume: 46, Issue:11	Oligopeptide cyclophilin inhibitors: a reassessment.
AID1206429	Inhibition of ABCB1 in human A2780adr cells pre-incubated for 30 mins followed by calcein AM addition and further incubated for 60 mins by calcein AM assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	HM30181 Derivatives as Novel Potent and Selective Inhibitors of the Breast Cancer Resistance Protein (BCRP/ABCG2).
AID72183	Inhibitory activity against human formylpeptide receptor (FPR) of human leukemia HL-60 cells	2002	Journal of medicinal chemistry, Oct-10, Volume: 45, Issue:21	Cyclosporins: structure-activity relationships for the inhibition of the human FPR1 formylpeptide receptor.
AID1293006	Tmax in pre-kidney transplant end stage renal disease patient (8 patients) blood at 10 mg/kg, po administered through solution by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1501265	Inhibition of ABCC1 in human H69AR cells assessed as reduction in calcein-AM efflux preincubated for 30 mins followed by calcein-AM addition measured at 60 secs interval for 60 mins by fluorescence assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID1771410	Inhibition of CD3/CD28 antibody-stimulated C57BL/6 mouse primary CD8-positive T lymphocytes activation assessed as proportion of CD69-positive cells at 50 nM incubated for 48 hrs by flow cytometry (Rvb = 93.42%)
AID672543	Inhibition of P-glycoprotein-mediated daunorubicin efflux from human CCRF-CEM/VCR1000 cells after 240 secs by FACS flow cytometric analysis	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1895159	Permeability across apical to basal side in human Caco-2 cells measured at 0.5 to 2 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID528322	Binding affinity to cyclophilin A by ELISA	2010	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22	Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
AID470249	Inhibition of human PBMC proliferation assessed as [3H]thymidine uptake at 5 uM after 3 days by scintillation counting	2009	Journal of natural products, Sep, Volume: 72, Issue:9	Oxygenated lignans from the fruits of Schisandra arisanensis.
AID624626	Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID94999	Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 1 nM	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.
AID1723059	Inhibition of human ABCB1 expressed in A2780/ADR cells preincubated for 30 mins followed by calcein AM addition and measured every 60 secs for 60 mins by fluorescence assay
AID1525921	Inhibition of MRP1 (unknown origin) expressed in human 2008/MRP1 assessed as reversal of doxorubicin resistance after 5 days by MTS/PMS assay	2019	Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18	Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
AID681611	TP_TRANSPORTER: transepithelial transport of digoxin (basal to apical) in Caco-2 cells	2003	Pharmaceutical research, Feb, Volume: 20, Issue:2	Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter.
AID706779	Cytotoxicity against human Jurkat cells after 4 days by MTT assay	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.
AID432798	Effect on calcineurine level in plasma of transplant patient by MVista microbiological assay	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID420713	Selectivity index, CC50 for splenocyte to IC50 for LPS-induced splenocytes proliferation	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Hirtellanines A and B, a pair of isomeric isoflavonoid derivatives from Campylotropis hirtella and their immunosuppressive activities.
AID326743	Inhibition of anti-CD3-induced IL2 production in BALB/c mouse	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
AID672898	Selectivity index ratio of CC50 for BALB/c mouse lymph node cells to IC50 for BALB/c mouse ConA-induced T cell proliferation	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Design, synthesis, biological evaluation and molecular modeling of novel 1,3,4-oxadiazole derivatives based on Vanillic acid as potential immunosuppressive agents.
AID581920	Cytotoxicity against african green monkey Vero cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1293010	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M1 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID238355	Inhibition of cyclophilin A rotamase	2004	Bioorganic & medicinal chemistry letters, Sep-06, Volume: 14, Issue:17	Synthesis and neurotrophic activity of nonimmunosuppressant cyclosporin A derivatives.
AID1292974	AUC (0 to infinity) in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as metabolite M1 at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID581776	Antiviral activity against HIV-1 3B infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID567810	Selectivity index, ratio of CC50 for BALB/c mouse T cells to IC50 for immunosuppressive activity in BALB/c mouse T cells	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Synthesis, biological evaluation of chrysin derivatives as potential immunosuppressive agents.
AID183137	Lymphocyte-decreasing effect against F344 rats.	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID558964	Inhibition of West Nile virus RdRp up to 100 uM	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID566106	Suppression of cardiac allograft rejection of C57BL/6 mouse to BALB/c mouse assessed as surviving days at 40 mg/kg, po treatment started from day of transplantation for 30 days by immunosuppressive assay	2011	Journal of medicinal chemistry, Jan-27, Volume: 54, Issue:2	Discovery of 7-N-piperazinylthiazolo[5,4-d]pyrimidine analogues as a novel class of immunosuppressive agents with in vivo biological activity.
AID680490	TP_TRANSPORTER: inhibition of Indinavir transepithelial transport (basal to apical) in Caco-2 cells	2000	The Journal of pharmacology and experimental therapeutics, Jan, Volume: 292, Issue:1	Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.
AID1699058	Inhibition of calcineurin in mouse lung macrophages assessed as reduction in LPS-induced TNFalpha production at 10 uM pre-incubated 4 hrs before LPS stimulation for 8 hrs by ELISA	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	A Peptidyl Inhibitor that Blocks Calcineurin-NFAT Interaction and Prevents Acute Lung Injury.
AID581933	Antiviral activity against HCV infected in human Huh 5.2 cells assessed as reduction in viral RNA level by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID657446	Selectivity index, ratio of CC50 for Balb/c mouse lymph node cells to IC50 for anti-CD3/antiCD8 co-stimulated mouse Balb/c mouse lymph node cells	2012	Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9	Design, synthesis, and biological evaluation of chalcone oxime derivatives as potential immunosuppressive agents.
AID437039	Immunosuppressive activity against concanavalin A-induced BALB/c mouse splenocytes assessed as inhibition of [3H]thymidine incorporation at 1 uM by liquid scintillation counting	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity.
AID1289133	Oral bioavailability in blood of healthy human subjects (8 subjects) at 10 mg/kg measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1221982	Fraction absorbed in human	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1218865	Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate	2012	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 40, Issue:8	The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
AID428051	Antiproliferative activity against rat H42E cells assessed as cell number	2009	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15	Design, synthesis and identification of novel colchicine-derived immunosuppressant.
AID681582	TP_TRANSPORTER: inhibition of Calcein-AM efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1209613	Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID581774	Antiviral activity against HIV-1 SF2 infected in human PBMC assessed as inhibition of viral replication by ELISA	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID573108	Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh5-2 cells assessed as reduction in replicon RNA after 4 days by luciferase assay	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.
AID1403368	Cytotoxicity against mouse HT22 cells assessed as cell viability at 5 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis and evaluation of 2-(3-arylureido)pyridines and 2-(3-arylureido)pyrazines as potential modulators of Aβ-induced mitochondrial dysfunction in Alzheimer's disease.
AID1293038	Volume of distribution at steady state in renal failure patient (5 patients) blood at 2.05 to 3.5 mg/kg, iv administered as infusion over 4 hrs by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID680102	TP_TRANSPORTER: intracellular accumulation in P388/S and P388/ADR cells	2000	Clinical and experimental pharmacology & physiology, Aug, Volume: 27, Issue:8	Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo.
AID114448	Compound was tested for Immunosuppression activity by mixed lymphocyte reaction (MLR) in murine splenocytes of mice	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Immunosuppressive cyclolignans.
AID1293034	Clearance in post-renal transplant patient (6 patients) plasma at 5 mg/kg, iv administered as infusion over 3 to 24 hrs by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID680489	TP_TRANSPORTER: inhibition of Ivermectin binding (IVM: 0.2 uM, CsA: 300-fold molar excess) in plasma membranes from CEM/VLB1.0 cells	1997	Biochemical pharmacology, Jan-10, Volume: 53, Issue:1	Reversal of P-glycoprotein-associated multidrug resistance by ivermectin.
AID161625	Resistance evaluated in an ascaris-induced nonhuman primate model of asthma after 6 hour at 25 mg/kg dose	2000	Journal of medicinal chemistry, Aug-10, Volume: 43, Issue:16	3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.
AID497686	Binding affinity to human cyclophilin 18	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Augmented photoswitching modulates immune signaling.
AID652500	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin-A-induced cell proliferation at 1 uM after 48 hrs by MTT assay	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	Synthetic N-alkylated iminosugars as new potential immunosuppressive agents.
AID95452	Inhibition of production of beta-galactosidase thymidine kinase RGA in Jurkat cells	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID523611	Antiviral activity against cyclosporine A/NIM-resistant HCV subtype 1b Con1 infected in human HuH7 cells assessed as reduction in viral RNA level after 48 hrs by MTS assay	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
AID1813129	Cytotoxicity against mouse L929 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers.
AID1771419	Anti-aplastic anaemia in immune-mediated bone marrow failure BALB/c mouse model assessed as increase in thymus index at 10 mg/kg, po administered for 14 days
AID1769566	Inhibition of ConA-induced IL-2 expression in BALB/c mouse T-lymphocyte measured after 24 hrs by ELISA	2021	Journal of natural products, 05-28, Volume: 84, Issue:5	Efophylins A and B, Two
AID1338177	Inhibition of P-gp in human MDA435/LCC6MDR cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 1 uM measured after 5 days by Cell Titer 96 Aqueous assay (Rvb = 139.3 +/- 7.5 nM)	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Extending the structure-activity relationship study of marine natural ningalin B analogues as P-glycoprotein inhibitors.
AID648440	Inhibition of PMA-induced JAK1 expression in human PBMC at 90 uM after 15 mins by Western blot analysis	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID679921	TP_TRANSPORTER: inhibition of Saquinavir transepithelial transport (basal to apical)(Saquinavir: 10 uM, CsA: 4 uM) in HCT8-cells	1998	The Journal of pharmacology and experimental therapeutics, Sep, Volume: 286, Issue:3	Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein.
AID558945	Antiviral activity against Vesicular stomatitis virus infected in human Huh7.5 cells at 8 to 20 uM after 16 hrs by plaque formation assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1228908	Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing vinblastine resistance measured as cell survival after 5 days by MTS assay	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID140779	The compound was tested in vitro for inhibition of proliferation in BDF1 mouse spleen cells stimulated with concanavalin A (ConA).	1995	Journal of medicinal chemistry, Oct-13, Volume: 38, Issue:21	Cyclosporin analogs modified in the 3,7,8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive.
AID680479	TP_TRANSPORTER: inhibition of MRK-1 uptake (MRK-1: 10 uM, CsA: 10 uM) in MDR1-expressing LLC-PK1 cells	2003	The Journal of pharmacology and experimental therapeutics, Mar, Volume: 304, Issue:3	Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID284364	Selectivity index, ratio of CC50 for BALB/c mouse spleen cells to IC50 for BALB/c mouse T cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	Discovery and synthesis of new immunosuppressive alkaloids from the stem of Fissistigma oldhamii (Hemsl.) Merr.
AID1370785	Selectivity index, ratio of CC50 for lymphocytes (unknown origin) to IC50 for ConA-induced T lymphocytes (unknown origin) proliferation	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	Spiroorthoester group-containing pregnane glycosides from the root barks of Periploca chrysantha and their inhibitory activities against the proliferation of B and T lymphocytes.
AID588982	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, OATP1B3	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID252956	Ratio of concentration that reduced cell viability to inhibitory concentration for LPS-induced B cell proliferation	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID679906	TP_TRANSPORTER: inhibition of Vinblastine efflux in MDR1-expressing BeWo cells	2003	American journal of physiology. Cell physiology, Sep, Volume: 285, Issue:3	Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer.
AID657640	Cytotoxicity against BALB/c mouse lymph node cells at 10 uM after 72 hrs MTT assay	2012	Bioorganic & medicinal chemistry, May-15, Volume: 20, Issue:10	Synthesis, biological evaluation and molecular docking studies of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
AID1322038	Immunosuppressive activity in human PMA/ionomycin stimulated Jurkat T cells assessed as suppression of IL2 production pretreated with cells followed by PMA/ionomycin stimulation measured after 13 hrs by ELISA	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Discovery and structure-activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents.
AID715593	Cardioprotective activity in New Zealand White rabbit ischemia/reperfusion model assessed as reduction of infarct to risk area ratio at 10 mg/kg administered bolus 1 min before reperfusion	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	Discovery of 6-[4-(6-nitroxyhexanoyl)piperazin-1-yl)]-9H-purine, as pharmacological post-conditioning agent.
AID1293024	Ratio of drug level in erythrocytes to plasma in healthy subject (8 subjects)	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID581958	Cytotoxicity against human HepAD38 cells	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID150756	Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID558965	Inhibition of West Nile virus NS5 polymerase at 0.8 uM	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID350876	Reduction of chemotaxis in human neutrophils assessed as inhibition of fMLP-OMe-induced cell migration pretreated 10 mins before fMLP-OMe challenge	2009	Bioorganic & medicinal chemistry, May-01, Volume: 17, Issue:9	1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors.
AID1199781	Inhibition of p-gp (unknown origin) in doxorubicin-resistant human K562/R7 cells assessed as increase in daunorubicin accumulation measured as fluorescence ratio at 10 uM incubated for 1 hr with 10 uM daunorubicin by flow cytometry relative to control	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells.
AID1533108	Inhibition of P-gp-mediated doxorubicin efflux in human Lucena 1 cells assessed as ratio of doxorubicin fluorescence intensity in presence of compound to doxorubicin fluorescence intensity in absence of compound at 0.098 uM preincubated for 1 hr followed	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1322040	Immunosuppressive activity in human anti-CD3/CD28 stimulated Jurkat T cells assessed as suppression of IL2 production at 1 uM pretreated with cells followed by anti-CD3/CD28 stimulation measured after 13 hrs by ELISA	2016	Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21	Discovery and structure-activity relationship studies of quinolinone derivatives as potent IL-2 suppressive agents.
AID1292984	Volume of distribution at steady state in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 4 mg/kg, iv by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID678833	TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell	1995	The Journal of clinical investigation, Oct, Volume: 96, Issue:4	Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
AID1289120	Volume of distribution in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID248451	In vitro concentration of compound required to inhibit ConA-induced T cell proliferation to 50% in BALB/c mice	2005	Journal of medicinal chemistry, Jul-14, Volume: 48, Issue:14	Synthesis and immunosuppressive activity of new artemisinin derivatives. 1. [12(beta or alpha)-Dihydroartemisininoxy]phen(ox)yl aliphatic acids and esters.
AID105426	Growth inhibitory activity on MDA-435/LCC6 (Pgp-positive) human breast cancer cells.	2002	Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2	C-7 analogues of progesterone as potent inhibitors of the P-glycoprotein efflux pump.
AID1293036	Protein binding in plasma (unknown origin) at 110 uCi by ultracentrifugation method	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID444054	Oral bioavailability in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1591784	Cytotoxicity against BALB/c mouse splenocytes assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	2019	Bioorganic & medicinal chemistry, 08-01, Volume: 27, Issue:15	Highly diverse cembranoids from the South China Sea soft coral Sinularia scabra as a new class of potential immunosuppressive agents.
AID1532103	Inhibition of ABCC1 in human H69AR cells assessed as calcein-AM accumulation preincubated for 30 mins followed by calcein-AM addition measured over 60 mins at 60 secs time interval by fluorescence assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID1201805	Inhibition of MDR1 in human NCI-ADR-RES cells assessed as increase in rhodamine-123 uptake at 50 uM after 1 hr by fluorescence assay relative to control	2015	European journal of medicinal chemistry, May-05, Volume: 95	Boronic species as promising inhibitors of the Staphylococcus aureus NorA efflux pump: study of 6-substituted pyridine-3-boronic acid derivatives.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID681120	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID624660	Inhibition of mycophenolic acid glucuronidation by human kidney microsomes	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID695338	Inhibition of human MRP1 expressed in 2008 cells at 10 uM preincubated for 30 mins prior to calcein AM addition measured every 60 secs up to 90 mins by calcein AM accumulation assay	2012	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21	4-Substituted-2-phenylquinazolines as inhibitors of BCRP.
AID680487	TP_TRANSPORTER: inhibition of JC-1 uptake (JC-1: ca 0.1 uM, CsA: 5 uM) in K562 and K562/ADR cells, flow cytometry	1997	Leukemia, Jul, Volume: 11, Issue:7	Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe.
AID1289159	Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 6.8 +/- 1.1 hrs during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1758183	Antiproliferative activity against human MCF7 cells assessed as inhibition rate at 10 uM incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID1889491	Cytotoxicity in BALB/c mouse Splenocyte assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID94998	Rhodamine-123 accumulation in K562 cells with or without expression of PGP protein at a concentration of 1 uM	2003	Journal of medicinal chemistry, May-22, Volume: 46, Issue:11	Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.
AID1289182	Ratio of clearance in blood to plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1289162	Clearance in plasma of post-renal transplant patient	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID762644	Antiviral activity against Hepatitis C virus	2013	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16	Cyclophilin inhibitors as antiviral agents.
AID1289160	Tmax in plasma of healthy human subjects (8 subjects) at 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1289177	Ratio of oral bioavailability in plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1209651	Apparent permeability from apical to basolateral side of MDCK1 cells expressing MDR1 at 25 uM after 2 hrs by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5	Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
AID711677	Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in adriamycin uptake at 5 uM after 1 hr by flow cytometry analysis	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID581763	Immunosuppressive activity in Sprague-Dawley rat KHL model assessed as percent T lymphocytes at 10 mg/kg, po administered once daily for 28 days by flow cytometry	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1364835	Inhibition of mTOR signaling pathway (unknown origin) in sub-genomic replicon 2A cells assessed as reduction in NS3 levels up to 400 nM by Western blot analysis relative to control	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	Functional evaluation of synthetic flavonoids and chalcones for potential antiviral and anticancer properties.
AID185525	Mean survival time of rats after skin allograft (oral administration) at 30 mg/kg	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID1289123	Oral bioavailability in plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1766762	Inhibition of benzmarone-stimulated MRP3 ATPase activity (unknown origin) in presence of GSH	2021	Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor.
AID444053	Renal clearance in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID393842	Inhibition of allogenic cells-stimulated proliferation in mouse T cells by mixed lymphocyte reaction method	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID1221962	Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY335979	2011	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2	Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID303928	Permeability in biomimetic membrane layer DMPC vesicles assessed as decrease in fluorescence at 30 uM by colorimetric mixed-vesicle assay	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability.
AID1874014	Antiviral activity against Hepatitis B virus infected in human HepG2 cells expressing NTCP assessed as inhibition of viral entry by measuring intracellular HBV DNA preincubated with compound for 2 hrs followed by viral infection and measured after 3 hrs b	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation.
AID1586223	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of LPS-stimulated B-cell proliferation by measuring [3H]-thymidine uptake preincubated for 48 hrs followed by LPS stimulation and [3H]-thymidine addition for 8 hrs measured afte	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Design and Synthesis of Marine Phidianidine Derivatives as Potential Immunosuppressive Agents.
AID581935	Antiviral activity against Yellow fever virus 17D infected in african green monkey Vero cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1140183	Increase in doxorubicin retention in P-gp-deficient human Me30966 cells at 5 uM after 2 hrs by flow cytometric analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID358652	Modulation of P-gp in human UO31 cells assessed as increase in DINIB-induced cytotoxicity at 0.4 to 6.3 ug/mL	2001	Journal of natural products, Dec, Volume: 64, Issue:12	Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
AID1338614	Inhibition of TSPO in mouse HT22 cells assessed as protection against amyloid beta (1 to 42)-induced mitochondrial membrane potential loss by measuring recovery of mitochondrial membrane potential at 5 uM preincubated for 10 mins followed by amyloid beta	2017	European journal of medicinal chemistry, Jan-05, Volume: 125	Discovery of benzimidazole derivatives as modulators of mitochondrial function: A potential treatment for Alzheimer's disease.
AID681155	TP_TRANSPORTER: increase in bodipy intracellular accumulation (Bodipy: 0.2 uM) in SK-E2 cells (expressing BSEP)	2003	Pharmaceutical research, Apr, Volume: 20, Issue:4	Fluorescent substrates of sister-P-glycoprotein (BSEP) evaluated as markers of active transport and inhibition: evidence for contingent unequal binding sites.
AID1293011	Drug metabolism in pre-kidney transplant end stage renal disease patient (8 patients) blood assessed as ratio of metabolite M1 AUC (0 to infinity) to parent compound AUC (0 to infinity) at 10 mg/kg, po by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID150759	P-gp activity was measured by a direct transport assay, using polarized LLC-mdr1a epithelial cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID711671	Inhibition of Pgp-mediated drug efflux in adriamycin-resistant human A2780 cells assessed as increase in intracellular adriamycin level at 5 uM after 40 mins by flow cytometry analysis	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Peptide-chlorambucil conjugates combat pgp-dependent drug efflux.
AID495176	Inhibition of PPIase activity of cyclophilin 18 by protease coupled assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Augmented photoswitching modulates immune signaling.
AID1140187	Inhibition of p-gp in doxorubicin-resistant human Saos2 cells assessed as intracellular doxorubicin distribution in nuclei at 5 uM after 2 to 3 hrs by laser scanning confocal microscopic analysis	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Voacamine modulates the sensitivity to doxorubicin of resistant osteosarcoma and melanoma cells and does not induce toxicity in normal fibroblasts.
AID1293029	Drug metabolism in cadaveric renal transplant recipient (21 recipients) blood assessed as ratio of metabolite M17 AUCt at steady state to parent compound AUCt at steady state at 8 mg/kg/day, po	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID768684	Inhibition of p-glycoprotein (unknown origin) expressed in human A2780Adr cells assessed as calcein-AM accumulation preincubated for 30 mins before calcein-AM addition measured up to 90 mins by fluorescence assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474099	Ratio of drug concentration at steady state in human at 20 to 600 mg/kg, po after 24 hrs to IC50 for human MRP2 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588993	Inhibitors of transporters of clinical importance in the absorption and disposition of drugs, MDR1	2010	Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3	Membrane transporters in drug development.
AID696201	Inhibition of Ca2+-induced mitochondrial permeability transition in human HL60 cells at 5 uM after 40 mins relative to control	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Small-molecular inhibitors of Ca²⁺-induced mitochondrial permeability transition (MPT) derived from muscle relaxant dantrolene.
AID1701155	Anti-autoimmune disease activity in OFA rat model of T-cell dependent B cell response assessed as reduction in SRBC-induced IgM producing B cells at 6 mg/kg, po QD for 4 days starting 2 days prior to immunization by ex vivo plaque forming assay relative t	2020	Journal of medicinal chemistry, 12-10, Volume: 63, Issue:23	Optimization of the
AID445149	Immunosuppressive activity in human splenocytes assessed as inhibition of [3H]thymidine incorporation after 4 days by allogenic mixed lymphocyte reaction assay	2009	Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20	Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
AID386623	Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	2008	Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19	Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID681581	TP_TRANSPORTER: inhibition of Fluo-3-AM efflux in NIH-3T3-G185 cells	2001	Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2	Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1224299	Induction of apoptosis in LLO118 TCR transgenic mouse LLO (190 to 205)-activated CD4-positive T cells assessed as live undivided cells at 100 nM after 48 hrs by CFSE dilution/flow cytometric analysis (Rvb = 41.6%)	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID448456	Induction of P-gp-mediated rhodamine 123 uptake in BBMEC	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	(3R,5S,7as)-(3,5-Bis(4-fluorophenyl)tetrahydro-1H-oxazolo[3,4-c]oxazol-7a-yl)methanol, a novel neuroprotective agent.
AID155303	Effect on proliferation of human peripheral blood mononuclear cells (PMBC) at 72 hr using MTT assay	2004	Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14	Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID150757	P-gp activity was measured by a direct transport assay, using polarized LLC-MDR1 epithelial cells	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
AID1289163	Clearance in blood of healthy human subjects	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID681482	TP_TRANSPORTER: Western in vivo, kidney of SD rat	1996	The American journal of physiology, May, Volume: 270, Issue:5 Pt 2	Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues.
AID1228911	Selectivity index, ratio of IC50 for mouse L292 cells to EC50 for modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversing paclitaxel resistance	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Potent and Nontoxic Chemosensitizer of P-Glycoprotein-Mediated Multidrug Resistance in Cancer: Synthesis and Evaluation of Methylated Epigallocatechin, Gallocatechin, and Dihydromyricetin Derivatives.
AID1062338	Therapeutic index, ratio of IC50 for mouse L929 cells to EC50 for modulation of p-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversal of paclitaxel resistance	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Structure-activity relationship study of permethyl ningalin B analogues as P-glycoprotein chemosensitizers.
AID358907	Increase in DINIB-induced cytotoxicity against human LOXIMVI at 0.4 to 6.3 ug/mL	2001	Journal of natural products, Dec, Volume: 64, Issue:12	Modulation of the multidrug-resistance phenotype by new tropane alkaloid aromatic esters from Erythroxylum pervillei.
AID1758181	Inhibition of P-glycoprotein in human MCF7/ADR cells assessed as reversal fold by measuring reduction in doxorubicin IC50 at 5 uM incubated for 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	Design, synthesis and bioactivity study on 5-phenylfuran derivatives as potent reversal agents against P-glycoprotein-mediated multidrug resistance in MCF-7/ADR cell.
AID685501	HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells	2012	Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22	Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1532163	Apparent permeability in low-efflux MDCK2 cells at 2 uM by lucifer yellow dye-based UPLC-MS analysis	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Lipophilic Permeability Efficiency Reconciles the Opposing Roles of Lipophilicity in Membrane Permeability and Aqueous Solubility.
AID1057950	Inhibition of MRP1 in human 2008 cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID444058	Volume of distribution at steady state in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID731548	Immunosuppressive activity in human RPMI1788 cells cocultured with human PBMC assessed as inhibition of [3H]thymidine incorporation incubated for 6 days prior to [3H]thymidine addition measured after 18 hrs by liquid scintillation counting	2013	Bioorganic & medicinal chemistry, Mar-01, Volume: 21, Issue:5	Synthesis of a 2,4,6-trisubstituted 5-cyano-pyrimidine library and evaluation of its immunosuppressive activity in a Mixed Lymphocyte Reaction assay.
AID310120	Inhibition of P-glycoprotein expressed in A2780/ADR cells by calcein AM assay	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	New functional assay of P-glycoprotein activity using Hoechst 33342.
AID324583	Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control	2007	Proceedings of the National Academy of Sciences of the United States of America, Nov-27, Volume: 104, Issue:48	Small molecule regulators of autophagy identified by an image-based high-throughput screen.
AID197947	In vitro inhibitory activity against HIV-1 RT in CEM4 cell line	2003	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24	Synthesis of non-immunosuppressive cyclophilin-Binding cyclosporin A derivatives as potential anti-HIV-1 drugs.
AID1895164	Permeability across apical to basal side in human Caco-2 cells preincubated with verapamil for 30 mins followed by compound addition measured at 0.5 to 2 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID67781	Reversal effect on the accumulation of [3H]- daunorubicin in mouse mammary carcinoma cell line EMT6/AR 1.0	1999	Bioorganic & medicinal chemistry letters, Feb-22, Volume: 9, Issue:4	Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.
AID130695	In vivo immunosuppressive activity in the delayed type hypersensitivity model induced by SRBC-TH cells in mouse after peroral administration	1999	Bioorganic & medicinal chemistry letters, Jun-07, Volume: 9, Issue:11	Isolation and synthesis of a novel immunosuppressive 17alpha-substituted dammarane from the flour of the Palmyrah palm (Borassus flabellifer).
AID1224302	Antiinflammatory activity in LLO118 TCR transgenic mouse IL-2-competent CD4-positive T cells assessed as inhibition of LLO (190 to 205)-induced IL-2 production at 0.01 to 100 nM for 2 days by flow cytometric analysis	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID1293004	Tmax in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg, po administered through solution by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID132491	Immunosuppressive activity on mouse allogenic MLR in vitro	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID655423	Immunosuppressive activity in C57BL/6 mouse transplanted with trunk skin of BALB/c mouse assessed as inhibition of skin graft rejection at 20 umol/kg, sc measured up to 19 days	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	Synthetic N-alkylated iminosugars as new potential immunosuppressive agents.
AID394914	Effect on humoral immune response in sheep red blood cells-immunized CBA mouse spleen assessed as number of antibody forming unit per 10'6 viable cells at 100 ug, ip by local hemolysis assay	2008	European journal of medicinal chemistry, Nov, Volume: 43, Issue:11	Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine.
AID1765678	Inhibition of calcineurin (unknown origin)	2021	Bioorganic & medicinal chemistry letters, 09-15, Volume: 48	Vomifoliol isolated from mangrove plant Ceriops tagal inhibits the NFAT signaling pathway with CN as the target enzyme in vitro.
AID393841	Inhibition of allogenic cells-stimulated proliferation in monkey T cells by mixed lymphocyte reaction method	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID581953	Antiviral activity against HPV-33 infected in CK1 cells assessed as inhibition of viral replication after 7 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1289168	Drug absorption in healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by Loo-Riegelman method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID648437	Inhibition of Con A-induced phospho-GATA3 expression in human PBMC at 90 uM after 72 hrs by flow cytometry	2012	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1	An iminosugar N-pentafluorobenzyl-1-deoxynojirimycin as a novel potential immunosuppressant for the treatment of Th2-related diseases.
AID1289134	Clearance in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID621446	Cytotoxicity against human Jurkat E6-1 cells assessed as cell viability at 10 uM after 72 hrs by MTT assay relative to control	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and biological evaluation of α,β-unsaturated lactones as potent immunosuppressive agents.
AID1293026	Oral bioavailability in healthy subject (8 subjects) blood at 10 mg/kg by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID1289135	Mean residence time in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID132677	In vitro inhibitory activity against mouse mixed lymphocyte reaction (MLR)	1998	Journal of medicinal chemistry, Aug-27, Volume: 41, Issue:18	Pyrazole bioisosteres of leflunomide as B-cell immunosuppressants for xenotransplantation and chronic rejection: scope and limitations.
AID102709	In vitro inhibition of interleukin-2 (IL-2) production induced by stimulating lymphocytes derived from mouse spleens with the mitogen canavalin A	1995	Journal of medicinal chemistry, May-26, Volume: 38, Issue:11	Preparation and in vitro activities of ethers of [D-serine]8-cyclosporin.
AID1586222	Immunosuppressive activity in BALB/c mouse splenocytes assessed as inhibition of concanavalin A stimulated T-cell proliferation by measuring [3H]-thymidine uptake preincubated for 48 hrs followed by concanavalin A stimulation and [3H]-thymidine addition f	2018	Journal of medicinal chemistry, 12-27, Volume: 61, Issue:24	Design and Synthesis of Marine Phidianidine Derivatives as Potential Immunosuppressive Agents.
AID94163	MDR-reversal property tested in vitro on KB-A1 cells, resistance was induced by adriamycin	1996	Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20	New purines and purine analogs as modulators of multidrug resistance.
AID326368	Inhibition of human Pgp in A2780 cells after 30 mins by calcein AM assay	2008	Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5	Functional assay and structure-activity relationships of new third-generation P-glycoprotein inhibitors.
AID1057951	Inhibition of MDR1 in human doxorubicin-resistant A2780adr cells assessed as Calcein AM accumulation treated 30 mins before Calcein AM addition measured up to 90 mins by fluorescence assay	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).
AID1674183	Inhibition of human BSEP expressed in HEK293 cell membrane vesicles assessed as reduction in 3H-TCA uptake incubated for 5 mins by radiodetection method	2020	Journal of medicinal chemistry, 10-22, Volume: 63, Issue:20	Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
AID1364650	Inhibition of ConA-induced cell proliferation of BALB/c mouse T-lymphocytes assessed as reduction in [3H]thymidine incorporation incubated for 48 hrs by beta scintillation counting method	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Absolute Configuration of Periplosides C and F and Isolation of Minor Spiro-orthoester Group-Containing Pregnane-type Steroidal Glycosides from Periploca sepium and Their T-Lymphocyte Proliferation Inhibitory Activities.
AID1895167	Tmax in ICR mouse at 20 mg/kg, po measured after 0.25 to 24 hrs by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 06-24, Volume: 64, Issue:12	Interplay among Conformation, Intramolecular Hydrogen Bonds, and Chameleonicity in the Membrane Permeability and Cyclophilin A Binding of Macrocyclic Peptide Cyclosporin O Derivatives.
AID420712	Immunosuppressive activity in splenocytes assessed as inhibition of LPS-induced proliferation after 48 hrs by [3H]thymidine incorporation assay	2009	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 19, Issue:13	Hirtellanines A and B, a pair of isomeric isoflavonoid derivatives from Campylotropis hirtella and their immunosuppressive activities.
AID1289181	Ratio of oral bioavailability in blood to plasma of healthy human subjects (8 subjects) at 10 mg/kg measured during high fat diet phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1327025	Inhibition of ABCC2 (unknown origin)	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.
AID1226785	Oral bioavailability in Wistar-Han rat at 10 mg/kg after 0.033 to 24 hrs by LC-MS/MS method	2015	Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11	Probing the Physicochemical Boundaries of Cell Permeability and Oral Bioavailability in Lipophilic Macrocycles Inspired by Natural Products.
AID1182022	Inhibition of human P-glycoprotein expressed in NCI/ADR-RES cells assessed as reduction of calcein-AM transport after 20 mins by fluorescence assay	2014	Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14	Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
AID581931	Antiviral activity against Feline coronavirus infected in CRFK assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1331008	Binding affinity to recombinant His-tagged Cyp18 (unknown origin) expressed in Escherichia coli BL21(DE3) assessed as blue shift by UV absorbance method	2016	Bioorganic & medicinal chemistry letters, 12-01, Volume: 26, Issue:23	Thioxylated cyclosporin A for studying protein-drug interactions.
AID132694	Inhibitory activity against the proliferation of lymphocytes in mouse allogenic mixed lymphocyte reaction (MLR).	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	Peptidic immunosuppressants from the fungus Trichoderma polysporum.
AID481439	Absolute bioavailability in human	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1443995	Hepatotoxicity in human assessed as drug-induced liver injury	2014	Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3	Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1169141	Apparent permeability in RRCK cells	2014	ACS medicinal chemistry letters, Oct-09, Volume: 5, Issue:10	EPSA: A Novel Supercritical Fluid Chromatography Technique Enabling the Design of Permeable Cyclic Peptides.
AID394065	Inhibition of human GM-CSF-induced proliferation in human HUO3 cells assessed as [3H]thymidine incorporation after 4 days by scintillation counting	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID681175	TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat	2002	Drug metabolism and pharmacokinetics, , Volume: 17, Issue:1	The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites.
AID1142015	Reversal of Pgp-1-mediated multidrug resistance in human SW620/Ad300 cells overexpressing ABCB1 assessed as potentiation of paclitaxel cytotoxicity at 3 uM treated for 2 hrs prior to paclitaxel challenge measured after 72 hrs by MTT assay relative to pacl	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Design and synthesis of human ABCB1 (P-glycoprotein) inhibitors by peptide coupling of diverse chemical scaffolds on carboxyl and amino termini of (S)-valine-derived thiazole amino acid.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1533116	Inhibition of P-gp-mediated Rho-123 efflux in human Lucena 1 cells at 25 uM preincubated for 1 hr followed by Rho-123 addition measured after 1 hr by flow cytometry	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID1289130	Mean absorption time in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID200742	Exogenous inhibition concentration of Serine/threonine protein phosphatase 2B (PP2B)	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID501984	Inhibition of irradiated BALB/c mouse splenocyte-stimulated IL2 secretion in 2C mouse splenocyte at 100 ng/mL after 24 hrs by mixed lymphocyte reaction	2010	Bioorganic & medicinal chemistry, Sep-01, Volume: 18, Issue:17	Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors.
AID1292978	Oral bioavailability in pre-kidney transplant end stage renal disease patient (8 patients) plasma at 10 mg/kg by HPLC analysis	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID652502	Immunosuppressive activity in BALB/c mouse splenocytes assessed as reduction in concanavalin-A-induced IL4 production at 1 uM after 48 hrs by ELISA	2011	ACS medicinal chemistry letters, Sep-08, Volume: 2, Issue:9	Synthetic N-alkylated iminosugars as new potential immunosuppressive agents.
AID359250	Reduction of P-gp-mediated [99mTc]sestamibi efflux in doxorubicin-resistant Brca1 and p53 deficient mouse mammary tumor T*23 xenografted mouse hereditary breast cancer model after 30 mins	2007	Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 104, Issue:29	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
AID1289122	Mean absorption time in blood of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID437042	Immunosuppressive activity against concanavalin A-induced BALB/c mouse splenocytes assessed as T-cells activation at 1 uM after 24 hrs by FACS assay	2009	Bioorganic & medicinal chemistry, Aug-01, Volume: 17, Issue:15	Synthesis and evaluation of a novel series of quinoline derivatives with immunosuppressive activity.
AID196261	Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 30 mg/kg	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID644406	Selectivity index, ratio of CC50 for lymph node T cell to IC50 for lymph node T cell	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Synthesis, molecular docking and biological evaluation of 1,3,4-oxadiazole derivatives as potential immunosuppressive agents.
AID558946	Antiviral activity against Dengue virus 2 infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID210154	In vitro inhibition of Ab formation from trinitrophenyl-lipopolysaccharide (TNP-LPS) B-cells.	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Aromatic quinolinecarboxamides as selective, orally active antibody production inhibitors for prevention of acute xenograft rejection.
AID594602	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral replication at 10 uM after 48 hrs by flow cytometry	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro.
AID444056	Fraction escaping gut-wall elimination in human	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1443980	Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch	2010	Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID496040	Inhibition of human recombinant CYP2C19 after 30 mins	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
AID1533115	Inhibition of P-gp-mediated Rho-123 efflux in human Lucena 1 cells at 12.5 uM preincubated for 1 hr followed by Rho-123 addition measured after 1 hr by flow cytometry	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Analogues of the Lignan Pinoresinol as Novel Lead Compounds for P-glycoprotein (P-gp) Inhibitors.
AID196255	Immunosuppressive activity against skin allograft in F344 recipient (rat) from LEW donor (rat) at a concentration of 1 mg/kg	2000	Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15	Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols.
AID95451	Inhibition of production of beta-galactosidase IL-2 RGA in Jurkat cells	2002	Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6	Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies.
AID1393013	Immunosuppressive activity in C57BL/6 mouse lymph node cells after 24 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 08-01, Volume: 28, Issue:14	Design and synthesis of plant cyclopeptide Astin C analogues and investigation of their immunosuppressive activity.
AID719607	Binding affinity to cyclophilin A by surface plasmon resonance analysis	2011	ACS medicinal chemistry letters, Jun-09, Volume: 2, Issue:6	Ranking high affinity ligands of low solubility by NMR spectroscopy.
AID1272184	Cytotoxicity against mouse lymph node cells after 24 hrs by MTT assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	(E)-1,3-diphenyl-1H-pyrazole derivatives containing O-benzyl oxime moiety as potential immunosuppressive agents: Design, synthesis, molecular docking and biological evaluation.
AID581950	Antiviral activity against HPV-33 infected in CK1 cells assessed as inhibition of viral replication after 3 days	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID185522	Mean survival time of rats after skin allograft (oral administration) at 100 mg/kg; toxic - animals died	1996	Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22	Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols.
AID1889493	Immunosuppressive activity in BALB/c mouse Splenocyte assessed as inhibition of LPS induced B-cell proliferation by [3H]-thymidine incorporation based beta scintillation counter analysis	2022	Journal of natural products, 02-25, Volume: 85, Issue:2	Ophiorrhines F and G, Key Biogenetic Intermediates of Ophiorrhine Alkaloids from
AID558963	Inhibition of West Nile virus nucleoside-triphosphatase up to 100 uM	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1224321	Immunosuppressive activity in lymphocytes by MLR assay	2014	ACS medicinal chemistry letters, May-08, Volume: 5, Issue:5	Biological evaluation of subglutinol a as a novel immunosuppressive agent for inflammation intervention.
AID38028	Tested for inhibitory activity against B lymphocyte proliferation induced by LPS; suppressed the proliferation no significant effect	1998	Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3	Immunomodulatory activity of thunberginol A and related compounds isolated from Hydrangeae Dulcis Folium on splenocyte proliferation activated by mitogens.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1501264	Inhibition of ABCB1 in human A2780/ADR cells assessed as reduction in calcein-AM efflux preincubated for 30 mins followed by calcein-AM addition measured at 60 secs interval for 60 mins by fluorescence assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
AID681854	TP_TRANSPORTER: inhibition of Digoxin uptake (Digoxin: 0.05 uM, CsA: 30 uM) in Oatp2-expressing LLC-PK1 cells	2002	Pharmaceutical research, Feb, Volume: 19, Issue:2	Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
AID714415	Cytotoxicity against human LCC-6 cells after 72 hrs	2012	Journal of medicinal chemistry, Mar-08, Volume: 55, Issue:5	Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
AID558942	Antiviral activity against Dengue virus 2 infected in human Huh7.5 cells at 8 to 20 uM after 48 hrs by plaque formation assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID706965	Immunosuppressive activity in mouse T cells assessed as inhibition of two way mixed lymphocyte reaction after 4 days by MTT assay	2012	Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19	Discovery of diverse human dihydroorotate dehydrogenase inhibitors as immunosuppressive agents by structure-based virtual screening.
AID1199783	Intrinsic cytotoxicity against human K562 cells assessed as cell survival at 10 uM after 24 hrs by MTT assay	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells.
AID409954	Inhibition of mouse brain MAOA	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1600403	Permeability in RRCK cells	2019	ACS medicinal chemistry letters, Jul-11, Volume: 10, Issue:7	Permeability of Cyclic Peptide Macrocycles and Cyclotides and Their Potential as Therapeutics.
AID209947	Tested for inhibitory activity against T lymphocyte proliferation induced by Con A at 10e-7 M; showed potent suppressive effect	1998	Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3	Immunomodulatory activity of thunberginol A and related compounds isolated from Hydrangeae Dulcis Folium on splenocyte proliferation activated by mitogens.
AID481444	Octanol-water partition coefficient, log P of the compound	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1874023	Inhibition of human CYP3A4 in pooled human liver microsomes using nifedipine as substrate incubated for 10 mins in the presence of NADP	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Entry inhibition of hepatitis B virus using cyclosporin O derivatives with peptoid side chain incorporation.
AID678713	Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID234690	Relative IC50 is the ratio of IC50 of the compound/IC50 CsA (IL2-RGA)	1995	Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17	The role of water molecules in the structure-based design of (5-hydroxynorvaline)-2-cyclosporin: synthesis, biological activity, and crystallographic analysis with cyclophilin A.
AID1771380	Inhibition of mouse CTLL-2 cells activity at 10 uM incubated for 24 hrs
AID1532102	Inhibition of ABCB1 in human A2780/ADR cells assessed as calcein-AM accumulation preincubated for 30 mins followed by calcein-AM addition measured over 60 mins at 60 secs time interval by fluorescence assay	2019	European journal of medicinal chemistry, Jan-01, Volume: 161	Synthesis and biological evaluation of quinazoline derivatives - A SAR study of novel inhibitors of ABCG2.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1756327	Inhibition of Salsolinol-induced oxidative stress in human SH-SY5Y cells assessed as reduction in superoxide radical formation at 0.5 uM measured after 24 hrs by DHE staining based fluorescence microscopy	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID681558	TP_TRANSPORTER: transepithelial transport of CPT-11(Lactone form) (basal to apical) in Mdr1a-expressing LLC-PK1 cells	2003	Pharmaceutical research, Jun, Volume: 20, Issue:6	Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
AID1327018	Inhibition of ABCC2 (unknown origin) expressed in MDCK2 cells assessed as inhibition of calcein-AM efflux measured after 30 mins in presence of ABCB1 inhibitor GF120918 and ABCC1 inhibitor MK-571 by flow cytometry	2016	European journal of medicinal chemistry, Oct-21, Volume: 122	2-Indolylmethylenebenzofuranones as first effective inhibitors of ABCC2.
AID624623	Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells	2001	The Journal of pharmacology and experimental therapeutics, Nov, Volume: 299, Issue:2	Rational use of in vitro P-glycoprotein assays in drug discovery.
AID1508553	Inhibition of amyloid beta (1 to 42)-induced mPTP opening in mouse HT22 cells assessed as reduction in mitochondrial membrane potential loss by measuring green to red fluorescence ratio at 5 uM preincubated for 10 mins followed by amyloid beta (1 to 42) a	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: Neuroprotection against amyloid-β-induced toxicity.
AID679123	TP_TRANSPORTER: transcellular transport in mdr1a-expressing LLC-PK1 cells	2007	Neuropharmacology, Feb, Volume: 52, Issue:2	Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
AID1209614	Reversible competitive inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro.
AID678721	Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis	2012	Chemical research in toxicology, Oct-15, Volume: 25, Issue:10	Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID339500	Binding affinity to human Cyclophilin A	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Simultaneous identification of multiple receptors of natural product using an optimized cDNA phage display cloning.
AID581922	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1813133	Reversal of P-glycoprotein mediated drug resistance in human LCC6MDR cells assessed as reversal of paclitaxel resistance measured after 5 days by Cell Titer-Glo luminescence assay	2021	European journal of medicinal chemistry, Dec-15, Volume: 226	Synthesis and evaluation of stereoisomers of methylated catechin and epigallocatechin derivatives on modulating P-glycoprotein-mediated multidrug resistance in cancers.
AID1289148	Elimination half life in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1289146	Mean absorption time in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during high fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1756334	Inhibition of salsolinol-induced mPTP opening in human SH-SY5Y cells assessed as fold change in fluorescence intensity at 0.5 uM measured after 24 hrs by calcein AM/CoCl2 based fluorescence microscopic analysis (Rvb = 0.49 +/-0.02 No_unit)	2021	European journal of medicinal chemistry, Mar-05, Volume: 213	Novel pentacyclic triterpenes exhibiting strong neuroprotective activity in SH-SY5Y cells in salsolinol- and glutamate-induced neurodegeneration models.
AID580942	Inhibition of human MDR1 expressed in mouse L5178 cells assessed as increase in intracellular accumulation of rhodamine 123 by FACSCalibur flow cytometry	2010	ACS medicinal chemistry letters, Nov-11, Volume: 1, Issue:8	From taxuspine x to structurally simplified taxanes with remarkable p-glycoprotein inhibitory activity.
AID558960	Antiviral activity against Dengue virus 1 infected in human Huh7.5 cells assessed as decrease in viral RNA synthesis at 8 uM after => 20 hrs by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Cyclosporine inhibits flavivirus replication through blocking the interaction between host cyclophilins and viral NS5 protein.
AID1707585	Antiviral activity against HBV infected in human HepG2-NTCP cells assessed as reduction in HBeAg secretion cells inoculated with virus for 4 hrs at room temperature and 37 degree C for 24 hrs followed inoculum changed with PMM medium for every 2 days unti
AID432797	Antifungal activity against Candida kefyr ATCC 46764 at 3 ug/ml after 14 to 18 hrs	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Effect of calcineurin inhibitors on posaconazole blood levels as measured by the MVista microbiological assay.
AID581939	Antiviral activity against Herpes simplex virus 1 McIntyre infected in human embryonic lung cells assessed as inhibition of viral replication	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.
AID1362386	Antiviral activity against HCV genotype 2a infected in human HuH7 cells after 3 days by dual-glo luciferase reporter gene assay	2018	Journal of medicinal chemistry, 11-08, Volume: 61, Issue:21	Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
AID1289175	Ratio of volume of distribution at steady state in plasma of healthy human subjects (8 subjects) at 4 mg/kg, iv and 10 mg/kg, po measured during low fat diet phase to high fat diest phase	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1681291	Antiinflammatory activity in Balb/cj mouse model of DSS-induced colitis assessed as reduction in disease activity index score at 25 mg/kg, po qd for 11 days measured daily during compound dosing	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Discovery of 9-Cyclopropylethynyl-2-((
AID1639217	Immunosuppressive activity in BALB/c mouse lymph node cells assessed as inhibition of concanavalin A stimulated T-cell proliferation measured after 48 hrs by CCK8 assay	2019	Journal of natural products, 04-26, Volume: 82, Issue:4	Phloroglucinols with Immunosuppressive Activities from the Fruits of Eucalyptus globulus.
AID1293032	Clearance in iv dosed renal transplant patient blood	1994	Journal of clinical pharmacology, Jan, Volume: 34, Issue:1	Pharmacokinetics of orally and intravenously administered cyclosporine in pre-kidney transplant patients.
AID394030	Immunosuppressive activity in po dosed kidney transplanted cynomolgus monkey assessed as graft survival at 150 to 300 ng/ml trough level	2003	Science (New York, N.Y.), Oct-31, Volume: 302, Issue:5646	Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor.
AID242628	Inhibitory concentration against proliferation of mouse splenocytes was determined by measuring mitochondrial dehydrogenase activity using MTT assay	2005	Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11	Synthetic iminosugar derivatives as new potential immunosuppressive agents.
AID681383	TP_TRANSPORTER: inhibition of Taxol transepithelial transport (basal to apical) in Caco-2 cells	2001	Pharmaceutical research, Feb, Volume: 18, Issue:2	A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
AID135185	Inhibition of paw edema formation in mouse after an ip dose of 50 mg/kg; Thickness of paw = 2.10+/-0.06 mm	1997	Journal of medicinal chemistry, Jun-20, Volume: 40, Issue:13	A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug.
AID1289152	Cmax in blood of healthy human subjects (8 subjects) at 10 mg/kg, po measured at 8.4 +/- 0.9 hrs during low fat diet phase by HPLC method	1990	Journal of clinical pharmacology, Jul, Volume: 30, Issue:7	Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346843	Human ABCG2 (ABCG subfamily)	2001	Biochemical and biophysical research communications, Jul-06, Volume: 285, Issue:1	Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells.
AID1345178	Human OATP1B1 (SLCO family of organic anion transporting polypeptides)	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1345827	Human FPR1 (Formylpeptide receptors)	1997	Biochemical pharmacology, Sep-15, Volume: 54, Issue:6	Inhibitory effects of spinorphin, a novel endogenous regulator, on chemotaxis, O2- generation, and exocytosis by N-formylmethionyl-leucyl-phenylalanine (FMLP)-stimulated neutrophils.
AID1346962	Human Sodium/bile acid and sulphated solute cotransporter 1 (SLC10 family of sodium-bile acid co-transporters)	2013	Molecular pharmaceutics, Mar-04, Volume: 10, Issue:3	Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP).
AID1346962	Human Sodium/bile acid and sulphated solute cotransporter 1 (SLC10 family of sodium-bile acid co-transporters)	1999	The Journal of pharmacology and experimental therapeutics, Dec, Volume: 291, Issue:3	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity.
AID1346209	Human peptidylprolyl isomerase A (5.2.-.- Cis-trans-isomerases)	1992	Proceedings of the National Academy of Sciences of the United States of America, May-01, Volume: 89, Issue:9	Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.
AID1345151	Human OATP1B3 (SLCO family of organic anion transporting polypeptides)	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1345178	Human OATP1B1 (SLCO family of organic anion transporting polypeptides)	2003	Naunyn-Schmiedeberg's archives of pharmacology, Nov, Volume: 368, Issue:5	Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins.
AID1345151	Human OATP1B3 (SLCO family of organic anion transporting polypeptides)	2007	Drug metabolism and disposition: the biological fate of chemicals, Aug, Volume: 35, Issue:8	Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1802994	UDP-glucuronosyltransferase Activity Assay from Article 10.3109/14756366.2010.518965: \\The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.\\	2011	Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 26, Issue:3	The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.
AID1804171	DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\	2020	Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7	Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1802450	Oatp1d1 Transport Assay from Article 10.1074/jbc.M113.518506: \\Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.\\	2013	The Journal of biological chemistry, Nov-22, Volume: 288, Issue:47	Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2013	Plant physiology, Jul, Volume: 162, Issue:3	A redox 2-Cys mechanism regulates the catalytic activity of divergent cyclophilins.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2009	Angewandte Chemie (International ed. in English), , Volume: 48, Issue:28	The thermodynamic influence of trapped water molecules on a protein-ligand interaction.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347168	HepG2 cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347149	Furin counterscreen qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347169	Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347150	Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508628	Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629	Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627	Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347155	Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347167	Vero cells viability qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	60 (0.21)	18.7374
1990's	10989 (38.03)	18.2507
2000's	10301 (35.65)	29.6817
2010's	6190 (21.42)	24.3611
2020's	1354 (4.69)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	2 (0.53%)	5.53%
Trials	3,802 (12.45%)	5.53%
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	16 (4.24%)	6.00%
Reviews	3,052 (9.99%)	6.00%
Reviews	0 (0.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	3,901 (12.77%)	4.05%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	83 (0.27%)	0.25%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	359 (95.23%)	84.16%
Other	19,709 (64.52%)	84.16%
Other	7 (100.00%)	84.16%
Other	19 (100.00%)	84.16%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (808)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation[NCT01028092]	Phase 3	327 participants (Actual)	Interventional	2009-03-31	Completed
Romiplostim in Combination With Ciclosporin Versus Ciclosporin in the Treatment of Newly Diagnosed Non-severe Aplastic Anemia[NCT06009497]	Phase 4	44 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy[NCT00001880]	Phase 2	42 participants (Actual)	Interventional	1999-03-12	Terminated(stopped due to Study was closed early due to lack of accrual)
A Study to Determine the Safety and Efficacy in Lipoprotein Lipase-Deficient Subjects After Intramuscular Administration of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein LipaseS447X[NCT01109498]	Phase 2/Phase 3	14 participants (Actual)	Interventional	2007-08-31	Active, not recruiting
Investigation of Flare and Remission in Atopic Dermatitis in an Integrated Longitudinal Trial: Effects of Systemic Treatment With Cyclosporine A[NCT03710044]	Phase 4	0 participants (Actual)	Interventional	2019-08-31	Withdrawn(stopped due to Strategic decision)
An Open Non Randomized Comparative Study Exploring Drug Interaction Between Colchicine and Calcineurin Inhibitors in 2 Groups (Ciclosporin Group and Tacrolimus Group) of Renal Graft Recipients[NCT01160276]	Phase 1	17 participants (Actual)	Interventional	2010-05-31	Completed
A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipient[NCT00452361]	Phase 4	31 participants (Actual)	Interventional	2007-04-30	Terminated
Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat SAA[NCT01182662]	Phase 2	30 participants (Anticipated)	Interventional	2010-08-31	Recruiting
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy[NCT00303719]	Phase 2	342 participants (Actual)	Interventional	2002-03-26	Terminated(stopped due to IRB Study Closure)
Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis. A Randomized Controlled Investigator-initiated Double-blind Trial.[NCT01231854]	Phase 4	15 participants (Actual)	Interventional	2010-11-30	Terminated(stopped due to delayed start of the trial, both treatment options already have market authorizations, study medication expired)
CLAG-M or FLAG-Ida Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study[NCT04375631]	Phase 1	120 participants (Anticipated)	Interventional	2020-12-03	Recruiting
Optimization of Cyclosporin Therapy in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response (DermAtOmics)[NCT05692843]	Phase 4	100 participants (Anticipated)	Interventional	2022-10-10	Recruiting
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis[NCT03844932]	Phase 2	235 participants (Actual)	Interventional	2019-01-24	Terminated(stopped due to The Sublimity Board of Directors carefully evaluated the IA data: the 9.6% treatment remission difference for 75mg BID vs placebo (due to an increase in placebo response rate) was determined not sufficient to continue to fund the study)
Long-term Outcome of Patients With Acute Ulcerative Colitis Treated With Cyclosporine Rescue Therapy.[NCT05219656]		182 participants (Actual)	Observational [Patient Registry]	2009-01-01	Completed
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (Cyclosporine)/MMF in de Novo Kidney Transplant Recipients[NCT00064701]	Phase 3	668 participants (Actual)	Interventional	2003-06-30	Completed
A Double-Blind, Placebo -Controlled, Randomized Study to Assess the Efficacy and Safety of Zenapax in Combination With CellCept, Cyclosporine, and Corticosteroids in Patients Undergoing Cardiac Transplantation.[NCT00048165]	Phase 4	434 participants (Actual)	Interventional	1999-08-31	Completed
A Phase II Study of Antithymocyte Globulin (ATG) and Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)[NCT00005937]	Phase 2	42 participants (Actual)	Interventional	2000-06-30	Completed
Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With the Association of Ciclosporine, Corticosteroids and Rituximab[NCT01135641]	Phase 2	25 participants (Actual)	Interventional	2010-06-30	Completed
Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function[NCT02274662]		0 participants	Expanded Access		Approved for marketing
Comparing Efficacy and Tolerability of Cyclosporine-A vs. Prednisolone for Induction of Remission in Auto-immune Hepatitis[NCT01170351]	Phase 3	55 participants (Actual)	Interventional	2005-12-31	Completed
Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone[NCT01288131]	Phase 3	8 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to We observed >90 % efficacy in cyclophosphamide and Prednisolone group for treatment of anti-i-HuEpo associated PRCA)
High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma[NCT01177371]	Phase 2	13 participants (Actual)	Interventional	1988-03-31	Completed
Polyomavirus BK Nephropathy After Renal Transplantation: Randomized Clinical Trial to Demonstrate That Switching to mTOR Inhibitor is More Effective Than a Reduction of Immunosuppressive Therapy[NCT01289301]	Phase 4	124 participants (Anticipated)	Interventional	2011-10-31	Not yet recruiting
A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Cyclosporine on the Pharmacokinetics of LY3502970 in Healthy Participants[NCT05573230]	Phase 1	32 participants (Actual)	Interventional	2022-10-17	Completed
A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Cyclosporine and Prednisone on the Pharmacokinetics and Safety of EDP-938 in Healthy Adult Subjects[NCT03750383]	Phase 1	48 participants (Actual)	Interventional	2018-11-02	Completed
A Randomized Phase Ⅱ, Trial With Sirolimus-containing Versus mTOR-inhibitor Free Immunosuppression in Patients Undergoing Living Donor Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria[NCT01374750]	Phase 2	45 participants (Actual)	Interventional	2010-05-31	Completed
The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study[NCT03666884]	Phase 4	36 participants (Actual)	Interventional	2015-10-10	Completed
Evaluating the Effectiveness of Intravenous Ciclosporin on Reducing Reperfusion Injury in Patients Undergoing Primary Percutaneous Intervention: a Double-blind Randomised Controlled Trial[NCT02390674]	Phase 2	54 participants (Actual)	Interventional	2015-03-31	Completed
A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Effect Of Cyclosporine On The Pharmacokinetics Of PF-04991532 In Healthy Adult Subjects[NCT01370343]	Phase 1	12 participants (Actual)	Interventional	2011-07-31	Completed
Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial[NCT02370550]	Phase 4	240 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Safety and Efficacy of Thymus Transplantation in Complete DiGeorge Anomaly, IND#9836[NCT01220531]		0 participants	Expanded Access		Approved for marketing
A Feasibility, Double Blind, Randomized, Crossover Study to Evaluate the Tolerability of Oph1 0.5% Cyclosporine Ophthalmic Formulation Compared to Restasis in Healthy Volunteers[NCT05184517]	Early Phase 1	20 participants (Anticipated)	Interventional	2022-03-31	Not yet recruiting
A Multicenter Randomized Trial of First Line Treatment for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Cyclosporin[NCT05459649]	Phase 2	253 participants (Anticipated)	Interventional	2022-07-20	Not yet recruiting
Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function[NCT05571332]		39 participants (Anticipated)	Interventional	2022-06-28	Recruiting
Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19[NCT04412785]	Phase 1	11 participants (Actual)	Interventional	2020-06-30	Completed
Allogeneic Stem Cell Transplantation for Patients With Hematological Malignancies Using Multiple Unrelated Cord Blood Units[NCT00547196]		10 participants (Actual)	Interventional	2005-08-16	Active, not recruiting
A Randomized Phase II Study to Compare ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation[NCT03602898]	Phase 2	0 participants (Actual)	Interventional	2021-06-01	Withdrawn(stopped due to Insufficient funding)
Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial[NCT02173106]	Phase 2	180 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Allogeneic Hematopoietic Cell Transplantation Using a Non-Myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Older Patients With Hematologic Malignancies[NCT00185640]	Phase 2	303 participants (Actual)	Interventional	2003-03-31	Completed
Evaluation of the Effect of Topical Application of Tacrolimus 0.03% (FK506) Eye Drops Versus Cyclosporine 0.05% Eye Drops in Treatment of Dry Eye in Secondary Sjogren Syndrome[NCT03865888]	Phase 3	60 participants (Actual)	Interventional	2018-10-30	Completed
DELTA Study Dutch Evaluation in Liver Transplantation To Assess the Efficacy of Cyclosporine A Microemulsion With C-2h Monitoring Versus Tacrolimus With Trough Monitoring in de Novo Liver Transplant Recipients[NCT00149994]	Phase 4	171 participants (Actual)	Interventional	2002-12-31	Completed
Phase III, Open, Randomized, Parallel-group Clinical Trial, to Evaluate the Efficacy and Safety of Treatment With Prednisone, Cyclosporine, Mycophenolic Acid Versus Prednisone and Mycophenolic Acid in Lupus Nephritis Type III-IV-V.[NCT01299922]	Phase 3	0 participants (Actual)	Interventional	2011-02-28	Withdrawn(stopped due to IT was impossible to find patients)
An Open-Label Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus[NCT01038167]	Phase 1	20 participants (Anticipated)	Interventional	2010-01-31	Completed
Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis[NCT01087398]	Phase 2/Phase 3	10 participants (Anticipated)	Interventional	2009-09-30	Recruiting
A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fasting Condition[NCT01080560]		36 participants (Actual)	Interventional	2007-08-31	Completed
Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma[NCT01811368]	Phase 2	20 participants (Anticipated)	Interventional	2013-03-12	Active, not recruiting
Transplantation of Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation or Cyclophosphamide/Fludarabine/Thiotepa/Total Body Irradiation Myeloablative Preparative Regimen[NCT00719888]	Phase 2	135 participants (Actual)	Interventional	2005-11-18	Active, not recruiting
A Randomized, Open-label, Comparative Evaluation of Conversion From Calcineurin Inhibitors to Sirolimus Versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients[NCT00038948]	Phase 3	830 participants (Actual)	Interventional	2002-01-31	Completed
Phase II Trial Of Non-Myeloablative Regimen Combining Melphalan, Fludarabine, And Anti-CD52 Monoclonal Antibody (CAMPATH-1H) Followed By An Unmodified Hematopoietic Cell Transplant From An HLA Compatible Related Or Unrelated Donor For Treatment Of Lymphoh[NCT00027560]	Phase 2	51 participants (Actual)	Interventional	2001-07-31	Completed
Chidamide Plus Post-transplantation Cyclophosphamide and Cyclosporine to Prevent Graft-versus-host Disease After Myeloablative Conditioning, Matched Peripheral-blood Stem-cell Transplantation[NCT03336632]	Phase 2	50 participants (Anticipated)	Interventional	2019-01-01	Not yet recruiting
Prospective Observational Trial to Evaluate Clinical Prognosis and the Risk Factors for Progression for Myasthenia Gravis Patients[NCT04101578]		2,000 participants (Anticipated)	Observational	2017-02-08	Recruiting
A Trial of Antigen-specific Immune Tolerance Induction in Mucopolysaccharidosis I (MPS I) Patients Initiating Enzyme Replacement Therapy With Aldurazyme® (Laronidase)[NCT00741338]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2008-09-30	Completed
A Randomized, Open-label, Single-dose, 2-period, 2-sequence, Crossover, Phase 1 Study to Evaluate the Effect of Cyclosporine, a P-glycoprotein, Breast Cancer Resistance Protein, and Organic-anion-transporting Polypeptide Inhibitor, on the Pharmacokinetics[NCT03768609]	Phase 1	18 participants (Actual)	Interventional	2018-12-06	Completed
Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis Compared to Standard Care --- a Pragmatic Observational Study[NCT04537689]	Phase 4	40 participants (Anticipated)	Interventional	2020-12-10	Recruiting
A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)[NCT02462252]	Phase 2	11 participants (Actual)	Interventional	2015-10-31	Completed
Ensayo Clínico Para Determinar La Eficacia Y Seguridad Del Colirio De Insulina En El Tratamiento Del Ojo Seco En Pacientes Con Ojo Seco[NCT05692739]	Phase 4	120 participants (Anticipated)	Interventional	2022-10-05	Recruiting
Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycop[NCT02416388]	Phase 2/Phase 3	3,100 participants (Anticipated)	Interventional	2015-01-31	Recruiting
A Comparison of PTCy-ATG and ATG Strategy in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis[NCT03689465]	Phase 4	260 participants (Anticipated)	Interventional	2018-10-29	Recruiting
Phase II/III, Multicenter, Double-Masked, Randomized, Parallel Group, Dose Ranging, Controlled Trial of Efficacy and Tolerance of Nova22007 (Cyclosporine A [CSA] 0.05% & 0.1% Ophthalmic Cationic Emulsion) Versus Vehicle in Patients With VKC[NCT00328653]	Phase 2/Phase 3	118 participants (Actual)	Interventional	2006-05-31	Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug Interactions Between ALXN2050 and Cyclosporine, Tacrolimus, and Mycophenolate Mofetil in Healthy Adult Participants[NCT05202145]	Phase 1	61 participants (Actual)	Interventional	2022-01-11	Completed
CIS002: An Open-Label, Multi-Center, Extension Study of Cyclosporine Inhalation Solution in Subjects Previously Enrolled in the APT Study CIS001[NCT00938236]	Phase 3	17 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to Parent study CIS001 was completed)
Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.[NCT03150134]	Phase 4	100 participants (Anticipated)	Interventional	2010-01-01	Recruiting
Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy[NCT03403023]		40 participants (Anticipated)	Interventional	2018-01-30	Not yet recruiting
A Sequential Multiple Assignment Randomized Trial (SMART) Developing and Optimizing Patient-Tailored Adaptive Treatment Strategies (ATS) for Acute Severe Ulcerative Colitis[NCT05867329]	Phase 4	162 participants (Anticipated)	Interventional	2023-09-30	Recruiting
A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease[NCT05733624]	Phase 2	116 participants (Actual)	Interventional	2023-01-05	Active, not recruiting
Brief Administration of Cyclosporine A to Induce the Stabilisation of the Diameter of Small Diameter Abdominal Aortic Aneurysms.[NCT02225756]	Phase 2	360 participants (Anticipated)	Interventional	2013-12-31	Recruiting
Ciclosporine and Extracorporal Photopheresis (ECP) Are Equipotent in Treating Severe Atopic Dermatitis (AD): A Randomized Cross-over Study Comparing Two Efficient Treatment Modalities[NCT02226068]		20 participants (Actual)	Interventional	2002-06-30	Completed
I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patients[NCT04488081]	Phase 2	1,500 participants (Anticipated)	Interventional	2020-07-31	Recruiting
Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome[NCT00357565]	Phase 2	20 participants (Anticipated)	Interventional	2005-11-30	Recruiting
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Prochymal® (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) For the Treatment of Acute GVHD in Patients Who Receive Allogeneic Hematopoietic Stem Cell Transplantation[NCT00136903]	Phase 2	32 participants (Actual)	Interventional	2005-04-27	Completed
A Phase I, Open-label, Randomized, Three-period Cross-over Study Evaluating the Effect of Cyclosporine on the Pharmacokinetics of Eltrombopag in Healthy Adult Subjects[NCT02281370]	Phase 1	39 participants (Actual)	Interventional	2014-11-05	Completed
Calcineurin-Sparing in a Steroid-free Maintenance Immunosuppression Protocol After Kidney Transplantation[NCT01062555]	Phase 1/Phase 2	527 participants (Actual)	Interventional	2006-10-01	Completed
A Multiple Dose, Multi-stage Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Colon Tissue Distribution of Cyclosporine Capsules (CyCol®) Compared to Intravenous Cyclosporine in Healthy Male Volunteers[NCT02130414]	Phase 1	48 participants (Actual)	Interventional	2014-07-31	Completed
A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation[NCT01650545]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2012-07-31	Completed
Cyclosporine in Hepatitis C Infection Viral Clearance Following Liver Transplantation[NCT00821587]	Phase 4	39 participants (Actual)	Interventional	2004-06-30	Completed
A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.[NCT03434730]	Phase 2	46 participants (Actual)	Interventional	2018-02-07	Active, not recruiting
Efficiency and Safety of Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis: a Non-randomized Controlled Study[NCT05353101]	Phase 1	48 participants (Actual)	Interventional	2020-07-01	Completed
Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）[NCT02203422]	Phase 3	0 participants (Actual)	Interventional	2014-07-31	Withdrawn(stopped due to No eligible patient was enrolled.)
Outcomes of Patients After Allogenic Hematopoietic Cell Transplantation With Decitabine-containing Conditioning Regimen and Acetylcysteine Treatment[NCT04945096]	Phase 3	100 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease[NCT01659606]	Phase 2	40 participants (Anticipated)	Interventional	2012-07-31	Active, not recruiting
A Randomized, Case Controlled Clinical Trial Evaluating the Efficiency and Safety of Luspatercept Plus Ciclosporin Versus Ciclosporin in Newly Diagnosed Transfusion Independent Non-severe Aplastic Anemia (NSAA).[NCT05399732]	Phase 2	90 participants (Anticipated)	Interventional	2022-07-31	Not yet recruiting
A Multicenter Collaborative Clinical Study of Umbilical Cord Blood Combined With Umbilical Cord Derived Mesenchymal Stem Cells in the Treatment of Bone Marrow Failure Disorders[NCT05794425]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2023-08-01	Recruiting
A 12 Month, Multicenter, Randomized, Parallel, Open-label Study, to Evaluate Renal Function and Efficacy of Everolimus With Basiliximab and Cyclosporine Microemulsion Discontinuation at 3 Month Post-transplant Versus Minimization, in de Novo Kidney Transp[NCT00154284]	Phase 3	114 participants (Actual)	Interventional	2005-07-31	Completed
A Randomised Clinical Trial of Treatment for Fluorouracil-Resistant Advanced Colorectal Cancer Comparing Standard Single-Agent Irinotecan Versus Irinotecan Plus Panitumumab and Versus Irinotecan Plus Ciclosporin [Panitumumab, Irinotecan & Ciclosporin in C[NCT00389870]	Phase 3	1,198 participants (Actual)	Interventional	2006-12-31	Completed
[NCT00000524]	Phase 2	0 participants	Interventional	1986-07-31	Completed
Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.[NCT02108301]	Phase 4	30 participants (Anticipated)	Interventional	2011-12-31	Active, not recruiting
Comparison of Effect of Cyclosporine Ophthalmic Emulsion 2% and Betamethasone Eye Drop on Intraocular Pressure, Conjunctival Hyperemia and Subjective Dry Eye Symptoms Following Trabeculectomy in Open Angle Glaucoma Patients[NCT02114073]	Phase 2	40 participants (Anticipated)	Interventional	2014-04-30	Completed
Assessment of Rituximab Therapeutic Response Versus Conventional Treatment in the Management of Refractory Nephrotic Syndrome[NCT05553496]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional	2022-09-25	Not yet recruiting
Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen[NCT02144025]	Phase 2	21 participants (Actual)	Interventional	2014-05-31	Completed
Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de Novo Cardiac Transplant: A Comparison Between Tacrolimus- and Cyclosporine- Based Immunoprophylactic Regimens With MPA TDM[NCT00157014]	Phase 3	111 participants (Actual)	Interventional	2004-05-10	Completed
Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-Coated Mycophenolate Sodium (EC-MPS) and Everolimus in Comparison to Standard Therapy With Enteric-Coated Mycophenolate Sodium (EC-MPS) a[NCT00154310]	Phase 4	300 participants (Actual)	Interventional	2005-06-30	Completed
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders[NCT05293509]	Phase 2	0 participants (Actual)	Interventional	2022-03-02	Withdrawn(stopped due to 0 accrual)
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT)[NCT00114777]	Phase 3	595 participants (Actual)	Interventional	2005-02-28	Completed
A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus[NCT00260208]	Phase 4	361 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to Study was prematurely terminated due to poor recruitment.)
Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study[NCT02181478]	Early Phase 1	6 participants (Actual)	Interventional	2015-07-22	Completed
A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia[NCT02203396]	Phase 2	40 participants (Anticipated)	Interventional	2014-08-31	Recruiting
A Pilot Study of EPOCH-F/R Induction Chemotherapy and Reduced-Intensity, HLA-Matched, Related Allogeneic Hematopoietic Stem Cell Transplantation, With Cyclosporine & Methotrexate GVHD Prophylaxis for Refractory or Relapsed Hematologic Malignancies[NCT00051311]	Phase 2	62 participants (Actual)	Interventional	2003-01-03	Completed
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas[NCT00043979]	Phase 2	60 participants (Actual)	Interventional	2002-09-19	Completed
Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer[NCT00074269]	Phase 2	5 participants (Actual)	Interventional	2003-07-31	Terminated(stopped due to Terminated early due to poor enrollment)
Phase II/III, Open-Label, Randomized, Controlled, Multiple-Dose Study of Efficacy and Safety of BMS-224818 (Belatacept) as Part of a Quadruple Drug Regimen in First Renal Transplant Recipients[NCT00035555]	Phase 2	230 participants (Actual)	Interventional	2001-03-31	Completed
Allogeneic Peripheral Blood Stem Cell Transplantation With Minimally Myelosuppressive Regimen of Pentostatin and Low-dose Total-body Irradiation[NCT00571662]	Phase 2	76 participants (Actual)	Interventional	2000-12-08	Completed
Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis: An Open Label Randomized Study[NCT05112263]		96 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
A Multicenter, Randomized, Parallel-group, Trial to Reduce Toxicity of Calcineurininhibitor-therapy in Steroid-free Longterm Immunosuppression in Pediatric and Adolescent Kidney Transplant Recipients[NCT00663455]	Phase 4	50 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to Recruitment goals were not achieved. Extension of the trial concept had to be abjected due to methodological reasons.)
A 12 Month, Single-center, Open-label, Randomized-controlled Trial to Investigate Efficacy, Safety and Tolerability of Everolimus in Combination With Cyclosporine A and Corticosteroid in de Novo Transplant Recipients of Expanded Criteria Donor Kidneys or [NCT02314312]	Phase 3	48 participants (Anticipated)	Interventional	2012-01-31	Active, not recruiting
Extended Follow-Up After Islet Transplantation in Type 1 Diabetes (CIT-08)[NCT01369082]		75 participants (Actual)	Observational	2011-05-31	Completed
Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia[NCT03896971]	Phase 4	66 participants (Actual)	Interventional	2019-11-15	Completed
A Randomized, Prospective Trial to Evaluate the Effect of Conversion From Tacrolimus to Cyclosporine A After Early Initiation of Insulin Therapy in Patients With New-onset Diabetes Mellitus After Kidney Transplantation[NCT01268995]	Phase 2	32 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to It was impossible to recruit the scheduled number of patients)
Topical Cyclosporine in the Treatment of Vernal Keratoconjunctivitis in a Rwandan Eye Clinic; a Prospective Randomized Double-masked Clinical Trial[NCT01211327]	Phase 4	366 participants (Actual)	Interventional	2008-07-31	Completed
CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation[NCT02887807]	Phase 3	0 participants (Actual)	Interventional	2017-01-31	Withdrawn
Phase II Study of Umbilical Cord/Placenta-Derived Mesenchymal Stem Cells to Treat RA and RARS of MDS[NCT01129739]	Phase 2	30 participants (Anticipated)	Interventional	2010-05-31	Recruiting
Multicenter Registry of Pediatric Lupus Nephritis in China[NCT03791827]		1,200 participants (Anticipated)	Observational	2018-12-01	Recruiting
A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy[NCT01282073]	Phase 3	62 participants (Anticipated)	Interventional	2011-03-31	Recruiting
Cyclosporine 0.1% Eye Drops as Prophylactic Treatment in Post Surgical Ocular Surface System Failure Within The Age[NCT04812951]	Early Phase 1	101 participants (Actual)	Interventional	2021-02-17	Completed
Clinical Research of Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Children With Stage 4/M Neuroblastoma: A Prospective, Single-arm, Phase II, Multi-center Trial[NCT05303727]	Phase 2	64 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
An Investigator-Masked, Randomized, Parallel-Group Study of the Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease[NCT03597139]	Phase 2	100 participants (Actual)	Interventional	2018-08-13	Completed
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled Clinical Trial to Investigate the Efficacy and Safety of Aerosolised Liposomal Ciclosporin A Versus Aerosolised Placebo in the Prevention of Bronchiolitis Obliterans Syndrome in Lung Tr[NCT01334892]	Phase 2/Phase 3	130 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to Interim analysis results revealed substantial increase of patient number, with unfeasible study prolongation.)
Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation[NCT02478424]	Phase 2	10 participants (Anticipated)	Interventional	2015-07-31	Not yet recruiting
Effect of Cyclosporine and Remote Ischemic Preconditioning on MDA, Calcium Cytosol Concentration, and Mitochondrial Edema in Reperfusion Ischemia Injury: Research on Tetralogy Fallot Patients With Correction Surgery[NCT05691764]		40 participants (Actual)	Interventional	2020-09-01	Completed
A Phase IIa Multi-Center, Randomized, Single-Blind Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation[NCT04107675]	Phase 2	6 participants (Actual)	Interventional	2020-02-11	Terminated(stopped due to Due to the low number of patients recruited and the slow enrollment pace of patients, on 18 March 2022, the sponsor decided to terminate the BOSTON-4 safety and tolerability trial ahead of time.)
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Treosulfan Based Preparative Regimen[NCT00796068]	Phase 2	130 participants (Actual)	Interventional	2009-02-24	Completed
A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (Anti-CD45) Antibody Followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)[NCT01300572]	Phase 1	16 participants (Actual)	Interventional	2012-01-31	Completed
LOW CYCLO: A Multicenter, Prospective, Randomized Study Evaluating the Benefit, on Renal Function, of Two Doses of Ciclosporine: Low Dose Versus Usual Dose, in Association With Mycophenolate and Corticoïds, in de Novo Cardiac Transplant[NCT00159159]	Phase 4	106 participants	Interventional	2004-03-31	Active, not recruiting
Relationships Between Pharmacokinetic and Pharmacodynamic Strategies for Assessment of the Risks for Acute Rejection and Side Effects of Mycophenolate Mofetil[NCT01292226]	Phase 2	45 participants (Actual)	Interventional	2006-12-31	Completed
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia[NCT01193283]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2010-08-31	Completed
Prograf® (Tacrolimus) as Secondary Intervention vs. Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure[NCT00637143]	Phase 4	107 participants (Actual)	Interventional	1999-04-30	Completed
Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders[NCT00636909]	Phase 2	25 participants (Actual)	Interventional	1999-07-31	Completed
Evaluation of SP14019-F-01 Topical Solution for the Treatment of Atopic Dermatitis. Pilot Study (CYCLATOP STUDY)[NCT02865356]	Phase 2	36 participants (Actual)	Interventional	2016-09-30	Completed
Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment[NCT02655705]	Phase 4	34 participants (Actual)	Interventional	2014-08-31	Completed
Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation[NCT00740467]	Phase 2	50 participants (Anticipated)	Interventional	2008-01-31	Recruiting
Once-a-day Regimen or Steroid Withdrawal in de Novo Kidney Transplant Recipients Treated With Everolimus, Cyclosporine and Steroids: a 12-month, Prospective, Randomized, Multicenter, Open-label Study. The EVIDENCE Study (EVerolImus Once-a-Day rEgimen With[NCT01023815]	Phase 3	330 participants (Actual)	Interventional	2009-04-30	Completed
Diabetogenicity of Cyclosporine and Tacrolimus[NCT00766909]	Phase 4	18 participants (Actual)	Interventional	2008-03-31	Completed
Rasburicase to Prevent Graft -Versus-Host Disease[NCT00513474]	Phase 1	46 participants (Actual)	Interventional	2008-01-31	Completed
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma[NCT00481832]	Phase 2	50 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Accrual Factor)
A Prospective Randomized Pilot Study Examining the Role and Effectiveness of Conversion to Sirolimus Versus CNI Reduction in Renal Transplant Patients With Prostate Cancer[NCT00922129]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2009-09-30	Withdrawn(stopped due to Study did not start up as planned.)
Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen[NCT00309842]	Phase 2	213 participants (Actual)	Interventional	2005-07-28	Completed
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan[NCT00619645]	Phase 2	8 participants (Actual)	Interventional	2007-06-30	Completed
Safety and Efficacy of Maraviroc-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Donor Transplantation[NCT02799888]	Phase 2	40 participants (Anticipated)	Interventional	2014-04-30	Recruiting
A Multicenter Pilot Study of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation With In-vivo T-cell Depletion to Evaluate the Role of NK Cells and KIR Mis-matches in Relapsed or Refractory High-risk Neuroblastoma.[NCT00874315]	Phase 2	0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to lack of accrual)
Ciclosporin to Protect Renal Function In Cardiac Surgery: CiPRICS A Phase II Double Blind Randomized Placebo Controlled Study[NCT02397213]	Phase 2	155 participants (Actual)	Interventional	2015-04-30	Completed
A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease[NCT02229955]	Phase 3	86 participants (Actual)	Interventional	2013-12-31	Completed
Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells to Augment Single or Double Myeloablative Cord Blood Transplantation in Patients With Hematologic Malignancies[NCT01175785]	Phase 2	15 participants (Actual)	Interventional	2010-08-31	Completed
Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia[NCT02838992]	Phase 4	130 participants (Anticipated)	Interventional	2017-02-28	Not yet recruiting
Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis Compared to Standard Care --- a Pragmatic Observational Study[NCT04239859]	Phase 4	40 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation[NCT04575779]		31 participants (Actual)	Observational	2018-07-10	Completed
[NCT02176733]	Phase 2	12 participants (Anticipated)	Interventional	2011-07-31	Recruiting
Sitagliptin Efficacy and Safety for Prevention of Acute Graft Versus Host Disease in Patients Receiving Alternative Donor Allogeneic Hematopoietic Stem Cell Transplantation[NCT05149365]	Phase 3	190 participants (Anticipated)	Interventional	2021-12-22	Recruiting
Efficacy of Cyclosporine Ophthalmic Emulsion in the Treatment of Dry Eye Syndrome in Contact Lens Wearers[NCT00335114]		40 participants	Interventional	2005-11-30	Completed
Cyclosporine as a Second-line Treatment of Primary Autoimmune Hemolytic Anemia[NCT05057468]	Phase 3	30 participants (Anticipated)	Interventional	2021-10-20	Recruiting
Oxidative Damage and Calcium-Activated Proteolytic Biomarkers After Traumatic Brain Injury and Effects of Acute Cyclosporine A[NCT02496975]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2017-08-07	Withdrawn(stopped due to Recent studies suggest that cyclosporine A has a very sharp biphasic dose-response problem that is going to make further clinical translation difficult.)
Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy[NCT02487069]		876 participants (Actual)	Interventional	2015-06-30	Completed
Multicenter, Randomized, Double-blind phⅢ Study of TJCS Eye Drops Group and Restasis Eye Drops Group for 12 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease.[NCT02461719]	Phase 3	158 participants (Actual)	Interventional	2014-01-31	Completed
A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies[NCT05579769]	Phase 2	32 participants (Anticipated)	Interventional	2022-11-04	Recruiting
A Phase III Randomized Study Comparing Busulfan-Total Body Irradiation Versus Cyclophosphamide-Total Body Irradiation Preparative Regimen in Patients With Advanced Myelodysplastic Syndrome (MDS) or MDS-Related Acute Myeloid Leukemia (AML) Undergoing HLA-I[NCT00005866]	Phase 3	240 participants (Anticipated)	Interventional	2000-02-29	Completed
A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H[NCT00047060]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2002-07-30	Completed
A Randomised Study to Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria[NCT03250143]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2016-12-06	Completed
Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic® Using Two Hour Neoral® Monitoring.[NCT02058875]	Phase 4	0 participants (Actual)	Interventional	2014-02-28	Withdrawn(stopped due to The study funder retracted their grant funding offer before contract signed.)
Comparison of Safety and Efficacy of de Novo Everolimus Plus Low Dose of Cyclosporine With Standard Dose of Cyclosporine Plus Cellcept on CMV and BK Virus Infections Prevention in Renal Transplant Patients[NCT04906304]		35 participants (Actual)	Interventional	2020-01-01	Completed
Prospective, Multicenter, Randomized, Open-label, Phase 2, Lasting 12 Weeks, Evaluating the Pharmacodynamics, Efficacy and Safety of Basiliximab in de Novo Adult Renal Transplant Patients at Low Risk Receiving Either a Cumulative Dose of Basiliximab of 40[NCT01596062]	Phase 2	16 participants (Actual)	Interventional	2012-03-31	Completed
Use of the NMF Biomarker as Predictive Diagnostic for Effective Use of Cyclosporine and Dupilumab in the Treatment of Atopic Dermatitis[NCT04878770]		318 participants (Anticipated)	Interventional	2021-08-16	Recruiting
Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis[NCT03180723]	Phase 3	30 participants (Anticipated)	Interventional	2017-07-01	Not yet recruiting
Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection[NCT02206789]		200 participants (Anticipated)	Interventional	2012-02-29	Recruiting
A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age < 55 Years With Primary Mantle-Cell-Lymphoma[NCT00946374]	Phase 2	20 participants (Anticipated)	Interventional	2004-07-31	Recruiting
Multicenter Uveitis Steroid Treatment (MUST) Trial[NCT00132691]	Phase 4	255 participants (Actual)	Interventional	2005-09-30	Completed
Optima: Optimizing Prograf Therapy in Maintenance Allografts II[NCT00905515]	Phase 4	63 participants (Actual)	Interventional	2003-08-31	Completed
Impact of Cyclosporine or Steroid Withdrawal at 3 Months Post Transplantation on Graft Function, Patient Survival and Cardiovascular Surrogate Markers the First 5 Years After Renal Transplantation.[NCT00903188]	Phase 4	152 participants (Anticipated)	Interventional	2008-10-31	Recruiting
A Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma[NCT00908180]	Phase 2	47 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
A Phase II Randomized Controlled Trial Comparing GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia or Myelodysplastic Syndrome: Selective Depletion of CD45RA+ Naïve T Cells (TND) vs. Post-Tr[NCT03970096]	Phase 2	120 participants (Anticipated)	Interventional	2019-11-19	Recruiting
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial[NCT03828019]	Phase 3	222 participants (Anticipated)	Interventional	2019-09-16	Active, not recruiting
A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoco[NCT01751126]	Phase 3	169 participants (Actual)	Interventional	2013-04-29	Completed
A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation (ITN024ST)[NCT00105235]	Phase 2	27 participants (Actual)	Interventional	2005-06-30	Completed
A Phase II, Randomized Study to Evaluate the Safety and Efficacy of Ex-Vivo Cultured Allogenic Mesenchymal Stem Cells For the Treatment of Extensive Chronic Graft Versus Host Disease[NCT00972660]	Phase 2	52 participants (Anticipated)	Interventional	2009-09-30	Enrolling by invitation
A Prospective Multicenter Open-label Randomized Study to Assess Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus Without Calcineurine Inhibitor in Combination With Enteric-coated Mycophenolate Sodium (EC-M[NCT00425308]	Phase 3	30 participants (Actual)	Interventional	2006-10-31	Completed
A Phase I, Open-label, Study of the Safety and Tolerability of Cyclosporine A (CsA) in Combination With Nab-paclitaxel in Patients With Metastatic Breast Cancer[NCT00983424]	Phase 1	14 participants (Actual)	Interventional	2010-02-28	Completed
A Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Therapeutic Benefit of an Initially Intensified Dosing Regimen of Mycophenolate Sodium Versus a Standard Dosing Regimen, in Combination With Cyclosporine and Corticosteroids in de[NCT00419926]	Phase 4	313 participants (Actual)	Interventional	2006-12-31	Completed
Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection With the Objective to Induce a Strong Specific HIV Immune Response Able to Control Viral Replication Without Highly Active Anti-Retroviral Therapy (HAART)[NCT00979706]	Phase 4	22 participants (Actual)	Interventional	2005-03-31	Completed
Multi-center, Open Label, Randomized Trial Comparing Single Versus Double Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia (BMT CTN #0501)[NCT00412360]	Phase 3	224 participants (Actual)	Interventional	2006-12-31	Completed
Phase I Feasibility Study of Clofarabine and Low Dose Total Body Irradiation (TBI) as a Non-myeloablative Preparative Regimen for Stem Cell Transplantation (SCT) for Hematologic Malignancies[NCT01041508]	Phase 1	36 participants (Anticipated)	Interventional	2010-02-28	Completed
Open Randomized Multi-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran (LMW-SD) in Islet Transplantation After Kidney Transplantation (CIT-01B)[NCT00790439]	Phase 2	0 participants (Actual)	Interventional	2008-07-31	Withdrawn(stopped due to Due to funding limitations)
Clinical Investigation of Aerosol Immunotherapy in COPD: A Phase I Placebo-Controlled Dose Escalation/Deescalation Trial of Aerosol Cyclosporine (CyIS) in Patients With Gold Stage III Chronic Obstructive Pulmonary Disease[NCT00783107]	Phase 1	8 participants (Actual)	Interventional	2007-10-31	Completed
Open, Single Center, Randomised, Parallel Group Pilot Study to Investigate a Calcineurin Free Immunosuppressive Treatment for de Novo Renal Transplant Recipients: A Comparison of a Rapamycin/MMF/Steroids Regime to a Cyclosporine A Neoral/MMF/Steroids Regi[NCT00812123]	Phase 4	127 participants (Actual)	Interventional	2001-01-31	Completed
Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients With Hematologic Diseases Using Haploidentical Family Donors and Sub-Myeloablative Conditioning With Campath 1H[NCT00058825]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2000-08-31	Terminated(stopped due to Slow accrual due to practice changes meant study would take too long to finish)
A Randomized Open-Label Study To Compare The Safety And Efficacy Of Conversion From A Calcineurin Inhibitor To Sirolimus Vs Continued Use Of A Calcineurin Inhibitor In Heart Transplant Recipients With Mild-Moderate Impaired Renal Function[NCT00369382]	Phase 4	121 participants (Actual)	Interventional	2006-09-30	Completed
Active Immunization of Sibling Stem Cell Transplant Donors Against Purified Myeloma Protein of the Stem Cell Recipient With Multiple Myeloma in the Setting of Non-Myeloablative, HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation[NCT00006184]	Phase 2	20 participants (Actual)	Interventional	2001-02-08	Completed
A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies[NCT00075478]	Phase 3	87 participants (Actual)	Interventional	2003-10-31	Completed
Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy[NCT04113915]		150 participants (Anticipated)	Observational	2019-11-30	Not yet recruiting
NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis[NCT02987257]	Phase 3	267 participants (Anticipated)	Interventional	2023-03-21	Recruiting
Effect of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects[NCT06005714]	Phase 1	36 participants (Actual)	Interventional	2023-08-15	Active, not recruiting
Reduction of Acute and Chronic Graft-versus-host Disease After Allogeneic Hematopoietic Stem-cell Transplantation by Adapting Cyclosporine Doses According to Calcineurin Activity : a Proof-of-concept Trial[NCT00948727]	Phase 2	39 participants (Actual)	Interventional	2004-01-31	Completed
A Two-Cohort, Randomised Sequence, Cross-over, Open-label Study to Assess the Effect of a Single Dose of Sodium Zirconium Cyclosilicate (SZC) on the Pharmacokinetics of Tacrolimus and Cyclosporin in Healthy Subjects[NCT04788641]	Phase 1	62 participants (Actual)	Interventional	2021-03-30	Completed
A Randomized, Controlled Trial of Cyclosporin A for Women With Unexplained Recurrent Miscarriage[NCT02706470]	Phase 2/Phase 3	384 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
Phase I/II Study of HLA-Matched Non-Myeloablative Peripheral Blood Mobilized Hematopoietic Progenitor Cell Transplantation as Treatment for Patients With Metastatic Renal Cell Carcinoma. A Multi-Center Trial.[NCT00005851]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2000-02-29	Completed
Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders[NCT00533923]	Phase 2	25 participants (Anticipated)	Interventional	2002-12-31	Completed
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study[NCT04009525]	Phase 4	800 participants (Anticipated)	Interventional	2019-06-01	Recruiting
A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Tran[NCT02660684]	Phase 4	39 participants (Actual)	Interventional	2008-02-29	Completed
A Randomized Trial for the Treatment of Relapsing Aplastic Anemia With Mycophenolate Mofetil (MMF) and Cyclosporine (CSA)[NCT00005935]	Phase 2	130 participants	Interventional	2000-06-30	Completed
A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors[NCT02653196]	Early Phase 1	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to The Principal Investigator left the institution.)
Autologous Serum Tears Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With Sjögren's Syndrome Dry Eye[NCT06013436]		30 participants (Actual)	Observational	2022-06-01	Completed
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics[NCT06013423]	Phase 2	54 participants (Anticipated)	Interventional	2024-02-06	Not yet recruiting
Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treat[NCT00520130]	Phase 1/Phase 2	92 participants (Actual)	Interventional	2007-10-30	Completed
A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis[NCT00542152]	Phase 4	115 participants (Actual)	Interventional	2007-06-30	Completed
Transplantation of Umbilical Cord Blood for Myeloid Leukemia Patients Not in CR With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen and UCB NK Cells[NCT00354172]	Phase 2	16 participants (Actual)	Interventional	2006-02-28	Terminated(stopped due to Competing study was started.)
A Phase II, Randomized, Double-blind, Placebo-controlled Study of a Controlled Release Minicapsule Formulation of Ciclosporin (CyCol™) in the Treatment of Mild to Moderate Ulcerative Colitis[NCT01033305]	Phase 2	118 participants (Actual)	Interventional	2010-03-31	Completed
Multi-center, Open-label, Prospective, Randomized, Parallel Group, Long-term Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a CNI-free Regimen and a CNI-low Dose Regimen[NCT00514514]	Phase 3	802 participants (Actual)	Interventional	2007-07-31	Completed
Alemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic Patients[NCT00895739]	Phase 2	50 participants (Anticipated)	Interventional	2006-06-30	Recruiting
A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients[NCT00483756]	Phase 2	338 participants (Actual)	Interventional	2007-08-31	Completed
Rapamycin and Regulatory T Cells in Renal Transplant Patients: a Two-year Randomized Prospective Study[NCT01014234]	Phase 2	56 participants (Actual)	Interventional	2008-07-31	Completed
Evaluation of Fludarabine, Busulfan and Alemtuzumab as a Reduced Toxicity Ablative Bone Marrow Stem Cell Transplant Regimen for Children With Stem Cell Defects, Marrow Failure Syndromes, or Myelodysplastic Syndrome (MDS)/Leukemia[NCT00301834]	Phase 2	35 participants (Actual)	Interventional	2005-01-31	Completed
A 24-month, Multi-center, Randomized, Open-label, Non-inferiority Study of Efficacy and Safety Comparing Two Exposures of Concentration-controlled Everolimus With Reduced Cyclosporine Versus 3.0 g Mycophenolate Mofetil With Standard Dose Cyclosporine in d[NCT00300274]	Phase 3	721 participants (Actual)	Interventional	2006-01-31	Completed
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Haematological Diseases Using a Reduced Intensity Conditioning Regimen[NCT00959231]	Phase 2	60 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate[NCT00988715]	Phase 1	17 participants (Actual)	Interventional	2010-04-21	Completed
Rheumatoid Arthritis: Tolerance Induction by Mixed Chimerism[NCT00282412]	Phase 1	4 participants (Actual)	Interventional	2002-09-30	Terminated(stopped due to No participant enrolled for three years. No plan to continue study.)
Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study[NCT01020734]	Phase 2	263 participants (Actual)	Interventional	2011-05-31	Completed
A 24-week, Double-blind, Randomized, Placebo-controlled, Multicenter Study, to Evaluate the Effectiveness of Cyclosporine 2,5 mg/kg/Day Bid Twice a Week on Reducing Relapse Rate, in Maintenance Patients With Chronic Plaque Psoriasis[NCT00438360]	Phase 3	243 participants (Actual)	Interventional	2006-05-31	Completed
The Effect of Topical 0.05% Cyclosporine Eye Drops on Post-refractive Surgery Dry Eye[NCT06043908]	Phase 4	60 participants (Anticipated)	Interventional	2022-08-31	Recruiting
The HAM Ciclosporin Study : an Observational Trial of Therapy in Early or Progressing HAM/TSP[NCT00773292]	Phase 2/Phase 3	7 participants (Actual)	Interventional	2006-08-31	Completed
Multicentre, Prospective, Randomized, Open-label Study Comparing the Efficacy and Safety of CellCept With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Standard Immunosuppression Comprising CellCept and Long-term Con[NCT02686619]	Phase 3	237 participants (Actual)	Interventional	2004-11-30	Completed
A Phase I/II Prospective, Randomized, Double Masked, Vehicle And Comparator Controlled, Dose Ranging Study Of CP-690,550 In Subjects With Dry Eye Disease.[NCT00784719]	Phase 1/Phase 2	327 participants (Actual)	Interventional	2008-11-30	Completed
A Single-Arm, Open-Label Study of the Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes[NCT00840827]	Phase 2	6 participants (Actual)	Interventional	2008-12-31	Terminated(stopped due to Lack of efficacy.)
A Study to Investigate the Impact of Pharmacogenetics on CellCept Use, in Patients Participating in a Study in Renal Transplantation[NCT00337493]	Phase 4	155 participants (Actual)	Interventional	2005-12-31	Completed
Treatment of Severe (Types II and III) Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation[NCT00705120]	Phase 1	9 participants (Actual)	Interventional	1995-11-30	Completed
Efficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland Dysfunction[NCT00705510]	Phase 4	70 participants (Actual)	Interventional	2008-05-31	Completed
Randomized, Open-label, Multi-Center Study Comparing Tacrolimus With Cyclosporin, Both Arms in Combination With Mycophenolate Mofetil and Corticosteroids for Prevention of Bronchiolitis Obliterans Syndrome in Lung Transplant Patients[NCT01429844]	Phase 3	274 participants (Actual)	Interventional	2001-01-31	Completed
The Use of Thymoglobulin in a Calcineurin Inhibitor and Steroid Minimization Protocol[NCT00706680]	Phase 4	30 participants (Anticipated)	Interventional	2008-02-29	Recruiting
A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions[NCT00919815]	Phase 2/Phase 3	73 participants (Actual)	Interventional	2010-08-31	Completed
Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy[NCT05674695]		2,500 participants (Anticipated)	Observational [Patient Registry]	2019-01-01	Recruiting
A Phase I Study of 90Y-DOTA-Peptide-Lym-1 With Peripheral Blood Stem Cell Support, Paclitaxel And Cyclosporin A In Patients With Non-Hodgkin's Lymphoma[NCT00008021]	Phase 1	0 participants	Interventional	2001-02-28	Active, not recruiting
[NCT01028443]	Phase 4	0 participants	Interventional		Completed
A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone.[NCT00919542]	Phase 2	12 participants (Actual)	Interventional	2010-07-31	Completed
A Multicenter, Randomized, Double-blind, and Open-label, Placebo-controlled Phase II Clinical Study of Trappa Ethanolamine Tablets Combined With Ciclosporin in Patients With Treatment of Non-severe Aplastic Anemia[NCT05797623]	Phase 2	78 participants (Anticipated)	Interventional	2023-04-26	Recruiting
A Multi-center, Randomized, Open-label, Parallel Group Study Investigating the Renal Tolerability, Efficacy and Safety of a CNI-free Regimen (Everolimus and MPA) Versus a CNI-regimen With Everolimus in Heart Transplant Recipients[NCT00862979]	Phase 4	162 participants (Actual)	Interventional	2009-02-24	Completed
Reduced Intensity Conditioning Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies at High Risk for Transplant Related Mortality With Standard Transplantation[NCT00795132]	Phase 2	47 participants (Actual)	Interventional	2004-04-30	Completed
A Phase 2 Study in Poor Risk Diffuse Large B-cell Lymphoma of Total Lymphoid Irradiation & Antithymocyte Globulin Followed by Matched Allogeneic Hematopoietic Transplantation as Consolidation to Autologous Hematopoietic Cell Transplantation[NCT00482053]	Phase 2	3 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Low accrual)
A Comparison of Effects of Short-term Low Dose Exposure of Advagraf® and Neoral® Microemulsion Cyclosporine A on Renal Perfusion and Function in Healthy Volunteers[NCT00818194]	Phase 1	18 participants (Actual)	Interventional	2008-04-30	Completed
A Multi-Center, Randomized, Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation[NCT00755781]	Phase 3	284 participants (Actual)	Interventional	2008-09-30	Completed
Optimum Immunosuppression in Renal Transplant Recipients at High Risk of Developing New Onset Diabetes After Transplantation: A Multicenter, Prospective, Controlled and Randomized Trial.[NCT01002339]	Phase 4	134 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Terminated: higher rate of acute rejection in the Cyclosporin A group)
Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation[NCT00777933]		131 participants (Actual)	Interventional	2000-07-31	Completed
A Phase II/III, Randomized, Open-Label, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofetil and Corticosteroids, As an Immunosuppressant Regimen [NCT00729768]	Phase 2/Phase 3	0 participants (Actual)	Interventional		Withdrawn
Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation[NCT06147375]		47 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen[NCT04195633]	Phase 2	60 participants (Anticipated)	Interventional	2021-01-25	Recruiting
A Phase III, Multicenter, Randomized, Controlled, Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Ophthalmic Cationic Emulsion Versus Vehicle in Patients With Moderate to Severe Dry Eye Syndrome[NCT00814515]	Phase 3	482 participants (Anticipated)	Interventional	2007-09-30	Completed
A Double-Blind Study Evaluating the Safety and Efficacy of Cyclosporine Ophthalmic Emulsion 0.05% [Restasis] in Subjects With Epiphora Secondary to Docetaxel [Taxotere] Treatment for Various Cancers[NCT00824811]	Phase 2	0 participants (Actual)	Interventional	2009-06-30	Withdrawn(stopped due to Slow accrual.)
An Extension to a 12-month, Open-label, Randomised, Multicenter, Sequential Cohort, Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of Oral AEB071 Versus Cyclosporine in Combination With Everolimus, Basiliximab and Corticosteroids in [NCT00820911]	Phase 2	175 participants (Actual)	Interventional	2008-09-30	Completed
[NCT00010361]		20 participants	Interventional	2000-11-30	Completed
A Phase II Study of Reduced Intensity Sibling Allogeneic Transplantation for Relapsed, Chemosensitive, PET-positive Hodgkin Lymphoma[NCT00907036]	Phase 2	49 participants (Anticipated)	Interventional	2009-07-31	Not yet recruiting
Postconditioning by Cyclosporin A in Pulmonary Transplantation[NCT02876250]	Phase 3	0 participants (Actual)	Interventional	2017-01-31	Withdrawn
Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics[NCT01706692]		750 participants (Anticipated)	Observational	2011-07-31	Recruiting
A Phase IV Open Label, Multicentre, Investigational Study of the Therapeutic Options for Subjects Discontinuing Efalizumab Therapy and Experiencing Inflammatory Disease Recurrence[NCT01079988]	Phase 4	41 participants (Actual)	Interventional	2004-02-29	Completed
Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes[NCT00704275]	Phase 4	60 participants (Anticipated)	Interventional	2007-06-30	Recruiting
A 24-month, Multi-center, Open-label, Randomized, Controlled Trial to Investigate Efficacy, Safety and Evolution of Cardiovascular Parameters in de Novo Renal Transplant Recipients After Early Calcineurin Inhibitor to Everolimus Conversion[NCT01114529]	Phase 3	828 participants (Actual)	Interventional	2010-08-09	Completed
Combined HLA-matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With Renal Failure[NCT00854139]	Phase 1	10 participants (Actual)	Interventional	2001-08-31	Completed
A Single-arm, Prospective Study of Cyclosporine in Combination With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma Refractory to Carfilzomib With High Expression of the Peptidylprolyl Isomerase A (PPIA) Gene in Myeloma Cells[NCT04813653]	Phase 1	10 participants (Anticipated)	Interventional	2021-04-18	Recruiting
Randomized Phase IIa Clinical Trial Of Cyclosporine For The Treatment Of COVID-19(+) Non-ICU Hospital Inpatients[NCT04492891]	Phase 2	47 participants (Actual)	Interventional	2020-11-23	Completed
Observational Acquired Haemophilia Registry[NCT01403740]		250 participants (Anticipated)	Observational	2011-09-30	Not yet recruiting
A Phase II Trial Combining Gemtuzumab Ozogamicin (Mylotarg) With Cyclosporine for the Treatment of Relapsed Acute Myeloid Leukemia in Adults Over Age 60[NCT00089050]	Phase 2	0 participants	Interventional	2004-05-31	Completed
A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease[NCT00350545]		37 participants (Actual)	Interventional	2006-08-31	Completed
Low Dose Cyclosporin and Methotrexate Therapy in New Onset Diabetes Mellitus[NCT00905073]		8 participants (Actual)	Interventional	1990-02-28	Completed
Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a CNI-free Regimen With Enteric-coated Mycophenolate Sodium and Everolimus in Comparison to Standard Therapy With Enteric-coated Mycophenolate Sodium and Ciclosporin Mic[NCT00332839]	Phase 4	93 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to The trial was terminated early due to slow enrollment. It was determined that the planned sample size of 300 could not be achieved.)
Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies[NCT01093586]	Phase 2	14 participants (Actual)	Interventional	2007-09-30	Completed
A Phase II Randomized Study Comparing Low Dose Alemtuzumab and Cyclosporine With Standard of Care for the Prevention of Chronic Extensive GVHD for Patients Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) for Hematological Malignan[NCT00775632]	Phase 2	78 participants (Actual)	Interventional	2008-10-31	Completed
A Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) in Multiple Myeloma Patients[NCT00899847]	Phase 2	9 participants (Actual)	Interventional	2009-05-31	Completed
Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies[NCT00916045]	Phase 2	40 participants (Anticipated)	Interventional	2009-09-30	Terminated(stopped due to Recruitment issues)
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)[NCT05600426]	Phase 3	234 participants (Anticipated)	Interventional	2023-01-25	Recruiting
A 12-month, Multicenter, Randomized, Open-label Study to Investigate Efficacy and Safety of Concentration Controlled Everolimus With Reduced Dose Cyclosporine A Versus Mycophenolate Mofetil With Standard Dose Cyclosporine A in de Novo Renal Transplant Adu[NCT00658320]	Phase 3	122 participants (Actual)	Interventional	2008-02-29	Completed
Multicenter Randomised Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients[NCT00809172]	Phase 3	100 participants (Actual)	Interventional	2008-12-31	Completed
Reduced Intensity Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) Supplemented With Donor Natural Killer (NK) Cell Infusions in Patients With High Risk Myeloid Malignancies Who Are Unsuitable for Fully Myeloablative Transplantation[NCT00303667]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2005-01-31	Completed
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Unrelated Donors for Treatment of Patients With High Risk Acute Lymphocytic Leukemia in Complete Remission - A Multicenter Trial[NCT00031655]	Phase 2	30 participants (Anticipated)	Interventional	2001-09-30	Completed
Evaluation of Efficacy, Safety and Tolerability of 0.05% Cyclosporine and 0.1% Tacrolimus Eye Drops in the Treatment of Chronic Ocular Graft-versus-host Disease[NCT05294666]	Phase 4	89 participants (Actual)	Interventional	2020-04-01	Completed
Phase II Trial of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for Treatment of Bronchiolitis Obliterans Syndrome[NCT01287078]	Phase 2	25 participants (Actual)	Interventional	2011-01-29	Completed
Phase II Study of Radiolabeled BC8 (Anti-CD45) Antibody Combined With Busulfan and Cyclophosphamide as Treatment for Acute Myelogenous Leukemia in First Remission Followed by HLA-Identical Related Peripheral Blood Stem Cell Transplantation[NCT00005940]	Phase 2	18 participants (Actual)	Interventional	1999-10-31	Completed
A Phase I Open-Label, Safety Study of Haploidentical Bone Marrow Transplantation (BMT) After Ex Vivo Treatment of Bone Marrow With Anti-B7.1 and Anti-B7.2 Antibodies[NCT00005988]	Phase 1	5 participants (Actual)	Interventional	2000-02-29	Completed
A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients[NCT00854802]		290 participants (Actual)	Interventional	2009-01-31	Completed
A Scandinavian Controlled, Randomized, Open-label, and Multi-centre Study Evaluating if Once-daily Tacrolimus or Twice-daily Cyclosporin, Reduces the 3-year Incidence of Chronic Lung Allograft Dysfunction After Lung Transplantation[NCT02936505]		249 participants (Actual)	Interventional	2016-10-12	Active, not recruiting
[NCT00006054]		0 participants	Interventional	2000-03-31	Terminated
Gemtuzumab Ozogamicin (GO), Fludarabine, And Low-Dose TBI Followed By Donor Stem Cell Transplantation For Patients With Advanced Acute Myeloid Leukemia Or Myelodysplastic Syndrome[NCT00008151]	Phase 2	0 participants	Interventional	2000-10-31	Completed
T-cell Depletion In Unrelated Donor Marrow Transplantation[NCT00006451]	Phase 3	0 participants (Actual)	Interventional	1996-04-30	Withdrawn(stopped due to Terminated (due to no accrual))
Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation[NCT00008307]	Phase 2	52 participants (Anticipated)	Interventional	1998-04-30	Active, not recruiting
High-Dose Chemotherapy Followed By Autologous Hematopoietic Stem Cell Support And One Of Two Regimens Aimed At Modifying Immune Reconstitution In Women With High Risk Stage 2 And Stage 3 Breast Cancer[NCT00008203]	Phase 3	0 participants	Interventional	1996-05-31	Completed
A Phase I, Open Label, Fixed-Sequence Study to Estimate the Effect of Tacrolimus and Cyclosporine on the Pharmacokinetics of CP-690,550 in Healthy Volunteers[NCT00860496]	Phase 1	24 participants (Actual)	Interventional	2009-06-30	Completed
Allogeneic Bone Marrow Transplantation for Marrow Failure States[NCT00005852]	Phase 2	0 participants	Interventional	1996-06-30	Terminated(stopped due to low accrual)
Immunosuppressive Drug Therapy in Membranous Lupus Nephropathy[NCT00001212]	Phase 2	45 participants	Interventional	1986-11-30	Completed
Treatment of T-Large Granular Lymphocyte (T-LGL) Lymphoproliferative Disorders With Cyclosporine[NCT00001533]	Phase 1	25 participants	Interventional	1996-09-30	Completed
A Double-Masked, Randomized, Vehicle-Controlled Pilot Study of the Treatment of Keratoconjunctivitis Sicca With Topical Cyclosporin A 0.1% Emulsion[NCT00001731]	Phase 2	30 participants	Interventional	1997-11-30	Completed
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus[NCT00797030]	Phase 4	20 participants (Actual)	Interventional	2006-10-31	Active, not recruiting
Effects of Conversion From Sirolimus Oral Solution to Tablets in Renal Transplant Recipients.[NCT00166842]	Phase 4	40 participants	Interventional	2002-09-30	Active, not recruiting
Mesenchymal Stem Cell for Treatment of Chronic Graft-versus-host Disease After Allogenetic Hematopoietic Stem Cell Transplantation[NCT04692376]	Phase 2	152 participants (Anticipated)	Interventional	2021-01-10	Recruiting
Pilot Study of the Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients Presenting With New Onset Diabetes After the 3rd Month Post-transplant.[NCT00171717]	Phase 4	39 participants (Actual)	Interventional	2004-02-29	Completed
An Open-label Study to Assess the Efficacy and Safety of Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Expressed by an Adeno-Associated Viral Vector After Intramuscular Administration in LPL-deficient Adult Subjects[NCT00891306]	Phase 2/Phase 3	5 participants (Actual)	Interventional	2009-02-28	Completed
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study[NCT02934217]	Phase 3	868 participants (Actual)	Interventional	2014-03-31	Completed
An Open-Label, Randomized, Prospective Multicenter Study To Compare The Efficacy And Safety Among 3 Immunosuppressant Treatment Regimens In Patients Receiving A Liver Transplant For ESLD Caused By Chronic Hepatitis C[NCT00163657]	Phase 4	312 participants (Actual)	Interventional	2002-07-31	Completed
A 12-month Study to Investigate the Correlations Between Cyclosporine Microemulsion C2 Levels (High, Medium and Low) and AUC0-4 With Regard to Outcome in de Novo Heart and Lung Transplantation - Identification of Target Cyclosporine Microemulsion C2 Level[NCT00154193]	Phase 4	190 participants (Actual)	Interventional	2004-06-30	Completed
Pharmacological Postconditioning During the Aortic Valvular Surgery[NCT00987207]	Phase 3	56 participants (Actual)	Interventional	2008-10-31	Completed
The Vienna Prograf and Endothelial Progenitor Cell Study[NCT00182559]	Phase 4	148 participants (Actual)	Interventional	2004-04-30	Completed
Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Non-Myeloablative Preparative Regimen[NCT00719849]	Phase 2	13 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to A new protocol was developed to replace this protocol in 2008, with removal of ATG and extension of MMF duration.)
Belatacept Conversion Trial in Renal Transplantation[NCT00402168]	Phase 2	173 participants (Actual)	Interventional	2007-01-31	Completed
A 6-month, Multicenter, Randomized, Open-label Study of Safety and Efficacy of Everolimus-based Regimen Versus Calcineurin Inhibitor (CNI)-Based Regimen in Maintenance Liver Transplant Recipients[NCT00267189]	Phase 3	145 participants (Actual)	Interventional	2005-11-30	Completed
A Prospective, Open-label, Controlled Multicenter Trial to Assess the Efficacy and Safety of an Induction Regimen of Cyclosporine Micro Emulsion, Enteric-coated Mycophenolate Sodium (EC-MPS) and Corticosteroids, Followed by Administration of Everolimus an[NCT00371826]	Phase 4	126 participants (Actual)	Interventional	2006-03-31	Completed
Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using a Positive Stem Cell Selection Technique for T Cell Depletion, Followed by Delayed T Cell Add-Back[NCT00378534]	Phase 2	116 participants (Actual)	Interventional	2006-09-30	Completed
Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)[NCT00256750]	Phase 3	738 participants (Actual)	Interventional	2005-03-31	Completed
An Open-label, Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of Chronic Graft Versus Host Disease After TLI/ARG Nonmyeloablative Allogeneic Stem Cell Transplantation[NCT00186628]	Phase 2	36 participants (Actual)	Interventional	2005-06-30	Completed
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma[NCT00185614]	Phase 2	63 participants (Actual)	Interventional	2000-08-31	Completed
A Multicenter, Open-label, Randomized, Two Arm Study to Investigate the Efficacy and Safety of a Therapy Avoiding Intraoperative Steroids in Combination With Basiliximab, Cyclosporine/Cyclosporine Microemulsion, and Steroids in Pediatric de Novo Liver Tra[NCT00149890]	Phase 3	77 participants (Actual)	Interventional	2004-03-31	Completed
Improving Drop Instillation Comfort of a Cyclosporine A Solution[NCT05957211]		40 participants (Anticipated)	Interventional	2023-05-19	Recruiting
A Randomized Single Dose Open Label Bioequivalence Study of Cyclosporine Capsules USP (Modified)100mg in Normal Healthy Male Subjects Under Fed Condition[NCT01080586]		36 participants (Actual)	Interventional	2007-09-30	Completed
A Multicenter, Open-label, Exploratory Study to Evaluate the Efficiency of Intravenously Administered Cyclosporine During the First 7 Days Post Transplant Followed by Treatment With Cyclosporine Micro Emulsion in de Novo Liver Transplant Recipients[NCT00332462]	Phase 4	34 participants (Actual)	Interventional	2006-05-31	Completed
A Double-blind Comparison of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drops in the Treatment of Vernal Keratoconjunctivits (VKC)[NCT01068054]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2003-06-30	Completed
Efficacy and Safety Study Comparing Concentration-controlled Everolimus in Two Doses (1.5 and 3.0 mg/Day Starting Doses) With Reduced Cyclosporine Versus 1.44 g Mycophenolic Acid (as Sodium Salt) With Standard Dose Cyclosporine in de Novo Renal Transplant[NCT00251004]	Phase 3	833 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment[NCT00065260]	Phase 2	54 participants (Actual)	Interventional	2003-11-06	Completed
An Open, Multi-center, Randomized Trial Comparing Haploidentical HSCTs From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies[NCT04547049]	Phase 3	160 participants (Anticipated)	Interventional	2020-09-01	Recruiting
A Phase II Study of Non-myeloablative Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Antithymocyte Globulin (ATG) In Patients With Cutaneous T Cell Lymphoma[NCT00896493]	Phase 2	38 participants (Actual)	Interventional	2009-05-31	Completed
Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock[NCT01901471]	Phase 2	0 participants (Actual)	Interventional	2015-09-30	Withdrawn
A Multicentric, Randomized, Opened Study to Evaluate Efficacy on Renal Function of an Immunosuppressant Regimen Based on Cyclosporine A Dose Reduction in Combination With Mycophenolate Mofetil, From the Second Year of Renal Transplantation[NCT00213590]	Phase 3	208 participants (Actual)	Interventional	2000-04-30	Completed
Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Metastatic Renal Cell Carcinoma[NCT00243009]	Phase 2	1 participants (Actual)	Interventional	2005-06-30	Terminated(stopped due to Due to a lack of a referal base, study was terminated.)
A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma[NCT01954784]	Phase 1	8 participants (Actual)	Interventional	2013-10-07	Terminated(stopped due to Funding unavailable)
A Randomized, Multi-center, Open Label Trial to Establish the Therapeutic Equivalence Between Neoral® and Gengraf® in Stable Renal Allograft Recipients [Gengraf Conversion Study][NCT01990118]	Phase 4	106 participants (Actual)	Interventional	2004-11-30	Completed
Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia[NCT01995331]	Phase 4	30 participants (Anticipated)	Interventional	2012-03-31	Active, not recruiting
Effect of Ciclosporin Eyedrops on Ocular Symptoms and Optical Quality in Patients With Sjögren Syndrome[NCT04597762]		12 participants (Actual)	Interventional	2020-08-31	Completed
Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease[NCT02004067]	Phase 4	100 participants (Actual)	Interventional	2013-01-31	Completed
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Hematopoietic Stem Cells From HLA-Compatible Related or Unrelated Donors in Patients With B Cell Lymphoid Malignancies[NCT00425802]	Phase 2	61 participants (Actual)	Interventional	2006-11-28	Completed
Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis.[NCT00050648]	Phase 1/Phase 2	20 participants (Actual)	Interventional	1997-10-31	Completed
[NCT00006055]		10 participants	Interventional	2000-03-31	Active, not recruiting
[NCT00005898]	Phase 1/Phase 2	30 participants	Interventional	2000-02-29	Completed
Phase II Pilot Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low Dose TBI and Post-Transplant Cyclosporine and Mycophenolate Mofetil Followed by Donor Lymphocyte Infusion for Therapy of Advanced[NCT00005941]	Phase 2	0 participants	Interventional	1999-11-30	Completed
Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)[NCT04304820]	Phase 2	39 participants (Anticipated)	Interventional	2020-05-07	Recruiting
Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease[NCT00567177]	Phase 4	40 participants (Anticipated)	Interventional	2007-11-30	Completed
A Phase I, Single-Center, Randomized, Vehicle-Controlled Study, Double-Blind for the Study Preparations and Observer-Blind for the Comparators to Determine the Antipsoriatic Efficacy and Tolerability of Topical Formulations With Ciclosporin in a Psoriasis[NCT00578370]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2007-11-30	Completed
Topical Cyclosporine and Disease Progression[NCT00567983]	Phase 4	80 participants (Anticipated)	Interventional	2007-12-31	Completed
A Randomized Open-Label Study Comparing the Efficacy and Safety of Sirolimus Combined With Daclizumab, Mycophenolate and Corticosteroids vs Cyclosporine, Mycophenolate and Corticosteroids in Renal Allograft Recipients Receiving Kidneys From Older Donors[NCT00195273]	Phase 3	61 participants (Actual)	Interventional	2004-11-30	Completed
Long-term Outcome of Patients With Acute Ulcerative Colitis After First Course of Intravenous Corticosteroids[NCT04564638]		217 participants (Actual)	Observational [Patient Registry]	2015-03-01	Completed
Utility of Low Doses of Corticosteroids and Cyclosporine Combined With Enoxaparin, in Patients With COVID-19 Pneumonia at the ISSSTE Regional Hospital, Puebla, During the Contingency Period Due to the SARS-Cov2 Pandemic[NCT04540926]	Phase 1/Phase 2	200 participants (Anticipated)	Interventional	2020-09-30	Not yet recruiting
An Open-label, Randomized, Crossover Study to Evaluate the Drug Interaction of Coadministered Cyclosporine on the Pharmacokinetics and Safety of Intravenous Administration of SyB V-1901 in Japanese Healthy Subjects[NCT04542252]	Phase 1	13 participants (Actual)	Interventional	2020-11-09	Completed
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in High Risk Patients and in Patients With Debilitating Hematologic Diseases[NCT00003838]	Phase 2	202 participants (Actual)	Interventional	1999-04-15	Completed
Cyclosporine Modulation of Drug Resistance in Combination With Pravastatin, Mitoxantrone, and Etoposide for Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML): A Phase 1/2 Study[NCT01342887]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2011-04-30	Terminated
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Pediatric Solid Tumors With Relapsed or Therapy Refractory Disease[NCT00112645]	Phase 1	10 participants (Anticipated)	Interventional	2005-04-30	Completed
A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only.[NCT00919776]	Phase 2	20 participants (Actual)	Interventional	2010-08-31	Completed
HLA Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease[NCT00578643]	Phase 2	15 participants (Actual)	Interventional	2004-03-31	Completed
A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients[NCT00658359]	Phase 2	178 participants (Actual)	Interventional	2008-08-31	Completed
Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study[NCT00976300]	Phase 2	40 participants (Actual)	Interventional	2002-01-31	Completed
Open Randomized Mult-Center Study to Evaluate Safety and Efficacy of Low Molecular Weight Sulfated Dextran in Islet Transplantation (CIT-01)[NCT00789308]	Phase 2	24 participants (Actual)	Interventional	2008-07-11	Completed
Multicentre, Open Study for the Setting up of Population Pharmacokinetic Models and Bayesian Estimators for Individual Dose Adjustment of Immunosuppressive Drugs (Cyclosporine, Tacrolimus, Mycophenolate Mofetil, Everolimus) During the First Year Post-graf[NCT00812786]	Phase 4	42 participants (Actual)	Interventional	2007-07-31	Completed
A Randomized Trial of Cyclosporine for Myocardial Protection During Open Heart Surgery[NCT00990795]	Phase 1	72 participants (Anticipated)	Interventional	2010-04-30	Terminated(stopped due to PI left institution.)
Total Marrow Irradiation and Myeloablative Chemotherapy Followed By Double Umbilical Cord BloodTransplantation In Patients With Refractory Acute Leukemia[NCT00686556]	Phase 1	12 participants (Actual)	Interventional	2012-08-31	Completed
A Prospective Randomized Study Comparing Rapamune and Tacrolimus vs. Cyclosporine and Methotrexate as Immune Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation, Using HLA-A, -B, -DRβ1 Identical Related or Unrelated Donors. A Nordic Multicen[NCT00993343]	Phase 3	215 participants (Actual)	Interventional	2007-09-30	Completed
A Comparative Study of Use of Cyclosporin Eye Before Cataract Surgery for the Prevention of Dry Eye[NCT04426240]	Phase 4	40 participants (Actual)	Interventional	2020-08-03	Completed
Randomized Trial of Cyclosporine + CAMPATH-1H (ALEMTUZUMAB) vs. Cyclosporine + METHOTREXATE in Patients Diagnosed With Mature B-cell Neoplasms - Chronic Lymphocytic Leukemia and Low-grade Lymphomas - Receiving Allogeneic Hematopoietic Stem Cell Transplant[NCT02701517]	Phase 2	72 participants (Anticipated)	Interventional	2003-09-30	Terminated(stopped due to The trial was stopped before the targeted number of patients was reached due to lack of support.)
A Phase II Study of Optimally Dosed Clofarabine in Combination With Low-Dose TBI to Decrease Relapse Rates After Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients With AML[NCT01252667]	Phase 2	44 participants (Actual)	Interventional	2011-01-25	Completed
A Multi-center, Randomized, Open Label, Controlled Study to Compare the Sustained Virological Response During Treatment With Neoral or Tacrolimus in Maintenance Liver Transplant Recipients Treated With Pegylated Interferon and Ribavirin for Recurrent Hepa[NCT00938860]	Phase 4	92 participants (Actual)	Interventional	2009-09-30	Completed
Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial[NCT02867800]	Phase 1	24 participants (Actual)	Interventional	2016-07-31	Active, not recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures[NCT02707393]	Phase 2/Phase 3	13 participants (Actual)	Interventional	2009-04-30	Completed
A Phase III Multicenter, Randomized Trial Comparing Tacrolimus/Sirolimus/Methotrexate Versus Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With [NCT00928018]	Phase 3	139 participants (Actual)	Interventional	2009-06-30	Completed
The Comparison Between Clinical and Paraclinical Effect of Iminoral Vs Neoral in Prevention of Acute Rejection in the First Year Afer Transplantation in De Novo Renal Transplant Patients[NCT00656695]	Phase 4	208 participants (Actual)	Interventional	2008-04-30	Completed
Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT[NCT02876679]	Phase 2	94 participants (Actual)	Interventional	2017-04-06	Completed
An Open-label Treatment Use Protocol of Cyclosporine Inhalation Solution (CIS) in Lung Transplant Recipients[NCT00633373]		0 participants	Expanded Access		No longer available
The Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic Anemia[NCT05660785]	Phase 2	54 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Low-dose Interleukin-2 in Combination With Standard Therapy Compared to Standard Therapy Alone in Adults With Active Idiopathic Inflammatory Myopathy[NCT04237987]	Phase 2	20 participants (Anticipated)	Interventional	2020-01-21	Not yet recruiting
[NCT00006056]		40 participants	Interventional	2000-03-31	Active, not recruiting
Calcineurin Inhibitor Minimisation in Renal Transplant Recipients With Stable Allograft Function: A Prospective Randomised Controlled Trial[NCT00541814]	Phase 4	90 participants (Anticipated)	Interventional	2007-10-31	Recruiting
Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies[NCT00534430]	Phase 2	30 participants (Actual)	Interventional	2000-02-29	Active, not recruiting
A Randomized Single-center Trial of Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation[NCT00563589]		30 participants (Anticipated)	Interventional	2003-08-31	Recruiting
A Phase I Study to Examine the Toxicity of Killer IG-Like Receptor (KIR) Mismatched Umbilical Cord Blood for Pediatric Patients With Malignant Solid Tumors[NCT00436761]	Phase 1	20 participants (Anticipated)	Interventional	2004-05-31	Active, not recruiting
Exploiting Synergy in Chronic Myelogenous Leukemia: A Phase Ib Evaluation of Dasatinib Plus Cyclosporine in Patients With Ph+ Leukemia (ESCAPE1b)[NCT01426334]	Phase 1	4 participants (Actual)	Interventional	2011-09-30	Terminated
Comparison Between Topical Mitomycin C and Cyclosporine After Primary Pterygium Surgery[NCT05627947]	Phase 1	57 participants (Actual)	Interventional	2021-01-01	Completed
An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients[NCT02904772]	Phase 2	0 participants (Actual)	Interventional	2016-10-31	Withdrawn(stopped due to uniQure, has decided not to renew the Marketing Authorization of Glybera in the EU. This decision is not related to any safety, efficacy or quality issue)
Phase II Trial of Non-Myeloablative Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Using Fludarabine, Low-Dose TBI, and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil (MMF) Followed by Donor Lymphocyte Infusion[NCT00006233]	Phase 2	0 participants	Interventional	2000-01-31	Completed
Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients: A Pilot Study[NCT02426502]		76 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil[NCT00006251]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2000-05-31	Completed
Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)[NCT00171743]	Phase 4	47 participants (Actual)	Interventional	2004-04-30	Completed
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol[NCT00866684]	Phase 4	44 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Insufficient patient recruitment)
A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone.[NCT00919451]	Phase 2	16 participants (Actual)	Interventional	2010-08-31	Completed
A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen[NCT00129961]	Phase 4	86 participants (Actual)	Interventional	2005-08-31	Completed
The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia[NCT02745717]	Phase 4	60 participants (Actual)	Interventional	2016-01-31	Completed
Ikervis for Prophylaxis of Dry Eye Disease Due to Graft vs Host Disease Post Allogeneic Haemtopoietic Stem Cell Transplant[NCT04636918]	Phase 4	40 participants (Anticipated)	Interventional	2019-11-28	Recruiting
Role of Th1, Th2 and Monokine Responses as Risk Factors of Acute and Chronic Renal Transplant Rejection - Impact of Different Immunosuppressive Protocols[NCT00150891]		84 participants (Actual)	Observational	1998-01-31	Completed
Effects of Treatment With Biological Agents on Endothelial Glycocalyx,Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study With Patients With CAD or Untreated Hypertension.[NCT02144857]	Phase 4	200 participants (Anticipated)	Interventional	2014-05-30	Recruiting
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases[NCT01962636]		200 participants (Anticipated)	Interventional	2016-12-31	Recruiting
A Prospective, Randomized, Open, Multicentric Study Intended to Evaluate the Efficacy and Tolerability of Sequential Treatment Based on Rabbit Anti-T-lymphocyte Serum, of Mycophenolate Mofetil and of Cyclosporin, Without Concomitant Corticosteroids, After[NCT00200551]	Phase 4	200 participants	Interventional	2001-01-31	Completed
Multitarget Therapy for Idiopathic Membranous Nephropathy[NCT04424862]	Phase 4	82 participants (Actual)	Interventional	2020-06-09	Completed
Effects of Cyclosporine A Pretreatment of Deceased Donor on Kidney Graft Function: A Randomized Controlled Trial[NCT02907554]	Phase 4	648 participants (Anticipated)	Interventional	2017-12-19	Recruiting
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia[NCT00550992]		445 participants (Anticipated)	Interventional	2006-01-31	Recruiting
A Pilot Randomized, Multicenter, Open-Label, Active Comparator-Controlled Trial Of A CP-690,550-Based Regimen In De Novo Kidney Allograft Recipients[NCT00556257]	Phase 2	0 participants (Actual)	Interventional	2007-08-31	Withdrawn
Intracanalicular Dexamethasone Used in Conjunction With Restasis (Cyclosporine Ophthalmic Emulsion) for the Treatment of Signs and Symptoms of Dry Eye Disease as Compared to Restasis With Lotemax (Loteprednol Etabonate Ophthalmic Suspension 0.5%) and Rest[NCT04555694]	Phase 4	30 participants (Actual)	Interventional	2020-10-01	Completed
Controlled Trial of Induction Therapy in Renal Transplantation[NCT00000936]	Phase 3	292 participants (Actual)	Interventional	1999-11-30	Terminated
AML-MVPCYA: ADDITION OF CYCLOSPORIN A TO THE COMBINATION OF MITOXANTRONE AND ETOPOSIDE (VP 16,213) TO OVERCOME RESISTANCE TO CHEMOTHERAPY IN REFRACTORY AML: A RANDOMIZED PHASE II STUDY[NCT00002688]	Phase 2	25 participants (Anticipated)	Interventional	1995-02-28	Active, not recruiting
A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS) IN PATIENTS UNDERGOING MARROW TRANSPLANTATION FROM RELATED DONORS MISMATCHED FOR ONE HLA ANTIGEN IN THE DIRECTION OF GRAFT-VERSUS-HOST DISEASE (GVHD)[NCT00002790]	Phase 1/Phase 2	0 participants (Actual)	Interventional	1996-03-31	Withdrawn
Phase I/II Trial of Decitabine and Allogeneic Peripheral Blood Stem Cells Transplantation for Treatment of Relapse Post Allogeneic Bone Marrow Transplantation[NCT00002832]	Phase 1/Phase 2	14 participants (Actual)	Interventional	1995-08-31	Completed
[NCT00004482]	Phase 2	40 participants	Interventional	1999-12-31	Completed
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantatio[NCT03246906]	Phase 2	160 participants (Anticipated)	Interventional	2017-09-11	Recruiting
Conversion Study to Optimize Immunosuppressive Regimen by Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction for Patients After Heart Transplantation in Lon-Term[NCT00359814]		23 participants (Actual)	Interventional	2004-11-30	Completed
A Phase I, 2-panel, Open-label, Randomized, Cross-over Trial in Healthy Subjects to Investigate the Effect of TMC435 at Steady-state on the Pharmacokinetics of the Immunosuppressants Cyclosporine and Tacrolimus[NCT01479881]	Phase 1	29 participants (Actual)	Interventional	2011-10-31	Completed
Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye[NCT01488396]	Phase 4	31 participants (Actual)	Interventional	2007-02-28	Completed
The Pharmacokinetic Interaction Between Pravastatin and Cyclosporine in Healthy Volunteers[NCT01497483]	Phase 1	21 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized Controlled Trial of Reducing Calcineruin Inhibitor Target Level by 50% Versus Converting to Rapamycin in Chronic Kidney Dysfunction Without Reversible Causes[NCT01492894]	Phase 4	0 participants (Actual)	Interventional	2008-01-31	Withdrawn(stopped due to study terminated due to low enrollment)
Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Cyclosporine: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects[NCT01494597]	Phase 1	24 participants (Actual)	Interventional	2011-11-30	Completed
Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea[NCT00348335]	Phase 4	35 participants (Actual)	Interventional	2006-06-30	Completed
Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation[NCT00349583]	Phase 4	0 participants	Interventional		Completed
Haploidentical Hematopoietic Stem Cell Transplantation in the Treatment of Hematological Malignancies Using CAMPATH-1H[NCT00458250]	Phase 1	10 participants (Anticipated)	Interventional	2006-09-30	Completed
Multicenter, Randomised, Double Masked, Controlled Studies on the Efficacy of Cyclosporine Eye Drop Treatment in Preventing Vernal Keratoconjunctivitis (VKC) Relapses and in Treating the Acute Phase.[NCT00426023]	Phase 3	48 participants (Anticipated)	Interventional	2007-02-28	Completed
Pilot Study of First-line Immunosuppressive Therapy Combined With Etoposide and Allogeneic Hematopoietic Cell Transplantation in Refractory/Reactivated Cases for Hemophagocytic Lymphohistiocytosis (HLH) in Adult Patients[NCT01547143]		12 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to The PI resigned the institute, and the rest investigators at the institute decided to terminate the study.)
[NCT00433277]		0 participants	Interventional		Active, not recruiting
SMD/ATG-CSA: Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome[NCT00488436]	Phase 4	25 participants (Anticipated)	Interventional	2002-05-31	Completed
Interstitial Fibrosis in Protocol Biopsies of Renal Allografts: A Prospective, Randomised Trial of Sirolimus Versus Cyclosporine.(Fibrasic)[NCT00493194]	Phase 4	100 participants (Anticipated)	Interventional	2005-05-31	Recruiting
Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms[NCT00399061]	Phase 4	55 participants (Actual)	Interventional	2006-11-30	Completed
[NCT02276001]	Phase 1	20 participants (Actual)	Interventional	2014-06-30	Completed
Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance[NCT00752479]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2008-05-31	Terminated(stopped due to Necessity of major revision of the protocol)
[NCT00502073]	Phase 3	0 participants	Interventional		Completed
NON-T-CELL DEPLETED HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING[NCT00521430]		30 participants (Anticipated)	Interventional	2004-04-30	Completed
Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye[NCT05605314]		500 participants (Anticipated)	Observational	2021-01-01	Recruiting
The Effect of Rimonabant Treatment on Cardiovascular Risk Factors in Renal Transplant Recipients -- Pilot Safety Study[NCT00525681]	Phase 4	18 participants (Actual)	Interventional	2007-09-30	Completed
Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents[NCT01678937]		31 participants (Actual)	Observational	2007-09-30	Completed
A Multicenter, Placebo Controlled, Restasis® Referenced, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome[NCT02917512]	Phase 2	114 participants (Actual)	Interventional	2016-03-31	Completed
Long-term Study of Ciclosporin for Atopic Dermatitis[NCT00232063]	Phase 3	0 participants	Interventional	2004-05-31	Completed
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early CNI Avoidance[NCT01266148]	Phase 4	115 participants (Actual)	Interventional	2009-11-30	Completed
[NCT00548301]	Phase 3	0 participants	Interventional		Completed
Allogeneic Hematopoietic Cell Transplantation for Patients With Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen[NCT00919503]	Phase 2	98 participants (Actual)	Interventional	2009-07-31	Completed
5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)[NCT02864706]	Phase 4	95 participants (Actual)	Interventional	2016-01-18	Completed
A Randomized Trial of Antithymocyte Globulin and Cyclosporine Versus Cyclophosphamide and Cyclosporine in the Treatment of Severe Aplastic Anemia[NCT00001626]	Phase 2	33 participants (Actual)	Interventional	1997-06-02	Completed
Pilot Study for Matched-Related Allogeneic Bone Marrow Transplantation for Metastatic Malignant Melanoma[NCT00003060]	Phase 1	6 participants (Anticipated)	Interventional	1995-03-31	Terminated(stopped due to lack of patient accrual)
Randomized Trial of Autologous GVHD for Refractory Lymphoma[NCT00003414]	Phase 3	50 participants (Anticipated)	Interventional	1997-10-31	Completed
Allogeneic Stem Cell Transplantation For Multiple Myeloma: A Two Step Approach To Reduce Toxicity Involving High Dose Melphalan and Autologous Stem Cell Transplant Followed By PBSC Allografting After Low Dose TBI[NCT00003954]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	1999-03-31	Completed
Conversion Study to Optimize Immunosuppressive Regimen by Withdrawal of Steroids, Cyclosporine A Dose Reduction and a Switch to Mycophenolatmofetile for Patients After Heart Transplantation in the Long-Term.[NCT00359658]		40 participants (Actual)	Interventional	2004-11-30	Completed
Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies[NCT01799460]		80 participants (Anticipated)	Observational	2010-12-31	Recruiting
A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.[NCT01469884]	Phase 4	30 participants (Actual)	Interventional	2011-11-30	Completed
SOAR, Interventional Phase II Single-arm Study to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Adult Patients With Severe Acquired Aplastic Anemia[NCT02998645]	Phase 2	54 participants (Actual)	Interventional	2017-05-11	Completed
A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation[NCT01427881]	Phase 2	43 participants (Actual)	Interventional	2011-09-30	Completed
A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older[NCT00066794]	Phase 2	69 participants (Actual)	Interventional	2004-07-31	Completed
Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol[NCT01695668]		75 participants (Actual)	Interventional	2011-08-31	Completed
A Pilot Study of Using Filgrastim-Primed Bone Marrow in Human Leukocyte Antigen (HLA) Matched Related Donor Allogenetic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies[NCT00253552]		4 participants (Actual)	Interventional	2004-05-31	Terminated(stopped due to Terminated at request of PI as study was outdated.)
A Phase II/III Study of Immunomodulation After High Dose Myeloablative Therapy With Autologous Stem Cell Rescue for Refractory/Relapsed Hodgkin Disease[NCT00070187]	Phase 2/Phase 3	24 participants (Actual)	Interventional	2003-11-30	Completed
Metabolic Pattern of Cyclosporine A - Association of Secondary- and Cyclic Metabolites With Acute Renal Failure in Heart Transplant Recipients[NCT00264355]	Phase 4	30 participants (Anticipated)	Interventional	2005-12-31	Completed
A Multi-centre, Randomized, Open-label, Study to Compare Conversion From Calcineurin Inhibitors to Rapamune Versus Standard Therapy in Established Renal Allograft Recipients on Maintenance Therapy With Mild to Moderate Renal Insufficiency.[NCT00273871]	Phase 3	190 participants	Interventional	2002-01-31	Completed
A Multi-Center Phase II Study of Nonmyeloablative Conditioning With TBI and Fludarabine for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Chronic Myeloid Leukemia in Chronic and Accelerated Phase[NCT00110058]	Phase 2	40 participants (Anticipated)	Interventional	2005-02-28	Completed
Pilot Study on Allogeneic Stem Cell Transplantation Following Conditioning With Fludarabine and an Alkylating Agent in Patients With High-Risk Chronic Lymphocytic Leukemia[NCT00281983]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2000-06-30	Completed
A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients[NCT00286624]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2003-03-31	Completed
A Cyclophosphamide/Fludarabine/Total Body Irradiation Preparative Regimen for Patients With Hematological Malignancy Receiving Unrelated Donor Umbilical Cord Blood Transplantation[NCT00290641]		68 participants (Actual)	Interventional	2001-04-30	Completed
Fludarabine and Low-Dose TBI Dose Escalation to Determine the Optimal Regimen for Achieving High Rates Engraftment of Unrelated Donor Peripheral Blood Stem Cell in Patients With Chronic Myeloid Leukemia - A Multi-Center Trial[NCT00119340]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2005-04-30	Completed
A Randomized Double Blinded Placebo-Controlled Phase III Trial Comparing Cyclosporine Plus Steroids With or Without Myfortic as Primary Treatment for Extensive Chronic Graft Versus Host Disease[NCT00298324]	Phase 3	34 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Due to slow accrual)
Ciclosporin + Antithymocyte Immunoglobulin + Avatrombpag Versus Ciclosporin + Avatrombpag for the Treatment of Severe Aplastic Anemia in the Elderly[NCT05996393]	Phase 4	60 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
A Phase II Trial of Total Body Irradiation Plus Metabolism-Based Cyclophosphamide Dosing as Preparative Therapy for Allogeneic Hematopoietic Cell Transplant for Patients With Hematological Malignancy[NCT00317785]	Phase 2	50 participants (Anticipated)	Interventional	2005-05-31	Completed
An Open-Label, Prospective, Randomized, Controlled, Multi-Center Study Assessing Fixed Dose Versus Concentration Controlled Cellcept® Regimens for Patients Following a Single Organ Renal Transplantation in Combination With Full Dose and Reduced Dose Calci[NCT00087581]	Phase 4	720 participants (Actual)	Interventional	2004-06-30	Completed
Hemophagocytic Lymphohistiocytosis[NCT00334672]	Phase 3	288 participants (Anticipated)	Interventional	2006-03-31	Active, not recruiting
A Pilot Study to Evaluate the Co-infusion of Ex Vivo Expanded Umbilical Cord Blood Progenitors With an Unmanipulated Cord Blood Graft in Patients Undergoing Umbilical Cord Blood Transplantation for Hematologic Malignancies[NCT00343798]	Phase 1	23 participants (Actual)	Interventional	2006-04-30	Completed
Pilot Trial of Two Dose Levels of Thymoglobulin® as Part of a Myeloablative-Conditioning for a HLA Identical Matched Related Donor (MRD) Stem Cell Transplant With Cyclosporine (CsA) as Posttransplant Graft vs Host Disease (GvHD) Prophylaxis[NCT00093587]		0 participants	Interventional	2004-08-31	Active, not recruiting
Low-Dose Total Body Irradiation and Fludarabine Followed By Unrelated Donor Stem Cell Transplantation for Patients With Fanconi Anemia - A Multicenter Trial[NCT00093743]	Phase 1	2 participants (Actual)	Interventional	2000-01-31	Completed
Protection by Ciclosporine A During Reperfused Acute Myocardial Infarction.[NCT00403728]	Phase 2/Phase 3	60 participants	Interventional	2004-09-30	Active, not recruiting
Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors[NCT00133887]	Phase 3	77 participants (Actual)	Interventional	2004-04-30	Completed
Effects of Cyclosporine A on Pancreatic Insulin Secretion[NCT00139035]	Phase 4	16 participants	Interventional	2005-04-30	Completed
Interruption of the Calcineurine Inhibitors (ICN) and Introduction of Mycophenolate Mofetil (MMF) in Liver Transplant Patients With Side Effects Due to ICN: Study of the Reduction of the Risks of Rejection by Mycophenolate Mofetil Therapeutic Drug Monitor[NCT00456235]	Phase 4	92 participants (Actual)	Interventional	2006-09-30	Completed
Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies[NCT00113828]	Phase 2	5 participants (Actual)	Interventional	2004-12-31	Terminated(stopped due to Insufficient accrual)
Prednisolone vs. Ciclosporine in Severe Atopic Eczema[NCT00445081]	Phase 4	66 participants (Anticipated)	Interventional	2007-03-31	Completed
Oasys vs. Extreme H20 Xtra 59[NCT00477763]	Phase 4	52 participants (Actual)	Interventional	2007-05-31	Completed
Role of Topical Immuonosuppressant in the Management of Spring Catarrh: a Comparative Study Between Cyclosporine A 2% and Tacrolimus 0.3%[NCT04705584]		180 participants (Anticipated)	Interventional	2021-01-31	Not yet recruiting
An Open-Label Study to Evaluate the Efficacy and Safety of Cyclosporine Reduction in de Novo Renal Allograft Recipients Receiving Sirolimus: a Dose Comparative Study[NCT00507793]	Phase 4	385 participants (Actual)	Interventional	2000-04-30	Completed
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis[NCT00148746]		0 participants	Interventional	2004-05-31	Completed
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy: a Multicenter, Randomized, Open-label, Parallel Controlled Study[NCT05839314]	Phase 4	480 participants (Anticipated)	Interventional	2023-05-09	Recruiting
[NCT01812954]		1 participants (Actual)	Observational	2013-03-31	Completed
A Multicenter Randomized Controlled Trial of Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of Idiopathic Membranous Nephropathy[NCT04743739]	Phase 3	126 participants (Anticipated)	Interventional	2021-04-14	Recruiting
Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)[NCT00001964]	Phase 2	104 participants (Actual)	Interventional	2000-03-17	Completed
Treatment of High Risk, Inherited Lysosomal And Peroxisomal Disorders by Reduced Intensity Hematopoietic Stem Cell Transplantation[NCT00383448]	Phase 2	38 participants (Actual)	Interventional	2006-09-30	Completed
Hematopoietic Cell Transplantation for Treatment of Patients With Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-Dose TBI and Fludarabine With or Without Campath®[NCT00553098]	Phase 2	29 participants (Actual)	Interventional	2006-06-30	Completed
Treatment of Subepithelial Infiltrates Secondary to Epidemic Keratoconjunctivitis: Corticosteroids Versus Cyclosporine Eyedrops: A Randomized Double-blind Study[NCT04376970]	Phase 4	51 participants (Actual)	Interventional	2017-04-01	Completed
Low-Dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection After Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders - A Multi-Cen[NCT00397813]	Phase 2	77 participants (Actual)	Interventional	2006-01-31	Completed
Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation[NCT00755040]	Phase 3	164 participants (Actual)	Interventional	2008-10-31	Completed
Tandem Autologous HCT/Nonmyeloablative Allogeneic HCT From HLA-Matched Related and Unrelated Donors Followed by Bortezomib Maintenance Therapy for Patients With High-Risk Multiple Myeloma[NCT00793572]	Phase 2	32 participants (Actual)	Interventional	2008-10-31	Completed
Phase II Study of Combination of Thymoglobulin, Cyclosporine, Methylprednisone, and Granulocyte Colony-stimulating Factor (GCSF) in Patients With Newly Diagnosed Aplastic Anemia or With Hypoplastic or Low/Intermediate-1 Risk Myelodysplastic Syndrome[NCT00806598]	Phase 2	53 participants (Actual)	Interventional	2005-05-31	Completed
Microvascular and Inflammatory Responses of 0.05 Cyclosporine Eye Drop (II) in Treatment of Mild to Moderate Dry Eye[NCT05131152]		100 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Randomized, Double-Blinded, Placebo-Controlled Protocol of Oral Cyclosporine in Patients With Advanced Stage Chronic Obstructive Pulmonary Disease[NCT00974142]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2009-09-30	Completed
A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine[NCT00987480]	Phase 2	45 participants (Actual)	Interventional	2009-09-25	Completed
Study of Cyclosporine in Post-LASIK Patients[NCT00991458]	Phase 2	621 participants (Actual)	Interventional	2009-10-31	Completed
Allogeneic Hematopoietic Stem Cell Transplantation for Standard Risk Inherited Metabolic Disorders[NCT01043640]	Phase 2	46 participants (Actual)	Interventional	2009-12-31	Completed
Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30)[NCT01105650]	Phase 2	13 participants (Actual)	Interventional	2010-07-31	Completed
Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation[NCT01235910]	Phase 4	1 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Study was stopped early due to difficulty finding patients who met I/E criteria.)
Combined Modality Radioimmunotherapy For Metastatic Breast Adenocarcinoma With Two Cycles Of Escalating Dose 90Y-DOTA-peptide-m170 and Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression[NCT00009763]	Phase 1	0 participants	Interventional	2001-03-31	Active, not recruiting
Treatment of Diamond Blackfan Anemia With Antithymocyte Globulin and Cyclosporine A[NCT00001749]	Phase 2	25 participants	Interventional	1998-07-31	Completed
Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet's Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)[NCT00167583]	Phase 3	37 participants (Actual)	Interventional	2004-11-30	Completed
An Open-label, 3-Treatment, 3-Period, Fixed Sequence Study in Healthy Subjects to Assess the Pharmacokinetics of Verinurad and Allopurinol When Administered Alone, and in Combination With Single Doses of Cyclosporine or Rifampicin[NCT04532918]	Phase 1	14 participants (Actual)	Interventional	2020-09-10	Completed
[NCT00549289]	Phase 3	0 participants	Interventional		Completed
A Randomized, Open-label Study to Compare the Safety and Efficacy of Cyclosporine Dose Reduction With Cyclosporine Elimination in De Novo Renal Allograft Recipients Receiving Rapamune.[NCT00195468]	Phase 4	280 participants (Anticipated)	Interventional	2004-03-31	Completed
A Multicenter, Randomized Open-label Pilot Study to Explore the Benefit of a Conversion From a Twice a Day Administration of Cyclosporine Microemulsion to a Once a Day Administration and to Identify the C2 Ranges to Target After Conversion in Stable Liver[NCT00171509]	Phase 4	61 participants (Actual)	Interventional	2004-05-31	Completed
Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis.[NCT00209859]	Phase 4	160 participants	Interventional	1998-10-31	Completed
6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program[NCT00956293]	Phase 4	207 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to The study was terminated because the required sample size of 240-260 de novo senior renal transplant patients was not achieved within a reasonable time.)
Transplantation of HLA Haploidentical Marrow Cells After Ex Vivo Exposure to Recipient Alloantigen in Presence of CTLA4-Ig - A Phase II Study of Tolerance Induction in Donor T Cells by Blockade of the CD80/CD86:CD28 Costimulatory Signal[NCT00005854]	Phase 2	0 participants	Interventional	1999-12-31	Completed
A Dose Finding Study of Total Body Irradiation for Conditioning Patients With Severe Aplastic Anemia Transplanted With Umbilical Cord Blood[NCT00354419]	Phase 1	30 participants (Anticipated)	Interventional	2006-02-28	Terminated(stopped due to Low accrual)
HLH-2004 Treatment Protocol[NCT00426101]	Phase 3	368 participants (Actual)	Interventional	2004-01-31	Completed
Efficacy and Safety of Maintenance Neoral Compared to Bitherapy Neoral-Imurel or Neoral-CellCept in Renal Transplantation[NCT00461825]	Phase 3	207 participants	Interventional	1998-07-31	Completed
A Drug-Drug Interaction Study Between Danoprevir/Low-dose Ritonavir and Cyclosporine, a Potent Inhibitor of OATP, in Healthy Subjects[NCT01514968]	Phase 1	18 participants (Actual)	Interventional	2011-12-31	Completed
Effect of Cequa™ in Subjects With Dry Eye Disease That Is Currently Inadequately Controlled While on Cyclosporine 0.05% Ophthalmic Emulsion[NCT04357795]	Phase 4	107 participants (Actual)	Interventional	2020-06-29	Completed
Phase Ⅱ/Ⅲ Clinical Trial, Multicenter, Randomized, Controlled, for the Evaluation of Efficacy and Safety of Therapy With Allogenic Mesenchymal Stem Cells in Patients With Chronic Graft Versus Host Disease[NCT01526850]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2012-02-29	Recruiting
Postgrafting Methotrexate and Cyclosporine for the Prevention of Graft-Versus-Host Disease[NCT00002456]	Phase 3	0 participants	Interventional	1986-05-31	Completed
A Randomized, Double-blind, Placebo Controlled, Parallel Group, Proof of Concept Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis[NCT01552629]	Phase 2	22 participants (Actual)	Interventional	2012-01-05	Completed
Allogeneic Peripheral Blood Progenitor Cell Transplantation Using Histocompatible Sibling-Matched Donor Cells After High-Dose Busulfan/Cyclophosphamide as Therapy for Hematologic Malignancies[NCT00003116]	Phase 2	66 participants (Actual)	Interventional	1997-05-31	Completed
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant[NCT00099736]	Phase 3	696 participants (Actual)	Interventional	2003-05-07	Completed
A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, a[NCT01504906]	Phase 1	20 participants (Actual)	Interventional	2012-01-31	Completed
A Phase I Clinical Trial to Study the Safety of a Sustained-Release Subconjunctival Cyclosporine Implant for Ocular Graft-vs-Host Disease (GVHD1)[NCT00102583]	Phase 1	4 participants (Actual)	Interventional	2004-10-14	Completed
Non-Myeloablative Chemotherapy Followed By Related Allogeneic Stem Cell Rescue In Patients With Advanced Renal Cell Carcinoma[NCT00006968]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2000-09-30	Completed
An Open Label Study to Evaluate the Effect of CellCept in Combination With Cyclosporine A and Steroids on Renal Function and the Prevention of Acute Rejection in Heart Transplant Patients.[NCT02091414]	Phase 3	36 participants (Actual)	Interventional	2006-08-31	Completed
Evaluation of Antibody Plus Delayed CSA vs CSA in Determining Delayed Graft Function in Cadaver Transplant Recipients[NCT00007787]		350 participants (Anticipated)	Interventional	2000-04-30	Completed
A Phase I Study Combining Escalating Doses of Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to Establish Mixed or Full Donor Chimerism [NCT00008177]	Phase 1	79 participants (Actual)	Interventional	1999-07-27	Completed
Transplantation of Unrelated Donor Hematopoietic Stem Cells for the Treatment of Hematological Malignancies[NCT00281879]	Phase 2	200 participants (Actual)	Interventional	2006-02-28	Terminated
Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil[NCT00008450]	Phase 1	6 participants (Actual)	Interventional	1997-08-11	Completed
Combined Modality Radioimmunotherapy For Hormone Refractory Metastatic Prostate Cancer With Two Cycles Of Escalating Dose 90Y-DOTA-Peptide-m170 And Fixed, Low Dose Paclitaxel With Blood Stem Cell Support And Cyclosporin For HAMA Suppression[NCT00009750]	Phase 1	0 participants	Interventional	2001-03-31	Active, not recruiting
Allogeneic Breast Protocol 1: T-Cell Depleted Allogeneic Blood Stem Cell Transplantation Using an Immunoablative Conditioning Regimen in Metastatic Breast Cancer[NCT00020176]	Phase 2	0 participants	Interventional	2000-06-30	Completed
A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia[NCT00022126]	Phase 2	6 participants (Actual)	Interventional	2002-11-30	Completed
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation From HLA Matched Sibling Donors For Treatment Of Patients With High Risk Acute Lymphocytic Leukemia In Complete Remission[NCT00027547]	Phase 1/Phase 2	0 participants	Interventional	2001-07-31	Completed
Low-Dose TBI and Fludarabine Followed by Nonmyeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Using Enhanced Postgrafting Immunosuppression for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial[NCT00027820]	Phase 1/Phase 2	106 participants (Actual)	Interventional	2001-08-31	Completed
Sibling Donor Cord Blood Banking and Transplantation[NCT00029380]	Phase 2	30 participants (Anticipated)	Interventional	1999-01-31	Completed
Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression[NCT00014235]		160 participants (Anticipated)	Interventional	2000-12-31	Completed
A Phase II Study of Anti-Thymocyte Globulin and Cyclosporine for Patients With Myelodysplastic Syndrome (MDS)[NCT00016419]	Phase 2	130 participants (Anticipated)	Interventional	2001-08-31	Completed
Conditioning With Targeted Busulfan, Cyclophosphamide and Thymoglobulin for Allogeneic Marrow or Peripheral Blood Stem Cell (PBSC) Transplantation for Myelodysplasia and Myeloproliferative Disorders[NCT00054340]	Phase 1/Phase 2	0 participants	Interventional	2002-10-31	Completed
Phase II Trial in Intrafamilial Allogeneic Cell Transplant in Patients With Metastatic Kidney Cancer[NCT00056095]	Phase 2	57 participants (Actual)	Interventional	2002-11-04	Completed
A Randomized Trial of a Novel Immunosuppressive Combination of ATG, CsA and Sirolimus (Rapamune) vs a Slow Taper Cyclosporine Regimen in Subjects With Severe Aplastic Anemia[NCT00061360]	Phase 2	77 participants (Actual)	Interventional	2003-06-26	Completed
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study[NCT00070174]	Phase 2	350 participants (Actual)	Interventional	2003-12-31	Completed
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OTI-010 in Subjects Who Receive HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies[NCT00081055]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
Focal Segmental Glomerulosclerosis Clinical Trial[NCT00135811]	Phase 3	207 participants (Anticipated)	Interventional	2004-11-30	Completed
Randomised, Double-Arm, Controlled, Open-Label Study Comparing Calcineurin Inhibitor-Free Immunosuppression (Zenapax®, CellCept® and Prednisolone) and Cyclosporine A Based Immunosuppression (Sandimmun Neoral®, CellCept® and Prednisolone) on the Outcome of[NCT00138970]	Phase 4	70 participants	Interventional	2002-01-31	Completed
[NCT00139009]	Phase 4	30 participants	Interventional	2005-06-30	Completed
Efficacy and Adverse Effects of Cyclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis[NCT00404482]		60 participants	Observational	1991-01-31	Completed
Investigator-Initiated, Use Study of Alefacept (Amevive) in Combination With Tapering Doses of Cyclosporine in Patients With Moderate to Severe Psoriasis[NCT00143806]	Phase 2	13 participants	Interventional	2003-10-31	Completed
Combined Modality Radioimmunotherapy For Non-Hodgkin's Lymphoma With Three Cycles Of 90Y-DOTA-peptide-Lym-1, Paclitaxel and Cyclosporin A[NCT00009776]	Phase 1	0 participants	Interventional	2001-03-31	Active, not recruiting
[NCT00017654]		3 participants	Interventional	2001-04-30	Active, not recruiting
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051)[NCT00022737]	Phase 3	220 participants (Actual)	Interventional	2002-10-31	Completed
A Double-Blind Randomized Trial of Steroid Withdrawal in Sirolimus- and Cyclosporine-Treated Primary Transplant Recipients[NCT00023244]	Phase 2	274 participants (Actual)	Interventional	2001-01-31	Terminated(stopped due to Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferative disorder)
Fludarabine And Busulfan As Conditioning For Patients With Chronic Myeloid Leukemia Or Myelodysplastic Syndrome Transplanted With Hematopoietic Stem Cells From HLA-Compatible Related Or Unrelated Donors[NCT00027924]	Phase 2	0 participants	Interventional	2001-10-31	Completed
Phase III Trial of Hydroxychloroquine + Standard Therapy for Chronic Graft-Versus-Host Disease[NCT00031824]	Phase 3	82 participants (Actual)	Interventional	2002-04-30	Completed
Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia[NCT00031980]	Phase 2	30 participants (Actual)	Interventional	2002-03-31	Completed
Prospective, Open-label, Single Arm Pilot Study Evaluating the Effect on Virological Response of the Switch From Tacrolimus to Cyclosporin Associated With a Peginterferon Alfa-2a / Ribavirin Bitherapy, in Non-responder or With Recurrent VHC+ Disease Liver[NCT00375895]	Phase 3	11 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Insufficient enrollment)
Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.[NCT05771012]		42 participants (Actual)	Interventional	2021-01-01	Completed
"Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation for the Treatment of Less Advanced Myelodysplasi"[NCT00024050]	Phase 2	0 participants	Interventional	2001-02-28	Completed
Delayed Donor Leukocyte Infusions in Patients Receiving Allogeneic PBSC Following Conditioning With Non-myeloablative Regimen for AIDS-Related Lymphoma (NHL and HD)[NCT00024128]	Phase 2	0 participants (Actual)	Interventional	2001-08-31	Withdrawn(stopped due to Withdrawn prior to initiation.)
Giant Cell Myocarditis Treatment Trial Pilot Study[NCT00027443]		40 participants (Anticipated)	Interventional	2001-08-31	Completed
Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation[NCT00055653]	Phase 2	0 participants	Interventional	2003-01-31	Completed
Augmenting the Magnitude of HAART-Induced Immune Restoration With the Use of Cyclosporine[NCT00031070]	Phase 2	40 participants	Interventional		Completed
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplantation for the Treatment of Relapsed Non-Hodgkin and Hodgkin Lymphoma[NCT00057954]	Phase 2	6 participants (Actual)	Interventional	2005-11-09	Terminated(stopped due to Slow accrual)
Phase I/II Study of Induction of Stable Mixed Chimerism After Bone Marrow Transplantation From HLA-Identical Donors in Children With Sickle Cell Disease[NCT00004485]	Phase 1/Phase 2	50 participants	Interventional	1999-12-31	Completed
Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia[NCT00066417]	Phase 2	51 participants (Anticipated)	Interventional		Terminated(stopped due to Trial was withdrawn for drug availability issues.)
Topical Cyclosporine A for the Treatment of Dry Eye: A Randomized Clinical Study[NCT04714099]	Phase 3	40 participants (Actual)	Interventional	2015-01-01	Completed
Immunomodulation by Ultraviolet B-Irradiation (UVB) to Facilitate Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies[NCT00068523]		10 participants (Actual)	Interventional	2003-06-30	Completed
Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria[NCT01642979]	Phase 2	120 participants (Anticipated)	Interventional	2012-07-31	Active, not recruiting
A Phase II Multicenter Randomized Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And Chronic Lymphocytic Leukemia (CLL)[NCT00041288]	Phase 2	10 participants (Actual)	Interventional	2001-10-31	Terminated(stopped due to Poor accrual and difficulty with multicenter logistics)
Rapamycin Use in CNI-Free Immunosuppression for Stabilization/Improvement of Renal Function After Heart Transplantation[NCT00123331]	Phase 4	40 participants	Interventional	2003-10-31	Completed
Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Maligna[NCT00078858]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2003-09-30	Completed
Low Dose Total-Body Irradiation And Fludarabine Followed By HLA Matched Allogeneic Stem Cell Transplantation For Hematologic Malgnancies - A Multi-Center Study[NCT00044954]	Phase 2	0 participants	Interventional	1999-11-30	Completed
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation From Haploidentical Related Donors For Hematologic Malignancies[NCT00080925]	Phase 1	20 participants (Anticipated)	Interventional	2004-02-29	Completed
A Randomized, Open-label Study Comparing the Effects of Low-dose Cyclosporine vs Cyclosporine Withdrawal on Renal Function in Kidney Transplant Patients Treated With CellCept and Daclizumab[NCT00048152]	Phase 3	539 participants (Actual)	Interventional	2000-12-31	Completed
A Prospective, Randomized, Open-label, Twenty-six Week Study of the Efficacy and Safety of Converting Kidney and Liver Transplant Recipients With Tacrolimus-associated Abnormal Glucose Metabolism to Cyclosporine Micro-emulsion With C2 Monitoring[NCT00150085]	Phase 4	50 participants (Actual)	Interventional	2004-02-29	Terminated
A Phase I/II Study of Immunologically Engineered rhG-CSF Mobilized Peripheral Blood Stem Cells (PBSC) for Allogeneic Transplant From HLA Identical, Related Donors for Treatment of Myeloid Malignancies[NCT00049634]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2002-01-31	Completed
Prospective Randomized Study to Characterize Risk Factors of Polyomavirus-related Transplant Nephropathy and the Impact of Three Immunosuppressive Regimens on Nephropathy Incidence[NCT00160966]	Phase 4	108 participants (Actual)	Interventional	2004-09-30	Completed
Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms[NCT00405457]	Phase 4	50 participants (Anticipated)	Interventional	2006-11-30	Completed
The Pharmacokinetics and Dosage Regimen of Sirolimus in a Cyclosporine or Tacrolimus-Based Immunosuppression in Renal Transplant Patients[NCT00166816]	Phase 4	40 participants	Interventional	2002-03-31	Active, not recruiting
A Randomized, Open Label Study to Evaluate the Effects of a Regimen With Sirolimus,Low Doses Cyclosporine and Steroids vs a Regimen With Sirolimus and Steroids, After an Induction Period With Basiliximab, Sirolimus,Cyclosporine and Steroids in de Novo Ren[NCT00167947]	Phase 3	150 participants (Anticipated)	Interventional	2005-01-31	Completed
A Six-month Open Label, Multicenter, Randomized Study to Evaluate the Incidence of New Onset Diabetes Mellitus and Glucose Metabolism in Patients Receiving Cyclosporine Microemulsion With C-2 Monitoring Versus Tacrolimus After de Novo Kidney Transplantati[NCT00171496]	Phase 4	693 participants (Actual)	Interventional	2003-10-31	Completed
A Phase III, Randomized, Multicentre, Double-Blind, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis Patients[NCT00408187]	Phase 3	642 participants (Actual)	Interventional	2006-12-31	Completed
Pilot Trial for Implementation of a MPA PK Monitoring Strategy[NCT00187915]		24 participants (Actual)	Interventional	2003-07-31	Completed
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults With Hematologic Malignancies[NCT00003661]	Phase 2	3 participants (Actual)	Interventional	1998-06-30	Completed
Polymorphism of the Cytochrome P450-system and the MDR-system in Renal Transplants Receiving the Immunosuppressive Drugs Tacrolimus, Sirolimus, Everolimus or Cyclosporine A[NCT00223054]		200 participants (Actual)	Observational	2005-03-31	Completed
A Trial of Reduced Intensity Conditioning and Transplantation of Haplotype Mismatched and KIR Class I Epitope-Mismatched Highly Purified CD34 Cells[NCT00085449]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2006-05-31	Withdrawn(stopped due to Funding cut, no patients enrolled)
A Controlled Randomized Open-label Multicenter Study Evaluating if Early Conversion to Everolimus (Certican) From Cyclosporine (Neoral) in de Novo Renal Transplant Recipients Can Improve Long-term Renal Function and Slow Down the Progression of Chronic Al[NCT00634920]	Phase 4	204 participants (Actual)	Interventional	2008-03-31	Completed
Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia[NCT00363779]	Phase 2	5 participants (Actual)	Interventional	2006-06-30	Terminated(stopped due to Study terminated due to low accrual and the investigator left the NIH.)
A PHASE I STUDY OF IRINOTECAN (CPT-11) WITH PHARMACOKINETIC MODULATION BY CYCLOSPORINE A AND PHENOBARBITAL[NCT00002759]	Phase 1	3 participants (Actual)	Interventional	1996-06-30	Completed
A Non-Myeloablative Conditioning Regimen With Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With B Cell Lymphoid Malignancies[NCT00387959]	Phase 2	17 participants (Actual)	Interventional	2006-07-31	Completed
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With High Risk Hemoglobinopathy Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism[NCT00427661]		8 participants (Actual)	Interventional	2002-06-30	Completed
The Prophylactic Use of Topical Cyclosporine A 0.05% (Restasis) to Prevent Onset and Progression of Graft-versus-host Disease-related Dry Eye[NCT00553735]	Phase 4	8 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to High number of withdrawals, appt. no-shows, or those lost to follow-up.)
Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms[NCT00565669]		20 participants (Actual)	Interventional	2007-10-31	Completed
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AM[NCT00568633]	Phase 3	58 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Poor accrual)
An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects[NCT03095547]	Phase 1	0 participants (Actual)	Interventional	2017-05-31	Withdrawn(stopped due to study no longer required in current format)
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation[NCT00609739]	Phase 1/Phase 2	1 participants (Actual)	Interventional	1999-06-30	Terminated(stopped due to Low accrual)
A Study of Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed by Matched Sibling Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia[NCT00630253]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2000-02-17	Completed
A Study to Investigate the Effect of Ciclosporin on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects[NCT01968057]	Phase 1	18 participants (Actual)	Interventional	2013-10-31	Completed
Non-Myeloablative Chemotherapy Followed by HLA-Matched Related Allogeneic Stem Cell Transplantation for Hematologic Malignancies[NCT00741455]		18 participants (Actual)	Interventional	2004-06-30	Completed
An 18 Month Extension to the Multicenter, Randomized, Open-label Trial (NCT00170885) to Evaluate the Safety, Tolerability, and Efficacy of Two Regimens of Everolimus Plus Cyclosporine Microemulsion, Given According to Different Blood Target Levels, in de [NCT01276457]	Phase 3	223 participants (Actual)	Interventional	2006-05-31	Completed
[NCT00827255]		35 participants (Actual)	Observational	2009-01-31	Completed
[NCT00884585]	Phase 3	176 participants (Actual)	Interventional	2009-05-31	Completed
"A Feasibility Study of Early Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms"[NCT02756572]	Phase 2	30 participants (Actual)	Interventional	2016-09-22	Completed
Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study[NCT04470804]	Phase 4	56 participants (Actual)	Interventional	2020-07-01	Completed
Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans[NCT01273207]	Phase 2	7 participants (Actual)	Interventional	2012-03-02	Completed
A Randomized, Placebo-controlled, Double-blind, Multicenter Study Investigating Basiliximab in Combination With MMF, Cyclosporine Microemulsion and Prednisone in the Prevention of Acute Rejection in Pediatric Renal Allograft Recipients[NCT00228020]	Phase 3	212 participants (Actual)	Interventional	2001-05-31	Completed
Verification Study of Ciclosporin for Atopic Dermatitis[NCT00232076]	Phase 3	0 participants	Interventional	2004-05-31	Completed
[NCT00268515]	Phase 2	0 participants	Interventional	1998-04-30	Completed
Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study[NCT00453388]	Phase 2	6 participants (Actual)	Interventional	2007-02-28	Completed
A Nonrandomized, Open-label, Multicenter, Sequential Phase Study to Evaluate the Safety and Efficacy of Cyclosporine Dose Reduction and Cyclosporine Elimination in Chinese De Novo Renal Allograft Recipients Receiving Rapamune[NCT00257387]	Phase 1/Phase 2	120 participants	Interventional	2004-06-30	Completed
Transplantation of Umbilical Cord Blood From Related and Unrelated Donors[NCT00290628]		43 participants (Actual)	Interventional	1999-10-31	Terminated(stopped due to Replaced with another study)
Open, Multicenter, Randomized Clinical Trial in Patients With Moderate-Severe Psoriasis (PASI > 10) to Compare the Efficacy of Mycophenolate Mofetil Versus Cyclosporine A.[NCT00295425]	Phase 2	50 participants	Interventional	2000-05-31	Active, not recruiting
Feasibility of Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Followed by Donor Lymphocyte Infusions for Children at High Risk for Complications With Conventional Transplantation[NCT00301860]		8 participants (Actual)	Interventional	2003-01-31	Terminated(stopped due to lack of efficacy)
A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia[NCT00319878]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2006-05-31	Recruiting
Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection[NCT04392531]	Phase 4	111 participants (Actual)	Interventional	2020-04-16	Completed
Safety and Efficacy of Low-dose Cyclosporine in Association With Everolimus to Minimize Renal Dysfunction in Heart Transplant Recipients[NCT00420537]	Phase 4	34 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to A cluster of adverse events in everolimus arm was noted.)
Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients[NCT05696977]	Phase 4	74 participants (Anticipated)	Interventional	2022-04-17	Recruiting
A Single-center, Single-arm, Prospective Clinical Study on the Efficacy and Safety of Cyclosporine Combined With Avatrombopag in the Treatment of Non-severe Aplastic Anemia in the Elderly[NCT06004752]	Phase 2	30 participants (Anticipated)	Interventional	2023-08-17	Recruiting
Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients[NCT01502774]	Phase 3	970 participants (Actual)	Interventional	2011-04-30	Completed
A Phase I Study of 90Y-BC8-DOTA Monoclonal Antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma[NCT01503242]	Phase 1	15 participants (Actual)	Interventional	2012-01-09	Completed
Evaluate Reversal of Pathological Epidermal Phenotype in Severe Atopic Dermatitis With Suppression of Immune Activation During Cyclosporine Therapy[NCT01149759]		9 participants (Actual)	Interventional	2010-06-30	Completed
Cyclosporine In Takotsubo Syndrome (CIT) Trial[NCT05946772]	Phase 2	204 participants (Anticipated)	Interventional	2024-02-29	Not yet recruiting
CYCLosporinE A in Reperfused Acute Myocardial Infarction Prospective, Controlled, Randomized, Multicentre Trial to Examine Whether a Single i.v. Bolus of Cyclosporine A Before PCI Can Reduce Myocardial Reperfusion Injury in Patients With STEMI.[NCT01650662]	Phase 3	410 participants (Actual)	Interventional	2012-01-31	Completed
[NCT00383396]	Phase 4	0 participants	Interventional		Completed
A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteer[NCT01692834]	Phase 1	65 participants (Actual)	Interventional	2009-06-30	Completed
A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome[NCT01693393]	Phase 2	30 participants (Actual)	Interventional	2010-03-31	Completed
Phase I/II Trial of Thymus Transplantation With Immunosuppression, #950[NCT00579527]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2005-12-19	Completed
The Biomarker for CYP3A-mediated Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients[NCT01699360]	Phase 4	600 participants (Anticipated)	Interventional	2012-09-30	Recruiting
An Open-Label, Single Sequence Study to Assess the Effect of a Single Dose of Cyclosporine on the Steady-State Pharmacokinetics of JNJ-28431754 (Canagliflozin) in Healthy Adult Subjects[NCT01718652]	Phase 1	18 participants (Actual)	Interventional	2011-02-28	Completed
Identification of Disease Progression Specific Biomarkers and Their Pharmacologic Modulation for Keratoconus.[NCT01746823]		200 participants (Anticipated)	Observational [Patient Registry]	2013-04-30	Recruiting
Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients[NCT01758107]	Phase 4	30 participants (Anticipated)	Interventional	2010-08-31	Recruiting
Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)[NCT01760096]	Phase 2	50 participants (Anticipated)	Interventional	2013-01-31	Active, not recruiting
A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.[NCT01762644]	Phase 3	0 participants (Actual)	Interventional	2015-08-31	Withdrawn(stopped due to This study was withdrawn prior to enrollment.)
A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate the Safety and Efficacy in Diminishing Insulin Requirements Utilizing Oral Cyclosporine With Oral Lansoprazole in Children and Adults With Existing Type 1 Diabetes Me[NCT01762657]	Phase 3	0 participants (Actual)	Interventional	2014-09-30	Withdrawn(stopped due to Study stopped prior to Patient Enrollment)
A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient[NCT01766375]	Phase 3	200 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease[NCT01768312]	Phase 3	84 participants (Actual)	Interventional	2012-08-23	Completed
Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial[NCT01786018]	Phase 2	42 participants (Anticipated)	Interventional	2013-02-28	Recruiting
Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients[NCT01788501]	Phase 2/Phase 3	50 participants (Actual)	Interventional	2011-11-30	Completed
Efficacy and Safety Study of Haporine-S in Subjects With Moderate to Severe Dry Eye, A Multicenter, Investigator(Assessor)Blind, Parallel Design, Non-inferiority Phase III Trial[NCT01804361]	Phase 3	90 participants (Actual)	Interventional	2013-03-31	Completed
A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies[NCT01810926]	Phase 2	130 participants (Anticipated)	Interventional	2011-09-30	Recruiting
An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT® (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)[NCT01825044]	Phase 2	16 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancie[NCT01231412]	Phase 3	174 participants (Actual)	Interventional	2010-11-30	Completed
A Phase 4 Study to Assess the Clinical Efficacy of Nanomicellular Cyclosporine 0.09% Versus Lifitegrast 5.0% for Central Corneal Stain Clearing Over 90 Days[NCT04172961]	Phase 4	100 participants (Anticipated)	Interventional	2020-02-01	Recruiting
Cord Blood Transplantation for Hematologic Malignancies and Bone Marrow Failure Syndromes[NCT00003270]	Phase 2	20 participants (Actual)	Interventional	1997-09-04	Completed
A Single-arm, Single-center Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.[NCT04688021]	Phase 2	46 participants (Anticipated)	Interventional	2020-12-03	Recruiting
Treatment of High Risk, Inherited Lysosomal and Peroxisomal Disorders by Reduced-Intensity Hematopoietic Cell Transplantation and Low-Dose Total Body Irradiation With Marrow Boosting by Volumetric-Modulated Arc Therapy (VMAT)[NCT01626092]		3 participants (Actual)	Interventional	2012-07-11	Completed
Cyclosporine in the Pharmacotherapy of Psoriasis[NCT00377325]	Phase 2	0 participants (Actual)	Interventional	2007-06-30	Withdrawn(stopped due to Study terminated by the DSMB due to low recruitment)
Killer Immunoglobulin-like Receptor (KIR) Incompatible Unrelated Donor Hematopoietic Cell Transplantation (SCT) for AML With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory and Relapsed Acute Myelogenous Leukemia (AML) in Children: A Children's Oncolo[NCT00553202]	Phase 2	158 participants (Actual)	Interventional	2008-01-31	Completed
Tear Film Markers in Dry Eye Syndrome: Impact of Immunomodulatory Therapy[NCT04515329]	Phase 4	0 participants (Actual)	Interventional	2023-12-08	Withdrawn(stopped due to No participants were enrolled. Study never started.)
A Pilot Study of a Sustained-Release Cyclosporine A Implant for Uveitis[NCT00001737]	Phase 1	10 participants	Interventional	1998-05-31	Completed
A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome[NCT00001839]	Phase 2	182 participants	Interventional	1998-12-31	Completed
Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene Mutations[NCT00001965]	Phase 2	32 participants	Interventional	1999-12-31	Completed
ALLOGENEIC AND SYNGENEIC MARROW TRANSPLANTATION IN PATIENTS WITH ACUTE NON-LYMPHOCYTIC LEUKEMIA[NCT00002547]	Phase 2	280 participants (Actual)	Interventional	1987-08-31	Completed
Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients With BCR-ABL Tyrosine Kinase Inhibitor Responsive Ph+ Acute Leukemia ? A Multi-center Trial[NCT00036738]	Phase 2	28 participants (Actual)	Interventional	2001-07-13	Completed
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance[NCT01445236]		25 participants (Anticipated)	Interventional	2011-09-30	Terminated(stopped due to Insufficient recruitment)
Phase 1 Pilot Study Using Autologous CD4+CD25+FoxP3+ T Regulatory Cells and Campath-1H to Induce Renal Transplant Tolerance[NCT01446484]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2011-10-31	Recruiting
Safety and Therapeutic Efficacy of Cyclosporine Plus Standard of Care Treatment on ARDS in COVID -19 Patients at Alexandria University Hospitals in 2021: a Comparative Study[NCT04979884]	Phase 3	102 participants (Actual)	Interventional	2022-01-03	Completed
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders[NCT00544115]	Phase 2	260 participants (Actual)	Interventional	2001-10-16	Active, not recruiting
Prospective, Multicenter, Randomized Open Study to Evaluate the Progression of Renal Graft Fibrosis According to the Epithelial-mesenchymal Transition (EMT) in de Novo Renal Transplant Recipients Treated Either by a CNI Free Immunosuppressive Regimen With[NCT01079143]	Phase 3	194 participants (Actual)	Interventional	2009-09-30	Completed
Phase II Study of Cyclosporin (Neoral) in Immune Activation and HIV Expression in Early HIV Disease[NCT00000880]	Phase 2	30 participants	Interventional		Completed
A Single-Center, Single-Arm, Open-Label, Self-Controlled, Drug-Drug Interaction Study of Hetrombopag Olamine and Ciclosporin in Healthy Subjects[NCT05088174]	Phase 1	26 participants (Actual)	Interventional	2020-09-03	Completed
Induction of Mixed Hematopoietic Chimerism in Older Patients With B-Cell Malignancies and in Selected Other Diseases, Using Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Do[NCT00003196]		63 participants (Actual)	Interventional	1997-09-30	Completed
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to[NCT04877288]	Phase 3	102 participants (Anticipated)	Interventional	2021-07-21	Recruiting
Cyclophosphamide and Antithymocyte Globulin Conditioning Regimen for Marrow Transplantation From HLA-Matched Family Members for Severe Aplastic Anemia: Effect of Marrow Cell Dose on Chronic Graft-vs.-Host Disease: A Multi-Center Trial[NCT00343785]	Phase 2	21 participants (Actual)	Interventional	2006-02-28	Completed
Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial[NCT00104858]	Phase 2	66 participants (Actual)	Interventional	2004-12-31	Completed
Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial[NCT00118352]	Phase 2	12 participants (Actual)	Interventional	2005-03-31	Completed
A Randomized, Open-label Study of the Effect of a Long-term Calcineurin Inhibitor-free Maintenance Regimen With CellCept and Sirolimus on Preservation of Renal Function and Prevention of Acute Rejection in Recipients of an Orthotropic Liver Transplant[NCT00118742]	Phase 4	293 participants (Actual)	Interventional	2005-08-31	Completed
[NCT01319773]	Phase 1	44 participants (Actual)	Interventional	2010-11-30	Completed
A Three-Part Phase 1 Study to Evaluate the Potential Drug Interaction Between ACH-0144471 and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adult Subjects[NCT05109390]	Phase 1	72 participants (Actual)	Interventional	2018-07-27	Completed
Multicenter Phase II Study for International Intraocular Retinoblastoma Classification Groups B, C & D Tumors Treated With Carboplatin-Etoposide-Vincristine-Cyclosporine-Focal Therapy Multimodality Protocol (OCRN Multicenter RB 2003)[NCT00110110]	Phase 2	71 participants (Anticipated)	Interventional	2004-06-30	Active, not recruiting
A Phase IV, Multicenter, Randomized, Single-blinded(Evaluator), Active-controlled, Parallel Study for Evaluating HA 0.15% Compared With Cyclosporine 0.05%, and Efficacy of Combination Therapy in Moderate to Severe Dry Eye Disease Patients[NCT04127851]	Phase 4	438 participants (Actual)	Interventional	2019-11-12	Completed
A Prospective, Open-label, Controlled, Randomized Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After 90 to 150 Days After Kidney Transplantation in Adults, Maintaining Corticosteroid and Mycophenolate Sodium C[NCT01455649]	Phase 4	30 participants (Anticipated)	Interventional	2011-11-30	Not yet recruiting
Prospective Randomized Trial Comparing CsA Versus Tacro After Campath Induction In Kidney Transplant Recipients[NCT01346397]		170 participants (Actual)	Observational [Patient Registry]	2009-04-30	Completed
Long-term Results of Topical Cyclosporine 0.05% in the Treatment of Atopic Keratoconjunctivitis[NCT00987467]		12 participants (Actual)	Interventional	2007-08-31	Completed
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome in Outpatient Haploidentical Hematopoietic Stem Cell Transplantation[NCT04781803]	Phase 2	32 participants (Anticipated)	Interventional	2021-03-25	Recruiting
An Investigator Initiated Multi-center Phase 4 Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients With Inadequate Effects From Previous Treatment (IKE-03, Switching Study)[NCT04775303]	Phase 4	90 participants (Anticipated)	Interventional	2020-09-25	Recruiting
Donor Statin Treatment for Prevention of Severe Acute GVHD After Nonmyeloablative Hematopoietic Cell Transplantation[NCT01527045]	Phase 2	47 participants (Actual)	Interventional	2012-09-25	Completed
Reduced-Intensity Allogeneic HSC Transplantation From HLA-Matched Related and Unrelated Donors for Patients With Multiple Myeloma - A Multi-Center Trial[NCT00054353]	Phase 1/Phase 2	16 participants (Actual)	Interventional	2002-10-31	Completed
Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation From HLA Matched Related Donors for Treatment of Older Patients With De Novo or Secondary Acute Myeloid Leukemia in First Complete Remission[NCT00045435]	Phase 2	17 participants (Actual)	Interventional	2002-04-30	Completed
Pentostatin and Donor Lymphocyte Infusion for Low Donor T-cell Chimerism After Hematopoietic Cell Transplantation - A Multi-center Trial[NCT00096161]	Phase 2	36 participants (Actual)	Interventional	2003-05-31	Completed
A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab[NCT00260689]	Phase 2	136 participants (Actual)	Interventional	2005-11-28	Completed
Evaluation of Maintaining Visual Performance Of Subjects Who Engage in Electronic Visual Tasking While Using Restasis (EMPOWER)[NCT02554981]	Phase 4	51 participants (Actual)	Interventional	2015-07-21	Completed
A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride[NCT03218657]		248 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action[NCT01990898]	Phase 2	26 participants (Actual)	Interventional	2013-11-30	Completed
A Randomized Trial of Early Conversion From Calcineurin Inhibitors (CNI) to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function[NCT01837043]	Phase 2	90 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment[NCT00944749]	Phase 2	23 participants (Actual)	Interventional	2009-08-31	Completed
A Multi-Center, Randomized Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in the Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP)[NCT00713193]	Phase 3	26 participants (Actual)	Interventional	2007-11-30	Completed
A Phase III, Randomized, Multicentre, Open-Label, Concentration-Controlled, Safety and Efficacy Study of Voclosporin and Tacrolimus in Renal Transplantation[NCT01586845]	Phase 3	0 participants (Actual)	Interventional	2013-03-31	Withdrawn
"A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN)"[NCT01180036]	Phase 2/Phase 3	130 participants (Actual)	Interventional	2011-11-30	Completed
CYclosporine A in Non-shockable Out-of-hospital Cardiac Arrest ResUScitation[NCT01595958]	Phase 3	796 participants (Actual)	Interventional	2010-06-30	Completed
Randomized, Multicenter, Open-label, Comparative Study of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI), Associating Myfortic ® and Neoral ® Compared to a CNI-free Treatment, Combining Myfortic ® and Certican ® , in Adult Patients Wi[NCT01595984]	Phase 3	90 participants (Actual)	Interventional	2012-05-03	Active, not recruiting
Observational Study of Visual Outcomes in Retinal Disease[NCT01613963]		2,000 participants (Anticipated)	Observational	2012-05-31	Enrolling by invitation
Belatacept Therapy for the Failing Renal Allograft[NCT01921218]	Phase 3	13 participants (Actual)	Interventional	2013-08-31	Completed
A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis[NCT03237936]	Phase 4	33 participants (Anticipated)	Interventional	2017-03-28	Recruiting
Non-Myeloablative Conditioning and Unrelated Umbilical Cord Blood Transplantation for Children and Adults With Serious Oncohematologic Diseases[NCT00255684]		16 participants (Actual)	Interventional	2003-12-31	Terminated(stopped due to low accrual)
A Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic Anemia[NCT00195624]	Phase 2	47 participants (Actual)	Interventional	2005-09-15	Completed
A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Double Lung Transplant[NCT03656926]	Phase 3	220 participants (Actual)	Interventional	2019-03-29	Active, not recruiting
A Comparative, Open-label Study to Evaluate Graft Function in de Novo Renal Allograft Recipients Treated With Either a 'Reduced Dose' or a 'Standard Dose' of Cyclosporine in Combination With Sirolimus and Corticosteroids[NCT00518375]	Phase 4	250 participants	Interventional	2000-04-30	Completed
Efficacy of Topical Cyclosporine Ophthalmic Emulsion for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy[NCT00349440]	Phase 4	93 participants (Actual)	Interventional	2006-09-30	Completed
Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence[NCT00317408]		96 participants (Anticipated)	Interventional	2004-04-30	Active, not recruiting
Dose-Finding Study for Cyclophosphamide as Conditioning Regimens for Bone Marrow Transplantation From Related Donors in Patients With Fanconi Anemia[NCT00317876]	Phase 1	25 participants (Actual)	Interventional	1998-06-30	Completed
[NCT00425724]	Phase 4	20 participants (Anticipated)	Interventional	2000-01-31	Completed
A Randomized, Open-Label Study of Continuous Therapy With Cyclosporine and Sirolimus Versus Induction With Cyclosporine and Sirolimus Followed by Continuous Therapy With Sirolimus in Renal Allograft Recipients[NCT00428064]	Phase 3	408 participants	Interventional	1998-05-31	Completed
Restasis® Ophthalmic Emulsion for the Treatment of Brittle Nails[NCT00986427]	Phase 2	24 participants (Actual)	Interventional	2009-07-31	Completed
A One-Directional, Open-label Drug Interaction Study to Investigate the Effects of Single-Dose Cyclosporine on Single-Dose Pharmacokinetics of Colchicine in Healthy Volunteers[NCT00983931]	Phase 1	24 participants (Actual)	Interventional	2008-08-31	Completed
The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye[NCT02199964]		4 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to Funding was terminated)
An Open-Label, Single-Sequence Study to Investigate the Effects of Cyclosporine on the Pharmacokinetics of BMS-986165 at Steady State in Healthy Male Participants[NCT03419910]	Phase 1	54 participants (Actual)	Interventional	2018-03-05	Completed
A Phase II Trial of High-Dose 90Y-Ibritumomab Tiuxetan (Anti-CD20) Followed by Fludarabine and Low-Dose Total Body Irradiation and HLA-Matched Allogeneic Hematopoietic Transplantation for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma[NCT01434472]	Phase 2	20 participants (Actual)	Interventional	2011-11-16	Terminated(stopped due to Terminated due to insufficient funding)
Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab-therapy[NCT00521924]	Phase 3	8 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Slow Enrollment)
ALLOGENEIC MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FOR AGNOGENIC MYELOID METAPLASIA WITH MYELOFIBROSIS[NCT00002792]	Phase 2	20 participants (Anticipated)	Interventional	1996-06-30	Completed
A Phase II Trial of Irinotecan (CPT-11) and Cyclosporine in Patients With 5-FU Refractory Advanced Colorectal Cancer[NCT00003950]	Phase 2	16 participants (Actual)	Interventional	2000-01-31	Completed
CAMP-010: PHASE I/II STUDY OF IN VIVO PURGING FOLLOWED BY HIGH DOSE CHEMOTHERAPY, AUTOLOGOUS HEMATOPOIETIC STEM CELL INFUSION AND IMMUNOTHERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA[NCT00002761]	Phase 1/Phase 2	0 participants (Actual)	Interventional	1996-02-29	Withdrawn(stopped due to PI left institution)
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age.[NCT00002785]	Phase 2	0 participants	Interventional	1996-07-31	Completed
Augmenting Bone Marrow With CD34 Enriched Peripheral Blood Hematopoietic Stem Cells for Allogeneic Transplantation of Hematologic Malignancies[NCT00004232]	Phase 1	0 participants	Interventional	1999-10-31	Completed
Pharmacokinetic/Dosimetry/MTNTD Study of 111In/90Y-2IT-BAD-m170 for Therapy in Metastatic Breast Cancer Patients With Post Therapy Support of Autologous Pretherapy Apheresed Peripheral Blood Stem Cells and Cyclosporin A Given for Suppression of HAMA Respo[NCT00003920]	Phase 1	18 participants (Anticipated)	Interventional	1996-04-30	Active, not recruiting
Use of G-CSF Stimulated HLA-Identical Allogeneic Peripheral Blood Stem Cells for Patients With High Risk Acute Myelogenous Leukemia or CML in Blast Crisis[NCT00002833]	Phase 2	53 participants (Actual)	Interventional	1994-10-31	Completed
Vincristine, Etoposide and Cyclosporine A in Concert With Standard Dose Radiation Therapy in Diffuse Intrinsic Brain Stem Glioma - A Phase I Study of Dose Escalation of Vincristine[NCT00003625]	Phase 1	7 participants (Actual)	Interventional	1998-12-31	Completed
The Unrelated Donor Marrow Transplantation Trial[NCT00003187]	Phase 2/Phase 3	19 participants (Actual)	Interventional	1995-05-31	Completed
An Open-Label, Comparative Study of the Effect of Sirolimus Versus Standard Treatment on Clinical Outcomes and Histologic Progression of Allograft Nephropathy in High Risk Pediatric Renal Transplant Patients[NCT00005113]	Phase 3	102 participants (Actual)	Interventional	1999-07-31	Terminated(stopped due to Inability to meet the accrual target of 213.)
T-Cell Depletion for Graft-Versus-Host Disease (GVHD) Prevention in High Risk Matched and Mismatched Allogeneic Bone Marrow Transplantation[NCT00005641]	Phase 2	0 participants	Interventional	1997-09-30	Terminated(stopped due to low study accrual)
A Single-centre, Open-label, Randomised, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Repeated Oral Doses of Ciclosporin on the Single-dose Pharmacokinetics of nASP2151 in Healthy Mean[NCT02280421]	Phase 1	26 participants (Actual)	Interventional	2014-10-31	Completed
A Prospective, Open-label, Randomized Trial Comparing Prograf and Neoral Use in Kidney Transplant Recipients of Hispanic Ethnicity[NCT00983645]	Phase 4	15 participants (Actual)	Interventional	2004-10-31	Terminated(stopped due to Insufficient funding)
Pilot Study of Cyclosporine A Dry Powder Inhalation in Lung Transplant Patients With Bronchiolitis Obliterans Syndrome[NCT00378677]	Early Phase 1	7 participants	Interventional	2007-02-28	Recruiting
A PHASE III RANDOMIZED STUDY COMPARING G-CSF MOBILIZED PERIPHERAL BLOOD STEM CELLS WITH MARROW AS THE SOURCE OF STEM CELLS FOR ALLOGENEIC TRANSPLANTS FROM HLA IDENTICAL, RELATED DONORS FOR THE TREATMENT OF CHRONIC MYELOID LEUKEMIA[NCT00002789]	Phase 3	100 participants (Anticipated)	Interventional	1996-05-31	Completed
Randomized Trial of Busulfan or Total Body Irradiation Conditioning Regimens for Children With Acute Lymphoblastic Leukemia[NCT00002961]	Phase 3	43 participants (Actual)	Interventional	1995-10-31	Terminated(stopped due to poor accrual)
A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation[NCT01789255]	Phase 2	12 participants (Actual)	Interventional	2013-06-30	Completed
A Phase 2, Multi-center, Randomized, Double-masked, Placebo (Vehicle)-Controlled Clinical Study With an Open Label Comparator Arm to Assess the Efficacy, Safety and Tolerability of Topical CyclASol® for Treatment of Dry Eye Disease[NCT02617667]	Phase 2	207 participants (Actual)	Interventional	2016-01-31	Completed
A Multicenter, Randomized, Double-Masked Study To Evaluate The Safety, Tolerability, And Efficacy Of SURF-100 Ophthalmic Solution (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination) In Subjects With Dry Eye Disease[NCT04734197]	Phase 2	351 participants (Actual)	Interventional	2021-01-11	Completed
A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.[NCT01936519]		24 participants (Actual)	Interventional	2013-12-16	Completed
A Prospective Randomised, Open-labeled, Trial Comparing Sirolimus-Containing Versus mTOR-Inhibitor-Free Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma[NCT00355862]	Phase 3	525 participants (Actual)	Interventional	2006-01-31	Completed
A Phase Ⅲ Clinical Study to Evaluate the Safety and Efficacy of MIL62 Injection in Participants With Primary Membranous Nephropathy[NCT05862233]	Phase 3	150 participants (Anticipated)	Interventional	2023-06-02	Recruiting
A Multicenter, Randomized, Controlled, Open Phase Ib/ Ⅱ Study Evaluating the Efficacy and Safety of Recombinant Humanized Monoclonal Antibody MIL62 Injection in the Treatment of Primary Membranous Nephropathy.[NCT05398653]	Phase 1/Phase 2	120 participants (Anticipated)	Interventional	2022-02-24	Recruiting
A Phase II Study of Cyclosporine in the Treatment of Angioimmunoblastic T-Cell Lymphoma[NCT00070291]	Phase 2	4 participants (Actual)	Interventional	2006-01-24	Terminated(stopped due to Slow accrual.)
A Phase II Study of Reduced Intensity Allogeneic Bone Marrow Transplant for the Treatment of Myelodysplastic Syndromes[NCT00045305]	Phase 2	17 participants (Actual)	Interventional	2006-10-24	Completed
Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)[NCT04795752]		350 participants (Anticipated)	Interventional	2021-04-23	Active, not recruiting
Effects of CEQUA™ on Objective and Subjective Dry Eye Findings Associated With Sjogren's Syndrome[NCT04835623]	Phase 4	50 participants (Anticipated)	Interventional	2021-06-21	Recruiting
[NCT00004323]	Phase 2	10 participants	Interventional	1995-02-28	Completed
Low-Dose TBI and Fludarabine Followed by Unrelated Donor Stem Cell Transplantation for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial[NCT00005799]		55 participants (Actual)	Interventional	1999-11-30	Completed
Post Transplant Infusion of Allogeneic CD8 Memory T-Cells as Consolidative Therapy After Non-myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Leukemia and Lymphoma[NCT02424968]	Phase 2	18 participants (Actual)	Interventional	2015-06-30	Completed
Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen[NCT00365287]	Phase 1/Phase 2	148 participants (Actual)	Interventional	2000-06-30	Completed
Cyclosporine Adverse Outcomes in Steroid Dependent and Frequent Relapsing Nephrotic Syndrome in Children;Single Center Study[NCT05588869]		30 participants (Anticipated)	Observational	2022-10-20	Not yet recruiting
A Single Center, Investigator-blinded Study of the Efficacy of Topical Cyclosporine 0.05% Ophthalmic Suspension (RESTASIS®) Under Occlusion Versus Vehicle in the Treatment of Brittle Nail Syndrome[NCT01064830]	Phase 2	21 participants (Actual)	Interventional	2010-02-28	Completed
A Study of the Safety, Tolerability and Pharmacokinetics of Oral CellCept® (Mycophenolate Mofetil, MMF) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids[NCT02630563]	Phase 2	9 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Due to extremely slow recruitment, infrequent use of combination triple therapy (MMF, cyclosporine, steroids), study was discontinued; Part 2 was not conducted.)
Umbilical Cord Blood Transplant With Co-Infusion of T Regulatory Cells[NCT00376519]	Phase 1	3 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Slow accrual)
Pilot Study of a Homeopathic Therapy in Combination With Cyclosporin (Restasis) in the Treatment of Dry Eye Disease[NCT01072526]	Phase 2	7 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Study personnel left institution before study completion)
A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia[NCT00322101]	Phase 3	25 participants (Actual)	Interventional	2006-01-31	Completed
Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia[NCT02845596]		40 participants (Anticipated)	Interventional	2016-08-31	Active, not recruiting
Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies[NCT01690520]	Phase 2	163 participants (Actual)	Interventional	2012-12-11	Completed
Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders[NCT04644016]	Phase 2	31 participants (Anticipated)	Interventional	2020-11-20	Recruiting
Compare the Safety and Effective of HLA-mismatched Microtransplantation With HLA-matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-risk[NCT02461121]	Phase 3	156 participants (Actual)	Interventional	2004-05-31	Completed
Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet's Disease Uveitis[NCT03209219]	Phase 3	28 participants (Actual)	Interventional	2017-06-30	Completed
A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Cyclosporine on the Plasma Pharmacokinetics of AT-527 in Healthy Adult Male Subjects[NCT04849299]	Phase 1	24 participants (Actual)	Interventional	2021-04-18	Completed
Peripheral Blood Stem Cell Transplantation in Patients With Advanced Malignancies Eligible for Allogeneic Transplantation From Matched Related Donors: A Randomized Study of Cyclosporine/Methotrexate or Cyclosporine/T-Cell Depletion (CD34 Cell Selection) f[NCT00003056]	Phase 3	105 participants (Actual)	Interventional	1997-04-01	Terminated(stopped due to Interim analysis indicated study should be terminated)
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases[NCT00003662]	Phase 2	90 participants (Anticipated)	Interventional	1998-08-31	Completed
The Effect of Locally Delivered Ciclosporin as an Adjunct to Healing After Treatment of Periodontal Pockets[NCT02366585]	Phase 2	23 participants (Actual)	Interventional	2015-03-31	Completed
Induction of Mixed Hematopoietic Chimerism Using Fludarabine, Low Dose TBI , PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil to be Followed by Donor Lymphocyte Infusion In Patients With Chronic Myeloid Leuke[NCT00003145]	Phase 2	18 participants (Actual)	Interventional	1997-08-31	Completed
A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy[NCT03170323]	Phase 4	128 participants (Anticipated)	Interventional	2018-07-01	Recruiting
The Efficacy and Safety of Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH[NCT05120687]		200 participants (Anticipated)	Observational	2021-10-15	Recruiting
A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With High Risk Hematologic Malignancies[NCT00003335]	Phase 2	44 participants (Actual)	Interventional	1998-01-31	Completed
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy[NCT00977977]	Phase 2	30 participants (Anticipated)	Interventional	2010-12-22	Recruiting
A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndr[NCT03128034]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2017-10-24	Suspended(stopped due to Administrative - FDA Comments)
A Phase 1, Open-label Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on the Single-dose Pharmacokinetics of Rilematovir[NCT05155007]	Phase 1	18 participants (Actual)	Interventional	2021-12-10	Completed
Clinical and Biological Responses to Repeated Administration of Low-dose Interleukin-2 in Patients With Type 1 Diabetes and a Residual Insulin Secretion[NCT05153070]	Phase 2	24 participants (Anticipated)	Interventional	2022-09-21	Recruiting
T Cell-Reduced Unrelated Donor Allogeneic Peripheral Blood Stem Cell Transplantation With Pentostatin and Low-Dose Total Body Irradiation[NCT00816413]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2008-09-30	Withdrawn(stopped due to Screenings yielded inadequate eligible subjects to enroll.)
Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Adult Severe Aplastic Anemia Participants Who Are Either Previously Untreated With IST or Refractory to IST[NCT05323617]	Phase 2	0 participants (Actual)	Interventional	2023-08-31	Withdrawn(stopped due to Operational)
A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine A (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Ane[NCT04328727]	Phase 2	36 participants (Actual)	Interventional	2020-11-04	Active, not recruiting
Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)[NCT01231841]	Phase 2	20 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Trial Of Autologous Stem Cell Transplant Followed By Mini-Allogeneic Stem Cell Transplant In Lieu Of Standard Allogeneic Bone Marrow Transplantation For Treatment Of Multiple Myeloma[NCT00014508]	Phase 2	0 participants	Interventional	2001-11-19	Completed
A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma[NCT03013933]	Phase 1	29 participants (Actual)	Interventional	2017-05-03	Active, not recruiting
A Phase 1 Study to Evaluate the Effect of BCX7353 on the Single Dose Pharmacokinetics of the P-gp Substrate Digoxin and the BCRP Substrate Rosuvastatin and the Effect of the P-gp Inhibitor Cyclosporine on the Single Dose Pharmacokinetics of BCX7353[NCT03136237]	Phase 1	54 participants (Actual)	Interventional	2017-02-17	Completed
Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients[NCT00611403]	Phase 2	137 participants (Actual)	Interventional	2007-12-31	Completed
Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy[NCT04376528]	Phase 4	89 participants (Anticipated)	Interventional	2021-06-16	Recruiting
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN[NCT02435901]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax® Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)[NCT01817582]	Phase 2	102 participants (Actual)	Interventional	2013-05-17	Completed
A Phase I, Open-Label, Crossover, Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus in Healthy Volunteers[NCT03083782]	Phase 1	12 participants (Actual)	Interventional	2017-04-18	Completed
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca[NCT02688556]	Phase 3	745 participants (Actual)	Interventional	2016-02-29	Completed
Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital[NCT04756492]		100 participants (Anticipated)	Observational	2021-02-15	Active, not recruiting
Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial[NCT00060424]	Phase 2	21 participants (Actual)	Interventional	2003-03-31	Completed
Allogeneic Hematopoietic Cell Transplantation of Positively Selected CD34+ Cells and Defined Inoculum of T Cells From Related Haploidentical Donors for Older Patients With Indolent Hematologic Malignancies[NCT00185692]	Phase 2	16 participants (Actual)	Interventional	2000-08-31	Completed
[NCT02121847]	Phase 4	40 participants (Actual)	Interventional	2014-04-03	Completed
Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial[NCT00040846]	Phase 2	60 participants (Actual)	Interventional	2001-11-30	Completed
Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients With Ocular Surface Disease: A Pilot Study[NCT04918823]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2021-07-15	Completed
Novel Use of Restasis (Cyclosporine Ophthalmic Emulsion 0.05%) on Application of PROSE Devices for Management of Patients With Ocular Surface Disease: A Pilot Study[NCT04735510]	Phase 3	0 participants (Actual)	Interventional	2021-05-31	Withdrawn(stopped due to study redesigned)
Impact of a Ciclosporin A Preconditioning for Prevention of Ischemia-reperfusion Injury After Renal Artery Stenosis Dilation[NCT03382301]	Phase 2	20 participants (Anticipated)	Interventional	2018-08-28	Recruiting
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH[NCT05936086]		160 participants (Anticipated)	Interventional	2023-04-20	Recruiting
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors[NCT04530487]	Phase 2	40 participants (Anticipated)	Interventional	2020-08-19	Recruiting
A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma[NCT00119392]	Phase 2	42 participants (Actual)	Interventional	2004-06-30	Completed
S0125, A Phase II Study Of Chimerism-Mediated Immunotherapy (CMI) Using Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation In Older Patients With Acute Myeloid Leukemia (AML) In First Complete Remission (A BMT Study)[NCT00053014]	Phase 2	5 participants (Actual)	Interventional	2003-04-30	Terminated(stopped due to Poor accrual)
Randomized Open Label Study Comparing the Metabolic Control of Kidney Transplant Recipients With Type 2 Diabetes Receiving Either Prograf or Neoral as Part of a ATG Induction, Prednisone Free and Monitored MMF Immunosuppressive Regimen.[NCT00296296]	Phase 4	29 participants (Actual)	Interventional	2005-06-30	Completed
Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS[NCT00520468]	Phase 2	15 participants (Actual)	Interventional	2004-06-30	Completed
A Multi-centre Phase II Trial of GVHD Prophylaxis Following Unrelated Donor Stem Cell Transplantation Comparing Thymoglobulin vs. Calcineurin Inhibitor or Sirolimus-based Post-transplant Cyclophosphamide[NCT04888741]	Phase 2	400 participants (Anticipated)	Interventional	2021-02-22	Recruiting
An Intention-to-Treat Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin Lymphoma[NCT00574496]	Phase 2	25 participants (Actual)	Interventional	2007-11-13	Completed
"MT2009-09: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Stem Cell Transplantation and Off-the-shelf Mesenchymal Stem Cells"[NCT01033552]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2010-01-31	Completed
[NCT00717418]		781 participants (Actual)	Observational	2004-09-30	Completed
[NCT01109056]	Phase 2	115 participants (Actual)	Interventional	2010-06-30	Completed
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation[NCT03842696]	Phase 1/Phase 2	49 participants (Anticipated)	Interventional	2020-02-04	Recruiting
A Randomized, Open-Label, Comparative Evaluation of Conversion From Calcineurin Inhibitor Treatment to Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy[NCT00086346]	Phase 3	607 participants (Actual)	Interventional	2002-12-31	Terminated
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood[NCT04895423]	Phase 4	160 participants (Anticipated)	Interventional	2021-11-25	Not yet recruiting
A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies[NCT00002831]	Phase 1/Phase 2	24 participants (Actual)	Interventional	1995-08-01	Completed
A Phase Ⅲ, Multicenter, Randomized, Double-blind, Active-controlled, Parallel Study of TJO-087 for Evaluating 32 Weeks Safety and Efficacy in Moderate to Severe Dry Eye Disease Patients[NCT05245604]	Phase 3	182 participants (Anticipated)	Interventional	2020-06-19	Recruiting
An Open-Label, 2-Period, Crossover Study to Determine the Effect of Multiple Oral Doses of Ezetimibe 20 mg on the Pharmacokinetics of a Single Oral Dose of Cyclosporine in Young, Healthy, Normal, Male and Female Subjects[NCT00653276]	Phase 1	13 participants (Actual)	Interventional	2003-11-30	Completed
In-Vivo Activated T-Cell Depletion to Prevent GVHD[NCT00594308]		10 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Treatment ineffective)
A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Mult[NCT01251575]	Phase 2	77 participants (Actual)	Interventional	2010-12-01	Completed
A Phase 1, Two-Part, Open-label Study in Healthy Adult Volunteers to Assess a Single Dose of Vadadustat as a Victim in Drug-Drug Interactions With Cyclosporine, Probenecid and Rifampin[NCT03801746]	Phase 1	40 participants (Actual)	Interventional	2018-07-20	Completed
Post Transplant Infusion of Allogeneic Cytokine Induced Killer Cells as Consolidative Therapy After Non-Myeloablative Allogeneic Transplantation in Patients With Myelodysplasia or Myeloproliferative Disorders[NCT01392989]	Phase 2	44 participants (Actual)	Interventional	2011-03-31	Completed
A Phase 2, Multi-center, Vehicle- and Sham-controlled, Randomized Study of RESTASIS® X in Patients With Moderate to Severe Dry Eye Disease[NCT02013791]	Phase 2	55 participants (Actual)	Interventional	2014-04-29	Terminated
A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up Evaluation at 12 Month After Transplant (NEVERWOUND St[NCT01410448]	Phase 3	383 participants (Actual)	Interventional	2011-11-30	Completed
Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection [NCT01938625]	Phase 2	35 participants (Actual)	Interventional	2013-12-12	Completed
Evaluation of the Safety and Efficacy of Cyclosporine A 0.05% Eye Drops in Management of Non- Necrotizing Herpetic Stromal Keratitis; a Prospective Controlled Clinical Trial[NCT05720715]	Phase 4	40 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Multi-center, Randomized, Double-blind, Active Comparator- Controlled, Parallel Study Evaluating the Efficacy and Safety of HE10 in Subjects With Dry Eye Syndrome[NCT02492412]	Phase 3	101 participants (Actual)	Interventional	2013-05-31	Completed
First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®)[NCT02472054]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2015-06-29	Completed
A Phase 2, Double-Blind, Placebo-Controlled Trial of Mycophenolate Mofetil Alone or With Voclosporin for Systemic Lupus: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment (DIVERT) (ALE10)[NCT05306873]	Phase 2	120 participants (Anticipated)	Interventional	2022-10-28	Recruiting
Efficacy of Oral Alitretinoin Versus Oral Cyclosporine in Patients With Severe Recurrent Vesicular Hand Eczema. A Randomized Prospective Open-label Trial With Blinded Outcome Assessment[NCT03026946]	Phase 3	76 participants (Anticipated)	Interventional	2017-05-29	Recruiting
A Phase 1, Randomized, Parallel-group, Open-label Study to Evaluate the Effect of Cyclosporine on the Single-dose Pharmacokinetics of Ozanimod and Major Active Metabolites in Healthy Adult Subjects[NCT04149678]	Phase 1	40 participants (Actual)	Interventional	2019-10-04	Completed
Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study[NCT02342145]	Phase 4	40 participants (Anticipated)	Interventional	2014-06-30	Recruiting
A Phase II, Multi-Center, Double-Masked, Randomized Study of NOVA22007 0.05% and 0.1% Cyclosporine Ophthalmic Cationic Emulsions Compared to Vehicle for the Treatment of the Signs and Symptoms of Dry Eye[NCT00739349]	Phase 2	132 participants (Actual)	Interventional	2008-08-31	Completed
A Trial Investigating the Effect of Probenecid and Ciclosporin on the Pharmacokinetics of SNAC in Healthy Subjects[NCT03466567]	Phase 1	21 participants (Actual)	Interventional	2018-03-15	Completed
A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome[NCT03461575]	Phase 3	209 participants (Actual)	Interventional	2018-01-22	Completed
Combined Topical Corticosteroid and Topical Cyclosporine-A for Management of COVID-19 Keratoconjunctivitis; a Pilot Study[NCT04451239]		12 participants (Anticipated)	Interventional	2020-06-30	Not yet recruiting
A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer[NCT02188264]	Phase 1	40 participants (Actual)	Interventional	2014-08-05	Active, not recruiting
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)[NCT01624805]	Phase 2	100 participants (Anticipated)	Interventional	2012-06-25	Recruiting
Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia[NCT01623167]	Phase 1/Phase 2	207 participants (Anticipated)	Interventional	2012-07-02	Recruiting
Transplantation of Umbilical Cord Blood in Patients With Hematological Malignancies Using a Reduced-Intensity Preparative Regimen (A Multi-Center Trial Coordinated by the FHCRC)[NCT00723099]	Phase 2	73 participants (Actual)	Interventional	2008-06-25	Completed
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial[NCT00005803]	Phase 1/Phase 2	76 participants (Actual)	Interventional	1999-09-30	Completed
A Phase I/II Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients With Hematologic Malignancies Using Busulfan, Fludarabine and Total Body Irradiation[NCT00245037]	Phase 1/Phase 2	147 participants (Actual)	Interventional	2005-06-30	Completed
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis[NCT02141672]	Phase 2	265 participants (Actual)	Interventional	2014-06-30	Completed
A 24-month, Multi-center, Single Arm, Prospective Study to Evaluate Renal Function, Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.[NCT01598987]	Phase 3	56 participants (Actual)	Interventional	2012-10-31	Completed
A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS[NCT05745701]	Phase 1	16 participants (Actual)	Interventional	2023-02-22	Completed
Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial)[NCT02016625]	Phase 1	32 participants (Actual)	Interventional	2013-12-31	Completed
A Randomized Study Comparing the Incidence of Acute Clinical or Subclinical Rejection With Two Dosing Regimens of CellCept in de Novo Renal Transplant Recipients Receiving Induction, Cyclosporine and Brief Steroid Therapy[NCT02005562]	Phase 3	252 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized Controlled Pilot Trial of Cyclosporine vs Steroids in DRESS[NCT04988256]	Early Phase 1	50 participants (Anticipated)	Interventional	2021-09-27	Enrolling by invitation
Prospective Randomised Marker-based Trial to Assess the Clinical Utility and Safety of Biomarker-guided Immunosuppression Withdrawal in Liver Transplantation[NCT02498977]	Phase 4	116 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
A Phase III, Extension Clinical Trial to Demonstrate Efficacy and Safety of Liposomal Cyclosprine A Via the PARI Investigational eFlow® Device and SoC in Treating Bronchiolitis Obliterans in Patients Post Single or Double Lung Transplant[NCT04039347]	Phase 3	262 participants (Anticipated)	Interventional	2020-03-12	Enrolling by invitation
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Immunologic or Histiocytic Disorders Using a Non-Myeloablative Preparative Regimen to Achieve Stable Mixed Chimerism[NCT00176865]	Phase 2	19 participants (Actual)	Interventional	2002-08-31	Completed
A Phase II Trial Combining Radiolabeled BC8 (Anti-CD45) Antibody With Fludarabine and Low Dose TBI Followed by Related or Unrelated PBSC Infusion and Post-Transplant Immunosuppression for Patients With Advanced AML or High Risk Myelodysplastic Syndrome[NCT00119366]	Phase 2	18 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Funding ended before target accrual was reached; participants are no longer being examined or receiving intervention.)
A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Single Lung Transplant[NCT03657342]	Phase 3	220 participants (Actual)	Interventional	2019-04-02	Active, not recruiting
Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination Wi[NCT00112593]		5 participants (Actual)	Interventional	1999-11-30	Completed
12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certican® Based Regimen Either in Combination With Cyclosporin A or Tacrolimus[NCT01843348]	Phase 3	612 participants (Actual)	Interventional	2012-12-27	Completed
Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression[NCT01820572]	Phase 3	446 participants (Actual)	Interventional	2013-03-27	Completed
A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation[NCT01950819]	Phase 4	2,037 participants (Actual)	Interventional	2013-12-03	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants That Achieved Engraftment

Number of participants that achieved engraftment based on blood Chimerism Cluster of differentiation 3 (CD3) analysis that is greater than or equal to 95%. (NCT00001880)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors	31

Number of Participants Who Developed Chronic GVHD

"Number of participants who developed Chronic Graft vs Host Disease (GVHD).~Chronic GVHD is defined as symptoms that persist or appear after 100 days since the time of stem cell transplantation." (NCT00001880)
Timeframe: Day 100 to year 2

Intervention	Participants (Count of Participants)
Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors	18

Number of Participants Who Received Donor Lymphocyte Infusion to Achieve Tumor Regression or Prevent Graft Failure

"To evaluate the effects of donor lymphocyte infusion (DLI) and cyclosporine A (CSA) withdrawal on tumor regression in participants who show progressive disease off of CSA and in the absence of grade > II GVHD, or who are at risk for graft failure due to incomplete donor T-cell engraftment will receive one or more DLI.~Tumor response assessed as follows:~Complete response (CR): disappearance of signs & symptoms of metastatic disease at least one month.~Partial response (PR): a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting at least one month. No new metastatic lesions may appear.~Stable disease (SD): tumor measurements not meeting the criteria of CR, PR, or PD.~Progressive disease (PD): increase of 25% or greater in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or development of new metastatic disease." (NCT00001880)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Stem Cell Transplantation in Patients With Progressive and Incurable Metastatic Solid Tumors	16

Acute Graft-Versus-Host Disease

Grade III-IV graft versus host disease (NCT00303719)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
High Risk Patients	2
Standard Risk Patients	79

Neutrophil and Donor Cell Engraftment

"Successful sustained engraftment is defined as primary neutrophil engraftment by day 42 and e90% donor cells at day 100, with or without DLI.~Engraftment based on absolute neutrophil count of donor origin > 0.5 x 10e9 /L for 3 days by day 42" (NCT00303719)
Timeframe: Day 42 and Day 100

Intervention	Participants (Count of Participants)
High Risk Patients	12
Standard Risk Patients	289

Overall Survival

(NCT00303719)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
High Risk Patients	8
Standard Risk Patients	181

Serious Adverse Events

Safety by development of severe adverse events within 100 days of transplant (NCT00303719)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
High Risk Patients	0
Standard Risk Patients	47

Transplant Related Mortality

> 30% transplant related mortality at 100 days (non-relapse). (NCT00303719)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
High Risk Patients	2
Standard Risk Patients	40

Graft Survival at One Year

"Graft survival defined as any participant who did not meet the criteria for graft loss, where graft loss is defined as any re-transplant, permanent return to dialysis (> 30 days), patient death, or participant whose outcome at one year was unknown.~Participants were only counted once regardless of how many criteria were met." (NCT00064701)
Timeframe: One year

Intervention	percentage of participants (Number)
Tacrolimus	91.5
Tacrolimus Modified Release	95.3
Cyclosporine	95.3

Kaplan-Meier Estimate of Graft Survival at the End of the Study

"Graft survival was defined as any participant who did not meet the definition of graft loss, where graft loss was any retransplant or the permanent return to dialysis (more than 30 days) or patient death.~Graft survival was censored at the time of last follow-up contact." (NCT00064701)
Timeframe: End of study (maximum time on study was 1,941 days).

Intervention	percentage of participants (Number)
Tacrolimus	82.7
Tacrolimus Modified Release	84.7
Cyclosporine	83.9

Kaplan-Meier Estimate of Patient Survival at the End of the Study

Patient survival was defined as any participant who was alive at the end of the study. Patient survival was censored at the time of last follow-up contact. (NCT00064701)
Timeframe: End of study (maximum time on study was 1,941 days).

Intervention	percentage of participants (Number)
Tacrolimus	91.2
Tacrolimus Modified Release	93.2
Cyclosporine	91.7

Number of Participants Experiencing Multiple Rejection Episodes

This analysis includes rejection episodes that were either confirmed by biopsy by the clinical site pathologist or were clinically treated. (NCT00064701)
Timeframe: one year

Intervention	participants (Number)
Tacrolimus	2
Tacrolimus Modified Release	4
Cyclosporine	8

Number of Participants Requiring Anti-lymphocyte Antibody Therapy for Treatment of Rejection

"Rejection episodes were confirmed by biopsy by the clinical site pathologist. Participants with histologically-proven Banff Grade II or III rejection or participants with steroid-resistant rejection were treated with anti-lymphocyte antibody treatment according to institutional practice.~Biopsies were graded according to the 1997 Banff criteria:~Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel." (NCT00064701)
Timeframe: one year

Intervention	participants (Number)
Tacrolimus	6
Tacrolimus Modified Release	8
Cyclosporine	18

Number of Participants Who Crossed Over Due to Treatment Failure

Participants were allowed to cross over to an alternative primary immunosuppressive regimen (either to the tacrolimus or cyclosporine treatment arms) to address an adverse event which led to randomized study drug discontinuation or in the case of severe or refractory rejection. Crossover to the modified release tacrolimus treatment arm was not permitted. (NCT00064701)
Timeframe: one year

Intervention	participants (Number)
Tacrolimus	6
Tacrolimus Modified Release	10
Cyclosporine	39

Number of Participants With Clinically Treated Acute Rejection Episodes

A clinically treated acute rejection episode was any biopsy-confirmed or suspected rejection episode that was treated with immunosuppressive therapy. (NCT00064701)
Timeframe: one year

Intervention	participants (Number)
Tacrolimus	25
Tacrolimus Modified Release	39
Cyclosporine	45

Number of Participants With Treatment Failure

Treatment failure was defined as the discontinuation of randomized study drug for any reason. Participants who met the definition of treatment failure were to be followed throughout the 12-month treatment period. (NCT00064701)
Timeframe: one year

Intervention	participants (Number)
Tacrolimus	33
Tacrolimus Modified Release	31
Cyclosporine	61

Patient Survival at One Year

Patient survival is defined as any participant who is known to be alive one year after the skin closure date. Participants who died or whose outcome was unknown at one year were considered to be non-survivors. (NCT00064701)
Timeframe: One year

Intervention	percentage of participants (Number)
Tacrolimus	93.9
Tacrolimus Modified Release	97.2
Cyclosporine	97.2

Percentage of Participants With Efficacy Failure

"Efficacy failure is defined as any participant who died, experienced a graft failure (permanent return to dialysis [> 30 days] or retransplant), had a biopsy-confirmed (Banff Grade ≥ I) acute rejection (BCAR), or was lost to follow-up.~Biopsies were graded according to the 1997 Banff criteria:~Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel." (NCT00064701)
Timeframe: one year

Intervention	percentage of participants (Number)
Tacrolimus	15.1
Tacrolimus Modified Release	14.0
Cyclosporine	17.0

Time to First Biopsy-confirmed Acute Rejection Episode

"Time to first biopsy-confirmed acute rejection episode defined as the number of days from skin closure (Day 0) to the date of biopsy. Rejection episodes were confirmed by biopsy by the clinical site pathologist and graded according to the 1997 Banff criteria:~Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel.~Acute rejection is defined as a grade ≥ I." (NCT00064701)
Timeframe: one year

Intervention	days (Median)
Tacrolimus	156.00
Tacrolimus Modified Release	11.00
Cyclosporine	52.00

Change From Month 1 in Creatinine Clearance at Month 6 and Month 12

Renal function was assessed by creatinine clearance, calculated using the Cockcroft-Gault formula. (NCT00064701)
Timeframe: Month 1, Month 6, and Month 12

Intervention	mL/min (Mean)
	At 6 months [N=184, 184, 167]	At 12 months [N=173, 182, 145]
Cyclosporine	-1.79	-0.25
Tacrolimus	0.83	1.50
Tacrolimus Modified Release	0.47	2.62

Change From Month 1 in Serum Creatinine at Month 6 and Month 12

Renal function was assessed by the change from Month 1 in serum creatinine six months and 12 months after transplant. (NCT00064701)
Timeframe: Month 1, Month 6, and Month 12

Intervention	mg/dL (Mean)
	At 6 months [N=184, 184, 169]	At 12 months [N=173, 182, 147]
Cyclosporine	-0.01	-0.04
Tacrolimus	-0.09	-0.08
Tacrolimus Modified Release	-0.08	-0.14

Percentage of Participants With Biopsy Confirmed Acute Rejection at 6 and 12 Months

"Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 1997 Banff criteria:~Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel.~Acute rejection is defined as a grade ≥ I." (NCT00064701)
Timeframe: Six months and 12 months

Intervention	percentage of participants (Number)
	At 6 Months	At 12 Months
Cyclosporine	11.8	13.7
Tacrolimus	3.8	7.5
Tacrolimus Modified Release	7.9	10.3

Severity of Acute Rejection

"Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 1997 Banff criteria:~Borderline: No intimal arteritis present but foci of mild tubulitis; Grade IA: Significant interstitial infiltration and foci of moderate tubulitis; Grade IB: Significant interstitial infiltration and foci of severe tubulitis; Grade IIA: Mild to moderate intimal arteritis in at least 1 arterial cross section Grade IIB: Severe intimal arteritis comprising >25% of the luminal area lost in at least 1 arterial cross section; Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel." (NCT00064701)
Timeframe: one year

Intervention	participants (Number)
	Grade I-A	Grade I-B	Grade II-A	Grade II-B	Grade III
Cyclosporine	14	6	6	1	2
Tacrolimus	8	4	3	1	0
Tacrolimus Modified Release	11	3	6	1	1

Number of Participants Who Developed Acute Rejection Episode Within 6 Months Post-Transplant

The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months post-transplant (PT). Participants with acute rejection included participants with a biopsy histology of International Society of Heart and Lung Transplant (ISHLT) Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up. (NCT00048165)
Timeframe: Up to 6 months PT

Intervention	participants (Number)
Daclizumab	77
Placebo	104

Number of Participants Who Developed Acute Rejection Episode Within the 12 Months PT

The acute rejection episode was a composite end-point of acute rejection and treatment failure within 6 months. Participants with acute rejection included participants with a biopsy histology of ISHLT Grade IIIA, IIIB, or IV and participants with hemodynamic compromise (HDC) who were treated for acute rejection (whether or not a biopsy was done and regardless of the grade of the biopsy). Participants who had treatment failure included participants who died within 6 months of transplantation before experiencing acute rejection or who were re-transplanted within 6 months of the primary transplantation and who did not experience an acute rejection or who were lost to follow-up (NCT00048165)
Timeframe: Up to 12 months PT

Intervention	participants (Number)
Daclizumab	97
Placebo	116

Mean Maintenance Doses of Mycophenolate Mofetil, Cyclosporine, and Cumulative Dose of Corticosteroids at 6 and 12 Months PT

The maintenance doses of mycophenolate mofetil (1.5g twice a day daily), cyclosporine (1-4 mg/kg IV or 2-6 mg/kg oral [PO]/nasogastric [NG] within 72 hours post-operative]), and cumulative dose of corticosteroids (500-1000 mg IV methylprednisolone pre-operative switched to oral at 0.5-1 mg/kg/day. Tapered to 0.2 mg/kg/d by Day 28, 0.1-0.15 mg/kg/day from Days 36 to 90, and 0.1-0.15 mg/kg/day from Days 120 to 180)at 6 and 12 months PT were reported. Maintenance dose was calculated as total dose per day summed over all days that a participant was administered drug within the specified time interval, divided by number of days that a participant took drug within that time interval. (NCT00048165)
Timeframe: Within 6 months and 12 months PT

Intervention	mg (Mean)
	MMF dose, 6 months PT (n=193, 201)	MMF dose,12 months PT (n=188, 194)	IV Cyclosporine dose, 6 months PT (n=2, 1)	IV Cyclosporine dose, 12 months PT (n=4, 2)	PO/NG Cyclosporine dose, 6 months PT (n=184, 182)	PO/NG Cyclosporine dose, 12 months PT (n=170, 170)	Cumulative corticosteroids,6 months PT(n=203, 206)	Cumulative corticosteroids,12 months PT(n=195,200)
Daclizumab	2522.2	2394.1	86.11	93.5	321.9	294.7	848.1	1199.6
Placebo	2450	2380.1	38.1	46.7	331.1	305.7	955.4	1288.9

Median Change From Baseline for LDL/HDL Ratio

(NCT00048165)
Timeframe: From Baseline (Day -2) to 3 months, and 6 months

Intervention	ratio (Median)
	LDL/HDL ratio,change at 3 months (n=91,89)	LDL/HDL ratio,change at 6 months (n=91, 99)
Daclizumab	-0.44	-0.50
Placebo	-0.12	-0.14

Median Change From Baseline for Lipid Profile (Total Cholesterol, Low Density Lipoproteins, High Density Lipoproteins, and Triglycerides)

Lipid profile included total cholesterol, low density lipoproteins (LDL), high density lipoproteins (HDL), and triglycerides (all total cholesterol, LDL, HDL, and triglycerides with unit milligram per decilitre [mg/dL]), were reported. The median change from baseline (Day -2) in lipid profile values at 3 months and 6 months was reported. (NCT00048165)
Timeframe: From Baseline (Day -2) to 3 months and 6 months

Intervention	mg/dL (Median)
	Total cholesterol, change at 3 months (n=119,119)	Total cholesterol, change at 6 months (n=126,130)	LDL, Change at 3 months (n=92,89)	LDL, Change at 6 months (n=91,99)	HDL, change at 3 months (n=97, 101)	HDL, change at 6 months (n=102,112)	Triglycerides,change at 3 months (n=104,108)	Triglycerides,change at 6 months (n=109,117)	LDL/HDL ratio,change at 3 months (n=91,89)	LDL/HDL ratio,change at 6 months (n=91, 99)
Daclizumab	0.65	0.28	0.25	0.03	0.34	0.23	0.26	0.20	-0.44	-0.50
Placebo	0.91	0.61	0.34	0.21	0.31	0.20	0.46	0.44	-0.12	-0.14

Median Time to First Acute Rejection Episode Within the First 6 Months and 12 Months PT

The median time to first acute rejection episode within first 6 months and 12 months PT was reported. (NCT00048165)
Timeframe: Within 6 months and 12 months PT

Intervention	days (Median)
	Within 6 months (n= 77, 104)	Within 12 months (n=97, 116)
Daclizumab	61	96
Placebo	21	26

Number of Acute Rejection Episodes Per Participant Within the First 6 Months and 12 Months PT

The number of participants with 0,1, 2, 3 or 4 episodes at 6 and 12 months PT were reported. An episode of acute rejection was defined according to the date of positive biopsy of Grade IIIA or worse or the date of start of treatment for HDC, whichever came first. (NCT00048165)
Timeframe: Within 6 months and 12 months PT

Intervention	participants (Number)
	Within 6 months, 0 episode	Within 6 months, 1 episode	Within 6 months, 2 episodes	Within 6 months, 3 episodes	Within 6 months, 4 episodes	Within 12 months, 0 episode	Within 12 months, 1 episode	Within 12 months, 2 episodes	Within 12 months, 3 episodes	Within 12 months, 4 episodes
Daclizumab	139	63	12	2	0	119	68	23	3	3
Placebo	114	82	19	2	1	102	90	19	5	2

Number of Participant Who Died Within 6 Months 12 Months and 3 Years PT

The survival of the graft and participants at 6,12 months and 3 years PT was reported (NCT00048165)
Timeframe: At 6 months, 12 months , 3 years PT

Intervention	participants (Number)
	Within 6 months	Within 12 months	Within 3 years
Daclizumab	16	21	NA
Placebo	10	12	NA

Number of Participants Using Monomurab Cluster of Differentiation 3, Orthoclone Polyclonal Antithymocyte Globulin or Antilymphocyte Globulin in the First 6 Months and 12 Months PT

The number of participants who received monomurab Cluster of differentiation 3, orthoclone, polyclonal antithymocyte globulin or antilymphocyte globulin for treatment of biopsy proven rejection or HDC within 6 and 12 months PT were reported. (NCT00048165)
Timeframe: Within 6 months and 12 months PT

Intervention	participants (Number)
	Within 6 months	Within 12 months
Daclizumab	17	23
Placebo	19	21

Number of Participants With Any Adverse Events and Any Serious Adverse Event, and Adverse Events Leading to Premature Withdrawal

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Pre-existing conditions which worsened during this study were reported as AEs. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect. (NCT00048165)
Timeframe: Up to 12 months

Intervention	participants (Number)
	Any AEs	Any SAE's	Any AEs leading to premature discontinuation
Daclizumab	214	108	14
Placebo	207	102	11

Number of Participants With Malignancies and Opportunistic Infections

The opportunistic infections included infections with Cytomegalovirus, Aspergillus, Candida, Pneumocystis, Cryptococcus, Listeria, Herpes simplex, Herpes zoster. For malignancy, participants with any type of malignancy whose date of onset or diagnosis was after randomization was reported. (NCT00048165)
Timeframe: Up to 12 months

Intervention	participants (Number)
	Participants with malignancies	Participants with opportunistic infections
Daclizumab	11	71
Placebo	11	80

Number of Participants With Marked Laboratory Abnormalities: Biochemistry Parameters

A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Biochemistry included blood urea nitrogen, creatinine, serum glutamic oxalacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), gamma-glutamyl transferase (GGT), phosphorous, total bilirubin, direct bilirubin, total protein, albumin, glucose, alkaline phosphatase, low density lipoprotein (LDH), uric acid, carbon dioxide, magnesium, sodium, potassium, chloride, calcium, LDL, HDL, total cholesterol, and triglycerides. (NCT00048165)
Timeframe: Up to 12 months

Intervention	participants (Number)
	SGPT-high (n=200, 200)	ALP-high (n=201, 200)	SGOT-high (n=201, 200)	GGT-high (n=180, 175)	LDH-high (n=194, 191)	Total bilirubin-high (n=201, 200)	BUN-high (n= 210, 200)	Creatinine-high (n=211, 203)	Albumin-low (n=198,197)	Total protein-high (n=195,196)	Total protein-low(n=195,196)	Cholesterol-high (n=174, 174)	Triglycerides-high (n=164, 164)	Carbondioxide-high (n=206, 197)	Carbondioxide-low (n=206, 197)	Chloride-high (n=211, 203)	Chloride-low (n=211, 203)	Potassium-high (n=211, 204)	Potassium-low (n=211, 204)	Sodium-high (n=211, 203)	Sodium-low (n=211, 203)	Calcium-low (n=207, 201)	Glucose fasting-high (n=210, 203)	Glucose fasting-low (n=210, 203)	Phosphate-high (n=199, 194)	Phosphate-low (n=199,194)	Uric acid high (n=191, 188)
Daclizumab	48	15	22	90	53	28	93	66	47	5	85	3	35	27	12	1	42	7	4	2	8	39	28	3	54	32	23
Placebo	45	7	25	74	54	20	95	64	50	0	79	4	30	21	5	3	36	7	2	1	11	44	27	3	48	26	20

Number of Participants With Marked Laboratory Abnormalities: Hematology Parameters

A marked reference range was predefined by Roche. The marked reference range is broader than the standard reference range. Values falling outside the marked reference range (low or high) that also represent a defined change from Baseline were considered marked laboratory abnormalities (i.e. potentially clinically relevant). Hematology included hemoglobin, hematocrit, white blood cell count (WBC) with differential (including granulocytes or neutrophils, basophils, eosinophils, monocytes, lymphocytes), platelets, and erythrocyte count (NCT00048165)
Timeframe: Up to 12 months

Intervention	participants (Number)
	Hematocrit-high (n=210, 203)	Hematocrit-low (n=210, 203)	Hemoglobin-high (n=210, 204)	Hemoglobin-low (n=210, 204)	Platelets-high (n=210, 203)	Platelets-low (n=210, 203)	RBC-high (n=209, 203)	RBC-low (n=209, 203)	Basophils-high (n=199, 195)	Eosinophils-high (n=199, 195)	Lymphocytes-high (n=199, 198)	Lymphocytes-low (n=199, 198)	Monocytes-high (n=199, 198)	Monocytes-low (n=199, 198)	Neutrophils-low (n= 199, 198)	WBC-high (n=207, 201)	WBC-low (n=207, 201)
Daclizumab	0	116	0	107	2	30	1	116	4	0	2	157	5	14	33	61	43
Placebo	0	117	0	112	1	22	2	106	4	0	2	157	6	20	33	57	29

Number of Participants With Worst ISHLT Biopsy Grade Within First 6 Months and 12 Months PT

The number of participants with Worst International Society of Heart and Lung Transplant (ISHLT) grade within first 6 months and 12 months PT were reported. ISHLT is a standardized grading method to determine the acute cellular rejection on endomyocardial biopsy ; where 0= no rejection, IA= focal (perivascular or interstitial) infiltrate without necrosis, IB= diffuse but sparse infiltrate without necrosis, II=one focus only with aggressive infiltration and/or focal myocyte damage, IIIA=multifocal aggressive infiltrates and/or myocyte damage, IIIB= diffuse inflammatory process with necrosis, IV= diffuse aggressive polymorphous and/or infiltrate and/or edema and/or hemorrhage and/or vasculitis, with necrosis (NCT00048165)
Timeframe: Within 6 months and 12 months PT

Intervention	participants (Number)
	Within 6 months, Grade 0	Within 6 months, Grade IA	Within 6 months, Grade IB	Within 6 months, Grade II	Within 6 months, Grade IIIA	Within 6 months, Grade IIIB	Within 6 months, Grade IV	Within 12 months, Grade 0	Within 12 months, Grade IA	Within 12 months, Grade IB	Within 12 months, Grade II	Within 12 months, Grade IIIA	Within 12 months, Grade IIIB	Within 12 months, Grade IV
Daclizumab	9	64	26	55	48	8	1	7	56	22	51	63	11	1
Placebo	5	51	28	38	74	15	1	4	39	21	47	85	15	1

Red Blood Cell Transfusion Independence

Red blood cell transfusion independence was documented as time from last transfusion of red cells to last day of transfusion free follow-up. Independence or response to the intervention was assessed by weekly blood counts. Transfusion independence was defined as no transfusion requirement for a 3 month period. Complete hematologic response is defined as the normalization of affected cells lines and less than 5% marrow blasts present. Partial hematologic response is defined as greater than 50% improvement from baseline to normal levels of all cell counts and greater than 50% decrease in marrow blasts. (NCT00005937)
Timeframe: 6 months

Intervention	participants (Number)
	Complete hematologic response	Partial hematologic response	No hematologic response
MDS Subjects Treated With ATG and CsA	6	10	21

Survival Rate at Day 100 After Allogeneic Transplant From Umbilical Cord Blood (UCB)

Number of surviving patients at Day 100 post-transplant divided by number of patients undergone transplantation. (NCT00547196)
Timeframe: From transplant to Day 100 post-transplant

Intervention	percentage of surviving patients (Number)
Regimen I (FTBI, Cyclophosphamide, Fludarabine)	100
Regimen III (TBI, Cyclophosphamide, Fludarabine)	100
Regimen IV (Fludarabine, Melphalan)	100

Survival Rate at Day 180 After Allogeneic Transplant From Umbilical Cord Blood (UCB)

Number of surviving patients at Day 180 post-transplant divided by number of patients undergone transplantation. (NCT00547196)
Timeframe: From transplant up to Day 180 post-transplant

Intervention	percentage of surviving patients (Number)
Regimen I (FTBI, Cyclophosphamide, Fludarabine)	60
Regimen III (TBI, Cyclophosphamide, Fludarabine)	100
Regimen IV (Fludarabine, Melphalan)	50

Acute Graft vs Host Disease (GvHD), All Evaluable

"The incidence of acute GvHD after transplantation was assessed per Glucksberg GvHD grade, a compound scale based on the following combinations of disease stages.~Skin Stages~0: No rash~1: Maculopapular (MP) rash <25% of body surface area~2: MP rash on 25-50% of body surface area~3: Generalized erythroderma (ED)~4: Generalized ED with bullous formation and desquamation~Liver Stages (Bilirubin in mg/dL)~0: <2~1: 2-3~2: 3.01-6~3: 6.01-15.0~4: >15~Gastrointestinal (GI) Stages (diarrhea)~0: None or < 500 mL/day~1: 500-999 mL/day~2: 1000-1499 mL/day~3: >1500 mL/day~4: Severe abdominal pain, with or without ileus~Glucksberg Overall grade~Grade 1: Skin 1/2; GI 0; Liver 0; Karnofsky performance scale (KPS) 90-100%~Grade 2: Skin 1-3; GI 1; Liver 1; KPS 70-80~Grade 2: Skin 2/3; GI 2/3; Liver 2-4; KPS 50-60~Grade 4: Skin 2-4; GI 2-4; Liver 2-4; KPS 30-40" (NCT00185640)
Timeframe: 100 days post-transplant

Intervention	percentage of participants (Number)
Non-myeloablative Transplantation	11

Acute Graft vs Host Disease (GvHD)

Intervention	percentage of participants (Number)
Non-myeloablative Transplantation	2.7

Incidence of Relapse

Reports the overall rate of disease relapse, occurring any time within 3 years after transplant (NCT00185640)
Timeframe: 3 years

Intervention	percentage of participants (Number)
Non-myeloablative Transplantation	53

Transplant-related Mortality

Reports the proportion of participants who expired within 1 year due to any complication or failure of the transplant. (NCT00185640)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Non-myeloablative Transplantation	6

Event-free Survival (EFS)

Reports the number and proportion of participants who neither died due to any cause nor experienced relapse. (NCT00185640)
Timeframe: 3 and 5 years

Intervention	Participants (Count of Participants)
	3 years	5 years
Non-myeloablative Transplantation	44	38

Overall Survival (OS)

(NCT00185640)
Timeframe: 3 and 5 years

Intervention	percentage of participants (Number)
	3 years	5 years
Non-myeloablative Transplantation	70	64

Percentage of Participants With an Occurrence of Biopsy Proven Acute Rejection (BPAR) During the First 3 Months Post de Novo Liver Transplantation.

A BPAR is defined when the investigator had a suspicion of an acute rejection, where the final clinical diagnosis confirmed the occurrence of an acute rejection, where a biopsy was performed that confirmed the presence of an acute rejection, and where anti-rejection treatment intervention was initiated. The efficacy measured the first rejections (clinically and biopsy proven rejections) at 3 months. (NCT00149994)
Timeframe: Month 3

Intervention	Percentage of Participants (Number)
Cyclosporine A	33.3
Tacrolimus	32.9

Nankivell Glomerular Filtration Rate (GFR)

Nankivell GFR: patients with baseline GFR of 20.0 to 40.0 mL/min and patients with baseline GFR of greater than 40.0 mL/min. GFR is an index of kidney function. A higher value means better kidney function. (NCT00038948)
Timeframe: 52 weeks

Intervention	mL/min (Mean)
SRL Conversion Strata 20.0-40.0 mL/Min	24.56
CNI Continuation Strata 20.0-40.0 mL/Min	27.24
SRL Conversion Strata >40.0 mL/Min	59.04
CNI Continuation Strata >40.0 mL/Min	57.73

First Occurrence of Biopsy-confirmed Acute Rejection, Graft Loss, or Death.

Number of patients who experienced for the first time either biopsy-confirmed acute rejection, graft loss, or death by weeks 52 and 104. Assessed by individual endpoint and as composite endpoint (all combined). (NCT00038948)
Timeframe: 52 and 104 weeks

,,,

Intervention	patients (Number)
	52 weeks - Acute rejection	52 weeks - Graft loss	52 weeks - Death	52 weeks - Missing	104 weeks - Acute rejection	104 weeks - Graft loss	104 weeks - Death	104 weeks - Missing
CNI Continuation Strata >40.0 mL/Min	3	3	1	1	9	8	3	8
CNI Continuation Strata 20.0-40.0 mL/Min	0	3	0	0	1	9	0	2
SRL Conversion Strata >40.0 mL/Min	8	3	6	5	27	12	13	13
SRL Conversion Strata 20.0-40.0 mL/Min	4	7	3	0	5	12	7	0

Acute Graft-versus-Host Disease Matched Related Patients

Grade III-IV Acute Graft-versus-Host Disease (NCT00027560)
Timeframe: up to 4 months post transplant

Intervention	participants (Number)
Matched Related Patients	1

Acute Graft-versus-Host Disease Unrelated and Mismatched Related Patients

Grade III-IV Acute Graft-versus-Host Disease (NCT00027560)
Timeframe: up to 4 months post transplant

Intervention	participants (Number)
Unrelated and Mismatched Related Patients	3

Extensive Chronic Graft-versus-Host Disease Matched Related Patients

(NCT00027560)
Timeframe: up to 2 years post transplant

Intervention	participants (Number)
Matched Related Patients	0

Extensive Chronic Graft-versus-Host Disease Unrelated and Mismatched Related Patients

(NCT00027560)
Timeframe: up to 2 years post transplant

Intervention	participants (Number)
Unrelated and Mismatched Related Patients	2

Overall Survival

(NCT00027560)
Timeframe: 12 months post transplant

Intervention	participants (Number)
TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES	37

Overall Survival

(NCT00027560)
Timeframe: 24 months post transplant

Intervention	participants (Number)
TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES	30

Number of Participants Who Achieved Immune Tolerance Induction

Immune tolerance induction success was defined as development of an anti-laronidase immunoglobulin G (IgG) antibody titer less than or equal to (<=) 1:3200 after 24 weeks of receiving full-dose (0.58 mg/kg) laronidase therapy. (NCT00741338)
Timeframe: 24 weeks after start of full-dose laronidase therapy

Intervention	participants (Number)
Cohort 1	0
Cohort 2	1

Percent Reduction of Urinary Glycosaminoglycan (uGAG) Level From Baseline to the End of Treatment/Early Withdrawal

Urinary Glycosaminoglycan (uGAG) Levels: concentration of glycosaminoglycan (GAG) relative to creatinine in urine. A greater decrease in uGAG level indicates a greater response. (NCT00741338)
Timeframe: Baseline, end of treatment/early withdrawal (up to 24 weeks after start of full-dose laronidase therapy)

Intervention	percent change in uGAG level (Median)
Cohort 1	-43.80
Cohort 2	-72.50

Change in Mean Daily Number of Unpreserved Artificial Tears Instillations in Period I

(NCT00328653)
Timeframe: Up to Month1

Intervention	instillations (Mean)
	Week1- Baseline	Week2- Baseline	Month1-Baseline
NOVA22007 0.05%	0.1	-0.4	-0.5
NOVA22007 0.1%	-0.1	-0.2	0.0
Vehicle	-0.5	-0.2	-0.4

Overall Rating of Objective Symptoms of VKC in Period I

"Overall rating of objective signs was to be assessed under the slit lamp by the Investigator and recorded on a five-point scale based on BenEzra trial (BenEzra 1986):~Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement with the papillary proliferations more extensive or similar to the situation recorded before treatment in at least one of the eyes.~The overall condition was assessed as better than before treatment in both eyes.~Total re-epithelialisation of the cornea although slight conjunctival and perilimbal hyperaemia and papillary proliferations remains in both eyes.~Only slight conjunctival hyperaemia without perilimbal injection or papillary proliferations in at least one eye~Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection." (NCT00328653)
Timeframe: Week 4

Intervention	Participants (Count of Participants)
	1.Intense congestion of conjunctival vessels, perilimbal injection, or corneal involvement.	2.The overall condition was assessed as better than before treatment in both eyes.	3.Total re-epithelialisation of the cornea	4.Only slight conjunctival hyperaemia in at least one eye	4.Both eyes were quiet with no papillary proliferations or conjunctival or perilimbal injection.
NOVA22007 0.05%	8	17	7	6	1
NOVA22007 0.1%	7	16	12	2	2
Vehicle	18	13	4	4	1

Overall Rating of Subjective Symptoms of VKC in Period I

"The primary criteria of the trial was the overall rating of subjective symptoms in ocular symptoms of VKC as compared to Baseline and assessed at Week 4 (Month 1) based on a five-point scale based on BenEzra trial (BenEzra 1986):~= Overall worsening of the subjective findings.~= No change in the symptoms.~= Slight improvement with the child still unable to participate in all normal daily activities.~= Marked improvement despite temporary mild itching or mucus discharge.~= Completely free of all symptoms." (NCT00328653)
Timeframe: Week 4

Intervention	Participants (Count of Participants)
	1- Overall worsening of the	2- No change in the symptoms	3- Slight improvement	4- Marked improvement	5- Completely free of all symptoms
NOVA22007 0.05%	1	3	15	19	1
NOVA22007 0.1%	4	2	11	20	2
Vehicle	7	5	10	15	3

Ocular Tolerance in Period I

Are the tested eye drops (other than concomitant tear substitute ) comfortable? (NCT00328653)
Timeframe: Up to Month1

Intervention	Participants (Count of Participants)
	Week172578942		Week172578944	Week172578943	Week272578942	Week272578943	Week272578944	Month172578942	Month172578943	Month172578944
	No	Yes
NOVA22007 0.05%	11
NOVA22007 0.1%	4
Vehicle	35
NOVA22007 0.05%	24
NOVA22007 0.1%	34
Vehicle	3
NOVA22007 0.05%	5
NOVA22007 0.1%	6
Vehicle	34
NOVA22007 0.05%	33
NOVA22007 0.1%	31
Vehicle	2
NOVA22007 0.05%	8
NOVA22007 0.1%	7
NOVA22007 0.05%	31
NOVA22007 0.1%	29

Phase I: Acute Rejection-Free Survival

Percent of participants at 6 months without acute rejection. (NCT01062555)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Phase I Arm 1	80
Phase I Arm 2	85

Phase I: The Minimization of Negative Side Effects - Graft Survival

Percent of participants at 6 months with a functioning graft (without graft failure). (NCT01062555)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Phase I Arm 1	99
Phase I Arm 2	99

Phase I: The Minimization of Negative Side Effects - Patient Survival

The percentage of patients alive at 6 month post transplant. (NCT01062555)
Timeframe: 6 months

Intervention	percentage of participants (Number)
Phase I Arm 1	99
Phase I Arm 2	98

Phase II: Acute Rejection-Free Survival

The percentage of patients without acute rejection at 7 years post transplant or at the end of study activities. Not all participants completed 7-year follow-up. (NCT01062555)
Timeframe: up to 7 years

Intervention	percentage of participants (Number)
Phase II Arm 1	76
Phase II Arm 2	81

Phase II: The Minimization of Negative Side Effects - Graft Survival

The percentage of patients with a functioning graft (without graft failure) at 7 years post transplant or at the end of study activities. Not all participants completed 7-year follow-up. (NCT01062555)
Timeframe: up to 7 years

Intervention	percentage of participants (Number)
Phase II Arm 1	80
Phase II Arm 2	78

Phase II: The Minimization of Negative Side Effects - Patient Survival

The percentage of patients alive at 7 years post transplant or at the end of study activities. Not all participants completed 7-year follow-up. (NCT01062555)
Timeframe: up to 7 years

Intervention	percentage of participants (Number)
Phase II Arm 1	89
Phase II Arm 2	85

Number Of Participants With Chronic Rejection Who Met Primary Combined End-point

Treatment failure defined as: BOS progression (> 20% decline lung function), re-transplant, or death (NCT01650545)
Timeframe: approximately 1 year

Intervention	Participants (Count of Participants)
Liposomal Aerosol Cyclosporine	2
Conventional Oral Immune Suppression	5

Overall Survival at 5 Years Follow-up

Number of participants surviving at 5 year follow-up (NCT01650545)
Timeframe: 5 years

Intervention	Participants (Count of Participants)
Liposomal Aerosol Cyclosporine	5
Conventional Oral Immune Suppression	0

Cytokine Analysis From BAL Fluid in Lung

Multiple cytokines were assessed as markers of lung inflammation that may be used in addition to biopsy data, collected per patient as clinically indicated during the follow-up interval. Values are reported as mean change from baseline in each group, per week (NCT01650545)
Timeframe: baseline to approximately 1 year

Intervention	pg/mL (Mean)
	lL-1beta	IL-2	IL-6	IL-8	IL-10	IL-17	TNF-alpha	IFN-gamma
Conventional Oral Immune Suppression	3.3	-0.3	6.3	37.5	0.1	0.1	-1.7	0
Liposomal Aerosol Cyclosporine	-2	-0.9	-2.0	13.6	0.1	0.4	1.9	0.5

Number of Participants With Less Than 100 Hepatitis C Virus RNA Copies/mL

Number of Participants with Undetectable or Less than 100 copies/ml Hepatitis C Viral Level --defined as SVR -Sustained Virologic Response (NCT00821587)
Timeframe: 6 months after completion of interferon based therapy

Intervention	Participants (Count of Participants)
Tacrolimus (TAC)	7
Cyclosporine (CsA)	7

Calculated Creatinine Clearance at 6 Month and 12 Month

"Creatinine clearance calculated by Cockcroft-Gault formula and summarized by mean, and standard deviation. Cockcroft-Gault formula to calculate Creatinine Clearance (CrCl[mL/min]) is shown below:~CrCl[mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit [kg], C is the serum concentration of creatinine [mg/dL], R = 1 if the patient is male and = 0.85 if female." (NCT00154284)
Timeframe: 6 month and 12 months

Intervention	mL/min (Mean)
	6 Month	12 Month
Everolimus (Certican) With Cyclosporine (Neoral) Continuation	63.6	65.6
Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal	72.9	72.3

Number of Participants With Biopsy-proven Acute Rejection (BPAR) Episodes, Graft Loss, Death or Loss to Follow-up

Renal biopsies were collected for all cases of suspected acute rejection. For these cases, regardless of initiation of anti-rejection treatment, a graft core biopsy had been performed within 48 hours. These biopsies were listed on the Kidney Allograft Biopsy eCRF and the results used for patient management for BPAR. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant. BPAR, graft loss, death, or loss to follow-up was analyzed by means of frequency tables. (NCT00154284)
Timeframe: Month 12

Intervention	Participants (Number)
	Biopsy-proven Acute Rejection (BPAR)	Graft Loss	Death	Loss to Follow-up
Everolimus (Certican) With Cyclosporine (Neoral) Continuation	10	0	0	0
Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal	10	0	0	0

Renal Function Measured by Calculated Glomerular Filtration Rate (GFR Calculated According to the Nankivell Formula)

"Nankivell's formula for calculated GFR is shown below:~GFR [mL/min] = 6.7/C + W/4 - UREA/2 - 100/H2+ 35 (25 for females). Where W is body weight at specific visit [kg], H is height at specific visit [m], C is the serum concentration of creatinine [mmol/L], and UREA is the serum concentration of urea [mmol/L]. UREA was calculated from blood urea nitrogen (BUN) lab data by: UREA = 2.1441*BUN. If a GFR value from Nankivell formula was less than 10 [mL/min], then the value was assigned as 10 [mL/min]." (NCT00154284)
Timeframe: At Month 3 and Month 12

Intervention	mL/min per 1.73 m^2 (Mean)
	GFR at 3 months (Pre-randomization)	GFR at 12 months
Everolimus (Certican) With Cyclosporine (Neoral) Continuation	68.5	63.6
Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal	69.2	68.3

Serum Creatinine at Month 6 and 12

serum creatinine summarized by mean and standard deviation (NCT00154284)
Timeframe: 6 month and 12 months

Intervention	µmol/L (Mean)
	6 Month	12 Month
Everolimus (Certican) With Cyclosporine (Neoral) Continuation	139.1	135.6
Everolimus (Certican) With Cyclosporine (Neoral) Withdrawal	120.1	123.0

Mean Cases of Acute Rejection (MCAR) Per Patient (Pediatric Population)

"MCAR represents the average number of acute rejections among all patients in each treatment group. Results were based on rejection episodes with endomyocardial biopsies.~Acute rejection was defined as a rejection with ISHLT Grade ≥3A or by the presence of hemodynamic compromise.~ISHLT Grades ≥3A include: Multifocal Moderate Rejection; Diffuse, Borderline Severe Acute Rejection; and Severe Acute Rejection." (NCT00157014)
Timeframe: 52 Weeks

Intervention	MCAR per patient (Mean)
Tacrolimus - Pediatric	0.60
Cyclosporine - Pediatric	0.50

Mean Cases of Acute Rejection (MCAR) Per Patient

Intervention	MCAR per patient (Mean)
Tacrolimus - Adult	0.15
Cyclosporine - Adult	0.17

Number of Cardiac Rejection Episodes Requiring Treatment (Pediatric Population)

A summary of rejection episodes requiring treatment regardless of biopsy grade or presence of hemodynamic compromise. (NCT00157014)
Timeframe: 52 Weeks

Intervention	Rejection Episodes (Number)
Tacrolimus - Pediatric	3
Cyclosporine - Pediatric	3

Number of Cardiac Rejection Episodes Requiring Treatment

The number of rejection episodes requiring treatment (medications started/ stopped, non-medication treatment, or both) regardless of biopsy grade or presence of hemodynamic compromise. (NCT00157014)
Timeframe: 52 Weeks

Intervention	Rejection Episodes (Number)
Tacrolimus - Adult	12
Cyclosporine - Adult	11

Number of Patients Requiring Antilymphocyte Antibodies or Steroids for Treatment of Severe Acute Rejection (Pediatric Population)

Severe Acute Rejection was defined as rejection with ISHLT Grade 4. (NCT00157014)
Timeframe: 52 Weeks

Intervention	Patients (Number)
Tacrolimus - Pediatric	0
Cyclosporine - Pediatric	0

Number of Patients Requiring Antilymphocyte Antibodies or Steroids for Treatment of Severe Acute Rejection

Severe Acute Rejection is defined as rejection with ISHLT Grade 4. (NCT00157014)
Timeframe: 52 Weeks

Intervention	Patients (Number)
Tacrolimus - Adult	0
Cyclosporine - Adult	0

Time to First Acute Rejection Episode Following de Novo Cardiac Transplant (Pediatric Population)

"Acute Rejection was defined as a rejection with ISHLT Grade ≥3A or by the presence of hemodynamic compromise.~ISHLT Grades ≥3A include: Multifocal Moderate Rejection; Diffuse, Borderline Severe Acute Rejection; and Severe Acute Rejection.~Time to first acute rejection is defined as: date of onset - date of transplant." (NCT00157014)
Timeframe: 52 Weeks

Intervention	Days (Mean)
Tacrolimus - Pediatric	56.3
Cyclosporine - Pediatric	49.0

Time to First Acute Rejection Episode Following de Novo Cardiac Transplant

Intervention	Days (Mean)
Tacrolimus - Adult	55.0
Cyclosporine - Adult	35.60

Changes in Circulating Markers of Inflammation and Oxidation: Cystatin-C (Pediatric Population)

Change is defined as Week 52 assessment - Pre-Transplant assessment (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	mg/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Pediatric	0.77	0.84	-0.01
Tacrolimus - Pediatric	0.86	0.87	-0.11

Changes in Circulating Markers of Inflammation and Oxidation: F2 Isoprostanes (Pediatric Population)

Change is defined as Week 52 assessment - Pre-Transplant assessment (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	pg/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Pediatric	104.68	66.48	-30.07
Tacrolimus - Pediatric	106.06	69.71	-38.31

Changes in Circulating Markers of Inflammation and Oxidation: hsCRP (Pediatric Population)

Change is defined as Week 52 assessment - Pre-Transplant assessment (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	mg/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Pediatric	12.08	2.43	-13.94
Tacrolimus - Pediatric	30.46	26.31	-7.85

Changes in Circulating Markers of Inflammation and Oxidation: Nitrotyrosine (Pediatric Population)

Change is defined as Week 52 assessment - Pre-Transplant assessment (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	nM (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Pediatric	12701.21	41147.62	21514.62
Tacrolimus - Pediatric	233.08	5462.99	5148.42

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: BNP

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~BNP= Brain Natriuretic Peptide" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	ng/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	4240.8	1856.8	-1446.7
Tacrolimus - Adult	4314.8	670.1	-4018.4

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Cystatin-C

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	mg/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	1.29	1.48	0.27
Tacrolimus - Adult	1.21	1.29	0.06

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: E-selectin

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	ng/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	98.96	80.93	-19.16
Tacrolimus - Adult	90.40	68.60	-18.58

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: F2 Isoprostanes

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	pg/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	53.94	50.44	-3.43
Tacrolimus - Adult	52.03	30.08	-13.29

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Fibrinogen

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	g/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	4.4	3.8	-0.5
Tacrolimus - Adult	4.4	3.4	-1.1

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: GSH/GSSG

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~GSH/GSSG= ratio of reduced to oxidised glutathione" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	Ratio (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	58.83	53.72	-5.55
Tacrolimus - Adult	55.07	51.69	-2.07

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Homocysteine

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	μmol/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	15.9	15.8	0.7
Tacrolimus - Adult	14.2	13.5	0.3

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: hsCRP

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~hsCRP= high-sensitivity C Reactive Protein" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	mg/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	21.83	3.95	-18.69
Tacrolimus - Adult	32.85	3.01	-34.32

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: IL-18

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	pg/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	496.2	427.2	-71.0
Tacrolimus - Adult	574.0	534.6	5.2

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: IL-6

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~IL= Interleukin" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	pg/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	2.54	0.90	-1.56
Tacrolimus - Adult	3.36	0.98	-2.84

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: MCP-1

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~MCP-1= monocyte chemoattractant protein-1" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	pg/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	193.63	180.90	-16.49
Tacrolimus - Adult	233.05	229.96	42.92

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Nitrotyrosine

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	nM (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	482.43	368.95	-99.79
Tacrolimus - Adult	422.63	451.88	71.44

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Osteopontin

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	ng/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	11.14	10.49	0.20
Tacrolimus - Adult	11.88	8.77	-2.22

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: s-ICAM

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~s-ICAM= soluble-intracellular adhesion molecule" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	ng/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	674.46	503.71	-183.96
Tacrolimus - Adult	766.58	590.30	-227.58

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: T-bars

"Change is defined as Week 52 assessment - Pre-Transplant assessment.~T-bars = thiobarbituric acid reactive substances" (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	nmol/mL (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	3.91	3.14	-0.77
Tacrolimus - Adult	3.78	3.25	-0.64

Changes in Circulating Markers of Inflammation, Oxidation, Growth, Apoptosis, Differentiation and Survival: Troponin T

Change is defined as Week 52 assessment - Pre-Transplant assessment. (NCT00157014)
Timeframe: Pre-Transplant and 52 Weeks

Intervention	ug/L (Mean)
	Pre-Transplant	Week 52	Change from Pre-Transplant at Week 52
Cyclosporine - Adult	0.28	0.04	-0.27
Tacrolimus - Adult	0.30	0.03	-0.32

Number of Acute Rejection Episodes by International Society of Heart and Lung Transplantation (ISHLT) Criteria (Pediatric Population)

"Acute rejection was defined as a rejection with ISHLT Grade ≥3A or by the presence of hemodynamic compromise.~ISHLT Grades ≥3A include: Multifocal Moderate Rejection; Diffuse, Borderline Severe Acute Rejection; and Severe Acute Rejection.~Patients may report more than one rejection episode." (NCT00157014)
Timeframe: 52 Weeks

Intervention	Rejection Episodes (Number)
	Total Acute Rejection Episodes	Acute Rejection Episodes with ISHLT Grade ≥3A	Acute Rejection Episodes w/ Hemodynamic Compromise
Cyclosporine - Pediatric	3	3	0
Tacrolimus - Pediatric	3	3	0

Number of Acute Rejection Episodes by International Society of Heart and Lung Transplantation (ISHLT) Criteria

"Acute rejection was defined as a rejection with ISHLT Grade ≥3A or by the presence of hemodynamic compromise.~ISHLT Grades ≥3A include: Multifocal Moderate Rejection; Diffuse, Borderline Severe Acute Rejection; and Severe Acute Rejection.~Patients may report more than one acute rejection." (NCT00157014)
Timeframe: 52 Weeks

Intervention	Rejection Episodes (Number)
	Total Acute Rejection Episodes	Acute Rejection Episodes with ISHLT Grade ≥3A	Acute Rejection Episodes w/ Hemodynamic Compromise
Cyclosporine - Adult	8	7	2
Tacrolimus - Adult	8	3	6

Number of Patients With Successful Steroid Taper or Withdrawal at Weeks 26 and 52 (Pediatric Population)

A successful steroid taper or withdrawal was defined as steroids (prednisone) being discontinued or tapered to the suggested dose level after week 26. (NCT00157014)
Timeframe: 26 Weeks and 52 Weeks

Intervention	Patients (Number)
	Week 26	Week 52
Cyclosporine - Pediatric	3	1
Tacrolimus - Pediatric	2	1

Number of Patients With Successful Steroid Taper or Withdrawal at Weeks 26 and 52

A successful steroid taper or withdrawal was defined as steroids (prednisone) being discontinued or tapered to the suggested dose level after week 26. (NCT00157014)
Timeframe: 26 Weeks and 52 Weeks

Intervention	Patients (Number)
	Week 26	Week 52
Cyclosporine - Adult	16	29
Tacrolimus - Adult	22	33

Number of Patients With Treatment Failure and Crossover for Treatment Failure (Pediatric Population)

"Treatment failure was defined as death, re-transplantation, withdrawal due to an Adverse Event, or a switch of main immunosuppressant medication, whichever came first.~Crossover was defined as a switch from originally administered primary immunosuppressant (tacrolimus or cyclosporine) to the alternate primary immunosuppressant." (NCT00157014)
Timeframe: 52 Weeks

Intervention	Patients (Number)
	Treatment Failures	Crossover for Treatment Failures
Cyclosporine - Pediatric	3	3
Tacrolimus - Pediatric	1	0

Number of Patients With Treatment Failure and Crossover for Treatment Failure

Intervention	Patients (Number)
	Treatment Failures	Crossover for Treatment Failures
Cyclosporine - Adult	11	8
Tacrolimus - Adult	6	2

The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies (Pediatric Population)

"The markers assessed were p-ERK ½, p-JNK and p-p38 MAPK.~The data for each biopsy marker were expressed as a ratio of its densitometry / densitometry of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).~Change is defined as Week 52 assessment- Week 2 assessment." (NCT00157014)
Timeframe: 2 Weeks and 52 Weeks

Intervention	Densitometry / Densitometry of GAPDH (Mean)
	p-ERK ½ - Week 2	p-ERK ½ - Week 52	p-ERK ½ - Change from Week 2	p-JNK - Week 2	p-JNK - Week 52	p-JNK - Change from Week 2	p-p38 MAPK - Week 2	p-p38 MAPK - Week 52	p-p38 MAPK - Change from Week 2
Cyclosporine - Pediatric	1.67	1.22	-0.27	0.91	0.82	0.04	0.43	0.58	0.34
Tacrolimus - Pediatric	1.74	0.93	-0.09	1.17	0.57	-0.21	0.83	0.24	-0.04

The Change in the Markers of Growth, Apoptosis, Inflammation and Oxidation Measured in Endomyocardial Biopsies

"The markers assessed were p-ERK ½ (phosphorylated extracellular signal-regulated kinase), p-JNK (phosphorylated jun N-terminal kinase) and p-p38 MAPK (phosphorylated mitogen-activated protein kinase).~The data for each biopsy marker were expressed as a ratio of its densitometry / densitometry of glyceraldehyde-3-phosphate dehydrogenase (GAPDH).~Change is defined as Week 52 assessment- Week 2 assessment." (NCT00157014)
Timeframe: 2 Weeks and 52 Weeks

Intervention	Densitometry / Densitometry of GAPDH (Mean)
	p-ERK ½ - Week 2	p-ERK ½ - Week 52	p-ERK ½ - Change from Week 2	p-JNK - Week 2	p-JNK - Week 52	p-JNK - Change from Week 2	p-p38 MAPK - Week 2	p-p38 MAPK - Week 52	p-p38 MAPK - Change from Week 2
Cyclosporine - Adult	0.90	0.79	-0.05	1.23	1.46	0.22	0.54	0.77	0.23
Tacrolimus - Adult	0.70	0.87	0.05	1.10	1.33	0.03	0.48	0.63	0.14

Renal Function (Nankivell Formula) at Month 12 Post Transplantation.

Renal function at the end of the trial assessed as mean absolute values of the glomerular filtration rate (GFR) calculated by Nankivell formula 12 months after renal transplantation. The Nankivell formula: GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)^2 + C ; where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. Estimated GFR is expressed in mL/min per 1.73m^2. (NCT00154310)
Timeframe: at Month 12 post transplantation

Intervention	mL/min /1.73m^2 (Mean)
Everolimus + Mycophenolate Sodium	71.84
Cyclosporine + Mycophenolate Sodium	61.24

Changes in Cardiovascular Risk From Month 4.5 to Final Assessment at Month 12

An updated 1991 Framingham coronary prediction algorithm was used to estimate the total risk of developing coronary heart diseases (CHD) over the course of 10 years. Risk was calculated separately for male and females. To calculate risk, points were assigned for each of the following risk factors: age, levels of LDL cholesterol, HDL cholesterol, blood pressure, cigarette smoking, and diabetes mellitus. The sum of the individual risk factor points gives a total point score, which ranges from -5 to 18 for men and -16 to 24 for women. Higher points indicate a higher risk for CHD. (NCT00154310)
Timeframe: Month 4.5 and Month 12

Intervention	Points (Mean)
	Male (n= 55, 37)	Female (n= 22, 35)	Total Population (n= 77, 72)
Cyclosporine + Mycophenolate Sodium	0.1	0.8	0.4
Everolimus + Mycophenolate Sodium	0.5	0.0	0.4

Number of Participants Who Experienced an Adverse Event or Serious Adverse Event

Additional information about the number of participants who experienced Adverse Events (greater than 5%) or Serious Adverse Events can be found in the Adverse Event section. (NCT00154310)
Timeframe: Aes from end of core study period (month 12) to end of follow-up period (month 60)

Intervention	Participants (Number)
	Adverse Events	Serious Adverse Events
Cyclosporine + Mycophenolate Sodium	145	86
Everolimus + Mycophenolate Sodium	155	95

Number of Participants With Occurrence of Biopsy Proven Acute Rejection (BPAR), Graft Loss or Death

The number of participants with occurrence of biopsy proven acute rejection (BPAR), graft loss, or death up to Month 12 during the randomized treatment period. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III according to Banff 97 classification. A graft core biopsy was performed prior to 24 hours following initiation of graft rejection therapy. The allograft is presumed to be lost on the day the patient starts dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss. (NCT00154310)
Timeframe: Up to Month 12

Intervention	Participants (Number)
	BPAR: Yes	BPAR: No	Graft Loss: Yes	Graft Loss: No	Death: Yes	Death: No
Cyclosporine + Mycophenolate Sodium	5	141	0	146	1	145
Everolimus + Mycophenolate Sodium	15	139	0	154	0	154

Number of Participants With Occurrence of Treatment Failures

Treatment failures defined as a composite endpoint of biopsy proven acute rejection, graft loss, death, loss to follow up and discontinuations due to lack of efficacy or toxicity, or conversion to another regimen (at least one condition must be present). (NCT00154310)
Timeframe: up to or at Month 12

Intervention	Participants (Number)
	Treatment failure: Yes	Treatment failure: No
Cyclosporine + Mycophenolate Sodium	23	123
Everolimus + Mycophenolate Sodium	29	125

Percentage of Participants Who Survived With a Graft at 12 Months Post-Transplant

Participant and graft survival at 12 months was summarized within each treatment group. Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine ≥ 6.0 mg/dL (530 μmol/L) as determined by central laboratory for ≥4 weeks or 56 or more consecutive days of dialysis. (NCT00114777)
Timeframe: Month 12 post-transplant

Intervention	percentage of participants (Number)
Belatacept More Intensive (MI) Regimen	85.9
Belatacept Less Intensive (LI) Regimen	88.0
Cyclosporin A (CsA)	84.8

Percentage of Participants With Chronic Allograft Nephropathy (CAN) at Month 12

Biopsy-proven CAN was determined by a blinded central histopathologist using the Banff 97 working classification of kidney transplant pathology. Onset of CAN was determined by the biopsy date when it was observed. Participants were considered as having CAN at 12 months if: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; Participant had graft loss during the first year post transplant; no biopsy available post 12 months and CAN not observed in biopsies prior to 12 months; no biopsy available either prior to or post 12 months; and the measured glomerular filtration rate from Month 3 to Month 12 decreases at least 10 mL/min/1.73m^2. All other participants with missing 12 month biopsy were considered having no CAN observed at 12 months. (NCT00114777)
Timeframe: At Month 12

Intervention	percentage of participants (Number)
Belatacept More Intensive (MI) Regimen	44.8
Belatacept Less Intensive (LI) Regimen	46.0
Cyclosporin A (CsA)	51.6

Calculated Glomerular Filtration Rate (GFR) at 6, 12, 24, 36 and 84 Months

GFR was assessed using a true measure of glomerular filtration via nonradiolabeled iothalamate clearance test using a validated procedure. Missing measured GFR assessments were imputed. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Months 6, 12, 24, 36 and 84

Intervention	participants (Mean)
	Month 6 (n = 161,152,153)	Month 12 (n = 159,154,154)	Month 24 (n = 152,158,154)	Month 36 (n = 152,154,143)	Month 84 (n = 69,79,51)
Belatacept Less Intensive (LI) Regimen	43.4	44.8	42.8	42.2	59.1
Belatacept More Intensive (MI) Regimen	43.6	44.4	44.4	42.7	57.6
Cyclosporin A (CsA)	35.5	36.5	34.9	31.5	44.6

Change in Calculated GFR at Months 12, 24, 36 and 84

Intervention	mL/min/1.73 m^2 (Mean)
	Month 12 (n = 159,154,154)	Month 24 (n = 146,154,149)	Month 36 (n = 146,150,139)	Month 84 (n = 67,76,49)
Belatacept Less Intensive (LI) Regimen	-0.6	-1.6	-2.1	10.4
Belatacept More Intensive (MI) Regimen	-0.7	-1.4	-2.9	7.5
Cyclosporin A (CsA)	-1.1	-3.6	-6.1	-4.0

Change in Total Cholesterol (TC), Non-HDL, LDL and HDL Cholesterol and Triglycerides at 12, 24 and 36

Dyslipidemia was defined as triglyceride ≥ 500 mg/dL [5.65 mmol/L], low density lipoprotein (LDL) ≥ 100 mg/dL [2.59 mmol/L], and elevated non-high density lipoprotein (HDL) ≥ 130 mg/dL [3.36 mmol/L]. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Months 12, 24 and 36

Intervention	mg/dL (Mean)
	Non-HDL (Month 12) (n=184,175,184)	TC (Month 12) (n =184,175,184)	Triglyceride (Month 12) (n=184,175,184)	HDL (Month 12) (n=184,175,184)	LDL (Month 12) (n=184,175,184)	Non--HDL (Month 24) (n=119,128,111)	TC (Month 24) (n=119,128,111)	Triglyceride (Month 24) (n=98,104,93)	HDL (Month 24) (n=119,128,111)	LDL (Month 24) (n=97,104,93)	Non-HDL (Month 36) (n=111,117,97)	TC (Month 36) (n=111,117,98)	Triglyceride (Month 36) (n=80,88,78)	HDL (Month 36) (n=111,117,97)	LDL (Month 36) (n=79,88,77)
Belatacept Less Intensive (LI) Regimen	134.2	184.1	153.2	49.8	102.4	129.8	178.0	147.0	48.2	101.4	132.2	181.9	154.3	49.6	106.0
Belatacept More Intensive (MI) Regimen	134.5	183.7	171.9	49.2	104.0	126.1	175.6	152.0	49.5	96.9	132.6	181.0	160.7	48.9	103.1
Cyclosporin A (CsA)	153.4	201.3	213.8	47.9	107.8	148.7	195.7	208.2	47.0	108.6	139.1	196.7	181.3	47.0	102.3

Mean Changes in Mental Component and Physical Component Health-Related Quality of Life (SF-36) From Baseline to Months 12, 24 and 36

The SF-36 is a 36-item self-administered questionnaire developed to assess health-related quality of life (QOL) and comprises 8 domains, including 4 physical (physical health, bodily pain, physical functioning and physical role limitations) and 4 mental (mental health, vitality, social functioning, and emotional role limitation) subscales. Responses are used to derive physical and mental component summary scores, ranging from 0 to 100, with higher scores indicating better QOL (0=Poorest Health; 100=Best Health). Mean change from baseline = post-baseline value - baseline value; a higher value signifies improvement. (NCT00114777)
Timeframe: Baseline and Months 12, 24 and 36

Intervention	units on SF-36 scale (Mean)
	Physical functioning (Month 12)	Role-physical (Month 12)	Bodily pain (Month 12)	General health (Month 12)	Vitality (Month 12)	Social functioning (Month 12)	Role-emotional (Month 12)	Mental health (Month 12)	Physical functioning (Month 24)	Role-physical (Month 24)	Bodily pain (Month 24)	General health (Month 24)	Vitality (Month 24)	Social functioning (Month 24)	Role-emotional (Month 24)	Mental health (Month 24)	Physical functioning (Month 36)	Role-physical (Month 36)	Bodily pain (Month 36)	General health (Month 36)	Vitality (Month 36)	Social functioning (Month 36)	Role-emotional (Month 36)	Mental health (Month 36)
Belatacept Less Intensive (LI) Regimen	3.6	6.2	0.9	2.4	3.6	3.5	2.4	1.7	3.5	6.1	0.0	2.0	3.1	5.0	3.0	1.9	3.0	5.8	0.3	0.9	2.5	4.6	2.4	0.7
Belatacept More Intensive (MI) Regimen	2.1	5.2	2.9	2.9	4.1	4.2	2.0	2.7	1.5	5.3	2.0	2.6	3.9	3.2	2.5	3.0	1.3	5.7	1.6	2.1	4.1	2.9	2.2	3.6
Cyclosporin A (CsA)	1.9	4.7	-0.7	2.1	2.9	2.1	3.5	2.4	0.7	4.3	-1.9	0.6	1.4	2.1	2.9	1.4	0.7	4.1	-2.2	-0.5	1.4	1.4	2.5	0.9

Mean Framingham Risk Score From Baseline to Months 12, 24 and 36

The risk score was calculated based on the total points from six variables: Age, Level of LDL-cholesterol, Level of HDL-cholesterol, Presence and severity of systolic or diastolic hypertension, Presence or absence of a history of diabetes mellitus and Presence or absence of a history recent cigarette smoking. Total scores can range from <-3 to >14, which translate to a 1% to 56% risk of developing coronary heart disease in 10 years. Totals in the 4 to 6 point range translate to a 7 to 11% risk and 8 to 10 point range translate to a 18 to 27% risk. (NCT00114777)
Timeframe: Baseline and Months 12, 24 and 36

Intervention	units on a scale (Mean)
	Month 12	Month 24	Month 36
Belatacept Less Intensive (LI) Regimen	4.5	4.6	4.9
Belatacept More Intensive (MI) Regimen	5.3	5.0	5.2
Cyclosporin A (CsA)	6.0	6.2	5.8

Measured Glomerular Filtration Rate (GFR) by Month 12 and 24

GFR was assessed using a true measure of glomerular filtration via nonradiolabeled iothalamate clearance test using a validated procedure. Missing measured GFR assessments were imputed. Here, 'n' signifies the number of evaluable participants for the reporting arm at the given time point. Missing measured GFR assessments were imputed to a GFR of zero. (NCT00114777)
Timeframe: At Month 12 and Month 24

Intervention	mL/min/1.73 m^2 (Mean)
	Month 12 (n = 154,151,154)	Month 24 (n = 136,139,136)
Belatacept Less Intensive (LI) Regimen	49.5	49.7
Belatacept More Intensive (MI) Regimen	52.1	51.5
Cyclosporin A (CsA)	45.2	45.0

Number of Participants Based on Severity of Acute Rejection Based on Banff Grade Level by Months 6, 12, 24, 36 and 84

Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Clinically suspected acute rejection was defined as an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output or fever and graft tenderness or serum creatinine that remains elevated within 14 days post--transplantation and clinical suspicion of acute rejection exists. (NCT00114777)
Timeframe: Months 6, 12, 24, 36 and 84

Intervention	participants (Number)
	Mild acute (IA) (Month 6)	Mild acute (IB) (Month 6)	Moderate acute (IIA) (Month 6)	Moderate acute (IB) (Month 6)	Severe acute (III) (Month 6)	Mild acute (IA) (Month 12)	Mild acute (IB) (Month 12)	Moderate acute (IIA) (Month 12)	Moderate acute (IB) (Month 12)	Severe acute (III) (Month 12)	Mild acute (IA) (Month 24)	Mild acute (IB) (Month 24)	Moderate acute (IIA) (Month 24)	Moderate acute (IB) (Month 24)	Severe acute (III) (Month 24)	Mild acute (IA) (Month 36)	Mild acute (IB) (Month 36)	Moderate acute (IIA) (Month 36)	Moderate acute (IIB) (Month 36)	Severe acute (III) (Month 36)	Mild acute (IA) (Month 84)	Mild acute (IB) (Month 84)	Moderate acute (IIA) (Month 84)	Moderate acute (IIB) (Month 84)	Severe acute (III) (Month 84)
Belatacept Less Intensive (LI) Regimen	4	2	15	8	0	4	2	17	8	0	4	2	17	9	0	4	2	18	9	0	4	6	18	9	0
Belatacept More Intensive (MI) Regimen	0	6	11	15	0	0	6	11	15	0	0	6	10	16	0	0	6	10	16	1	0	6	12	16	1
Cyclosporin A (CsA)	2	2	16	5	0	2	2	17	5	0	2	3	18	5	0	2	4	18	5	0	2	4	18	5	0

Number of Participants Using Lymphocyte Depleting Therapy and Steroid-Resistant for Acute Rejection by Months 6, 12, 24, and 36.

Acute rejection was defined as central biopsy proven rejection that was either clinically suspected by protocol defined reasons or clinically suspected by other reasons and treated. Lymphocyte -depletion therapy for treatment of an episode of acute was defined as a participant treated with therapy and provided not treated with steroids earlier while steroid resistant acute rejection was defined as participants initially treated with steroids alone for suspected acute rejection for at least 2 days and then followed by the start of lymphocyte -depletion therapy. (NCT00114777)
Timeframe: Months 6, 12, 24 and 36

Intervention	participants (Number)
	Only corticosteroid treated (Month 6)	Corticosteroid resistant (Month 6)	Lymphocyte-depleting treated (Month 6)	Only corticosteroid treated (Month 12)	Corticosteroid resistant (Month 12)	Lymphocyte-depleting treated (Month 12)	Only corticosteroid treated (Month 24)	Corticosteroid resistant (Month 24)	Lymphocyte-depleting treated (Month 24)	Only corticosteroid treated (Month 36)	Corticosteroid resistant (Month 36)	Lymphocyte-depleting treated (Month 36)
Belatacept Less Intensive (LI) Regimen	16	2	5	16	2	5	19	1	7	19	1	7
Belatacept More Intensive (MI) Regimen	14	2	13	14	2	13	13	2	14	13	2	14
Cyclosporin A (CsA)	9	2	4	10	2	4	11	2	4	11	2	4

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 36

AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards. (NCT00114777)
Timeframe: Day 1 to Month 36

Intervention	participants (Number)
	AEs	SAEs	AEs leading to Discontinuation	SAEs leading to Discontinuation	Related AEs	Related SAEs	Deaths
Belatacept Less Intensive (LI) Regimen	174	139	36	31	106	51	15
Belatacept More Intensive (MI) Regimen	182	149	34	31	115	60	22
Cyclosporin A (CsA)	184	146	44	28	141	58	17

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Related AEs and SAEs, AEs Leading to Discontinuation and Who Died up to Month 84

Intervention	participants (Number)
	AEs	SAEs	AEs leading to Discontinuation	SAEs leading to Discontinuation	Deaths
Belatacept Less Intensive (LI) Regimen	113	104	14	104	21
Belatacept More Intensive (MI) Regimen	104	94	14	94	14
Cyclosporin A (CsA)	87	73	7	7	9

Number of Participants With Anti-Hypertensive Medications Used to Control Hypertension at 12, 24 and 36 Months

Participants were determined to have hypertension at a particular time point if standardized systolic blood pressure ≥ 130 mm Hg or standardized diastolic blood pressure ≥ 80 mm Hg or participant had received an antihypertensive medication(s) for hypertension. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Baseline and Months 12, 24 and 36

Intervention	participants (Number)
	1-2 Medications at Month 12 (n=184,175,184)	≥ 3 Medications at Month 12 (n=184,175,184)	1-2 Medications at Month 24 (n=177,170,179)	≥ 3 Medications at Month 24 (n=177,170,179)	1-2 Medications at Month 36 (n=151,145,143)	≥ 3 Medications at Month 36 (n=151,145,143)
Belatacept Less Intensive (LI) Regimen	79	66	79	65	67	60
Belatacept More Intensive (MI) Regimen	82	76	80	78	65	70
Cyclosporin A (CsA)	76	93	71	89	51	79

Number of Participants With Clinically Significant Changes in Vital Signs up to 36 Months

Participants with abnormal blood pressure, body weight and body temperature outside the defined normal range were graded as clinically significant vital signs by the investigator. (NCT00114777)
Timeframe: Day 1 to Month 36

Intervention	participants (Number)
	Heart Rate	Body Temperature	Body Weight
Belatacept Less Intensive (LI) Regimen	0	0	0
Belatacept More Intensive (MI) Regimen	0	0	0
Cyclosporin A (CsA)	0	0	0

Number of Participants With Laboratory Test Abnormalities up to 36 Months

Participants with laboratory values outside the defined normal range were graded as clinically significant laboratory abnormalities by the investigator. Subjects were analyzed for Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase(AST), Hemoglobin, Platelet Count, Leukocytes, Bilirubin, Creatinine, Calcium, Bicarbonate, Potassium, Magnesium, Sodium, Phosphorus, Albumin, Uric Acid and Protein. Laboratory abnormalities were assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. Here 'n' signifies those subjects evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Day 1 to Month 36

Intervention	participants (Number)
	Hemoglobin (Low) (n=177,172,181)	Platelet Count (Low) (n=177,172,181)	Leukocytes (Low) (n=177,172,181)	ALP (High) (n=177,172,182)	ALT (High) (n=177,172,181)	AST (High) (n=177,172,181)	Bilirubin, Total (High) (n=177,172,182)	Creatinine (High) (n=177,172,182)	Calcium, Total (Low) (n=177,172,182)	Calcium, Total (High) (n=177,172,182)	Bicarbonate (Low) (n=176,171,181)	Bicarbonate (High) (n=176,171,181)	Potassium, Serum (Low)(n=177,172,181)	Potassium, Serum (High)(n=177,172,181)	Magnesium, Serum (Low)(n=177,172,181)	Magnesium, Serum (High)(n=177,172,181)	Sodium, Serum (Low)(n=177,172,181)	Sodium, Serum (High)(n=177,172,181)	Phosphorus (Low) (n=177,172,182)	Albumin (Low) (n=177,172,182)	Uric Acid (High) (n=177,172,182)	Protein, Urine (High) (n=173,168,177)
Belatacept Less Intensive (LI) Regimen	24	1	5	1	2	1	2	117	14	2	1	0	3	6	3	4	16	0	58	4	34	37
Belatacept More Intensive (MI) Regimen	25	2	10	1	4	1	0	125	19	2	2	0	6	8	6	6	18	0	66	2	31	44
Cyclosporin A (CsA)	16	2	8	0	4	0	1	128	10	1	2	0	9	11	1	9	23	1	44	1	60	43

Percentage of Participants Using Lipid-Lowering Therapy at 12, 24, and 36 Months

Dyslipidemia was defined as triglyceride ≥ 500 mg/dL [5.65 mmol/L], low density lipoprotein (LDL) ≥ 100 mg/dL [2.59 mmol/L], and non-elevated high density lipoprotein (HDL) ≥ 130 mg/dL [3.36 mmol/L]. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Months 12, 24 and 36

Intervention	percentage of participants (Number)
	Month 12 (n=184.175,184)	Month 24 (n=184,175,184)	Month 36 (n=151,145,143)
Belatacept Less Intensive (LI) Regimen	40.0	42.3	45.5
Belatacept More Intensive (MI) Regimen	43.5	47.8	52.3
Cyclosporin A (CsA)	46.2	51.1	60.8

Percentage of Participants Who Have an Acute Rejection by Months 6, 12, 24, 36 and 84

Intervention	percentage of participants (Number)
	Month 6	Month 12	Month 24	Month 36	Month 84
Belatacept Less Intensive (LI) Regimen	16.6	17.7	18.3	18.9	19.4
Belatacept More Intensive (MI) Regimen	17.4	17.4	17.4	17.9	19.0
Cyclosporin A (CsA)	13.6	14.1	15.2	15.8	15.8

Percentage of Participants Who Survived With a Graft at 24 and 36 Months Post-Transplant

Participant and graft survival at 12 months was summarized within each treatment group. Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss will be defined as a sustained level of serum creatinine ≥ 6.0 mg/dL (530 μmol/L) as determined by central laboratory for ≥ 4 weeks or 56 or more consecutive days of dialysis. (NCT00114777)
Timeframe: Month 24 and Month 36 post-transplant

Intervention	percentage of participants (Number)
	Month 24	Month 36
Belatacept Less Intensive (LI) Regimen	84.0	82.3
Belatacept More Intensive (MI) Regimen	82.6	80.4
Cyclosporin A (CsA)	82.6	79.9

Percentage of Participants With a Measured Glomerular Filtration Rate (GFR) <60 mL/Min Per 1.73 m^2 at Month 12 or a Decrease in Measured GFR >=10 mL/Min Per 1.73 m^2 From Month 3 to Month 12

GFR was assessed using a true measure of glomerular filtration via non-radiolabeled iothalamate clearance test using a validated procedure. (NCT00114777)
Timeframe: From Month 3 to Month 12

Intervention	percentage of participants (Number)
	Measured GFR <60 mL/min/1.73 m^2 (Month 12)	GFR ≥ 10 mL/min/1.73 m^2 (Month 3 to Month 12)
Belatacept Less Intensive (LI) Regimen	62.1	27.2
Belatacept More Intensive (MI) Regimen	55.7	17.6
Cyclosporin A (CsA)	67.4	24.7

Percentage of Participants With Graft Loss or Death to Month 84

Participant and graft survival at 84 months was summarized within each treatment group. (NCT00114777)
Timeframe: Randomization to date of death, up to 84 months

Intervention	percentage of participants (Number)
	Graft Loss or Death	Graft Loss	Death	Death with Functioning Graft
Belatacept Less Intensive (LI) Regimen	30.9	13.1	21.1	17.7
Belatacept More Intensive (MI) Regimen	29.3	11.4	20.1	17.9
Cyclosporin A (CsA)	28.3	15.8	15.8	12.5

Percentage of Participants With New Onset Diabetes Mellitus (NODM) at 12, 24 and 36 Months.

NODM was defined as participant who did not have diabetes prior to randomization. Participants were determined for NODM if the participant received an antidiabetic medication for a duration of at least 30 days, or at least two fasting plasma glucose (FPG) tests indicate that FPG is ≥ 126 mg/dL (7.0 mmol/L). (NCT00114777)
Timeframe: Months 12, 24 and 36

Intervention	percentage of participants (Number)
	12 Month	24 Month	36 Month
Belatacept Less Intensive (LI) Regimen	5.1	7.4	9.6
Belatacept More Intensive (MI) Regimen	2.3	3.0	5.3
Cyclosporin A (CsA)	9.3	9.3	9.3

Percentage of Subjects Who Used Anti-Hypertensive Medications to Control Hypertension at Months 12, 24 and 36

Participants were determined to have hypertension at a particular time point if standardized systolic blood pressure ≥ 130 mm Hg or standardized diastolic blood pressure ≥ 80 mm Hg or subject had received an anti-hypertensive medication(s) for hypertension. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Months 12, 24 and 36

Intervention	percentage of participants (Number)
	Month 12 (n = 184,175,184)	Month 24 (n = 177,170,179)	Month 36 (n = 151,145,143)
Belatacept Less Intensive (LI) Regimen	83.4	84.7	87.6
Belatacept More Intensive (MI) Regimen	87	89.3	89.4
Cyclosporin A (CsA)	87.0	89.4	90.9

Systolic and Diastolic Blood Pressure (BP) at 12, 24 and 36 Months

Participants were determined to have hypertension at a particular time point if standardized systolic blood pressure ≥ 130 mm Hg or standardized diastolic blood pressure ≥ 80 mm Hg or participant had received an anti-hypertensive medication(s) for hypertension. Here 'n' signifies those participants evaluable for this measure at specified time points for each arm, respectively. (NCT00114777)
Timeframe: Months 12, 24 and 36

Intervention	mmHg (Mean)
	Diastolic BP (Month 12) (n= 184,175,184)	Systolic BP (Month 12) (n= 184,175,184)	Diastolic BP (Month 24) (n= 120,129,120)	Systolic BP (Month 24) (n= 120,129,120)	Diastolic BP (Month 36) (n= 112,119,108)	Systolic BP (Month 36) (n= 112,119,108)
Belatacept Less Intensive (LI) Regimen	78.3	140.9	77.0	136.7	75.2	134.7
Belatacept More Intensive (MI) Regimen	77.8	141.4	78.2	138.82	75.4	134.9
Cyclosporin A (CsA)	81.8	149.5	81.7	146.8	77.2	140.7

Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)

BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died. (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	Participants (Number)
Cyclosporin A	45
Tacrolimus	42

Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) ≥ 2

The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) ≥2 was calculated. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died. Assessment of hepatic fibrosis was performed with liver biopsies read centrally. Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis. Higher score indicates greater fibrosis. (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	Participants (Number)
Cyclosporin A	77
Tacrolimus	71

Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis

Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver. (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	Participants (Number)
Cyclosporin A	16
Tacrolimus	17

Number of Participants With Fibrosing Cholestatic Hepatitis

Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well. The presence of FCH was reported based on the diagnosis given by the investigator. (NCT00260208)
Timeframe: 1 year post-transplantation

Intervention	Participants (Number)
Cyclosporin A	9
Tacrolimus	6

Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant (Intent to Treat Population)

Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	Participants (Number)
Cyclosporin A	63
Tacrolimus	54

Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) ≥ 2] Within 1 Year Post-transplant

Intervention	Participants (Number)
Cyclosporin A	63
Tacrolimus	52

Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant

HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed. (NCT00260208)
Timeframe: Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant

Intervention	IU/µL (Mean)
	Day 1 (n=116, 111)	Day 3 (n= 136, 120)	Day 8 (n= 122, 117)	Day 29 (n=128, 109)	Month 6 (n=96, 98)	Month 12 (n= 85, 88)
Cyclosporin A	0.71	0.98	1.58	2.56	3.45	3.17
Tacrolimus	0.62	0.91	1.45	2.74	3.14	3.13

Mean Value of Liver Function Tests at 1 Year Post-transplantation

"The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant:~Serum glutamic pyruvic transaminase (SGPT)~Serum Glutamic Oxaloacetic Transaminase (SGOT)~Bilirubin~Alkaline Phosphate~γ-Glutamyltransferase (GGT)" (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	IU/L (Mean)
	SGPT (n= 112, 112)	SGOT (n= 112,112)	Bilirubin (n= 111, 115)	Alkaline Phosphate (n= 111, 115)	GGT (n= 103, 110)
Cyclosporin A	100.5	92.0	40.3	174.7	182.2
Tacrolimus	81.7	72.8	19.3	152.9	168.5

Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation

Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died. (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	Participants (Number)
	Death	Graft loss	Death or Graft loss	Graft loss with re-transplantation
Cyclosporin A	15	8	19	3
Tacrolimus	15	13	23	8

Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection

Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy. BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection. (NCT00260208)
Timeframe: 1 year post-transplant

Intervention	Participants (Number)
	Treated acute rejection	Biopsy prove acute rejection (BPAR)	Sub-clinical rejection
Cyclosporin A	28	28	4
Tacrolimus	22	19	4

Median Cycles of Induction Chemotherapy With Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, and Prednisone Given to Recipients

Median cycles of induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone given to recipients. (NCT00051311)
Timeframe: Up to cycle 3

Intervention	Cycles (Median)
Recipient	2

Median Time to Neutrophil Recovery

Neutrophil recovery is defined as a neutrophil count ≥5000 µl for three consecutive days. (NCT00051311)
Timeframe: Up to 2 months after stem cell transplant

Intervention	Days (Median)
Recipient	14

Median Time to Platelet Recovery

Platelet recovery is defined as >50,000 mm3 platelet cell count after transfusion. (NCT00051311)
Timeframe: Up to 2 months after stem cell transplant

Intervention	Days (Median)
Recipient	13

Number of Recipients Evaluable Who Achieved Full Donor Chimerism at Day+100

Recipients who achieved engraftment with donor chimerism. Engraftment is defined as a target peripheral blood cluster of differentiation 4 (CD4) count of 100 cells/ul after induction therapy. (NCT00051311)
Timeframe: Day+100

Intervention	Participants (Count of Participants)
Recipient	29

Number of Recipients Who Developed Chronic Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis

Here is the number of recipients who developed chronic graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV chronic GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV chronic GVHD can occur in the skin, liver, and/or gut. Grade 1: rash < 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea >1500 ml/d. Grade 4: desquamation and bullae, total bilirubin >15 mg/dl, and pain +/- ileus. (NCT00051311)
Timeframe: At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)

Intervention	Participants (Count of Participants)
Recipient	23

Number of Recipients With Non-serious Adverse Events

Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence. (NCT00051311)
Timeframe: Date treatment consent signed to date off study, approximately 58 months and 13 days.

Intervention	Participants (Count of Participants)
Recipient	31

Percentage of Recipients Who Achieved Donor Chimerism at Day +14

Intervention	percentage of recipients (Number)
Recipient	90

Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for Graft Versus Host Disease (GVHD) Prophylaxis

Here is the number of recipients who developed grades I-IV acute graft versus host disease (GVHD) following a combination of cyclosporine and a mini-dose methotrexate regimen for graft-versus-host disease (GVHD) prophylaxis. Grades I-IV acute GVHD clinical staging was assessed by the Glucksberg Criteria. Grade I-IV acute GVHD can occur in the skin, liver, and/or gut. Grade 1: rash < 25% body surface area (BSA), total bilirubin 2-3 mg/dl, and diarrhea 500-1000 ml/d. Grade 2: 25-50% BSA, total bilirubin 3-6 mg/dl, and diarrhea 1000-1500 ml/d. Grade 3: generalized erythroderma, total bilirubin 6-15 mg/dl, and diarrhea >1500 ml/d. Grade 4: desquamation and bullae, total bilirubin >15 mg/dl, and pain +/- ileus. (NCT00051311)
Timeframe: At least 100 days of follow-up post reduced-intensity stem cell transplantation (RIST)

Intervention	Participants (Count of Participants)
	Grade I GVHD	Grade II GVHD	Grade III GVHD	Grade IV GVHD
Recipient	1	7	6	0

Number of Recipients With a Response to Reduced-intensity Stem Cell Transplantation (RIST)

Complete remission (CR) is complete disappearance of all detectable signs and symptoms of lymphoma for a period of at least one month. Complete remission unconfirmed (CRu) is a residual lymph node mass > 1.5 cm in greatest transverse diameter will be considered CRu if it has regressed by more than 75% in the SPD, does not change over at least one month, is negative by PET or gallium, and is negative on any biopsies obtained (biopsy not required). Progressive disease (PD) is a 25% or greater increase in SPD of all measured lesions compared to the smallest previous measurements, or appearance of any new lesion(s). (NCT00051311)
Timeframe: At least 100 days after post reduced-intensity stem cell transplantation (RIST).

Intervention	Participants (Count of Participants)
	Complete Remission or Complete Remission Unconfirmed	Progressive Disease
Recipient	15	16

Cluster of Differentiation 4 (CD4) Reconstitution

The median CD4 count with a range of 85-1565 (absolute count) was used to determine recovery and were considered recovered if in this range. The CD4 count was established by flow cytometry testing. (NCT00043979)
Timeframe: Day +28-42

Intervention	mm(3) (Median)
Arm 2-Recipients	284

Early Post Transplantation Relapse

Participants who experienced recurrence or progression of disease following transplant. (NCT00043979)
Timeframe: up to 300 days

Intervention	Days (Median)
Arm 2-Recipients	100

Median Progression Free Survival

Progression free survival was based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months

Intervention	Months (Median)
Arm 2-Recipients	15.9

Median Time to Reach a Platelet Count of 50,000/mm(3)

Days for participants to achieve a platelet count of 50,000/mm(3). (NCT00043979)
Timeframe: up to 43 days

Intervention	Days (Median)
Arm 2-Recipients	15

Median Time to Reach Absolute Neutrophil Count of 500/mm(3)

Days for participants to achieve a neutrophil count of 500/mm(3). (NCT00043979)
Timeframe: up to 12 days

Intervention	Days (Median)
Arm 2-Recipients	9

Number of Participants Who Experienced Graft Versus Tumor Effect (GVT)

GVT is defined as tumor response after day 42 post-transplantation without cytotoxic therapy. (NCT00043979)
Timeframe: up to day 100

Intervention	Participants (Count of Participants)
Arm 2-Recipients	0

Number of Participants With Engraftment

Engraftment is defined as rapid conversion to complete donor chimerism and is assessed by blood counts and chimerism, >95% donor engraftment at day 100 in >75% of patients. (NCT00043979)
Timeframe: 100 days

Intervention	Participants (Number)
Arm 2-Recipients	23

Toxicity

Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00043979)
Timeframe: 16.5 months

Intervention	Participants (Number)
Arm 2-Recipients	30

Best Response Post-Hematopoietic Stem Cell Transplant EOCH (Etoposide, Vincristine, Cyclophosphamide, and Doxorubicin)

Response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST). RECIST criteria offer a simplified, conservative, extraction of imaging data for wide application in clinical trials. They presume that linear measures are an adequate substitute for 2-D (dimensional) methods and registers four response categories: Complete response (CR) is disappearance of all target lesions. Partial response (PR) is 30% increase in the sum of the longest diameter of target lesions. Progressive disease (PD) is 20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) is small changes that do not meet above criteria. For the purposes of this study very good partial response ((VGPR) is >75% reduction in disease) was also employed. (NCT00043979)
Timeframe: up to 10 cycles of therapy or 280 days

Intervention	Participants (Count of Participants)
	Complete Response (CR)	Progressive Disease (PD)	Partial Response (PR)	Very Good Partial Response (VGPR)
Arm 2-Recipients	2	4	4	2

Median Survival From Date of Progression

Median survival from date of progression is based on the time from on-study date until progression or last follow-up. (NCT00043979)
Timeframe: up to 77 months

Intervention	Months (Median)
	Participants who did not receive a transplant(n=7)	Participants who received a transplant (n=23)
Arm 2-Recipients	3.3	19.1

Number of Participants to Complete Conversion to >95% Donor Chimerism

Participants who tolerated the transplantation regimen and accepted >95% of the donors blood, marrow, and/or tissue. (NCT00043979)
Timeframe: up to 30 days

Intervention	Participants (Count of Participants)
	Day +14	Day +28
Arm 2-Recipients	23	23

Number of Participants With Acute and Chronic GVHD

Acute GVHD as by Modified Glucksberg Criteria occurring before day 100. Chronic GVHD as per Seattle criteria occurring after day 100. (NCT00043979)
Timeframe: up to 5 years or death

Intervention	participants (Number)
	acute GVHD	chronic GVHD
Recipients -Cyclosporine GVHD Prophylaxis	12	12
Recipients -Tacrolimus/Sirolimus GVHD Prophylaxis	5	5

Post-Hematopoietic Stem Cell Transplant (HSCT) Radiotherapy

Site of radiotherapy (high energy radiation) and/or toxicity experienced by the participants post HSCT radiotherapy. Grading was preformed using the Modified Glucksberg Criteria. (NCT00043979)
Timeframe: up to 6 cycles or 168 days

Intervention	Participants (Count of Participants)
	Chest wall; G2 skin	Abdomen; G4 GI	Pancreas; G4 LFTs, G4 pancreatitis	Pleura, mediastinum; G4 LFTs, G2 mucositis	Chest wall; G4 skin, G3 mucositis	Spine, skull; G2 nausea+vomiting, G2 fatigue	Pelvis; G4 enteritis	Pulmonary (cyberknife)	Brain; B3 mucositis	Whole lung; G3 mucositis, G3 skin, G5 lung	L arm, R shoulder, B/L femur
Arm 2-Recipients	1	1	1	1	1	1	1	1	1	1	1

Two Year Survival Rate for Patients Undergoing Allo-Hematopoietic Stem Cell Transplant

Participants who are alive at two years following Allo-Hematopoietic Stem Cell Transplant. (NCT00043979)
Timeframe: 2 years

Intervention	percentage of participants (Number)
	From date of enrollment	From date of transplantation
Arm 2-Recipients	39.1	34.8

Frequency of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1 Month Post Allografting

(NCT00074269)
Timeframe: 1 month post allografting

Intervention	Participants (Count of Participants)
Treatment	5

Number of Participants With Acute and Chronic Graft-versus-host Disease (GVHD)

(NCT00074269)
Timeframe: 100 days post transplant

Intervention	Participants (Count of Participants)
Treatment	3

Number of Participants With Adverse Events

(NCT00074269)
Timeframe: 5 years post transplant

Intervention	Participants (Count of Participants)
Treatment	5

Number of Participants With Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes

Long-term Engraftment of Allogeneic Stem Cells and Lymphocytes based on cell counts of ANC >1000 for 3 consecutive days and platelet count of >50,000 (NCT00074269)
Timeframe: 30 days post transplant

Intervention	Participants (Count of Participants)
Treatment	5

Overall Survival

(NCT00074269)
Timeframe: 1 year from the time of transplant

Intervention	days (Median)
Treatment	279.4

Progression-free Survival

Progression assessed by CT scan (NCT00074269)
Timeframe: From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

Intervention	days (Median)
Treatment	110

Response as Measured at 12 Months Post Allografting

response (partial and complete) assessed by CT scan at 12 months post allografting (NCT00074269)
Timeframe: From date of transplant until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months

Intervention	Participants (Count of Participants)
Treatment	3

Number of Participants With an Episode of Clinically-suspected and Biopsy-proven Acute Rejection (CSPAR)

No participant was to receive treatment for acute rejection without a biopsy to confirm the diagnosis. CSPAR=Clinically-suspected rejection, defined as an increase in serum creatinine ≥0.5 mg/dL compared with the baseline value in the absence of other factors known to adversely affect renal function, and biopsy-proven rejection, which includes all cases in which a biopsy was read by the central pathologist as demonstrating acute rejection regardless of the reason why the biopsy was performed. (NCT00035555)
Timeframe: By Month 6 posttransplant (From Day 1 to Month 6)

Intervention	Participants (Number)
Belatacept: More Intensive (MI) Regimen	5
Belatacept: Less Intensive (LI) Regimen	4
Cyclosporine Regimen	6

Mean Iohexol Clearance

Iohexol, a true glomerular filtration marker, is used to measure glomerular filtration rate. (NCT00035555)
Timeframe: By Months 1, 6, and 12 posttransplant (Day 1 to Months 1, 6, and 12)

Intervention	mL/min per 1.73 m^2 (Mean)
	Month 1 (n=53, 51, 48)	Month 6 (n=41, 41, 31)	Month 12 (n=32, 37, 27)
Belatacept: Less Intensive (LI) Regimen	60.2	64.5	62.1
Belatacept: More Intensive (MI) Regimen	59.7	62.2	66.3
Cyclosporine Regimen	54.0	56.0	53.5

Mean LDL Cholesterol, HDL Cholesterol, Total Cholesterol, Triglyceride, and Non-HDL Levels

LDL=low-density lipoprotein; HDL=high-density lipoprotein. Total cholesterol=LDL + HDL + very low-density (VLDL) cholesterol. VLDL=triglycerides divided by 5. Non-HDL cholesterol=Total cholesterol minus HDL cholesterol. (NCT00035555)
Timeframe: By Months 1, 6, and 12 posttransplant (Day 1 to Months 1, 6, and 12)

Intervention	mg/dL (Mean)
	LDL cholesterol: Month 1 (n=69, 69, 66)	LDL cholesterol: Month 6 (n=63, 66, 55)	LDL cholesterol: Month 12 (n=61, 60, 52)	HDL cholesterol: Month 1 (n=68, 68, 64)	HDL cholesterol: Month 6 (n=62, 65, 62)	HDL cholesterol: Month 12 (n=60, 57, 48)	Total cholesterol: Month 1 (n=69, 69, 65)	Total cholesterol: Month 6 (n=63, 65, 54)	Total cholesterol: Month 12 (n=60, 58, 50)	Triglycerides: Month 1 (n=69, 69, 65)	Triglycerides: Month 6 (n=63, 65, 54)	Triglycerides: Month 12 (n=60, 58, 50)	Non-HDL: Month 1 (n=68, 68, 64)	Non-HDL cholesterol: Month 6 (n=62, 64, 51)	Non-HDL cholesterol: Month 12 (n=59, 56, 48)
Belatacept: Less Intensive (LI) Regimen	120	121	125	68	56	56	210	202	201	147	168	152	142	143	144
Belatacept: More Intensive (MI) Regimen	129	125	120	64	54	53	222	204	198	168	177	176	159	150	145
Cyclosporine Regimen	137	131	125	70	62	59	239	224	212	185	198	186	169	165	151

Number of Participants Meeting Marked Abnormality Criteria for Select Hemolytic, Blood Chemistry, and Urinalysis Laboratory Test Results

Normal laboratory values: Hemoglobin (g/dL): Males (18-64 years) 13.8-17, (65 years and older) 11.8-16.8; Females (18-64 years) 12.0-15.6, F (65 years and older) 11.1-15.5. Platelets (per mm^3) 130,000-400,000. Leukocytes (18 years and older) 3.8-10.8 1000/uL. ALT (u/L)(13 years and older) 0-48. (NCT00035555)
Timeframe: Days 8 and Months 1, 3, 6, 9, and 12 posttransplant (from Day 1)

Intervention	Participants (Number)
	Hemoglobin, low	Hemoglobin, high	Platelet count, low	Platelet count, high	Leukocytes, low	Leukocytes, high	Alanine aminotransferase (ALT), low	ALT, high
Belatacept: More Intensive (MI) Regimen	13	NA	1	NA	1	NA	NA	9
Belatacept:Less Intensive (LI) Regimen	7	NA	0	NA	4	NA	NA	3
Cyclosporine Regimen	9	NA	3	NA	5	NA	NA	7

Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Treatment-related SAEs, Discontinuations Due to SAEs, Adverse Events (AEs), Treatment-related AEs, and Discontinuations Due to AEs

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. (NCT00035555)
Timeframe: Day 1 (posttransplant) continuously to 56 days following last dose of study medication

Intervention	Participants (Number)
	Deaths	SAEs	Treatment-related SAEs	Discontinuations due to SAEs	AEs	Treatment-related AEs	Discontinuations due to AEs
Belatacept: Less Intensive (LI) Regimen	0	52	23	14	69	40	15
Belatacept: More Intensive (MI) Regimen	0	50	21	13	73	43	13
Cyclosporine Regimen	2	42	21	10	68	50	14

Number of Participants With Hypertension

Hypertension is defined as diastolic blood pressure ≥90 mm Hg and/or systolic blood pressure ≥140 mm Hg or, the use of any antihypertensive medication. (NCT00035555)
Timeframe: By Months 6 and 12 posttransplant (Day 1 to Months 6 and 12)

Intervention	Participants (Number)
	At Month 6	At Month 12
Belatacept: Less Intensive (LI) Regimen	15	12
Belatacept: More Intensive (MI) Regimen	16	14
Cyclosporine Regimen	18	11

Number of Participants With Posttransplant Diabetes Mellitus

Posttransplant diabetes mellitus is defined as the need for treatment of hyperglycemia with either an oral agent or insulin for a total of >4 weeks or hemoglobin A1c (HbA1c) >7% in a participant not known to be diabetic prior to transplantation (NCT00035555)
Timeframe: By Months 1, 3, 6, 9, and 12 posttransplant (Day 1 to Months 1, 3, 6, 9, and 12 )

Intervention	Participants (Number)
	Up to Month 1: All events	Month 1: Hyperglycemia medication	Month 1: HbA1c >7%	Up to Month 3: All events	Up to Month 3: Hypoglycemic medication	Up to Month 3: HbA1c >7%	Up to Month 6: All events	Up to Month 6: Hyperglycemia medication	Up to Month 6: HbA1c >7%	Up to Month 9: All events	Up to Month 9: Hyperglycemia medication	Up to Month 9: HbA1c >7%	Up to Month 12: All events	Up to Month 12: Hyperglycemia medication	Up to Month 12: HbA1c >7%
Belatacept: Less Intensive (LI) Regimen	0	0	0	1	0	1	3	0	3	3	0	3	4	0	4
Belatacept: More Intensive (MI) Regimen	5	0	5	5	0	5	6	0	6	8	2	7	8	2	7
Cyclosporine Regimen	1	1	0	3	2	1	4	2	2	5	2	3	7	3	4

Percentage of Participants Who Had Chronic Allograft Nephropathy

Based on postbaseline biopsies (NCT00035555)
Timeframe: By Months 6 and 12 posttransplant (Day 1 to Months 6 and 12)

Intervention	Percentage of participants (Number)
	Month 6 (n= 32, 33, 27)	Month 12 (n=52, 54, 45)
Belatacept: Less Intensive (LI) Regimen	9.1	20.4
Belatacept: More Intensive (MI) Regimen	18.8	28.8
Cyclosporine Regimen	33.3	44.4

Percentage of Participants Who Used Antihypertensive Medication

Hypertension is defined as diastolic blood pressure ≥90 mm Hg and/or systolic blood pressure ≥140 mm Hg (NCT00035555)
Timeframe: By Months 6 and 12 posttransplant (Day 1 to Months 6 and 12)

Intervention	Percentage of participants (Number)
	Month 6: Total requiring at least 1 medication	Month 6: Requiring 1 medication	Month 6: Requiring 2 medications	Month 6: Requiring 3 medications	Month 6: Requiring 4 medications	Month 6: Requiring 5 medications	Month 6: Requiring 6 medications	Month 6: Requiring >6 medications	Month 12: Total requiring at least 1 medication	Month 12: Requiring 1 medication	Month 12: Requiring 2 medications	Month 12: Requiring 3 medications	Month 12: Requiring 4 medications	Month 12: Requiring 5 medications	Month 12: Requiring 6 medications	Month 12: Requiring >6 medications
Belatacept: Less Intensive (LI) Regimen	78.6	27.1	28.6	14.3	7.1	1.4	0.0	0.0	71.6	26.9	9.0	9.0	7.5	0.0	0.0	0.0
Belatacept: More Intensive (MI) Regimen	87.7	24.7	23.3	23.3	11.0	2.7	2.7	0.0	79.7	21.7	23.2	23.2	8.7	5.8	1.4	0.0
Cyclosporine Regimen	88.4	21.7	31.9	21.7	11.6	1.4	0.0	0.0	86.4	20.3	22.0	22.0	15.3	3.4	0.0	0.0

Percentage of Participants With Acute Rejection or Presumed Acute Rejection (PAR)

Throughout this study, acute rejection=clinically-suspected and biopsy-proven acute rejection (BPAR). Clinically-suspected rejection is defined as an increase in serum creatinine ≥0.5 mg/dL compared with the baseline value in the absence of other factors known to adversely affect renal function. BPAR includes all cases in which a biopsy was read by the central pathologist as demonstrating acute rejection regardless of the reason why the biopsy was performed. PAR is defined as an elevation in SCr ≥0.5 mg/dL compared with the baseline value in the absence of other factors known to adversely affect renal function that led the investigator to suspect that the participant had experienced acute rejection, and in whom either the biopsy did not confirm acute rejection and the participant received treatment for acute rejection or the participant received treatment for acute rejection without a biopsy to confirm the diagnosis. (NCT00035555)
Timeframe: By Months 6 and 12 posttransplant (Day 1 to Months 6 and 12)

Intervention	Percentage of participants (Number)
	Month 6: Acute rejection or PAR	Month 12: Acute rejection or PAR	Month 6: PAR	Month 12: PAR
Belatacept: Less Intensive (LI) Regimen	9	10	3	4
Belatacept: More Intensive (MI) Regimen	11	11	5	5
Cyclosporine Regimen	10	11	1	3

Percentage of Participants With Biopsy-proven Acute Rejection (BPAR) or Who Received Treatment for Acute Rejection

BPAR includes all cases in which a biopsy read by the central pathologist demonstrates acute rejection, regardless of the reason that the biopsy was performed. A participant was reported as having had an episode of treated acute rejection if he or she received antirejection therapy during an episode of rejection (clinically-suspected or biopsy-proven rejection). (NCT00035555)
Timeframe: By Months 3, 6, and 12 posttransplant (Day 1 to Months 3, 6, and 12)

Intervention	Percentage of participants (Number)
	By Month 3	By Month 6	By Month 12
Belatacept: Less Intensive (LI) Regimen	29.6	32.4	38.0
Belatacept: More Intensive (MI) Regimen	21.6	23.0	28.4
Cyclosporine Regimen	17.8	24.7	27.4

Percentage of Participants With Biopsy-proven Acute Rejection (BPAR) Through Months 6 and 12

BPAR includes all cases in which a biopsy read by the central pathologist demonstrates acute rejection, regardless of the reason that the biopsy was performed. (NCT00035555)
Timeframe: Through Months 6 and 12 posttransplant (From Day 1 to Months 6 and 12)

Intervention	Percentage of participants (Number)
	Up to 6 months	Up to 12 months
Belatacept: Less Intensive (LI) Regimen	23.9	29.6
Belatacept: More Intensive (MI) Regimen	14.9	18.9
Cyclosporine Regimen	17.8	17.8

Incidence of Acute and Chronic Graft-versus-host Disease

Incidence of acute and chronic graft-versus-host disease. Acute GVHD usually occurs during the first three months following transplant. Chronic GVHD usually develops after the third month post-transplant. (NCT00571662)
Timeframe: twice weekly until day 100 up to 1 year post transplant

Intervention	Percent of Particpants (Number)
	Acute GVHD	Chronic GVHD
Cohort I	31	33

Kinetics of Immunologic Reconstitution

Rate of return of immune cells after allogeneic transplantation (NCT00571662)
Timeframe: at day 100 post transplantation

Intervention	percentage of cells in peripheral blood (Median)
	CD3 cells	CD4 cells	CD8 cells
Day + 28 Post Transplant	7	3.5	1.7
Study Baseline	13	5	5

Percent of Participants With Chimerism: Full Donor Chimerism Defined as >95% Donor CD3+ Cell in Blood as Assessed by DNA Fingerprinting

the efficacy of the regimen as determined by engraftment rate and establishment of donor hematopoietic chimerism at day +28 and day +70. (NCT00571662)
Timeframe: days +28 and +70

Intervention	percent of participants (Median)
	Day 28	Day 70
Cohort I	85	90

Responses to Therapy

event-free and overall survival at 12 months (NCT00571662)
Timeframe: every 6 mo. up to 2 years

Intervention	Percent of Participants (Number)
	Event free survival	Overall survival
Cohort I	52	59

Toxicity for the Combination of Pentostatin and Low Dose Total Body Irradiation (TBI)

(NCT00571662)
Timeframe: Conditioning regimen to count recovery (D + 28 post transplant)

Intervention	Participants (Count of Participants)
	Absolute neutrophil count < 500/mm^3	platelet count < 20,000/mm^3	Grade 3 or 4 Fever	Grade 3 or 4 hypokalemia	Grade 3 or 4 bacteremia	Grade 3 or 4 infection	Grade 3 or 4 renal toxicity	Grade 3 or 4 thromboembolism
Cohort I	40	29	2	1	2	6	1	1

Change From Baseline in Burning/Stinging Post Dose Instillation on Day 28

"Burning/Stinging was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no burning/stinging and 100 corresponds to worst burning/stinging." (NCT03597139)
Timeframe: Day 28

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-12.3
Comparator	-20.1

Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1

"Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 1. The VAS scale is 0 - 100, where 0 corresponds to no discomfort and 100 corresponds to maximal discomfort." (NCT03597139)
Timeframe: 1-minute Post Dose 1 installation (Day 1)

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	7.9
Comparator	3.5

Change From Baseline in Drop Discomfort Post Dose Instillation on Day 28

"Drop Discomfort was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment 1 minute post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no discomfort and 100 corresponds to maximal discomfort." (NCT03597139)
Timeframe: Day 28

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	11.8
Comparator	6.1

Change From Baseline in Eye Dryness Post Dose Instillation on Day 28

"Eye dryness was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no eye dryness and 100 corresponds to worst eye dryness." (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-35.0
Comparator	-34.6

Change From Baseline in Eye Pain Post Dose Instillation on Day 28

"Eye pain was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no eye pain and 100 corresponds to worst eye pain." (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-13.9
Comparator	-19.9

Change From Baseline in Foreign Body Sensation Post Dose Instillation on Day 28

"Foreign Body Sensation was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no foreign body sensation and 100 corresponds to worst foreign body sensation." (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-19.7
Comparator	-20.7

Change From Baseline in Itching Post Dose Instillation on Day 28

"Itching was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no itching and 100 corresponds to worst itching." (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-26.9
Comparator	-28.1

Change From Baseline in Photophobia Post Dose Instillation on Day 28

"Photophobia was assessed using the Individual Symptom Severity Assessment Visual Analog Scale (VAS) where the subject will complete the assessment post-instillation on Day 28. The VAS scale is 0 - 100, where 0 corresponds to no photophobia and 100 corresponds to worst photophobia." (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-23.1
Comparator	-26.2

Change From Baseline in the Total of All Individual Symptom Severity Assessment Scores

The Individual Symptom Severity Assessment Visual Analog Scale (VAS) includes Burning/Stinging (scale 0 - 100; 0 = no Burning/Stinging, 100 = worst Burning/Stinging), Foreign Body Sensation (scale 0 - 100; 0 = no Foreign Body Sensation, 100 = worst Foreign Body Sensation), Photophobia (scale 0 - 100; 0 = no Photophobia, 100 = worst Photophobia), Eye Pain (scale 0 - 100; 0 = no Eye Pain, 100 = worst Eye Pain), Eye Dryness (scale 0 - 100; 0 = no Eye Dryness, 100 = worst Eye Dryness), and Itching (scale 0 - 100; 0 = no Itching, 100 = worst Itching). The total sum of all 6 symptoms (Burning/Stinging, Foreign Body Sensation, Photophobia, Eye Pain, Eye Dryness, Itching) were evaluated (scale 0 - 600; 0 = no visual symptoms, 600 = worst visual symptoms). (NCT03597139)
Timeframe: Day 28

Intervention	mm (Mean)
Voclosporin Ophthalmic Solution (VOS)	-130.9
Comparator	-149.6

Change From Baseline in Fluorescein Corneal Staining (FCS) Score

The FCS score was summarized for each eye separately. Each of the 5 sections of cornea (superior, inferior, nasal, temporal, central) were graded using the National Eye Institute (NEI) scale; 0, 1 (mild), 2 (moderate), or 3 (severe). The total score was obtained by summing each of the 5 sections of the cornea from 0 - 15. Lower scores indicate less staining and therefore a better outcome. (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
	Left Eye	Right Eye
Comparator	-0.2	-0.7
Voclosporin Ophthalmic Solution (VOS)	-2.2	-2.2

Change From Baseline in Symptom Assessment in Dry Eye Score (SANDE)

"The Symptom Assessment in Dry Eye (SANDE) is a subjective rating performed by the subjects for the frequency and severity of their dry eye symptoms. The total length of the line is 100mm. For Frequency of Symptoms 0mm = rarely and 100mm = all the time. For Severity of Symptoms 0mm = very mild and 100mm = very severe. Subjects were asked to subjectively rate the frequency and severity of their symptoms by placing an X on the relevant horizontal line. The length of the line between the rarely or very mild starting point and the first point where the subject's mark crosses each line was measured and recorded in millimeters." (NCT03597139)
Timeframe: Day 28

Intervention	mm (Mean)
	Frequency	Severity
Comparator	-37.9	-36.1
Voclosporin Ophthalmic Solution (VOS)	-28.0	-24.9

Change From Baseline in Unanesthetized Schirmer Test Score

The Schirmer Test Score recorded tear production on test strips. The Schirmer tear test was conducted 1 hour following administration of VOS/Comparator and 20 minutes following fluorescein corneal staining. Using a ruler and/or the millimeters recorded on the strips, a point halfway between the two lines was measured and this was recorded as the amount of wetting. Lower scores indicate less tear production and therefore a worse outcome. Normal tear production is ≥10mm of wetting on the test strip, and severe dry eye is <5mm of wetting on the test strip. (NCT03597139)
Timeframe: 28 days

Intervention	mm (Mean)
	Left Eye	Right Eye
Comparator	3.0	3.3
Voclosporin Ophthalmic Solution (VOS)	8.5	8.2

CsA Whole Blood Concentrations and CsA Whole Blood Trough Levels

Whole Blood concentrations (Week 0) are at pre-dose, directly after end of inhalation, 15, 30, and 45 minutes, and 1, 1.5, 2, and 4 hours after end of inhalation, and whole blood trough levels (CsA concentration) at Weeks 2, 4, 8, and 12 were calculated. (NCT04107675)
Timeframe: Weeks 0 (pre-dose, directly after end of inhalation, 15, 30, 45, 60 min, 1.5 h, 2h, 4h), 2, 4, 8, and 12

Intervention	ng/ml (Mean)
	Week 0 - predose	Directly after end of inhalation	15 min	30 min	45 min	1 hour	1.5 hours	2 hours	4 hours	Whole Blood Trough Levels - Week 2	Whole Blood Trough Levels - Week 4	Whole Blood Trough Levels - Week 8	Whole Blood Trough Levels - Week 12
L-CsA 10 mg Plus Standard of Care	12.2115	84.6510	73.5110	68.3640	70.1555	117.8030	115.4350	67.0700	33.3425	48.6725	16.2465	18.7280	23.0195
L-CsA 5 mg Plus Standard of Care	0.0000	19.3420	30.0500	26.9400	23.2780	19.4395	16.0300	13.4045	8.3950	4.6365	16.8475	9.0405	0.0000
Liposomal Placebo Plus Standard of Care	11.7750	12.1760	11.2440	13.1780	13.3145	14.0835	13.0425	10.9615	7.6615	6.0500	6.3000	4.9500	4.9500

Number of Local Tolerability Events of Interest From Baseline to Visit 3 (Week 4)

The local tolerability events of interest taken into consideration were: Cough, Wheezing, Bronchospasm, Throat irritation and Change from baseline in FEV1 to Visit 3. (NCT04107675)
Timeframe: at Week 4 (visit 3)

Intervention	number of local events (Number)
	Any Local Tolerability Event	Cough	Wheezing	Bronchospasm	Throat irritation	Change in FEV1
L-CsA 10 mg Plus Standard of Care	1	0	0	0	1	0
L-CsA 5 mg Plus Standard of Care	5	1	0	0	3	1
Liposomal Placebo Plus Standard of Care	4	1	0	0	2	1

Number of Local Tolerability Events of Interest From Baseline to Week 12

Intervention	number of events (Number)
	Any Local Tolerability Event	Cough	Wheezing	Bronchospasm	Throat irritation	Change in FEV1
L-CsA 10 mg Plus Standard of Care	1	0	0	0	1	0
L-CsA 5 mg Plus Standard of Care	7	2	0	0	4	1
Liposomal Placebo Plus Standard of Care	6	2	0	0	3	1

Number of Participants With AE and sAE of Different Level of Severity During the First 12 Weeks of Treatment

"An adverse event (AE) is any untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine. An adverse event can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.~A serious adverse event is an adverse event that results in death, is life-threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a birth defect." (NCT04107675)
Timeframe: During the first 12 weeks of treatment

Intervention	Participants (Count of Participants)
	Any TEAEs	Mild TEAEs	Moderate TEAEs	Severe TEAEs	Serious TEAEs	Related TEAEs	COVID-19 related TEAEs	Patients discontinued study due to TEAEs	Patients discontinued treatment due to TEAEs	TEAEs Leading to Death
L-CsA 10 mg Plus Standard of Care	2	2	1	0	1	1	0	0	1	0
L-CsA 5 mg Plus Standard of Care	1	1	0	0	0	1	0	0	0	0
Liposomal Placebo Plus Standard of Care	1	1	0	0	0	1	0	0	0	0

Number of Participants With AE and sAE of Different Level of Severity During the First 4 Weeks of Treatment

Intervention	Participants (Count of Participants)
	Any TEAEs	Mild TEAEs	Moderate TEAEs	Severe TEAEs	Serious TEAEs	Related TEAEs	COVID-19 related TEAEs	Patients discontinued study due to TEAEs	Patients discontinued treatment due to TEAEs	TEAEs Leading to Death
L-CsA 10 mg Plus Standard of Care	1	1	0	0	0	1	0	0	0	0
L-CsA 5 mg Plus Standard of Care	1	1	0	0	0	1	0	0	0	0
Liposomal Placebo Plus Standard of Care	1	1	0	0	0	1	0	0	0	0

Duration (Days) Until Participants Obtained Platelet Engraftment

Summarized using a range and median of measure in days until participants reached platelet engraftment. Platelet engraftment was defined as the first of 7 consecutive days when the platelet count exceeded 20 x 109/L (untransfused). (NCT00796068)
Timeframe: At 6 months

Intervention	days (Median)
Arm I (Low Risk for Graft Failure)	31
Arm II (High Risk for Graft Failure)	31

Incidence of Acute or Chronic Graft-versus-host Disease (GVHD)

Overall GVHD is determined based on the organ stage, response to treatment and whether GVHD was a major cause of death. Chronic GVHD will be defined according to the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Described as mild, moderate, or severe as graded according to the attached Organ Scoring Sheet. Symptoms consistent with both chronic and acute GVHD occurring after day 100 will be considered overlap chronic GVHD syndrome. (NCT00796068)
Timeframe: At 1 year

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	7
Arm II (High Risk for Graft Failure)	6

Incidence of Clinically Significant Infections

Collected and graded according to the modified National Cancer Institute Common Toxicity Criteria. (NCT00796068)
Timeframe: At 6 months

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	53
Arm II (High Risk for Graft Failure)	61

Incidence of Relapse or Disease Progression

Cumulative incidence estimates using non-relapse mortality as competitive event. (NCT00796068)
Timeframe: Up to 2 years

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	17
Arm II (High Risk for Graft Failure)	11

Non-relapse Mortality

Death of any cause other than relapse or disease progression was considered. (NCT00796068)
Timeframe: Up to 2 years

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	8
Arm II (High Risk for Graft Failure)	10

Number of Participants Surviving by 1 Year

Overall survival was measured from the first day of CBT infusion until death from any cause. (NCT00796068)
Timeframe: At 1 year

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	51
Arm II (High Risk for Graft Failure)	47

Number of Participants Surviving up to 2 Years Without Disease Progression

Progression-free survival is the time interval from start of treatment to documented evidence of disease progression. Disease progression was defined by European LeukemiaNet 2017 criteria and International Working Group (IWG) within 3 years of transplant. (NCT00796068)
Timeframe: Up to 2 years

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	37
Arm II (High Risk for Graft Failure)	41

Number of Participants With Acute Graft-versus-host Disease (GVHD) Grade II-IV by Day 100

Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening. Diagnosing and grading acute GVHD is based on clinical findings (the organ stage, response to treatment and whether GVHD was a major cause of death) and frequently varies between transplant centers and independent reviewers. (NCT00796068)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	36
Arm II (High Risk for Graft Failure)	37

Number of Participants With Graft Failure/Rejection

"Patients will be considered primary graft failure provided they meet any criteria listed below, in the absence of documented disease persistence/recurrence or active bone marrow infection (ex. Cytomegalovirus (CMV)):~i. Absence of 3 consecutive days with neutrophils >500/u1 combined with host CD3+ peripheral blood chimerism ≥50% at day 42 ii. Absence of 3 consecutive days with neutrophils >500/u1 under any circumstances at day 55 iii. Death after day 28 with neutrophil count <100/u1 without any evidence of engraftment (< 5% donor CD3+) iv. Primary autologous count recovery with < 5% donor CD3+ peripheral blood chimerism at count recovery and without relapse" (NCT00796068)
Timeframe: Up to 100 days

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	2
Arm II (High Risk for Graft Failure)	5

Number of Participants With Secondary Graft Failure

Secondary graft failure is defined as decline of neutrophil count to <500/ul with loss of donor chimerism after day 55 (NCT00796068)
Timeframe: Up to 2 years

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	0
Arm II (High Risk for Graft Failure)	0

Number of Patients With Non-relapse Mortality (NRM)

Defined as death from any cause without sign of disease progression or relapse. Loss to follow up are censored, whereas disease relapse or progression are considered competing risks. (NCT00796068)
Timeframe: At day -200

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	7
Arm II (High Risk for Graft Failure)	6

The Number of Participants Alive at Two-years Follow up.

Overall survival of participants after two-years of follow up. (NCT00796068)
Timeframe: Up to 2 years

Intervention	Participants (Count of Participants)
Arm I (Low Risk for Graft Failure)	50
Arm II (High Risk for Graft Failure)	44

Achievement of Remission

"Number of participants who are in complete remission (CR) 4 weeks after transplant. CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:~Normal bone marrow with blasts <5% with normal cellularity, normal megakaryopoiesis, > 15% erythropoiesis and > 25% granulocytopoiesis~Normalization of blood counts (no blasts, platelets > 100000/mm3, granulocytes >1500/mm3)~No extramedullary disease." (NCT01300572)
Timeframe: 4 weeks after transplant

Intervention	Participants (Count of Participants)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	13

Disease-free Survival

Number of study participants who are alive and remains in complete remission after transplant. (NCT01300572)
Timeframe: 100 days after transplant

Intervention	participants (Number)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	7

Duration of Remission

"Median time to relapse after achieving complete remission (CR). CR is defined as complete resolution of all signs of myelodysplasia or leukemia for at least 4 weeks with all of the following:~Normal bone marrow with blasts <5% with normal cellularity, normal megakaryopoiesis, > 15% erythropoiesis and > 25% granulocytopoiesis~Normalization of blood counts (no blasts, platelets > 100000/mm3, granulocytes >1500/mm3)~No extramedullary disease.~Relapse Criteria:~After CR: >5% blasts in the bone marrow and/or peripheral blood~After partial remission (PR): increase of blasts cells in the marrow to >50% of those during PR~Extramedullary disease confirmed cytologically or histologically." (NCT01300572)
Timeframe: 1 year

Intervention	days (Median)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	213

Overall Survival

Number of participants who are still alive after transplant with or without disease. (NCT01300572)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	7

Rates of Donor Chimerism

Number of participants who has 100% donor chimerism within 100 days after transplant (NCT01300572)
Timeframe: Up to 100 days post-transplant

Intervention	Participants (Count of Participants)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	14

Rates of Engraftment

Average number of days to ANC >= 500 after transplant (NCT01300572)
Timeframe: Up to 84 days post-transplant

Intervention	days (Mean)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	16

The MTD of Radiation Delivered Via 90Y-DOTA-BC8 When Combined With FLU and 2 Gy TBI as a Preparative Regimen for Patients Aged ≥ 18 With Advanced AML, ALL, and High-risk MDS.

The MTD will be defined as the dose that is associated with a true DLT rate of 25%. The highest dose achieved was 28 Gy but none of the patients experienced a DLT. Thus, the MTD was not reached. (NCT01300572)
Timeframe: Within the first 30 days following transplant

Intervention	Gy (Number)
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	28

Estimation of Absorbed Radiation Doses to Normal Organs, Marrow and Tumor

The amount of energy absorbed per unit weight of the organ or tissue is called absorbed dose and is expressed in units of gray (Gy). One gray dose is equivalent to one joule radiation energy absorbed per kilogram of organ or tissue weight. (NCT01300572)
Timeframe: Approximately day -20 to day -12 prior to transplant

Intervention	Gy (Mean)
	Average absorbed dose to the marrow	Average absorbed dose to the liver	Average abosorbed dose total body	Average absorbed dose to the spleen
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	11.4	17.2	3.1	70

Rates of Non-relapse Mortality

Transplant-related deaths within 100 days after transplant (NCT01300572)
Timeframe: Within the first 100 days following transplant

Intervention	Participants (Count of Participants)
	Severe refractory GVHD	Bacterial infection
Treatment (90Y-BC8, Allogeneic PBSC or Bone Marrow Transplant)	1	1

Percentage of Participants Surviving

(NCT01292226)
Timeframe: Day 1, Weeks 2, 4, 12, 24, and 28

Intervention	percentage of participants (Number)
MMF Monotherapy	97.7

Percentage of Participants With Acute Rejection

Diagnosis of acute rejection was suspected in any participant with an increase in serum creatinine greater than or equal to (≥) 25 percent (%). All suspected acute rejections were confirmed by biopsy. The start date of acute rejection was identified as the date of biopsy. (NCT01292226)
Timeframe: Day 1, Weeks 2, 4, 12, 24, and 28

Intervention	percentage of participants (Number)
MMF Monotherapy	9.1

Percentage of Participants With Biopsy-Proven Acute Rejection (BPAR)

BPAR was defined according to 1997 Banff Criteria as a biopsy Banff grade of IA, IB, IIA, IIB, or III. Grade IA was defined as significant interstitial infiltration with greater than (>)25% of parenchyma affected, and foci of moderate tubulitis with >4 mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IB was defined as significant interstitial infiltration with >25% parenchyma affected, and foci of severe tubulitis with >10% mononuclear cells per tubular cross section or group of 10 tubular cells. Grade IIA was defined as mild to moderate intimal arteritis. Grade IIB was defined as severe intimal arteritis comprising >25% of the luminal area. Grade III was defined as transmural arteritis and/or arterial fibrinoid changes and necrosis of medial smooth muscle cells. (NCT01292226)
Timeframe: Day 1, Weeks 2, 4, 12, 24, and 28

Intervention	percentage of participants (Number)
MMF Monotherapy	4.5

Percentage of Participants With Graft Loss

An allograft was presumed to be lost if a participant started dialysis and was not able to subsequently be removed from dialysis. (NCT01292226)
Timeframe: Day 1, Weeks 2, 4, 12, 24, and 28

Intervention	percentage of participants (Number)
MMF Monotherapy	2.3

Time to Rejection

The mean time, in days, from the date of enrollment to date of biopsy confirming acute rejection. (NCT01292226)
Timeframe: Day 1, Weeks 2, 4, 12, 24, and 28

Intervention	days (Mean)
MMF Monotherapy	23.67

Free MPA (mcg/mL) by Visit

Drug quantification of free MPA in the plasma was measured at T = 0, 40, and 120 mins. (NCT01292226)
Timeframe: Weeks 2, 4, 12, 24, safety follow-up (Week 28), and any unscheduled visits

Intervention	mcg/mL (Mean)
	T=0, Week 2 (n=40)	T=0, Week 4 (n=39)	T=0, Week 12 (n=33)	T=0, Week 24 (n=32)	T=0, safety follow-up (n=3)	T=0, unscheduled visit (n=7)	T=0, overall mean value (n=154)	T=40, Week 2 (n=41)	T=40, Week 4 (n=42)	T=40, Week 12 (n=35)	T=40, Week 24 (n=35)	T=40, safety follow-up (n=3)	T=40, unscheduled visit (n=7)	T=40, overall mean value (n=163)	T=120, Week 2 (n=43)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, Week 24 (n=35)	T=120, safety follow-up (n=3)	T=120, unscheduled visit (n=7)	T=120, overall mean value (n=165)
MMF Monotherapy	0.03	0.04	0.03	0.03	0.01	0.04	0.03	0.11	0.11	0.11	0.38	0.06	0.09	0.17	0.11	0.11	0.16	0.10	0.10	0.07	0.12

IMPDH Expression I by Visit and Timepoint

IMPDH I gene expression was measured by real time polymerase chain reaction (QRT-PCR) based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of messenger ribonucleic acid (mRNA) copies per cell (copies/cell). (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits

Intervention	number of mRNA copies/cell (Mean)
	T=0, BL (n=44)	T=0, Week 2 (n=41)	T=0, Week 4 (n=42)	T=0, Week 12 (n=34)	T=0, Week 24 (n=34)	T=0, safety follow-up (n=3)	T=0, unscheduled visit (n=7)	T=0, mean value (n=205)	T=120, BL (n=0)	T=120, Week 2 (n=43)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, Week 24 (n=34)	T=120, safety follow-up (n=3)	T=120, unscheduled visit (n=7)	T=120, mean value (n=164)
MMF Monotherapy	2.32	32.29	3.16	4.10	1.95	11803.48	4.00	181.48	0	4146.17	1692.11	1556.06	3.02	107.30	1038.52	1899.45

IMPDH Expression II by Visit and Timepoint

IMPDH II gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell. (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits

Intervention	number of mRNA copies/cell (Mean)
	T=0, BL (n=44)	T=0, Week 2 (n=41)	T=0, Week 4 (n=42)	T=0, Week 12 (n=34)	T=0, Week 24 (n=34)	T=0, safety follow-up (n=3)	T=0, unscheduled visit (n=7)	T=0, mean value (n=205)	T=120, BL (n=0)	T=120, Week 2 (n=43)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, Week 24 (n=34)	T=120, safety follow-up (n=3)	T=120, unscheduled visit (n=7)	T=120, mean value (n=164)
MMF Monotherapy	115.33	113.43	117.16	112.43	114.21	123.86	116.57	114.82	0	304.64	148.32	143.11	109.00	140.51	167.19	180.71

Inosine MonoPhosphate DeHydrogenase (IMPDH) Activity by Visit and Timepoint

"IMPDH activity in peripheral blood mononuclear cells (PBMCs) was measured at 2 timepoints per visit, 0 and 120 minutes and presented in enzyme units. The unit of measure of enzyme activity is U. One U is defined as the amount of the enzyme that produces a certain amount of enzymatic activity that is, the amount that catalyzes the conversion of 1 micro mole of substrate per minute under pre-specified conditions (temperature, pH)." (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits

Intervention	enzyme units (Mean)
	T=0, BL (n=44)	T=0, Week 2 (n=42)	T=0, Week 4 (n=42)	T=0, Week 12 (n=35)	T=0, Week 24 (n=34)	T=0, safety follow-up (n=0)	T=0, unscheduled visit (n=7)	T=0, mean value (n=204)	T=120, BL (n=0)	T=120, Week 2 (n=42)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, Week 24 (n=34)	T=120, safety follow-up (n=0)	T=120, unscheduled visit (n=7)	T=120, mean value (n=160)
MMF Monotherapy	5.01	3.96	3.89	6.74	9.58	0	6.00	5.65	0	3.06	3.10	3.75	6.39	0	3.89	3.97

Interleukin 8 (IL-8) Expression by Visit and Timepoint

IL-8 gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell. (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits

Intervention	number of mRNA copies/cell (Mean)
	T=0, BL (n=44)	T=0, Week 2 (n=41)	T=0, Week 4 (n=42)	T=0, Week 12 (n=34)	T=0, Week 24 (n=34)	T=0, safety follow-up (n=3)	T=0, unscheduled visit (n=7)	T=0, mean value (n=205)	T=120, BL (n=0)	T=120, Week 2 (n=43)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, Week 24 (n=34)	T=120, safety follow-up (n=3)	T=120, unscheduled visit (n=7)	T=120, mean value (n=164)
MMF Monotherapy	4532.72	29960.41	54101.30	1829.87	10391.60	1254.29	19148.94	20748.32	0.0	1028.93	21227.11	12022.83	9418.65	397887.30	220.14	17512.31

MPA Area Under the Concentration - Time Curve From Time 0 to 12 Hours (AUC0-12) (mcg/mL) by Visit

The AUC0-12 of MPA was estimated on the validated limited sampling strategy, AUC (milligrams multiplied by height over liter [mg.h/L]) = 7.182 + 4.607 multiplied by (*) concentration at 0 minutes (C0)+ 0.998 * the concentration at 40 minutes (C0.67) + 2.149 * the concentration at 120 minutes (C2). (NCT01292226)
Timeframe: Predose and 40 minutes and 2 hours postdose at Weeks 2, 4, 12, and 24, and at the Safety follow-up (Week 28)

Intervention	mcg*hr/mL (Mean)
	Week 2 (n=41)	Week 4 (n=42)	Week 12 (n=35)	Week 24 (n=35)	Follow-up (n=3)
MMF Monotherapy	38.3	39.7	39.7	39.8	29.7

Percentage of Participants With Gastrointestinal Toxicities

Gastrointestinal adverse events (AEs) according to WHO worst grade observed. (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-up Visit)

Intervention	percentage of participants (Number)
	Abdominal pain (moderate)	Abdominal pain (severe)	Anal fissure (mild)	Diarrhoea (mild)	Diarrhoea (moderate)	Diarrhoea (severe)	Dyspepsia (mild)	Gastritis (moderate)	Gastritis erosive (moderate)	Gingival hyperplasia (mild)	Haemorrhoids (mild)	Intra-abdominal haematoma (mild)	Nausea (moderate)	Stomatitis (mild)	Vomiting (mild)	Vomiting (moderate)	Vomiting (severe)
MMF Monotherapy	2.22	2.22	2.22	4.44	2.22	2.22	2.22	2.22	2.22	2.22	2.22	2.22	2.22	2.22	2.22	4.44	4.44

Percentage of Participants With Hematologic Toxicity

Hematological toxicities graded according to WHO worst grade observed (Grade 1=mild, Grade 2=moderate). (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)

Intervention	percentage of participants (Number)
	Grade 1 hemoglobin decreased	Grade 1 leukocytes decreased	Grade 2 leukocytes decreased	Grade 1 granulocytes decreased	Grade 2 granulocytes decreased	Grade 1 platelets decreased	Grade 1 bilirubin increased	Grade 2 bilirubin increased	Grade 1 hypoglycemia	Grade 1 alkaline phosphatase increased	Grade 2 alkaline phosphatase increased	Grade 1 aspartate aminotransferase increased	Grade 1 alanine aminotransferase increased	Grade 2 alanine aminotransferase increased	Grade 1 cholesterol increased	Grade 2 cholesterol increased	Grade 1 triglycerides increased	Grade 2 triglycerides increased	Grade 1 blood urea nitrogen increased	Grade 2 blood urea nitrogen increased
MMF Monotherapy	13.33	11.11	8.89	6.67	6.67	6.67	4.44	2.22	4.44	13.33	2.22	6.67	8.89	2.22	26.67	8.89	24.44	2.22	2.22	2.22

Percentage of Participants With Infection

Infections were graded according to the World Health Organization (WHO) worst grade observed. (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up)

Intervention	percentage of participants (Number)
	Acarodermatitis (mild)	Bronchitis (moderate)	Cytomegalovirus (CMV) infection (mild)	CMV infection (moderate)	CMV infection (severe)	CMV viraemia (mild)	Gastroenteritis proteus (severe)	Gastrointestinal infection (severe)	Legionella infection (life-threatening)	Oral herpes (mild)	Sepsis (life-threatening)	Tracheitis (mild)	Urethritis (mild)	Urinary tract infection (mild)	Urinary tract infection (moderate)
MMF Monotherapy	2.22	2.22	13.33	8.89	4.44	2.22	2.22	2.22	2.22	2.22	2.22	2.22	2.22	28.89	2.22

Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Gastrointestinal Toxicity

The Spearman's rank correlation coefficient was computed by ranking the data from 2 time points, 0 minutes and 120 minutes, and using the ranks in the Pearson product-moment correlation formula. In case of ties, the averaged ranks were used. (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, and 24

Intervention	correlation coefficient (Number)
	IMPDH I expression (n=334)	IMPDH II expression (n=351)
MMF Monotherapy	0.082	0.030

Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Hematologic Toxicity

Intervention	correlation coefficient (Number)
	IMPDH I expression (n=334)	IMPDH II expression (n=351)
MMF Monotherapy	-0.116	-0.004

Spearman's Rank Correlation Coefficient Between IMPDH Expression and Risk of Infection

Intervention	correlation coefficient (Number)
	IMPDH I expression (n=334)	IMPDH II expression (n=351)
MMF Monotherapy	0.045	0.047

Spearman's Rank Correlation Coefficient Between IMPDH I Expression and Free Fraction

Intervention	correlation coefficient (Number)
	p Free fraction, T=0 (n=140)	p Free fraction, T=120 (n=143)
MMF Monotherapy	0.047	0.080

Spearman's Rank Correlation Coefficient Between IMPDH I Expression and MPA Levels

Intervention	correlation coefficient (Number)
	Free MPA, T=0 (n=141)	Free MPA, T=120 (n=143)	Total MPA, T=0 (n=147)	Total MPA, T=120 (n=143)
MMF Monotherapy	0.073	-0.024	0.037	-0.140

Spearman's Rank Correlation Coefficient Between IMPDH II Expression and Free Fraction

Intervention	correlation coefficient (Number)
	p Free fraction, T=0 (n=144)	p Free fraction, T=120 (n=153)
MMF Monotherapy	-0.027	0.015

Spearman's Rank Correlation Coefficient Between IMPDH II Expression and MPA Levels

Intervention	correlation coefficient (Number)
	Free MPA, T=0 (n=145)	Free MPA, T=120 (n=153)	Total MPA, T=0 (n=152)	Total MPA, T=120 (n=153)
MMF Monotherapy	0.007	0.073	-0.001	0.084

Spearman's Rank Correlation Coefficient Between IMPDH Inhibition and Risk of Acute Rejection

Intervention	correlation coefficient (Number)
	IMPDH I expression, T=0 (n=189)	IMPDH I expression T=120 (n=145)	IMPDH II expression, T=0 (n=196)	IMPDH II expression (T=120, n=155)	MPDH Activity, T=0 (n=198)	IMPDH Activity, T=120 (n=155)
MMF Monotherapy	0.030	0.083	-0.062	-0.010	-0.121	-0.004

Spearman's Rank Correlation Coefficient Between MPA Levels and IMPDH Activity

Intervention	correlation coefficient (Number)
	Free MPA, T=0 (n=144)	Free MPA, T=120 (n=153)	Total MPA, T=0 (n=152)	Total MPA, T=120 (n=153)
MMF Monotherapy	0.063	0.028	0.034	-0.050

Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Gastrointestinal Toxicity

Intervention	correlation coefficient (Number)
	Free MPA (n=300)	Total MPA (n=308)	AUC MPA (n=152)
MMF Monotherapy	0.106	0.142	0.187

Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Hematologic Toxicity

Intervention	correlation coefficient (Number)
	Free MPA (n=300)	Total MPA (n=308)	AUC MPA (n=152)
MMF Monotherapy	-0.004	-0.037	-0.038

Spearman's Rank Correlation Coefficient Between MPA Levels and Risk of Infection

Intervention	correlation coefficient (Number)
	Free MPA (n=300)	Total MPA (n=308)	AUC MPA (n=152)
MMF Monotherapy	-0.020	0.063	0.030

Total Mycophenolate Acid (MPA) by Visit and Timepoint

Drug quantification of total MPA (micrograms per milliliter [mcg/mL]) in the plasma was measured at time (T) = 0 minutes (min), 40 mins, and 120 mins. (NCT01292226)
Timeframe: Weeks 2, 4, 12, 24, and 28 (Safety Follow-Up Visit), and any unscheduled visits

Intervention	mcg/mL (Mean)
	T=0, Week 2 (n=41)	T=0, Week 4 (n=42)	T=0, Week 12 (n=35)	T=0, Week 24 (n=35)	T=0, safety follow-up (n=3)	T=0, unscheduled visit (n=7)	T=0, overall mean value (n=163)	T=40, Week 2 (n=43)	T=40, Week 4 (n=42)	T=40, Week 12 (n=35)	T=40, Week 24 (n=35)	T=40, safety follow-up (n=3)	T=40, unscheduled visit (n=7)	T=40, overall mean value (n=165)	T=120, Week 2 (n=41)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, safety follow-up (n=3)	T=120, Week 24 (n=35)	T=120, unscheduled visit (n=7)	T=120, overall mean value (n=163)
MMF Monotherapy	1.75	1.87	1.79	1.90	1.16	1.32	1.79	6.44	6.96	7.23	6.47	5.71	4.06	6.63	8.86	8.95	8.57	4.91	10.04	7.03	8.92

Tumor Necrosis Factor (TNF) Expression by Visit and Timepoint

TNF gene expression was measured by QRT-PCR based cytokine measurement of PBMCs at 2 timepoints per visit, 0 and 120 minutes and expressed as number of mRNA copies/cell. (NCT01292226)
Timeframe: BL and Weeks 2, 4, 12, and 24, and safety follow-up (Week 28) and any unscheduled visits

Intervention	number of mRNA copies/cell (Mean)
	T=0, BL (n=44)	T=0, Week 2 (n=41)	T=0, Week 4 (n=42)	T=0, Week 12 (n=34)	T=0, Week 24 (n=34)	T=0, safety follow-up (n=3)	T=0, unscheduled visit (n=7)	T=0, mean value (n=205)	T=120, BL (n=0)	T=120, Week 2 (n=43)	T=120, Week 4 (n=42)	T=120, Week 12 (n=35)	T=120, Week 24 (n=34)	T=120, safety follow-up (n=3)	T=120, unscheduled visit (n=7)	T=120, mean value (n=164)
MMF Monotherapy	4532.72	29960.41	54101.30	1829.87	10391.60	1254.29	19148.94	20748.32	0	1028.93	21227.11	12022.83	9418.65	397887.30	220.14	17512.31

Blood Counts and Adverse Event Profile After 6 Months of Treatment.

The safety endpoint will be toxicity profile after 6 months of treatment. The efficacy endpoint is complete response rate at 6 months, with complete response defined as blood counts no longer meeting the standard criteria for severe pancytopenia in severe aplastic anemia. (NCT01193283)
Timeframe: 6 months

Intervention	participants (Number)
	Complete response	Partial Response	No Response
SAA Hematologic Response	4	5	12

Biopsy Proven Acute Rejection (BPAR) Rate Between Randomization and Month 12

"Occurrence of BPAR (after randomization) between arm B (steroid withdrawal group) and arm c (standard twice-a-day group).~BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III according to Banff 1997 grading with 2007 update." (NCT01023815)
Timeframe: Month 3 to Month 12

Intervention	Participants (Number)
Group B - Steroid Withdrawal Group	9
Group C - Standard Twice-a-day Group	2

Changes in the Estimated Glomerular Filtration Rate (eGFR) Between Randomization (Month 3) and Month 12

eGFR by Nankivell, in terms of descriptive statistics and change vs randomization visit - to compare the changes in the estimated GFR (Nankivell) between randomization and Month 12 in the steroid withdrawal group (Group B) to the change observed in the standard twice-a-day group (Group C), for non-inferiority (NCT01023815)
Timeframe: Month 3 to Month 12

Intervention	mL/min (Mean)
Group B - Steroid Withdrawal Group	-1.7
Group C - Standard Twice-a-day Group	2.5

Number of Participants With Graft and Patient Survival After Randomization

"Graft Survival, calculated from the date of transplantation to the date of irreversible graft failure signified by return to long-term retransplantation or the date of the last follow-up during the period when the transplant was still functioning or to the date of death.~Patient survival, calculated from the date of transplantation to the date of death or the date of the last follow-up." (NCT01023815)
Timeframe: Month 3 to Month 12

Intervention	Participants (Number)
Group B - Steroid Withdrawal Group	68
Group C - Standard Twice-a-day Group	71

Treatment Failure Rate

Occurrence or not of treatment failure in each patient. Treatment failure was defined as a composite endpoint of biopsy-proven acute rejection (a biopsy graded IA, IB, IIA, IIB or III according to Banff '97 grading with 2007 update), graft loss, death or lost to follow-up occurring after randomization (V5) and within M12 (V9). (NCT01023815)
Timeframe: Between randomization (Month 3) and Month 12

Intervention	Participants (Number)
Group A - Once-a-day Regimen	3
Group B - Steroid Withdrawal Group	10
Group C - Standard Twice-a-day Group	2

Change in Estimated Creatine Clearance

At each visit, estimated creatinine clearance was measured in the local laboratory to analyze the evolution of the renal function. The following indirect measures of renal function were computed: estimated creatinine clearance according to Cockcroft and Gault formula and MDRD formula. (NCT01023815)
Timeframe: M3, M12

Intervention	mL/min (Mean)
	Using Cockcroft and Gault model @ month 3	Using Cockcroft and Gault model @ month 12	Using MDRD-4 formular @ month 3	Using MDRD-4 formular @ month 12
Group B - Steroid Withdrawal Group	64.8	62.3	57.9	53.6
Group C - Standard Twice-a-day Group	63.0	66.9	58.8	61.8

Change in Serum Creatinine

Serum creatinine (a blood measurement) is an important indicator of renal health because it is an easily-measured by-product of muscle metabolism. Measuring serum creatinine is a simple test and it is the most commonly used indicator of renal function. (NCT01023815)
Timeframe: M3, M12

Intervention	mg/dL (Mean)
	Serum Creatinine @ month 3	Serum Creatinine @ month 12
Group B - Steroid Withdrawal Group	1.4	1.5
Group C - Standard Twice-a-day Group	1.4	1.4

Number of Participant With Adverse Events (AE)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. (NCT00513474)
Timeframe: Up to 71 months

Intervention	Participants (Count of Participants)
Rasburicase Group	21
Control Group	21

Percentage of Participants With Grades II to IV Acute Graft-Versus-Host Disease (aGVHD)

"aGVHD severity was determined using International Bone Marrow Transplant Registry (IBMTR) scale stage and grade of the skin, liver and gut. Stage 1: Skin=maculopapular rash <25% of body surface; Liver=Bilirubin 2-3 mg/dL and Gut=500-999 mL diarrhea/day or peristent nausea with histologic evidence of GvHD. Stage 2: Skin=maculopapular rash 25-50% of body surface; Liver=Bilirubin 3.1-6 mg/dL and Gut=1000-1499 mL diarrhea/day. Stage 3: Skin=maculopapular rash >50% of body surface; Liver=Bilirubin 6.1-15 mg/dL and Gut=≥1500 mL diarrhea/day. Stage 4: Skin=generalized erythroderma with bulla formation; Liver=Bilirubin >15 mg/dL and Gut=severe abdominal pain.~Grade 1: Stage 1-2 rash; no liver or gut involvement. Grade II: Stage 3 rash, or stage 1 liver involvement, or stage 1 gut involvement. Grade III: None to stage 3 skin rash with stage 2-3 liver, or stage 2-4 gut involvement. Grade IV: Stage 4 skin rash, or stage 4 liver involvement." (NCT00513474)
Timeframe: Up to 71 months

Intervention	percentage of participants (Number)
Rasburicase Group	24
Control Group	57

Uric Acid Levels

Blood was collected and analyzed at a laboratory for serum uric acid levels reported in milligrams(mg)/deciliter(dL). Data is presented for those participants who experienced Grade II to IV aGVHD and those participants who did not experience Grade II to IV aGVHD at pre-transplant and post-transplant. (NCT00513474)
Timeframe: Pre-transplant Day -7 to Day -1 and Post-transplant Day 0 to Day 6

Intervention	mg/dL (Mean)
	Day -7	Day -6	Day -5	Day -4	Day -3	Day -2	Day -1	Day 0	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6
Control Group	4.157	3.419	2.967	2.579	2.358	1.867	1.71	2.163	2.671	2.778	2.805	2.758	2.579	2.653
Rasburicase Group	0.1	0.075	0.086	0.1	0.067	0.081	0.438	0.938	1.624	2.076	2.271	2.548	2.595	2.705

Achieving Full Donor Chimerism

Achieving full donor chimerism (donor T cells >95%): Blood was sent for donor cell percentage measured by short tandem repeat (STR) at post-transplant Day 30; Day 60; Day 90; Day 120; Day 180; Day 270; and Day 360. Full donor chimerism is defined as donor CD3+ cells > 95%. (NCT00481832)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
T & B Cell Mobilization Auto & Allo HCT	10

Event-free Survival (EFS)

"Event-free survival (EFS) as determined for participants who receive both planned transplants, for a minimum of 3 years.~Events are defined as disease progression/relapse and death of all causes." (NCT00481832)
Timeframe: 3 years

Intervention	percentage of participants (Number)
T & B Cell Mobilization Auto & Allo HCT	35

Incidence of Acute Graft Versus Host Disease (GvHD)

The development of GvHD in vaccinated patients of any grade and at 6 months. (NCT00481832)
Timeframe: 6 Months

Intervention	Participants (Count of Participants)
T & B Cell Mobilization Auto & Allo HCT	3

Incidence of Chemotherapy-associated Pneumonitis

Interstitial pneumonitis (IP) is a risk associated with high-dose carmustine (BCNU) or other chemotherapy drugs used for transplantation. IP is diagnosed by 1) a decrease of >25% in DLCO compared with pre-transplant PFT DLCO values or 2) a drop of 7% or more in oxygen saturation after exertion. (NCT00481832)
Timeframe: 3 years

Intervention	Participants (Count of Participants)
T & B Cell Mobilization Auto & Allo HCT	16

Incidence of Chronic Graft Versus Host Disease (GvHD)

The development of GvHD in vaccinated patients of any grade at 6 months. (NCT00481832)
Timeframe: 3 years

Intervention	Participants (Count of Participants)
T & B Cell Mobilization Auto & Allo HCT	3

Median Time to Neutrophile Engraftment

Complete blood counts were measured daily after allogeneic transplant. Time to neutrophil engraftment is defined as the number of days it takes to reach an absolute neutrophils count (ANC) >500, counting from the day of transplant. (NCT00481832)
Timeframe: up to 45 days

Intervention	Days (Median)
T & B Cell Mobilization Auto & Allo HCT	17

Median Time to Platelet Engraftment

Complete blood counts were measured daily after allogeneic transplant. Time to platelet engraftment is defined as the number of days it takes to reach platelet count >20,000, counting from the day of transplant. (NCT00481832)
Timeframe: Up to 45 days

Intervention	Days (Median)
T & B Cell Mobilization Auto & Allo HCT	11

Overall Mortality Rate

Overall mortality is determined by Kaplan-Meier estimation. The overall morality rate is expressed as the percentage of patients who died for any reason, including disease-related death. (NCT00481832)
Timeframe: 3 years

Intervention	percentage of participants (Number)
T & B Cell Mobilization Auto & Allo HCT	56

Overall Survival (OS)

Overall Survival (OS) 3 years after transplant, for participants who received both transplants, as determined by Kaplan-Meier estimation. (NCT00481832)
Timeframe: 3 years

Intervention	percentage of participants (Number)
T & B Cell Mobilization Auto & Allo HCT	57

Relapse Rate

Relapse rate (disease recurrence) 3 years after transplant, for participants who received both transplants, as determined by Kaplan-Meier estimation. (NCT00481832)
Timeframe: 3 years

Intervention	percentage of participants (Number)
T & B Cell Mobilization Auto & Allo HCT	27

Number of Participants Who Died Due to Transplant

Determine the incidence of transplant-related mortality at 6 months after UCBT (NCT00309842)
Timeframe: At Month 6

Intervention	Participants (Count of Participants)
Unrelated UCBT for Blood Cancers	58

Number of Participants Who Were Alive at 1 Year Transplant Overall Survival

Number of patients alive at 1 year after transplant. (NCT00309842)
Timeframe: at 1 year

Intervention	Participants (Count of Participants)
Unrelated UCBT for Blood Cancers	130

Number of Participants With Chronic Graft-Versus-Host Disease

"Determine the incidence of chronic GVHD at 1 year after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria.~Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level." (NCT00309842)
Timeframe: Year 1

Intervention	Participants (Count of Participants)
Unrelated UCBT for Blood Cancers	39

Number of Participants With Neutrophil Engraftment

Determine the incidence of neutrophil engraftment at day 42 after UCBT Patients diagnosed with graft failure (failure of absolute neutrophil count ANC > 5 x 10^8/L of donor origin by day +42) (NCT00309842)
Timeframe: Day 42

Intervention	Participants (Count of Participants)
Unrelated UCBT for Blood Cancers	21

Number of Participants With Platelet Engraftment

Determine the incidence of platelet engraftment (platelet recovery >50,000/uL) at 6 months after UCBT. (NCT00309842)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Unrelated UCBT for Blood Cancers	159

Percentage Chimerism at 1 Year

Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28. (NCT00309842)
Timeframe: 1 Year

Intervention	percentage of donor cells (Mean)
Unrelated UCBT for Blood Cancers	99.1

Percentage Chimerism at 2 Years

Intervention	percentage of donor cells (Mean)
Unrelated UCBT for Blood Cancers	100

Percentage Chimerism at 6 Months

Intervention	percentage of donor cells (Mean)
Unrelated UCBT for Blood Cancers	98.1

Percentage Chimerism on Day 100

Intervention	percentage of donor cells (Mean)
Unrelated UCBT for Blood Cancers	98.1

Percentage Chimerism on Day 21

Intervention	percentage of donor cells (Mean)
Unrelated UCBT for Blood Cancers	92.6

Number of Participants With Acute Graft-Versus-Host Disease

"Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria following Przepiorka et al, 1995, Consensus Clinical Stage and Grade of Acute GVHD.~Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level." (NCT00309842)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
	Grade II-IV	Grade III-IV
Unrelated UCBT for Blood Cancers	106	49

Number of Patients Alive 24 Months Post Day 100 Transplant

Patients will be followed for survival for 24 months post day 100 transplant. (NCT00619645)
Timeframe: 24 months post day 100 transplant

Intervention	Participants (Count of Participants)
RIST for Heme Malignancies	3

Number of Patients With Day 100 Transplant-related Mortality

Patients were followed for death and whether or not that death was attributed to the day 100 transplant via physician assessment for 24 months after day 100 transplant. (NCT00619645)
Timeframe: 24 months after day 100 transplant

Intervention	Participants (Count of Participants)
RIST for Heme Malignancies	1

Efficacy of Nonmyeloablative Preparative Regimen

Proportion of subjects achieving a complete response. Complete response (CR) is defined as: disappearance of all signs and symptoms of cutaneous T-cell lymphomas (CTCL) for a period of at least one month. (NCT00047060)
Timeframe: 36 months

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	4

Number of Participants Overall Survival

Number of participants overall survival following stem cell transplant. Overall survival is defined as number participants alive following stem cell transplant (NCT00047060)
Timeframe: up to 5 years

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	3

Number of Participants That Experienced Engraftment

Number of participants that experienced engraftment following stem cell transplant. Engraftment is defined as neutrophil count is greater than 0.5 x10^9. (NCT00047060)
Timeframe: up to 100 days

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	5

Number of Participants That Experienced Graft Failure

Number of participants that experienced graft failure. Graft failure is defined as: the failure to achieve sustained engraftment following stem cell transplantation. (NCT00047060)
Timeframe: up to 100 days

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	0

Number of Participants That Experienced Platelet Recovery

Number of participants that experienced platelet recovery up to day 100 following stem cell transplant. Platelet recovery is defined as platelet count is greater than 50 x 10^9/l without platelet transfusion. (NCT00047060)
Timeframe: up to 100 days

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	5

Number of Participants That Experienced Red Blood Cell Recovery

Number of participants that experienced red blood cell recovery following stem cell transplant. Red blood cell recovery is defined as achieving transfusion independence. (NCT00047060)
Timeframe: up to 100 days

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	5

Number of Participants That Remained Disease-free

Number of participants that remained Disease-free survival following stem cell transplant. Disease-free survival is defined as survival free of disease relapse or disease progression following stem cell transplant. (NCT00047060)
Timeframe: up to 100 days

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	4

Number of Participants Who Experienced Transplant Related Mortality

Number of Participants who experienced transplant related mortality by day 100 (NCT00047060)
Timeframe: day 100

Intervention	Participants (Count of Participants)
Stem Cell Transplant Therapy With Campath-1H	0

Median Time in Months to Achieve Full Myeloid and Full Donor T-cell Chimerism

Median time in months to achieve full myeloid and full donor T-cell Chimerism. Myeloid (CD34+) and T-cell (CD3+) chimerisms were determined by PCR analysis of short tandem repeats (STR). Full donor chimerism is defined as >95% donor- derived cells in the peripheral blood in a specific lineage. (NCT00047060)
Timeframe: Up to 22 months

Intervention	months (Median)
	Myeloid Chimerism	Donor T-cell Chimerism
Stem Cell Transplant Therapy With Campath-1H	9	7

Number of Participant Who Experienced Chronic Graft Versus Host Disease

"Number of participant who experienced chronic graft versus host disease (GVHD) following stem cell transplant The diagnosis of clinical features of chronic-GVHD was determined prospectively and classified retrospectively into limited or extensive based on the Revised Seattle Classification. Chronic GvHD severity categorized as limited is defined as: localized skin lesions with or without limited hepatic involvement and extensive is defined as: generalized skin involvement, major hepatic complications, or involvement of any other organ." (NCT00047060)
Timeframe: Day 100 up to 3 years

Intervention	Participants (Count of Participants)
	Limited	Extensive
Stem Cell Transplant Therapy With Campath-1H	3	0

Number of Participants Who Experienced Acute GVHD Grades II-IV

"Number of participants who experienced acute GVHD grades II-IV~Acute-GVHD was graded and staged prospectively using criteria from the 1994 Consensus Conference on Acute- GVHD Grading.~Grades are defined as:~Grade II: Skin = rash on 25-50 percent body surface area; Liver = Total Bilirubin 3.1-6.0 mg/dL; Lower GI = Diarrhea 1001-1500 mL/day.~Grade III: Skin = Rash on >50% of body surface; Liver = Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI = Diarrhea > 1500 mL/day.~Grade IV: Skin = Generalized erythroderma plus bullous formation; Liver = Total Bilirubin >15 mg/dL; Lower GI = Severe abdominal pain with or without ileus.~Grade II GVHD as moderate, grade III as severe, and grade IV life-threatening." (NCT00047060)
Timeframe: up to 100 days

Intervention	Participants (Count of Participants)
	Grade II	Grade III-IV
Stem Cell Transplant Therapy With Campath-1H	0	1

Area Under the Curve (AUC) of CD25 Saturation by Basiliximab From Day 0 to Day 84

CD25 saturation is the percentage of T cells expressing CD25. Mean AUC of CD25 was calculated only for patients who received two Simulect® injections. (NCT01596062)
Timeframe: Day 84 (Week 12) after transplantation

Intervention	Weeks * Percentage of saturated CD25 (Mean)
Simulect 40mg + Neoral + Myfortic + Steroids	8.4
Simulect 80mg + Neoral + Myfortic + Steroids	11.1
Simulect 80mg + Certican + Myfortic + Steroids	9.7

AUC of Basiliximab Binding to CD25 Receptors From Day 0 to Day 84

Mean AUC was calculated only for patients who received two Simulect injections. (NCT01596062)
Timeframe: Day 84 (Week 12) post-transplantation

Intervention	Weeks * Percentage of T cells (Mean)
Simulect 40mg + Neoral + Myfortic + Steroids	7.0
Simulect 80mg + Neoral + Myfortic + Steroids	9.9
Simulect 80mg + Certican + Myfortic + Steroids	8.4

Estimated Glomerular Filtration Rate (eGFR) at Day 8 and Week 24

(MDRDa formula) with imputation by last observation carried forward (LOCF) (NCT01596062)
Timeframe: Day 8, Week 24

Intervention	mL/min/1.73m^2 (Mean)
	Day 8	Week 24 (n= 3, 6, 6)
Simulect 40mg + Neoral + Myfortic + Steroids	35.0	31.9
Simulect 80mg + Certican + Myfortic + Steroids	49.9	54.4
Simulect 80mg + Neoral + Myfortic + Steroids	53.8	55.7

Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) According to Type and Severity

Antibody mediated acute rejection: C4d deposition, presence of circulating antidonor antibody, morphologic evidence of acute tissue injury such as acute tubular necrosis-like minimal inflammation or capillary and/or glomerular inflammation and/or thromboses or arterial inflammation. Cellular acute rejection: acute T-cell mediated rejection Type IA: Significant interstitial infiltration (> 25% of parenchyma) and foci of moderate tubulitis (> 4 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IB: Significant interstitial infiltration (> 25% of parenchyma) and foci of severe tubulitis (> 10 mononuclear cells/tubular cross section or group of 10 tubular cells) Type IIA: Mild to moderate intimal arteritis. Type IIB: Severe intimal arteritis comprising > 25% of the lumenal area. Type III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation). (NCT01596062)
Timeframe: Day 84 (Week 12), Week 24 post-transplantation

Intervention	Percentage of participants (Number)
	Day 84 (Week 12): Antibody mediated AR - No	Day 84 (Week 12): Antibody mediated AR - Yes	Day 84 (Week 12): Cellular AR - No	Day 84 (Week 12): Cellular AR - Yes	Day 84 (Week 12): Banff type lA	Day 84 (Week 12): Banff type lB	Day 84 (Week 12): Banff type llA	Day 84 (Week 12): Banff type llB	Day 84 (Week 12): Banff type lll (C AR)	Week 24: Antibody mediated AR - No	Week 24: Antibody mediated AR - Yes	Week 24: Cellular AR - No	Week 24: Cellular AR - Yes	Week 24: Banff type lA	Week 24: Banff type lB	Week 24: Banff type llA	Week 24: Banff type llB	Week 24: Banff type lll
Simulect 40mg + Neoral + Myfortic + Steroids	66.7	33.3	100.0	0.0	0.0	0.0	0.0	0.0	0.0	66.7	33.3	100.0	0.0	0.0	0.0	0.0	0.0	0.0
Simulect 80mg + Certican + Myfortic + Steroids	85.7	14.3	57.1	42.9	14.3	14.3	0.0	14.3	0.0	85.7	14.3	57.1	42.9	0.0	28.6	0.0	14.3	0.0
Simulect 80mg + Neoral + Myfortic + Steroids	100.0	0.0	83.3	16.7	0.0	16.7	0.0	0.0	0.0	100.0	0.0	83.3	16.7	0.0	16.7	0.0	0.0	0.0

Percentage of Participants With of Biopsy Proven Acute Rejection (BPAR)

BPAR is one of the components of treatment failure. One assessment of efficacy was BPAR. Renal graft biopsies were performed and the renal tissue was examined to determine if there was acute rejection of the renal transplant. (NCT01596062)
Timeframe: Day 84 (Week 12), Week 24 post-transplantation

Intervention	Percentage of participants (Number)
	Day 84 (Week 12): No	Day 84 (Week 12):Yes	Week 24: No	Week 24:Yes
Simulect 40mg + Neoral + Myfortic + Steroids	66.7	33.3	66.7	33.3
Simulect 80mg + Certican + Myfortic + Steroids	42.9	57.1	42.9	57.1
Simulect 80mg + Neoral + Myfortic + Steroids	83.3	16.7	83.3	16.7

Percentage of Participants With of Treatment Failures

Treatment failure was defined either as a BPAR, a graft loss, a death or a loss to follow-up. An extended treatment failure was also defined including treated borderline lesions, BPAR, graft loss, death or loss to follow-up. Treated borderline lesions were considered as acute rejection by investigators and DMC experts. (NCT01596062)
Timeframe: Day 84 (Week 12), Week 24

Intervention	Percentage of participants (Number)
	Day84 (Week 12): BPAR and/or borderline lesions-No	Day84 (Week 12):BPAR and/or borderline lesions-Yes	Day 84 (Week 12): Graft loss - No	Day 84 (Week 12): Graft loss - Yes	Day 84 (Week 12): Death - No	Day 84 (Week 12): Death - Yes	Day 84 (Week 12): Loss to follow-up - No	Day 84 (Week 12): Loss to follow-up - Yes	Week 24: BPAR or borderline lesions - No	Week 24: Graft loss - No	Week 24: Death - No	Week 24: Loss to follow-up - No	Week 24: Loss to follow-up - Yes	Week 24: BPAR or borderline lesions - Yes	Week 24: Graft loss - Yes	Week 24: Death - Yes
Simulect 40mg + Neoral + Myfortic + Steroids	66.7	33.3	66.7	33.3	100.0	0.0	100.0	0.0	66.7	66.7	100.0	100.0	0.0	33.3	33.3	0.0
Simulect 80mg + Certican + Myfortic + Steroids	14.3	85.7	100.0	0.0	100.0	0.0	100.0	0.0	14.3	100.0	100.0	100.0	0.0	85.7	0.0	0.0
Simulect 80mg + Neoral + Myfortic + Steroids	66.7	33.3	100.0	0.0	100.0	0.0	100.0	0.0	66.7	100.0	100.0	100.0	0.0	33.3	0.0	0.0

Percentage of T-cells That Bind Basiliximab to CD25 Receptors

This is the percentage of T cells binding basiliximab at all timepoints. (NCT01596062)
Timeframe: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation

Intervention	Percentage of T cells (Mean)
	Day 0 (before injection)	Day 0 (2 hours after injection)	Day 1 (n= 3, 5, 7)	Day 4 (before injection): (n= 3, 6, 6)	Day 4 (2 hours after injection): (n= 3, 5, 5)	Day 6: (n= 3, 6, 6)	Day 14: (n= 3, 6, 6)	Day 21: (n= 3, 6, 6)	Day 28: (n= 3, 6, 6)	Day 42: (n= 3, 6, 5)	Day 56: (n= 3, 6, 5)	Day 84 (Week 12): (n= 3, 6, 5)
Simulect 40mg + Neoral + Myfortic + Steroids	0.0	95.3	70.0	100.0	100.0	91.7	100.0	89.0	76.3	47.3	53.0	6.7
Simulect 80mg + Certican + Myfortic + Steroids	4.7	81.6	91.4	53.0	81.2	98.3	93.8	85.8	82.7	78.8	75.2	15.8
Simulect 80mg + Neoral + Myfortic + Steroids	0.0	96.2	64.8	59.0	83.4	99.0	89.0	87.7	91.0	84.0	88.8	57.7

Proportion of CD3+, CD4+, CD8+, CD19+ and CD56+ T Cells

Cell counts of various subpopulations of T, B and NK lymphocytes (CD3, CD4, CD8, CD19 and CD56) (flow cytometry). (NCT01596062)
Timeframe: Day 0, Day 6, Day 42, Day 84 (Week 12)

Intervention	10^9 cells/L (Mean)
	CD3 cells count at Day 0 (before injection)	CD3 cells count at Day 6: (n= 3, 6, 6)	CD3 cells count at Day 42: (n= 3, 6, 5)	CD3 cells count at Day 84 (Week 12): (n= 3, 6, 6)	CD4 cells count at Day 0 (before injection)	CD4 cells count at Day 6: (n= 3, 6, 6)	CD4 cells count at Day 42: (n= 3, 6, 5)	CD4 cells count at Day 84 (Week 12): (n= 3, 6, 6)	CD8 cells count at Day 0 (before injection)	CD8 cells count at Day 6: (n= 3, 6, 6)	CD8 cells count at Day 42: (n= 3, 6, 5)	CD8 cells count at Day 84 (Week 12): (n= 3, 6, 6)	CD19 cells count at Day 0 (before injection)	CD19 cells count at Day 6: (n=3, 6, 6)	CD19 cells count at Day 42: (n= 3, 6, 5)	CD19 cells count at Day 84 (Week 12): (n= 3, 6, 6)	CD56 cells count at Day 0 (before injection)	CD56 cells count at Day 6: (n= 3, 6, 6)	CD56 cells count at Day 42: (n= 3, 6, 5)	CD56 cells count at Day 84 (Week 12): (n= 3, 6, 6)
Simulect 40mg + Neoral + Myfortic + Steroids	0.5	0.6	0.5	0.8	0.4	0.5	0.3	0.6	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1
Simulect 80mg + Certican + Myfortic + Steroids	0.7	0.9	1.1	1.1	0.5	0.6	0.8	0.7	0.2	0.2	0.4	0.3	0.1	0.2	0.2	0.1	0.2	0.2	0.2	0.1
Simulect 80mg + Neoral + Myfortic + Steroids	0.9	1.1	1.2	1.2	0.6	0.7	0.8	0.8	0.3	0.3	0.3	0.3	0.1	0.2	0.2	0.1	0.2	0.1	0.2	0.1

Saturation Rate of CD25 Antigen Saturation by Basiliximab

CD25 saturation is the percentage of T cells expressing CD25 (NCT01596062)
Timeframe: Day 0, Day 1, Day 4, Day 6, Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84 (Week 12) post-transplantation

Intervention	percentage of T cells (Mean)
	Day 0 (before injection)	Day 0 (2 hours after injection)	Day 1	Day 4 (before injection); (n= 3, 6, 6)	Day 4 (2 hours after injection): (n= 3, 6, 5)	Day 6: (n= 3, 6, 6)	Day 14: (n= 3, 6, 6)	Day 21: (n= 3, 6, 6)	Day 28: (n= 3, 6, 6)	Day 42: (n= 3, 6, 5)	Day 56: (n= 3, 6, 5)	Day 84 (Week 12): (n= 3, 6, 5)
Simulect 40mg + Neoral + Myfortic + Steroids	0.0	93.7	95.7	100.0	96.7	98.7	98.3	100.0	95.3	78.3	65.0	0.0
Simulect 80mg + Certican + Myfortic + Steroids	0.0	94.7	99.0	93.7	84.8	94.0	97.3	92.5	92.7	99.2	94.2	14.2
Simulect 80mg + Neoral + Myfortic + Steroids	0.0	96.7	97.7	96.2	96.3	100.0	96.7	94.5	100.0	100.0	93.3	67.5

Cataract - Incident Cataract

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant	90.7
Systemic Therapy	44.9

Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis

Best-corrected visual acuity was measured as the number of letters read from standard logarithmic visual acuity charts by study-certified examiners who were masked to treatment. Visual acuity was measured at all study visits. The primary outcome was eye-specific change in visual acuity from baseline to 2-year follow-up. Positive change values indicate improved vision while negative change values indicate vision has gotten worse. A change of 7.5 letters is considered clinically meaningful. (NCT00132691)
Timeframe: 24 months

Intervention	letters (Mean)
Flucinolone Acetonide Implant	6.0
Systemic Therapy	3.2

Change in Self-reported Vision-related Function as Measured by the National Eye Institute 25-Item Visual Function Questionnaire (NEI-VFQ 25) Vision Targeted Composite Score From Baseline to 24 Months

The NEI-VFQ 25 measures the effect of visual disability/symptoms with generic health and task-oriented domains. The range for the composite score is 0 to 100; higher scores are associated with better visual function. A change of 4 to 6 points is considered to be a clinically meaningful difference. (NCT00132691)
Timeframe: 24 months

Intervention	units on a scale (composite score) (Mean)
Fluocinolone Acetonide Implant	11.44
Systemic Therapy	6.80

Change in SF-36 Mental Component Score From Baseline to 24 Months

Self-reported health related QoL was measured with the SF 36 survey. The mental component score for the SF 36 is a summary measure of mental health primarily based on the social functioning, role emotional, mental health and vitality domains. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. (NCT00132691)
Timeframe: 24 months

Intervention	units on a scale (Mean)
Flucinolone Acetonide Implant	2.55
Systemic Therapy	-1.1

Change in SF-36 Physical Component Score From Baseline to 24 Months

Self-reported health related QoL was measured with the SF 36 survey. The physical component score for the SF 36 is a summary measure of physical health primarily based on the physical functioning, role physical, bodily pain and general health domains of the survey. The score is scaled to a population norm with a mean of 50 and standard deviation of 10. Higher scores represent better outcomes. The mean change in scores between baseline and 24 months was calculated for each treatment group. A 3 to 5 point difference is considered to be clinically meaningful. (NCT00132691)
Timeframe: 24 months

Intervention	units on a scale (Mean)
Flucinolone Acetonide Implant	1.15
Systemic Therapy	-1.8

Diabetes Mellitus

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of participants (Number)
Flucinolone Acetonide Implant	1.0
Systemic Therapy	3.6

Glaucoma - Incident

Glaucoma was diagnosed by a glaucoma specialist through review of visual fields, clinical data, and fundus images. (NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant	16.5
Systemic Therapy	4.0

Hyperlipidemia - Incident

LDL greater than or equal to 160 mg/mL (NCT00132691)
Timeframe: 24 months

Intervention	percentage of participants at risk (Number)
Flucinolone Acetonide Implant	9.8
Systemic Therapy	11.0

Hypertension Diagnosis Requiring Treatment

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of participants (Number)
Flucinolone Acetonide Implant	4.6
Systemic Therapy	10.5

Intraocular Pressure - Incident IOP Elevation >= 10 mmHg Above Baseline

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Fluocinolone Acetonide Implant	51.8
Systemic Therapy	15.5

Intraocular Pressure - Incident IOP Greater Than or Equal to 24 mm Hg

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant	53.1
Systemic Therapy	18.7

Intraocular Pressure - Incident IOP Greater Than or Equal to 30 mm Hg

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant	32.8
Systemic Therapy	6.3

Intraocular Pressure - IOP-lowering Surgery

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant	26.2
Systemic Therapy	3.7

Intraocular Pressure (IOP) - Incident Use of IOP-lowering Medical Therapy (Percentage of Eyes With Uveitis That Were Not Being Treated With IOP-lowering Medical Therapy at Baseline and Underwent IOP Lowering Therapy During the 24 Month Follow-up.

The percentage of subjects who used topical or systemic treatment for elevated IOP at any time during the 2 year follow-up and were not on IOP-lowering therapy at baseline is reported. (NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis at risk (Number)
Flucinolone Acetonide Implant	61.1
Systemic Therapy	20.1

Macular Edema

center point macular thickness >= 240 micrometers assessed on OCT (Stratus OCT-3 [Carl Zeiss Meditec, Dublin, CA]) as graded by Central Reading Center (NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis (Number)
Flucinolone Acetonide Implant	22
Systemic Therapy	30

Mortality

(NCT00132691)
Timeframe: 24 months

Intervention	percentage of participants (Number)
Flucinolone Acetonide Implant	1.6
Systemic Therapy	0

Uveitis Activity

Uveitis activity was determined by clinician assessment at each study visit. The study ophthalmologist evaluated each eye as active, inactive/never had uveitis or cannot assess. (NCT00132691)
Timeframe: 24 months

Intervention	percentage of eyes with uveitis (Number)
Fluocinolone Acetonide Implant	12
Systemic Therapy	29

Change in Risk Factors for Cardiovascular Morbidity and Chronic Graft Dysfunction as Evidenced by Blood Levels of Homocysteine

(NCT00905515)
Timeframe: 3 years

Intervention	ng/dL (Median)
Remaining on CsA	4.75
Reduced TAC	4.72
Standard TAC	4.89

Optimal Dose of Calcineurin Inhibitor in Long-term Maintenance Kidney Transplant Patients

(NCT00905515)
Timeframe: 3 years

Intervention	ng/dL (Mean)
Remaining on CsA	130.2
Reduced TAC	5.24
Standard TAC	6.90

Renal Function in Patients Converted From Cyclosporine to Prograf

(NCT00905515)
Timeframe: 3 years

Intervention	Change in serum creatinine (mg/dL) (Mean)
Remaining on CsA	0.05
Reduced TAC	0
Standard TAC	0.10

Average Penalties Adjusted Composite Efficacy Score (CFS) Score Over the 4 Months

"Efficacy was assessed every month during the 4-month treatment phase and compared with Baseline using a composite criterion based on:~Keratitis assessed by the modified Oxford scale (7-point ordinal scale, score 0, 0.5, and 1 to 5). On this modified scale, the score 0 corresponded to no staining dots and the score 0.5 to three or less staining dots. A CFS grade of 0 represented complete corneal clearing.~Need for rescue medication.~Occurrence of corneal ulceration.~An efficacy score was calculated as follows:~Patient's score at month X = CFS (Baseline) - CFS (Month X) + penalty (ies) Penalty for rescue medication: -1 (per course, with a maximum of 2 courses between 2 scheduled visits) Penalty for corneal ulceration: -1 (per occurrence).~A positive value indicated improvement.~The maximum CFS is five and the minimum cannot be set due to the number of rescue medication and ulceration which decreases the penalty adjusted CFS." (NCT01751126)
Timeframe: over the 4 months

Intervention	Penalties Adjusted CFS Score (Mean)
High Dose Regimen	2.06
Low Dose Regimen	1.93
Placebo	1.34

Best Corrected Distance Visual Acuity (BCDVA) in 4-month Randomized Period I

Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicates poor vision. (NCT01751126)
Timeframe: Up to Month4

,,,,,

Intervention	letters (Mean)
	Analysis Eye-Baseline	Analysis Eye-Month 1	Analysis Eye-Month 2	Analysis Eye-Month 3	Analysis Eye-Month 4	Analysis Eye-Month 4/ Early Termination
Change From Baseline in LogMAR- High Dose	0	-0.036	-0.071	-0.110	-0.127	-0.135
Change From Baseline in LogMAR- Low Dose	0	-0.058	-0.073	-0.089	-0.110	-0.091
Change From Baseline in LogMAR- Placebo	0	-0.027	0.003	-0.066	-0.109	-0.097
LogMAR - High Dose Regimen	0.293	0.263	0.221	0.172	0.149	0.158
LogMAR - Low Dose Regimen	0.209	0.160	0.146	0.110	0.097	0.114
LogMAR-Placebo	0.302	0.285	0.331	0.273	0.237	0.217

Best Corrected Distance Visual Acuity (BCDVA) in 8-month Safety FU Period- Period II

Best corrected distance visual acuity (BCDVA) was measured with the patient's best correction and recorded in LogMAR (log of the Minimum Angle of Resolution) A negative LogMar BCDVA measure shows an improvement, whereas positive values indicate poor vision. (NCT01751126)
Timeframe: Up to Month12

,,,,,

Intervention	letters (Mean)
	Analysis Eye-Baseline (Month 4)	Analysis Eye-Month 6	Analysis Eye-Month 8	Analysis Eye-Month 10	Analysis Eye-Month 12	Analysis Eye-Month 12/ Early Termination
Change From Baseline in LogMAR- High Dose	0	-0.024	-0.015	-0.014	-0.020	-0.016
Change From Baseline in LogMAR- Placebo	0	-0.017	-0.029	-0.044	-0.030	-0.030
Change From Baseline in LogMAR- Total	0	-0.022	-0.019	-0.023	-0.023	-0.020
LogMAR - High Dose Regimen	0.152	0.128	0.141	0.141	0.134	0.136
LogMAR - Placebo	0.250	0.258	0.222	0.207	0.220	0.220
LogMAR-Total	0.181	0.168	0.165	0.160	0.160	0.161

Number of Courses of Rescue Medication in Period I

Use of rescue medication: the total number of topical corticosteroid courses was assessed at each visit during the 4-month efficacy evaluation treatment period. (NCT01751126)
Timeframe: Up to Month4

Intervention	Participants (Count of Participants)
	Month1, zero course	Month 1, one course	Month1, two courses	Month2, zero course	Month 2, one course	Month 2, two courses	Month3, zero course	Month3, one course	Month 3, two courses	Month4, zero course	Month4, one course	Month 4, two courses	Month 4/Early Termination, zero course	Month 4/Early Termination, one course	Month 4/Early Termination, two courses
High Dose Regimen	51	3	0	45	6	2	43	7	1	42	6	2	46	7	3
Low Dose Regimen	41	7	2	43	2	2	42	2	2	41	2	1	46	5	3
Placebo	44	11	2	38	11	3	34	12	4	38	8	2	43	11	4

Proportion of Participants Successfully Withdrawn and Remain Off Immunosuppressants

This measure of tolerance induction includes the proportion of participants who qualify for immunosuppression withdrawal as determined by a review of individual clinical results by a protocol withdrawal committee, were successfully withdrawn from immunosuppressants, and remained off immunosuppressants at the time the trial ended. Successful withdrawal definition: participants who remain off immunosuppression for at least 8 weeks and do not restart immunosuppressant drugs after successful withdrawal. (NCT00105235)
Timeframe: From 1 year post- transplantation until study completion or participant termination (participants followed up to 48 months post-transplant)

Intervention	Proportion of Participants (Number)
Alemtuzumab	0.1

Proportion of Participants Successfully Withdrawn From Immunosuppressants

This measure of tolerance induction includes the proportion of participants who qualify for immunosuppression withdrawal as determined by a review of individual clinical results by a protocol withdrawal committee. Successful withdrawal definition: participants who remain off immunosuppression for at least 8 weeks. (NCT00105235)
Timeframe: From 1 year post- transplantation until study completion or participant termination (participants followed up to 48 months post-transplant)

Intervention	Proportion of Participants (Number)
Alemtuzumab	0.2

Proportion of Participants Who Had Graft Loss or Death

Proportion of participants who had liver graft loss or who died or terminated from the study within 2 years of initiating immunosuppression withdrawal (NCT00105235)
Timeframe: Within 2 years after initiation of immunosuppression withdrawal

Intervention	Proportion of Participants (Number)
Alemtuzumab	0

Proportion of Participants Who Have Graft Loss or Death

Proportion of participants who had liver graft loss or who died within 1 year of undergoing transplantation. Note: Participants who discontinued treatment or terminated the study prior to 1 year post transplantation are considered treatment failures and are included in this measure. (NCT00105235)
Timeframe: Within 1 year of post-transplantation

Intervention	Proportion of Participants (Number)
Alemtuzumab	0.22

Number of Events: Immunosuppression-related Complications

Certain events are associated with immunosuppression. This measure looks at post-transplant infection, post-transplant malignancies, post-transplant diabetes, and post-transplant renal failure. Immunosuppression withdrawal is intended to reduce these type of events. However, reduction in immunosuppression can lead to complications in liver and renal function, as measured by acute rejection, chronic rejection, and post-transplant renal failure. Lower numbers for any of these events indicates greater success with transplantation and immunosuppression withdrawal (where applicable) (NCT00105235)
Timeframe: From transplantation until study completion or participant termination (participants followed up to 60 months)

,,,

Intervention	Events (Number)
	Acute Rejection	Chronic Rejection	Post-transplant Infection	Post-transplant Malignancies	Post-transplant Diabetes	Post-transplant Renal Failure
Completed Withdrawal and Remains Off Immunosuppression	0	0	2	0	0	0
Completed Withdrawal and Restarted Immunosuppression	0	0	10	0	0	2
Discontinued Immunosuppression Withdrawal	0	0	11	0	1	1
Withdrawal Never Started	6	1	76	1	0	11

Change in Glomerular Filtration Rate Estimated by Iohexol Plasma Clearance 12 Months After Randomization Between the 2 Groups of Patients.

Primary efficacy endpoint: between treatment analysis of change in iohexol plasmatic clearance (mL/min) from baseline to Month 12 (M12) (NCT00425308)
Timeframe: From Baseline to Month 12

Intervention	(mL/min) (Least Squares Mean)
Cyclosporine	-4.07
Enteric-coated Mycophenolate Sodium (EC-MPS)	10.30

Change in the Glomerular Filtration Rate Estimated by Iohexol Plasma Clearance 12 Months After Randomization Between the 2 Groups of Patients Who Completed Trial

Primary efficacy endpoint: between treatment analysis of change in iohexol plasmatic clearance (mL/min) from baseline to Month 12 (M12) (NCT00425308)
Timeframe: From Baseline to Month 12

Intervention	(mL/min) (Least Squares Mean)
Cyclosporine	1.46
Enteric-coated Mycophenolate Sodium (EC-MPS)	12.00

Assessing Cardiovascular Risk Factors Based on Fasting C-reactive Protein (CRP).

Blood chemistry - C-reactive Protein (CRP) (mg/L) (NCT00425308)
Timeframe: From Baseline to Month 3, 6, and 12

Intervention	mg/L (Mean)
	Baseline [N = 13; N = 14]	Month 3 [N = 11; N = 11]	Month 6 [N = 11; N = 9]	Month 12 [N = 14; N = 12]
Cyclosporine	11.4	6.3	8.0	34.2
Enteric-coated Mycophenolate Sodium (EC-MPS)	3.0	10.3	5.6	12.6

Assessing Cardiovascular Risk Factors Based on Fasting Glucose.

Blood chemistry - fasting glycemia (mmol/L) (NCT00425308)
Timeframe: From Baseline to Month 1, 3, 6, 9, and 12

Intervention	mmol/L (Mean)
	Baseline [N = 15; N = 15]	Month 1 [N = 15; N = 15]	Month 3 [N = 14; N = 15]	Month 6 [N = 14; N = 14]	Month 9 [N = 12; N = 13]	Month 12 [N = 14; N = 13]
Cyclosporine	5.5	5.2	5.6	5.5	5.3	4.8
Enteric-coated Mycophenolate Sodium (EC-MPS)	5.2	5.3	5.2	5.1	5.6	5.4

Assessing Cardiovascular Risk Factors Based on Fasting High-density Lipoprotein (HDL) Cholesterol, Low-density Lipoprotein (LDL) Cholesterol.

(NCT00425308)
Timeframe: From Baseline to Month 3, 6, and 12

Intervention	mmol/L (Mean)
	Baseline LDL [N = 10; N = 14]	Baseline HDL [N = 10; N = 14]	Month 3 LDL [N = 12; N = 14]	Month 3 HDL [N = 12; N = 13]	Month 6 LDL [N = 12; N = 12]	Month 6 HDL [N = 12; N = 12]	Month 12 LDL [N = 10; N = 11]	Month 12 HDL [N = 10; N = 11]
Cyclosporine	3.4	1.5	3.2	1.7	3.2	1.6	3.0	1.7
Enteric-coated Mycophenolate Sodium (EC-MPS)	3.1	1.5	3.4	1.5	3.3	1.4	3.2	1.5

Assessing Cardiovascular Risk Factors Based on Fasting Total Cholesterol.

Blood chemistry - total cholesterol (mmol/L) (NCT00425308)
Timeframe: From Baseline to Month 1, 3, 6, 9, and 12

Intervention	mmol/L (Mean)
	Baseline [N = 13; N = 14]	Month 1 [N = 11; N = 14]	Month 3 [N = 13; N = 14]	Month 6 [N = 12; N = 12]	Month 9 [N = 9; N = 12]	Month 12 [N = 12; N = 11]
Cyclosporine	5.7	5.0	5.3	5.5	5.4	5.6
Enteric-coated Mycophenolate Sodium (EC-MPS)	6.0	5.7	5.6	5.7	5.4	5.8

Assessing Cardiovascular Risk Factors Based on Fasting Triglycerides.

(NCT00425308)
Timeframe: From Baseline to Month 1, 3, 6, 9, and 12

Intervention	mmol/L (Mean)
	Baseline [N = 11; N = 14]	Month 1 [N = 10; N = 14]	Month 3 [N = 13; N = 14]	Month 6 [N = 12; N = 12]	Month 9 [N = 10; N = 12]	Month 12 [N = 12; N = 11]
Cyclosporine	2.4	2.1	2.0	1.9	1.9	2.3
Enteric-coated Mycophenolate Sodium (EC-MPS)	1.8	2.0	2.2	2.1	2.2	2.3

Change in Renal Function Assessed by Creatinine Clearance at Month 3, Month 6 and Month 12

Change in creatinine clearance, Nankivell formula (mL/min/1.73m²) from baseline to M12 (NCT00425308)
Timeframe: From Baseline to Month 3, 6, and 12

Intervention	mL/min/1.73m² (Mean)
	Baseline [N = 12; N = 13]	Month 3 [N = 10; N = 14]	Month 6 [N = 10; N = 12]	Month 12 [N = 7; N = 11]
Cyclosporine	56.3	57.3	50.3	48.7
Enteric-coated Mycophenolate Sodium (EC-MPS)	60.3	67.1	68.1	70.1

Change in Renal Function Assessed by Proteinuria at Month 3, Month 6 and Month 12

Change in proteinuria (g/24h) from baseline to M12 (NCT00425308)
Timeframe: From Baseline to Month 3, 6, and 12

Intervention	g/24h (Mean)
	Baseline [N = 9; N = 10]	Month 3 [N = 9; N = 8]	Month 6 [N = 6; N = 5]	Month 12 [N = 7; N = 10]
Cyclosporine	0.44	0.53	0.44	0.48
Enteric-coated Mycophenolate Sodium (EC-MPS)	0.47	0.24	0.33	0.75

Change in Renal Function Assessed by Serum Creatinine at Month 3, Month 6 and Month 12

(NCT00425308)
Timeframe: From Baseline to Month 3, 6, and 12

Intervention	µmol/L (Mean)
	Baseline [N = 13; N = 14]	Month 3 [N = 12; N = 14]	Month 6 [N = 12; N = 13]	Month 12 [N = 13; N = 14]
Cyclosporine	161.7	156.6	170.8	227.7
Enteric-coated Mycophenolate Sodium (EC-MPS)	153.2	138.9	139.8	130.4

Number of Participants With Biopsy-proven Acute Rejection (BPAR) at Month 6 and Month 12.

(NCT00425308)
Timeframe: Month 6 and 12

Intervention	participants (Number)
	Yes: treatment failure Month 6	No: treatment failure Month 6	Yes: treatment failure Month 12	No: treatment failure Month 12
Cyclosporine	0	0	1	12
Enteric-coated Mycophenolate Sodium (EC-MPS)	0	0	0	14

Number of Participants With Treatment Failures Assessed by Biopsy-proven Acute Rejection (BPAR), Graft Loss/Re-transplantation, Death or Lost to Follow-up at Month 12.

(NCT00425308)
Timeframe: Month 12

Intervention	participants (Number)
	BPAR 12 months	Graft Loss 12 months	Death 12 months	Lost to Follow-up 12 months
Cyclosporine	1	0	1	0
Enteric-coated Mycophenolate Sodium (EC-MPS)	0	0	0	0

Number of Patients With Treatment Failure 6-months Post Transplant Measured by the Combined Incidence of Biopsy Proven Acute Rejection, Graft Loss, and Death

To evaluate therapeutic benefit by comparing the efficacy defined as the number of participants with treatment failure (biopsy-proven acute rejection [BPAR], graft loss [GFL] or death) at 6 months post-transplant. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.) (NCT00419926)
Timeframe: 6 months

Intervention	number of participants (Number)
Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen	33
Standard Mycophenolate Sodium (Myfortic) Dosing Regimen	36
Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen	26
Standard Mycophenolate Sodium (Myfortic) Dosing Regimen	35

Comparison of Overall Treatment Failure at Days 21 and 84 Post-transplantation Assessed by Biopsy Proven Acute Rejection (BPAR), GFL, and Death

The overall treatment differences of the number of participants with at least one occurrence of the composite event BPAR, GFL or death at study days 21 and 84 post-transplantation. BPAR was defined as a biopsy graded IA, IB, IIA, IIB or III using Banff 2000 classification. A graft core biopsy was performed within 24 hours of initiation of anti-rejection therapy. GFL was defined as the day the allograft was presumed lost (the day the patient started dialysis, the day of nephrectomy or the day of irreversible graft loss demonstrated by imaging techniques.) (NCT00419926)
Timeframe: 21 and 84 days

Intervention	number of participants (Number)
	Day 84	Day 21
Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen	20	33	14	26
Standard Mycophenolate Sodium (Myfortic) Dosing Regimen	21	34	20	33

Renal Function Assessed by Glomerular Filtration Rate (GFR)at Each Visit

The Modification of Diet in Renal Disease (MDRD) formula was used to calculate the GFR. Serum creatinine levels, age, sex and race were used to estimate the GFR levels in mL/min/1.73m^2. (NCT00419926)
Timeframe: at 21 days, 84 days and 180 days

Intervention	(mL/min/1.73m^2) (Mean)
	At 21 days	At 84 days	At 180 days
Intensified Mycophenolate Sodium (Myfortic) Dosing Regimen	47.3	52.1	53.5
Standard Mycophenolate Sodium (Myfortic) Dosing Regimen	46.8	51.8	51.3

Number of Participants With Engraftment Syndrome

(NCT00412360)
Timeframe: Day 100 post-transplant

Intervention	Participants (Count of Participants)
Single UCB Transplant	11
Double UCB Transplant	7

Percentage of Participants With Disease-free Survival

Disease-free survival is defined as survival without relapse of the primary disease. (NCT00412360)
Timeframe: 1 year post-randomization

Intervention	percentage of participants (Number)
Single UCB Transplant	70
Double UCB Transplant	64

Percentage of Participants With Overall Survival

Overall survival is defined as survival of death from any cause. (NCT00412360)
Timeframe: 1 year post-randomization

Intervention	percentage of participants (Number)
Single UCB Transplant	73
Double UCB Transplant	65

Percentage of Participants With Relapse

Relapse is defined by either morphological or cytogenetic evidence of AML, ALL, CML, or MDS consistent with pre-transplant features. Testing for recurrent malignancy in the blood, marrow or other sites will be used to assess relapse after transplantation. (NCT00412360)
Timeframe: 1 year post-randomization

Intervention	percentage of participants (Number)
Single UCB Transplant	12
Double UCB Transplant	14

Percentage of Participants With Treatment-related Mortality

Treatment related mortality is defined as death without relapse of the primary disease. (NCT00412360)
Timeframe: 1 year post-randomization

Intervention	percentage of participants (Number)
Single UCB Transplant	19
Double UCB Transplant	22

Percentage of Participants With Acute Graft-versus-host Disease (GVHD)

"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL~2-3 mg/dL~3.01-6 mg/dL~6.01-15.0 mg/dL~>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT00412360)
Timeframe: Day 100 post-randomization

Intervention	percentage of participants (Number)
	Acute GVHD Grade II-IV	Acute GVHD Grade III-IV
Double UCB Transplant	56	23
Single UCB Transplant	57	13

Percentage of Participants With Chronic GVHD

Incidences of chronic GVHD will be graded per Shulman et al. 1980. This reference categorizes chronic GVHD as either limited or extensive. For this outcome, participants developing either type are considered to have a chronic GVHD event. (NCT00412360)
Timeframe: 1 year post-randomization

Intervention	percentage of participants (Number)
	Chronic GVHD	Extensive Chronic GVHD
Double UCB Transplant	32	15
Single UCB Transplant	30	9

Percentage of Participants With Neutrophil and Platelet Engraftment

Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for three consecutive measurements on different days. The first of the three days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 50,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days. (NCT00412360)
Timeframe: Days 42 and 100

Intervention	percentage of participants (Number)
	Neutrophil Engraftment at Day 42	Platelet Engraftment at Day 100
Double UCB Transplant	88	65
Single UCB Transplant	89	76

Time to Neutrophil and Platelet Engraftment

Platelet engraftment is defined as achieving platelet counts greater than 50,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days. (NCT00412360)
Timeframe: 2 years post-transplant

Intervention	days (Median)
	Neutrophil Engraftment	Platelet Engraftment
Double UCB Transplant	23	84
Single UCB Transplant	21	58

2-year Overall Survival

Overall survival (OS) was calculated from the time of transplant to death from any cause or censored at last follow-up. Survival data were analyzed by Kaplan-Meier method. (NCT00058825)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Stem Cell Transplant	33.3

2-year Relapse-free Survival

Relapse-free survival (RFS) was calculated from the time of transplant to the date of relapse, death, or last follow-up, whichever occurred first. Survival data were analyzed by Kaplan-Meier method. (NCT00058825)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Stem Cell Transplant	25.9

Median Time to Engraftment With the Isolex/CLINIMACs System

Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days. (NCT00058825)
Timeframe: 30 days

Intervention	days (Median)
Isolex	12
CLINIMACs	12

Number of Patients Who Engrafted With the Isolex/CLINIMACs System

Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days. (NCT00058825)
Timeframe: 30 days

Intervention	participants (Number)
Isolex	15
CLINIMACs	7

Time in Days to ANC Engraftment

Engraftment was defined as the day of absolute neutrophil counts (ANC) exceeded 0.5 X 10^9/L on the first of 3 days. (NCT00058825)
Timeframe: 30 days

Intervention	days (Median)
Stem Cell Transplant	12

Transplant Related Mortality (TRM)

Percentage of patients with transplant related mortality (NCT00058825)
Timeframe: 100 days

Intervention	percentage of participants (Number)
Stem Cell Transplant	0

Acute Graft Versus Host Disease

Number of patients with Acute Graft Versus Host Disease within 100 days post-transplant (NCT00058825)
Timeframe: 100 days

Intervention	participants (Number)
	Grade 0	Grade I	Grade II	Grade III	Grade IV
Stem Cell Transplant	26	0	0	1	0

Chronic Graft Versus Host Disease

Number of patients with Chronic Graft Versus Host Disease within 1 year post-transplant (NCT00058825)
Timeframe: 1 year

Intervention	participants (Number)
	Yes	No
Stem Cell Transplant	1	26

Donor Chimerism Engraftment of Greater Than 50%

Number of patients that engrafted who showed a chimerism (donor cells) of greater than 50% in the first 30 days (NCT00058825)
Timeframe: 30 days

Intervention	participants (Number)
	Yes	No
Stem Cell Transplant	20	2

Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)

The change in creatinine clearance over time assessed using the random coefficient slope of the regression line with creatinine clearance as the dependent variable and study day as the independent variable. Time points calculated as study days, relative to time of randomization of study medication. Observed data multiplied by a scale factor of 365 to express an annual change. (NCT00369382)
Timeframe: Baseline to discontinuation (up to Week 52)

Intervention	mL/min/1.73m^2 (Number)
Cyclosporine or Tacrolimus	-0.740
Sirolimus (SRL)	1.571

Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline

Creatinine clearance at baseline calculated using Cockcroft-Gault equation and adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2. (NCT00369382)
Timeframe: Baseline

Intervention	mL/min/1.73m^2 (Mean)
Cyclosporine or Tacrolimus	57.09
Sirolimus (SRL)	57.75

Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline

Creatinine clearance calculated using MDRD equation. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2. (NCT00369382)
Timeframe: Baseline

Intervention	mL/min/1.73m^2 (Mean)
Cyclosporine or Tacrolimus	55.39
Sirolimus (SRL)	54.47

Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization

Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is greater than or equal to (≥) 90 milliliters per minute per 1.73 meters squared (mL/min/1.73m^2). Change from baseline=CC at Week 52 minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center. (NCT00369382)
Timeframe: Baseline and Week 52

Intervention	mL/min/1.73m^2 (Least Squares Mean)
Cyclosporine or Tacrolimus	-1.35
Sirolimus (SRL)	3.03

Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy

(NCT00369382)
Timeframe: Baseline up to Week 52

Intervention	Participants (Number)
Sirolimus (SRL)	21

Number of Participants Requiring Antibody Use in Treatment of Acute Rejection

Number of participants requiring antilymphocyte antibody therapy with suspected or biopsy-proven, steroid-resistant, acute rejection with or without hemodynamic compromise. Acute rejection based on ISHLT 1990 criteria: all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis. (NCT00369382)
Timeframe: Baseline to Week 52

Intervention	Participants (Number)
Cyclosporine or Tacrolimus	1
Sirolimus (SRL)	0

Serum Creatinine Level at Baseline

Intervention	mcmol/L (Mean)
Cyclosporine or Tacrolimus	125.42
Sirolimus (SRL)	126.21

Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 4, 16, 24, 32, and 40 Weeks Post-randomization

Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center. (NCT00369382)
Timeframe: Baseline and Weeks 4, 16, 24, 32, and 40

Intervention	mL/min/1.73m^2 (Least Squares Mean)
	Week 4	Week 16	Week 24	Week 32	Week 40
Cyclosporine or Tacrolimus	-0.20	-2.16	-1.91	-0.76	0.34
Sirolimus (SRL)	2.96	3.79	2.15	2.22	2.70

Change From Baseline in Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at 4, 16, 24, 32, 40 and 52 Weeks Post-randomization

Creatinine clearance calculated using MDRD equation. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function. Least squares mean adjusted for baseline calculated creatinine clearance (MDRD) and center. (NCT00369382)
Timeframe: Baseline and Weeks 4, 16, 24, 32, 40 and 52

Intervention	mL/min/1.73m^2 (Least Squares Mean)
	Week 4	Week 16	Week 24	Week 32	Week 40	Week 52
Cyclosporine or Tacrolimus	-0.00	-1.92	-1.47	-0.15	0.69	-0.90
Sirolimus (SRL)	3.18	4.30	2.54	2.44	2.69	3.26

Change From Baseline in Serum Creatinine Level at 4, 16, 24, 32, 40, and 52 Weeks Post-randomization

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent. Change from baseline=creatinine level at Week x minus baseline level where higher scores represented decreased kidney function. Least squares mean adjusted for treatment group and center. (NCT00369382)
Timeframe: Baseline and Weeks 4, 16, 24, 32, 40, and 52

Intervention	mcmol/L (Least Squares Mean)
	Week 4	Week 16	Week 24	Week 32	Week 40	Week 52
Cyclosporine or Tacrolimus	1.68	7.96	8.02	4.08	2.44	4.76
Sirolimus (SRL)	-4.95	-5.52	-0.89	-2.80	2.81	-4.39

Number of Participants With Acute Rejection

Based on International Society for Heart and Lung Transplantation [ISHLT] 1990 criteria: rejections Grade 3A or higher, rejection accompanied by hemodynamic compromise or requiring treatment. Grade 3A or higher included: multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis. Biopsies performed for clinically suspected rejection (for cause), site's standard of care (site protocol biopsy), or protocol mandated. (NCT00369382)
Timeframe: Baseline to Week 52

Intervention	Participants (Number)
	For cause biopsies (n=57, 57)	Standard of Care biopsies (n=11, 11)	Protocol mandated biopsies (n=0, 39)
Cyclosporine or Tacrolimus	1	0	NA
Sirolimus (SRL)	5	2	7

Number of Participants With Biopsy-confirmed Acute Rejection by Severity

Severity of acute rejection summarized using revised 2005 ISHLT criteria. Grade 0R: no rejection, Grade 1R: Focal (perivascular or interstitial) infiltrate without necrosis, diffuse but sparse infiltrate without necrosis, or one focus only with aggressive infiltration and/or focal myocyte damage, Grade 2R:Multifocal aggressive infiltrates and/or myocyte damage, and Grade 3R:Diffuse inflammatory process with necrosis, or diffuse aggressive polymorphous with necrosis, increased infiltrate, changes in edema, hemorrhage and vasculitis. (NCT00369382)
Timeframe: Baseline to Week 52

Intervention	Participants (Number)
	Grade 0R protocol mandated	Grade 0R for cause	Grade 0R site protocol	Grade 1R protocol mandated	Grade 1R for cause	Grade 1R site protocol	Grade 2R protocol mandated	Grade 2R for cause	Grade 2R site protocol	Grade 3R protocol mandated	Grade 3R for cause	Grade 3R site protocol
Cyclosporine or Tacrolimus	NA	0	0	NA	0	0	NA	0	0	NA	1	0
Sirolimus (SRL)	0	0	0	0	0	0	6	4	1	1	1	1

Immune Response

Immune cell depletion is defined as immunosuppression of participants T cells prior to transplant measured by cluster of differentiation 4 (CD4) counts (i.e. cells) > 50 cells per ul.Immune T-cell depletion helps to reduce the ability to reject allogeneic cells in participants and is required for engraftment. Engraftment is the body's ability to accept donor cells. (NCT00006184)
Timeframe: 105 days

Intervention	Particpants (Number)
Recipient - Chemotherapy Group	7

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module. (NCT00006184)
Timeframe: 9 years

Intervention	Participants (Count of Participants)
Recipient - Chemotherapy Group	10
Donor - Vaccination Generation Group	10

Incidence of Chronic Extensive GVHD

Percentage patients with chronic extensive GVHD, estimated by cumulative incidence methods (NCT00075478)
Timeframe: 3 years after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	72
Arm II (TBI, Transplant, GVHD Prophylaxis)	48

Incidence of Grades II-IV Acute GVHD

Percentage patients with grades II-IV GHVD, estimated by cumulative incidence methods (NCT00075478)
Timeframe: 120 days after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	46
Arm II (TBI, Transplant, GVHD Prophylaxis)	32

Incidence of Graft Rejection

Donor CD3 chimerism less than 5% (NCT00075478)
Timeframe: 1 year after transplant

Intervention	participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	0
Arm II (TBI, Transplant, GVHD Prophylaxis)	2

Incidence of Non-relapse Mortality

Percentage of NRM as estimated by cumulative incidence methods with competing risks (NCT00075478)
Timeframe: 3 years after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	7
Arm II (TBI, Transplant, GVHD Prophylaxis)	9

Incidence of Relapse-related Mortality

Percentage of death following relapse/progression, estimated by cumulative incidence methods (NCT00075478)
Timeframe: 3 years after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	28
Arm II (TBI, Transplant, GVHD Prophylaxis)	37

Incidence of Relapse/Progression

Percentage of relapse estimated by cumulative incidence methods (NCT00075478)
Timeframe: 3 years after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	40
Arm II (TBI, Transplant, GVHD Prophylaxis)	55

Overall Survival

Percentage of patients surviving as estimated by Kaplan-Meier. (NCT00075478)
Timeframe: 3 years after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	65
Arm II (TBI, Transplant, GVHD Prophylaxis)	54

Progression-free Survival

Percentage of patients with progression-free survival, estimated by cumulative incidence methods (NCT00075478)
Timeframe: 3 years after transplant

Intervention	percentage of participants (Number)
Arm I (Chemotherapy, TBI, Transplant, GVHD Prophylaxis)	53
Arm II (TBI, Transplant, GVHD Prophylaxis)	36

Days to Engraftment of Lymphocytes

Lymphocyte recovery: designated by the first of 3 consecutive days with absolute lymphocyte count (ALC) above 500/mm(3). (NCT00520130)
Timeframe: 2 years

Intervention	Days (Median)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	16
B - Cyclosporine (AC Arm)	76

Days to Engraftment of Neutrophils

Days to engraftment is defined as neutrophil recovery: designated by the first of 3 consecutive days with an absolute neutrophil count (ANC) above 500/mm(3). (NCT00520130)
Timeframe: 2 years

Intervention	Days to neutrophil engraftment (Median)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	11
B - Cyclosporine (AC Arm)	9

Days to Engraftment of Platelets

Platelet recovery: designated by the first of 7 days where the platelet count remains above 20,000/mm(3) without transfusion support (NCT00520130)
Timeframe: 2 years

Intervention	Days (Median)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	19
B - Cyclosporine (AC Arm)	14

Early Treatment Related Mortality

Any death occurring within 28 days after transplantation in a patient in continuous remission. (NCT00520130)
Timeframe: Less than or equal to 28 days after transplantation

Intervention	participants (Number)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	1
B - Cyclosporine (C) Arm	0

Overall Survival

Time between the first day of transplant to the day of death. (NCT00520130)
Timeframe: Patients were followed for an average of up to 5 years.

Intervention	Months (Median)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	41.7
B - Cyclosporine (AC) Arm	18.8

Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)

Acute GVHD is assessed by the 1994 Consensus Conference on Acute GVHD Grading criteria. See Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8., for grading criteria. (NCT00520130)
Timeframe: 6 months

Intervention	percentage of participants (Number)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	42
B - Cyclosporine (AC) Arm	38

Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)

Acute GVHD is assessed by the 1994 Consensus Conference on acute GVHD Grading criteria. See Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8., for grading criteria. (NCT00520130)
Timeframe: 6 months

Intervention	percentage of participants (Number)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	13
B - Cyclosporine (AC) Arm	21

Percentage of Participants With Late Treatment Related Mortality

Any death occurring 28 days or more after transplantation in a patient in continuous remission. (NCT00520130)
Timeframe: Greater than 28 days after transplantation

Intervention	percentage of participants (Number)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	28
B - Cyclosporine (AC) Arm	29

Toxicities

Here are the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00520130)
Timeframe: 103 months and 22 days

Intervention	participants (Number)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	43
B - Cyclosporine (AC) Arm	42

Changes in CD8 T Cell Receptor Vbeta Repertoire

Ribonucleic acid (RNA) was extracted from sorted CD4 and cluster of differentiation 8 (CD8) T cells and analyzed for Vbeta repertoire by nested polymerase chain reaction (PCR) analysis using Vbeta family specific primers and a labeled constant region primer (spectratyping). The receptor repertoire diversity was calculated from spectratyping data by creating a normal standard for repertoire diversity from healthy normal controls and assessing the divergence of individual patient's T cell receptor repertoire from these standard normal donor values. In this Vbeta repertoire divergence index, lower numbers are consistent with a more normal highly diverse repertoire, and high numbers represent a highly skewed, oligoclonal repertoire. The assay is described in Memon SA et al, J Immunol Methods, 2012, 375: 84-92. The repertoire diversity of the CD4 and CD8 T cells of the donor infusion is shown for comparison. (NCT00520130)
Timeframe: Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant

Intervention	Divergence index (Median)
	1 month	3 months	6 mo (TMS=7; AC= 9)	12 mo (TMS=7; AC= 9)	Donor CD8 cells (TMS=8; AC= 8)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	62	54	62	55	47
B - Cyclosporine (AC) Arm	78	81	84	89	43

Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire

Intervention	Divergence index (Median)
	1 month	3 months	6 mo (TMS=7; AC= 9)	12 mo (TMS=7; AC=9)	Donor CD4 cells (TMS=8; AC=8)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	48	31	35	30	23
B - Cyclosporine (AC) Arm	90	66	75	67	22

Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations

Cluster of Differentiation 3 (CD3)+CD4+ and CD3+Cluster of Differentiation 8 (CD8)+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count. (NCT00520130)
Timeframe: 2 weeks, and 1, 3, 6, 12 and 24 months post transplant

Intervention	Cells/µl (Median)
	2 weeks	1 month	3 months	6 months	12 months	24 months
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	171	285	297	387	447	451
B - Cyclosporine (AC) Arm	0	21	61	121	132	373

Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations

Cluster of differentiation 3 (CD3)+cluster of differentiation 4 (CD4)+ and CD3+CD8+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count. (NCT00520130)
Timeframe: 2 weeks, 1, 3, 6, 12 and 24 months post transplant

Intervention	Cells/µl (Median)
	2 weeks	1 month	3 months	6 months	12 months	24 months
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	72	204	334	429	485	434
B - Cyclosporine (AC) Arm	1	6	54	158	243	502

Immune Reconstitution of Normal Killer (NK) Cells

Cluster of differentiation 3 (CD3) - cluster of differentiation 56 (CD56) + Natural Killer (NK) cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count. (NCT00520130)
Timeframe: 2 weeks, and 1, 3, 6, 12, and 24 months post transplant

Intervention	Cells/µl (Median)
	2 weeks	1 month	3 months	6 months	12 months	24 months
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	123	270	134	136	134	133
B - Cyclosporine (AC) Arm	15	31	124	202	150	307

Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)

Chronic GVHD is assessed by the 2005 Chronic GVHD Consensus Project. First the individual organ scoring is done, and then based on that the Global score is determined (mild-moderate-severe). See Citation: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56., for grading criteria. (NCT00520130)
Timeframe: 2 years post transplant

Intervention	percentage of participants (Number)
	Moderate or Severe cGVHD	Severe cGVHD
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	50	28
B - Cyclosporine (AC) Arm	12	5

Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells

The percentage of C-C motif chemokine receptor 7 (CCR7)+CD45RA+ naïve T cells within the CD4 T cell populations was determined by flow cytometry. (NCT00520130)
Timeframe: Recipient recovery at 6, 12 and 24 months post transplant

Intervention	% of naive (CCR7+CD45RA+) CD4 Cells (Median)
	6 mo (TMS=28; AC= 28)	12 mo (TMS=25; AC= 21)	24 mo (TMS=18; AC= 13)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	24	22	20
B - Cyclosporine (AC) Arm	1	7	25

Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells

The percentage of CCR7+CD45RA+ naïve T cells within the CD4 and CD8 T cell populations was determined by flow cytometry. (NCT00520130)
Timeframe: Recipient recovery at 6, 12 and 24 months post transplant

Intervention	% of naive (CCR7+CD45RA+) CD8 Cells (Median)
	6 mo (TMS=28; AC= 28)	12 mo (TMS=25; AC= 21)	24 mo (TMS=18; AC= 13)
A - Tacrolimus, Methotrexate, Sirolimus (TMS) Arm	20	17	16
B - Cyclosporine (AC) Arm	3	6	6

Number of Participants (Patients) Who Attained Neutrophil Engraftment

"Defined as absolute neutrophils (ANC) > 5 x 10^8/Liter for 3 consecutive days.~ANC is the real number of white blood cells (WBCs) that are neutrophils. The absolute neutrophil count is commonly called the ANC. The ANC is not measured directly. It is derived by multiplying the WBC count times the percent of neutrophils in the differential WBC count. The percent of neutrophils consists of the segmented (fully mature) neutrophils) + the bands (almost mature neutrophils). The normal range for the ANC = 1.5 to 8.0 (1,500 to 8,000/mm3)." (NCT00354172)
Timeframe: Day 42 Post Transplant

Intervention	Participants (Number)
Evaluable Patients	13

Number of Participants (Patients) Who Attained Platelet Engraftment

Platelet engraftment is defined as platelet counts > 50 x 10^9/Liter for 3 consecutive days. (NCT00354172)
Timeframe: 1 Year Post Transplant

Intervention	Participants (Number)
Evaluable Patients	5

Number of Participants (Patients) Who Died by 12 Months

Number of patients who died after receiving treatment within 12 months post transplant. (NCT00354172)
Timeframe: 1 year Post Transplant

Intervention	Participants (Number)
Evaluable Patients	14

Number of Participants (Patients) Who Died by 24 Months

Number of patients who died after receiving treatment within 24 months post transplant. (NCT00354172)
Timeframe: 2 years post-transplant

Intervention	Participants (Number)
Evaluable Patients	15

Number of Participants (Patients) Who Died Due to Transplant.

Patients who had transplant-related mortality (TRM). TRM = adverse event(s) that occur(s) after the patient has received a transplant, the principal investigator decides it is related to the procedure and the patient dies within 6 months. (NCT00354172)
Timeframe: 6 Months Post Transplant

Intervention	Participants (Number)
Evaluable Patients	4

Number of Participants (Patients) Who Experienced Relapse by 12 Months

Number of patients who experienced recurrence or progression of disease from the time of transplant. (NCT00354172)
Timeframe: 1 Year Post Transplant

Intervention	Participants (Number)
Evaluable Patients	10

Number of Participants (Patients) Who Experienced Relapse by 24 Months

Number of patients who experienced recurrence or progression of disease from the time of transplant. (NCT00354172)
Timeframe: 2 Years Post transplant

Intervention	Participants (Number)
Evaluable Patients	11

Number of Participants (Patients) Who Were Disease-free and Alive at 12 Months

Number of patients who were alive and free of disease (malignancy) at 12 months after transplant. (NCT00354172)
Timeframe: 12 Months Post transplant

Intervention	Participants (Number)
Evaluable Patients	1

Number of Participants (Patients) Who Were Disease-free and Alive at 6 Months

Number of patients who were alive and free of disease (malignancy) at 6 months after transplant. (NCT00354172)
Timeframe: 6 Months Post Transplant

Intervention	Participants (Number)
Evaluable Patients	2

Number of Participants (Patients) With Acute Graft-versus-host Disease (GVHD) Grade II-IV

Graft-versus-host disease (GVHD) is a common complication of transplantation in which functional immune cells in the transplanted marrow recognize the recipient as foreign and mount an immunologic attack. The acute or fulminant form of the disease (aGVHD) is normally observed within the first 100 days post-transplant, and is a major challenge to transplants owing to associated morbidity and mortality. Acute GVHD is staged as follows: overall grade (skin-liver-gut) with each organ staged individually from a low of I to a high of IV. Patients with grade IV GVHD usually have a poor prognosis. (NCT00354172)
Timeframe: Day 100 Post Transplant

Intervention	Participants (Number)
Evaluable Patients	6

Number of Participants (Patients) With Acute Graft-versus-Host Disease at Grade III-IV

Intervention	Participants (Number)
Evaluable Patients	1

Number of Participants (Patients) With Chronic Graft-Versus-Host Disease

The chronic form of graft-versus-host-disease (cGVHD) normally occurs after 100 days. The appearance of moderate to severe cases of cGVHD adversely influences long-term survival. (NCT00354172)
Timeframe: Day 100 through 1 Year Post Transplant

Intervention	Participants (Number)
Evaluable Patients	1

Number of Participants (Patients) With Successful Natural Killer Cell Expansion

Defined by an absolute circulating donor-derived natural killer cell count of >100 cells/microliter 10-13 days after infusion with <5% donor T and B cells in the mononuclear population (NCT00354172)
Timeframe: 10-13 Days Post Infusion

Intervention	Participants (Number)
Evaluable Patients	3

Number of Patients Who Were Disease-free and Alive at 24 Months

Number of patients who were alive and free of disease (malignancy) at 24 months after transplant. (NCT00354172)
Timeframe: 24 Months Post transplant

Intervention	Participants (Number)
Evaluable Patients	0

Chimerism After Double Umbilical Cord Blood Transplant (UCBT)

Calculation of Median (range) of percentage of donor cells engrafted (present) in the recipient (patient). (NCT00354172)
Timeframe: Day 21, Day 100, 6 Months

Intervention	Percentage of Engrafted Cells (Median)
	Day 21	Day 100	6 Months
Evaluable Patients	92	100	96.5

GFR at Month 12 Utilizing Cockcroft-Gault Formula

Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl)For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model (NCT00514514)
Timeframe: From randomization at BL2 (Month 3) to Month 12 post-transplant

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	60.18
CNI Free Regimen	64.87
CNI Low Regimen	61.16

GFR at Month 12 Utilizing Modification of Diet in Renal Disease (MDRD) Method

"Change in GFR (Modification of Diet in Renal Disease calculated using the -MDRD formulat:~For men: GFR = 170 × (serum creatinine -0,999)×(age-0,176) x (urea nitrogen -0,17) × (albumin0,318) For women: GFR = 170 × (serum creatinine -0,999) × (age-0,176) × (urea nitrogen -0,17) x (albumin0,318) × 0.762 with urea nitrogen = urea / 2.144. ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate." (NCT00514514)
Timeframe: From randomization at BL2 (Month 3) to Month 12 post-transplant

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	50.23
CNI Free Regimen	56.36
CNI Low Regimen	50.24

GFR at Month 60 Utilizing Cockcroft-Gault Formula

Cockcroft-Gault formula: For men: GFR= ((140-age) × body weight in kg)∕(72 x serum creatinine in mg∕dl) For women: GFR= (0.85×(140-age) × body weight in kg)∕(72 x serum creatinine in mg/dl), ), last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model (NCT00514514)
Timeframe: From randomization at BL2 (Month 3) to Month 60 post-transplant

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	55.92
CNI Free Regimen	61.6
CNI Low Regimen	52.91

GFR at Month 60 Utilizing Modification of Diet in Renal Disease (MDRD) Method

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	47.56
CNI Free Regimen	53.41
CNI Low Regimen	44.79

GFR Calculated Via Nankivell Formula at Month 60

Change in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate. (NCT00514514)
Timeframe: From randomization at BL2 (Month 3) to Month 60

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	60.24
CNI Free Regimen	66.98
CNI Low Regimen	58.74

GFR Via Nankivell Formula at Month 12 - All Regimens

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	63.03
CNI Free Regimen	68.59
CNI Low Regimen	63.08

GFR Via Nankivell Method at Month 12 - CNI-Free vs Standard Regimen

Demonstrate superiority of CNI-Free vs Standard Regimen in GFR using the Nankivell formula (GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)² + C where where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kilograms, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. The calculated GFR is expressed in mL/min per 1.73m², last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model, with treatment, center, donor type (deceased vs. living) as factors and BL2-value at V4/M3/BL2 as covariate. P-values are not adjusted (NCT00514514)
Timeframe: From randomization at BL2 (Month 3) to Month 12 post-transplant

Intervention	ml/min/1.73m² (Least Squares Mean)
Standard Regimen	63.03
CNI Free Regimen	68.59
CNI Low Regimen	63.08

Mean Change in Serum Creatinine From Month 3 to Month 12

Change in venous blood serum creatinine. Last observation carried forward (LOCF) was used for imputation of missing values, ANCOVA model (NCT00514514)
Timeframe: From randomization at BL2 (Month 3) to Month 12 post-transplant

Intervention	mg/dl (Least Squares Mean)
Standard Regimen	1.66
CNI Free Regimen	1.58
CNI Low Regimen	1.76

Mean Change in Serum Creatinine From Month 3 to Month 60

Intervention	mg/dl (Least Squares Mean)
Standard Regimen	1.94
CNI Free Regimen	1.69
CNI Low Regimen	2.01

Change From BL2 (Month 3) to Month 12 in Cardiovascular Risk (Framingham Score; 10-year Cardiovascular Risk)

The Framingham Score (based on LDL cholesterol level) estimates the coronary heart disease risk (%) of developing one of the following coronary heart diseases: angina pectoris, myocardial infarction, or coronary disease death, over the course of 10 years. (NCT00514514)
Timeframe: From Baseline 2 (Month 3) to Month 12

Intervention	Percent risk (Mean)
	Baseline 1/Visit 1 (n=165,171,161)	Baseline 2/Month 3 (n=165,171,161)	Month 12 (n=158,166,156)	Change from Baseline 2 to Month 12 (n=158,166,156)
CNI Free Regimen	10.2	8.8	9.1	0.4
CNI Low Regimen	9.5	9.3	8.7	-0.7
Standard Regimen	10.9	10.3	9.4	-0.7

Efficacy Event Data After Month 12 to Month 60

Efficacy events were: Biopsy-proven acute rejection (BPAR), graft loss, death, and treatment failure (defined as composite endpoint of BPAR, graft loss, death, loss to follow-up, discontinuation due to lack of efficacy or due to toxicity). (NCT00514514)
Timeframe: Events starting after Month 12

Intervention	Participants (Number)
	BPAR	Graft loss	Death	Lost to follow-up	Discontinuation due to adverse event	Therapy failure (composite endpoint)
CNI Free Regimen	13	7	4	15	8	35
CNI Low Regimen	12	3	9	13	4	36
Standard Regimen	13	7	7	17	10	38

Efficacy Event Data Baseline 2 (Month 3) to Month 12

Intervention	Participants (Number)
	BPAR	Graft loss	Death	Lost to follow-up	Discontinuation due to lack of efficacy	Discontinuation due to adverse event	Therapy failure composite
CNI Free Regimen	20	2	2	0	3	44	58
CNI Low Regimen	13	1	2	0	1	27	35
Standard Regimen	13	1	3	0	2	25	34

Efficacy Event Data From Baseline 2 (Month 3) to Month 6

Intervention	Participants (Number)
	BPAR	Graft loss	Death	Lost to follow-up	Discontinuation due to lack of efficacy	Discontinuation due to adverse event	Therapy failure composite
CNI Free Regimen	15	1	1	0	2	26	37
CNI Low Regimen	10	1	0	0	1	13	19
Standard Regimen	6	0	1	0	1	8	14

Glomerular Filtration Rate (GFR) at Month 12

GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is greater than (>) 90 milliliter per minute (mL/min), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure. (NCT00483756)
Timeframe: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12

Intervention	mL/min (Mean)
Cyclosporine	54.14
CP-690,550 15 mg for Months 1 to 6	65.05
CP-690,550 15 mg for Months 1 to 3	65.37

Glomerular Filtration Rate (GFR) at Month 6

GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous bolus over 5 minutes immediately after morning dosing of CP-690,550 or CsA on day of GFR evaluation. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure. (NCT00483756)
Timeframe: 2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6

Intervention	mL/min (Mean)
Cyclosporine	57.29
CP-690,550 15 mg for Months 1 to 6	67.54
CP-690,550 15 mg for Months 1 to 3	73.93

Number of Participants With Clinically Significant Infections

Intervention	participants (Number)
Cyclosporine	61
CP-690,550 15 mg for Months 1 to 6	88
CP-690,550 15 mg for Months 1 to 3	83

Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant

Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 mg/dL and >=20% from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hrs of the time of biopsy. (NCT00483756)
Timeframe: Baseline up to Month 12

Intervention	participants (Number)
Cyclosporine	9
CP-690,550 15 mg for Months 1 to 6	11
CP-690,550 15 mg for Months 1 to 3	7

Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant

Clinical BPAR was a BPAR (category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification) associated with an increase in serum creatinine of >= 0.3 milligram per deciliter (mg/dL) and >=20 percent (%) from pre-rejection baseline. The increase in serum creatinine was assessed based on the comparison of baseline and the highest serum creatinine recorded within 24 hours (hrs) of the time of biopsy. (NCT00483756)
Timeframe: Baseline up to Month 6

Intervention	participants (Number)
Cyclosporine	9
CP-690,550 15 mg for Months 1 to 6	11
CP-690,550 15 mg for Months 1 to 3	7

Number of Participants With Progression of Chronic Allograft Lesions at Month 12

Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]).The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 12 Banff-CS greater than the implantation biopsy score indicated progression of lesions. (NCT00483756)
Timeframe: Month 12

Intervention	participants (Number)
Cyclosporine	29
CP-690,550 15 mg for Months 1 to 6	18
CP-690,550 15 mg for Months 1 to 3	19

36-Item Short-Form Health Survey (SF-36)

"SF-36: standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. These 8 aspects can also be summarized as physical and mental component scores. Total of 11 variables were analyzed (8 subscales,2 composite subscales and Question(Q) 2 how would you rate your health in general now?(range 1=better, 5=worst). The score for a section (except Q2) is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning)." (NCT00483756)
Timeframe: Baseline, Month 6, 12

Intervention	units on a scale (Mean)
	Baseline: Bodily Pain (n=79,68,71)	Baseline: General Health (n=79,68,72)	Baseline: Mental Health (n=78,68,72)	Baseline: Physical Functioning (n=79,68,72)	Baseline: Role Emotional (n=79,68,71)	Baseline: Role Physical (n=79,68,71)	Baseline: Social Functioning (n=79,68,72)	Baseline: Vitality (n=78,68,72)	Baseline: Physical Component (n=78,68,71)	Baseline: Mental Component (n=78,68,71)	Baseline: Q2-Health in General Now (n=80,68,72)	Month 6: Bodily Pain (n=78,63,65)	Month 6: General Health (n=78,63,65)	Month 6: Mental Health (n=78,63,65)	Month 6: Physical Functioning (n=77,63,65)	Month 6: Role Emotional (n=77,63,65)	Month 6: Role Physical (n=77,63,65)	Month 6: Social Functioning (n=78,63,65)	Month 6: Vitality (n=78,63,65)	Month 6: Physical Component (n=77,63,65)	Month 6: Mental Component (n=77,63,65)	Month 6: Q2-Health in General Now (n=78,63,65)	Month 12: Bodily Pain (n=73,58,56)	Month 12: General Health (n=73,57,56)	Month 12: Mental Health (n=73,57,56)	Month 12: Physical Functioning (n=73,58,56)	Month 12: Role Emotional (n=71,57,56)	Month 12: Role Physical (n=71,57,56)	Month 12: Social Functioning (n=73,57,56)	Month 12: Vitality (n=73,57,56)	Month 12: Physical Component (n=71,57,56)	Month 12: Mental Component (n=71,57,56)	Month 12: Q2-Health in General Now (n=73,58,56)
CP-690,550 15 mg for Months 1 to 3	49.56	42.39	48.69	45.88	43.79	42.51	44.38	50.29	45.05	47.13	2.63	50.88	47.36	48.81	46.91	46.77	45.87	47.88	51.95	47.82	49.09	2.72	49.48	44.71	46.91	46.99	46.21	45.20	47.18	51.69	47.03	47.91	2.84
CP-690,550 15 mg for Months 1 to 6	51.43	42.46	44.85	44.46	43.82	42.28	41.14	48.04	45.85	44.18	2.57	49.76	46.70	48.35	45.74	45.40	43.11	45.14	52.13	46.22	48.30	2.65	51.07	46.79	49.43	46.88	47.31	44.19	46.87	51.45	46.84	49.47	2.69
Cyclosporine	52.89	44.77	49.15	44.03	46.19	41.26	47.42	49.77	44.85	49.41	2.78	51.87	47.87	50.47	47.06	48.06	46.48	50.34	54.22	47.93	51.60	2.74	51.12	48.94	51.93	47.19	46.13	46.57	49.63	54.25	47.98	51.12	2.75

End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)

"ESRD-SCL:43-item disease specific self-administered questionnaire. Participants' rated questionAt the moment,how much do you suffer?for each item on 5 point scale,ranged (Ra) 0(not at all)to 4(extremely).Consisted of 6 subscales:cardiac and renal dysfunction;Ra 0-28,increased(In) growth of gum and hair;Ra 0-20,limited cognitive capacity;Ra 0-32,limited physical capacity;Ra 0 - 40,side effects (SEs) of corticosteroids;Ra 0-20,transplantation associated psychological distress(TAPD);Ra 0-32(higher scores=greater dysfunction for each subscale).Total score:0-172,higher scores=greater dysfunction." (NCT00483756)
Timeframe: Baseline, Month 6, 12

Intervention	units on a scale (Mean)
	Baseline:Cardiac and Renal Dysfunction(n=76,61,71)	Baseline: In Growth of Gum and Hair (n=76,61,70)	Baseline: Limited Cognitive Capacity (n=77,62,71)	Baseline: Limited Physical Capacity (n=76,61,71)	Baseline: SEs of Corticosteroids (n=76,61,71)	Baseline: TAPD (n=77,62,71)	Month 6:Cardiac and Renal Dysfunction(n=77,63,64)	Month 6: In Growth of Gum and Hair (n=77,63,64)	Month 6: Limited Cognitive Capacity (n=77,64,65)	Month 6: Limited Physical Capacity (n=77,63,64)	Month 6: SEs of Corticosteroids (n=77,63,64)	Month 6: TAPD (n=77,64,65)	Month 12:Cardiac and Renal Dysfunction(n=70,57,55)	Month 12: In Growth of Gum and Hair (n=70,57,55)	Month 12: Limited Cognitive Capacity (n=71,58,55)	Month 12: Limited Physical Capacity (n=70,57,55)	Month 12: SEs of Corticosteroids (n=70,56,55)	Month 12: TAPD (n=71,57,55)
CP-690,550 15 mg for Months 1 to 3	0.64	0.18	0.64	0.72	0.48	1.16	0.50	0.24	0.68	0.62	0.69	0.85	0.49	0.29	0.85	0.73	0.72	0.96
CP-690,550 15 mg for Months 1 to 6	0.70	0.16	0.76	0.79	0.56	1.21	0.40	0.23	0.70	0.67	0.54	0.78	0.51	0.19	0.79	0.69	0.56	0.90
Cyclosporine	0.76	0.19	0.67	0.80	0.45	0.98	0.59	0.67	0.64	0.69	0.65	0.62	0.51	0.58	0.68	0.63	0.50	0.58

Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation

GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using abbreviated MDRD equation. GFR by abbreviated MDRD equation= 186 * (serum creatinine)^(-1.154) * (age in years)^(-0.203) * (0.742 if female) * (1.210 if black). A normal GFR is >90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure. (NCT00483756)
Timeframe: Month 1, 3, 6, 9, 12

Intervention	mL/min per 1.73 m^2 (Mean)
	Month 1	Month 3	Month 6	Month 9	Month 12
CP-690,550 15 mg for Months 1 to 3	64.81	62.27	63.33	62.76	64.17
CP-690,550 15 mg for Months 1 to 6	61.49	62.45	61.49	62.52	63.88
Cyclosporine	55.29	54.36	55.01	55.39	54.99

Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation

GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight*(140 minus age in years) divided by (72*serum creatinine). For females value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure. (NCT00483756)
Timeframe: Month 1, 3, 6, 9, 12

Intervention	mL/min (Mean)
	Month 1	Month 3	Month 6	Month 9	Month 12
CP-690,550 15 mg for Months 1 to 3	73.55	74.16	76.30	76.40	78.09
CP-690,550 15 mg for Months 1 to 6	71.12	74.41	74.71	76.41	78.41
Cyclosporine	67.23	68.08	69.21	70.05	69.67

Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation

GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR by MDRD equation = 170 * (serum creatinine)^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration)^(-0.170) * (serum albumin concentration)^(0.318).A normal GFR is >90 mL/min/1.73 square meter (m^2), although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure. (NCT00483756)
Timeframe: Month 1, 3, 6, 9, 12

Intervention	mL/min/1.73 m^2 (Mean)
	Month 1	Month 3	Month 6	Month 9	Month 12
CP-690,550 15 mg for Months 1 to 3	63.61	62.81	64.04	63.61	64.59
CP-690,550 15 mg for Months 1 to 6	59.93	62.20	61.84	62.98	64.25
Cyclosporine	52.89	53.55	54.16	54.11	53.94

Glomerular Filtration Rate (GFR) by The Nankivell Equation

GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated was estimated by creatinine clearance (CLcr) using Nankivell equation. CLcr by Nankivell equation= (6.7 per serum creatinine) plus (0.25*body weight) minus (0.5*serum urea) minus (100 per height square) plus (35 for male/25 for female). A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure. (NCT00483756)
Timeframe: Month 1, 3, 6, 9, 12

Intervention	mL/min (Mean)
	Month 1	Month 3	Month 6	Month 9	Month 12
CP-690,550 15 mg for Months 1 to 3	73.66	72.91	74.49	74.22	75.41
CP-690,550 15 mg for Months 1 to 6	71.53	73.58	73.23	74.29	75.58
Cyclosporine	65.85	65.80	66.75	66.85	66.88

Lymphocyte Subset

The absolute cell counts of cluster of differentiation 3 (CD3): T-lymphocytes, cluster of differentiation 19 (CD19): B-lymphocytes, and cluster of differentiation 56 (CD56): assumed natural killer cells, were determined using flow cytometry. (NCT00483756)
Timeframe: Month 1, 3, 6, 12

Intervention	cells per microliter (Mean)
	CD3: Month 1 (n=60,54,47)	CD3: Month 3 (n=59,44,34)	CD3: Month 6 (n=47,34,31)	CD3: Month 12 (n=45,29,26)	CD19: Month 1 (n=60,54,47)	CD19: Month 3 (n=58,44,34)	CD19: Month 6 (n=47,34,31)	CD19: Month 12 (n=45,29,26)	CD56: Month 1 (n=60,54,47)	CD56: Month 3 (n=58,44,34)	CD56: Month 6 (n=47,34,31)	CD56: Month 12 (n=45,29,26)
CP-690,550 15 mg for Months 1 to 3	1327.2	1007.1	970.39	956.04	416.70	185.68	173.10	181.46	112.23	65.38	65.00	77.23
CP-690,550 15 mg for Months 1 to 6	1256.7	894.20	811.74	796.76	409.39	189.41	151.03	180.03	116.65	86.86	68.06	96.00
Cyclosporine	1555.0	1273.2	1267.9	1352.5	280.58	154.47	125.26	120.18	166.47	143.14	170.23	168.91

Number of Participants Who Died

(NCT00483756)
Timeframe: Month 6, 12

Intervention	participants (Number)
	Month 6 (n=86,69,69)	Month 12 (n=80,57,55)
CP-690,550 15 mg for Months 1 to 3	0	0
CP-690,550 15 mg for Months 1 to 6	2	2
Cyclosporine	2	2

Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)

Intervention	participants (Number)
	Month 6 (n=100,83,83)	Month 12 (n=96,74,71)
CP-690,550 15 mg for Months 1 to 3	20	23
CP-690,550 15 mg for Months 1 to 6	22	24
Cyclosporine	29	30

Number of Participants With Efficacy Failure

Efficacy failure was the first occurrence of clinical BPAR diagnosed by the central pathologist or graft loss including participant death. (NCT00483756)
Timeframe: Month 6, 12

Intervention	participants (Number)
	Month 6 (n=98,84,80)	Month 12 (n=94,74,67)
CP-690,550 15 mg for Months 1 to 3	14	16
CP-690,550 15 mg for Months 1 to 6	19	20
Cyclosporine	21	22

Number of Participants With Graft Loss

Graft loss was defined as graft nephrectomy, participant death, re-transplantation, or return to dialysis for >=6 consecutive weeks. (NCT00483756)
Timeframe: Month 6, 12

Intervention	participants (Number)
	Month 6 (n=85,68,72)	Month 12 (n=79,56,58)
CP-690,550 15 mg for Months 1 to 3	3	3
CP-690,550 15 mg for Months 1 to 6	1	1
Cyclosporine	1	1

Number of Participants With Treated Clinical Acute Rejection

Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment. (NCT00483756)
Timeframe: Month 6, 12

Intervention	participants (Number)
	Month 6 (n=95,86,80)	Month 12 (n=92,76,69)
CP-690,550 15 mg for Months 1 to 3	18	18
CP-690,550 15 mg for Months 1 to 6	23	26
Cyclosporine	21	25

Disease-free Survival With Correction of Disease at One Year Post Transplantation

"Patients deemed alive and well at follow-up timepoint later than 1-year post-transplantation" (NCT00301834)
Timeframe: 1 year post-transplantation

Intervention	participants (Number)
Single Arm - Transplant Pre-conditioning Per Study Protocol	22

Number of Participants Achieving Durable Engraftment (Presence of Donor Cells) at 6 Weeks Post Transplantation

Peripheral blood chimerism studies were performed by quantitative real time polymerase chain reaction (qPCR) evaluation of differential short tandem repeat DNA sequences (NCT00301834)
Timeframe: 6 weeks post-transplant

Intervention	participants (Number)
Single Arm - Transplant Pre-conditioning Per Study Protocol	31

Cytomegalovirus (CMV) Viral Infection and Disease Symptoms

polymerase chain reaction testing for presence of CMV weekly until at least day +100 then every 2 weeks until T-cell reconstitution as defined by cluster of differentiation 4 (CD4) > 200 cells/mm3. Median time to T-cell reconstitution was 6 months. (NCT00301834)
Timeframe: Up to one year post-transplant

Intervention	participants (Number)
	Positive CMV Viral Load Assay	Symptomatic CMV disease
CMV Seronegative Participants	1	0
CMV Seropositive Participants	12	0

Toxicity Grade ≥ 3 From Start of Conditioning Through the First Year Post Transplantation

(NCT00301834)
Timeframe: 1 year post-transplantation

Intervention	participants (Number)
	Grade 3-4 acute Graft-Versus-Host Disease	Grade 3-4 mucositis
Single Arm	2	16

Treatment-related Mortality at 100 Days and 1 Year Post Transplantation

(NCT00301834)
Timeframe: 100 days and 1 year

Intervention	participants (Number)
	Transplantation-related mortality 0-100 days	Transplantation-related mortality 100-365 days
Single Arm - Transplant Pre-conditioning Per Study Protocol	2	1

Change From Baseline in the Average Maximum Intimal Thickness at Month 12

Maximum intimal thickness was assessed using Intravascular Ultrasound (IVUS). IVUS is a technique for taking ultrasound pictures of the wall of an artery from inside the artery itself. It shows the thickness of the artery wall and any narrowing of the artery. (NCT00300274)
Timeframe: Baseline, Month 12

Intervention	mm (Mean)
Everolimus 1.5 mg	0.03
Everolimus 3.0 mg	0.04
Mycophenolate Mofetil	0.07

Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12

Cardiac allograft vasculopathy is defined as a 0.5 mm increase in maximum intimal thickness as measured by Intravascular Ultrasound (IVUS) in at least one matched slice between baseline and Month 12. (NCT00300274)
Timeframe: 12 Months

Intervention	Percentage of participants (Number)
Everolimus 1.5 mg	12.5
Everolimus 3.0 mg	21.6
Mycophenolate Mofetil	26.7

Percentage of Participants With Composite Efficacy Failure at 12 Months

"Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.~Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides.~Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment." (NCT00300274)
Timeframe: 12 Months

Intervention	Percentage of participants (Number)
Everolimus 1.5 mg	35.1
Everolimus 3.0 mg	35.1
Mycophenolate Mofetil	33.6

Percentage of Participants With Composite Efficacy Failure at 24 Months

"Composite efficacy failure was defined as Biopsy Proven Acute Rejection (BPAR) of International Society for Heart and Lung Transplantation grade ≥ 3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up.~Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.~Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline and/or use of inotropic treatment." (NCT00300274)
Timeframe: 24 Months

Intervention	Percentage of participants (Number)
Everolimus 1.5 mg	39.4
Everolimus 3.0 mg	41.1
Mycophenolate Mofetil	41.3

Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months

Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 316 (start day of the Month 12 visit window). (NCT00300274)
Timeframe: 12 Months

Intervention	Percentage of participants (Number)
Everolimus 1.5 mg	11.7
Everolimus 3.0 mg	11.9
Mycophenolate Mofetil	8.9

Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months

Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 631 (start day of 24 Month visit window). (NCT00300274)
Timeframe: 24 Months

Intervention	Percentage of participants (Number)
Everolimus 1.5 mg	15.2
Everolimus 3.0 mg	16.1
Mycophenolate Mofetil	15.1

Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months

"GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:~GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R~C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1" (NCT00300274)
Timeframe: 24 Months

Intervention	mL/min/1.73^2 (Mean)
Everolimus 1.5 mg	59.50
Everolimus 3.0 mg	61.84
Mycophenolate Mofetil	64.52

Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months

"GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula:~GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1" (NCT00300274)
Timeframe: 12 Months

Intervention	mL/min/1.73^2 (Mean)
Everolimus 1.5 mg	59.21
Everolimus 3.0 mg	59.78
Mycophenolate Mofetil	64.37

Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24

"Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.~Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/ or use of inotropic treatment." (NCT00300274)
Timeframe: 24 Months

Intervention	Percentage of participants (Number)
	AR associated with HDC	BPAR of ISHLT grade ≥ 3A	Death	Graft loss/re-transplant
Everolimus 1.5 mg	4.3	24.1	10.6	2.5
Everolimus 3.0 mg	3.6	28.6	11.9	3.0
Mycophenolate Mofetil	5.2	27.3	9.2	3.7

Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12

"Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides.~Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/or use of inotropic treatment." (NCT00300274)
Timeframe: 12 Months

Intervention	Percentage of participants (Number)
	AR associated with HDC	BPAR of ISHLT ≥ 3A	Death	Graft loss/re-transplant
Everolimus 1.5 mg	3.9	22.3	7.8	1.4
Everolimus 3.0 mg	3.0	25.6	10.1	3.0
Mycophenolate Mofetil	2.6	24.7	4.8	1.8

Survival

The number of participants who survived treatment (NCT00282412)
Timeframe: up to 5 years

Intervention	Participants (Count of Participants)
Hematopoietic Stem Cell Transplantation	2

Change From Baseline in Body Surface Area (BSA) Affected by Psoriasis

BSA is a measure of the percentage of body surface affected by psoriasis. Using the Mosteller Formula: BSA = BSA (m²) = ( [Height(in) x Weight(lbs) ]/ 3131 )½ . A covariance analysis was performed on all variables, with value assessed at visit 2 as covariate and center as effect. For each variable the changes versus the last available measures were computed (NCT00438360)
Timeframe: Baseline and week 24

Intervention	BSA (m^2) (Mean)
Cyclosporine A	8.12
Placebo	10.45

Change From Baseline in Psoriasis Area and Severity Index (PASI) Score

Intervention	Units on a scale (Mean)
Cyclosporine A	5.70
Placebo	6.86

Change From Baseline in Visual Analogue Scale (VAS) for Patient Self Assessment of Pruritus

Target lesion pruritus as measured by the Visual Analog Scale (VAS) from 0 to 100 mm at week 24 compared to baseline (with 0 being no pruritis and 100 being maximum pruritis). (NCT00438360)
Timeframe: Baseline and week 24

Intervention	Units on a scale (Mean)
Cyclosporine A	17.32
Placebo	25.44

Proportion of Participants With Clinical Relapse

Clinical relapse was defined as worsening of psoriasis associated with a Psoriasis Area and Severity Index (PASI) >75% of the PASI score assessed before the continuous treatment, or when the investigator or the patient judged it necessary to change the treatment. (NCT00438360)
Timeframe: 24 weeks

Intervention	proportion of participants (Number)
Cyclosporine A	0.369
Placebo	0.456

Number of Participants With Relapse Rate (Success or Failure), as Assessed by Psoriasis Area and Severity Index (PASI) Score

PASI is an index used for assessing and grading the severity of psoriatic lesions and their response to therapy. The PASI produces a numeric score that can range from 0 (best) to 72 (worst), with the highest score representing complete erythroderma of severest degree. Relapse is considered a worsening of psoriasis associated to a PASI score >75% of PASI score recorded before starting induction therapy with CsA (before study start). Each patient was considered as failure (relapse occurrence) if rate was >= 75%. In all the other cases the patient was considered as success (no relapse). (NCT00438360)
Timeframe: 24 weeks

Intervention	Participants (Number)
	Success at 6 months	Failure at 6 months
Cyclosporine A	87	73
Placebo	36	43

Change in Timed Walk Rank Between Baseline and 12 Weeks

"Change in the time taken to walk 10 meters 0 - 12 weeks compared with baseline. A timed walk rank was created to take into account the use of walking aids.~Timed walk rank was calculated by ranking the time to walk 10 meters over all patients and visits, in the following order (highest/worst score to lowest/best score): unable to walk; able to walk, but not able to complete 10 meters (ranked on distance walked and time taken); able to walk 10 meters with a bilateral aid; able to walk 10 meters with a unilateral aid; able to walk 10 meters unaided (all ranked on time taken).~Decrease in score means improvement. All evaluable patients were ranked on the time taken. There is no specific range for the rank scores. Upper and lower limits vary with the number of participants evaluated" (NCT00773292)
Timeframe: 0, 12 weeks

Intervention	rank (Mean)
Ciclosporin	-7

Number of Patient With Lack of Objective Clinical Improvement

"Lack of objective clinical improvement after three months of therapy. Objective improvement was defined as any of the following comparing baseline measurements to 12, 24 and 48 weeks: i) one point decrease in the IPEC 1 scale (Instituto de Pesquisa Clínica Evandro Chagas), ii) >30% improvement in 10 m timed walk, iii) visual analogue pain score reduced by >2 points, iv) reduction of frequency or nocturia by greater than one or reduction of residual volume by more than 10% at two consecutive visits.~Proof of concept study and therefore outcomes report is descriptive only. No statistical test appropriate." (NCT00773292)
Timeframe: up to 12 months

Intervention	Participants (Count of Participants)
Ciclosporin	0

Percentage of Participants Who Achieved >=10 mm Schirmer Wetting Score With Anesthesia at Week 8

Schirmer test was performed 2 to 3 minutes after 1 drop of proparacaine 0.5% was placed in lower conjunctival fornix and superior bulbar conjunctiva of each eye. It was used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Week 8

Intervention	percentage of participants (Number)
Placebo Twice Daily	32.6
CP-690,550, 0.0003% Twice Daily	27.9
CP-690,550, 0.001% Twice Daily	48.9
CP-690,550, 0.003% Twice Daily	31.3
CP-690,550, 0.005% Twice Daily	24.4
CP-690,550, 0.005% Once Daily	25.6
Restasis Twice Daily	38.1

Percentage of Participants Who Achieved Greater Than or Equal to (>=) 10 Millimeter (mm) Schirmer Wetting Score Without Anesthesia at Week 8

Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 millimeter (mm). If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Week 8

Intervention	percentage of participants (Number)
Placebo Twice Daily	20.0
CP-690,550, 0.0003% Twice Daily	17.8
CP-690,550, 0.001% Twice Daily	25.5
CP-690,550, 0.003% Twice Daily	18.8
CP-690,550, 0.005% Twice Daily	26.1
CP-690,550, 0.005% Once Daily	27.3
Restasis Twice Daily	35.6

Percentage of Participants With Ocular Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Ocular AEs are the events which are localized in the ocular region. (NCT00784719)
Timeframe: Baseline up to Week 8

Intervention	percentage of participants (Number)
Placebo Twice Daily	25.5
CP-690,550, 0.0003% Twice Daily	21.7
CP-690,550, 0.001% Twice Daily	31.9
CP-690,550, 0.003% Twice Daily	22.9
CP-690,550, 0.005% Twice Daily	22.9
CP-690,550, 0.005% Once Daily	22.7
Restasis Twice Daily	36.2

Percentage of Participants With Systemic Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Systemic AEs are the events which are not localized but occur throughout the systemic circulation. (NCT00784719)
Timeframe: Baseline up to Week 8

Intervention	percentage of participants (Number)
Placebo Twice Daily	27.7
CP-690,550, 0.0003% Twice Daily	8.7
CP-690,550, 0.001% Twice Daily	29.8
CP-690,550, 0.003% Twice Daily	27.1
CP-690,550, 0.005% Twice Daily	18.8
CP-690,550, 0.005% Once Daily	18.2
Restasis Twice Daily	23.4

Time to Achieve >= 10mm Schirmer Test Score Without Anesthesia

Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Baseline through Week 8

Intervention	days (Median)
Placebo Twice Daily	NA
CP-690,550, 0.0003% Twice Daily	NA
CP-690,550, 0.001% Twice Daily	59.00
CP-690,550, 0.003% Twice Daily	58.00
CP-690,550, 0.005% Twice Daily	NA
CP-690,550, 0.005% Once Daily	57.00
Restasis Twice Daily	NA

Time to Achieve >= 5 Units Decrease in Ocular Comfort Index (OCI) Score

OCI: validated questionnaire to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contained 12 questions, each measured on a 7-point Likert scale ranging from 0 (never) to 6 (always/severe). Total score was transformed to range of 0 to 100, higher score indicated more ocular discomfort. Negative change from baseline indicated improvement. (NCT00784719)
Timeframe: Baseline through Week 8

Intervention	days (Median)
Placebo Twice Daily	15.00
CP-690,550, 0.0003% Twice Daily	8.50
CP-690,550, 0.001% Twice Daily	15.00
CP-690,550, 0.003% Twice Daily	9.50
CP-690,550, 0.005% Twice Daily	9.00
CP-690,550, 0.005% Once Daily	15.00
Restasis Twice Daily	16.00

Time to Achieve 100 Percent (%) Clearance of Corneal Staining

Corneal staining was assessed by instilling sodium fluorescein dye in the eye and after 1 to 2 minutes, observing for corneal staining with the aid of a yellow filter and slit lamp. The cornea was divided into five different zones and each corneal zone was graded independently using a 0 to 3 grading scale; where 0=none, 1=slight, 2=moderate, 3=severe. Results from study eye were to be reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Baseline through Week 8

Intervention	days (Median)
Placebo Twice Daily	NA
CP-690,550, 0.0003% Twice Daily	NA
CP-690,550, 0.001% Twice Daily	NA
CP-690,550, 0.003% Twice Daily	NA
CP-690,550, 0.005% Twice Daily	NA
CP-690,550, 0.005% Once Daily	NA
Restasis Twice Daily	NA

Change From Baseline in Corneal Staining Scores at Week 1, 2, 4, 6 and 8

Corneal staining was assessed using fluorescein dye, a yellow filter, and a slit lamp. The cornea was divided into 5 different zones. Each corneal zone was graded independently using a 0 to 3 grading scale; where 0=none, 1=slight, 2=moderate, 3=severe. Sum of scores of each zone led to total score. Total score range: 0 to 15, higher score indicated greater staining. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	units on a scale (Mean)
	Baseline (n=47,46,47,48,48,44,47)	Change at Week 1 (n=45,45,47,47,44,42,44)	Change at Week 2 (n=44,46,46,48,45,44,44)	Change at Week 4 (n=44,43,45,48,44,39,43)	Change at Week 6 (n=43,44,43,48,42,41,43)	Change at Week 8 (n=45,46,47,48,47,44,45)
CP-690,550, 0.0003% Twice Daily	5.63	-0.89	-1.15	-1.02	-1.39	-1.39
CP-690,550, 0.001% Twice Daily	5.83	-0.87	-1.00	-1.33	-1.21	-1.28
CP-690,550, 0.003% Twice Daily	6.73	-1.32	-1.98	-1.40	-1.75	-1.58
CP-690,550, 0.005% Once Daily	6.36	-1.17	-1.52	-2.10	-2.27	-2.64
CP-690,550, 0.005% Twice Daily	6.21	-0.20	-0.91	-0.82	-1.31	-1.47
Placebo Twice Daily	6.64	-1.16	-1.02	-2.48	-2.21	-2.67
Restasis Twice Daily	6.85	0.02	-0.61	-1.00	-1.49	-1.18

Change From Baseline in Daily Artificial Tear Use at Week 1, 2, 4, 6 and 8

Daily artificial tear use was assessed by collecting data on daily number of drops of artificial tear instilled in the eye using a participant diary. Decrease in daily artificial tear use indicated improvement. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	drops/day (Mean)
	Baseline (n=47,46,47,48,48,43,47)	Change at Week 1 (n=45,46,47,48,47,43,45)	Change at Week 2 (n=44,46,45,48,47,42,44)	Change at Week 4 (n=44,44,45,48,45,41,44)	Change at Week 6 (n=44,44,46,48,43,40,43)	Change at Week 8 (n=46,46,47,48,47,43,46)
CP-690,550, 0.0003% Twice Daily	3.0	-1.1	-1.2	-1.5	-1.5	-1.6
CP-690,550, 0.001% Twice Daily	3.0	-0.8	-0.8	-0.9	-0.9	-1.0
CP-690,550, 0.003% Twice Daily	2.5	-0.8	-0.9	-1.0	-1.1	-1.2
CP-690,550, 0.005% Once Daily	2.8	-1.1	-1.0	-1.2	-1.3	-1.5
CP-690,550, 0.005% Twice Daily	3.0	-0.9	-0.9	-0.9	-1.0	-1.1
Placebo Twice Daily	3.4	-0.7	-0.9	-1.1	-1.5	-1.2
Restasis Twice Daily	2.9	-0.6	-0.6	-0.8	-0.7	-0.9

Change From Baseline in Interpalpebral Conjunctival Staining Score at Week 1, 2, 4, 6 and 8

Interpalpebral conjunctival staining was performed 1 minute following ocular administration of lissamine green dye with aid of slit lamp. Based on Oxford grading system, bulbar conjunctiva was divided into 2 zones: nasal, temporal. Staining were graded using a 6-point scale (0=absent, 5=severe). Total score=sum of 2 zone scores. Total score range: 0 to 10, higher score=higher damage to eyes due to dryness. Negative change from baseline indicated improvement. Results from study eye are reported. Study eye is the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	units on a scale (Mean)
	Baseline (n=47,46,47,48,48,43,47)	Change at Week 1 (n=45,45,47,47,44,42,43)	Change at Week 2 (n=44,46,46,48,45,43,44)	Change at Week 4 (n=44,43,45,48,44,39,43)	Change at Week 6 (n=43,44,43,48,42,41,43)	Change at Week 8 (n=45,46,47,48,47,43,45)
CP-690,550, 0.0003% Twice Daily	2.17	-0.38	-0.26	-0.53	-0.73	-0.57
CP-690,550, 0.001% Twice Daily	2.21	-0.34	-0.37	-0.60	-0.44	-0.62
CP-690,550, 0.003% Twice Daily	2.38	-0.13	-0.29	-0.27	-0.46	-0.63
CP-690,550, 0.005% Once Daily	1.91	0.17	-0.19	0.18	0.02	-0.14
CP-690,550, 0.005% Twice Daily	2.17	-0.45	-0.44	-0.11	-0.12	-0.13
Placebo Twice Daily	2.77	-0.44	-0.89	-1.11	-0.84	-0.82
Restasis Twice Daily	2.43	-0.09	0.05	-0.07	-0.14	-0.18

Change From Baseline in National Eye Institute Visual Functioning Questionnaire 25-item Score (NEI-VFQ-25) at Week 8

NEI-VFQ-25 questionnaire included 25 items based on which overall composite VFQ score and 12 subscales were derived: general health (GH), general vision (GV), ocular pain (OP), near activities (NAct), distance activities (DA), social functioning (SF), mental health (MH), role difficulties (RD), dependency, driving, color vision (CV) and peripheral vision (PV). Response to each question converted to 0-100 score. Each subscale, total score=average of items contributing to score. For each subscale and total score, score range: 0 to 100, higher score=less symptoms/better visual functioning. (NCT00784719)
Timeframe: Baseline, Week 8

,,,,,,

Intervention	Units on a scale (Mean)
	Baseline: GH (n=46,46,47,48,48,43,47)	Baseline: GV (n=47,46,47,48,48,43,47)	Baseline: OP (n=47,46,47,48,48,43,47)	Baseline: NAct (n=47,46,47,48,48,43,47)	Baseline: DA (n=47,46,47,48,48,43,47)	Baseline: SF (n=47,46,47,48,48,43,47)	Baseline: MH (n=47,46,47,48,48,43,47)	Baseline: RD (n=47,46,47,48,48,43,47)	Baseline:dependency (n=47,45,47,47,48,43,47)	Baseline:driving (n=46,44,45,46,41,41,44)	Baseline: CV (n=46,46,47,48,48,43,47)	Baseline: PV (n=47,46,46,48,46,43,47)	Baseline: Overall (n=47,46,47,48,48,43,47)	Change at Week 8: GH (n=42,43,44,48,41,40,41)	Change at Week 8: GV (n=43,43,44,48,41,40,41)	Change at Week 8: OP (n=43,43,44,48,41,40,41)	Change at Week 8: NAct (n=43,43,44,48,41,40,41)	Change at Week 8: DA (n=43,43,44,48,41,40,41)	Change at Week 8: SF (n=43,43,44,48,41,40,41)	Change at Week 8: MH (n=43,43,44,48,41,40,41)	Change at Week 8: RD (n=43,43,44,48,41,40,41)	Change Week 8:dependency(n=43,42,44,47,41,40,41)	Change at Week 8:driving (n=42,41,42,46,33,38,39)	Change at Week 8: CV (n=42,43,44,48,41,40,41)	Change at Week 8: PV (n=43,43,44,48,39,40,41)	Change at Week 8: Overall (n=43,43,44,48,41,40,41)
CP-690,550, 0.0003% Twice Daily	66.85	75.65	59.51	70.92	77.36	93.21	73.23	72.83	93.89	76.89	96.20	82.61	79.30	-2.91	1.86	11.63	8.62	5.43	2.62	9.59	5.52	1.19	3.46	2.33	4.07	5.13
CP-690,550, 0.001% Twice Daily	62.77	73.62	61.17	76.60	81.38	93.88	77.53	76.33	94.33	77.22	93.62	85.87	81.08	0.00	1.36	13.35	4.17	3.03	2.27	4.55	4.55	1.89	3.27	3.98	1.70	3.98
CP-690,550, 0.003% Twice Daily	66.15	72.50	53.65	64.41	72.05	86.46	64.84	61.98	81.91	78.44	90.10	80.21	73.19	2.08	3.75	9.38	7.12	4.43	3.39	5.34	5.47	4.61	0.36	2.08	3.65	4.50
CP-690,550, 0.005% Once Daily	66.86	70.70	56.40	72.00	71.90	87.79	72.67	68.02	87.79	71.65	91.28	79.65	75.40	-0.63	5.00	16.56	7.40	8.85	6.88	10.63	12.50	7.08	8.22	5.63	6.88	8.67
CP-690,550, 0.005% Twice Daily	59.90	72.08	55.47	66.06	73.00	89.84	67.97	67.71	88.02	71.54	93.75	79.89	75.06	1.22	1.46	11.59	10.87	8.84	5.79	11.28	8.23	5.39	3.91	2.44	6.41	7.15
Placebo Twice Daily	65.22	72.77	59.31	68.62	73.76	89.10	72.34	68.09	88.48	73.64	89.67	77.13	75.62	0.00	1.86	15.12	7.17	6.78	3.20	10.61	6.98	7.56	6.15	4.76	11.05	7.44
Restasis Twice Daily	57.98	73.19	50.27	64.36	69.33	85.64	70.35	68.09	89.72	71.12	90.43	80.32	73.97	1.83	-0.49	9.45	9.96	5.89	8.23	5.95	0.00	2.24	3.95	4.88	6.71	5.15

Change From Baseline in Ocular Comfort Index (OCI) Score at Week 1, 2, 4, 6 and 8

OCI: validated questionnaire to measure the frequency and intensity of 6 common dry eye symptoms: dryness, grittiness, stinging, eye tiredness, pain, and itching. It contains 12 questions, each measured on a 7-point Likert scale ranging from 0 (never) to 6 (always/severe). Total score was transformed to range of 0 to 100, higher score indicated more ocular discomfort. Negative change from baseline indicated improvement. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	units on a scale (Mean)
	Baseline (n=47,46,47,48,48,44,47)	Change at Week 1 (n=45,45,47,47,44,41,43)	Change at Week 2 (n=44,46,46,48,45,43,44)	Change at Week 4 (n=44,43,45,48,44,41,43)	Change at Week 6 (n=43,44,43,48,42,41,43)	Change at Week 8 (n=45,46,47,48,47,44,44)
CP-690,550, 0.0003% Twice Daily	43.9	-5.9	-6.0	-7.6	-9.1	-9.9
CP-690,550, 0.001% Twice Daily	44.8	-4.2	-6.2	-6.8	-8.8	-8.0
CP-690,550, 0.003% Twice Daily	46.0	-3.9	-5.9	-5.7	-7.5	-7.4
CP-690,550, 0.005% Once Daily	42.3	-4.3	-4.4	-6.1	-7.3	-8.8
CP-690,550, 0.005% Twice Daily	45.4	-7.7	-7.6	-8.5	-8.0	-8.4
Placebo Twice Daily	45.0	-3.7	-6.3	-8.9	-10.1	-9.6
Restasis Twice Daily	47.4	-3.8	-6.8	-5.2	-7.2	-7.1

Change From Baseline in Ocular Surface Disease Index (OSDI) Total and Subscale Score at Week 1, 2, 4, 6 and 8

OSDI is a validated instrument for ocular surface disease. It has 12 items, each measured on 5-point Likert scale (0=none of the time, 4=all the time). Based on these item scores, a total OSDI score (question 1 [Q1]-Q12) and three subscale scores can be derived: Ocular Symptom (Q1-Q3), Vision-related function (Q4-Q9), and Environmental trigger (Q10-Q12). Each derived score ranges from 0 to 100, with a higher score indicates worse condition. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	units on a scale (Mean)
	Baseline:total (n=47,46,46,48,48,43,47)	Baseline:symptoms (n=47,46,46,48,48,43,47)	Baseline:function (n=46,46,45,48,47,43,44)	Baseline:triggers (n=46,41,42,45,42,41,43)	Change at Week 1:total (n=45,45,46,47,44,40,43)	Change at Week 1:symptoms (n=45,45,46,47,44,40,43)	Change at Week 1:function (n=43,45,44,47,43,39,39)	Change at Week 1:triggers (n=43,39,39,43,38,35,39)	Change at Week 2:total (n=44,46,45,48,45,43,44)	Change at Week 2:symptoms (n=44,46,45,48,45,43,44)	Change at Week 2:function (n=42,46,42,48,43,43,41)	Change at Week 2:triggers (n=42,40,40,38,35,39,40)	Change at Week 4:total (n=44,43,44,48,44,41,43)	Change at Week 4:symptoms (n=44,43,44,48,44,41,43)	Change at Week 4:function (n=43,42,42,47,41,41,40)	Change at Week 4:triggers (n=43,36,39,43,36,37,39)	Change at Week 6:total (n=43,44,42,48,42,41,43)	Change at Week 6:symptoms (n=43,44,42,48,42,41,43)	Change at Week 6:function (n=42,44,38,46,40,41,40)	Change at Week 6:triggers (n=40,38,37,41,34,38,39)	Change at Week 8:total (n=45,46,46,48,32,35,39)	Change at Week 8:symptoms (n=45,46,46,48,47,43,44)	Change at Week 8:function (n=44,46,45,48,46,43,41)	Change at Week 8:triggers(n=44,41,42,45,,41,41,41)
CP-690,550, 0.0003% Twice Daily	35.6	38.8	28.8	49.8	-5.1	-4.1	-3.7	-12.0	-6.2	-6.2	-5.8	-7.9	-7.2	-8.5	-4.7	-10.4	-9.1	-10.0	-7.0	-13.0	-8.5	-8.9	-6.4	-14.2
CP-690,550, 0.001% Twice Daily	31.5	38.6	23.5	42.0	-6.3	-8.5	-4.4	-6.6	-8.6	-11.5	-5.5	-8.8	-8.1	-13.4	-6.3	-5.8	-7.9	-12.3	-5.1	-9.7	-7.6	-11.6	-4.5	-8.4
CP-690,550, 0.003% Twice Daily	41.8	45.7	38.3	46.1	-8.9	-8.2	-9.1	-10.2	-8.9	-11.5	-7.6	-9.4	-9.7	-10.9	-8.5	-9.8	-10.9	-11.4	-9.6	-9.2	-8.8	-11.6	-9.2	-6.4
CP-690,550, 0.005% Once Daily	35.6	35.9	31.3	44.8	-9.2	-6.9	-9.1	-15.0	-10.3	-9.7	-7.0	-19.2	-11.3	-10.4	-7.3	-21.5	-14.0	-13.4	-9.3	-24.5	-12.7	-14.3	-9.2	-19.6
CP-690,550, 0.005% Twice Daily	37.8	41.7	31.8	45.6	-6.5	-6.3	-4.4	-14.7	-4.7	-6.9	-3.5	-10.1	-10.0	-10.8	-5.1	-16.3	-8.1	-7.1	-3.7	-12.4	-9.5	-10.5	-6.2	-13.5
Placebo Twice Daily	37.6	39.7	31.8	46.7	-6.8	-5.9	-6.1	-7.9	-8.7	-9.1	-8.6	-9.9	-11.5	-12.1	-10.2	-13.5	-10.5	-11.2	-9.1	-13.2	-11.0	-13.1	-9.1	-12.2
Restasis Twice Daily	41.8	47.3	36.1	50.3	-4.7	-4.5	-7.3	-2.4	-7.3	-7.6	-8.6	-5.5	-7.0	-6.6	-8.7	-4.7	-7.7	-9.1	-8.3	-5.9	-6.6	-7.4	-6.8	-4.8

Change From Baseline in Schirmer Wetting Score With Anesthesia at Week 8

,,,,,,

Intervention	mm (Mean)
	Baseline (n=47,46,47,48,48,43,47)	Change at Week 8 (n=43,43,45,48,41,39,42)
CP-690,550, 0.0003% Twice Daily	7.58	0.13
CP-690,550, 0.001% Twice Daily	6.63	2.56
CP-690,550, 0.003% Twice Daily	6.67	1.48
CP-690,550, 0.005% Once Daily	7.92	0.83
CP-690,550, 0.005% Twice Daily	7.85	-0.44
Placebo Twice Daily	6.56	2.24
Restasis Twice Daily	8.14	1.74

Change From Baseline in Schirmer Wetting Score Without Anesthesia at Week 1, 2, 4, 6 and 8

Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	mm (Mean)
	Baseline (n=47,46,47,48,48,44,47)	Change at Week 1 (n=45,45,47,47,44,42,43)	Change at Week 2 (n=44,46,46,48,45,44,44)	Change at Week 4 (n=44,43,45,48,44,39,43)	Change at Week 6 (n=43,44,43,47,42,41,43)	Change at Week 8 (n=45,46,47,48,47,44,45)
CP-690,550, 0.0003% Twice Daily	4.40	1.68	1.63	2.69	1.41	2.30
CP-690,550, 0.001% Twice Daily	4.02	0.80	2.67	2.56	1.59	2.19
CP-690,550, 0.003% Twice Daily	3.77	2.07	3.13	1.72	1.76	3.59
CP-690,550, 0.005% Once Daily	4.40	2.68	3.43	4.21	4.65	3.76
CP-690,550, 0.005% Twice Daily	4.43	1.80	2.74	1.66	3.64	2.60
Placebo Twice Daily	4.15	2.06	2.43	2.42	1.86	1.89
Restasis Twice Daily	4.74	3.60	3.84	4.06	3.87	4.48

Change From Baseline in Tear Break-up Time (TBUT) at Week 1, 2, 4, 6 and 8

TBUT was the time interval between the last complete blink and the first appearance of a dry spot, or disruption in the tear film. It was measured under a slit lamp following instillation of fluorescein dye in the eye using a stopwatch. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Baseline, Week 1, 2, 4, 6, 8

,,,,,,

Intervention	seconds (Mean)
	Baseline (n=47,46,47,48,48,43,47)	Change at Week 1 (n=45,45,47,47,44,42,44)	Change at Week 2 (n=44,46,46,48,45,43,44)	Change at Week 4 (n=44,43,45,48,44,39,43)	Change at Week 6 (n=43,44,43,48,42,41,43)	Change at Week 8 (n=45,46,47,48,47,43,45)
CP-690,550, 0.0003% Twice Daily	3.96	0.60	1.04	0.61	0.36	0.51
CP-690,550, 0.001% Twice Daily	4.32	0.21	0.24	-0.11	-0.01	-0.18
CP-690,550, 0.003% Twice Daily	4.65	-0.27	-0.44	-0.30	-0.71	-0.04
CP-690,550, 0.005% Once Daily	3.90	-0.51	0.04	-0.08	-0.21	0.31
CP-690,550, 0.005% Twice Daily	4.12	-0.07	-0.18	0.10	0.13	0.08
Placebo Twice Daily	3.50	0.17	0.03	0.48	1.03	0.55
Restasis Twice Daily	3.95	-0.14	0.36	0.52	0.59	0.52

Percentage of Participants Who Achieved >=10 mm Schirmer Wetting Score Without Anesthesia at Week 1, 2, 4 and 6

Schirmer test without anesthesia: well standardized test used to estimate tear flow stimulated reflexly by insertion of a filter paper strip into the conjunctival sac for 5 min. The length of wetting was recorded to the nearest 0.5 mm. If the wetting line was oblique, halfway point was used. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Week 1, 2, 4, 6

,,,,,,

Intervention	percentage of participants (Number)
	Week 1	Week 2	Week 4	Week 6
CP-690,550, 0.0003% Twice Daily	9.1	20.0	20.9	9.1
CP-690,550, 0.001% Twice Daily	6.4	23.9	17.8	16.3
CP-690,550, 0.003% Twice Daily	14.9	16.7	10.4	12.8
CP-690,550, 0.005% Once Daily	16.7	22.7	28.2	39.0
CP-690,550, 0.005% Twice Daily	11.6	25.0	16.3	34.1
Placebo Twice Daily	20.0	18.2	18.2	20.9
Restasis Twice Daily	30.2	36.4	30.2	34.9

Percentage of Participants Who Demonstrated 100% Clearance of Corneal Staining

Corneal staining was assessed using fluorescein dye, yellow filter, slit lamp. Cornea was divided into 5 different zones. Each corneal zone was graded independently using 0 to 3 grading scale:0=none, 1=slight, 2=moderate, 3=severe. Sum of scores of each zone led to total score. Total score range: 0 to 15, higher score indicated greater staining. Results from study eye are reported. Study eye is the 'worse eye', defined as the eye with worse Schirmer test score without anesthesia score at baseline. (NCT00784719)
Timeframe: Week 1, 2, 4, 6, 8

,,,,,,

Intervention	percentage of participants (Number)
	Week 1	Week 2	Week 4	Week 6	Week 8
CP-690,550, 0.0003% Twice Daily	0.0	4.3	2.3	6.8	6.5
CP-690,550, 0.001% Twice Daily	0.0	0.0	4.4	7.0	4.3
CP-690,550, 0.003% Twice Daily	0.0	4.2	6.3	4.2	10.4
CP-690,550, 0.005% Once Daily	4.8	4.5	2.6	7.3	15.9
CP-690,550, 0.005% Twice Daily	0.0	0.0	2.3	7.1	6.4
Placebo Twice Daily	2.2	2.3	4.5	4.7	6.7
Restasis Twice Daily	0.0	0.0	4.7	7.0	4.5

Percentage of Participants With >= 10 Units Decrease in Total OSDI Score

OSDI is a validated instrument for ocular surface disease. It has 12 items, each has a raw score measured on 5-point Likert scale (0=none of the time, 4=all the time). Based on these item scores, a total OSDI score can be derived which ranges from 0 to 100; a higher score indicates worse ocular disease. (NCT00784719)
Timeframe: Week 1, 2, 4, 6, 8

,,,,,,

Intervention	percentage of participants (Number)
	Week 1	Week 2	Week 4	Week 6	Week 8
CP-690,550, 0.0003% Twice Daily	37.8	45.7	44.2	52.3	50.0
CP-690,550, 0.001% Twice Daily	34.8	40.0	38.6	35.7	41.3
CP-690,550, 0.003% Twice Daily	46.8	43.8	50.0	52.1	47.9
CP-690,550, 0.005% Once Daily	40.0	39.5	41.5	51.2	46.5
CP-690,550, 0.005% Twice Daily	45.5	33.3	45.5	40.5	44.7
Placebo Twice Daily	37.8	50.0	47.7	46.5	40.0
Restasis Twice Daily	37.2	43.2	44.2	39.5	38.6

Percentage of Participants With >= 5 Units Decrease in Total OCI Score

,,,,,,

Intervention	percentage of participants (Number)
	Week 1	Week 2	Week 4	Week 6	Week 8
CP-690,550, 0.0003% Twice Daily	53.3	52.2	60.5	68.2	71.7
CP-690,550, 0.001% Twice Daily	38.3	45.7	55.6	72.1	59.6
CP-690,550, 0.003% Twice Daily	53.2	62.5	58.3	62.5	60.4
CP-690,550, 0.005% Once Daily	43.9	48.8	51.2	51.2	59.1
CP-690,550, 0.005% Twice Daily	56.8	57.8	65.9	61.9	57.4
Placebo Twice Daily	44.4	56.8	68.2	72.1	64.4
Restasis Twice Daily	39.5	52.3	46.5	51.2	52.3

Percentage of Participants With Ocular Tolerability Assessment

Ocular tolerability assessment included evaluation of severity and duration of the 5 symptoms: burning/stinging, blurred vision, ocular discomfort, pain, tearing. Severity was assessed on a 4-point scale, where 0=none, 1=mild, 2=moderate and 3=severe. Duration was assessed as immediate (if subsided within 5 minutes [<5 min] after application) or persistent (if continued beyond 5 minutes [>=5 min] after application). (NCT00784719)
Timeframe: Baseline up to Week 8

,,,,,,

Intervention	percentage of participants (Number)
	Ocular discomfort:none	Ocular discomfort:mild	Ocular discomfort:moderate	Ocular discomfort:severe	Ocular discomfort:moderate/severe, duration>=5 min	Burning sensation:none	Burning sensation:mild	Burning sensation:moderate	Burning sensation:severe	Burning sensation:moderate/severe,duration>=5 min	Pain:none	Pain:mild	Pain:moderate	Pain:severe	Pain:moderate/severe, duration >=5 min	Tearing:none	Tearing:mild	Tearing:moderate	Tearing:severe	Tearing:moderate/severe, duration >= 5 min	Blurred vision:none	Blurred vision:mild	Blurred vision:moderate	Blurred vision:severe	Blurred vision:moderate/severe, duration >=5 min
CP-690,550, 0.0003% Twice Daily	50.0	28.3	19.6	2.2	10.9	43.5	39.1	15.2	2.2	2.2	80.4	10.9	6.5	2.2	0.0	63.0	26.1	10.9	0.0	2.2	54.3	30.4	15.2	0.0	2.2
CP-690,550, 0.001% Twice Daily	53.2	25.5	19.1	2.1	8.5	23.4	59.6	14.9	2.1	2.1	80.9	8.5	6.4	4.3	0.0	68.1	21.3	10.6	0.0	6.4	53.2	34.0	12.8	0.0	4.3
CP-690,550, 0.003% Twice Daily	52.1	29.2	14.6	4.2	10.4	33.3	39.6	22.9	4.2	0.0	85.4	6.3	6.3	2.1	0.0	72.9	16.7	10.4	0.0	2.1	58.3	27.1	8.3	6.3	4.2
CP-690,550, 0.005% Once Daily	69.8	18.6	9.3	2.3	7.0	32.6	48.8	16.3	2.3	4.7	88.4	7.0	2.3	2.3	0.0	69.8	11.6	18.6	0.0	4.7	44.2	34.9	18.6	2.3	7.0
CP-690,550, 0.005% Twice Daily	46.8	44.7	8.5	0.0	4.3	29.8	53.2	14.9	2.1	4.3	85.1	12.8	2.1	0.0	0.0	66.0	29.8	4.3	0.0	0.0	51.1	36.2	8.5	4.3	6.4
Placebo Twice Daily	55.6	33.3	11.1	0.0	4.4	26.7	55.6	17.8	0.0	0.0	82.2	13.3	4.4	0.0	2.2	55.6	40.0	4.4	0.0	0.0	51.1	40.0	6.7	2.0	0.0
Restasis Twice Daily	34.1	34.1	25.0	6.8	22.7	18.2	40.9	36.4	4.5	11.4	61.4	25.0	9.1	4.5	0.0	47.7	29.5	11.4	11.4	6.8	36.4	40.9	20.5	2.3	2.3

Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 18

Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula at Month 18 cGFR (in mL/min/1.73 m2) = 186.3*(C-1.154)*(A-0.203)*G*R where C = the serum concentration of creatinine (mg/dL), A = age (years), G = 0.742 when gender is female, otherwise G = 1, R = 1.21 when race is black, otherwise R = 1. (NCT00862979)
Timeframe: Month 18

Intervention	mL/min (Mean)
CNI-regimen	54.2
CNI-free-regimen	66.9

Reciprocal Creatinine Slope Between Month 6 and Month 18

Reciprocal Creatinine Slope is an indication of renal function over time with a higher slope value indicating an improvement in renal function. (NCT00862979)
Timeframe: Between Month 6 and Month 18

Intervention	1/(μmol/L)/(hour) (Mean)
CNI-regimen	0.045
CNI-free-regimen	0.403

Calculated Glomerular Filtration Rate (cGFR) According to Cockcroft-Gault at Month 12 and 18

Calculated Glomerular Filtration Rate (cGFR) according to Cockcroft-Gault at Month 12 and 18. For men: GFR=(140-Age) x Body weight (kg) / 72 x Serum Creatinine (mg/dl) For women: GFR=0.85 (140 -Age) x Body weight(kg)/ 72 x Serum Creatinine (mg/dl) (NCT00862979)
Timeframe: Month 12 and 18

Intervention	mL/min (Mean)
	Month 12	Month 18
CNI-free-regimen	69.8	66.9
CNI-regimen	54.2	54.2

Occurrence of Major Cardiac Events (MACE) From Month 6 to 18

Major cardiac events (MACE) was defined as one of the following: any death, myocardial infarction, coronary artery bypass grafting (NCT00862979)
Timeframe: Month 6 to Month 18

Intervention	Occurences (Number)
	Myocardial infarction	Death
CNI-free-regimen	0	1
CNI-regimen	1	0

Occurrence of Treatment Failures From Month 6 to 9 and Month 9 to 18

Treatment failure was defined as composite endpoint of biopsy proven acute rejection of ISHLT 1990 grade ≥ 3A resp. ISHLT 2004 grade ≥ 2R, acute rejection episodes associated with hemodynamic compromise, graft loss / re-transplant, death, loss to follow up (at least one condition must be present). If participant had an occurrence in each period it was counted for each period. (NCT00862979)
Timeframe: Month 6 to Month 9; Month 9 to Month 18

Intervention	Occurences (Number)
	Month 6 to Month 9 Treatment failure - all reasons	Month 9 to Month 18 Treatment failure-all reasons
CNI-free-regimen	4	15
CNI-regimen	1	3

Serum Creatinine at Month 6, 8, 9, 10 12 and 18

Serum Creatinine is an indicator of renal function measured in the blood (NCT00862979)
Timeframe: Month 6, 8, 9, 10 12 and 18

Intervention	μmol/L (Mean)
	Month 6	Month 8	Month 9	Month 10	Month 12	Month 18
CNI-free-regimen	1.49	1.27	1.24	1.20	1.22	1.27
CNI-regimen	1.53	1.44	1.58	1.53	1.53	1.50

Number of High Risk Pediatric Patients With Successful Sustained Donor Engraftments

Assessed donor engraftment in very high risk pediatric patients. (NCT00795132)
Timeframe: 24 months

Intervention	participants (Number)
Related BM PBSC	16
Unrelated BM PBSC	18
Unrelated Cord Blood	10

Number of Participants Who Experienced Transplantation-related Mortality (TRM)

Cumulative incidence transplantation-related mortality (TRM) (NCT00795132)
Timeframe: 24 months

Intervention	participants (Number)
Related BM PBSC	0
Unrelated BM PBSC	5
Unrelated Cord Blood	1

Two Year Overall Survival

The probability that a given patient will be alive two years after transplantation. (NCT00795132)
Timeframe: 24 months

Intervention	probability (Mean)
Related BM PBSC	0.501
Unrelated BM PBSC	0.395
Unrelated Cord Blood	0.438

Event-free Survival (EFS) Per Protocol

Event-free survival (EFS) through 4 years, as assessed in participants with poor-risk recurrent or primary refractory DLBCL treated with TLI and ATG followed by matched allogeneic hematopoietic cell transplantation as a consolidation to HCT. Event is defined as tumor progression or death. (NCT00482053)
Timeframe: 48 months

Intervention	months (Median)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	48

Incidence of Chronic Graft vs Host Disease (GvHD)

The incidence of chronic graft vs host disease (GvHD) is reported as any events within 3 years. Note that GvHD was assessed per investigator judgement. There was no protocol-specified criteria of GvHD. (NCT00482053)
Timeframe: 3 years

Intervention	Participants (Count of Participants)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	0

Median Time to Neutrophil Engraftment After Allogeneic Transplant

Reported as neutrophil engraftment after allogeneic transplant, defined as absolute neutrophil count (ANC) > 500/µL, counting from the day of transplant. (NCT00482053)
Timeframe: within 1 month

Intervention	Days (Median)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	10.5

Median Time to Neutrophil Engraftment After Autologous Transplant

Reported as neutrophil engraftment after autologous transplant, defined as absolute neutrophil count (ANC) > 500/µL, counting from the day of transplant. (NCT00482053)
Timeframe: within 1 month

Intervention	Days (Median)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	11

Median Time to Platelet Engraftment After Allogeneic Transplant

Reported as platelet engraftment after allogeneic transplant, defined as platelet count > 20,000/µL, counting from the day of transplant. (NCT00482053)
Timeframe: within 1 month

Intervention	Days (Median)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	10

Median Time to Platelet Engraftment After Autologous Transplant

Reported as platelet engraftment after autologous transplant, defined as platelet count > 20,000/µL, counting from the day of transplant. (NCT00482053)
Timeframe: within 1 month

Intervention	Days (Median)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	19

Overall Survival (OS)

To evaluate the overall and transplant related mortality rate, reported as the number of subjects remaining alive 3 years after transplant. (NCT00482053)
Timeframe: 3 years

Intervention	Participants (Count of Participants)
Auto-HCT Followed by Allo-HCT for Poor-risk DLBCL	2

Blood Pressure

Diastolic pressure (mmHg) (NCT01002339)
Timeframe: 1 year

Intervention	mmHg (Mean)
Tacrolimus With Rapid Steroid Withdrawal	76.67
Tacrolimus With Steroids Minimization	74.59
CsA With Steroid Minimization	76.64

Blood Pressure

Systolic pressure (mmHg) (NCT01002339)
Timeframe: 1 year

Intervention	mmHg (Mean)
Tacrolimus With Rapid Steroid Withdrawal	135.36
Tacrolimus With Steroids Minimization	133.97
CsA With Steroid Minimization	136.28

Changes of Carotid Intima-media Thickness Over Time

absolute difference between carotid intima-media thickness at study end versus baseline. (NCT01002339)
Timeframe: 1 year

Intervention	mm (Mean)
Tacrolimus With Rapid Steroid Withdrawal	0.12
Tacrolimus With Steroids Minimization	0.04
CsA With Steroid Minimization	0.01

Lipidic Profile (Cholesterol)

Lipidic Profile (total cholesterol) (NCT01002339)
Timeframe: 1 year

Intervention	mg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal	169.05
Tacrolimus With Steroids Minimization	178.24
CsA With Steroid Minimization	168.89

Lipidic Profile (HDL-c)

(NCT01002339)
Timeframe: 1 year

Intervention	mg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal	44.84
Tacrolimus With Steroids Minimization	49.29
CsA With Steroid Minimization	48.35

Lipidic Profile (LDL-c)

(NCT01002339)
Timeframe: 1 year

Intervention	mg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal	94.00
Tacrolimus With Steroids Minimization	95.43
CsA With Steroid Minimization	88.65

Lipidic Profile (Triglycerides)

(NCT01002339)
Timeframe: 1 year

Intervention	mg/dl (Mean)
Tacrolimus With Rapid Steroid Withdrawal	159.44
Tacrolimus With Steroids Minimization	145.59
CsA With Steroid Minimization	160.78

Number of Antihypertensive Drugs Patients Reported Taking.

(NCT01002339)
Timeframe: 1 year

Intervention	number of antihypertensive drugs (Median)
Tacrolimus With Rapid Steroid Withdrawal	2
Tacrolimus With Steroids Minimization	2
CsA With Steroid Minimization	2

Patients Treated With Insulin or Oral Antidiabetic Drugs

(NCT01002339)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal	20
Tacrolimus With Steroids Minimization	15.4
CsA With Steroid Minimization	2.6

Percentage of Patients Using Acetylsalicylic Acid (ASA)

(NCT01002339)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal	53.9
Tacrolimus With Steroids Minimization	48.7
CsA With Steroid Minimization	52.8

Percentage of Patients Using Statins

(NCT01002339)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal	56.
Tacrolimus With Steroids Minimization	61.5
CsA With Steroid Minimization	73.7

Primary Outcome Measure (Glucose Intolerance)

Glycemia >=140 and <200 mg/dl, 2 hours after a standard oral glucose tolerance test. Measured values: glucose intolerance at 1 year defined by ADA criteria. (NCT01002339)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal	26.9
Tacrolimus With Steroids Minimization	31.0
CsA With Steroid Minimization	33.3

Proteinuria

(NCT01002339)
Timeframe: 1 year

Intervention	mg/day (Mean)
Tacrolimus With Rapid Steroid Withdrawal	208
Tacrolimus With Steroids Minimization	241
CsA With Steroid Minimization	343.2

Rejection

Biopsy proven acute rejection. Measured variable: Rate of Biopsy proven acute rejection. (NCT01002339)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Tacrolimus With Rapid Steroid Withdrawal	11.4
Tacrolimus With Steroids Minimization	4.8
CsA With Steroid Minimization	21.4

Renal Function

Estimated Glomerular Filtration Rate (ml/min/1.73 m^2) (NCT01002339)
Timeframe: 1 year

Intervention	ml/min/1.73 m^2 (Mean)
Tacrolimus With Rapid Steroid Withdrawal	51.9
Tacrolimus With Steroids Minimization	47.4
CsA With Steroid Minimization	44.6

"Primary Outcome Measure New Onset Diabetes After Renal Transplantation (NODAT)"

American Diabetes Association criteria (ADA) including an oral glucose tolerance test. (NCT01002339)
Timeframe: 1 year

Intervention	percentage of participants (Number)
	% of patients with NODAT	% of patients without NODAT
CsA With Steroid Minimization	7.9	92.1
Tacrolimus With Rapid Steroid Withdrawal	34.1	65.9
Tacrolimus With Steroids Minimization	23.1	76.9

Patient's Global Psoriasis Assessment (PGPA)

"The PGPA consisted of a single self-explanatory item:~On a scale from 0 to 10, with 0 being no psoriasis and 10 the worst psoriasis that you can imagine, please rate the state of your psoriasis right now.~Note: Consider only your skin condition and do not consider other aspects that may be related to your psoriasis (such as psoriatic arthritis)." (NCT01079988)
Timeframe: 12 weeks

Intervention	PGPA score (Mean)
Cyclosporin	5.1
Retinoids	4.0
Systemic Corticosteroids	5.5
Methotrexate	4.8
Systemic Corticosteroids/Methotrexate	4.5

Physician's Global Assessment (PGA) of Change Over Time (Good or Better)

"The PGA response was classified according to the following categories by changes in all clinical signs and symptoms as compared to baseline:~Cleared: Remission except for residual manifestations such as mild erythema (100% improvement) Excellent: Improvement of 75%-99% except for residual manifestations such as mild erythema Good: Improvement of 50%-74%" (NCT01079988)
Timeframe: 12 weeks

Intervention	participants (Number)
Cyclosporin	7
Retinoids	0
Systemic Corticosteroids	2
Methotrexate	9
Systemic Corticosteroids/Methotrexate	0

Estimated Glomerular Filtration Rate (eGFR)

Assessment of renal function by comparing change from randomization to Month 12 in eGFR (MDRD4) between treatment arms (Full analysis set). Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR [mL/min/1.73m˄2] = 186.3*(C˄-1.154)*(A˄-0.203)*G*R. DEFINITIONS: C = serum concentration of creatinine [mg/dL]; A = age [years]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1 (NCT01114529)
Timeframe: Month 12

Intervention	mL/min/1.73m^2 (Mean)
Everolimus	64.1
Standard CNI (Tac)	61.5
Standard CNI (CsA)	58.4

Change in Left Ventricular Mass Index (LVMi) From Randomization to Month 12 and Month 24

Evolution of left ventricular mass and hypertrophy were evaluated by left ventricular mass index (LVMi) assessed by echocardiography. LVMi is derived using a standard formula from dimensional measurements on the echocardiogram. Analysis of covariance was applied with treatment, center (as a random effect), and donor type as factors and LVMi at Randomization as covariate. (NCT01114529)
Timeframe: Randomization, Month 12 and Month 24

Intervention	g/m^2.7 (Mean)
	Randomization	Month 12	Month 24
Everolimus	50.30	49.95	46.66
Standard CNI (CsA)	51.13	50.96	47.91
Standard CNI (Tac)	51.08	48.98	45.63

Comparison of Incidence Rates of Efficacy Endpoints Between Treatment Arms (Full Analysis Set - 24 Month Analysis)

(treated BPAR ≥ IB, graft loss or death)A comparison of the incidence rates for the individual components of the composite efficacy endpoint between treatment arms (NCT01114529)
Timeframe: at 24 months post-transplantation

Intervention	Number of incidence (Number)
	Composite failure: tBPAR>=IB, graft loss, death	Composite tBPAR>=IB, graft loss, death, loss f/u	Composite of graft loss or Death	tBPAR>=IB	Graft loss	Death	Suspected Acute rejection	Subclinical Acute rejection	Acute rejection (AR)	Treated Acute rejection (tAR)	biopsy proven acute rejection (BPAR)	treated biopsy proven acute rejection (tBPAR)	tBPAR=IA	tBPAR=IB	tBPAR=IIA	tBPAR=IIB	tBPAR=III	Antibody tBPAR	Antibody mediated rejection (AMR)
Everolimus	27	35	10	18	4	8	61	0	52	40	37	32	16	14	3	2	0	2	16
Standard CNI (CsA)	8	15	4	5	2	4	19	0	15	14	13	13	8	5	1	0	0	1	3
Standard CNI (Tac)	8	14	6	3	2	5	27	0	14	9	8	7	3	3	0	0	0	1	4

Incidence of Composite Efficacy Endpoint for Each Arm at Month 12 and Month 24

Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)*, (2) graft loss**, or (3) death . *A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. **Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis or re-transplanted. (NCT01114529)
Timeframe: at 12 months and month 24 post-transplantation

Intervention	Number of incidence (Number)
	Month 12	Month 24
Everolimus	21	27
Standard CNI (CsA)	8	8
Standard CNI (Tac)	4	8

WHO(World Health Organization) COVID-19 Clinical Severity Scale

WHO(World Health Organization) COVID-19 clinical severity scale. Score 0-9. 0=Uninfected, 8=Death. (NCT04492891)
Timeframe: on day 14

Intervention	units on a scale (Median)
Arm A Cyclosporine	2
Arm B Standard of Care	2

Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose.

Participants that have successfully tapered prednisone to a dose of 0.25 mg/kg/Day by 6 Months without clinical relapse. (NCT00350545)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Rituximab + Prednisone Arm	14

Participants Who Reduced Steroid Use at One Year After Enrollment on the Trial

Participants that decreased total daily corticosteroids ≤ 0.25mg/kg one year after rituximab infusion began (NCT00350545)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Rituximab + Prednisone Arm	14

Failure-free Survival at 6 and 12 Months Post-Rituximab Initiation

Failure-free survival (FFS) was defined as participants who are surviving with no relapse and second line of cGVHD treatment. (NCT00350545)
Timeframe: 6 and 12 Months

Intervention	Participants (Count of Participants)
	6 month FFS	12 month FFS
Rituximab + Prednisone Arm	28	21

Number of Participants With Complete and/or Partial GVHD Response

To have physician documentation of clinical GVHD response using organ staging and scoring scale- NIH clinical GVHD consensus response criteria applied 6 months after rituximab infusion began (NCT00350545)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
	Complete response	Partial response
Rituximab + Prednisone Arm	12	15

Overall Survival

Overall survival at 6 and 12 months (NCT00350545)
Timeframe: 6 and 12 months

Intervention	Participants (Count of Participants)
	6 month overall survival	12 month overall survival
Rituximab + Prednisone Arm	33	30

Number of Participants Who Experienced Adverse Events and Death

Participants were monitored for adverse events, serious adverse events and deaths thorughout the prospective and follow-up phases of the study. (NCT00332839)
Timeframe: 12 months

Intervention	Participants (Number)
	Adverse events (serious and non-serious)	Serious adverse events	Deaths
Calcineurin Inhibitor (CNI) Group	44	11	1
Certican Group	44	12	1

Disease Free

Number of participants that were disease free (NCT01093586)
Timeframe: At 1 year

Intervention	Participants (Count of Participants)
Arm I	4

Disease Free

Number of participants that were disease free (NCT01093586)
Timeframe: At 2 years

Intervention	Participants (Count of Participants)
Arm I	4

Hematologic Engraftment

Number of participants that were able to complete engraftment by day 42. (NCT01093586)
Timeframe: On day +42

Intervention	Participants (Count of Participants)
Arm I	10

Incidence of Acute Graft-versus-host Disease (GVHD)

Number of participants that had acute GVHD (NCT01093586)
Timeframe: At 100 days

Intervention	Participants (Count of Participants)
Arm I	11

Incidence of Chronic GVHD

Number of participants that have chronic GVHD. Chronic GVHD will be diagnosed and graded on clinical and histological criteria from the Center for International Blood and Marrow Transplant Research (CIBMTR) (NCT01093586)
Timeframe: At 1 year

Intervention	Participants (Count of Participants)
Arm I	1

Occurrence of Serious Infections

Number of participants that had infections (NCT01093586)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Arm I	13

Overall Survival

Number of participants alive at 180 days post engraftment. (NCT01093586)
Timeframe: On day +180

Intervention	Participants (Count of Participants)
Arm I	8

Overall Survival

Number of participants that were alive. (NCT01093586)
Timeframe: At 1 year

Intervention	Participants (Count of Participants)
Arm I	6

Overall Survival

Number of participants that were alive. (NCT01093586)
Timeframe: At 2 years

Intervention	Participants (Count of Participants)
Arm I	4

Recurrence or Relapse

Number of subjects that had disease recurrence (NCT01093586)
Timeframe: one year in patients post UCBT

Intervention	Participants (Count of Participants)
Arm I	2

Recurrence or Relapse

Number of subjects that had disease recurrence (NCT01093586)
Timeframe: two years post transplant

Intervention	Participants (Count of Participants)
Arm I	2

Toxicity Related to UCB Transplantation and Cytoreduction as Assessed by CTC v3.0

Number of participants that experienced toxicity related to the transplant (NCT01093586)
Timeframe: by day +42

Intervention	Participants (Count of Participants)
Arm I	8

Transplant Related Mortality

Number of subjects that died because of transplant (NCT01093586)
Timeframe: On day 100 post transplant

Intervention	Participants (Count of Participants)
Arm I	2

Transplant Related Mortality

Number of subjects that died because of transplant (NCT01093586)
Timeframe: On day 180 post transplant

Intervention	Participants (Count of Participants)
Arm I	6

Complete Response Rate (CRR)

"Complete response rate (CRR) was assessed as all of:~Negative immunoflixation on the serum and urine~Disappearance of any soft tissue plasmacytomas~< 5% plasma cells in bone marrow" (NCT00899847)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	3

Event-free Survival (EFS)

To evaluate the graft versus myeloma effect by monitoring rate of event-free survival (EFS) (NCT00899847)
Timeframe: 2 years after the last participant is enrolled

Intervention	percentage of participants (Number)
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	44

Incidence of Graft Versus Host Disease (GvHD)

To evaluate the incidence acute GvHD of this tandem autologous/allogeneic transplant setting (NCT00899847)
Timeframe: 2 years after the last participant is enrolled.

Intervention	Participants (Count of Participants)
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	1

Overall Response Rate (ORR)

Overall response rate (ORR) = Complete Response Rate (CRR) + Partial Response Rate (PRR) (NCT00899847)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Autologous-Allogeneic Peripheral Blood Stem Cell Transplant	7

Overall Survival (OS)

To evaluate the graft versus myeloma effect by monitoring rate of overall survival (OS) (NCT00899847)
Timeframe: 2 years after the last participant is enrolled

Intervention	percentage of participants (Number)
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	67

Partial Response Rate (PRR)

"Partial response rate (PRR) was assessed as~> 50% reduction in serum M-protein plus urine M-protein reduction by 90% or < 200 mg/24 hr~If serum M-protein is not measurable, then > 50% reduction in the involved serum free light chain~If involved serum free light chain is not measurable, then > 50% reduction in the bone marrow plasma cell percentage + > 50% reduction in the size of any soft tissue plasmacytoma." (NCT00899847)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Autologous-Allogeneic Peripheral Blood Stem Cell Transplant	4

Median Time to Engraftment After Allo-PBSC Transplant

"Engraftment is assessed as:~Neutrophil engraftment is > 0.5 x 10⁹/L after cytopenia~Platelet engraftment is > 20 x 10⁹/L after cytopenia" (NCT00899847)
Timeframe: 1 month

Intervention	Days (Median)
	Neutrophil Engraftment	Platelet Engraftment
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	24	10

Median Time to Engraftment After Auto-PBSC Transplant

"Engraftment is assessed as:~Neutrophil engraftment is > 0.5 x 10⁹/L after cytopenia~Platelet engraftment is > 20 x 10⁹/L after cytopenia" (NCT00899847)
Timeframe: 1 month

Intervention	Days (Median)
	Neutrophil Engraftment	Platelet Engraftment
Autologous-Allogeneic Hematopoietic Stem Cell Transplant	11	15

Core Study: Number Participants With Combined Graft Loss, Death or Loss to Follow-up

"The allograft was presumed to be lost on the day the patient starts dialysis and was not able to stop dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss.~A loss to follow-up in graft loss, death or loss to follow-up is a patient who did not experience graft loss or death and whose last day of contact was prior to Day 316, i.e. prior to the Month 12 visit window." (NCT00658320)
Timeframe: 12 months

Intervention	Participants (Number)
Everolimus + Reduced Dose of Cyclosporine	5
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	3

Core Study: Renal Function Measured by Calculated Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula

"Modification of Diet in Renal Disease (MDRD) formula is:~Calculated GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where~C is the serum concentration of creatinine [mg/dL],~A is patient age at sample collection date [years],~G=0.742 when gender is female, otherwise G=1,~R=1.21 when race is black, otherwise R=1" (NCT00658320)
Timeframe: Month 12

Intervention	mL/min/1.73m^2 (Median)
Everolimus + Reduced Dose of Cyclosporine	58.00
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	55.25

Extension Study: Renal Function Measured by Calculated Glomerular Filtration Rate (cGFR) Using the Modification of Diet in Renal Disease (MDRD) Formula

Intervention	mL/min/1.73m^2 (Median)
Everolimus + Reduced Dose of Cyclosporine	59.80

Extension Study: Renal Function Measured by Calculated Glomerular Filtration Rate (cGFR) Using the Modification of Diet in Renal Disease (MDRD) Formula

"Renal function was assessed by glomerular filtration rate (GFR) using the MDRD formula:~GFR [mL/min/1.73m2] = 186.3*(C-1.154)*(A-0.203)*G*R C is the serum concentration of creatinine [mg/dL] A is age [years] G = 0.742 when gender is female, otherwise G=1 R = 1.21 when race is black, otherwise R=1~Loss to follow up (in In Primary Core Outcome Measure) is composite efficacy failure and contains incidence of treated BPAR, graft loss, death or loss to follow-up" (NCT00658320)
Timeframe: Month 24

Intervention	mL/min/1.73m^2 (Median)
Everolimus + Reduced Dose of Cyclosporine	58.90
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	54.95

Core Study: Number of Patients With Composite Efficacy Endpoint

"The composite efficacy endpoint consisted of treated biopsy proven acute rejection (BPAR) episodes, graft loss, death or loss to follow-up. A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. The allograft was presumed to be lost on the day the patient starts dialysis and was not able to stop dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss.~For the individual components (including loss of follow-up)of the composite endpoint, patients are counted for the first event to occur." (NCT00658320)
Timeframe: 12 months

Intervention	Participants (Number)
	Composite Efficacy Endpoint	Treated BPAR	Graft Loss	Death	Loss to follow up (see caveats)
Everolimus + Reduced Dose of Cyclosporine	7	3	0	0	4
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	7	5	0	0	2

Extension Study: Cyclosporine Trough Levels

Blood was collected at all visits after Day 3 for trough (collected 5 minutes before study drug dose) cyclosporine levels and was analyzed at a central laboratory using immunoassay. (NCT00658320)
Timeframe: Month 24, Month 48

Intervention	ng/mL (Mean)
	Month 24	Month 48 (n=7,0)
Everolimus + Reduced Dose of Cyclosporine	54.1	34.2
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	105.5	NA

Extension Study: Everolimus Trough Levels

Blood was collected at all visits after Day 3 for trough (collected 5 minutes before study drug dose) everolimus levels and was analyzed at a central laboratory using liquid chromatography mass spectrometry. (NCT00658320)
Timeframe: Month 24, Month 48

Intervention	ng/mL (Mean)
	Month 24	Month 48 (n=8)
Everolimus + Reduced Dose of Cyclosporine	5.258	4.408

Extension Study: Number of Participants With Adverse Events and Serious Adverse Events

Additional information about Adverse Events can be found in the Adverse Event Section. (NCT00658320)
Timeframe: 24 Months

Intervention	Participants (Number)
	Adverse Events	Serious Adverse Events
Everolimus + Reduced Dose of Cyclosporine	50	30
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	50	30

Extension Study: Number of Participants With Combined Efficacy Endpoint: Graft Loss, Death, Loss to Follow-up and/or Treated Biopsy Proven Acute Rejection (BPAR)

"Graft loss was defined as the day the patient started dialysis and was not able to subsequently be removed from dialysis or re-transplant.~Loss-to-follow was a patient who did not experience a treated BPAR, graft loss or death and whose last day of contact was prior to Month 24.~A Graft Biopsy was done within 48 hours of suspect rejection. Biopsies were read by the local pathologist according to the updated Banff '97 criteria.~Treated BPAR was based on local laboratory biopsy results and was defined as a biopsy Banff criteria graded IA to III that was treated with anti-rejection therapy." (NCT00658320)
Timeframe: 24 Months

Intervention	Participants (Number)
	Combined Efficacy Endpoint	Treated BPAR	Graft Loss	Death	Loss to follow-up
Everolimus + Reduced Dose of Cyclosporine	4	3	0	0	1
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	5	5	0	0	0

Extension Study: Renal Function Measured by Calculated Glomerular Filtration Rate (GFR) Using the Nankivell Formula

"The Nankivell formula was used to calculate GFR at Month 24:~GFR[mL/min]=6.7/C + W/4 - UREA/2 - 100/H^2 + 35 (25 for females) W= body weight [kg] H= height [m] C= serum creatinine [mmol/L] UREA= serum urea [mmolL]" (NCT00658320)
Timeframe: Month 24, Month 48

Intervention	mL/min (Mean)
	Month 24	Month 48 (9,0)
Everolimus + Reduced Dose of Cyclosporine	63.49	60.16
Mycophenolate Mofetil (MMF) + Standard Dose of Cyclosporine	59.24	NA

Disease-free Survival at 1 Year

Number of patients alive without evidence of disease at 1 year after transplant (NCT00303667)
Timeframe: 1 Year

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	0
SCT w/Donor Natural Killer Cells - Extended Schema	3

Disease-free Survival at 6 Months

Number of patients alive without evidence of disease at 6 months after transplant (NCT00303667)
Timeframe: Month 6

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	0
SCT w/Donor Natural Killer Cells - Extended Schema	4

In Vivo Expansion of a Donor NK Cells NK Cell Product

Number of patients with in vivo expansion of donor NK cells. In vivo expansion of NK cell is defined as detection of >100 donor-derived NK cells per microliter of blood. (NCT00303667)
Timeframe: 12 - 14 days after NK cell infusion

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Extended Schema	19

Incidence of Chronic Graft Versus Host Disease

Chronic graft versus host disease is a severe long term complication created by infusion of donor cells into a foreign host (NCT00303667)
Timeframe: 1 Year

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	0
SCT w/Donor Natural Killer Cells - Extended Schema	0

Incidence of Grade III-IV Acute Graft Versus Host Disease

Grade III-IV acute graft versus host disease is a severe short term complication created by infusion of donor cells into a foreign host (NCT00303667)
Timeframe: Month 6

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	0
SCT w/Donor Natural Killer Cells - Extended Schema	0

Incidence of Post-transplant Lymphoproliferative Disorder (PTLD)

Post-transplant lymphoproliferative disorder (PTLD) is a virally-driven cancer of the lymphoid cells caused by immunosuppressive drugs taken after allogeneic stem cell transplantation to prevent or control graft versus host disease. (NCT00303667)
Timeframe: 1 Year

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	0
SCT w/Donor Natural Killer Cells - Extended Schema	3

Number of Patients With Disease Relapse

Disease relapse is the recurrence of leukemia in patients who had cleared their leukemia after treatment. Patients with persistent leukemia are not evaluable for relapse. (NCT00303667)
Timeframe: 1 Year

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	5
SCT w/Donor Natural Killer Cells - Extended Schema	12

Number of Patients With Graft Failure

Number of patients with graft failure defined as <500 donor neutrophils count by day 28 in the absence of residual or relapsed leukemia (NCT00303667)
Timeframe: Day 28

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	1
SCT w/Donor Natural Killer Cells - Extended Schema	4

Number of Patients With Treatment-Related Mortality

Death within the first 100 days related to treatment in patients without relapse or persistent disease. (NCT00303667)
Timeframe: Day 100

Intervention	participants (Number)
SCT w/Donor Natural Killer Cells - Short Schema	1
SCT w/Donor Natural Killer Cells - Extended Schema	13

Disease Progression at Baseline With Decline in FEV1 Greater Than 10%

Participants with progressive disease at baseline with decline in FEV1 greater than 10% (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	2
Inhaled Cyclosporine in Lung Transplant Recipients	0

Disease Progression at Baseline With Stablization of FEV1

Participants with progressive disease at baseline with stablization of FEV1 (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	2
Inhaled Cyclosporine in Lung Transplant Recipients	0

Disease Stability at Baseline With Stablization in FEV1 and Greater Than 25% Decline in Systemic Immunosuppression

Participants with stable disease at baseline with stablization in FEV1 and greater than 25% decline in systemic immunosuppression (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	3
Inhaled Cyclosporine in Lung Transplant Recipients	0

Overall Non-response to Treatment

Participants who did not respond to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	7
Inhaled Cyclosporine in Lung Transplant Recipients	2

Overall Response to Treatment Based on Positive Response to Cyclosporine Inhalation Solution (CIS)

Participants who responded to treatment with cyclosporine inhalation solution (CIS) (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	9
Inhaled Cyclosporine in Lung Transplant Recipients	0

Stable Disease at Baseline With Stablization of FEV1 and no Change or Increase in Systemic Immunosuppresion

Participants with stable disease at baseline with stablization of FEV1 and no change or increase in systemic immunosuppresion (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	4
Inhaled Cyclosporine in Lung Transplant Recipients	2

Stable or Progressive Disease at Baseline With Greater Than 20% of Decline in FEV1

Participants with stable or progressive disease at baseline with greater than 20% of decline in FEV1 (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	1
Inhaled Cyclosporine in Lung Transplant Recipients	0

Stable or Progressive Disease at Baseline With Improvement of FEV1

Participants with stable or progressive disease at baseline with improvement of FEV1 (NCT01287078)
Timeframe: 18 weeks

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Recipients	4
Inhaled Cyclosporine in Lung Transplant Recipients	0

Freedom From Acute Rejection or HCV Recurrence or Treatment Failure

"Freedom from acute rejection (Banff>grade 2 with RAI score>4) or freedom from HCV recurrence (Batts/Ludwig>Stage 2, or >Grade 3) that requires HCV antiviral therapy or treatment failure (patient death, graft loss, premature withdrawal from study regimen or treatment with more than 1 dose of corticosteroids for presumptive rejection without a biopsy to confirm the rejection; reported values represent the Number of participants with Freedom From Acute Rejection or HCV Recurrence or Treatment Failure" (NCT00163657)
Timeframe: 12 months

Intervention	participants (Number)
Treatment Arm 1	69
Treatment Arm 2	70
Treatment Arm 3	133

Freedom From HCV Recurrence Within First Year That Requires HCV Antiviral Therapy and Freedom From Treatment Failure

Participants would have their blood drawn and tested for the HCV virus to determine if they had recurrence (NCT00163657)
Timeframe: 12 month post transplant

Intervention	participants (Number)
Treatment Arm 1	39
Treatment Arm 2	39
Treatment Arm 3	72

Incidence of Chronic Graft-versus-host-disease (GVHD) at 1 Year

"Number of participants with chronic graft-versus-host-disease (GVHD) at 1 year.~Clinical Limited cGVHD~Oral abnormalities consistent with cGVHD, a positive skin or lip biopsy, and no other manifestations of cGVHD.~Mild liver test abnormalities (alkaline phosphatase <2 x upper limit of normal, AST or ALT <3 x upper limit of normal and total bilirubin <1.6) with positive skin or lip biopsy, and no other manifestations of cGVHD.~Less than 6 papulosquamous plaques, macular-papular or lichenoid rash involving <20% of body surface area (BSA), dyspigmentation involving <20% BSA, or erythema involving <50% BSA, positive skin biopsy, and no other manifestations of cGVHD.~Ocular sicca (Schirmer's test <5mm with no more than minimal ocular symptoms), positive skin or lip biopsy, and no other manifestations of cGVHD.~Vaginal or vulvar abnormalities with positive biopsy, and no other manifestations of cGVHD." (NCT00719849)
Timeframe: 1 year post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	0
Cyclophosphamide/Fludarabine/TBI/ATG	3

Incidence of Clinically Significant Infections at 1 Year

Number of participants with clinically significant infections at 1 year (NCT00719849)
Timeframe: 1 year post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	3
Cyclophosphamide/Fludarabine/TBI/ATG	3

Incidence of Clinically Significant Infections at 2 Years

Number of participants with clinically significant infections at 2 years (NCT00719849)
Timeframe: 2 years post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	3
Cyclophosphamide/Fludarabine/TBI/ATG	3

Incidence of Clinically Significant Infections at 6 Months

Number of participants with clinically significant infections at 6 months (NCT00719849)
Timeframe: 6 months post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	3
Cyclophosphamide/Fludarabine/TBI/ATG	3

Incidence of Grade II-IV Acute Graft-versus-host-disease (GVHD) at Day 100

"Number of participants with Grade II-IV acute graft-versus-host-disease (GVHD) at day 100.~Acute GVHD Staging and Grading:~Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)" (NCT00719849)
Timeframe: Day 100 post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	3
Cyclophosphamide/Fludarabine/TBI/ATG	6

Incidence of Grade III-IV Acute Graft-versus-host-disease (GVHD) at Day 100

"Number of participants with Grade III-IV acute graft-versus-host-disease (GVHD) at day 100.~Acute GVHD Staging and Grading:~Overall grade 1: stage 1-2 skin, no liver or gut Overall grade 2: stage 3 skin or stage 1 liver or stage 1 gut Overall grade 3: stage 4 skin or stage 2-4 liver or stage 2-4 gut (without GVHD as a major contributing cause of death) Overall grade 4: stage 4 skin or stage 2-4 liver or stage 2-3 gut (with GVHD as a major contributing cause of death)" (NCT00719849)
Timeframe: Day 100 post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	2
Cyclophosphamide/Fludarabine/TBI/ATG	1

Incidence of Neutrophil Engraftment at Day 42

Number of participants with neutrophil engraftment at day 42 (NCT00719849)
Timeframe: Day 42 post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	3
Cyclophosphamide/Fludarabine/TBI/ATG	7

Incidence of Non-relapse Mortality at 6 Months

Number of Participants with Non-relapse Mortality at 6 Months (NCT00719849)
Timeframe: 6 months post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	2
Cyclophosphamide/Fludarabine/TBI/ATG	2

Incidence of Platelet Engraftment at 6 Months

Number of participants with platelet engraftment at 6 months (NCT00719849)
Timeframe: 6 months post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	2
Cyclophosphamide/Fludarabine/TBI/ATG	2

Incidence of Relapse at 1 Year

"Number of participants with relapse at 1 year.~Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated." (NCT00719849)
Timeframe: 1 year post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	1
Cyclophosphamide/Fludarabine/TBI/ATG	4

Incidence of Relapse at 2 Years

"Number of participants with relapse at 2 years.~Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated." (NCT00719849)
Timeframe: 2 years post transplant

Intervention	Participants (Count of Participants)
Cyclophosphamide/Fludarabine/TBI	1
Cyclophosphamide/Fludarabine/TBI/ATG	5

Probability of Progression-free Survival at 1 Year

Kaplan-Meier estimate of the probability of progression-free survival at 1 year (NCT00719849)
Timeframe: 1 year post transplant

Intervention	progression free survival probability (Number)
Cyclophosphamide/Fludarabine/TBI	0.25
Cyclophosphamide/Fludarabine/TBI/ATG	0.38

Probability of Progression-free Survival at 2 Years

Kaplan-Meier estimate of the probability of progression-free survival at 2 years (NCT00719849)
Timeframe: 2 years post transplant

Intervention	progression free survival probability (Number)
Cyclophosphamide/Fludarabine/TBI	0.25
Cyclophosphamide/Fludarabine/TBI/ATG	0.25

Probability of Survival at 1 Year

Kaplan-Meier estimate of the probability of survival at 1 year (NCT00719849)
Timeframe: 1 year post transplant

Intervention	survival probability (Number)
Cyclophosphamide/Fludarabine/TBI	0.25
Cyclophosphamide/Fludarabine/TBI/ATG	0.50

Probability of Survival at 2 Years

Kaplan-Meier estimate of the probability of survival at 2 years (NCT00719849)
Timeframe: 2 years post transplant

Intervention	survival probability (Number)
Cyclophosphamide/Fludarabine/TBI	0.25
Cyclophosphamide/Fludarabine/TBI/ATG	0.38

Chimerism

Count of participants who experienced dominance of one cord blood unit (defined by >or= 95% contribution of one cord blood unit to BM and all PB fractions -- CD3+, CD33+, CD56+, and CD19+) at 7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant. (NCT00719849)
Timeframe: 7 days, 14 days, 21 days, 28 days, 56 days, and 80 days, 6 months, 1 and 2 years post transplant

Intervention	Participants (Count of Participants)
	Day 7	Day 14	Day 21	Day 28	Day 56	Day 80	6 months	1 year	2 years
Cyclophosphamide/Fludarabine/TBI	0	0	1	1	1	1	2	2	2
Cyclophosphamide/Fludarabine/TBI/ATG	0	0	1	5	5	6	7	7	7

Long Term Period: Percentage of Participants With New Onset Diabetes Mellitus Up to Month 36- All Randomized Participants Who Entered LT Period

A participant who did not have diabetes prior to randomization is determined to have new onset diabetes mellitus if they received an antidiabetic medication for a duration of at least 30 days or at least two fasting plasma glucose (FPG) tests indicated that FPG is >=126 mg/dL. Percentage was the number of participants with new onset of diabetes mellitus divided by the number of participants without pre-randomization diabetes. (NCT00402168)
Timeframe: Baseline (screening) up to Month 36 post randomization

Intervention	percentage of participants (Number)
Belatacept 5 mg/kg	6.9
Calcineurin Inhibitor (CNI)	4.8

Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 12 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening. Randomization/First Dose was on Day 1. (NCT00402168)
Timeframe: Baseline to 12 months post randomization

Intervention	mL/min/1.73 m^2 (Mean)
Belatacept 5 mg/kg	7.0
Calcineurin Inhibitor (CNI)	2.1

Mean Change From Baseline in Calculated Glomerular Filtration Rate (GFR) With Imputed Values to 6 Months Post Randomization - All Randomized Participants (Intent-to-Treat Population)

Calculated GFR assessment used the modification of diet in renal disease (MDRD) formula. GFR was measured as mL/min/1.73 m^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Baseline = value at screening. (NCT00402168)
Timeframe: Baseline to 6 months post randomization

Intervention	mL/min/1.73 m^2 (Mean)
Belatacept 5 mg/kg	6.9
Calcineurin Inhibitor (CNI)	1.1

Percentage of Participants With a Composite Endpoint of Death, Graft Loss and Acute Rejection at Month 12

Percentage=number with composite divided by number randomized. Graft loss was functional loss or physical loss. Functional loss = sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that participant undergoes re-transplantation. AR: if either a or b: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy-proven AR (grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy-proven AR, and the participant was treated for it. (NCT00402168)
Timeframe: 12 Months post randomization

Intervention	percentage of participants (Number)
Belatacept 5 mg/kg	7.1
Calcineurin Inhibitor (CNI)	1.1

Percentage of Participants With New Onset Diabetes Mellitus - All Randomized Participants

Intervention	percentage of participants (Number)
Belatacept 5 mg/kg	1.7
Calcineurin Inhibitor (CNI)	2.9

Long Term Period: Mean Change From Baseline to 54 Months Post Randomization in Calculated GFR on Imputed Values at Specified Timepoints - Intent to Treat (ITT) Participants Who Entered LT Period

ITT=participants randomized to their original treatment arm and who entered the LT period are presented. Baseline=value at screening. Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m^2. For death or graft loss participants, calculated GFR (cGFR) value of 0 was imputed and carried forward after death or graft loss up to the end of the analysis period. Sponsor discontinued the CNI treatment arm in Year 3, and participants treated with CNI could elect to switch to belatacept. If a participant did not switch to belatacept, they were required to discontinue from the study. Therefore, efficacy results from Month 36 through Month 54 are difficult to interpret. No formal comparisons were planned between the belatacept and CNI treatment groups post Month 36, and the data up to the final database lock should be interpreted with caution. (NCT00402168)
Timeframe: Baseline, Month 3, 6, 12, 18, 24, 30, 36, 42, 48, 54

Intervention	mL/min/1.73 m^2 (Mean)
	Month 3 (n=81, 81)	Month 6 (n=80, 77)	Month 12 (n=81, 81)	Month 18 (n=81, 75)	Month 24 (n=81, 78)	Month 30 (n=80, 69)	Month 36 (n=57, 52)	Month 42 (n=71, 54)	Month 48 (n=16, 32)	Month 54 (n=14, 26)
Belatacept 5 mg/kg	5.1	7.1	7.1	8.8	8.8	9.1	7.7	9.1	-1.7	-0.9
Calcineurin Inhibitor (CNI)	0.4	2.3	2.8	0.1	-0.0	0.1	3.9	0.6	4.2	2.4

Long Term Period: Mean Change From Baseline to Month 54 in Diastolic Blood Pressure

Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in mmHg. Baseline was value at screening. Only those participants who entered long term period were evaluated. (NCT00402168)
Timeframe: Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54

Intervention	mmHg (Mean)
	Month 6 (n=78,73)	Month 12 (n=77,71)	Month 18 (n=77,1)	Month 24 (n=77,1)	Month 30 (n=75,6)	Month 36 (n=75,13)	Month 42 (n=74,29)	Month 48 (n=73, 32)	Month 54 (n=72, 33)
Belatacept 5 mg/kg	-2.0	-2.5	-1.7	-3.9	-1.8	-1.9	-1.7	-3.2	-1.1
Calcineurin Inhibitor (CNI)	-2.2	-1.0	10.0	13.0	5.7	-1.6	-3.8	-3.6	-3.6

Long Term Period: Mean Change From Baseline to Month 54 in Serum Creatinine- ITT Participants Who Entered LT Period

Baseline was value at screening. Serum creatinine was measured in mg/dL. Only participants who entered into Long Term Period were included in the analysis. (NCT00402168)
Timeframe: Baseline, Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54

Intervention	mg/dL (Mean)
	Month 3 (n=81,81)	Month 6 (n=81,77)	Month 12 (n=81,81)	Month 18 (n=80,75)	Month 24 (n=80,77)	Month 30 (n=78, 68)	Month 36 (n=55, 51)	Month 42 (n=68, 53)	Month 48 (n=12, 31)	Month 54 (n=10, 25)
Belatacept 5 mg/kg	-0.1	-0.1	-0.1	-0.1	-0.1	-0.2	-0.1	-0.2	-0.2	-0.3
Calcineurin Inhibitor (CNI)	0.0	-0.0	-0.0	0.1	0.0	0.0	-0.0	0.0	-0.1	-0.1

Long Term Period: Mean Change From Baseline to Month 54 in Systolic Blood Pressure

Blood pressure was measured while the participant was sitting quietly for 5 minutes and was measured in millimeters of mercury (mmHg). Baseline was value at screening. Only those participants who entered long term period were evaluated. (NCT00402168)
Timeframe: Baseline, Months 6, 12, 18, 24, 30, 36, 42, 48, 54

Intervention	mmHg (Mean)
	Month 6 (n=78,73)	Month 12 (n=77,71)	Month 18 (n=77,1)	Month 24 (n=77,1)	Month 30 (n=75, 6)	Month 36 (n=75,13)	Month 42 (n=74, 29)	Month 48 (n=73,32)	Month 54 (n=72,33)
Belatacept 5 mg/kg	-3.6	-4.6	-4.4	-6.0	-3.6	-6.6	-5.4	-4.4	-4.9
Calcineurin Inhibitor (CNI)	-0.4	-4.2	9.0	4.0	-0.5	1.2	-3.5	-3.7	-3.8

Long Term Period: Number of Participants Meeting Marked Laboratory Abnormality Criteria - All ITT Participants Who Entered the Long Term Period

Upper limits of normal (ULN). Hemoglobin: < 8 g/dL; Platelet count: < 50*10^9 c/L; Leukocytes: < 2.0*10^3 c/µL; Lymphocytes (absolute): < 0.5*10^3 c/µL; Neutrophils: < 1.0*10^3 c/µL; Alanine Aminotransferase (ALT): > 5.0*ULN Units per liter (U/L); bilirubin: > 3.0*ULN mg/dL; Creatinine: > 3.0*ULN mg/dL; Calcium: < 7 mg/dL; Bicarbonate: > 12.5 mg/dL; Potassium: < 3.0 meq/L or > 6.0 meq/L; Magnesium >2.6 meq/L; Sodium: < 130 meq/L; Phosphorus: < 2.0 mg/dL; Uric Acid: > 10 mg/dL. (NCT00402168)
Timeframe: Baseline (Screening), up to Year 6 of the Study

Intervention	participants (Number)
	Hemoglobin Low	Platelet Count Low	Leukocytes Low	Lymphocytes Low	Neutrophils Low	ALT High	Bilirubin High	Creatinine High	Calcium Low	Bicarbonate Low	Potassium Low	Potassium High	Magnesium High	Sodium Low	Phosphorus Inorganic Low	Uric Acid High
Belatacept 5 mg/kg	1	1	0	5	1	0	0	0	0	0	2	1	6	2	7	7
Calcineurin Inhibitor (CNI)	0	1	1	5	2	1	1	1	2	1	1	3	1	1	3	7

Long Term Period: Number of Participants Who Survived With a Functioning Graft or Survived With Pure Graft Loss or Death With Functioning Graft - ITT Participants Who Entered the LT Period

Graft loss = either pure graft loss (participant survived to the end of the study period after graft loss) or death with functioning graft. Pure graft loss = either functional loss or physical loss. Functional loss = a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation. The table was designed with built-in redundancy to capture all possible combinations of death and/or graft loss, but not all lines can be summed to reach the total number surviving and the total number who die and/or lose grafts. If a participant experiences pure graft loss and dies at a later date independent of the graft loss event, they are counted only once in the cumulative tabulation of death or graft loss. Only the first event experienced by the participant counted toward the cumulative total. (NCT00402168)
Timeframe: Post Months 24, 36, 48, up to Year 6 of the Study

Intervention	participants (Number)
	Month 24 Surviving with Functioning Graft	Month 24 Graft Loss or Death	Month 24 Graft Loss	Month 24 Death	Month 36 Surviving with Functioning Graft	Month 36 Graft Loss or Death	Month 36 Graft Loss	Month 36 Death	Month 36 Death with Functioning Graft	Month 48 Surviving with Functioning Graft	Month 48 Graft Loss or Death	Month 48 Graft Loss	Month 48 Death	Month 48 Death with Functioning Graft	up to year 6 Surviving with Functioning Graft	up to year 6 Graft Loss or Death	up to year 6 Graft Loss	up to year 6, Death	up to year 6 Death with Functioning Graft
Belatacept 5 mg/kg	80	1	1	0	79	2	1	1	1	78	3	1	2	2	76	5	1	4	4
Calcineurin Inhibitor (CNI)	80	1	1	0	80	1	1	0	0	80	1	1	0	0	80	1	1	0	0

Long Term Period: Number of Participants With Acute Rejection (AR) - All Randomized Participants in LT Period

AR was defined: if either a or b was satisfied: (a) the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification grade IA or higher as assessed by the blinded central pathologist); (b) the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 working classification of kidney transplant pathology was used to categorize the severity of the AR. (NCT00402168)
Timeframe: Post Month 12 up to Year 6 of the Study

Intervention	participants (Number)
	Total Number	Mild Acute IA	Mild Acute IB	Moderate Acute IIA	Moderate Acute IIB	Severe Acute III
Belatacept 5 mg/kg	5	0	1	3	1	0
Calcineurin Inhibitor (CNI)	4	0	1	2	1	0

Long Term Period: Number of Participants With AEs of Special Interest - All Randomized Participants Who Entered the Long Term Period

Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections, Thrombolic/embolic events, Autoimmune Disease, Malignancy, Peri-infusional reactions (only belatacept treatment group was IV) , Acute Peri-infusional events occurring within 24 hours of injection, Pulmonary Edema and Congestive Heart Failure. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00402168)
Timeframe: First dose after randomization (Day 1) to last dose, plus 56 days, up to Year 6 of the Study

Intervention	participants (Number)
	Malignancies	Serious Infections	Thrombolic/embolic	Peri-infusional Events	Acute Peri-infusional Events	Autoimmune Disease	Pulmonary Edema/Congestive Heart Failure
Belatacept 5 mg/kg	8	26	3	37	5	2	3
Calcineurin Inhibitor (CNI)	9	26	0	0	0	1	2

Long Term Period: Number of Participants With SAEs, Death, Discontinuation Due to AEs - All Randomized Participants Who Entered the Long Term Period

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. (NCT00402168)
Timeframe: First dose after randomization (Day 1) to 56 days post last dose, up to Year 6 of the Study

Intervention	participants (Number)
	Deaths	SAEs	Treatment Related SAEs	Discontinued Due to SAEs	Treatment Related AEs	Discontinued Due to AEs
Belatacept 5 mg/kg	4	45	18	1	38	1
Calcineurin Inhibitor (CNI)	0	40	14	2	43	3

Mean Change From Baseline in SF-36 Questionnaire Physical Component Score and in Mental Component Score at Month 12 - All Randomized Participants

SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The subscale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The subscale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The subscale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. Baseline was at randomization or prior to first dose. Baseline = value at screening. The subscale scores were transformed using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life. (NCT00402168)
Timeframe: Baseline, Month 12

Intervention	units on a scale (Mean)
	MCS (n=64, 75)	PCS (n=64, 75)
Belatacept 5 mg/kg	0.3	0.5
Calcineurin Inhibitor (CNI)	-0.7	0.8

Mean Change From Baseline to Month 12 for Eight Domain Scores of Quality of Life (QoL) Instrument SF-36 - All Randomized Participants

"SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 8 domains of physical and mental component summaries: physical function, role limitations due to physical problems, pain, general health perception, and vitality, social function, role limitations due to emotional problems, and mental health.~All domains were scored using norm-based methods that standardized the scores to a mean of 50 and a standard deviation of 10 in the general population. The scores range from a minimum of 0 to a maximum of 100, with a higher score indicating better quality of life." (NCT00402168)
Timeframe: Baseline (screening) to Month 12

Intervention	units on a scale (Mean)
	Bodily Pain (n=74,79)	General Health (n=75,79)	Mental Health (n=73,79)	Physical Functioning (n=67,75)	Role Emotional (n=75,79)	Role Physical (n=75,79)	Social Functioning (n=75,79)	Vitality (n=73,79)
Belatacept 5 mg/kg	0.7	1.6	0.7	-0.5	-1.4	0.5	0.9	0.2
Calcineurin Inhibitor (CNI)	0.3	0.9	-0.1	0.8	-0.4	0.2	-0.5	-0.2

Mean Change From Baseline to Month 6 and to Month 12 in Serum Creatinine - All Randomized Participants

Baseline was value at screening or prior to first dose of study drug. Serum creatinine was measured in milligrams per deciliter (mg/dL). Baseline = value at screening. (NCT00402168)
Timeframe: Baseline to Month 6 and Month 12 Post Randomization

Intervention	mg/dL (Mean)
	Month 6 (n=81,82)	Month 12 (n=81,86)
Belatacept 5 mg/kg	-0.1	-0.1
Calcineurin Inhibitor (CNI)	-0.0	-0.0

Number of Participants Meeting Marked Laboratory Abnormality Criteria From Baseline up to Month 12 - Randomized and Treated Participants

Upper limits of normal (ULL). Leukocytes: < 2.0*10^3 cells per microliter (c/µL); Lymphocytes (absolute): < 0.5*10^3 c/µL; bilirubin: > 3.0*ULN milligrams per deciliter (mg/dL); Potassium: < 3.0 milliequivalents per liter (meq/L) or > 6.0 meq/L; Magnesium >2.6 meq/L; Sodium: < 130 meq/L; Phosphorus: < 2.0 mg/dL; Uric Acid: > 10 mg/dL. Baseline = value at screening. (NCT00402168)
Timeframe: Baseline up to Month 12

Intervention	participants (Number)
	Leukocytes Low	Lymphocytes Low	Bilirubin High	Potassium Low	Potassium High	Magnesium High	Sodium Low	Phosphorus Inorganic Low	Uric Acid High
Belatacept 5 mg/kg	0	4	0	1	1	5	1	5	4
Calcineurin Inhibitor (CNI)	1	0	1	1	0	1	1	2	6

Number of Participants Who Had Any Study Drug Dose Alteration by Month 12 Due to Any Reason - Randomized and Treated Participants

Reasons for study drug dose modification included categories of decline in renal function (as determined by the investigator), treatment of acute rejection, and other reasons. More than 1 reason could be given for dose alteration. (NCT00402168)
Timeframe: Month 12

Intervention	participants (Number)
	Number with Dose Alteration (Any Reason)	Decline in renal function	Treatment of Acute Rejection	Other
Belatacept 5 mg/kg	15	0	0	15
Calcineurin Inhibitor (CNI)	62	4	0	61

Number of Participants With Acute Rejection (AR) by Months 6 and 12 Post Randomization - All Randomized Participants

AR defined: if either a or b was satisfied: a: the reason for clinical suspicion was reported to be an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness and the episode was a case of biopsy proven AR (AR of Banff histopathologic classification Grade IA or higher as assessed by the blinded central pathologist); b: the reason for clinical suspicion was reported to be something other than: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; the episode was a case of biopsy proven AR, and the participant was treated for this episode. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR is defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. (NCT00402168)
Timeframe: At 6 and 12 months post randomization

Intervention	participants (Number)
	Total Number by Month 6	By Month 6 Mild Acute (IA)	Month 6 Mild Acute (IB)	Month 6 Moderate Acute (IIA)	Month 6 Moderate Acute (IIB)	Month 6 Severe Acute (III)	Total Number by Month 12	Month 12 Mild Acute (IA)	Month 12 Mild Acute (IB)	Month12 Moderate Acute (IIA)	Month 12 Moderate Acute (IIB)	Month 12 Severe Acute (III)
Belatacept 5 mg/kg	6	1	1	3	1	0	6	1	1	3	1	0
Calcineurin Inhibitor (CNI)	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Anti-Donor Human Leukocyte Antigen (HLA) Positive Antibodies

Samples were obtained at Day 1 (first dose), Week 24, and Week 52 (or end of therapy). This was a cumulative summary in that once a participant was positive, that participant remained positive for later time points. Evaluation of anti-donor HLA antibodies was performed by an external laboratory (Emory University, Atlanta, Georgia). (NCT00402168)
Timeframe: Month 6 and Month 12 Post Randomization

Intervention	participants (Number)
	Baseline (n=80,82)	Month 6 (n=82,82	Month 12 (n=82, 83)
Belatacept 5 mg/kg	3	3	3
Calcineurin Inhibitor (CNI)	3	4	4

Number of Participants With Serious Adverse Events (SAEs), Deaths, and Discontinuation Due to Adverse Events (AEs) From First Dose up to Month 12

Intervention	participants (Number)
	Deaths	SAEs	Treatment Related SAEs	Discontinued due to SAEs	Treatment Related AEs	Discontinued due to AEs
Belatacept 5 mg/kg	0	20	9	1	24	1
Calcineurin Inhibitor (CNI)	1	17	4	0	27	0

Participants Who Switched From CNI to Belatacept in Long Term Period : Mean Change in Calculated GFR Based on Imputed Values From Day of Switch to Week 96 Post Switch

Calculated GFR assessment used the MDRD formula. GFR was measured as mL/min/1.73 m^2. For death or graft loss participants, calculated GFR (cGFR) value 10 was used, for other participants who had a post baseline cGFR value missing, but had baseline value and at least 2 post baseline values available, which were at least 120 days apart, linear regression model was used to impute the cGFR value. Day of Switch = the first belatacept infusion day. (NCT00402168)
Timeframe: Day of Switch (first belatacept dose) to Week 96 Post Switch

Intervention	mL/min/1.73 m^2 (Mean)
	Week 4 Post Switch (n=30)	Week 12 Post Switch (n=33)	Week 24 Post Switch (n= 29)	Week 48 Post Switch (n= 12)	Week 96 Post Switch (n= 8)
Belatacept 5 mg/kg in Participants Switched During LT Period	1.3	3.3	2.1	0.3	0.1

Participants Who Switched to Belatacept in Long Term Period: Number of Participants With AEs and SAEs

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Day of Switch = the first belatacept infusion day. (NCT00402168)
Timeframe: Day of Switch (first dose of belatacept ) to last dose plus 56 days, up to Year 6 of the Study

Intervention	participants (Number)
	AEs	SAEs
Belatacept 5 mg/kg in Participants Switched During LT Period	32	9

Percentage of Participants Surviving With a Functioning Graft, Have Graft Loss or Death (Graft Loss, Death, Death With Functioning Graft) By Month 6 and Month 12 Post Randomization

Graft loss was defined as either functional loss or physical loss. Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 mg/dL (530 μmol/L) for ≥ 4 weeks or administration of a maintenance dialysis regimen for at least 56 days or impairment of renal function to such a degree that the participant undergoes re-transplantation. (NCT00402168)
Timeframe: At 6 and 12 months post randomization

Intervention	percentage of participants (Number)
	Month 6 Surviving with Functioning Graft	Month 6 Graft Loss or Death	Month 6 Graft Loss	Month 6 Death	Month 6 Death with Functioning Graft	Month 12 Surviving with Functioning Graft	Month 12 Graft Loss or Death	Month 12 Graft Loss	Month 12 Death	Month 12 Death with Functioning Graft
Belatacept 5 mg/kg	100.0	0.0	0.0	0.0	0.0	100.0	0.0	0.0	0.0	0.0
Calcineurin Inhibitor (CNI)	98.9	1.1	0.0	1.1	1.1	98.9	1.1	0.0	1.1	1.1

Ridit Score at Month 12 - All Randomized Participants

The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, Inc. 1991) was used. Ridit scores were calculated at 12 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5. (NCT00402168)
Timeframe: Month 12

Intervention	Ridit score (Number)
	Symptom Distress (n=46,44)	Symptom Occurrence (n=46,45)
Belatacept 5 mg/kg	0.5162	0.5074
Calcineurin Inhibitor (CNI)	0.5014	0.4998

Mean Change From Baseline in Cockcroft-Gault Calculated Creatinine Clearance (CrCl)

"The primary variable was renal function assessed by calculated creatinine clearance using the Cockcroft-Gault formula, and was assessed at all visits.~CrCl[mL/min] = (140 - A) * W / (72 * C) * R. Where A is age at sample date [years], W is body weight at specific visit [kg], C is the serum concentration of creatinine [mg/dL], R = 1 if the patient is male and = 0.85 if female." (NCT00267189)
Timeframe: From baseline to 6 months

Intervention	mL/min (Mean)
Group 1 (Everolimus)	0.99
Group 2 (Control)	2.26

Number of Patients With Discontinuation of Study Medication

(NCT00267189)
Timeframe: 6 months

Intervention	Patients (Number)
	Total # of discontinuation of study medication	Adverse Event	Patient withdrew consent	Abnormal laboratory value(s)	Administrative problems
Group 1 (Everolimus)	18	14	2	1	1
Group 2 (Control)	1	0	1	0	0

Percentage of Patients With Efficacy Failure (Biopsy Proven Acute Rejection [BPAR], Graft Loss or Death)

The composite efficacy failure endpoint encompasses at least one of: biopsy proven acute rejection, graft loss, or death for the patient. BPAR was defined as a clinically suspected acute rejection confirmed by biopsy. Acute rejection episodes were recorded as Liver Allograft Rejection. The allograft was presumed to be lost if a patient had a liver retransplant or died. (NCT00267189)
Timeframe: 6 months

Intervention	Percentage of patients (Number)
	Composite efficacy failure (total)	Biopsy proven acute rejection	Graft Loss	Death
Group 1 (Everolimus)	2.8	1.4	0	1.4
Group 2 (Control)	1.4	1.4	0	0

Calculated Glomerular Filtration Rate (cGFR) After Kidney Transplant to Evaluate Kidney Function (12 Months Analysis)

The glomerular filtration rate (GFR) was calculated by the Nankivell formula: GFR = 6.7 / Scr + BW / 4 - Surea / 2-100 / (height)^ 2 + C where Scr is the serum creatinine concentration expressed in mmol/L, BW the body weight in kg, Surea the serum urea in mmol/L, height in m, and the constant C is 35 for male and 25 for female patients. (NCT00371826)
Timeframe: At Month 12

Intervention	mL/min per 1.73 m^2 (Mean)
Calcineurin Inhibitor (CNI) Withdrawal	65.2
CNI+MPA+ Steroid	69.3
Steroid Withdrawal	66.9

Creatinine Clearance (CrCl) Calculated by the Cockcroft-Gault Formula (12 Months Analysis)

"Creatinine clearance were calculated according to the Cockcroft-Gault formula:~CrCl (males) = (140-A) × BW/(72 × Cr) CrCl (females) = CrCl (males) × 0.85 where A is age [years], BW is body weight [kg], and Cr is the serum concentration of creatinine [mg/dL].~The Cockcroft-Gault formula estimates creatinine clearance based on serum creatinine level, body weight, and age." (NCT00371826)
Timeframe: At Month 12

Intervention	mL/min (Mean)
Calcineurin Inhibitor (CNI) Withdrawal	66.1
CNI+MPA+ Steroid	67.8
Steroid Withdrawal	63.2

Mean Serum Creatinine (12 Months Analysis)

(NCT00371826)
Timeframe: At Month 12

Intervention	umol/L (Mean)
Calcineurin Inhibitor (CNI) Withdrawal	118.9
CNI+MPA+ Steroid	161.0
Steroid Withdrawal	148.6

Mean Urine Albumin/Creatinine Ratio (ACR) as Measurement of Proteinuria (12 Months Analysis)

Proteinuria is measured by spot morning urine Albumin/Creatinine Ratio [ACR]. When the ACR is more than or equal to 30 mg/mmol then it is known as proteinuria. (NCT00371826)
Timeframe: At Month 12

Intervention	mg/mg (Mean)
Calcineurin Inhibitor (CNI) Withdrawal	0.2
CNI+MPA+ Steroid	0.1
Steroid Withdrawal	0.1

Number of Participants Hospitalized for Reasons Other Than Primary Transplantation (12 Months Analysis)

This analysis is reporting number of participants hospitalized for reasons (such as acute rejection, infection, gastrointestinal (GI) events, cardiovascular event, metabolic disorder and Other) other than primary transplantation. (NCT00371826)
Timeframe: Month 12

Intervention	Participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	34
CNI+MPA+ Steroid	31
Steroid Withdrawal	13

Number of Participants Hospitalized for Reasons Other Than Primary Transplantation (36 Months Analysis)

Intervention	Participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	16
CNI+MPA+ Steroid	30
Steroid Withdrawal	1

Number of Participants With Antibody-mediated Rejection Per Treatment Group (12 Months Analysis)

(NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	5
CNI+MPA+ Steroid	2
Steroid Withdrawal	2

Number of Participants With Biopsy Proven Acute Rejection (BPAR) Per Treatment Group (12 Months Analysis)

A biopsy-proven acute rejection is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification. (NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	15
CNI+MPA+ Steroid	6
Steroid Withdrawal	5

Number of Participants With Composite Endpoint of Treatment Failure (12 Months Analysis)

"Composite endpoint of treatment failure includes biopsy-proven acute rejection (BPAR), graft loss, death and loss-to-follow-up. A BPAR is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification.~The allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, then the day of nephrectomy was the day of graft loss." (NCT00371826)
Timeframe: Month 12

Intervention	Participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	16
CNI+MPA+ Steroid	8
Steroid Withdrawal	11

Number of Participants With Erythropoietin Usage (12 Months Analysis)

(NCT00371826)
Timeframe: Month 12

Intervention	participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	20
CNI+MPA+ Steroid	10
Steroid Withdrawal	8

Number of Participants With Erythropoietin Usage (36 Months Analysis)

(NCT00371826)
Timeframe: Month 36

Intervention	participants (Number)
Calcineurin Inhibitor (CNI) Withdrawal	5
CNI+MPA+ Steroid	7
Steroid Withdrawal	2

Calculated Glomerular Filtration Rate (cGFR) After Kidney Transplant to Evaluate Kidney Function (36 Months Analysis)

Intervention	mL/min per 1.73 m^2 (Mean)
	Month 24 (n= 23, 36, 4)	Month 36 (n= 19, 35, 3)
Calcineurin Inhibitor (CNI) Withdrawal	69.5	71.6
CNI+MPA+ Steroid	71.8	69.1
Steroid Withdrawal	67.0	61.0

Change in Bone Mineral Density Between Week 2 and Month 24 (36 Months Analysis)

Measurements of bone mineral density (BMD) by Dual Energy X-ray Absorptiometry (DEXA) were done at Week 2 and Month 24. Change in BMD between week 2 and Month 24 were done for neck of femur and lumbar spine. (NCT00371826)
Timeframe: Week 2, Month 24

Intervention	g/cm^2 (Mean)
	Neck of Femur (Month 24- Week 2)	Lumbar Spine (Month 24 - Week 2)
Calcineurin Inhibitor (CNI) Withdrawal	0.2	-0.0
CNI+MPA+ Steroid	-0.1	-0.1
Steroid Withdrawal	-0.1	-0.0

Creatinine Clearance Calculated by the Cockcroft-Gault Formula (36 Months Analysis)

Intervention	mL/min (Mean)
	At Month 12 (n= 23, 39, 4)	At Month 18 (n=22, 36, 4)	At Month 24 (n= 23, 36, 4)	At Month 36 (n= 23, 39, 4)
Calcineurin Inhibitor (CNI) Withdrawal	69.8	69.9	65.6	66.3
CNI+MPA+ Steroid	71.7	73.7	72.8	67.5
Steroid Withdrawal	63.7	66.2	63.7	62.7

Mean Serum Creatinine (36 Months Analysis)

(NCT00371826)
Timeframe: At Month 12, 18, 24 and 36

Intervention	umol/L (Mean)
	At Month 12 (n= 23, 39, 4)	At Month 18 (n= 22, 36, 4)	At Month 24 (n = 23, 36, 4)	At Month 36 (n= 19, 35, 3)
Calcineurin Inhibitor (CNI) Withdrawal	112.7	113.6	119.9	119.4
CNI+MPA+ Steroid	123.0	121.4	123.7	131.8
Steroid Withdrawal	146.8	146.3	146.5	176.0

Mean Short-form 36 Health Survey (SF-36) Score as a Measure of Quality of Life Assessment (12 Months Analysis)

"SF-36 measures impact of disease on overall quality of life (QoL). 36-item survey has 8 subscales. The 8 subscales are: Physical functioning (PF), Role-physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role-emotional (RE) and Mental health (MH).~Score for eash sub-scale has been standardized with the use of norm-based methods based on assessment of the general U.S. population free of chronic conditions. Scores range from 1-100 with a mean=50 and a standard deviation=10. A higher score indicates less impact on QoL." (NCT00371826)
Timeframe: At Month 12

Intervention	units on a scale (Mean)
	Physical functioning (PF)	Role-physical (RP)	Bodily pain (BP)	General health (GH)	Vitality (VT)	Social Functioning (SF)	Role-emotional (RE)	Mental health (MH)
Calcineurin Inhibitor (CNI) Withdrawal	78.7	72.9	73.6	67.1	62.7	74.5	72.2	73.3
CNI+MPA+ Steroid	76.9	78.2	81.5	71.2	72.4	81.1	81.1	79.1
Steroid Withdrawal	82.0	100.0	96.8	86.8	85.0	97.5	100.0	92.8

Mean Short-form 36 Health Survey (SF-36) Score as a Measure of Quality of Life Assessment (36 Months Analysis)

"SF-36 measures impact of disease on overall quality of life (QoL). 36-item survey has 8 subscales. The 8 subscales are : Physical functioning (PF), Role-physical (RP), Bodily pain (BP), General health (GH), Vitality (VT), Social functioning (SF), Role-emotional (RE) and Mental health (MH).~Score for each sub-scale has been standardized with the use of norm-based methods based on assessment of the general U.S. population free of chronic conditions. Scores range from 1-100 with a mean=50 and a standard deviation=10. A higher score indicates less impact on QoL." (NCT00371826)
Timeframe: At Month 24

Intervention	units on a scale (Mean)
	Physical functioning (PF)	Role-physical (RP)	Bodily pain (BP)	General health (GH)	Vitality (VT)	Social Functioning (SF)	Role-emotional (RE)	Mental health (MH)
Calcineurin Inhibitor (CNI) Withdrawal	84.3	75.0	81.6	71.6	70.0	85.9	72.9	77.5
CNI+MPA+ Steroid	87.6	77.4	85.0	69.8	72.7	80.6	83.9	77.9
Steroid Withdrawal	90.0	100.0	84.0	67.0	60.0	68.8	33.3	62.0

Mean Urine Albumin/Creatinine Ratio [ACR] as Measurement of Proteinuria (36 Months Analysis)

Proteinuria is measured by spot morning urine Albumin/Creatinine Ratio [ACR]. When the ACR is more than or equal to 30 mg/mmol then it is known as proteinuria. (NCT00371826)
Timeframe: At Month 12, 18, 24 and 36

Intervention	mg/mmol (Mean)
	At 12 Month (n = 18, 32, 2)	At 18 Month (n= 17, 31, 2)	At 24 Month ( n= 16, 29, 1)	At 36 Month ( n= 15, 25, 0)
Calcineurin Inhibitor (CNI) Withdrawal	23.5	28.2	30.0	30.6
CNI+MPA+ Steroid	8.1	8.1	6.6	23.4
Steroid Withdrawal	4.8	5.3	7.0	NA

Number of Participants With Antibody-mediated Rejection Per Treatment Group (36 Months Analysis)

(NCT00371826)
Timeframe: At Month 12, 24 and 36

Intervention	Participants (Number)
	At Month 12	At Month 24	At Month 36
Calcineurin Inhibitor (CNI) Withdrawal	1	1	1
CNI+MPA+ Steroid	0	0	2
Steroid Withdrawal	0	0	0

Number of Participants With Any Wound Problems (36 Months Analysis)

Patients with any wound healing problem such as infection related to kidney surgery, dehiscence, lymphocele, hernia, seroma, hematoma, ureteral anastomotic complication and other were reported in this analysis. (NCT00371826)
Timeframe: At Month 12, 24 and 36

Intervention	Participants (Number)
	At Month 12	At Month 24	At Month 36
Calcineurin Inhibitor (CNI) Withdrawal	6	9	10
CNI+MPA+ Steroid	11	13	13
Steroid Withdrawal	2	2	2

Number of Participants With Biopsy Proven Acute Rejection (BPAR) Influenced by Demographic Characteristics and Morbidities (12 Months Analysis)

The influence of demographic characteristics and comorbidities on incidence of BPAR were analyzed in the following way: Demographic characteristics were age (<55 years, ≥55 years), Expanded criteria Donor (ECD) organ (donor age >60 years or donor non heart-beating and donor age >50), gender, living vs. deceased donor, Body Mass Index (BMI) classes (underweight <18.5, normal 18.5 - <25.0, overweight 25.0 - <30.0, obesity 30.0 and above), years on dialysis before transplantation (<1, 1-5, >5 years). Comorbidities were diabetes, hypertension, cardiovascular diseases/events, nephrosclerosis, glomerulonephritis/glomerular disease, polycystic disease, and Cytomegalovirus status. (NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
	Age < 55 years	Age > = 55 years	ECD Organ	NO ECD Organ	Male	Female	Living donor	Deceased donor	BMI < 18.5	BMI 18.5 - <25	BMI 25 - <30	BMI >= 30	Years on dialysis before transplantation: None	< 1 Year on dialysis before transplantation	1 - 5 Years on dialysis before transplantation	> 5 Years on dialysis before transplantation	Diabetes mellitus: No	Diabetes mellitus: Yes	Hypertension: No	Hypertension: Yes	Cardiovascular disease : No	Cardiovascular disease: Yes	Nephrosclerosis: No	Nephrosclerosis: Yes	Glomerulonephritis/glomerular disease : No	Glomerulonephritis/glomerular disease: Yes	Cytomegalovirus : Negative	Cytomegalovirus : Positive
Calcineurin Inhibitor (CNI) Withdrawal	11	4	3	12	11	4	9	6	0	5	8	2	1	3	8	3	10	5	2	13	4	11	15	0	8	7	2	13
CNI+MPA+ Steroid	5	1	0	6	6	0	6	0	1	2	3	0	0	3	1	2	4	2	1	5	3	3	6	0	5	1	2	4
Steroid Withdrawal	4	1	2	3	4	1	2	3	0	3	1	1	0	1	2	2	4	1	0	5	2	3	4	1	3	2	0	5

Number of Participants With Biopsy Proven Acute Rejection (BPAR) Influenced by Demographic Characteristics and Morbidities (36 Months Analysis)

The influence of demographic characteristics and comorbidities on incidence of BPAR were analyzed in the following way: Demographic characteristics were age (<55 years, ≥55 years), Expanded Criteria Donor [ECD] organ (donor age >60 years or donor non heart-beating and donor age >50), gender, living vs. deceased donor, Body Mass Index (BMI) classes (underweight <18.5, normal 18.5 - <25.0, overweight 25.0 - <30.0, obesity 30.0 and above), years on dialysis before transplantation (<1, 1-5, >5 years). Comorbidities were diabetes, hypertension, cardiovascular diseases/events, nephrosclerosis, glomerulonephritis/glomerular disease, polycystic disease, and Cytomegalovirus status. (NCT00371826)
Timeframe: At Month 36

Intervention	Participants (Number)
	Age < 55 years	Age > = 55 years	ECD Organ	NO ECD Organ	Male	Female	Living donor	Deceased donor	BMI < 18.5	BMI 18.5 - <25	BMI 25 - <30	BMI >= 30	Years on dialysis before transplantation: None	< 1 Year on dialysis before transplantation	1 - 5 Years on dialysis before transplantation	> 5 Years on dialysis before transplantation	Diabetes mellitus: No	Diabetes mellitus: Yes	Hypertension: No	Hypertension: Yes	Cardiovascular disease : No	Cardiovascular disease: Yes	Nephrosclerosis: No	Nephrosclerosis: Yes	Glomerulonephritis/glomerular disease : No	Glomerulonephritis/glomerular disease: Yes	Cytomegalovirus : Negative	Cytomegalovirus : Positive
Calcineurin Inhibitor (CNI) Withdrawal	6	0	0	6	4	2	5	1	1	1	4	0	0	3	2	1	3	3	1	5	3	3	6	0	4	2	1	5
CNI+MPA+ Steroid	7	1	0	8	7	1	6	2	0	3	4	1	1	4	2	1	6	2	1	7	5	3	7	1	7	1	4	4
Steroid Withdrawal	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Number of Participants With Biopsy Proven Acute Rejection (BPAR) Per Treatment Group (36 Months Analysis)

A biopsy-proven acute rejection is defined as a biopsy graded IA, IB, IIA, IIB, or III as per Banff 97 classification. (NCT00371826)
Timeframe: At Month 12, 24 and 36

Intervention	Participants (Number)
	At Month 12	At Month 24	At Month 36
Calcineurin Inhibitor (CNI) Withdrawal	4	5	6
CNI+MPA+ Steroid	4	5	8
Steroid Withdrawal	0	0	0

Number of Participants With Composite Endpoint of Treatment Failure (36 Months Analysis)

Intervention	Participants (Number)
	At Month 12	At Month 24	At Month 36
Calcineurin Inhibitor (CNI) Withdrawal	4	6	7
CNI+MPA+ Steroid	4	6	10
Steroid Withdrawal	0	0	0

Number of Participants With Employment Status (12 Months Analysis)

"The various employment status reported are:~Employed/self employed full time~Employed part time~Unemployed~Homemaker~Volunteer~Permanently disabled~Non-permanently disable~Retired~Other" (NCT00371826)
Timeframe: At screening (at day 0 +/- 7 days ), At Month 12

Intervention	Participants (Number)
	Screening visit: Employed/self employed full time	Month 12: Employed/self employed full time	Screening visit: Employed part time	Month 12: Employed part time	Screening visit: Unemployed	Month 12: Unemployed	Screening visit: Homemaker	Month 12 : Homemaker	Screening visit: Volunteer	Month 12: Volunteer	Screening visit: Permanently disabled	Month 12: Permanently disabled	Screening visit: Non-permanently disabled	Month 12: Non-permanently disabled	Screening visit: Retired	Month 12: Retired	Screening visit: Other	Month 12: Other
Calcineurin Inhibitor (CNI) Withdrawal	18	6	9	3	10	6	3	2	1	1	2	1	1	1	4	1	1	1
CNI+MPA+ Steroid	21	14	7	5	8	1	5	5	0	0	2	2	2	0	2	2	0	0
Steroid Withdrawal	9	2	4	0	10	6	5	2	0	0	0	0	0	0	1	0	1	0

Number of Participants With Employment Status (36 Months Analysis)

Intervention	Participants (Number)
	Screening visit: Employed/self employed full time	Month 36: Employed/self employed full time	Screening visit: Employed part time	Month 36: Employed part time	Screening visit: Unemployed	Month 36: Unemployed	Screening visit: Homemaker	Month 36 : Homemaker	Screening visit: Permanently disabled	Month 36: Permanently disabled	Screening visit: Non-permanently disabled	Month 36: Non-permanently disabled	Screening visit: Retired	Month 36: Retired	Screening visit: Other	Month 36: Other
Calcineurin Inhibitor (CNI) Withdrawal	5	4	4	3	5	3	3	3	0	0	0	0	0	0	1	1
CNI+MPA+ Steroid	10	10	7	4	7	6	3	3	1	1	1	1	2	2	0	0
Steroid Withdrawal	1	1	0	0	1	0	1	1	0	0	0	0	0	0	0	0

Number of Participants With Histological Evidence Chronic Allograft Nephropathy (CAN) (12 Months Analysis)

"A per-protocol biopsy was performed at Baseline and Month 12 and read by an independent blinded pathologist in order to assess chronic allograft nephropathy. Chronic rejection is characterized by a slow progressive decline in renal function and is typically preceded by the histological picture of chronic allograft nephropathy. The presence of biopsy confirmed Grade I, II or III chronic allograft nephropathy by Banff 97 criteria was assessed on all optional biopsies obtained for clinical suspicion of chronic rejection.~Data summarized by 3 categories. Yes - Patients with histological evidence of CAN ; No - Patients with histological evidence of CAN and Not Done - Central protocol defined kidney allograft biopsies were not done." (NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
	YES	NO	Not Done
Calcineurin Inhibitor (CNI) Withdrawal	8	15	7
CNI+MPA+ Steroid	6	26	8
Steroid Withdrawal	2	5	3

Number of Participants With Histological Evidence Chronic Allograft Nephropathy (CAN) (36 Months Analysis)

"Chronic rejection is characterized by a slow progressive decline in renal function and is typically preceded by the histological picture of chronic allograft nephropathy. The presence of biopsy confirmed Grade I, II or III chronic allograft nephropathy by Banff 97 criteria was assessed on all optional biopsies obtained for clinical suspicion of chronic rejection.~Data summarized by 3 categories. Yes - Patients with histological evidence of CAN ; No - Patients with histological evidence of CAN and Not Done - Central protocol defined kidney allograft biopsies were not done." (NCT00371826)
Timeframe: At Month 36

Intervention	Participants (Number)
	YES	NO	Not Done
Calcineurin Inhibitor (CNI) Withdrawal	2	8	8
CNI+MPA+ Steroid	1	16	14
Steroid Withdrawal	1	1	1

Number of Participants With New Onset Diabetes Mellitus After Transplantation (NODAT) and Impaired Fasting Glucose (36 Months Analysis)

"The symptoms of new onset diabetes mellitus after transplantation (NODAT) and impaired fasting glucose are defined as any of the following conditions:~Patients receiving glucose lowering treatment~2 fasting plasma glucose (FPG) values >= 126 mg/dL or 2 random plasma glucose (RPG) values >= 200 mg/dL or FPG value >= 126 mg/dL and 1 RPG value >= 200 mg/dL~Diabetes reported as treatment emergent AE with end date > Day 15" (NCT00371826)
Timeframe: At Month 36

Intervention	Participants (Number)
	Glucose lowering treatment	FPG or RPG	Diabetes as treatment emergent AE	Any of the above symptoms
Calcineurin Inhibitor (CNI) Withdrawal	5	3	5	6
CNI+MPA+ Steroid	10	2	4	11
Steroid Withdrawal	2	1	2	2

Number of Participants With Notable Abnormal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) as Measurement of Effect of Treatment on Cardiovascular Health (12 Months Analysis)

"Notable abnormal systolic blood pressure is defined as :~Either an increase of >=30 that results in >=180 or >200 (mm/Hg)~OR a decrease of >=30 that results in <=90 or <75 (mm/Hg)from baseline~Notable abnormal diastolic blood pressure is defined as :~Either an increase of >=20 that results in >=105 or >115 (mm/Hg)~OR a decrease of >=20 that results in <=50 or <40 (mm/Hg) from baseline" (NCT00371826)
Timeframe: Baseline, Overall post-baseline up to 12 month

Intervention	Participants (Number)
	SBP: >=180 mm/Hg or 200 mm/Hg	SBP: < = 90 mm/Hg or < 200 mm/Hg	DBP : >=105 mm/Hg or >115 mm/Hg	DBP: <=50 mm/Hg or <40 mm/Hg
Calcineurin Inhibitor (CNI) Withdrawal	5	1	3	1
CNI+MPA+ Steroid	5	0	6	4
Steroid Withdrawal	7	0	5	0

Number of Participants With Notable Abnormal Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) as Measurement of Effect of Treatment on Cardiovascular Health (36 Months Analysis)

"Notable abnormal systolic blood pressure is defined as :~Either an increase of >=30 that results in >=180 or >200 (mm/Hg)~OR a decrease of >=30 that results in <=90 or <75 (mm/Hg) from baseline~Notable abnormal diastolic blood pressure is defined as :~Either an increase of >=20 that results in >=105 or >115 (mm/Hg)~OR a decrease of >=20 that results in <=50 or <40 (mm/Hg) from baseline" (NCT00371826)
Timeframe: Baseline, Overall post baseline up to Month 36

Intervention	Participants (Number)
	SBP: >=180 mm/Hg or 200 mm/Hg	SBP: < = 90 mm/Hg or < 200 mm/Hg	DBP : >=105 mm/Hg or >115 mm/Hg	DBP: <=50 mm/Hg or <40 mm/Hg
Calcineurin Inhibitor (CNI) Withdrawal	3	1	2	1
CNI+MPA+ Steroid	4	0	5	4
Steroid Withdrawal	1	0	1	0

Number of Participants With Notable Abnormalities in Total Cholesterol and Triglycerides as Measurement of Effect of Treatment on Cardiovascular Health (12 Months Analysis)

"Notable abnormal total cholesterol is defined as : High: >= 9.1 mmol/L , normal range is 0.00 - 5.17 mmol/L~Notable abnormal triglycerides is defined as : High: >= 8.5 mmol/L, normal range is 0.30 - 2.00 mmol/L" (NCT00371826)
Timeframe: Overall post baseline up to month 12

Intervention	Participants (Number)
	Total Cholesterol: High (n = 48, 47,30)	Triglycerides : High (n= 48, 46, 30)
Calcineurin Inhibitor (CNI) Withdrawal	6	1
CNI+MPA+ Steroid	0	0
Steroid Withdrawal	3	0

Number of Participants With Notable Abnormalities in Total Cholesterol and Triglycerides as Measurement of Effect of Treatment on Cardiovascular Health (36 Months Analysis)

Intervention	Participants (Number)
	Total Cholesterol: High	Triglycerides : High
Calcineurin Inhibitor (CNI) Withdrawal	6	0
CNI+MPA+ Steroid	0	1
Steroid Withdrawal	1	0

Number of Participants With Post Transplant Diabetes Mellitus (PTDM) and Impaired Fasting Glucose (12 Months Analysis)

"The symptoms of post transplant diabetes mellitus (PTDM) and impaired fasting glucose are defined as any of the following conditions:~Patients receiving glucose lowering treatment~Fasting plasma glucose (FPG) >= 126 mg/dL on 2 separate occasions~Hemoglobin subtype A1c (HbA1c) > 6.5%~Diabetes reported as treatment emergent AE with end date > Day 15" (NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
	Glucose lowering treatment	FPG >= 126 mg/dL on 2 separate occasions	HbA1c > 6.5%	Diabetes as treatment emergent AE	Any of the above symptoms
Calcineurin Inhibitor (CNI) Withdrawal	10	6	12	8	19
CNI+MPA+ Steroid	9	0	3	2	10
Steroid Withdrawal	5	5	5	3	8

Number of Participants With Sub Clinical Acute Rejection (12 Months Analysis)

"Based on Banff 97 criteria, sub clinical acute rejection can be:~GRADE IA - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 tubular cells).~GRADE IB - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>10 mononuclear cells/tubular cross section or group of 10 tubular cells).~GRADE IIA - Cases with significant interstitial infiltration and mild to moderate intimal arteritis (v1).~GRADE IIB - Cases with moderate to severe intimal arteritis comprising >25% of the luminal area (v2).~GRADE III - Cases with transmural arteritis or fibrinoid change and necrosis of medial smooth muscle cells (v3).~Borderline category is used when no intimal arteritis is present, but there are foci of mild tubulitis (1 to 4 mononuclear cells/tubular cross section)." (NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
	NO	Borderline	Grade IA	Grade IB	Grade IIA	Grade IIB	Grade III	Not Done
Calcineurin Inhibitor (CNI) Withdrawal	20	2	1	0	0	0	0	7
CNI+MPA+ Steroid	29	2	0	1	0	0	0	8
Steroid Withdrawal	5	2	0	0	0	0	0	3

Number of Participants With Sub Clinical Acute Rejection (36 Months Analysis)

"Based on Banff 97 criteria, sub clinical acute rejection can be:~GRADE IA - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>4 mononuclear cells/tubular cross section or group of 10 tubular cells).~GRADE IB - Cases with significant interstitial infiltration (>25% of parenchyma affected) and foci of moderate tubulitis (>10 mononuclear cells/tubular cross section or group of 10 tubular cells).~GRADE IIA - Cases with significant interstitial infiltration and mild to moderate intimal arteritis (v1).~GRADE IIB - Cases with moderate to severe intimal arteritis comprising >25% of the luminal area (v2).~GRADE III - Cases with transmural arteritis or fibrinoid change and necrosis of medial smooth muscle cells (v3).~Borderline' category is used when no intimal arteritis is present, but there are foci of mild tubulitis (1 to 4 mononuclear cells/tubular cross section)." (NCT00371826)
Timeframe: At Month 36

Intervention	Participants (Number)
	Month 36: NO	Month 36: Borderline	Month 36: Grade IA	Month 36: Grade IB	Month 36: Grade IIA	Month 36: Grade IIB	Month 36: Grade III	Month 36: Not Done
Calcineurin Inhibitor (CNI) Withdrawal	9	1	0	0	0	0	0	8
CNI+MPA+ Steroid	15	1	1	0	0	0	0	14
Steroid Withdrawal	2	0	0	0	0	0	0	1

Number of Participants With Wound Problems(12 Months Analysis)

Intervention	Participants (Number)
	Any wound healing problem	Infection related to kidney surgery	Dehiscence	Lymphocele	Hernia	Seroma	Hematoma	Ureteral anastomotic complication	Other
Calcineurin Inhibitor (CNI) Withdrawal	16	2	3	3	3	4	4	2	3
CNI+MPA+ Steroid	15	4	2	4	2	9	0	1	1
Steroid Withdrawal	9	3	2	3	1	3	2	1	0

Number of Patient Survival and Graft Survival (12 Months Analysis)

(NCT00371826)
Timeframe: At Month 12

Intervention	Participants (Number)
	Patient Survival	Graft Survival
Calcineurin Inhibitor (CNI) Withdrawal	49	49
CNI+MPA+ Steroid	46	45
Steroid Withdrawal	30	30

Number of Patient Survival and Graft Survival (36 Months Analysis)

(NCT00371826)
Timeframe: At Month 12, 24 and 36

Intervention	Participants (Number)
	Month 12: Patient Survival	Month 12: Graft Survival	Month 24: Patient Survival	Month 24: Graft Survival	Month 36: Patient Survival	Month 36: Graft Survival
Calcineurin Inhibitor (CNI) Withdrawal	23	23	23	23	23	23
CNI+MPA+ Steroid	39	39	39	39	39	39
Steroid Withdrawal	4	4	4	4	4	4

Number of Participants Who Develop Extensive GVHD

"Number of participants with extensive, Chronic Graft vs Host Disease (GVHD). Extensive chronic GVHD is defined as GVHD occurring after day 100 that did not meet the definition of limited chronic GVHD.~Extensive disease presents either with generalized skin involvement, or with localized skin involvement or hepatic dysfunction plus at least one of the following:~Liver histology showing chronic progressive hepatitis, bridging necrosis, or cirrhosis~Involvement of the eye (Schirmer's test with less than 5 mm wetting) (see Diagnosis and classification of Sjögren's syndrome)~Involvement of minor salivary glands or oral mucosa (as demonstrated on labial or mucosal biopsy specimen)~Involvement of any other target organ" (NCT00378534)
Timeframe: 36 months

Intervention	Participants (Count of Participants)
T Cell Depletion Transplant Participants	18

Number of Participants Who Developed Limited Chronic GVHD

"Number of incidences of participants who developed Limited Chronic Graft vs Host Disease (GVHD).~Limited disease is characterized by localized skin involvement and/or evidence of hepatic dysfunction.~Limited disease is associated with a favorable outcome without systemic therapy, while extensive disease patients have an unfavorable outcome." (NCT00378534)
Timeframe: 36 months

Intervention	Participants (Count of Participants)
T Cell Depletion Transplant Participants	8

Number of Participants With Relapse of Disease

Number of participants with relapse of disease by day 200 (NCT00378534)
Timeframe: Day 200

Intervention	Participants (Count of Participants)
T Cell Depletion Transplant Participants	17

Number of Participants Who Developed Acute GVHD Grades I, II, III, IV

"Number of participants who developed Acute Graft vs Host Disease (GVHD) Grades I, II, III, IV as defined by CIMBTR criteria for Organ Stages of Acute GVHD.~Grades are defined as:~Grade I: Skin = Maculopapular rash< 25% of body surface area (BSA); Liver = Total Bilirubin 2-3 mg/dL; Lower GI = stool output/day is 500-999 mL/day.~Grade II: Skin = rash on 25-50 percent body surface area; Liver = Total Bilirubin 3.1-6.0 mg/dL; Lower GI = Diarrhea 1001-1500 mL/day.~Grade III: Skin = Rash on >50% of body surface; Liver = Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI = Diarrhea > 1500 mL/day.~Grade IV: Skin = Generalized erythroderma plus bullous formation; Liver = Total Bilirubin >15 mg/dL; Lower GI = Severe abdominal pain with or without ileus.~Grade I GVHD is characterized as mild disease, grade II GVHD as moderate, grade III as severe, and grade IV life-threatening." (NCT00378534)
Timeframe: 100 days

Intervention	Participants (Count of Participants)
	Acute GVHD, Grade I	Acute GVHD, Grade II	Acute GVHD, Grade III	Acute GVHD, Grade IV
T Cell Depletion Transplant Participants	14	16	9	1

Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System

Subjects with hematological malignancies receiving a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation followed by an infusion of stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a delayed T cell depletion add back as donor lymphocyte infusion at day 90. The subjects receiving allogeneic stem cell transplantation will have stem cell product prepared using Miltenyi CliniMacs system to determine the overall survival and non-relapse mortality at day +200. (NCT00378534)
Timeframe: Day 200

Intervention	participants (Number)
	Survival at day 200	Non-relapse mortality
T Cell Depletion Transplant Participants	43	4

Mean Change in Calculated Glomerular Filtration Rate (cGFR) From Month 6 to Month 12

Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: GFR = 170 x [SCr/0.95]^(-0.999) x [Age]^(-0.176) x [0.762 if participant is female] x [1.180 if participant is black] x [BUN]^(-0.170) x [Alb]^(+0.318); Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m^2 (NCT00256750)
Timeframe: Month 6 to Month 12

Intervention	mL/Min/1.73 m^2 (Mean)
Cyclosporine	2.3
Belatacept LI	4.7
Belatacept MI	5.1

Percent of Non-dyslipidemic Participants With Incidence of Dyslipidemia Post-Transplantation by Month 12

Incidence of dyslipidemia was defined as the proportion of participants who developed dyslipidemia after randomization and transplantation. Dyslipidemia was defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia = hypertriglyceridemia (TGs >= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL >= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL >= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs >= 200 mg/dL [2.26 mmol/L]). The TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N >=5. Otherwise exact method is used. (NCT00256750)
Timeframe: Randomization to Month 12

Intervention	percentage of participants (Number)
Cyclosporine	80.0
Belatacept LI	63.8
Belatacept MI	70.9

Percent of Participants at Baseline With Controlled Hypertension Post Transplantation by Month 12

Controlled hypertension was defined as a SBP < 130 mm Hg and a DBP < 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP < 130 mm Hg and a DBP < 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP (NCT00256750)
Timeframe: Day 1 to Month 12

Intervention	percentage of participants (Number)
Cyclosporine	21.4
Belatacept LI	28.6
Belatacept MI	24.6

Percent of Participants Experiencing Acute Rejection (AR) Post-transplant by Month 12

Acute rejection was defined as a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence was defined if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. AR was defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. (NCT00256750)
Timeframe: Day 1 to Month 12

Intervention	percentage of participants (Number)
Cyclosporine	7.2
Belatacept LI	17.3
Belatacept MI	21.9

Percent of Participants Surviving With a Functioning Graft by Month 12

Intervention	percentage of participants (Number)
Cyclosporine	92.8
Belatacept LI	96.5
Belatacept MI	95.4

Percent of Participants Using At Least One Anti-Hyperlipidemic Medication

This analysis is based on all participants who were followed up at least 1092 days after transplantation. (NCT00256750)
Timeframe: Month 36

Intervention	percentage of participants (Number)
Cyclosporine	56.6
Belatacept LI	46.2
Belatacept MI	47.9

Percent of Participants Using At Least One Anti-Hypertensive Medication to Control Hypertension at Month 36

This analysis was based on all participants who had been followed up at least 1092 days after transplantation. Hypertension was defined in according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. In addition, all participants who had a SBP < 130 mm Hg and a DBP < 80 mm Hg who received an antihypertensive medication(s) for the indication of hypertension or with a medical history of hypertension were included in this definition. Systolic blood pressure = SBP; Diastolic blood pressure = DBP (NCT00256750)
Timeframe: Month 36

Intervention	percentage of participants (Number)
Cyclosporine	92.9
Belatacept LI	81.9
Belatacept MI	83.9

Percent of Participants Using Polyclonal Antilymphocyte Preparations for Impaired Renal Function and Anticipated Delayed Graft Function by Month 12

A participant was considered to have delayed graft function (DGF), if treated with dialysis within the first week (Day 1 - 8) after transplantation. The use of polyclonal antilymphocyte preparations (LDT) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated DGF following transplantation and were not permitted in belatacept-treated participants, except for the treatment of acute rejection. Participants treated with LDT began CsA at the discretion of the investigator by Day 7. LDT could also have been used in participants who met >= 1 of the following criteria, observed in the presence of a transplant artery and vein and no evidence of hydronephrosis by sonogram: Urine output < 250 mL/12 hours, no significant improvement (< 1 milligram per deciliter (mg/dL)) in serum creatinine from baseline value over the first 24 - 72 hours post-transplant, or dialysis treatment. (NCT00256750)
Timeframe: Randomization to Month 12

Intervention	percentage of participants (Number)
Cyclosporine	3.6
Belatacept LI	0.4
Belatacept MI	0.5

Percent of Participants With a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12 or With a Decrease in mGFR Greater Than or Equal to 10 mL/Min/1.73m^2 From Month 3 to Month 12

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 mg/dL. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in SCr of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. (NCT00256750)
Timeframe: Month 12; Month 3 to Month 12

Intervention	percentage of participants (Number)
Cyclosporine	77.9
Belatacept LI	54.2
Belatacept MI	55.0

Percent of Participants With a Decrease in Measured Glomerular Filtration Rate (mGFR) Greater Than or Equal to 10mL/Min/1.73m^2 From Month 3 to Month 12

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A change in GFR of at least 10 mL/min/1.73 m^2 was used as the approximate change in serum creatinine (SCr) of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. Month 3 = baseline (NCT00256750)
Timeframe: Month 3 to Month 12

Intervention	percentage of participants (Number)
Cyclosporine	28.2
Belatacept LI	23.4
Belatacept MI	23.0

Percent of Participants With a Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m^2 at Month 12

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m^2 was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 milligrams per deciliter (mg/dL). (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	67.6
Belatacept LI	43
Belatacept MI	43.5

Percent of Participants With Controlled Dyslipidemia at Month 12

Prevalence of controlled dyslipidemia = the proportion of participants at any given time who met the stated definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs >= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL >= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL >= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs >= 200 mg/dL [2.26 mmol/L]). Controlled dyslipidemia defined as participants who received successful pharmacologic treatment for 1 of the above stated dyslipidemias, and their lipid values fell below the thresholds described. TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N >=5. Otherwise exact method is used. (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	18.1
Belatacept LI	15.5
Belatacept MI	15.5

Percent of Participants With Development of Anti-Donor HLA Positive Antibodies by Month 84

Only participants who had non-missing test result for Class I or Class II anti-donor HLA antibodies were included in analysis and only participants who had at least one non-NA test result or finding were counted. This was a cumulative summary (excluding baseline) and once a participant was positive, that participant remained positive for the later time point. Acute rejection (AR) defined: a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence defined: if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. AR defined as allograft biopsies of Banff 97 classification Grade IA or greater (higher scores indicate more severe rejection). Evaluated by blinded central independent pathologist. (NCT00256750)
Timeframe: Randomization to Month 84

Intervention	percentage of participants (Number)
Cyclosporine	11.6
Belatacept LI	3.1
Belatacept MI	1.4

Percent of Participants With Incidence of Hypertension Post-Transplantation at Month 12

The incidence of hypertension was defined as the proportion of participants who developed hypertension after randomization and transplantation. Specifically, the incidence of hypertension was assessed only after the Week 4 visit. This period allowed for adequate stabilization and resolution of transient changes. If participants received antihypertensive medication for the indication of hypertension at this (or later) time point, they were considered to have developed hypertension. Hypertension was defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	75.0
Belatacept LI	53.8
Belatacept MI	57.1

Percent of Participants With Prevalence of Chronic Allograft Nephropathy (CAN) at Month 12

Prevalence of CAN = if participant met any of the following conditions: a: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; b: participant had graft loss during the first year post transplant; c: no biopsy was available post 12 months and CAN not observed in biopsies prior to 12 months, but the measured GFR from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2; d: no biopsy available either prior to or post 12 months, and the measured GFR (incorporated missing data imputation) from Month 3 to Month 12 decreased at least 10 mL/min/1.73m^2. CAN = All allograft biopsies evaluated for presence and severity of CAN by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Onset of CAN determined by the biopsy date when it was observed. (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	32.4
Belatacept LI	23.9
Belatacept MI	18.3

Percent of Participants With Prevalence of Controlled Hypertension at Month 12

The prevalence of controlled hypertension was defined as the proportion of participants at any given time who met the definition of controlled hypertension. Controlled hypertension was defined as a SBP < 130 mm Hg and a DBP < 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Participants with a SBP < 130 mm Hg and a DBP < 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	21.0
Belatacept LI	28.0
Belatacept MI	24.7

Percent of Participants With Prevalence of Dyslipidemia at Month 12

The prevalence of dyslipidemia was defined as the proportion of participants at any given time who met the definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs >= 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL >= 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL >= 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs >= 200 mg/dL [2.26 mmol/L]). TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if N >=5. Otherwise exact method is used. (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	52.9
Belatacept LI	44.7
Belatacept MI	46.1

Percent of Participants With Prevalence of Hypertension Post-Transplantation at Month 12

The prevalence of hypertension was defined as the proportion of participants at any given time who meet the definition of hypertension. Hypertension defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for participants with chronic kidney disease. This definition is based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	91.0
Belatacept LI	89.8
Belatacept MI	88.6

Percent of Participants With Subclinical Rejection at Month 12

Subclinical rejection defined as histological findings by the central pathologist consistent with acute rejection, but lacking its clinical correlate. Acute rejection defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence defined if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. (NCT00256750)
Timeframe: Month 12

Intervention	percentage of participants (Number)
Cyclosporine	5.2
Belatacept LI	4.7
Belatacept MI	4.3

Mean Blood Pressure at Month 84

Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the participant arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart. (NCT00256750)
Timeframe: Month 84

Intervention	mmHg (Mean)
	Diastolic Blood Pressure (n=82, 125, 112)	Systolic Blood Pressure (n=82, 125, 112)
Belatacept LI	75.8	126.7
Belatacept MI	75.1	126.0
Cyclosporine	78.6	129.0

Mean Change in the Value of the Eight Domain Scores Using SF-36 From Baseline Up To Months 6, 12, 24, and 36

SF-36 was a Participant-Reported Quality of Life (QoL) Short Form (SF) questionnaire measuring health-related quality of life (HRQL) covering 2 scale measures: physical component summary (PCS) and mental component summary (MCS). PCS represented by 4 domains: physical function, role limitations due to physical problems, pain, and general health perception. MCS represented by 4 domains: vitality, social function, role limitations due to emotional problems, and mental health. Their scores were computed based on weighted combinations of the 8 domain scores, which were transformed to a range from 0 to 100; 0= worst HRQL, 100=best HRQL. Higher scores reflect better health-related functional status. Scoring is standardized using the norm-based scoring method where data is scored in relation to the U.S. general population having a mean of 50 and a standard deviation of 10. Scores below 50 are below the U.S. general population norm and above 50 are above the U.S. general population norm. (NCT00256750)
Timeframe: Baseline to Months 6, 12, 24, and 36

Intervention	units on a scale (Mean)
	Bodily Pain, Month 6 (n=189,201,189)	General Health, Month 6 (n=189,201,190)	Mental Health, Month 6 (n=188,198,190)	Physical Functioning, Month 6 (n=189,201,190)	Role Emotional, Month 6 (n=188,200,186)	Role-Physical, Month 6 (n=188,201,187)	Social Functioning, Month 6 (n=189,201,190)	Vitality, Month 6 (n=188,198,190)	Bodily Pain, Month 12 (n=194,205,195)	General Health, Month 12 (n=194,206,195)	Mental Health, Month 12 (n=194,203,195)	Physical Functioning, Month 12 (n=194,206,194)	Role Emotional, Month 12 (n=192,205,191)	Role-Physical, Month 12 (n=193,205,191)	Social Functioning, Month 12 (n=194,205,195)	Vitality, Month 12 (n=194,203,195)	Bodily Pain, Month 24 (n=192,207,197)	General Health, Month 24 (n=193,207,197)	Mental Health, Month 24 (n=193,203,195)	Physical Functioning, Month 24 (n=193,207,197)	Role Emotional, Month 24 (n=192,206,196)	Role-Physical, Month 24 (n=193,207,195)	Social Functioning, Month 24 (n=193, 207,197)	Vitality, Month 24 (n=193,203,196)	Bodily Pain, Month 36 (n=191,207,196)	General Health, Month 36 (n=193,207,197)	Mental Health, Month 36 (n=191,204,195)	Physical Functioning, Month 36 (n=192,206,197)	Role Emotional, Month 36 (n=192,207,195)	Role-Physical, Month 36 (n=192,207,195)	Social Functioning, Month 36 (n=192,207,197)	Vitality, Month 36 (n=191,204,195)
Belatacept LI	4.5	7.1	5.2	5.3	5.8	8.4	6.8	9.0	4.8	7.7	6.0	6.2	6.6	10.3	7.7	9.2	3.3	7.2	4.6	5.7	6.0	9.4	7.4	7.9	4.2	6.6	4.1	5.3	5.6	9.2	7.0	7.3
Belatacept MI	4.6	7.3	6.1	5.6	6.9	9.6	6.9	9.9	5.5	7.6	5.0	5.8	5.9	10.4	8.0	9.7	4.1	6.8	4.0	5.5	5.9	10.7	6.3	8.0	3.0	5.8	3.4	5.1	5.0	8.9	5.6	7.3
Cyclosporine	2.9	6.7	4.7	4.7	4.7	6.4	6.0	7.5	3.1	6.0	4.4	4.7	5.7	8.3	6.4	7.0	3.2	5.1	3.2	4.1	4.7	7.4	5.9	6.2	2.3	4.1	1.8	4.4	3.3	6.8	5.1	4.9

Mean Change of the Measured Glomerular Filtration Rate (mGFR) From Month 3 to Month 12 and From Month 3 to Month 24

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2. (NCT00256750)
Timeframe: Month 3 to Month 12; Month 3 to Month 24

Intervention	mL/min/1.73m^2 (Mean)
	Baseline (Month 3) to Month 12 (n=195, 206, 200)	Baseline (Month 3) to Month 24 (n=184, 199, 192)
Belatacept LI	1.2	5.3
Belatacept MI	4.4	4.2
Cyclosporine	-1.7	-2.0

Mean Changes in the Value of Physical and Mental Components Using SF-36 From Baseline Up To Months 6, 12, 24, and 36

Intervention	units on a scale (Mean)
	Mental Component Score; Month 6 (n=187, 197, 184)	Physical Component Score; Month 6 (n=187, 197, 184	Mental Component Score; Month 12 (n=192, 200, 189)	Physical Component Score; Month 12 (n=192,200,189)	Mental Component Score; Month 24 (n=191,202,193)	Physical Component Score; Month 24 (n=191,202,193)	Mental Component Score; Month 36 (n=190,203,191)	Physical Component Score; Month 36 (n=190,203,191)
Belatacept LI	6.2	6.2	6.8	7.1	5.7	6.5	5.1	6.5
Belatacept MI	7.3	6.7	6.2	7.8	5.1	7.3	4.5	6.1
Cyclosporine	5.4	5.0	5.4	5.5	4.4	5.1	2.6	4.9

Mean Relative to an Identified Distribution (Ridit) Value of Symptom Occurrence and Symptom Distress Using Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSDS-59R)

The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess the occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, Inc. 1991) was used. Ridit scores were calculated at baseline and at 6, 12, 24, and 36 months for overall symptom occurrence score and overall symptom distress. The Ridit score reflects the probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. The reference group was constituted by the frequency distribution of the responses of all participants on all items at baseline. The ridit of the reference group is by definition, 0.5. (NCT00256750)
Timeframe: Months 6, 12, 24, 36

Intervention	Ridit score (Mean)
	Symptom Distress, Month 6 (n=157, 164, 155)	Symptom Occurrence, Month 6 (n=166, 176, 165)	Symptom Distress, Month 12 (n=169, 185, 169)	Symptom Occurrence, Month 12 (n=173, 188, 173)	Symptom Distress, Month 24 (n=182, 195, 179)	Symptom Occurrence, Month 24 (n=184, 197, 184)	Symptom Distress, Month 36 (n=184, 196, 183)	Symptom Occurrence, Month 36 (n=186, 197, 187)
Belatacept LI	0.4407	0.4495	0.4510	0.4519	0.4584	0.4574	0.4746	0.4732
Belatacept MI	0.4451	0.4459	0.4546	0.4525	0.4646	0.4593	0.4892	0.4846
Cyclosporine	0.4643	0.4721	0.4751	0.4776	0.4798	0.4804	0.5000	0.5000

Mean Systolic Blood Pressure and Diastolic Blood Pressure

Intervention	mmHg (Mean)
	Systolic; Month 12 (n=188, 193, 191)	Diastolic; Month 12 (n=188, 193, 191)	Systolic; Month 24 (n=160, 185, 174)	Diastolic; Month 24 (n=160, 185, 174)	Systolic; Month 36 (n=145, 180, 166)	Diastolic; Month 36 (n=145, 180, 166)
Belatacept LI	131.4	78.7	130.5	78.3	127.7	76.6
Belatacept MI	132.7	79.3	129.8	77.8	126.0	76.1
Cyclosporine	138.7	81.9	135.4	80.3	133.5	79.5

Mean Value of Lipid Parameters

Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, and triglycerides (TGs). (NCT00256750)
Timeframe: Months 12, 24, 36

Intervention	mg/dL (Mean)
	non-HDL Cholesterol; Month 12 (n=189, 195, 192)	Total Cholesterol; Month 12 (n=189, 195, 192)	HDL Cholesterol; Month 12 (n=189, 195, 192)	LDL Cholesterol; Month 12 (n=187, 186, 183)	Triglyceride; Month 12 (n=187, 186, 183)	non-HDL Cholesterol; Month 24 (n=166, 190, 181)	Total Cholesterol; Month 24 (n=166, 190, 181)	HDL ; Month 24 (n=166, 190, 181)	LDL Cholesterol; Month 24 (n=164, 186, 168)	Triglyceride; Month 24 (n=164, 186, 168)	non-HDL Cholesterol; Month 36 (n=154, 184, 176)	Total Cholesterol; Month 36 (n=154, 184, 176)	HDL Cholesterol; Month 36 (n=154, 184, 176)	LDL Cholesterol; Month 36 (n=142, 170, 161)	Triglyceride; Month 36 (n=142, 170, 161)
Belatacept LI	131.5	182.4	50.8	102.1	149.4	126.7	175.3	48.6	98.6	143.4	122.4	171.3	48.9	96.7	132.7
Belatacept MI	131.7	181.3	49.7	100.8	155.0	127.0	175.4	48.5	96.5	151.2	122.1	170.7	48.6	92.5	144.0
Cyclosporine	144.1	191.5	47.4	107.3	184.6	145.1	193.5	48.4	109.1	179.5	142.2	190.7	48.5	107.6	179.1

Mean Value of Physical and Mental Components Using SF-36 Questionnaire

Intervention	units on a scale (Mean)
	Mental Component Score; Month 6 (n=191, 205, 189)	Physical Component Score; Month 6 (n=191,205,189)	Mental Component Score; Month 12 (n=198,210,194)	Physical Component Score; Month 12 (n=198,210,194)	Mental Component Score; Month 24 (n=200,214,198)	Physical Component Score; Month 24 (n=200,214,198)	Mental Component Score; Month 36 (n=203,218,201)	Physical Component Score; Month 36 (n=203,218,201)
Belatacept LI	49.9	48.9	50.3	49.6	49.6	49.0	48.7	49.2
Belatacept MI	51.1	49.2	49.9	50.3	48.8	49.9	48.3	48.7
Cyclosporine	49.4	47.3	49.5	47.5	48.3	47.3	46.9	47.1

Mean Value of the Calculated Glomerular Filtration Rate (cGFR) With Imputation

Intervention	mL/min/1.73 m^2 (Mean)
	Month 6 (n=189, 185, 170)	Month 12 (n=199, 200, 201)	Month 24 (n=182, 201, 191)	Month 36 (n=171, 190, 186)
Belatacept LI	62.6	65.4	65.4	65.8
Belatacept MI	62.4	65.2	65.5	65.2
Cyclosporine	48.8	50.1	47.9	44.4

Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire

Intervention	units on a scale (Mean)
	Bodily Pain, Month 6 (n=193, 207, 193)	General Health, Month 6 (n=193, 207, 194)	Mental Health, Month 6 (n=192, 206, 194)	Physical Functioning, Month 6 (n=193, 207, 194)	Role Emotional, Month 6 (n=192, 206, 191)	Role-Physical, Month 6 (n=192, 207, 192)	Social Functioning, Month 6 (n=193, 207, 194)	Vitality, Month 6 (n=192, 206, 194)	Bodily Pain, Month 12 (n=200, 213, 199)	General Health, Month 12 (n=200, 214, 199)	Mental Health, Month 12 (n=200, 213, 199)	Physical Functioning, Month 12 (n=200, 214, 198)	Role Emotional, Month 12 (n=198, 213, 196)	Role-Physical, Month 12 (n=199, 213, 196)	Social Functioning, Month 12 (n=200, 213, 199)	Vitality, Month 12 (n=200, 213, 199)	Bodily Pain, Month 24 (n=203, 219, 205)	General Health, Month 24 (n=203, 219, 205)	Mental Health, Month 24 (n=201, 215, 199)	Physical Functioning, Month 24 (n=203, 219, 205)	Role Emotional, Month 24 (n=202, 218, 205)	Role-Physical, Month 24 (n=203, 219, 204)	Social Functioning, Month 24 (n=203, 219, 205)	Vitality, Month 24 (n=201, 215, 200)	Bodily Pain, Month 36 (n=204, 219, 205)	General Health, Month 36 (n=205, 219, 206)	Mental Health, Month 36 (n=203, 219, 204)	Physical Functioning, Month 36 (n=204, 218, 206)	Role Emotional, Month 36 (n=204, 219, 205)	Role-Physical, Month 36 (n=204, 219, 205)	Social Functioning, Month 36 (n=204, 219, 206)	Vitality, Month 36 (n=203, 219, 204)
Belatacept LI	52.5	48.2	50.3	48.3	46.0	45.2	47.8	55.5	52.7	48.8	50.7	49.0	46.8	47.1	48.4	55.7	51.4	48.4	49.7	48.7	46.4	46.6	48.6	54.5	52.3	47.7	48.9	48.1	46.0	46.3	48.1	53.6
Belatacept MI	52.7	49.0	51.3	48.0	46.8	46.7	47.9	56.2	53.7	49.2	50.3	48.1	45.9	47.5	49.1	56.0	52.5	48.7	49.3	48.0	46.0	48.0	47.7	54.2	51.0	47.5	48.7	47.8	45.3	46.2	47.1	53.4
Cyclosporine	50.6	47.9	50.1	47.4	44.6	43.2	47.5	54.0	50.8	46.9	49.8	47.2	45.8	45.0	47.6	53.3	51.0	46.2	48.5	46.5	44.8	44.1	47.3	52.5	50.0	45.5	47.4	46.8	43.5	43.6	46.6	51.4

Mean Value of the Measured Glomerular Filtration Rate (mGFR)

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m^2. (NCT00256750)
Timeframe: Months 3, 12, 24

Intervention	mL/min/1.73m^2 (Mean)
	Month 3 (n=201, 215, 209)	Month 12 (n=199, 206, 200)	Month 24 (n=185, 199, 192)
Belatacept LI	61.7	63.4	67.9
Belatacept MI	59.9	65.0	65.0
Cyclosporine	51.9	50.4	50.5

Number of Participants Meeting Marked Laboratory Abnormality Criteria Post-transplant by Month 36

"Upper limit of normal (ULN). Units per Liter (U/L). Cells per microliter (c/µL). Grams per deciliter (g/dL). Milligrams per deciliter (mg/dL).Cells per Liter (c/L). Milliequivalents/Liter (mEq/L).~Hemoglobin (low): <8.0 g/dL; Platelet count: <50*10^9 c/L; Leukocytes: <2*10^3 c/µL; Alkaline phosphatase (ALP): >5.0*ULN U/L; Alanine aminotransferase (ALT): >5.0*ULN U/L; Asparate aminotransferase (AST): >5.0*ULN U/L; Bilirubin Total: >3.0*ULN mg/dL; Creatinine: >3.0*ULN mg/dL; Calcium Total: low if <7.0 mg/dL or high if >12.5 mg/dL; Bicarbonate: <11.0 mEq/L; Potassium serum: low if <3.0 mEq/L or high if >6.0 mEq/L; Magnesium serum: low is <0.8 mEq/L or high if >2.46 mEq/L; Sodium serum: low if <130.0 mEq/L or high if >155.0 mEq/L; Phosphorus inorganic: <2.0 mg/dL; Albumin: <2 g/dL; Uric acid: >10 mg/dL; Protein urine: >=3+" (NCT00256750)
Timeframe: Baseline to Month 36

Intervention	participants (Number)
	Hemoglobin, low (n=213, 226, 219)	Platelet count, low (n=213, 226, 218)	Leukocytes, low (n=213, 226, 219)	Alkaline phosphatase, high (n=214, 226, 219)	Alanine aminotransferase, high (n=214, 226, 219)	Aspartate aminotransferase, high (n=214, 226, 219)	Bilirubin total, high (n=214, 226, 219)	Creatinine, high (n=213, 223, 219)	Calcium total, low (n=214, 226, 219)	Calcium total, high (n=214, 226, 219)	Bicarbonate, low (n=214, 226, 219)	Bicarbonate, high (n=214, 226, 219)	Potassium serum, low (n=213, 223, 219)	Potassium serum, high (n=213, 223, 219)	Magnessium serum, low (n=214, 225, 219)	Magnessium serum, high (n=214, 225, 219)	Sodium serum, low (n=214, 226, 219)	Sodium serum, high (n=214, 226, 219)	Phosphorus inorganic, low (n=213, 224, 219)	Albumin, low (n=214, 226, 219)	Uric acid, high (n=214, 226, 219)	Protein in urine, high (n=213, 224, 217)
Belatacept LI	25	1	5	4	6	3	0	50	8	1	0	0	13	9	2	12	8	1	100	0	7	30
Belatacept MI	27	0	5	0	4	3	0	52	4	0	0	0	12	4	1	14	9	0	112	0	11	36
Cyclosporine	26	0	10	1	6	2	1	48	7	0	1	0	4	13	1	9	21	0	75	0	42	33

Number of Participants Treated for Acute Rejection (AR) Regardless of Histological Findings by Month 36

Allograft rejection includes any episode of rejection including: clinically suspected rejection, treated rejection, any central biopsy-proven acute rejection (BPAR), and acute rejection (AR: a subset of BPAR) defined as central biopsy-proven rejection that was either clinically suspected by protocol-defined reasons or by other reasons and was treated. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence ( either an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of AR) and renal biopsy confirmation biopsy demonstrating a Banff 97 working classification of kidney transplant pathology classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the highest Banff grade for each participant was counted. (NCT00256750)
Timeframe: Randomization to Month 36

Intervention	participants (Number)
	Month 6	Month 12	Month 24	Month 36
Belatacept LI	68	72	74	76
Belatacept MI	70	75	81	82
Cyclosporine	43	56	63	69

Number of Participants Who Recovered Completely From an Episode of Acute Rejection (AR) by Month 12

Acute rejection (AR) = a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Complete recovery following AR defined as serum creatinine [SCr] levels returned to baseline. Recovery calculated using 2 algorithms: Algorithm 1 = last laboratory measurement prior to onset of AR (baseline and first laboratory measurement after 84 days since onset of AR = resolution); Algorithm 2 = lowest laboratory measurement on or after transplantation and prior to onset day of AR (baseline and lowest laboratory measurement after onset on first AR up to Month 12 = resolution) (NCT00256750)
Timeframe: Randomization to Month 12

Intervention	participants (Number)
	Algorithm 1	Algorithm 2
Belatacept LI	29	34
Belatacept MI	39	43
Cyclosporine	13	13

Number of Participants With Acute Rejection (AR) Post-transplant in Terms of Severity Using Banff Grades by Month 36

Acute rejection was defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: if either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted. (NCT00256750)
Timeframe: Randomization to Month 36

Intervention	participants (Number)
	Mild Acute (IA); Month 6	Mild Acute (IB); Month 6	Moderate Acute (IIA); Month 6	Moderate Acute (IIB); Month 6	Severe Acute (III); Month 6	Mild Acute (IA); Month 12	Mild Acute (IB); Month 12	Moderate Acute (IIA); Month 12	Moderate Acute (IIB); Month 12	Severe Acute (III); Month 12	Mild Acute (IA); Month 24	Mild Acute (IB); Month 24	Moderate Acute (IIA); Month 24	Moderate Acute (IIB); Month 24	Severe Acute (III); Month 24	Mild Acute (IA); Month 36	Mild Acute (IB); Month 36	Moderate Acute (IIA); Month 36	Moderate Acute (IIB); Month 36	Severe Acute (III); Month 36
Belatacept LI	4	9	14	10	1	4	8	16	10	1	4	8	16	10	1	4	8	16	10	1
Belatacept MI	7	3	16	20	2	7	3	17	20	2	7	3	18	22	3	7	3	18	22	3
Cyclosporine	1	5	5	1	0	3	5	6	2	0	4	7	6	3	0	5	7	6	3	0

Number of Participants With Adverse Events of Special Interest by Month 84

Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections and Infestations, Thrombolic/embolic events, and Malignancy. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/ abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Time frame is from randomization to the event date, or to the last dose date+56, or to Month 84 (Day 2548), whichever is the earliest. (NCT00256750)
Timeframe: Randomization to Month 84

Intervention	participants (Number)
	Malignancies	Cytomegalovirus (CMV) Infections	BK Polyoma Virus Infections	Herpes Virus Infections	Fungal Infections	Tuberculosis Infections	Central Nervous System (CNS) Infections	Pulmonary edema or Congestive Heart Failure	Auto-immune Events
Belatacept LI	16	24	10	37	47	1	0	4	8
Belatacept MI	20	20	15	37	55	5	1	5	6
Cyclosporine	22	19	6	29	42	2	0	12	8

Number of Participants With Antihyperlipidemic Medication by Intensity Level

An intensity level was associated with the dose level of the statin based anti-hyperlipidemic agent. Any other agent (i.e., non-statin therapy) used as an antihyperlipidemic were considered Level I treatment intensity. Multiple daily dose levels during a period were averaged to compute the daily dose during that period. Level I = 20 mg fluvastatin (flu), 10 mg lovastatin (lova), 10 mg pravastatin (prav), 5-10 mg simvastatin (sim); Level II = 10 mg atorvastatin (atorv), 40 mg flu, 20 mg lova, 20 mg prav, 5 mg rosuvastatin (rosu), 20 mg sim, 10/10 vytorin; Level III = 20 mg atorv, 80 mg flu, 40 mg lova, 40 mg prav, 10 mg rosu, 40 mg sim, 10/20 vytorin; Level IV = 40 mg atorv, 80 mg lova, 80 mg prav, 20 mg rosu, 80 mg sim, 10/40 vytorin; Level V = 80 mg atorv, 40 mg rosu, 10/80 vytorin. Concomitant use of a statin and an agent of another class elevated the intensity level of the statin therapy by 1 level; therefore, an intensity level of greater than V was possible. (NCT00256750)
Timeframe: Month 36

Intervention	participants (Number)
	Intensity Level I	Intensity Level II	Intensity Level III	Intensity Level IV	Intensity Level V	Intensity Level VI
Belatacept LI	15	27	32	16	1	1
Belatacept MI	17	39	23	9	4	0
Cyclosporine	17	46	27	8	4	1

Number of Participants With Serious Adverse Events, Death, Discontinuation Due to Adverse Events by Month 84

Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00256750)
Timeframe: Randomization to Month 84

Intervention	participants (Number)
	Deaths	SAEs	Discontinued due to SAEs	Discontinued due to AEs
Belatacept LI	7	113	8	11
Belatacept MI	7	117	6	14
Cyclosporine	9	107	5	12

Percent of Participants Surviving With a Functioning Graft

Intervention	percentage of participants (Number)
	Month 24	Month 36
Belatacept LI	94.7	92.0
Belatacept MI	94.1	92.2
Cyclosporine	90.5	88.7

Percent of Participants Using Lymphocyte Depleting Therapy (LDT) for the Initial Treatment of Acute Rejection (AR) by Month 36

The use of LDT (thymoglobulin or antithymocyte gamma globulin [ATGAM]) was permitted only for participants randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated delayed graft function following transplantation. Acute rejection (AR) defined as a clinico-pathological event requiring clinical evidence (an unexplained rise of serum creatinine ≥ 25% from baseline creatinine or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed) and biopsy confirmation. AR defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each participant was counted. (NCT00256750)
Timeframe: Randomization to Month 36

Intervention	percentage of participants (Number)
	Month 6	Month 12	Month 24	Month 36
Belatacept LI	4.4	4.4	4.4	4.4
Belatacept MI	5.9	5.9	5.9	5.9
Cyclosporine	0.5	0.9	1.4	1.8

Percent of Participants With Composite Endpoint or Death, Graft Loss or Acute Rejection by Month 36

Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter (μmol/L) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the participant underwent retransplant. Acute rejection was defined as central biopsy proven rejection that was either (1) clinically suspected by protocol defined reasons or (2) clinically suspected by other reasons and treated. Death and graft loss were not imputed. (NCT00256750)
Timeframe: Randomization to Month 36

Intervention	percentage of participants (Number)
	Month 12	Month 24	Month 36
Belatacept LI	19.5	19.9	20.8
Belatacept MI	25.1	27.9	28.3
Cyclosporine	13.6	18.1	19.9

Percent of Participants With Corticosteroid Resistant Acute Rejection (AR) by Month 36

Steroid-resistant acute rejection (AR) defined as the use of lymphocyte-depletion therapy following treatment with corticosteroids. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: either a or b was satisfied: a) an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 international standardized histopathological working classification of kidney transplant pathology. Only the episode with the highest Banff grade for each participant was counted. (NCT00256750)
Timeframe: Randomization to Month 36

Intervention	percentage of participants (Number)
	Month 6	Month 12	Month 24	Month 36
Belatacept LI	4.0	5.3	5.3	5.3
Belatacept MI	5.9	6.4	6.4	6.8
Cyclosporine	0.0	0.0	0.5	0.5

Percent of Participants With Incidence of New Onset Diabetes Mellitus by Month 36

The incidence of new onset diabetes mellitus defined as participants who developed diabetes mellitus after randomization and transplantation. Participants that did not have diabetes prior to randomization were determined to have new onset diabetes mellitus if (i) the participant received an anti-diabetic medication for a duration of at least 30 days or (ii) at least two fasting plasma glucose (FPG) tests indicate that FPG is >=126 mg/dL (7.0 mmol/L). New onset diabetes mellitus (NODM) = post-transplant diabetes mellitus (PTDM) (NCT00256750)
Timeframe: Week 4 post-transplantation to Month 36

Intervention	percentage of participants (Number)
	Month 12	Month 24	Month 36
Belatacept LI	4.2	5.4	6.5
Belatacept MI	7.1	8.3	10.3
Cyclosporine	9.9	10.5	11.1

Percent of Participants With Prevalence of Acute Rejection (AR) by Month 36

Prevalence of AR = participants with the stated definition of AR at any given time. AR defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each participant was counted. Clinical evidence = if either a or b was satisfied: a: an unexplained rise of serum creatinine ≥ 25% from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. (NCT00256750)
Timeframe: Randomization to Month 36

Intervention	percentage of participants (Number)
	Month 6 (n=221, 226, 219)	Month 24 (n=221, 226, 219)	Month 36 (n=221, 226, 219)
Belatacept LI	16.8	17.3	17.3
Belatacept MI	21.9	24.2	24.2
Cyclosporine	5.4	9.0	9.5

Chronic Graft-vs-Host Disease (cGvHD)

The cumulative percentage of participants who develop chronic graft-vs-host disease (cGvHD). Chronic cGvHD was defined as at least one instance of a clinically-accepted marker for cGvHD (see Filipovich, et al. Biology of Blood and Marrow Transplantation. 2005;11:945-955) (NCT00186628)
Timeframe: 4 years

Intervention	percentage of participants (Number)
Prophylactic Rituximab	20

Incidence of Relapse

Subjects who Relapsed following after Allogeneic HSCT (NCT00186628)
Timeframe: 4 years

Intervention	Participants (Count of Participants)
Prophylactic Rituximab	18

Overall Survival

(NCT00186628)
Timeframe: 4 years

Intervention	Percentage of participants by disease (Number)
Prophylactic Rituximab (CLL Patients)	73
Prophylactic Rituximab (MCL Patients)	69

Mortality

Number of participants who died within 100 days and within 1 year, non-relapse and associated with relapse. (NCT00186628)
Timeframe: Day 100 and 1 year

Intervention	Participants (Number)
	Mortality within 100 days, all causes	Nonrelapse mortality within 1 year	Relapse + mortality within 1 year
Prophylactic Rituximab	0	1	2

Acute Graft-vs-Host-Disease (aGvHD)

Development of acute graft-vs-host-disease (aGvHD) within 6 months, for participants receiving Allo-HCT. (NCT00185614)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Auto- Then Allo-HCT	7

Event-free Survival (EFS)

"Event-free survival (EFS) as determined for all participants who received the initial Auto-HCT treatment. Event was defined as any of the following within 3 years of the participant's last infusion of Auto-HCT or Allo-HCT: relapse; death; or last follow-up if there is no data to document the participant remained alive at 3 years." (NCT00185614)
Timeframe: 3 years

Intervention	Participants (Count of Participants)
	Auto-HCT only	Auto-HCT then Allo-HCT	All Participants
Auto- Then Allo-HCT	0	24	24

Overall Survival (OS)

Overall Survival (OS) as determined for all participants who received the initial Auto-HCT treatment, as assessed from the date of the last transplant. (NCT00185614)
Timeframe: 3 years

Intervention	participants (Number)
	Auto-HCT only	Auto-HCT then Allo-HCT	All Participants
Auto- Then Allo-HCT	1	41	42

Relapse Rate

Relapse rate as determined for all participants who received the initial Auto-HCT treatment. Relapse was protocol-specified as progressive disease, indicated by an increase as compared to pre-Auto-HCT baseline, of serum or urine monoclonal protein >25%; bone marrow plasmacytosis >25%; or bone lesions on skeletal survey (any increase). (NCT00185614)
Timeframe: 3 years

Intervention	participants (Number)
	Auto-HCT only	Auto-HCT then Allo-HCT	All Participants
Auto- Then Allo-HCT	2	29	31

Number of Participants With Biopsy Proven Acute Rejection (BPAR) Episodes Within the First Three Months

At biopsy of transplanted tissue sample, acute rejection has an onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever, and hypertension. (NCT00149890)
Timeframe: 3 months

Intervention	Participants (Number)
With Intraoperative Steroids	20
Without Intraoperative Steroids	26

Time of Onset of a First Biopsy Proven Acute Rejection

"Biopsied Tissue shows rejection at onset 2-60 days after transplantation, with interstitial vascular endothelial cell swelling, interstitial accumulation of lymphocytes, plasma cells, immunoblasts, macrophages, neutrophils; tubular separation with edema/necrosis of tubular epithelium; swelling and vacuolization of the endothelial cells, vascular edema, bleeding and inflammation. Clinical signs and symptoms include malaise, fever and hypertension~." (NCT00149890)
Timeframe: 6 months

Intervention	Months (Median)
With Intraoperative Steroids	1.93
Without Intraoperative Steroids	0.75

Number of Participants With at Least One Biopsy Proven Acute Rejection (BPAR) Episode, Graft Loss or Death Within the First Three Months Post-transplantation

Graft loss is defined as being listed for a re-transplantation. The analysis was based on the locally performed biopsy assessments. Generally, patients not experiencing a relevant event (i.e., acute rejection, graft loss or death) were censored with the last visit date. (NCT00149890)
Timeframe: 3 months after treatment

Intervention	Participants (Number)
	Stratum age < 2 years (N=21, 24)	Stratum age 2-16 years (N=18, 14)	Total (N= 39, 38)
With Intraoperative Steroids	8	14	22
Without Intraoperative Steroids	15	11	26

Number of Participants With Bacterial, Viral and Fungal Infections During Six Months

To evaluate the safety of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the episodes of bacterial, viral and fungal infections during six months. (NCT00149890)
Timeframe: 6 months

Intervention	Participants (Number)
	Fungal	Viral	Bacterial
With Intraoperative Steroids	16	15	10
Without Intraoperative Steroids	16	14	18

Number of Participants With Steroid Resistant Rejection Episodes Within Three and Six Months

To evaluate the efficacy of a regimen with intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids as measured by the incidence of steroid resistant rejection episodes within three and six months. (NCT00149890)
Timeframe: 3 and 6 months

Intervention	Participants (Number)
	Within 3 months post treatment	Within 6 months post treatment
With Intraoperative Steroids	2	2
Without Intraoperative Steroids	2	2

Percentage of Participants Experiencing Death or Graft Loss Within Three and Six Months After Transplantation

Graft loss is defined as being listed for a re-transplantation. (NCT00149890)
Timeframe: 3 months and 6 months

Intervention	Percentage of participants (Number)
	Death within 3 months post treatment	Death within 6 months post treatment	Graft Loss within 3 months post treatment	Graft Loss within 6 months post treatment
With Intraoperative Steroids	0.0	0.0	5.1	5.1
Without Intraoperative Steroids	2.6	2.6	2.6	5.3

Percentage of Participants With Treatment Failure Within Three and Six Months

To evaluate the proportion of patients with treatment failure treated with a therapy consisting of intraoperative versus without intraoperative steroids in combination with basiliximab, cyclosporine/cyclosporine microemulsion and steroids within three and six months. (NCT00149890)
Timeframe: 3 and 6 months

Intervention	Percentage of participants (Number)
	3 month: Age < 2 years (N= 21, 24)	3 month: Age 2-16 years (N= 18, 14)	3 Month: Total	6 month: Age < 2 years (N= 21, 24)	6 month: Age 2-16 years (N= 18, 14)	6 Month: Total
With Intraoperative Steroids	0.00	11.11	5.13	0.00	11.11	5.13
Without Intraoperative Steroids	4.17	7.14	5.26	4.17	7.14	5.26

Incidence of Biopsy Proven Acute Rejection During the First 3 Months Post de Novo Liver Transplantation

Number of patients with biopsy proven acute rejection (BPAR) within 3 months after post de novo liver transplantation. In all suspected rejection episodes an allograft biopsy was performed within a 48 hour period of initiation of an anti-rejection therapy. A designated pathologist graded the biopsies according to the Banff criteria into mild, moderate or severe BPAR. (NCT00332462)
Timeframe: 3 months

Intervention	Participants (Number)
	patients with BPAR within 3 months after Tx : YES	patients with BPAR within 3 months after Tx : NO
Cyclosporine (Sandimmun®)	8	26

Incidence, Safety and Tolerability of Cyclosporine Intravenous (i.v.) During 6 Months Post de Novo Liver Transplantation

The secondary efficacy endpoints included: the incidence of BPAR at 6 months; the incidence of treated acute rejection (TAR) / steroid-resistant acute rejection at 3 and 6 months; the incidence of BPAR with moderate/severe histological grading at 3 and 6 months; time to the first BPAR, the first TAR / steroid-resistant acute rejection and BPAR with moderate/severe histological grading; patient death at 3 and 6 months; and graft loss at 3 and 6 months. (NCT00332462)
Timeframe: 3 or 6 months after transplantation

Intervention	Participants (Number)
	Patients with BPAR : YES	Patients with BPAR : NO	Patients with TAR : YES	Patients with TAR : NO	Patients w/ steroid-resistant acute rejection:YES	Patients w/ steroid-resistant acute rejection:NO	BPAR w/ moderate/severe histological grading:YES	BPAR w/ moderate/severe histological grading:NO	Occurence of Death : YES	Occurence of Death : NO	Occurence of Graft loss : YES	Occurence of Graft loss : NO
3 Months After Transplantation	NA	NA	7	27	2	32	4	30	3	31	3	31
6 Months After Transplantation	10	24	8	26	3	31	4	30	3	31	3	31

Non-inferiority Analysis of Renal Function, Calculated by Glomerular Filtration Rate (cGFR) Using Modification of Diet in Renal Disease (MDRD) Formula

"Modification of Diet in Renal Disease (MDRD) formula is:~GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where~C is the serum concentration of creatinine [mg/dL],~A is patient age at sample collection date [years],~G=0.742 when gender is female, otherwise G=1,~R=1.21 when race is black, otherwise R=1" (NCT00251004)
Timeframe: at 12 months

Intervention	mL/min/1.73m^2 (Number)
Low-dose Everolimus Group	54.66
High-dose Everolimus Group	51.41
Control Group	52.24

Non-inferiority Analysis on Percentage of Participants With Composite Efficacy Endpoints

The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. In the definition of composite efficacy failure, loss to follow-up includes patients who did not experience treated BPAR, graft loss or death on or after day 1 and whose last day of contact was prior to day 316, the start day of the 12 month visit window. (NCT00251004)
Timeframe: 12 months

Intervention	Percentage of Participants (Number)
Low-dose Everolimus Group	27.1
High-dose Everolimus Group	21.5
Control Group	25.3

Percentage of Participants With the Composite Incidence of Graft Loss, Death or Loss to Follow up at 12 Months Post-transplantation

"Graft loss was defined as graft loss (the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis) and re-transplant.~A loss to follow-up patient in the composite endpoint of graft loss, death or loss to follow-up (the main secondary efficacy endpoint) was a patient who did not experience graft loss or death from day 1 and whose last day of contact was prior to study day 316." (NCT00251004)
Timeframe: 12 months

Intervention	Percentage of participants (Number)
Low-dose Everolimus Group	11.6
High-dose Everolimus Group	9.7
Control Group	9.4

Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis

The primary efficacy endpoint was the 12 month analysis of primary efficacy failure defined as a composite endpoint including treated biopsy proven acute rejection (BPAR), graft loss, death or loss to follow-up. A treated BPAR episode was defined as a biopsy graded IA, IB, IIA, IIB, or III that was treated with anti-rejection therapy. Graft loss was defined as the allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis as well as re-transplant. (NCT00251004)
Timeframe: 12 months

Intervention	Participants (Number)
	Composite Endpoint (n)	--Death	--Graft Loss	--Treated BPAR	--Lost to follow up
Control Group	70	6	9	50	9
High-dose Everolimus Group	60	9	13	38	6
Low-dose Everolimus Group	75	8	13	48	12

Number of Participants With Robust Hematologic Recovery With Reticulocyte or Platelet Count

Number of participants with robust hematologic recovery with reticulocyte or platelet count ≥ 50,000/uL (NCT00065260)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
r-ATG /Cyclosporine	9
Alemtuzumab (Campath-1H)	9

Percentage of Cumulative Incidence of Clonal Evolution in Participants

Percent of cumulative incidence of clonal evolution in participants to either paroxysmal nocturnal hemoglobinuria (PNH), myelodysplasia or acute leukemia. (NCT00065260)
Timeframe: 3 years

Intervention	Percentage of Cumulative Incidence (Number)
r-ATG /Cyclosporine	16
Alemtuzumab (Campath-1H)	5

Percentage of Cumulative Incidence of Relapse in Participants

Percentage of cumulative incidence of relapse of disease in participants (NCT00065260)
Timeframe: 3 year

Intervention	percentage of cumulative incidence (Number)
r-ATG /Cyclosporine	19
Alemtuzumab (Campath-1H)	9

Participants no Longer Meeting Criteria for Severe Aplastic Anemia.

Number of participants no longer meeting the criteria for severe aplastic anemia as measured by response to treatment at 6 months (NCT00065260)
Timeframe: 6 months

Intervention	participants (Number)
	No Response	Partial Response	Complete Response
Alemtuzumab (Campath-1H)	17	9	0
r-ATG /Cyclosporine	18	9	0

Percentage of Participants no Longer Meeting Criteria for Severe Aplastic Anemia.

Percentage of participants no longer meeting the criteria for severe aplastic anemia as measured by response to treatment (NCT00065260)
Timeframe: 3 months and 6 months

Intervention	percentage of participants (Number)
	3 Months	6 Months
Alemtuzumab (Campath-1H)	19	37
r-ATG /Cyclosporine	19	33

Event Free Survival (EFS)

Event-free survival (EFS) is the time measurement between the day of allogeneic transplant and the first documented recurrence or death from any cause (Kaplan-Meier estimate). (NCT00896493)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	40

Event Free Survival (EFS)

Intervention	percentage of participants (Number)
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	26

Number of Participants With Chronic Graft-versus-host Disease (GVHD)

Cumulative incidence at 6 months (any grade). GvHD was assessed using the 2015 NIH consensus criteria. (NCT00896493)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	9

Overall Survival (OS)

Overall survival (OS) is the time measurement between the day of allogeneic transplant and death from any cause (Kaplan-Meier estimate). (NCT00896493)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	68

Overall Survival (OS)

Overall survival (OS) is the time measurement between the day of allogeneic transplant and death from any cause (Kaplan-Meier estimate). (NCT00896493)
Timeframe: 5 years

Intervention	percentage of participants (Number)
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	56

Progression-Free Survival (PFS) at 180 Days

Progression-Free Survival (PFS; time to disease progression or death from any cause) assessed at 180 days (Kaplan-Meier estimate). Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00896493)
Timeframe: 180 days

Intervention	percentage of participants (Number)
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	73

Mortality

Total count of non-relapsed mortality and mortality from relapsed disease. (NCT00896493)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
	Non-relaped, treatment related	Non-relaped, not treatment related	Disease relapse
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	5	1	15

Number of Participants With Acute Graft-versus-host Disease (GVHD)

Cumulative incidence at 6 months. GvHD was assessed using the 2015 NIH consensus criteria. (NCT00896493)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
	Any Grade	Grade II-IV
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	9	5

Treatment Related Mortality

(NCT00896493)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
	Acute GVHD	Chronic GVHD	Secondary malignancy	Hepatitis B	Hemorrhage secondary to anticoagulation
Total Lymphoid Irradiation & Anti-thymocyte Immunoglobulin	1	1	1	1	1

Immune Reconstruction/CD4+ Count at 1 Year

(NCT00425802)
Timeframe: 1 year

Intervention	cells/microliter (Median)
Treatment	333

Immune Reconstruction/CD4+ Count at 3 Months

(NCT00425802)
Timeframe: 3 months

Intervention	cells/microliters (Median)
Treatment	253

Immune Reconstruction/CD4+ Count at 6 Months

(NCT00425802)
Timeframe: 6 months

Intervention	cells/microliter (Median)
Treatment	312

Incidence of Chronic GVHD at 1 Year

(NCT00425802)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Treatment	14

Incidence of Moderate to Severe Grades II to IV Graft Versus Host Disease (GVHD) at 100 Days

(NCT00425802)
Timeframe: 100 days

Intervention	percentage of patients (Number)
Treatment	18

Overall Survival at 1 Year

(NCT00425802)
Timeframe: 1 year

Intervention	percentage of participants (Number)
Treatment	90

Time to Neutrophil Engraftment

(NCT00425802)
Timeframe: 2 years

Intervention	days (Median)
Treatment	15

Time to Platelet Engraftment

(NCT00425802)
Timeframe: 1 year

Intervention	days (Median)
Treatment	12

Mean Creatinine Clearance Rate - 3 Months

Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance rate was calculated using the Nankivell formula. Normal values for healthy, young males are in the range of 100-135 ml/min and for females 90-125 ml/min. A low creatinine clearance indicates poor kidney function. (NCT00195273)
Timeframe: 3 months

Intervention	ml/min (Mean)
Sirolimus	55.200
Cyclosporine (CsA)	51.878

Mean Creatinine Clearance Rate

Intervention	ml/min (Mean)
Sirolimus	56.800
Cyclosporine (CsA)	53.449

Number of Patients With Acute Rejection

The diagnosis of acute rejection was made via kidney biopsy (Banff criteria). The Banff criteria are standardized diagnostic categories based on histological assessments (e.g., cell types and distributions). Biopsy was performed before initiation of anti-rejection therapy, or at least within 24 hours of the start of therapy. (NCT00195273)
Timeframe: 3 and 12 months

Intervention	patients (Number)
	3 months	12 months
Cyclosporine (CsA)	9	10
Sirolimus	3	5

Patient and Graft Survival

Graft survival is measured by graft loss which is defined as removal of the transplant. (NCT00195273)
Timeframe: 12 months

Intervention	patients (Number)
	Patient survival	Graft loss
Cyclosporine (CsA)	29	3
Sirolimus	31	0

Median Days to Neutrophil Engraftment

Median days to neutrophil recovery. Neutrophil recovery is defined as the first day of two consecutive days in which the ANC was 500 K/ml or greater unsupported by growth factors or granulocyte transfusion. (NCT00003838)
Timeframe: Day 30

Intervention	Days (Median)
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	14
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	15

Number of Participants Overall Survival

Number of participants overall survival. Overall survival is defined as number participants alive following stem cell transplant (NCT00003838)
Timeframe: enrollment to date of death, up to 5 years

Intervention	Participants (Count of Participants)
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	17
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	48

Number of Participants That Remained Disease-free Survival

Intervention	Participants (Count of Participants)
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	26
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	56

Number of Participants Who Experienced Transplant Related Mortality

Number of Participants who experienced transplant related mortality by Day 200 (NCT00003838)
Timeframe: 200 days

Intervention	Participants (Count of Participants)
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	5
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	4

Number of Participant Who Experienced Chronic Graft Versus Host Disease Following Stem Cell Transplant

"Number of participant who experienced chronic graft versus host disease (GVHD) following stem cell transplant~The diagnosis of clinical features of chronic-GVHD was determined prospectively and classified retrospectively into limited or extensive based on the Revised Seattle Classification. Chronic GvHD severity categorized as limited is defined as: localized skin lesions with or without limited hepatic involvement and extensive is defined as: generalized skin involvement, major hepatic complications, or involvement of any other organ." (NCT00003838)
Timeframe: Day 100 up to 3 years

Intervention	Participants (Count of Participants)
	Limited	Extensive
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	12	19
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	13	27

Number of Participants Who Experienced Acute GVHD Grades II-IV

"Number of participants who experienced acute GVHD grades II-IV~Acute-GVHD was graded and staged prospectively using criteria from the 1994 Consensus Conference on Acute-GVHD Grading.~Grades are defined as:~Grade II: Skin = rash on 25-50 percent body surface area; Liver = Total Bilirubin 3.1-6.0 mg/dL; Lower GI = Diarrhea 1001-1500 mL/day.~Grade III: Skin = Rash on >50% of body surface; Liver = Total Bilirubin 6.1 - 15.0 mg/dL; Lower GI = Diarrhea > 1500 mL/day.~Grade IV: Skin = Generalized erythroderma plus bullous formation; Liver = Total Bilirubin >15 mg/dL; Lower GI = Severe abdominal pain with or without ileus.~Grade II GVHD as moderate, grade III as severe, and grade IV life-threatening." (NCT00003838)
Timeframe: Up to Day 100

Intervention	Participants (Count of Participants)
	Grade II	Grade III-IV
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	6	14
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	16	18

Number of Participants With Complete Donor Myeloid (CD34+) and T-cell (CD3+) Chimerism

Number of participants with complete donor myeloid chimerism. Myeloid (CD34+) and T-cell (CD3+) chimerisms were determined by PCR analysis of short tandem repeats (STR). Complete donor chimerism is defined as >95% donor-derived cells in the peripheral blood in a specific lineage. (NCT00003838)
Timeframe: Up to Day 100

Intervention	Participants (Count of Participants)
	complete donor myeloid (CD34+) chimerism	complete T-cell (CD3+) chimerism
Group A: Stem Cell Transplant in High Risk for Transplant Related Complications and Mortality	29	30
Group B: Stem Cell Transplant in Debilitating Hematologic Diseases	55	56

Maximum Tolerated Doses Mitoxantrone Hydrochloride and Etoposide When Combined With Cyclosporine and Pravastatin Sodium

"Determine the doses of mitoxantrone and etoposide that, when combined with CSA and pravastatin, meet minimum standards for both efficacy and toxicity and have the highest efficacy rate among several mitoxantrone and etoposide doses.~Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0." (NCT01342887)
Timeframe: After completion of first 2 courses, up to 22 weeks

Intervention	doses tolerated (Number)
Treatment (Immunosuppression, Enzyme Inhibitor, and Chemo)	0

Number of Patients That Have Complete Donor Chimerism After Transplant.

To estimate the likelihood of complete donor chimerism for patients with CGD using busulfan, cyclophosphamide, fludarabine and alemtuzumab (Campath 1H) as conditioning therapy for SCT from 5/6 or 6/6 HLA-matched unrelated or 5/6 or 6/6 HLA phenotype-matched related donors. (NCT00578643)
Timeframe: 120 days post transplant

Intervention	participants (Number)
Allogeneic Unrelated Transplant	13

Percentage of Participants With Engraftment

To estimate the engraftment rate for patients with CGD using busulfan, cyclophosphamide, fludarabine and alemtuzumab (Campath 1H) as conditioning therapy for SCT from 5/6 or 6/6 HLA-matched unrelated or 5/6 or 6/6 HLA phenotype-matched related donors. (NCT00578643)
Timeframe: 28 days post transplant

Intervention	percentage of participants (Number)
Allogeneic Unrelated Transplant	100

Least Squares Means of Measured Glomerular Filtration Rate (GFR) (Iohexol Serum Clearance in Milliliters Per Minute [mL/Min])

Glomerular filtration rate (GFR): an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using iohexol serum clearance. For determination of iohexol serum clearance, iohexol was administered as an intravenous (IV) bolus over 5 minutes immediately after morning dosing of Tofacitinib or CsA on day of GFR evaluation. Blood samples for iohexol (3 millilitres [mL] each to provide a minimum of 1 mL serum) were collected into appropriately labeled tubes containing no additives at 120, 180, 240, and 300 minutes after the end of the iohexol IV bolus. A normal GFR is greater than (>) 90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR less than (<) 15 mL/min indicated kidney failure. (NCT00658359)
Timeframe: Month 36

Intervention	mL/min (Least Squares Mean)
Cyclosporine	67.63
Tofacitinib Less Intensive (LI)	76.86
Tofacitinib More Intensive (MI)	75.86

Percentage of Participants Discontinuing From the Study

Discontinuations were due to any reason including those occurring as a result of protocol Amendments 3 and 4. (NCT00658359)
Timeframe: Months 12 through 72.

Intervention	Percentage of Participants (Number)
Cyclosporine	43.8
Tofacitinib Less Intensive (LI)	75.0
Tofacitinib More Intensive (MI)	85.2

Percentage of Participants With Malignancies

All treatment-emergent malignancies in Study A3921050 were included as collected on the Malignancy Case Report Form page. (NCT00658359)
Timeframe: Months 12 through 72.

Intervention	Percentage of Participants (Number)
Cyclosporine	10.9
Tofacitinib Less Intensive (LI)	13.3
Tofacitinib More Intensive (MI)	14.8

Percentage of Participants With Progression of Chronic Allograft Lesions at Month 36

Progression of chronic allograft lesions was defined as an increase in the Banff chronicity score (Banff-CS) in biopsy from the implantation (baseline) biopsy in a given participant. Banff-CS was the sum of the Banff scores for the 4 chronic basic lesions (allograft glomerulopathy [cg] + interstitial fibrosis [ci] + tubular atrophy [ct] + vascular intimal thickening [cv]). The Banff-CS ranged from 0-12, higher score indicated greater lesions and Month 36 Banff-CS greater than the implantation biopsy score indicated progression of lesions. (NCT00658359)
Timeframe: Month 36

Intervention	Percentage of Participants (Number)
Cyclosporine	87.50
Tofacitinib Less Intensive (LI)	77.78
Tofacitinib More Intensive (MI)	87.50

Kaplan-Meier Analysis of Percent of Participants With Graft Survival With Death Censored by Visit

Graft loss was defined as graft nephrectomy, subject death, retransplantation, or return to dialysis for at least 6 consecutive weeks. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. Included data up to 2 months postdose in the clinical Follow-up visit. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of participants (Number)
	Month 12	Month 15	Month 18 (n=62,59,51)	Month 24 (n=59,58,45)	Month 30 (n=55,42,31)	Month 36 (n=53,32,16)	Month 42 (n=46,32,15)	Month 48 (n=44,32,15)	Month 54 (n=43,31,14)	Month 60 (n=40,26,13)	Month 66 (n=35,23,11)	Month 72 (n=31,20,11)
Cyclosporine	100.00	100.00	100.00	100.00	98.31	96.48	96.48	96.48	96.48	96.48	96.48	96.48
Tofacitinib Less Intensive (LI)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
Tofacitinib More Intensive (MI)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Kaplan-Meier Analysis of Percentage of Participants Surviving by Visit

The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. Included data up to 2 months postdose in the clinical Follow-up visit. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of Participants (Number)
	Month 12	Month 15 (n=64,60,53)	Month 18 (n=61,59,51)	Month 24 (n=59,58,44)	Month 30 (n=55,42,31)	Month 36 (n=53,32,16)	Month 42 (n=45,32,15)	Month 48 (n=44,32,15)	Month 54 (n=43,31,14)	Month 60 (n=40,26,13)	Month 66 (n=35,23,11)	Month 72 (n=31,20,11)
Cyclosporine	100.00	100.00	98.41	98.41	98.41	98.41	96.27	96.27	94.09	94.09	94.09	94.09
Tofacitinib Less Intensive (LI)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
Tofacitinib More Intensive (MI)	100.00	98.15	98.15	94.22	94.22	90.97	90.97	90.97	90.97	90.97	90.97	90.97

Kaplan-Meier Analysis of Percentage of Participants With Clinically Significant Infection by Visit

Clinically significant infection was defined as the presence of documented infection confirmed by culture, biopsy, genomic, or serologic findings post-randomization and requiring hospitalization or parenteral anti-infective treatment, or otherwise deemed significant by the investigator. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of Participants (Number)
	Month 12	Month 15 (n=59,54,44)	Month 18 (n=57,52,41)	Month 24 (n=54,48,34)	Month 30 (n=49,34,23)	Month 36 (n=46,28,12)	Month 42 (n=40,28,11)	Month 48 (n=37,28,11)	Month 54 (n=36,25,10)	Month 60 (n=34,21,10)	Month 66 (n=29,19,8)	Month 72 (n=24,15,7)
Cyclosporine	4.69	7.81	9.40	11.02	12.80	14.62	14.62	16.81	19.05	19.05	19.05	21.94
Tofacitinib Less Intensive (LI)	8.33	10.00	13.33	18.33	25.42	27.83	27.83	27.83	33.08	36.13	36.13	40.12
Tofacitinib More Intensive (MI)	3.70	18.52	20.46	24.49	29.46	34.89	34.89	34.89	34.89	34.89	34.89	43.03

Kaplan-Meier Analysis of Percentage of Participants With Combined Banff Rejection by Visit

Banff 97: standard classification for scoring and classifying rejection of kidney transplant biopsies in 6 diagnostic categories: normal, antibody-mediated rejection, borderline changes: 'suspicious' for acute cellular rejection, acute/active cellular rejection, chronic/sclerosing allograft nephropathy, and other. Combined Banff rejection was calculated from categories of antibody-mediated rejection (Category 2) plus borderline changes (Category 3) plus acute rejection (Category 4), as interpreted by the central pathologist. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of Participants (Number)
	Month 12	Month 15 (n=51,52,45)	Month 18 (n=49,52,43)	Month 24 (n=46,50,37)	Month 30 (n=44,37,23)	Month 36 (n=41,28,12)	Month 42 (n=34,28,11)	Month 48 (n=33,28,11)	Month 54 (n=33,27,10)	Month 60 (n=31,23,9)	Month 66 (n=26,20,9)	Month 72 (n=24,18,9)
Cyclosporine	15.63	20.31	21.91	23.57	23.57	25.30	27.44	27.44	27.44	27.44	27.44	27.44
Tofacitinib Less Intensive (LI)	13.33	13.33	13.33	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00
Tofacitinib More Intensive (MI)	11.11	16.67	16.67	18.60	21.41	21.41	21.41	21.41	21.41	21.41	21.41	21.41

Kaplan-Meier Analysis of Percentage of Participants With Efficacy Failure by Visit

Efficacy failure was the first occurrence of BPAR diagnosed by the central pathologist or graft loss including participant death. BPAR (category acute rejection) was interpreted by the central blinded pathologist according to the Banff 97 working classification. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of Participants (Number)
	Month 12	Month 15 (n=58,54,49)	Month 18 (n=56,54,49)	Month 24 (n=54,54,46)	Month 30 (n=53,52,46)	Month 36 (n=51,48,42)	Month 42 (n=44,47,41)	Month 48 (n=43,44,38)	Month 54 (n=41,44,36)	Month 60 (n=41,44,35)	Month 66 (n=39,42,29)	Month 72 (n=35,28,19)
Cyclosporine	6.25	7.81	10.99	10.99	12.64	15.94	19.59	21.42	23.25	23.25	23.25	23.25
Tofacitinib Less Intensive (LI)	10.00	10.00	10.00	10.00	10.00	15.19	15.19	18.84	18.84	18.84	18.84	22.81
Tofacitinib More Intensive (MI)	5.56	9.26	9.26	14.81	14.81	16.71	18.69	18.69	18.69	20.95	20.95	20.95

Kaplan-Meier Analysis of Percentage of Participants With First Biopsy Proven Acute Rejection (BPAR) by Visit

BPAR was category acute rejection as interpreted by the central blinded pathologist according to the Banff 97 working classification. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of Participants (Number)
	Month 12	Month 15 (n=59,54,50)	Month 18 (n=57,54,48)	Month 24 (n=55,53,42)	Month 30 (n=51,37,28)	Month 36 (n=48,28,14)	Month 42 (n=40,28,13)	Month 48 (n=38,28,13)	Month 54 (n=38,27,12)	Month 60 (n=36,23,11)	Month 66 (n=31,20,10)	Month 72 (n=28,18,10)
Cyclosporine	6.25	7.81	9.40	9.40	9.40	11.18	13.34	13.34	13.34	13.34	13.34	13.34
Tofacitinib Less Intensive (LI)	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Tofacitinib More Intensive (MI)	5.56	7.41	7.41	7.41	7.41	7.41	7.41	7.41	7.41	7.41	7.41	7.41

Kaplan-Meier Analysis of Percentage of Participants With Treated Clinical Acute Rejection by Visit

Treated clinical acute rejection was defined as an acute rejection episode that was diagnosed based on local biopsy readout and received anti-rejection treatment. The 'Number' and 'Other Confidence Interval Level' columns represent cumulative proportions and 60% confidence intervals (CIs) as estimated from the fitted Kaplan-Meier curves for each treatment at scheduled visits. (NCT00658359)
Timeframe: Months 12, 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	Percentage of Participants (Number)
	Month 12	Month 15 (n=53,56,48)	Month 18 (n=51,54,46)	Month 24 (n=49,52,40)	Month 30 (n=46,37,27)	Month 36 (n=42,29,14)	Month 42 (n=36,29,13)	Month 48 (n=34,29,13)	Month 54 (n=33,28,12)	Month 60 (n=30,24,11)	Month 66 (n=25,21,9)	Month 72 (n=22,18,9)
Cyclosporine	14.06	17.19	18.75	18.75	20.48	23.94	27.56	27.56	29.69	29.69	29.69	29.69
Tofacitinib Less Intensive (LI)	6.67	6.67	10.00	11.67	11.67	11.67	11.67	11.67	11.67	11.67	11.67	11.67
Tofacitinib More Intensive (MI)	9.26	11.11	11.11	11.11	11.11	11.11	11.11	11.11	11.11	11.11	11.11	11.11

Least Square Means of Estimated GFR Calculated Using the Nankivell Equation by Visit

"GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR was calculated using Nankivell formula, where:~Creatinine clearance (mL/min) = 6.7/serum creatinine (millimols per litre [mmol/L]) - serum urea (mmol/dL)/2 + actual body weight (kilograms [kg])/4 - 100/Height (metres [m])^2 + (35 for male or 25 for female).~A normal GFR for adults is > 90 mL/min. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure.~Model contained treatment, visit and treatment by visit interaction as fixed effects. An unstructured variance-covariance structure was used." (NCT00658359)
Timeframe: Month 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	minutes per milliliter (min/mL) (Least Squares Mean)
	Month 15	Month 18	Month 24 (n=58,54,41)	Month 30 (n=51,37,27)	Month 36 (n=51,32,15)	Month 42 (n=44,31,15)	Month 48 (n=42,30,14)	Month 54 (n=41,31,13)	Month 60 (n=37,24,12)	Month 66 (n=34,20,11)	Month 72 (n=30,17,11)
Cyclosporine	69.57	70.93	69.78	68.41	68.94	68.82	67.68	65.59	70.08	68.99	68.65
Tofacitinib Less Intensive (LI)	82.33	82.41	82.63	84.27	81.10	81.24	80.08	79.63	77.80	76.74	81.68
Tofacitinib More Intensive (MI)	82.96	82.91	83.49	82.02	81.50	77.81	75.28	75.82	74.19	75.01	72.92

Least Squares Means of End-Stage Renal Disease (ESRD) Symptom Checklist (SCL) -Transplantation Modules at Months 24 and 36

"ESRD-SCL: a 43-item disease specific self-administered questionnaire. Participants' rated the question At the moment,how much do you suffer? for each item on a 5 point scale, range (Ra) from 0 (not at all) to 4 (extremely). Consisted of 6 subscales: Cardiac and Renal (CR) dysfunction; Ra 0 to 28, Increased(In) Growth of Gum and Hair (IGGH); Ra 0 to 20, Limited Cognitive Capacity (LCC); Ra 0 to 32, Limited Physical Capacity (LPC); Ra 0 to 40, Side Effects (SEs) of Corticosteroids; Ra 0 to 20, Transplantation Associated Psychological Distress (TAPD); Ra 0 to 32. Total Score: 0 to 172, higher scores indicate greater dysfunction.~Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used." (NCT00658359)
Timeframe: Months 24, 36

Intervention	Score on a scale (Least Squares Mean)
	Month 24 Limited Physical Capacity (n=40,33,23)	Month 24 Limited Cognitive Capacity	Month 24 CR Dysfunction (n=40,33,23)	Month 24 SE of Corticosteroids (40, 33, 23)	Month 24 IGGH (n=40,33,23)	Month 24 TAPD	Month 24 Global Score (n=40,33,23)	Month 36 Limited Physical Capacity (n=33,21,8)	Month 36 Limited Cognitive Capacity (n=34,21,8)	Month 36 Cardiac and Renal Dysfunction (n=33,21,8)	Month 36 SE of Corticosteroids (n=33,21,8)	Month 36 IGGH (n=33,20,8)	Month 36 TAPD (n=34,21,8)	Month 36 Global Score (n=33,21,8)
Cyclosporine	0.59	0.63	0.63	0.42	0.54	0.61	0.58	0.71	0.67	0.58	0.44	0.54	0.77	0.64
Tofacitinib Less Intensive (LI)	0.70	0.71	0.58	0.57	0.19	0.77	0.62	0.69	0.73	0.57	0.39	0.33	0.82	0.63
Tofacitinib More Intensive (MI)	0.71	0.75	0.53	0.60	0.17	0.63	0.59	0.88	0.85	0.76	0.58	0.23	0.68	0.70

Least Squares Means of Estimated GFR (eGFR) (mL/Min/1.73 Square Meter [m^2]) Calculated by the Modification of Diet in Renal Disease (MDRD) Equation With Last Observation Carried Forward (LOCF) Plus Imputation (eGFR=0 for Graft Loss/Death) by Visit

"GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was calculated using MDRD equation. GFR (mL/min/1.73 m^2) by MDRD equation = 170 * (serum creatinine [mg/dL])^(-0.999) * (age in years)^(-0.176) * (0.762 if female) * (1.18 if black) * (blood urea nitrogen concentration [mg/dL])^(-0.170) * (serum albumin concentration [g/dL])^(0.318). A normal GFR is >90 mL/min/1.73 m^2, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min/1.73 m^2 indicated kidney failure.~Model contained treatment, visit and treatment by visit interaction as fixed effects. An unstructured variance-covariance structure was used." (NCT00658359)
Timeframe: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	mL/min/1.73m^2 (Least Squares Mean)
	Month 15	Month 18	Month 24	Month 30	Month 36	Month 42	Month 48	Month 54	Month 60	Month 66	Month 72
Cyclosporine	56.25	58.13	56.30	53.82	54.37	53.59	51.69	48.64	50.43	49.70	49.62
Tofacitinib Less Intensive (LI)	72.12	71.66	71.93	73.10	69.09	68.29	65.27	65.25	63.82	63.33	64.27
Tofacitinib More Intensive (MI)	70.22	69.69	68.20	64.44	63.27	62.14	60.81	60.79	59.20	59.47	59.21

Least Squares Means of Estimated GFR Calculated Using the Cockcroft-Gault Equation by Visit

"GFR: an index of kidney function. GFR described the flow rate of filtered fluid through the kidney. GFR was measured directly or estimated using established formulas. GFR (mL/min) was calculated using Cockcroft-Gault equation. GFR by Cockcroft-Gault equation= body weight (kg)*(140 minus age in years) divided by (72*serum creatinine [mg/dL]). For females value obtained was multiplied by 0.85. A normal GFR is >90 mL/min, although children and older people usually have a lower GFR. Lower values indicated poor kidney function. A GFR <15 mL/min indicated kidney failure.~Model contained treatment, visit and treatment by visit interaction as fixed effects. An unstructured variance-covariance structure was used." (NCT00658359)
Timeframe: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	min/mL (Least Squares Mean)
	Month 15	Month 18	Month 24 (n=58,54,42)	Month 30 (n=51,38,29)	Month 36 (n=51,32,15)	Month 42 (n=44,31,15)	Month 48 (n=42,30,14)	Month 54 (n=41,31,13)	Month 60 (n=37,24,12)	Month 66 (n=34,20,11)	Month 72 (n=30,17,11)
Cyclosporine	72.74	73.56	72.70	70.70	70.71	69.63	67.63	65.81	70.52	69.09	68.34
Tofacitinib Less Intensive (LI)	87.22	87.52	87.72	89.24	85.91	85.95	83.96	82.78	78.54	79.09	85.50
Tofacitinib More Intensive (MI)	87.67	87.12	87.62	87.15	85.64	81.88	77.42	77.60	74.18	74.52	73.05

Least Squares Means of Fasting Serum Glucose Levels (mg/dL) by Visit

Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A compund symmetry variance-covariance structure was used. (NCT00658359)
Timeframe: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	mg/dL (Least Squares Mean)
	Month 15 (n=59,58,49)	Month 18	Month 24 (n=58,54,41)	Month 30 (n=50,38,27)	Month 36 (n=51,32,15)	Month 42 (n=44,31,15)	Month 48 (n=42,30,14)	Month 54 (n=41,31,13)	Month 60 (n=37,23,12)	Month 66 (n=34,20,11)	Month 72 (n=30,17,11)
Cyclosporine	104.42	113.01	112.23	105.27	95.88	107.10	101.14	114.50	109.75	104.42	107.01
Tofacitinib Less Intensive (LI)	102.10	106.17	107.81	108.01	106.27	114.43	109.86	110.62	106.64	103.25	105.22
Tofacitinib More Intensive (MI)	107.18	107.56	102.47	107.70	106.03	94.16	104.07	127.38	107.49	108.55	99.82

Least Squares Means of Severity of Dyspepsia Assessment (SODA) Subscales at Months 24 & 36

"SODA:17-item health scale, assessed participant-reported perceptions of dyspepsia; consists of 3 subscales: Pain Intensity (PI, 6-items to assess pain and intensity of abdominal discomfort; Range: 2 to 47, higher score indicates greater pain and abdominal discomfort), Non-Pain Symptoms (NPS, 7-items to assess severity and impact of non-pain symptoms: burping/belching, heartburn, bloating, flatulence, sour taste, nausea, and bad breath; Range: 7 to 35, higher scores indicate increased symptom severity and influence), and Satisfaction (4-items to assess degree of satisfaction with abdominal discomfort; Range: 2 to 23, higher scores indicate more satisfaction).~Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used." (NCT00658359)
Timeframe: Months 24, 36

Intervention	Score (Least Squares Mean)
	Month 24 PI Total Converted Score (n=46,39,24)	Month 24 NPS Converted Score	Month 24 Satisfaction Converted Score (n=49,41,24)	Month 36 PI Total Converted Score (n=40,27,10)	Month 36 NPS Converted Score (n=42,28,10)	Month 36 Satisfaction Converted Score (n=42,28,10)
Cyclosporine	9.51	11.44	17.22	9.63	11.31	17.44
Tofacitinib Less Intensive (LI)	7.66	11.24	18.11	8.03	11.14	17.90
Tofacitinib More Intensive (MI)	10.73	12.25	16.33	10.59	12.44	16.31

Least Squares Means of Short Form 36 Version 2 (SF-36 V2) Component and Domain Scores at Months 24 and 36

SF-36 v2 is a self-administered 36-item generic health status measure with 8 general health concepts which are the weighted sums of the questions in their section: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health. Each scale is transformed into a 0 (minimum) to 100 (maximum) scale on the assumption each question carries equal weight. These concepts were also summarized into 2 summary scores; Physical Component Summary and Mental Component Summary (both a 0-100 scale). The 8 subscales, 2 summary scores and transition Question 2 (TR Scale, measured on a scale of 1 [minimum] to 5 [maximum]) were subjected to analysis. Higher domain, summary scores, and TR scale scores indicate better health status. Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. First-order autoregressive variance-covariance structure was used. (NCT00658359)
Timeframe: Months 24, 36

Intervention	Score on a scale (Least Squares Mean)
	Month 24: Physical Functioning	Month 24: Role Physical	Month 24: Bodily Pain	Month 24: General Health	Month 24: Vitality	Month 24: Social Functioning	Month 24: Role Emotional	Month 24: Mental Health	Month 24: TR Scale Score	Month 24: Physical Component Summary	Month 24: Mental Component Summary	Month 36 (n=35,21,10): Physical Functioning	Month 36 (n=35,21,10): Role Physical	Month 36 (n=35,21,10): Bodily Pain	Month 36 (n=35,21,10): General Health	Month 36 (n=35,21,10): Vitality	Month 36 (n=35,21,10): Social Functioning	Month 36 (n=35,21,10): Role Emotional	Month 36 (n=35,21,10): Mental health	Month 36 (n=35,21,10): TR Scale Score	Month 36 (n=35,21,10): Physical Component Summary	Month 36 (n=35,21,10): Mental Component Summary
Cyclosporine	49.04	46.36	51.37	46.51	53.31	49.55	44.65	49.52	2.63	49.00	48.65	48.62	48.00	50.57	46.06	53.01	48.96	46.35	50.21	2.46	48.55	49.45
Tofacitinib Less Intensive (LI)	47.00	47.72	51.66	48.25	53.27	49.41	48.47	47.83	2.85	48.99	49.62	46.97	48.52	52.66	47.83	54.45	51.43	51.97	51.84	2.65	48.00	53.50
Tofacitinib More Intensive (MI)	45.47	44.40	51.47	47.60	55.07	49.95	44.17	53.08	2.86	46.57	51.92	46.18	46.00	50.19	47.02	57.43	48.33	47.58	50.59	2.83	47.07	52.32

Least Squares Means of Total Serum Cholesterol Levels (Milligrams Per Deciliter [mg/dL]) by Visit

Model contained treatment, visit and treatment by visit interaction as fixed effects and Baseline (predose in Study A3921030) as a covariate. A first-order autoregressive variance-covariance structure was used. (NCT00658359)
Timeframe: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72

Intervention	mg/dL (Least Squares Mean)
	Month 15	Month 18	Month 24 (n=58,54,40)	Month 30 (n=52,37,26)	Month 36 (n=51,32,15)	Month 42 (n=44,31,15)	Month 48 (n=42,30,14)	Month 54 (n=41,31,13)	Month 60 (n=37,23,12)	Month 66 (n=34,20,11)	Month 72 (n=31,17,11)
Cyclosporine	199.14	200.51	198.78	193.99	198.62	200.36	196.56	193.66	190.10	191.00	188.74
Tofacitinib Less Intensive (LI)	213.49	212.67	212.30	211.59	211.14	220.29	228.83	222.86	220.47	218.77	209.12
Tofacitinib More Intensive (MI)	196.27	193.50	185.57	202.73	192.97	208.77	188.83	183.17	184.14	189.15	182.60

Least Squares Means of Total Serum High Density Lipoprotein (HDL) Cholesterol Levels (mg/dL) by Visit

Intervention	mg/dL (Least Squares Mean)
	Month 15	Month 18	Month 24 (n=58,54,40)	Month 30 (n=52,37,26)	Month 36 (n=51,32,15)	Month 42 (n=44,31,15)	Month 48 (n=42,30,14)	Month 54 (n=41,31,13)	Month 60 (n=37,23,12)	Month 66 (n=34,20,11)	Month 72 (31,17,11)
Cyclosporine	49.88	50.47	51.47	49.55	50.46	53.24	54.59	54.55	54.72	54.69	52.80
Tofacitinib Less Intensive (LI)	59.67	59.87	59.84	60.45	59.92	59.32	61.67	60.18	60.20	62.12	58.80
Tofacitinib More Intensive (MI)	55.20	55.78	53.52	53.84	54.59	58.59	53.55	52.38	58.98	56.08	54.93

Least Squares Means of Total Serum Low Density Lipoprotein (LDL) Cholesterol Levels (mg/dL) by Visit

Intervention	mg/dL (Least Squares Mean)
	Month 15 (n=54,54,48)	Month 18	Month 24 (n=55,49,40)	Month 30 (n=49,36,25)	Month 36 (n=47,31,15)	Month 42 (n=42,27,15)	Month 48 (n=41,27,14)	Month 54 (n=40,28,13)	Month 60 (n=36,21,12)	Month 66 (n=32,19,11)	Month 72 (n=30,16,11)
Cyclosporine	113.09	112.82	111.14	106.79	112.81	110.98	109.03	107.21	105.37	104.31	109.18
Tofacitinib Less Intensive (LI)	119.71	119.36	119.15	125.24	123.27	122.51	127.65	128.39	123.71	123.74	116.17
Tofacitinib More Intensive (MI)	108.72	109.87	104.63	112.44	109.54	121.74	105.59	96.60	97.79	102.44	96.11

Least Squares Means of Total Serum Triglycerides (mg/dL) by Visit

Intervention	mg/dL (Least Squares Mean)
	Month 15	Month 18	Month 24 (n=58,54,40)	Month 30 (n=52,37,26)	Month 36 (n=51,32,15)	Month 42 (n=44,31,15)	Month 48 (n=42,30,14)	Month 54 (n=41,31,13)	Month 60 (n=37,23,12)	Month 66 (n=34,20,11)	Month 72 (n=31,17,11)
Cyclosporine	177.33	181.92	183.79	182.49	174.01	178.93	166.38	163.57	156.27	165.83	143.03
Tofacitinib Less Intensive (LI)	171.21	163.26	162.80	137.05	145.27	183.09	196.86	169.18	173.20	174.19	165.10
Tofacitinib More Intensive (MI)	167.38	145.05	142.07	178.56	152.98	148.62	156.12	178.24	142.27	158.73	161.28

Mean Absolute Neutrophil Counts (ANC) (Kelvin Per Millimeter Cubed [K/mm^3]) by Visit

Follow-up visit included Month 74 visit for completers and 2-month postdose visit for early withdrawals. (NCT00658359)
Timeframe: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 and Follow-up

Intervention	k/mm^3 (Mean)
	Month 15 (n=55,56,47)	Month 18	Month 24 (n=54,52,39)	Month 30 (n=48,35,26)	Month 36 (n=51,30,15)	Month 42 (n=40,31,15)	Month 48 (n=41,30,13)	Month 54 (n=38,26,11)	Month 60 (n=37,20,11)	Month 66 (n=34,19,11)	Month 72 (n=31,17,11)	Follow-up (n=51,46,41)
Cyclosporine	4.53	4.59	4.62	4.69	4.48	4.30	3.86	4.11	4.30	4.53	4.33	4.65
Tofacitinib Less Intensive (LI)	4.23	3.87	3.99	3.48	3.72	3.90	3.47	3.42	3.97	3.86	3.44	3.75
Tofacitinib More Intensive (MI)	4.33	4.83	4.38	4.55	4.62	4.49	3.86	4.27	4.01	4.28	4.73	4.37

Mean Glycosylated Hemoglobin (HBA1c) (Percent [%]) by Visit

HbA1c is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The normal range for the HbA1c test is between 4% and 5.6%. HbA1c levels between 5.7% and 6.4% indicate increased risk of diabetes and levels of 6.5% or higher indicate diabetes. (NCT00658359)
Timeframe: Months 24, 36, 48, 60, 72

Intervention	Percentage (Mean)
	Month 24	Month 36 (n=50,32,15)	Month 48 (n=43,31,14)	Month 60 (n=37,23,12)	Month 72 (n=31,16,11)
Cyclosporine	6.35	6.16	6.15	6.36	6.52
Tofacitinib Less Intensive (LI)	6.16	5.92	6.16	6.26	6.34
Tofacitinib More Intensive (MI)	6.37	6.69	6.59	6.28	6.33

Mean Hemoglobin (Hgb) (Grams Per Deciliter [g/dL]) by Visit

Follow-up visit included Month 74 visit for completers and 2-month postdose visit for early withdrawals. (NCT00658359)
Timeframe: Months 15, 18, 24, 30, 36, 42, 48, 54, 60, 66, 72 and Follow-up

Intervention	g/dL (Mean)
	Month 15 (n=58,59,48)	Month 18	Month 24 (n=57,54,41)	Month 30 (n=48,37,28)	Month 36 (n=52,32,15)	Month 42 (n=41,31,15)	Month 48 (n=42,31,13)	Month 54 (n=40,29,11)	Month 60 (n=37,20,12)	Month 66 (n=34,19,11)	Month 72 (n=31,17,11)	Follow-up (n=51,47,41)
Cyclosporine	13.20	13.15	13.35	13.21	13.30	13.24	13.05	13.22	13.29	13.02	13.10	12.49
Tofacitinib Less Intensive (LI)	13.14	13.31	13.58	13.66	13.91	13.99	14.01	13.98	14.40	14.62	14.22	13.23
Tofacitinib More Intensive (MI)	13.35	13.50	13.58	13.82	13.44	13.67	13.28	13.60	13.41	13.42	13.23	13.72

Mean Trough Levels of Cyclosporine by Visit

All CsA samples were taken predose (collected 0 to 10 minutes prior to the morning dose). (NCT00658359)
Timeframe: Predose: Months 18, 24, 36, 48, 60, 72

Intervention	ng/mL (Mean)
	Month 18	Month 24 (n=54)	Month 36 (n=50)	Month 48 (n=39)	Month 60 (n=35)	Month 72 (n=23)
Cyclosporine	113.88	89.52	101.10	88.54	95.00	135.30

Mean Trough Levels of Tofacitinib by Visit

The dates and times were recorded for the 6 doses of tofacitinib administered before each scheduled pharmacokinetic (PK) sampling. The participant was instructed to follow a 12 hourly schedule for these 6 doses of tofacitinib, with each dose administered within 1 hour of the scheduled time. Trough samples were collected 0 to 10 minutes prior to the morning dose. 1 hour postdose samples were required within 10 minutes of the nominal time point. Samples taken at -2 hours predose and at time points >1 hour post dose were required within 30 minutes of the nominal time point. (NCT00658359)
Timeframe: Months 18 and 24 (-2 hours, predose, 1 hour, 2 hours), Month 30 (predose, 1 hour and 2 hours), Month 36 (predose, 1, 2, and 4 hours), Months 42, 48, 54, 60, 66, 72 (predose and 2 hours)

Intervention	ng/mL (Mean)
	Month 18 Predose -2 hours (n=31,22)	Month 18 Predose	Month 18 1 hour (n=58,45)	Month 18 2 hours (n=26,23)	Month 24 Predose -2 hours (n=18,15)	Month 24 Predose (n=50,32)	Month 24 1 hour (n=49,31)	Month 24 2 hours (n=28,15)	Month 30 Predose (n=35,21)	Month 30 1 hour (n=35,21)	Month 30 2 hours (n=34,19)	Month 36 Predose (n=31,15)	Month 36 1 hour (n=30,14)	Month 36 2 hours (n=30,15)	Month 36 4 hours (n=30,15)	Month 42 Predose (n=31,14)	Month 42 2 hours (n=30,12)	Month 48 Predose (n=32,14)	Month 48 2 hours (n=32,12)	Month 54 Predose (n=30,11)	Month 54 2 hours (n=30,10)	Month 60 Predose (n=23,10)	Month 60 2 hours (n=23,10)	Month 66 Predose (n=22,10)	Month 66 2 hours (n=21,10)	Month 72 Predose (n=16,8)	Month 72 2 hours (n=16,8)
Tofacitinib Less Intensive (LI)	13.20	12.45	56.62	59.55	11.71	9.93	44.06	37.73	8.70	39.15	38.07	6.35	46.09	38.11	24.03	11.42	35.27	7.58	38.46	7.86	41.18	6.58	39.43	7.53	36.17	8.30	38.55
Tofacitinib More Intensive (MI)	10.68	15.27	56.58	56.60	8.95	7.42	41.93	34.15	6.89	44.12	37.16	8.33	38.07	31.76	21.46	7.00	34.33	13.78	41.10	7.09	48.03	7.31	38.98	5.81	41.12	5.37	38.93

Percentage of Participants by Proteinuria Category by Visit

Proteinuria was defined as the presence of an excess of serum proteins in the urine. Normal value of proteinuria is below 0.15 grams per 24 hours (g/24 hr). Follow-up visit included Month 74 visit for completers and 2-month postdose visit for early withdrawals. (NCT00658359)
Timeframe: Months 24, 36, 48, 60, 72 and Follow-up

Intervention	Percentage of Participants (Number)
	Month 24: >200 mg/day	Month 24: >500 mg/day	Month 24: >1500 mg/day	Month 24: >500 Increase from Baseline	Month 36: >200 mg/day (n=42,30,13)	Month 36: >500 mg/day (n=42,30,13)	Month 36: >1500 mg/day (n=42,30,13)	Month 36: >500 Increase from Baseline (n=42,30,13)	Month 48: >200 mg/day (n=36,29,12)	Month 48: >500 mg/day (n=36,29,12)	Month 48: >1500 mg/day (n=36,29,12)	Month 48: >500 Increase in Baseline (n=36,29,12)	Month 60: >200 mg/day (n=29,20,10)	Month 60: >500 mg/day (n=29,20,10)	Month 60: >1500 mg/day (n=29,20,10)	Month 60: >500 Increase in Baseline (n=29,20,10)	Month 72: >200 mg/day (n=22,15,9)	Month 72: >500 mg/day (n=22,15,9)	Month 72: >1500 mg/day (n=22,15,9)	Month 72: >500 Increase in Baseline (n=22,15,9)	Follow-up: >200 mg/day (n=46,34,39)	Follow-up: >500 mg/day (n=46,34,39)	Follow-up: >1500 mg/day (n=46,34,39)	Follow-up: >500 Increase in Baseline (n=46,34,39)
Cyclosporine	15.7	3.9	2.0	2.0	14.3	2.4	2.4	0	16.7	5.6	2.8	0	10.3	10.3	3.4	0	9.1	4.5	0	0	13.0	6.5	2.2	0
Tofacitinib Less Intensive (LI)	27.7	6.4	2.1	0	26.7	3.3	3.3	0	31.0	17.2	6.9	3.4	20.0	15.0	5.0	5.0	20.0	20.0	13.3	0	17.6	8.8	5.9	0
Tofacitinib More Intensive (MI)	19.4	8.3	5.6	0	15.4	0	0	0	0	0	0	0	10.0	0	0	0	22.2	11.1	0	11.1	20.5	5.1	2.6	2.6

Number of Non-Relapse Mortalities (NRM)

Number of patients who expired without disease progression/relapse. (NCT01252667)
Timeframe: 100 days post-transplant

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	1
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	0
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	1

Number of Participants Surviving Overall

Number of patients surviving overall post-transplant. (NCT01252667)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	2
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	1
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	22

Number of Participants Surviving Progression-free.

Number of patients surviving without progressive disease post-transplant. Progression is defined as the presence of >5% aberrant blasts by morphology on a marrow aspirate or the presence of circulating blasts in the peripheral blood. (NCT01252667)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	2
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	1
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	21

Number of Participants Who Graft Rejected.

Number of patients who graft rejected post-transplant. Graft rejection is defined as <5% donor peripheral blood T cells (CD3+). (NCT01252667)
Timeframe: 1 Year post-transplant.

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	0
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	0

Number of Participants With Minimal Residual/Recurring Disease (MRD) Post-transplant

Number of patients with MRD post-transplant, detected in the bone marrow as cytogenetic abnormalities or <5% monoclonal blasts by flow cytometry. (NCT01252667)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	2
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	0
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	6

Part 1: Number of Participants With Dose Limiting Toxicities (DLT)

"The primary objective of part 1 is to determined the highest dose of clofarabine that can be tolerated safely in conjunction with nonmyeloablative transplant. If three patients successfully transplant without DLT, dose escalation occurs. If one of those three patients experiences DLT an additional three patients will be treated using the same dose. If a second DLT is observed in the first 3-6 patients, or if three patients are successfully transplanted without DLT at the highest dose the study will proceed to Part 2 using the maximum tolerated dose.~A Clofarabine related dose-limiting toxicity is defined as a grade 4 toxicity involving the lungs, heart, liver (not resolving in 48 hours), kidneys (not resolving in 48 hours), gastrointestinal tract, and/or central nervous system." (NCT01252667)
Timeframe: 14 days post-transplant

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	0
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	0

Part 2: Number of Participants With Relapsed Disease

Number of high risk patients with relapsed disease after receiving the maximum dose of clofarabine. Relapse is defined as the presence of >5% aberrant blasts by morphology on a marrow aspirate or the presence of circulating blasts in the peripheral blood. (NCT01252667)
Timeframe: 6 months post-transplant

Intervention	Participants (Count of Participants)
Part 1 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	0
Part 2 - Dose 1 (30 mg/m^2 Clofarabine)	0
Part 2 - Dose 2 (40 mg/m^2 Clofarabine)	0
Part 2 - Dose 3 (50 mg/m^2 Clofarabine)	3

Pharmacokinetics (PK) of Clofarabine

Pharmacokinetic measurement of the volume of plasma from which clofarabine is completely removed per unit time. Clearance normalized to actual body weight. Pharmacokinetic analyses were performed on only a subset of patients and no aggregate calculations were made using the data. (NCT01252667)
Timeframe: Blood was drawn on day -6 before the first clofarabine dosing, at the end of the infusion, and at 3, 4, 5, 6 and 24 hours after the start of infusion. Only pre-dose samples were drawn on days -5, -4, and -3.

Intervention	L/h/kg (Number)
	ID 1	ID 2
Part 1 - Dose 2 (40 mg/m^2 Clofarabine)	0.53	0.37

Pharmacokinetics (PK) of Clofarabine

Intervention	L/h/kg (Number)
	ID 4	ID 5	ID 6
Part 1 - Dose 3 (50 mg/m^2 Clofarabine)	0.29	0.40	0.50

Number of Participants for Relapse Rate

Defined as reappearance of detectable Hepatitis C Virus (HCV) RNA at 24 weeks after completion of antiviral treatment when HCV RNA was undetectable at the end of treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) (NCT00938860)
Timeframe: Week 24

Intervention	Participants (Number)
Neoral	5
Tacrolimus	7

Number of Participants for the End of Treatment Response (ETR)

ETR defined as non-detectable HCV RNA at the completion of AV treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) (NCT00938860)
Timeframe: Week 80

Intervention	Participants (Number)
Neoral	24
Tacrolimus	27

Number of Participants of Early Viral Response (EVR)

EVR defined as non-detectable HCV RNA or a ≥2 logs reduction of HCV RNA at 12 weeks after initiation of antiviral treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) (NCT00938860)
Timeframe: Week 12

Intervention	Participants (Number)
Neoral	28
Tacrolimus	30

Number of Participants of Rapid Viral Response (RVR)

RVR defined as non-detectable HCV RNA 4 weeks after initiation of antiviral treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) (NCT00938860)
Timeframe: Week 4

Intervention	Participants (Number)
Neoral	4
Tacrolimus	5

Number of Participants of True Non-responder Rate

Defined as failure to achieve at least a 2 log reduction of Hepatitis C virus (HCV) RNA. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) (NCT00938860)
Timeframe: Week 80

Intervention	Participants (Number)
Neoral	7
Tacrolimus	5

Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus

The achievement of SVR, defined as HCV RNA below limit of detection at the end of AV treatment, 24 weeks after end of AV treatment (W24 post). A dichotomous variable (SVR achieved: Yes/No) was computed. A patient was classified as non-responder (SVR not achieved) if HCV RNA was detectable at the completion of antiviral treatment, at W24post, or at any time between W24 and completion of antiviral treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) (NCT00938860)
Timeframe: Week 24

Intervention	Participants (Number)
Neoral	12
Tacrolimus	10

Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline)

Ishak-Knodell Score: 0=No fibrosis; 01=Fibrous expansion of some portal areas, with or without short fibrous septa; 02=Fibrous expansion of most portal areas, with or without short fibrous septa; 03=Fibrous expansion of most portal areas, with occasional portal to portal (P-P) bridging; 04=Fibrous expansion of portal areas, with marked bridging (portal to portal (P-P) as well as portal to central (P-C)); 05=Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); 06=Cirrhosis, probable or definite, Participants showing an increase of Ishak Knodell fibrosis score by at least one level (increase of ≥1) (NCT00938860)
Timeframe: Week 80

Intervention	Participants (Number)
Neoral	3
Tacrolimus	5

Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components

Efficacy failure (biopsy proven acute rejection (BPAR), graft loss, or death (NCT00938860)
Timeframe: Week 80

Intervention	Number of events (Number)
	BPAR, graft loss, or death	BPAR	Graft loss or death	Death
Neoral	2	1	1	1
Tacrolimus	1	0	1	1

Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason

Defined as number of patients with dose reduction or discontinuation of AV therapy due to poor tolerability (NCT00938860)
Timeframe: Week 80

Intervention	Participants (Number)
	Neoral Antiviral treatment: Ribavirin	Neoral Antiviral treatment: Peg-IFN	Tacrolimus Antiviral treatment: Ribavirin	Tacrolimus Antiviral treatment: Peg-IFN
Neoral	25	10	0	0
Tacrolimus	0	0	23	11

To Compare 2-year Overall Survival of Patients With Lymphoma Undergoing RIC SCT Between Those Receiving Tacrolimus/Sirolimus/Methotrexate and Those Receiving Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil

(NCT00928018)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Sirolimus-Containing Regimen	70
Sirolimus-Free Regimen	68

To Compare 2-year Progression-free Survival Between the Two Treatment Arms

(NCT00928018)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Sirolimus-Containing Regimen	61
Sirolimus-Free Regimen	58

To Compare the 2-year Cumulative Incidence of Chronic GVHD Between the Two Treatment Arms.

(NCT00928018)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Sirolimus-Containing Regimen	59
Sirolimus-Free Regimen	63

To Compare the 180-day Cumulative Incidence of Grades II-IV and Grades III-IV Acute GVHD Between the Two Treatment Arms

(NCT00928018)
Timeframe: 6 months

Intervention	percentage of participants (Number)
	Grade II-IV aGVHD	Grade III-IV aGVHD
Sirolimus-Containing Regimen	9	3
Sirolimus-Free Regimen	25	4

To Compare the 2-year Cumulative Incidences of Disease Progression and of Non-relapse Mortality Between the Two Treatment Arms

(NCT00928018)
Timeframe: 2 years

Intervention	percentage of participants (Number)
	Cumulative incidence of relapse/progression	Non-relapse mortality
Sirolimus-Containing Regimen	26	14
Sirolimus-Free Regimen	30	12

To Compare the 2-year of Overall Survival, Progression-free Survival, Cumulative Incidences of Progression and Non-relapse Mortality Between the Treatment Arms for Each Histology Studied.

(NCT00928018)
Timeframe: 2 years

,,,

Intervention	percentage of participants (Number)
	Overall Survival	Progression Free Survival	Cumulative Incidence of Progression	Non-relapse mortality
Aggressive Group: Sirolimus-Containing Regimen	54	46	32	21
Aggressive Group: Sirolimus-Free Regimen	76	64	27	9
Indolent Group: Sirolimus-Containing Regimen	82	71	21	8
Indolent Group: Sirolimus-Free Regimen	63	53	33	15

Cumulative Incidence of Relapse With Transplant-related Death as the Competing Risk: Diagnosis Groups Are Compared.

Fine and Gray estimate of cumulative incidence of Relapse, with Death as the competing risk. Estimate is at five years post-transplant. Ninety-five percent confidence interval is by logit transformation of Greenwood variance to keep the interval within the probability space of 0% to 100%. (NCT00534430)
Timeframe: Date of Transplant to Five Years post-Transplant. Estimate is at Five Years post-Transplant.

Intervention	percentage of relapse probability (Number)
AML/1CR	0
AML/R1	0
AML/IF	30
Active ALL	50

Disease-free Survival at Five Years Post-transplant

Kaplan-Meier estimate of an event of relapse or death estimated at five years post-transplant. 95% confidence intervals were calculated from the logit transform of the Greenwood variance. The transformation was necessary to keep the estimate within the probability space of 0 to 100%. (NCT00534430)
Timeframe: Date of transplant to five years post-transplant

Intervention	percentage of survival probability (Number)
Busulfan, FTBI and VP16	40

Overall Survival at 5 Years Post-Transplant.

Kaplan-Meier estimate of an event of death estimated at five years post-transplant. 95% confidence intervals were calculated from the logit transform of the Greenwood variance. The transformation was necessary to keep the estimate within the probability space of 0 to 100%. (NCT00534430)
Timeframe: Date of Transplant to Five Years post-Transplant

Intervention	percentage of survival probability (Number)
Busulfan, FTBI and VP16	40

Overall Survival Comparing Diagnosis Groups

Intervention	percentage of survival probability (Number)
AML/1CR	67
AML/R1	50
AML/IF	30
Active ALL	33

Death Due to NMSC

(NCT00129961)
Timeframe: up to 24 months

Intervention	participants (Number)
Sirolimus (SRL) Based Regimen	0
Calcineurin Inhibitor (CNI) Based Regimen	0

Graft Survival Measured by Graft Loss

Graft loss was defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for >8 consecutive weeks), retransplant, or death. (NCT00129961)
Timeframe: up to 24 months

Intervention	graft loss (Number)
Sirolimus (SRL) Based Regimen	2
Calcineurin Inhibitor (CNI) Based Regimen	1

Nankivell-Calculated Glomerular Filtration Rate (GFR)

GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using Nankivell. A normal GFR is > 90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poor kidney function. A GFR <15 is consistent with kidney failure. (NCT00129961)
Timeframe: At 24 months (week 104)

Intervention	units on scale (Mean)
Sirolimus (SRL) Based Regimen	72.49
Calcineurin Inhibitor (CNI) Based Regimen	68.42

New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year

The number of new biopsy-confirmed NMSC lesions per subject per year was calculated by summarizing the total number of new BCC and SCC lesions reported over the observation period and standardizing it to an annual rate by multiplying by 365 and dividing by days on study. (NCT00129961)
Timeframe: up to 24 months

Intervention	Standardized Yearly Rate of NMSC (Number)
Sirolimus (SRL) Based Regimen	1.31
Calcineurin Inhibitor (CNI) Based Regimen	2.48

Number of Lesion Free Subjects

The overall number of subjects who were lesion free were compared between treatment groups with the Cochran Mantel Haenszel test stratified by baseline NMSC stratum. Within each stratum, the Fisher exact test was used to compare the proportions of lesion free subjects between treatment groups. (NCT00129961)
Timeframe: up to 24 months

Intervention	participants (Number)
Sirolimus (SRL) Based Regimen	17
Calcineurin Inhibitor (CNI) Based Regimen	9

Number of Participants That Died

(NCT00129961)
Timeframe: up to 24 months

Intervention	participants (Number)
Sirolimus (SRL) Based Regimen	1
Calcineurin Inhibitor (CNI) Based Regimen	1

Number of Recurrent NMSC Lesions Per Subject-year

Recurrent NMSC lesions is defined as recurring at the site of a previously treated lesion. (NCT00129961)
Timeframe: up to 24 months

Intervention	lesions per participant year (Number)
Sirolimus (SRL) Based Regimen	0.107
Calcineurin Inhibitor (CNI) Based Regimen	0.134

Number of Subjects Who Discontinue Assigned Therapy

(NCT00129961)
Timeframe: up to 24 months

Intervention	participants (Number)
Sirolimus (SRL) Based Regimen	31
Calcineurin Inhibitor (CNI) Based Regimen	23

Number of Subjects With Biopsy-Confirmed Acute Rejection

(NCT00129961)
Timeframe: up to 24 months

Intervention	subjects (Number)
Sirolimus (SRL) Based Regimen	0
Calcineurin Inhibitor (CNI) Based Regimen	1

Serum Creatinine Level

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatinine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males, however the normal values are age-dependent as elderly patients typically have smaller muscle mass. (NCT00129961)
Timeframe: At 24 months (Week 104)

Intervention	μmol/L (Mean)
Sirolimus (SRL) Based Regimen	139.35
Calcineurin Inhibitor (CNI) Based Regimen	135.23

Spot Urine Protein:Creatinine Ratio

Subjects' urine protein:creatinine ratios were summarized by each scheduled visit, and the nonparametric Wilcoxon rank sum test was used to compare the difference between groups. (NCT00129961)
Timeframe: At 24 months (Week 104)

Intervention	ratio (mg/mg) (Median)
Sirolimus (SRL) Based Regimen	0.14
Calcineurin Inhibitor (CNI) Based Regimen	0.12

Subjects Reporting Incidence of Metastatic Disease Related to NMSC.

The number of subjects with metastatic disease related to NMSC. (NCT00129961)
Timeframe: up to 24 months

Intervention	participants (Number)
Sirolimus (SRL) Based Regimen	1
Calcineurin Inhibitor (CNI) Based Regimen	3

Time to First Biopsy Confirmed New NMSC Lesion.

The time to first biopsy confirmed new NMSC lesion starts at 1 day post randomization to biopsy and/or treatment of newly confirmed NMSC lesion. (NCT00129961)
Timeframe: up to 24 months

Intervention	number of days (Median)
Sirolimus (SRL) Based Regimen	380
Calcineurin Inhibitor (CNI) Based Regimen	163

Grade Distribution of NMSC Lesions

Number of subjects with at least 1 biopsy-confirmed new squamous cell carcinoma (SCC) or basal cell carcinoma (BCC). (NCT00129961)
Timeframe: up to 24 months

Intervention	participants (Number)
	SCC Well differentiated	SCC Moderately differentiated	SCC Poorly differentiated	SCC Invasive	SCC In Situ	SCC Invasive with Perineural Invasion	SCC Invasive without Perineural Invasion	BCC Superficial	BCC Nodular	BCC Infiltrative
Calcineurin Inhibitor (CNI) Based Regimen	17	14	1	24	27	1	24	16	15	6
Sirolimus (SRL) Based Regimen	5	9	1	10	12	2	8	7	11	2

Percentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC)

(NCT00129961)
Timeframe: up to 24 months

Intervention	Percentage of Participants (Number)
	SCC	BCC
Calcineurin Inhibitor (CNI) Based Regimen	69	31
Sirolimus (SRL) Based Regimen	67	33

DEQ-5 Score

Dry Eye Questionnaire-5 (5 questions about dry eye symptoms rated from 0, or never to 5, or constantly) total score of 0-22 with higher scores representing worse symptoms at weeks 4, 8 and 12 from baseline (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	Score on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12
Restasis	14.4	12.2	10.6	9.4
Restasis and Dextenza	14.1	10.6	11.3	10.3
Restasis and Lotemax	14.4	11.0	9.1	10.2

Mean Conjunctival Staining

"The mean conjunctival staining (guided by use of lissamine green) at weeks 4, 8 and 12 from baseline based on the National Eye Institute grading scale.~Conjunctival staining was scored from 0 to 3 on the scale (none, better to heavy, worse) in six regions of the cornea and summed for a total score of 0-18." (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	Score on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12
Restasis	0.4	0.5	0.3	0.7
Restasis and Dextenza	0.5	0.3	0.4	0.8
Restasis and Lotemax	1.5	0.9	0.8	1.0

Mean Ocular Surface Staining From Baseline

"The primary outcome measure was the mean corneal surface staining (guided by use of fluorescein and lissamine green) at weeks 4, 8 and 12 from baseline based on the National Eye Institute grading scale.~Corneal fluorescein staining was scored from 0 to 3 on the scale (none, better to heavy, worse) in five regions of the cornea and summed for a total score of 0-15." (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	Score on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12
Restasis	0.5	1.1	0.3	0.5
Restasis and Dextenza	0.6	0.6	0.5	0.7
Restasis and Lotemax	0.8	0.9	0.0	0.6

Mean Schirmer Tear Test 1 Score

Schirmer Tear Test 1 score, measuring tear production, as measured by a Schirmer's test strip with anesthetic (mm/5min on a strip 0-35mm. 0 mm is worse, >15 indicates normal production) at week 4, 8 and 12 from Baseline. (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	Score on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12
Restasis	11.6	10.1	10.8	9.6
Restasis and Dextenza	14.9	15.4	15.8	12.3
Restasis and Lotemax	10.3	12.9	12.4	10.1

Meibomian Gland Scores

Meibomian gland scoring on a scale of 1-4 (1 represents clear, liquid secretions and 4 is no secretions) in three regions (nasal, central, temporal) and summed for a single score between 3-12 at Week 4, 8 and 12 from baseline (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	Score on a scale (Mean)
	Baseline	Week 4	Week 8	Week 12
Restasis	9.2	7.2	8.2	7.3
Restasis and Dextenza	8.7	7.6	8.3	8.7
Restasis and Lotemax	7.1	6.7	6.3	6.0

Tear Breakup Time (Seconds)

The time it takes (in seconds) for the tear film to break after blinking at Week 4, 8 and 12 from Baseline (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	Seconds (Mean)
	Basline	Week 4	Week 8	Week 12
Restasis	5.7	7.4	7.1	7.3
Restasis and Dextenza	6.6	8.0	7.7	7.7
Restasis and Lotemax	5.4	6.1	6.2	6.1

Tear Osmolarity

"Tear osmolarity as measured by TearLab (275-307 is considered homeostatic range) at Week 4, 8 and 12 from Baseline." (NCT04555694)
Timeframe: Baseline to Week 4, Week 8 and Week 12

Intervention	mOsM/L (Mean)
	Baseline	Week 4	Week 8	Week 12
Restasis	306.9	307.9	295.3	304.6
Restasis and Dextenza	295.5	304.4	303.9	299.5
Restasis and Lotemax	311.3	307.7	300.1	304.4

Average Level of Protenuria at Week 52

Proteinuria is measured as the ratio of albumin/creatinine mg/mmol. Measurements were taken from participants urine samples. (NCT01266148)
Timeframe: 52 weeks

Intervention	mg/mmol (Mean)
Everolimus	7.2
Control	1.2

Measured Glomerular Filtration Rate (mGFR), 12 Months After Heart Transplantation

Measured Glomerular Filtration Rate (mGFR) describes the flow rate of filtered fluid through the kidney. GFR is equal to the clearance rate when any solute is freely filtered and is neither reabsorbed nor secreted by the kidneys. The rate therefore measured is the quantity of the substance in the urine that originated from a calculable volume of blood. Participants' urine was used for this assessment at week 52 after heart transplant. (NCT01266148)
Timeframe: Week 52

Intervention	mGFR ml/min (Mean)
Everolimus	79.8
Control	61.5

Calculated Glomerular Filtration Rate From Pre-Transplantation to Week 52

Calculated Glomerular Filtration Rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end of week 52. (NCT01266148)
Timeframe: Day 1, weeks 7 to 11 and of week 52

Intervention	mGFR mL/min (Mean)
	Day 1 (n= 46, 48)	Weeks 7 to 11 (n=50, 51)	Week 52 (n= 45, 55)
Control	66.1	69.6	69.3
Everolimus	65.4	84.9	104.5

Change in Calculated Glomerular Filtration Rate From Pre-transplantation to Week 52

Change in calculated glomerular filtration rate from pre-transplantation to week 52 was calculated according to the Modification of Diet in Renal Disease (MDRD) method. Measurements were taken prior to transplant (day 1), between weeks 7 to 11 and end week 52. (NCT01266148)
Timeframe: Day 1, weeks 7 to 11(baseline) and of week 52

Intervention	mGFR mL/min (Mean)
	Day 1 (n= 43, 47)	Weeks 7 to 11 (n= 46, 49)	Week 52 (n= 42, 53)
Control	-12.6	-6.8	-8.0
Everolimus	-13.0	7.4	27.8

Change in Quality of Life - Euro Quality of Life 5D (EQ-5D)

Change in Quality of Life was assessed via the EQ-5D questionnaire which consists of: EQ-5D-5L descriptive system and EQ Visual Analogue scale (EQ VAS). The EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems). The patient indicates his/her health state by checking the most appropriate statement. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions are combined in a 5-digit number describing the respondent's health state. The possible score is 1 to 5 where a lower number indicates improvement. The EQ VAS records the patient's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. The score is 0 to 100 where a higher score represents improvement. (NCT01266148)
Timeframe: Pre transplant and 52 weeks

Intervention	Units on a scale (Mean)
	EQ-5D-5L pre- transplant (n=45,49)	EQ-5D-5L at week 52 (n=41,44)	EQ VAS pre- transplant (n=41,48)	EQ VAS at week 52 (n=41,42)
Control	0.5069	0.8367	38.9	79.4
Everolimus	0.5750	0.8329	46.0	80.0

Change in Quality of Life Assessed by SF-36 (Minnesota Living With Heart Failure Questionnaire ([MLHF)]) From Pre-transplant to Week 52 of Treatment

Change in Quality of Life was assessed via the SF-36 (Minnesota Living with Heart Failure questionnaire ([MLHF)]) before transplant surgery and at week 52 of treatment. The SF-36 is a validated, self-administered questionnaire. The questionnaire, which includes 36 questions measures 8 dimensions of health: physical function, role-physical, bodily pain, general health, vitality, social function, role-emotional, and mental health. Scores can be summarized in 2 summary components assessing physical and mental health. Items in each dimension are coded, aggregated, summed, and transformed into a scale ranging from 0 (worse health) to 100 (best health). (NCT01266148)
Timeframe: Pre transplant and 52 weeks

Intervention	Units on a scale (Mean)
	Physical Health pre- transplant	Physical Health at week 52	Mental Health pre- transplant	Mental Health at week 52
Control	32.9	48.8	38.7	53.9
Everolimus	30.8	48.8	46.2	51.5

Lipid Profile at 12 Months

Total Cholesterol, LDL-Chol, HDL-Chol and TG at week 52. Measurements were taken via participants blood samples. (NCT01266148)
Timeframe: 52 weeks

Intervention	mmol/L (Mean)
	Total cholesterol	LDL-C	HDL-C
Control	5.1	2.8	1.6
Everolimus	5.3	2.9	1.6

Number of Rejections Leading to Hemodynamic Compromise

Number of all rejections were recorded through the duration of the study with the intent to identify rejections leading to hemodynamic compromise. (NCT01266148)
Timeframe: 52 weeks

Intervention	rejections (Number)
	Total rejection	Treated rejection	Rejections with hemodynamic compromise
Control	128	17	0
Everolimus	185	43	0

Occurrence of Treatment Failures up to 12 Months After Transplant

Treatment failure was defined as the number of participants who died or lost their graft at any timepoint througout the duration of the study. (NCT01266148)
Timeframe: 52 weeks

Intervention	participants (Number)
	Treatment failure (death)	Graff loss	Total treatment failures (graft loss + death
Control	3	0	3
Everolimus	2	0	2

Progression of Chronic Allograft Vasculopathy (CAV) Based on Incidence of Chronic Allograft Vasculopathy (CAV) From Baseline to Week 52

the progression of chronic allograft vasculopathy (CAV) assessed by intravascular ultrasound (IVUS) examinations, measured the incidence of CAV (in percent of patients) at baseline and at week 52. Incidence of CAV represents percent of patients having a MIT (maximal intima thickness) > 0.5 mm. (NCT01266148)
Timeframe: Baseline and week 52

Intervention	Percentage of patients (Number)
	No CAV at baseline (week 7)	CAV at baseline (week 7)	No CAV at week 52	CAV at week 52
Control	47.9	52.1	35.4	64.6
Everolimus	43.5	56.5	50	50

Progression of Chronic Allograft Vasculopathy (CAV) Based on Maximal Intimal Thickness (MIT) From Baseline to Week 52

The progression of chronic allograft vasculopathy (CAV) was assessed by intravascular ultrasound (IVUS) examinations and measured Maximal Intimal Thickness (MIT)(in mm). A major coronary epicardial artery (preferentially the left-anterior descending coronary artery) was imaged, and the MIT parameters were recorded at baseline and at week 52. (NCT01266148)
Timeframe: Baseline and week 52

Intervention	mm (Mean)
	Baseline (Week 7)	Week 52
Control	0.56	0.65
Everolimus	0.52	0.55

Disease Response at One Year Following Hematopoietic Cell Transplantation

Number of patients with no evidence of disease at one year following transplant (NCT00919503)
Timeframe: 1 year following transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	78
Regimen B (UBCT)	8

Immune Reconstitution Following Hematopoietic Cell Transplantation

Number of patients with immune reconstitution (defined by a normal range CD3) at 1 year post transplant (NCT00919503)
Timeframe: 1 year following transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	39
Regimen B (UBCT)	4

Non-relapse Mortality

Number of patients who experienced non-relapse mortality by 1 year following transplant (NCT00919503)
Timeframe: 1 year following transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	2
Regimen B (UBCT)	5

Number of Participants With Infections

Number of participants with clinically significant infections (bacterial, fungal, viral) requiring treatment within 100 days following transplant (NCT00919503)
Timeframe: 100 days post transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	57
Regimen B (UBCT)	9

Number of Patients With Grade II-IV Acute Graft-versus-host Disease

Number of patients diagnosed with overall grade II-IV acute GVHD by Day 100 post transplant (NCT00919503)
Timeframe: Day 100 post transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	44
Regimen B (UBCT)	8

Number of Patients With of Chronic Graft-versus-host Disease

Number of patients diagnosed with chronic GVHD and requiring systemic immunosuppression within 1 year following transplant (NCT00919503)
Timeframe: 1 year following transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	29
Regimen B (UBCT)	5

Overall Survival

Number of patients alive at 1 year following transplant (NCT00919503)
Timeframe: 1 year following transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	80
Regimen B (UBCT)	9

Preliminary Efficacy

Number of patients engrafted (>5% donor CD3+ peripheral blood chimerisms) at 1 year following transplant (NCT00919503)
Timeframe: 1 year following transplant

Intervention	Participants (Count of Participants)
Regimen A (PBSCT and BMT)	83
Regimen B (UBCT)	10

Donor Chimerism CD3 at 100 Days Post Transplant

Number of patients with peripheral blood donor chimerism for CD3 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant. (NCT00919503)
Timeframe: Day 100 post transplant

Intervention	Participants (Count of Participants)
	Greater than equal to 95%	50 - 94%	5-49%	Less than 5%
Regimen A (PBSCT and BMT)	49	29	6	0
Regimen B (UBCT)	7	2	1	1

Donor Chimerism CD33 at Day 100 Post Transplant

Number of patients with peripheral blood donor chimerism for CD33 less than 5%, 5-49%, 50-94% and greater than or equal to 95% at 100 days post transplant. (NCT00919503)
Timeframe: 100 days post transplant

Intervention	Participants (Count of Participants)
	Greater than equal to 95%	50-94%	5-49%	Less than 5%
Regimen A (PBSCT and BMT)	72	8	4	0
Regimen B (UBCT)	7	2	2	1

Change From Baseline in the Euro Quality of Life 5D

"Change from baseline in Euro Quality of Life-5D from 3 Year Follow-Up to 5 to 7 Year Follow-Up Baseline Visit 1 (ITT Set)~Euro Quality of Life 5D (EQ-5D): is a descriptive system of healthrelated quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) each of which can be assessed as one of three levels of severity (no problems/some or moderate problems/extreme problems). A Visual Analogue Scale (VAS)-scale is also included in the EQ-5D questionnaire.~The EQ-5D index is calculated based on the United Kingdom Time Trade-Off (TTO) N3 value set which converts the five dimensions scores into a single measure with a possible range from -0.163 (worst possible health state) to +1 (perfect health). A positive change from baseline indicates an improvement in Quality of Life." (NCT02864706)
Timeframe: Baseline, 5-7 year visit

Intervention	scores on the scale (Mean)
Everolimus	0.2323
Control	0.2982

Change From Baseline in Visual Analog Scale (VAS)

"Change in visual analog scale (VAS) from baseline to the 5 to 7 Year follow up visit.~0 is no pain; and 10 is the worst possible pain" (NCT02864706)
Timeframe: baseline, at the 5-7 year visit

Intervention	mm (Mean)
Everolimus	35.6
Control	34.0

Measured Glomerular Filtration Rate (mGFR)

Renal function as assessed by measured Glomerular Filtration Rate (mGFR) (Cr-EDTA or iohexol clearance). Baseline Visit 1 and Patient 4252 excluded from the intent treat analysis set. (NCT02864706)
Timeframe: at the 5-7 year follow-up visit

Intervention	mL/min/1.73m2 (Least Squares Mean)
Everolimus	74.7
Control	62.4

Percent of Participants With Incidence of Coronary Allograft Vasculopathy (CAV)

"Cardiac Allograft Vasculopathy (CAV) was defined as mean maximal intimal thickness (MIT)~≥0.5 mm, measured for the entire matched pullback recording by intravascular ultrasound (IVUS). The incidence of CAV at 5-7 years was compared between groups using the Cochran-Mantel-Haenszel test with stratification according to baseline distribution of CAV incidence." (NCT02864706)
Timeframe: at the 5-7 year follow-up

Intervention	percent of participants (Number)
Everolimus	53
Control	74

Progression of Cardiac Allograft Vasculopathy (CAV) Recorded by Intravascular Ultrasound (IVUS)

Intervention	mm (Mean)
Everolimus	0.13
Control	0.23

Myocardial Structure and Function

Myocardial structure and function by echocardiography assessment measured by ventricular end systolic diameter. (NCT02864706)
Timeframe: within 5-7 years

Intervention	cm (Mean)
	LVESD (left ventricular end systolic diameter)	LVEDD (left ventricular end diastolic diameter)
Control	3.1	4.9
Everolimus	3.1	4.7

Number of Participants With Beck Depression Inventory (BDI)

Beck Depression Inventory (BDI) Score has the following categories of depression. Normal, Mild, Moderate Severe and Missing. (NCT02864706)
Timeframe: at the 5-7 year visit

Intervention	Participants (Count of Participants)
	Normal	Mild	Moderate	Severe	Missing
Control	13	4	5	0	5
Everolimus	15	6	2	1	3

Quality of Life by SF-36 Change From Pre-transplantation to 5-7 Year Follow-up

This Quality of life Short Form Survey with 36 items (Minnesota Living with Heart Failure Questionnaire)was administered to patients pre-transplantation and after transplantation at the 5-7 year visit. This data represents the change. The survey consist of scores on a scale. Each form is scaled from 0 t 100. 0 = maximum disability and 100 equals no disability. (NCT02864706)
Timeframe: at the 5-7 year visit

Intervention	scores on a scale (Mean)
	Physical Health Summary	Mental Health Summary	Physical Functioning	Role Physical	Bodily Pain	General Health	Vitality	Social Functioning	Role Emotional	Mental Health
Control	13.2	15.3	40.8	55.1	7.2	23.4	28.9	43.9	42.8	14.4
Everolimus	16.8	10.4	36.7	50.2	10.3	25.7	30.0	39.9	23.8	8.6

Duration of First Hematologic Response

"Duration of first hematologic response is the time from the date of the start of first response to the date of first relapse. Relapse is defined as no longer meeting definition of PR or CR. Kaplan-Meier method was used for the analysis. If no relapse occurred, the participant was censored at the date of last contact. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR was defined as any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement:~ANC >500/μL~Platelet count >20 000/μL~Reticulocyte count >60 000/μL.~CR was defined as all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements:~ANC >1 000/μL~Platelet count >100 000/μL~Hemoglobin >10 g/L" (NCT02998645)
Timeframe: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

Intervention	Days (Median)
Eltrombopag + Cyclosporine	351.0

Overall Hematologic Response Rate by 3 Months

"Overall hematologic response rate by 3 months was defined as the percentage of participants with CR or PR any time on or before 3 months.~PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement:~ANC >500/μL~Platelet count >20 000/μL~Reticulocyte count >60 000/μL~CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements:~ANC > 1 000/μL~Platelet count >100 000/μL~Hemoglobin >10 g/L" (NCT02998645)
Timeframe: Up to 3 months

Intervention	Percentage of participants (Number)
Eltrombopag + Cyclosporine	40.7

Overall Hematologic Response Rate by 6 Months

"Overall hematologic response rate by 6 months was defined as the percentage of participants with complete response (CR) or partial response (PR) any time on or before 6 months.~PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement:~Absolute neutrophil count (ANC) >500/μL~Platelet count >20 000/μL~Reticulocyte count >60 000/μL~CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements:~ANC > 1 000/μL~Platelet count >100 000/μL~Hemoglobin >10 g/L" (NCT02998645)
Timeframe: Up to 6 months

Intervention	Percentage of participants (Number)
Eltrombopag + Cyclosporine	46.3

Percentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia

"The percentage of participants with evolution to myelodysplasia, PNH and acute leukemia occurring at any time during the study. Clonal evolution to myelodysplasia was defined as a new marrow cytogenic abnormality with or without characteristic dysplastic marrow findings. Clonal evolution to leukemia was defined as greater than 20% peripheral blood and/or marrow blasts. Clonal evolution to paroxysmal nocturnal hemoglobinuria (PNH) was defined as a clone at baseline < 10% that rose to greater than 50% on study.~Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24" (NCT02998645)
Timeframe: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

Intervention	Percentage of participants (Number)
Eltrombopag + Cyclosporine	0

Change From Baseline in Scores of FACT - Thrombocytopenia 18 (FACT-TH18) Patient Reported Outcome

"The FACT-TH18 is comprised of FACT-G and a thrombocytopenia specific questionnaire. FACT-G consists of 27-items divided into 4 domains (physical, social, emotional and functional well-being). FACT-TH18 has 18 additional items which asks the patient to rate degree of thrombocytopenia. All items of the FACT-TH18 use a 5 point scale ranging from 0 to 4, with 0 = not at all and 4 = very much. Total FACT-TH18 score is the sum of physical, social, emotional and functional well-being scores, and thrombocytopenia subscale. Score ranges from 0 to 180, with higher scores indicating better QoL. A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24." (NCT02998645)
Timeframe: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)

Intervention	Score on a scale (Median)
	Week 2 (Treatment period 1) - Responders	Week 4 (Treatment period 1) - Responders	Week 6 (Treatment period 1) - Responders	Week 8 (Treatment period 1) - Responders	Week 10 (Treatment period 1) - Responders	Week 12 (Treatment period 1) - Responders	Week 14 (Treatment period 1) - Responders	Week 16 (Treatment period 1) - Responders	Week 18 (Treatment period 1) - Responders	Week 20 (Treatment period 1) - Responders	Week 22 (Treatment period 1) - Responders	Week 24 (Treatment period 1) - Responders	Week 26 (Treatment period 1) - Responders	End of treatment period 1 - Responders	Week 38 (Treatment period 2)- Responders	Week 53 (Treatment period 2)- Responders	Month 24 (Treatment period 2)- Responders	End of treatment period 2 - Responders	Week 2 (Treatment period 1) - Non-Responders	Week 4 (Treatment period 1) - Non-Responders	Week 6 (Treatment period 1) - Non-Responders	Week 8 (Treatment period 1) - Non-Responders	Week 10 (Treatment period 1) - Non-Responders	Week 12 (Treatment period 1) - Non-Responders	Week 14 (Treatment period 1) - Non-Responders	Week 16 (Treatment period 1) - Non-Responders	Week 18 (Treatment period 1) - Non-Responders	Week 20 (Treatment period 1) - Non-Responders	Week 22 (Treatment period 1) - Non-Responders	Week 24 (Treatment period 1) - Non-Responders	Week 26 (Treatment period 1) - Non-Responders	End of treatment period 1 - Non-Responders
Eltrombopag + Cyclosporine	2.3	-1.5	8.4	9.0	3.4	9.3	6.4	7.8	13.9	11.8	13.5	14.5	18.2	13.9	21.7	22.0	35.7	6.9	0.6	2.1	-1.5	2.0	5.2	1.8	2.8	2.1	0.5	2.4	-1.3	0.7	-1.4	-1.4

Change From Baseline in Scores of Functional Assessment of Cancer Therapy - General (FACT-G) Patient Reported Outcome

"The FACT-G consists of 27-items divided into 4 domains (physical well-being, social well-being, emotional and functional well-being). All items of the FACT-G use a 5 point scale ranging from 0 to 4 with a 0 rating being not at all and a 4 rating being very much. Total FACT-G score is the sum of physical well-being score, social well-being score, emotional well-being score and functional well-being score. Score ranges from 0 to 108, with higher scores indicating better quality of life (QoL). A positive change from baseline indicates improvement in the QoL.~Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders.~Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24." (NCT02998645)
Timeframe: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)

Intervention	Score on a scale (Median)
	Week 2 (Treatment period 1) - Responders	Week 4 (Treatment period 1) - Responders	Week 6 (Treatment period 1) - Responders	Week 8 (Treatment period 1) - Responders	Week 10 (Treatment period 1) - Responders	Week 12 (Treatment period 1) - Responders	Week 14 (Treatment period 1) - Responders	Week 16 (Treatment period 1) - Responders	Week 18 (Treatment period 1) - Responders	Week 20 (Treatment period 1) - Responders	Week 22 (Treatment period 1) - Responders	Week 24 (Treatment period 1) - Responders	Week 26 (Treatment period 1) - Responders	End of treatment period 1 - Responders	Week 38 (Treatment period 2)- Responders	Week 53 (Treatment period 2)- Responders	Month 24 (Treatment period 2)- Responders	End of treatment period 2 - Responders	Week 2 (Treatment period 1) - Non-Responders	Week 4 (Treatment period 1) - Non-Responders	Week 6 (Treatment period 1) - Non-Responders	Week 8 (Treatment period 1) - Non-Responders	Week 10 (Treatment period 1) - Non-Responders	Week 12 (Treatment period 1) - Non-Responders	Week 14 (Treatment period 1) - Non-Responders	Week 16 (Treatment period 1) - Non-Responders	Week 18 (Treatment period 1) - Non-Responders	Week 20 (Treatment period 1) - Non-Responders	Week 22 (Treatment period 1) - Non-Responders	Week 24 (Treatment period 1) - Non-Responders	Week 26 (Treatment period 1) - Non-Responders	End of treatment period 1 - Non-Responders
Eltrombopag + Cyclosporine	-2.0	-3.0	-0.3	0.0	-1.3	0.8	1.0	-2.0	3.0	-1.0	1.0	1.8	1.0	-1.0	5.7	4.0	22.0	13.5	-0.3	-1.0	-3.6	1.5	-0.9	-0.3	-0.3	0.3	-2.6	-1.5	-1.0	2.7	-2.7	-2.0

Change From Baseline in Scores of Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT- Fatigue) Patient Reported Outcome

"The FACIT- Fatigue is a 13-item fatigue subscale that asks the patient to rate their degree of tiredness, weakness and fatigue. All items of the FACIT-Fatigue use a 5-point scale ranging from 0 to 4 with a 0 rating being not at all and a 4 rating being very much. Total score ranges from 0 to 52. Negatively worded items were reverse scored before summing so that higher total scores indicate less fatigue. A positive change from baseline indicates improvement.~Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders.~Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24." (NCT02998645)
Timeframe: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)

Intervention	Score on a scale (Median)
	Week 2 (Treatment period 1) - Responders	Week 4 (Treatment period 1) - Responders	Week 6 (Treatment period 1) - Responders	Week 8 (Treatment period 1) - Responders	Week 10 (Treatment period 1) - Responders	Week 12 (Treatment period 1) - Responders	Week 14 (Treatment period 1) - Responders	Week 16 (Treatment period 1) - Responders	Week 18 (Treatment period 1) - Responders	Week 20 (Treatment period 1) - Responders	Week 22 (Treatment period 1) - Responders	Week 24 (Treatment period 1) - Responders	Week 26 (Treatment period 1) - Responders	End of treatment period 1 - Responders	Week 38 (Treatment period 2)- Responders	Week 53 (Treatment period 2)- Responders	Month 24 (Treatment period 2)- Responders	End of treatment period 2 - Responders	Week 2 (Treatment period 1) - Non-Responders	Week 4 (Treatment period 1) - Non-Responders	Week 6 (Treatment period 1) - Non-Responders	Week 8 (Treatment period 1) - Non-Responders	Week 10 (Treatment period 1) - Non-Responders	Week 12 (Treatment period 1) - Non-Responders	Week 14 (Treatment period 1) - Non-Responders	Week 16 (Treatment period 1) - Non-Responders	Week 18 (Treatment period 1) - Non-Responders	Week 20 (Treatment period 1) - Non-Responders	Week 22 (Treatment period 1) - Non-Responders	Week 24 (Treatment period 1) - Non-Responders	Week 26 (Treatment period 1) - Non-Responders	End of treatment period 1 - Non-Responders
Eltrombopag + Cyclosporine	3.0	2.0	4.0	6.0	4.5	5.5	6.5	6.0	7.0	6.0	6.0	6.0	7.0	6.0	6.0	8.0	9.0	11.5	-0.5	-2.0	0.0	-1.0	0.5	-1.0	-1.5	-0.5	-6.0	-6.0	-4.0	-7.0	-8.0	-4.0

Longest Duration of Transfusion Independence (Platelet or RBC)

"Longest duration of transfusion independence (platelet or RBC) by 6 months and by 24 months (responders only). Transfusion independence was defined as no transfusions required in at least a 28-day period for platelet transfusion and at least 56-day period for RBC transfusion. The duration of the longest interval with transfusion independence was summarized using Kaplan-Meier analysis.~Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders.~Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24" (NCT02998645)
Timeframe: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

Intervention	Days (Median)
	Day 1 to 6 months- Responders	Day 1 to 24 months- Responders	Day 1 to 6 months- Non-Responders
Eltrombopag + Cyclosporine	NA	NA	87.0

Overall Hematologic Response Rate at 12 and 24 Months

"Overall hematologic response rate at 12 and 24 months was defined as the percentage of participants with CR or PR at 12 and 24 months respectively.~PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement:~ANC>500/μL~Platelet count >20 000/μL~Reticulocyte count >60 000/μL~CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements:~ANC > 1 000/μL~Platelet count >100 000/μL~Hemoglobin >10 g/L" (NCT02998645)
Timeframe: 12 and 24 months

Intervention	Percentage of participants (Number)
	At 12 months	At 24 months
Eltrombopag + Cyclosporine	18.5	18.5

Percentage of Participants Who Were Platelet Transfusion Independent

"Percentage of participants who were platelet transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no platelet transfusion for at least 28 days.~Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders.~Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24." (NCT02998645)
Timeframe: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

Intervention	Participants (Count of Participants)
	Day 1 to 6 months- Responders	Day 1 to 24 months- Responders	Day 1 to 6 months- Non-responders
Eltrombopag + Cyclosporine	25	25	13

Percentage of Participants Who Were Red Blood Cells (RBC) Transfusion Independent

"Percentage of participants who were RBC transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no RBC transfusion for at least 56 days.~Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders.~Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24." (NCT02998645)
Timeframe: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

Intervention	Participants (Count of Participants)
	Day 1 to 6 months- Responders	Day 1 to 24 months- Responders	Day 1 to 6 months- Non-Responders
Eltrombopag + Cyclosporine	17	20	5

Pharmacokinetic Parameter- AUCtau of Eltrombopag When Combined With Cyclosporine

AUCtau is the area under the curve calculated to the end of the dosing interval (tau). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day. (NCT02998645)
Timeframe: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

Intervention	hourmicrogram/milliliter (hug/mL) (Geometric Mean)
	East/Southeast Asian ethnicity	Non-East/Southeast Asian ethnicity
Eltrombopag + Cyclosporine	686	727

Pharmacokinetic Parameter- CLss/F of Eltrombopag When Combined With Cyclosporine

CLss/F is the apparent systemic (or total body) clearance at steady state from plasma. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day. (NCT02998645)
Timeframe: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

Intervention	milliliter/hour (mL/h) (Geometric Mean)
	East/Southeast Asian ethnicity	Non-East/Southeast Asian ethnicity
Eltrombopag + Cyclosporine	146	206

Pharmacokinetic Parameter- Cmax of Eltrombopag When Combined With Cyclosporine

Cmax is the observed maximum plasma concentration following administration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 microgram/milliliter (ug/mL). Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day. (NCT02998645)
Timeframe: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose.

Intervention	microgram/milliliter (ug/mL) (Geometric Mean)
	East/Southeast Asian ethnicity	Non-East/Southeast Asian ethnicity
Eltrombopag + Cyclosporine	29.1	38.7

Pharmacokinetic Parameter- Ctrough of Eltrombopag When Combined With Cyclosporine

Ctrough is the pre-dose plasma concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day. (NCT02998645)
Timeframe: Week 2 at pre-dose

Intervention	microgram/milliliter (ug/mL) (Geometric Mean)
	East/Southeast Asian ethnicity	Non-East/Southeast Asian ethnicity
Eltrombopag + Cyclosporine	19.3	27.2

Pharmacokinetic Parameter- Tmax of Eltrombopag When Combined With Cyclosporine

Tmax is the time to reach peak or maximum concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day. (NCT02998645)
Timeframe: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

Intervention	Hours (Median)
	East/Southeast Asian ethnicity	Non-East/Southeast Asian ethnicity
Eltrombopag + Cyclosporine	5.79	3.75

Pharmacokinetic Parameter-AUClast of Eltrombopag When Combined With Cyclosporine

AUClast is the area under the curve calculated to the last quantifiable concentration point (Tlast). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day. (NCT02998645)
Timeframe: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose

Intervention	hourmicrogram/milliliter (hug/mL) (Geometric Mean)
	East/Southeast Asian ethnicity	Non-East/Southeast Asian ethnicity
Eltrombopag + Cyclosporine	583	702

Relapse Rate by 6 and 24 Months

"Relapse was defined as no longer meeting the definition of PR (and not CR). Relapse rate by 6 months and 24 was defined as the percentage of responders by 6 months who relapsed prior to 6 months or prior to 24 months respectively. Responders by 6 months were participants who achieved CR or PR any time on or before 6 months. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.~PR: any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement:~ANC>500/μL~Platelet count>20 000/μL~Reticulocyte count>60 000/μL.~CR: all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements:~ANC>1 000/μL~Platelet count>100 000/μL~Hemoglobin>10 g/L" (NCT02998645)
Timeframe: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)

Intervention	Percentage of participants (Number)
	By 6 months	By 24 months
Eltrombopag + Cyclosporine	32.0	44.0

Chronic GVHD Requiring Systemic Immunosuppressive Treatment

Chronic GVHD will be defined by National Institutes of Health (NIH) criteria and requiring systemic treatment. A reduction in the cumulative incidence of GVHD from ~35% to ~15% at 1 year would represent a reasonable goal. A sample size of 42 patients provides 90% power to observe such a difference with one-side 5% type-1 error. (NCT01427881)
Timeframe: At 1 year after transplantation

Intervention	percent of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	16

Disease-free Survival

Disease-free survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	73.8

Donor Engraftment

Donor engraftment is defined as the count (percent) of patients with full donor chimerism. Full donor chimerism is defined as at least 95% donor CD3 cells in peripheral blood. (NCT01427881)
Timeframe: At day 28

Intervention	Participants (Count of Participants)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	6

Graft Failure

Descriptive statistics will be used to assess the incidence of primary graft failure and secondary graft failure. Primary graft failure is defined as failure to achieve a sustained neutrophil count of >= 500/uL by >= 28 days post-transplant. Secondary graft failure is defined as the decline in neutrophil count to < 500/uL after achieving engraftment which is unrelated to infection or drug effect and is unresponsive to stimulation by growth factors. (NCT01427881)
Timeframe: By greater than or equal to 28 days post-transplant

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	2

Non-relapse Mortality

Defined as death in the absence of recurrent or progressive malignancy after HCT. Non-relapse morality will be assessed with the use of cumulative incidence plots. This secondary endpoint will be characterized and presented as a cumulative incidence. (NCT01427881)
Timeframe: At 2 years

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	14

Overall Survival

Overall survival will be evaluated as Kaplan-Meier estimates. (NCT01427881)
Timeframe: At 1 year post-transplant

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	75.6

Persistent or Recurrent Malignancy After HCT

Recurrent or progressive malignancy will be assessed with the use of cumulative incidence plots. Recurrent malignancy will be defined by hematologic criteria. Recurrent malignancy will also be defined as any unplanned medical intervention designed to prevent progression of malignant disease in patients who have molecular, cytogenetic or flow-cytometric evidence of malignant cells after transplantation. (NCT01427881)
Timeframe: At 2 years

Intervention	percentage of patients (Number)
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	17

Grades II-IV and III-IV Acute GVHD

Grades II-IV and III-IV GVHD will be assessed with the use of cumulative incidence plots. (NCT01427881)
Timeframe: Through day +100 post-transplant

Intervention	percentage of patients (Number)
	Grades II-IV GVHD	Grades III-IV GVHD
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	77	0

Hematologic Recovery

Descriptive statistics will be used to assess the median days of neutrophil and platelet recovery. The day of neutrophil recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the absolute neutrophil count is > 500/uL. The day of platelet recovery is defined as the first day of three consecutive lab values on different days, after the conditioning regimen-induced nadir of blood counts, that the platelet count is >= 20,000/uL without platelet transfusion support in the seven days prior. (NCT01427881)
Timeframe: Up to day +100

Intervention	days (Median)
	Neutrophil Engraftment	Platelet Engraftment
Treatment (TBI, PBSCT, and Cyclophosphamide GVHD Prophylaxis)	19	14

Progression of Dry Eye Severity

Dry eye is one of the major symptoms of ocular GVHD in bone-marrow transplant recipients, worsening of dry eye symptoms may be indicative of worsening ocular GVHD conditions. (NCT01695668)
Timeframe: 1 year

Intervention	patients with increased dry eye severity (Number)
Lotemax	15
Restasis	12

Number of Patients Whose Death Was Related to the Transplant

In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation. (NCT00383448)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treated Patients	2

Number of Patients With Acute Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host. Acute GVHD can occur once the donor's cells have engrafted in the transplant recipient. The symptoms typically appear within weeks after transplant. (NCT00383448)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treated Patients	3

Number of Patients With Chronic Graft Versus Host Disease (GVHD)

Graft-Versus-Host Disease is a severe complication created by infusion of donor cells into a foreign host. Chronic GVHD can appear at any time after allogeneic transplant or several years after transplant. (NCT00383448)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treated Patients	2

Number of Patients With Donor Cell Engraftment

Donor Cell Engraftment is defined as the process of transplanted stem cells reproducing new cells. (NCT00383448)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treated Patients	26

Clinical Significant Infection, Requiring Treatment, Within 100 Days Post Transplant

Number of patients who experienced a clinical significant infection, requiring treatment, within 100 days post transplant. (NCT00553098)
Timeframe: 100 days

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	21

Disease Response by 1 Year Post Transplant

Number of patients at 1 year with disease response (defined as no clinical evidence of active disease and/or sufficient level of donor chimerisms to prevent disease recurrence) (NCT00553098)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	15

Greater Than 50% CD19+ Donor Chimerisms at 1 Year Post Transplant

Number of Patients Who Achieve Greater Than 50% CD19+ Donor Chimerisms at 1 Year Post Transplant (NCT00553098)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	16

Greater Than 50% CD33+ Donor Chimerisms at 1 Year Post Transplant

Number of patients who achieve greater than 50% CD33+ donor chimerisms at 1 year post transplant. (NCT00553098)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	8

Immune Reconstitution by 1 Year Post Transplant

Number of patients with normal range CD3 at 1 year post transplant (NCT00553098)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	7

Number of Patients Diagnosed With Acute GVHD

Number of patients diagnosed with acute GVHD by Day 100 post transplant (NCT00553098)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	18

Number of Patients Diagnosed With Chronic GVHD

Number of patients diagnosed with chronic GVHD within 1 year post transplant (NCT00553098)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	8

Number of Patients Diagnosed With Overall Grade 1 or Grade 2 Acute GVHD

Number of patients diagnosed with overall grade I or grade II acute GVHD by Day 100 post transplant (NCT00553098)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	12

Number of Patients Diagnosed With Overall Grade III or Grade IV Acute GVHD

Number of patients diagnosed with overall Grade III or Grade IV Acute GVHD by Day 100 post transplant (NCT00553098)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	6

Number of Patients Who Achieve Greater Than 50% Donor T-cell Chimerism

The study will be considered a success and the protocol worthy of further study if there is sufficient evidence that this rate is greater than the 50% rate observed in the most recently transplanted patients with nonmalignant disorders. Analyses will be carried out separately for the alemtuzumab recipients and the TBI recipients. We will be 80% confidence of success if a one-sided 80% confidence interval for the proportion of patients with successful chimerism exceeds 50%. Cumulative incidence will be used to evaluate the probability of chimerism. (NCT00553098)
Timeframe: At 1 year post transplant

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	13

Overall Survival

Number of patients alive at 1 year (NCT00553098)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Low Dose Radiation)	19

Number of Patients Who Engrafted

Continued engraftment will be defined as the detection of donor T-cells (CD3+) as a proportion of the total T-cell of greater than 5%. (NCT00397813)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Arm A - Dose Level 1	35
Arm A - Dose Level 2	0
Arm A - Dose Level 3	0
Arm B - Dose Level 1	12
Arm B - Dose Level 2	4
Arm B - Dose Level 3	24

Number of Patients Who Had Infections

Number of patients who experienced bacterial, fungal, or viral infections. (NCT00397813)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Arm A - Dose Level 1	24
Arm A - Dose Level 2	0
Arm A - Dose Level 3	0
Arm B - Dose Level 1	12
Arm B - Dose Level 2	4
Arm B - Dose Level 3	24

Number of Patients With HCT Failure.

HCT failure will be defined as graft rejection (defined as < 5% donor T-cell chimerism) or disease progression within 200 days of transplant. (NCT00397813)
Timeframe: 200 days

Intervention	Participants (Count of Participants)
Arm A - Dose Level 1	4
Arm A - Dose Level 2	0
Arm A - Dose Level 3	0
Arm B - Dose Level 1	5
Arm B - Dose Level 2	3
Arm B - Dose Level 3	2

Number of Patients With Progression-free Survival

Evidence of disease progression will be an indication for therapeutic intervention. Defined as any evidence by morphologic or flow cytometric evaluation of the bone marrow aspirate of an incremental increase in 5% blasts in MDS/CMML; defined as any evidence of blastic transformation in agnogenic myeloid metaplasia/atypical CML; and defined as progressive erythrocytosis, thrombocytosis, or evidence of leukemic transformation in polycythemia vera and essential thrombocythemia. (NCT00397813)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Arm A - Dose Level 1	24
Arm A - Dose Level 2	0
Arm A - Dose Level 3	0
Arm B - Dose Level 1	1
Arm B - Dose Level 2	2
Arm B - Dose Level 3	11

Number of Patients With Relapse/Progression

Intervention	Participants (Count of Participants)
Arm A - Dose Level 1	6
Arm A - Dose Level 2	0
Arm A - Dose Level 3	0
Arm B - Dose Level 1	6
Arm B - Dose Level 2	3
Arm B - Dose Level 3	6

Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo)

Data analysis will be performed on an intention-to-treat basis. Logistic regression will be used to estimate the odds ratio and 95% confidence interval of the two treatment groups with the adjustment of baseline covariates. Outcome comparisons for categorical/dichotomous variables will be assessed by 2 test or Fisher's exact test where expected cell frequencies were <5; continuous variables will be compared by X/2 test or by Mann-Whitney U test where the data are strongly skewed. (NCT00755040)
Timeframe: Up to 2 years after transplantation

Intervention	participants (Number)
Arm I	9
Arm II	8

Number of Patients Surviving Overall

Number of subjects surviving two years post autologous transplant. (NCT00793572)
Timeframe: At 2 years after the autograft

Intervention	Participants (Count of Participants)
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	21

Number of Patients Surviving Progression-free

"Number of subjects surviving without progressive disease post-transplant.~Progressive disease criteria:~Greater than 25% increase in serum (absolute increase must be ≥0.5 g/dL) or urine (absolute increase must be ≥200 mg/24h) M proteins compared to best response status after autologous transplant.~Appearance of new lytic bone lesions or plasmacytomas." (NCT00793572)
Timeframe: At 2 years after the autograft

Intervention	Participants (Count of Participants)
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	14

Number of Patients With Chronic GVHD

Number of subjects with classic chronic or chronic extensive GVHD post allogeneic transplant. (NCT00793572)
Timeframe: 1 year post allo

Intervention	Participants (Count of Participants)
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	10

Number of Patients With Grade II-IV Acute GVHD

"Number of patients who developed acute GVHD post allogeneic transplant.~aGVHD Stages~Skin:~- a maculopapular eruption involving < 25% BSA~- a maculopapular eruption involving 25 - 50% BSA~- generalized erythroderma~- generalized erythroderma w/ bullous formation and often w/ desquamation~Liver:~- bilirubin 2.0 - 3.0 mg/100 mL~- bilirubin 3 - 5.9 mg/100 mL~- bilirubin 6 - 14.9 mg/100 mL~- bilirubin > 15 mg/100 mL~Gut:~Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.~aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death" (NCT00793572)
Timeframe: 100 days post allo transplant

Intervention	Participants (Count of Participants)
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	14

Number of Patients With Toxicities Related to Bortezomib Maintenance Therapy

Number of subjects with toxicities related to bortezomib maintenance therapy post-transplant. (NCT00793572)
Timeframe: Up to 100 days after the autograft or allograft

Intervention	Participants (Count of Participants)
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	1

Number of Patients With Non-relapse Mortality

Number of subjects with non-relapse mortalities post allogeneic transplant. (NCT00793572)
Timeframe: 200 and 365 days after allo

Intervention	Participants (Count of Participants)
	200 days post allo	1 Year post allo
Tandem Auto-/Nonmyeloablative Allo-HCT and Maintenance Therapy	1	1

Overall Response

Complete response (CR) was defined as normalization of peripheral blood and bone marrow with <5% blasts, a peripheral absolute neutrophil count (ANC) >/= 1 * 10^9/l, hemoglobin >/= 100g/l, and a platelet count >/= * 10^9/l, Partial Response (PR) was defined as transfusion independence with a peripheral blood ANC >=/ 0.05 * 10^9/l, a platelet count >/= 20 * 10^9/l, and a hemoglobin >/= 40 g/l. Hematologic improvement was defined as a clinically relevant increase in hemoglobin, platelets or absolute neutrophil count. (NCT00806598)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Assessed first at 3 months on study, continuing monthly up to 3 years.

Intervention	participants (Number)
	Complete Response	Partial Response	Hematological Improvement
Thymoglobulin + Cyclosporin	8	8	4

Effects of Cyclosporin A on Respiratory Function - Change in Exercise Capacity by a Shuttle Walk Distance Measured in Feet

Measurement of exercise capacity by a shuttle walk distance measured in feet at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). The purpose of the shuttle walk test is to see how far and fast a patient can walk (without stopping for a rest) by following a series of time signals.Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	feet (Median)
Cyclosporine	230
Placebo	220

Effects of Cyclosporin A on Respiratory Function - Change in the Percentage of Post Predicted Value of Forced Expiratory Volume in 1 Second

Outcome measured the change in the percentage of post predicted value of forced expiratory volume in 1 second at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	Percentage of post predicted value (Median)
Cyclosporine	-0.02
Placebo	-0.02

Effects of Cyclosporin A on Respiratory Function - Change in the Percentage of Post Predicted Value of Forced Vital Capacity

Outcome measured the change in the percentage of post predicted value of forced vital capacity at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	Percentage of post predicted value (Median)
Cyclosporine	-0.01
Placebo	0.07

Effects of Cyclosporin A on Symptoms - Change in Scores on a Shortness of Breath Scale

Scores on a shortness of breath scale (University of California at San Diego Dyspnea scale): shortness of breath questionnaire scores are summed as a total score ranging from 0-120 with higher scores indicating more severe breathlessness. Assessments were performed at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	units on a scale (Median)
Cyclosporine	39
Placebo	39

Peripheral Blood T Cell Biomarkers Over 16 Week Treatment Interval - Change in the Percentage of Cluster of Differentiation 4 (CD4)

Outcome measured the change in the percentage of cluster of differentiation 4 (CD4) at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	% of cells expressing biomarkers (Median)
Cyclosporine	-3.1
Placebo	3.6

Peripheral Blood T Cell Biomarkers Over 16 Week Treatment Interval - Change in the Percentage of Cluster of Differentiation 8 and Cluster of Differentiation 28

Outcome measured the change in the percentage of peripheral blood T cell biomarkers - cluster of differentiation 8 (CD8), cluster of differentiation 28 (CD28) at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	% of cells expressing biomarkers (Median)
Cyclosporine	-0.78
Placebo	-1.6

Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 4+ Interleukin-2

Outcome measured the change in the percentage of peripheral blood T cell biomarkers - cluster of differentiation 4+ interleukin-2 at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	% of cells expressing biomarkers (Median)
Cyclosporine	-1.7
Placebo	4.7

Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 8 and Major Histocompatibility Complex II

Outcome measured the change in the percentage of peripheral blood cells expressing biomarker - cluster of differentiation 8 (CD8), major histocompatibility complex (MHC) II at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	% of cells expressing biomarkers (Median)
Cyclosporine	-2.4
Placebo	0.5

Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 8+ Interferon Gamma

Outcome measured the change in the percentage of peripheral blood T cell biomarkers - CD8+interferon gamma at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	% of cells expressing biomarkers (Median)
Cyclosporine	-4.1
Placebo	4.4

Peripheral Blood T Cell Biomarkers Over Treatment Interval - Change in the Percentage of Cluster of Differentiation 8+ Tumor Necrosis Factor

Outcome measured the change in the percentage of peripheral blood T cell biomarkers - CD8+ tumor necrosis factor at midpoint assessment (Week 8) and at the conclusion of treatment (Week 16). Values expressed as median (full range). (NCT00974142)
Timeframe: at Week 8 and Week 16

Intervention	% of cells expressing biomarkers (Median)
Cyclosporine	0.0
Placebo	2.3

Pharmacokinetic - Pharmacodynamic Relationship of Oral Cyclosporine and Biomarkers of an Adaptive Immune Response - Cyclosporine Blood Levels

Cyclosporine blood levels on therapy over 16 week treatment interval were measured at Weeks 2, 4, 6, 8, 10, 12 & 16. The median for each participant was found and then the overall median was determined. Values expressed as median (full range). (NCT00974142)
Timeframe: 16 weeks

Intervention	ng/mL (Median)
Cyclosporine	147

Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients - Number of Patients That Developed Infection Requiring Systemic Antibiotic Therapy

Clinical diagnosis of infection which requires systemic antibiotic therapy during the 16 week study interval at Week 2, 4, 6, 8, 10, 12 and 16. Outcome measured the number of subjects who developed an infection requiring systemic antibiotic therapy during the study treatment interval. (NCT00974142)
Timeframe: 16 weeks

Intervention	Participants (Count of Participants)
Cyclosporine	1
Placebo	1

Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients - Number of Patients That Developed Renal Insufficiency

Development of renal insufficiency defined as > 30% elevation in serum creatinine above baseline which required dose modification of the cyclosporine over 16 week treatment interval at Week 2, 4, 6, 8, 10, 12 and 16. Outcome measured the number of subjects who developed renal insufficiency during the study treatment interval. (NCT00974142)
Timeframe: 16 weeks

Intervention	Participants (Count of Participants)
Cyclosporine	4
Placebo	1

Safety Profile of Oral Cyclosporin A Immunotherapy in Advanced Stage Chronic Obstructive Pulmonary Disease Patients- Nephrotoxicity - Measured by Serum Creatinine

Measurement of nephrotoxicity by monitoring serum creatinine over 16 week treatment interval. Mean serum creatinine values were assessed at Week 2, 4, 6, 8, 10, 12 and 16. The mean values of all measurements for each participant were calculated and then the mean across participants was calculated. Values expressed as mean ± SD. (NCT00974142)
Timeframe: 16 weeks

Intervention	mg / dL (Mean)
Cyclosporine	0.94
Placebo	0.88

Disease-free Survival at 3 Years

"Defined as time from date of transplant to relapse, graft rejection or graft failure, or death.~Primary non-engraftment is diagnosed when the participants fails to achieve an ANC >/= 500/ul at any time in the first 28 days post-transplant.~For participants with MDS or AML, relapse will be analyzed as to type and genetic origin of the MDS/leukemic cells. These will be defined by an increasing number of blasts in the marrow over 5% by the presence of circulating peripheral blasts, or by the presence of blasts in any extramedullary site. Cytogenetic analysis of the marrow and/or peripheral blood will also be obtained for the diagnosis of relapse." (NCT00987480)
Timeframe: 3 years

Intervention	percentage of participants (Number)
Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected	77.8

Overall Survival at 3 Years

Overall Survival is defined as time from date of transplant to event (death from any cause) or last follow-up. (NCT00987480)
Timeframe: 3 years

Intervention	percentage of participants (Number)
Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected	80

The Incidence of Acute GvHD

(NCT00987480)
Timeframe: 100 days

Intervention	percentage of participants (Number)
Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected	6.7

The Incidence of Early Transplant Related Mortality

(NCT00987480)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Chemotherapy-based Cytoreductive Regimen Plus a CD34+ Selected	0

Time to Cure

Time to cure is defined as the number of days after laser in situ keratomileusis (LASIK) surgery that the patient has corneal sensitivity (the capability of the cornea to respond to stimulation) ≥ 50 millimeters in all 9 regions of both eyes after LASIK surgery. A patient is considered cured at the first of 2 consecutive visits meeting these criteria. The Inter-Quartile Range presented is actually the 25th Quantile and the 75th Quantile obtained from the Kaplan-Meier Model. (NCT00991458)
Timeframe: 6 Months

Intervention	Days (Median)
Cyclosporine 0.010% Eye Drops	189.0
Cyclosporine 0.005% Eye Drops	194.0
Placebo (Vehicle for Cyclosporine)	189.0

Time to Worst Outcome Post-LASIK Surgery in Tear Film Assessment

The time to the worst outcome post-LASIK surgery in tear film stability is assessed using the Ocular Scatter Index (OSI). The OSI is calculated by an instrument which takes images of the eye over time. OSI values ≥3.0 indicate lower tear film quality resulting in a loss of visual acuity. The worst outcome post-LASIK surgery is defined as the shortest time to OSI ≥3 across both eyes and post-LASIK surgery months 3 to 6. (NCT00991458)
Timeframe: Months 3 to 6

Intervention	Seconds (Mean)
Cyclosporine 0.010% Eye Drops	11.2
Cyclosporine 0.005% Eye Drops	12.0
Placebo (Vehicle for Cyclosporine)	11.5

Worst Outcome Post-LASIK Surgery in Reading Speed Assessment

Reading speed is determined using the MNREAD™ Reading Card. The MNREAD™ reading card is designed to simulate a normal every day reading scenario using binocular vision (both eyes at the same time). The MNREAD™ Reading speed is calculated as (60) X [Number of words on card - (reading errors)]/ (number of seconds until the card is read). The worst outcome is defined as the smallest number of words per minute across post-LASIK surgery months 3 to 6. (NCT00991458)
Timeframe: Months 3 to 6

Intervention	Words Per Minute (WPM) (Mean)
Cyclosporine 0.010% Eye Drops	173.0
Cyclosporine 0.005% Eye Drops	173.7
Placebo (Vehicle for Cyclosporine)	167.4

Percentage of Patients With Cumulative Poor Vision

Cumulative Poor Vision is determined binocularly per patient (using both eyes at the same time) from the Poor Vision question on the Ocular Surface Disease Index (OSDI) questionnaire. Severity of poor vision is graded on a 5-point scale (0 = none of the time, 1 = some of the time, 2 = half of the time, 3 = most of the time, 4 = all of the time). Cumulative poor vision is defined as at least one poor vision score ≥ 1 beginning at Month 3 post-LASIK. (NCT00991458)
Timeframe: Month 3, Month 4, Month 5, Month 6

Intervention	Percentage of Patients (Number)
	Month 3	Month 4	Month 5	Month 6
Cyclosporine 0.005% Eye Drops	18.7	22.5	26.3	26.8
Cyclosporine 0.010% Eye Drops	15.0	17.9	21.7	23.7
Placebo (Vehicle for Cyclosporine)	19.0	23.9	24.9	26.3

Donor Cell Chimerism Following Transplant

Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. (NCT01043640)
Timeframe: 6 months

Intervention	percentage of donor cells (Mean)
Transplant Patients	94

Donor Cell Chimerism Following Transplant

Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. (NCT01043640)
Timeframe: Day 100

Intervention	percentage of donor cells (Mean)
Transplant Patients	90

Donor Cell Chimerism Following Transplant

Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. (NCT01043640)
Timeframe: Day 28

Intervention	percentage of donor cells (Mean)
Transplant Patients	95

Donor Cell Chimerism Following Transplant

Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. (NCT01043640)
Timeframe: Day 42

Intervention	percentage of donor cells (Mean)
Transplant Patients	93

Donor Cell Chimerism Following Transplant

Donor cell chimerism is defined as the percentage of bone marrow and blood cells in the recipient that are of donor origin. (NCT01043640)
Timeframe: One year

Intervention	percentage of donor cells (Mean)
Transplant Patients	99

Number of Patients Who Died Peri-Transplant

Peri-transplant is defined as within 100 days of transplant. (NCT01043640)
Timeframe: By Day 100 Post Transplant

Intervention	Participants (Count of Participants)
Transplant Patients	2

Number of Patients With Donor Derived Engraftment

Donor derived engraftment is defined as 80 percent or greater donor cells in the recipient's bone marrow and blood cells. (NCT01043640)
Timeframe: Day 100 Post Transplant

Intervention	Participants (Count of Participants)
Transplant Patients	42

Number of Patients With Grade 0 Graft-Versus-Host Disease (GVHD)

"GVHD grading is performed using modified Glucksberg criteria and is as follows:~grade 0: absence of any skin, liver and/or gastrointestinal (GI) involvement grade 1: skin stage 1 or 2 only grade 2: skin stage 3 or liver stage 1 or lower GI stage 1 or upper GI involvement grade 3: skin stage 0 - 3 plus liver stage 2-4 or lower GI stage 2-3 grade 4: skin stage 4 or lower GI stage 4" (NCT01043640)
Timeframe: Day 100 Post Transplant

Intervention	Participants (Count of Participants)
Transplant Patients	32

Number of Patients With Grade 1 Graft-Versus-Host Disease (GVHD)

Intervention	Participants (Count of Participants)
Transplant Patients	2

Number of Patients With Grade 2 Graft-Versus-Host Disease (GVHD)

Intervention	Participants (Count of Participants)
Transplant Patients	5

Number of Patients With Grade 3 Graft-Versus-Host Disease (GVHD)

Intervention	Participants (Count of Participants)
Transplant Patients	2

Number of Patients With Grade 4 Graft-Versus-Host Disease (GVHD)

Intervention	Participants (Count of Participants)
Transplant Patients	5

Number of Participants With Progressive Disease at One Year

(NCT01105650)
Timeframe: 1 Year

Intervention	Participants (Count of Participants)
Arm 1: CsA	2
Arm 2: CsA/Methylprednisolone (10mg)/6 Doses of Interleukin-2	1
Arm 3: CsA/Methylprednisolone (1mg)/6 Doses of Interleukin-2	5

Overall Survival

Number of participants alive at 1 year. (NCT01105650)
Timeframe: 1 Year

Intervention	participants (Number)
Arm 1: CsA	0
Arm 2: CsA/Methylprednisolone (10mg)/6 Doses of Interleukin-2	1
Arm 3: CsA/Methylprednisolone (1mg)/6 Doses of Interleukin-2	3

Response Rate

Response includes Complete Response (CR), Partial Response (PR), and Stable Disease (SD) as defined by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v.1.1) for target lesions and assessed by CT or MRI. Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease. (NCT01105650)
Timeframe: Month 3

Intervention	participants (Number)
Arm 1: CsA	1
Arm 2: CsA/Methylprednisolone (10mg)/6 Doses of Interleukin-2	2
Arm 3: CsA/Methylprednisolone (1mg)/6 Doses of Interleukin-2	4

Time to Disease Progression

Time from study entry until progressive disease or data collection cutoff. (NCT01105650)
Timeframe: 1 Year

Intervention	days (Median)
Arm 1: CsA	52
Arm 2: CsA/Methylprednisolone (10mg)/6 Doses of Interleukin-2	98
Arm 3: CsA/Methylprednisolone (1mg)/6 Doses of Interleukin-2	100

Aliskiren Plasma Concentrations

"Maximum plasma concentration; area under the concentration-time curve, half-life, oral clearance~The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any PK (e.g.(AUCs) for this study." (NCT01235910)
Timeframe: 2 weeks

Intervention	ng*h/ml/mg (Number)
Aliskiren	NA

Blood Pressure

The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any blood pressure for this study. (NCT01235910)
Timeframe: 2 weeks

Intervention	mmHg (Number)
Aliskiren	NA

Dose-normalized Cyclosporine Area Under the Plasma Concentration-time Curve (AUC)

The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any cyclosporine PK (e.g.(AUCs) for this study. (NCT01235910)
Timeframe: 7 days, 14 days, 30 days (End of Study)

Intervention	ng*h/ml/mg (Number)
Aliskiren	NA

Geometric Mean Ratio of Area Under Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) for Verinurad

Evaluation of a single dose of cyclosporine or rifampicin on the PK of verinurad. Verinurad AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
Period 1: Verinurad + Allopurinol	90.25
Period 2: Verinurad + Allopurinol + Cyclosporine	215.1
Period 3: Verinurad + Allopurinol + Rifampicin	138.0

Geometric Mean Ratio of Area Under the Plasma Concentration-time Curve From Zero to Time of Last Quantifiable Concentration (AUClast) for Verinurad

Evaluation of a single dose of cyclosporine or rifampicin on the PK of verinurad. Verinurad AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
Period 1: Verinurad + Allopurinol	79.67
Period 2: Verinurad + Allopurinol + Cyclosporine	208.6
Period 3: Verinurad + Allopurinol + Rifampicin	133.4

Geometric Mean Ratio of Maximum Observed Plasma Peak Concentration (Cmax) for Verinurad

Evaluation of a single dose of cyclosporine or rifampicin on the PK of verinurad. Verinurad Cmax ratio of geometric mean of test treatment (verinurad+allopurinol with [cyclosporine or rifampicin], relative to reference treatment (verinurad+allopurinol alone) in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	ng/mL (Geometric Mean)
Period 1: Verinurad + Allopurinol	13.30
Period 2: Verinurad + Allopurinol + Cyclosporine	33.96
Period 3: Verinurad + Allopurinol + Rifampicin	26.09

Apparent Total Body Clearance of Drug From Plasma After Extravascular Administration (CL/F) for Verinurad and Allopurinol

CL/F for verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Liter/Hours (Mean)
	Verinurad	Allopurinol
Period 1: Verinurad + Allopurinol	92.30	77.12
Period 2: Verinurad + Allopurinol + Cyclosporine	36.32	78.09
Period 3: Verinurad + Allopurinol + Rifampicin	55.99	73.29

Area Under Plasma Concentration-time Curve From Zero to 24 Hours Post-dose AUC(0-24) of Verinurad, M1, M8, Allopurinol and Oxypurinol

AUC(0-24) of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
	Verinurad	M1	M8	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	62.02	86.23	79.80	3982	100700
Period 2: Verinurad + Allopurinol + Cyclosporine	192.2	314.4	38.02	3914	95080
Period 3: Verinurad + Allopurinol + Rifampicin	118.4	242.9	48.81	4163	98460

Geometric Mean Ratio of AUCinf for Allopurinol and Oxypurinol

Evaluation of a single dose of cyclosporine or rifampicin on the PK of allopurinol and oxypurinol. AUCinf ratio of geometric means of test geometric means of test treatment, relative to reference treatment in each treatment period is reported. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	3982	196500
Period 2: Verinurad + Allopurinol + Cyclosporine	3914	181900
Period 3: Verinurad + Allopurinol + Rifampicin	4163	195500

Geometric Mean Ratio of AUCinf for Verinurad Metabolites: M1 and M8

Evaluation of a single dose of cyclosporine or rifampicin on the PK of verinurad metabolites M1 and M8. AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
	M1	M8
Period 1: Verinurad + Allopurinol	119.5	110.3
Period 2: Verinurad + Allopurinol + Cyclosporine	348.7	60.98
Period 3: Verinurad + Allopurinol + Rifampicin	264.9	77.35

Geometric Mean Ratio of AUClast for Allopurinol and Oxypurinol

Evaluation of a single dose of cyclosporine or rifampicin on the PK of allopurinol and oxypurinol. AUClast ratio of geometric means of test geometric means of test treatment, relative to reference treatment in each treatment period is reported. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	3889	183600
Period 2: Verinurad + Allopurinol + Cyclosporine	3821	170600
Period 3: Verinurad + Allopurinol + Rifampicin	4080	182100

Geometric Mean Ratio of AUClast for Verinurad Metabolites: M1 and M8

Evaluation of a single dose of cyclosporine or rifampicin on the PK of verinurad metabolites M1 and M8. AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period is reported. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	h*ng/mL (Geometric Mean)
	M1	M8
Period 1: Verinurad + Allopurinol	111.6	101.8
Period 2: Verinurad + Allopurinol + Cyclosporine	341.9	51.95
Period 3: Verinurad + Allopurinol + Rifampicin	260.6	73.23

Geometric Mean Ratio of Cmax for Allopurinol and Oxypurinol

Evaluation of a single dose of cyclosporine or rifampicin on the PK of allopurinol and oxypurinol. Cmax ratio of geometric means of test geometric means of test treatment, relative to reference treatment in each treatment period is reported. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	ng/mL (Geometric Mean)
	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	1947	6064
Period 2: Verinurad + Allopurinol + Cyclosporine	1457	5876
Period 3: Verinurad + Allopurinol + Rifampicin	1597	6051

Geometric Mean Ratio of Cmax for Verinurad Metabolites: M1 and M8

Evaluation of a single dose of cyclosporine or rifampicin on the PK of verinurad metabolites M1 and M8. Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	ng/mL (Geometric Mean)
	M1	M8
Period 1: Verinurad + Allopurinol	17.24	15.57
Period 2: Verinurad + Allopurinol + Cyclosporine	47.14	3.839
Period 3: Verinurad + Allopurinol + Rifampicin	48.70	6.002

Half-life Associated With Terminal Slope (λz) of a Semi-logarithmic Concentration Time Curve (t½λz) of Verinurad, M1, M8, Allopurinol and Oxypurinol

t½λz of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Hours (Mean)
	Verinurad	M1	M8	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	20.31	18.04	18.25	1.210	23.19
Period 2: Verinurad + Allopurinol + Cyclosporine	14.73	13.05	21.90	1.261	22.36
Period 3: Verinurad + Allopurinol + Rifampicin	15.03	12.52	14.89	1.170	23.76

Mean Residence Time of the Unchanged Drug in the Systemic Circulation (MRTinf) for Verinurad and Allopurinol

MRTinf for verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Hours (Geometric Mean)
	Verinurad	Allopurinol
Period 1: Verinurad + Allopurinol	21.28	2.316
Period 2: Verinurad + Allopurinol + Cyclosporine	11.05	2.713
Period 3: Verinurad + Allopurinol + Rifampicin	12.60	2.496

Metabolite:Parent (MP) AUCinf Ratios for M1 and M8: Verinurad

Metabolite:parent (MP) AUCinf ratios for M1 and M8: verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Ratio (Geometric Mean)
	M1:verinurad	M8:verinurad
Period 1: Verinurad + Allopurinol	1.324	1.222
Period 2: Verinurad + Allopurinol + Cyclosporine	1.621	0.2834
Period 3: Verinurad + Allopurinol + Rifampicin	1.919	0.5604

Metabolite:Parent (MP) AUClast Ratios for M1 and M8: Verinurad

Metabolite:parent (MP) AUClast ratios for M1 and M8: verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Ratio (Geometric Mean)
	M1:verinurad	M8:verinurad
Period 1: Verinurad + Allopurinol	1.400	1.278
Period 2: Verinurad + Allopurinol + Cyclosporine	1.639	0.2491
Period 3: Verinurad + Allopurinol + Rifampicin	1.955	0.5491

Metabolite:Parent (MP) Cmax Ratios for M1 and M8: Verinurad

Metabolite:parent (MP) Cmax ratios for M1 and M8: verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Ratio (Geometric Mean)
	M1: verinurad	M8: verinurad
Period 1: Verinurad + Allopurinol	1.296	1.171
Period 2: Verinurad + Allopurinol + Cyclosporine	1.388	0.1130
Period 3: Verinurad + Allopurinol + Rifampicin	1.866	0.2300

Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

Assessment the safety and tolerability of verinurad and allopurinol in combination with cyclosporine or rifampicin (NCT04532918)
Timeframe: From screening (Day -28 to -2) until Follow-up or Early Termination (7-14 days after last verinurad dose)

Intervention	Participants (Count of Participants)
	Any AE	Any AE with outcome = death	Any SAE	Any AE leading to discontinuation of study drug	Any AE leading to withdrawal from study
Period 1: Verinurad + Allopurinol	2	0	0	0	0
Period 2: Verinurad + Allopurinol + Cyclosporine	10	0	0	1	1
Period 3: Verinurad + Allopurinol + Rifampicin	3	0	1	0	0

Terminal Elimination Rate Constant (λz) of Verinurad, M1, M8, Allopurinol and Oxypurinol

λz of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	1/Hours (Geometric Mean)
	Verinurad	M1	M8	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	0.03842	0.04293	0.04163	0.5770	0.03086
Period 2: Verinurad + Allopurinol + Cyclosporine	0.06101	0.06518	0.04497	0.5616	0.03169
Period 3: Verinurad + Allopurinol + Rifampicin	0.05557	0.06417	0.05133	0.5950	0.02990

Time to Reach Peak or Maximum Plasma Concentration (Tmax) for Verinurad, M1, M8, Allopurinol and Oxypurinol

tmax of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Hours (Median)
	Verinurad	M1	M8	Allopurinol	Oxypurinol
Period 1: Verinurad + Allopurinol	4.03	4.02	4.52	0.50	4.00
Period 2: Verinurad + Allopurinol + Cyclosporine	5.00	5.98	8.00	1.00	4.00
Period 3: Verinurad + Allopurinol + Rifampicin	4.00	4.00	5.00	1.00	3.00

Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Based on the Terminal Phase) (Vz/F) of Verinurad and Allopurinol

Vz/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Liters (Mean)
	Verinurad	Allopurinol
Period 1: Verinurad + Allopurinol	2455	133.5
Period 2: Verinurad + Allopurinol + Cyclosporine	721.8	137.9
Period 3: Verinurad + Allopurinol + Rifampicin	1153	122.6

Volume of Distribution (Apparent) at Steady State Following Extravascular Administration (Vss/F) of Verinurad and Allopurinol

Vss/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period. (NCT04532918)
Timeframe: Days 1 to 5 (pre-dose and post-dose)

Intervention	Liters (Geometric Mean)
	Verinurad	Allopurinol
Period 1: Verinurad + Allopurinol	1768	174.5
Period 2: Verinurad + Allopurinol + Cyclosporine	385.2	208.0
Period 3: Verinurad + Allopurinol + Rifampicin	685.0	179.9

Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death

Participants with adverse events (serious plus non-serious), serious adverse events and death were reported. (NCT00956293)
Timeframe: Months 6, 12, 24, 36, 48 and 60

Intervention	Participants (Number)
	Adverse events (serious and non-serious)	Serious adverse events	Deaths
Control Group	21	11	0
Everolimus Group	50	28	0

Percentage of Participants Discontinuing Immunosuppressants (MMF) for More Than 14 Consecutive Days or 30 Cumulative Days Within 24 Weeks of Transplantation

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
MMF + CsA	13.89

Percentage of Participants Lost To Follow Up Within 24 Weeks of Transplantation

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
MMF + CsA	0.0

Percentage of Participants Requiring Use of Additional Immunosuppressants Not Specified in the Protocol Within 24 Weeks of Transplantation

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
MMF + CsA	0.0

Percentage of Participants With Graft Loss Within 24 Weeks of Transplantation

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
MMF + CsA	0.0

Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and During Treatment

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
	Serum creatinine	BUN
MMF + CsA	13.89	72.22

Percentage of Participants With Abnormal Serum Creatinine and BUN Values at Baseline and Normal Values During Treatment

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
	Serum creatinine	BUN
MMF + CsA	16.67	2.78

Percentage of Participants With Biopsy Proven Acute Rejection (BPAR) by Week

Percentage of participants with BPAR of greater than or equal to (≥) International Society of Heart and Lung Transplant (ISHLT) Grade III. The ISHLT graded symptoms on a scale of Grade 0 through VI. Grade 0 equals (=) no rejection. Grade IA = regional (perivascular or interstitial) infiltration and no necrosis, and grade IB = dissemination but little infiltration and no necrosis. Grade II = 1 focus of invasive infiltration with or without (+/-) associated cardiomyocyte necrosis. Grade IIIA = 2 or more foci of invasive infiltration +/- associated cardiomyocyte necrosis, and grade IIIB = diffuse inflammatory pathological changes associated with cardiomyocyte necrosis. Grade IV = diffuse, infiltrative multi-foci +/- edema; +/- hemorrhage; and +/-vasculitis. (NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
	Day 1	Week 1	Week 2	Week 4	Week 8	Week 12	Week 16	Week 20	Week 24
MMF + CsA	0.0	0.0	2.78	2.78	2.78	2.78	2.78	2.78	2.78

Percentage of Participants With Normal Serum Creatinine and Blood Urea Nitrogen (BUN) Values At Baseline (BL) And During Treatment

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
	Serum creatinine	BUN
MMF + CsA	47.22	8.33

Percentage of Participants With Normal Serum Creatinine and BUN Values at Baseline and Abnormal Values During Treatment

(NCT02091414)
Timeframe: Day 1, Weeks 1, 2, 4, 8, 12, 16, 20 and 24

Intervention	percentage of participants (Number)
	Serum creatinine	BUN
MMF + CsA	22.22	16.67

100-day Overall Survival

Proportion of patients who survived 100 days or more after enrolled on the study (NCT00057954)
Timeframe: Assessed at least twice a week for the first 60 days and weekly until day 100.

Intervention	Proportion of participants (Number)
Transplant	0.83

Progression-free Survival

Progression-free survival was defined as time from enrollment to disease progression or death from any cause, whichever occurred first. Patients who did not have progression-free survival events were censored at last date of disease assessment. (NCT00057954)
Timeframe: Assessed day 100 post transplant and every 3 months during year 1, every 6 months during years 2-3, then every 12 months during years 4-5 or through diagnosis of disease progression

Intervention	days (Median)
Transplant	104

Proportion of Participants With Successful Engraftment

(NCT00057954)
Timeframe: Assessed daily during inpatient stay

Intervention	Proportion of participants (Number)
Transplant	1

Measured Glomerular Filtration Rate

Progression of renal function measured by mean mGFR at 36 months after renal TX. The mGFR was measured using Iohexol or Cr-EDTA clearance according to local practice. (NCT00634920)
Timeframe: Month 36

Intervention	mL/min/1.73m^2 (Mean)
Everolimus (CNI-free)	48.2
Control (CsA)	46.1

Measured Glomerular Filtration Rate

To compare the efficacy between treatment regimens by assessing the difference in renal function evaluated by mean measured glomerular filtration rate (mGFR) 12 months after renal transplantation (TX). The mGFR was measured using Iohexol or Cr-EDTA clearance according to local practice. (NCT00634920)
Timeframe: Month 12

Intervention	mL/min/1.73m^2 (Mean)
Everolimus (CNI-free)	51.5
Control (CsA)	47.8

Time to First Malignancy

This is the time to first diagnosed malignancy. Malignancies (skin- or solid cancer) were listed whether they reoccurred in situ, were metastatic or de novo. This is shown as mean time. (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Months (Mean)
Everolimus (CNI-free)	35.5
Control (CsA)	35.1

Time to Treatment Failure

Treatment failure was defined as graft loss or death.Time to treatment failure is shown as mean time to treatment failure. (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Days (Mean)
Everolimus (CNI-free)	972.7
Control (CsA)	959.5

Calculated Glomerular Filtration Rate

The GFR was calculated according to the Modification of Diet in Renal Disease Study Group (MDRD) method, the Cockcroft-Gault method, and the Nankivell formula. cGFR was calculated from blood samples collected at predefined time points. (NCT00634920)
Timeframe: Months 12, 36

Intervention	mL/min/1.73m^2 (Mean)
	MDRD M12	MDRD M36	Cockcroft-Gault M12	Cockcroft-Gault M36	Nankivel M12	Nankivel M36
Control (CsA)	60.1	57.4	45.6	42.1	61.8	58.9
Everolimus (CNI-free)	65.0	59.4	45.4	43.1	66.3	61.8

Health-related Quality of Life (QoL) as Measured by EuroQoL EQ-5D

Health-related QoL was assessed using the EQ-5D questionnaire. The EQ-5D self-report questionnaire consists of the EQ-5D descriptive system that measures health-related quality of life on 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which can take one of three responses. The responses record three levels of severity (no problems/moderate problems/severe problems) within a particular EQ-5D dimension. Scores are transformed to a range of 0-1, in which higher scores reflect better health status. (NCT00634920)
Timeframe: Before randomization, Months 12, 36

Intervention	scores on a scale (Mean)
	Before Randomization (Week 7)	Month 12	Month 36
Control (CsA)	0.8693	0.8470	0.8422
Everolimus (CNI-free)	0.8430	0.8155	0.8285

Lipid Profile for Apolipoprotein

Blood lipid levels of patients in both groups for Apolipoprotein (Apo) A1 and B. (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	g/L (Mean)
	Month 12: Apolipoprotein A1	Month 24: Apolipoprotein A1	Month 36: Apolipoprotein A1	Month 12: Apolipoprotein B	Month 24: Apolipoprotein B (	Month 36: Apolipoprotein B
Control (CsA)	1.46	1.36	1.56	0.923	1.058	0.934
Everolimus (CNI-free)	1.59	1.55	1.70	0.935	1.178	0.984

Lipid Profile for HDL-C, LDL-C,Total Cholesterol, and Triglycerides

Blood lipid levels of patients in both groups: HDL-C, LDL-C,Total cholesterol, and triglycerides. (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	mmol/L (Mean)
	Month 12: HDL Cholesterol	Month 24: HDL Cholesterol	Month 36: HDL Cholesterol	Month 12: LDL Cholesterol	Month 24: LDL Cholesterol	Month 36: LDL Cholesterol	Month 12: Total Cholesterol	Month 24: Total Cholesterol	Month 36: Total Cholesterol	Month 12: Triglycerides	Month 24: Triglycerides	Month 36: Triglycerides
Control (CsA)	1.419	1.409	1.529	3.130	2.925	2.822	5.318	5.112	4.830	1.868	1.757	1.580
Everolimus (CNI-free)	1.486	1.477	1.495	3.569	3.381	3.206	6.091	5.823	5.595	2.461	2.288	2.164

Number of Antihypertensive Drugs Taken

(NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Number of antihypertensive dugs (Mean)
	Month 12	Month 24	Month 36
Control (CsA)	2.5	2.4	2.2
Everolimus (CNI-free)	2.5	2.5	2.0

Number of Lipid-lowering Drugs Taken

(NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Number of lipid-lowering drugs (Mean)
	Month 12	Month 24	Month 36
Control (CsA)	0.8	0.9	0.8
Everolimus (CNI-free)	0.9	1.0	0.9

Percentage of Participants on Antihypertensive Drugs

(NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Percentage of participants (Number)
	Month 12: No antihypertensive drugs	Month 12: Has antihypertensive drugs	Month 24: No antihypertensive drugs	Month 24: Has antihypertensive drugs	Month 36: No antihypertensive drugs	Month 36: Has antihypertensive drugs
Control (CsA)	3.3	96.7	5.3	94.7	12.8	87.2
Everolimus (CNI-free)	9.2	90.8	4.2	95.8	15.6	84.4

Percentage of Participants on Lipid-lowering Drugs

(NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Percentage of participants (Number)
	Month 12	Month 24	Month 36
Control (CsA)	60.0	65.0	63.0
Everolimus (CNI-free)	75.0	78.0	73.0

Percentage of Participants Who Developed CAN (Chronic Allograft Nephropathy)

Assessed by protocol biopsies findings (Banff 1997 lesion scores and morphometry of the interstitial space) (NCT00634920)
Timeframe: Month 12, Month 36

Intervention	Percentage of participants (Number)
	Month 12	Month 36
Control (CsA)	1.0	64.0
Everolimus (CNI-free)	1.0	59.0

Percentage of Participants Who Had Donor Specific Antibodies (DSA)

Venous blood was drawn for donor specific (DSA) measurements prior to transplantation and at the final visit (36 months). The blood sample was first screened for the presence of PRA i.e. donor specific Immunoglobulin-G antibodies against specific HLA antigens. If PRA antibodies were detected, the blood sample was tested for specific DSAs on single antigen Luminex beads (coated with single HLA class I or II molecules). In this way, the specificity of these antibodies could be determined. (NCT00634920)
Timeframe: Month 36

Intervention	Percentage of participants (Number)
	ND (not done)	Negative	Positive
Control (CsA)	9.0	70.0	21.0
Everolimus (CNI-free)	7.0	78.0	15.0

Percentage of Participants With Biopsy Proven Acute Rejection (BPAR)

A BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III (Banff 97 classification). Biopsy graded IA: Significant interstitial infiltration (> 25% of parenchyma) and foci of moderate tubulitis (> 4 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IB: Significant interstitial infiltration (> 25% of parenchyma) and foci of severe tubulitis (> 10 mononuclear cells/tubular cross section or group of 10 tubular cells). Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising > 25% of the lumenal area. (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Percentage of participants (Number)
	Month 12: lA	Month 12: lB	Month 12: llA	Month 12: llB	Month 24: lA	Month 24: lB	Month 36: lA	Month 36: lB
Control (CsA)	4.4	0.0	2.2	1.1	4.4	3.3	1.1	0.0
Everolimus (CNI-free)	19.6	10.9	2.2	2.2	5.4	1.1	2.2	1.1

Percentage of Participants With Graft Loss or Death

The allograft was presumed to be lost on the day the patient started dialysis and was not able to subsequently be removed from dialysis. If the patient underwent a graft nephrectomy, the day of nephrectomy was the day of graft loss. Graft loss was considered an SAE (serious adverse event). (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Percentage of participants (Number)
	Month 12: Event First Year	Month 12: No Event First Year	Month 24: Event Second Year	Month 24: No Event Second Year	Month 36: Event Third Year	Month 36: No Event Third Year
Control (CsA)	0.0	100.0	1.1	98.9	2.2	97.8
Everolimus (CNI-free)	0.0	100.0	1.1	98.9	0.0	100.0

Percentage of Participants With Treatment Failures

Treatment failure was defined as graft loss or death. (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	Percentage of participants (Number)
	Month 12: No Failure	Month 12: Failure	Month 24: No Failure	Month 24: Failure	Month 36: No Failure	Month 36: Failure
Control (CsA)	100.0	0.0	98.8	1.2	96.7	3.3
Everolimus (CNI-free)	100.0	0.0	98.8	1.2	98.8	1.2

Progression of Measured Glomerular Filtration Rate

Change in renal progression measured by mean mGFR from week 7 to Month 36 (NCT00634920)
Timeframe: Week 7, Week 52, Month 36

Intervention	mL/min/1.73m^2 (Mean)
	Week 7	Week 52	Change from week 7 to Week 52	Month 36	Change from week 7 to Month 36
Control (CsA)	47.8	47.8	0.0	46.1	-1.7
Everolimus (CNI-free)	46.3	51.5	5.6	48.2	1.3

Proteinuria (Measured as Urine Albumin/Creatinine Ratio (mg/mmol))

"Proteinuria is when a large amount of protein, that should remain circulating in a person's blood, is spilled into their urine and eliminated from the body." (NCT00634920)
Timeframe: Months 12, 24, 36

Intervention	mg/mmol (Mean)
	Month 12	Month 24	Month 36
Control (CsA)	11.27	24.55	80.73
Everolimus (CNI-free)	17.31	62.83	78.78

Number of Participants With Adverse Events

Here are the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00363779)
Timeframe: 3 months

Intervention	Participants (Number)
LGL Patients Administered Cyclosporine	5

Survival at 1 Year After Transplantation

The number of patients survival status 1 year after transplantation (NCT00387959)
Timeframe: 1 Year after transplant

Intervention	participants (Number)
	Alive at 1 Year Post Transplant	Died Prior to 1 Year Post Transplant
Unrelated Donor Umbilical Cord Transplant	10	6

Development of GVHD Within 1 Year of BMT

GVHD is assessed by physical exam, bloodwork and biopsy. (NCT00427661)
Timeframe: 1 year

Intervention	participants (Number)
AHSC in Severe SCD	2

Engraftment at 1 Year Post BMT.

Measurement of total PBMC chimerism (NCT00427661)
Timeframe: 1 year

Intervention	participants (Number)
AHSC in Severe SCD	6

Incidence of Grade 2-4 Acute GVHD.

(NCT00427661)
Timeframe: 100 days

Intervention	participants with grade 2-4 AGVHD (Number)
Experimental	1

Incidence and Severity of Ocular Adverse Event

Incidence and severity of ocular adverse events, as identified by eye examination and visual acuity testing. (NCT00553735)
Timeframe: 18 Months

Intervention	participants (Number)
Cyclosporine A 0.05%	2
Artificial Tear	2

Change in Schirmer's Scores

The Schirmer score is a score on a scale - minimum is 0 and the highest is 35 mm. Above 15 mm is normal and less than 5 is severe dry eyes. A positive score means there was an improvement, 0 will be no change from baseline and a negative one that there was a decreased in tears. This change was calculated by subtracting the baseline value from the 3 months value (3 mo Schirmer's - baseline Schirmer's = amount of change). (NCT00565669)
Timeframe: baseline to 3 months

Intervention	score on a scale (Mean)
Blink Tears	-.30
Systane	-1.06

Complete Donor Hematopoietic Cell Chimerism

Complete donor hematopoietic cell chimerism was evaluated in transplant recipients. Complete donor chimerism will be assessed as the presence of > 95% donor T-cells (CD3+) in the blood. The outcome is reported as the percentage of participants that achieve complete donor chimerism, a number without dispersion. (NCT00568633)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Allo-HSCT + TLI + ATG	56

Disease-free Survival (DFS)

Disease-free survival is defined as the time interval between the date of attaining a first complete remission (CR) and the date of relapse. Disease free survival (DFS) will compared to conventional therapy vs Non-myeloablative Host Conditioning (NMA HCT). The outcome is reported as the number of participants which never experienced disease relapse (without dispersion). (NCT00568633)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Allo-HSCT + TLI + ATG	5
Best Standard Care	9

Early Graft Loss

Early graft loss means a failure to achieve donor T-cell chimerism of > 5% at any time after transplant. The outcome is reported as the percentage of participants that experience early graft loss, a number without dispersion. (NCT00568633)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Allo-HSCT + TLI + ATG	4

Non-relapse Mortality

Non-relapse mortality is defined as death that occurs after therapy, from any cause except a cause associated with relapse. This will be reported as the number of participants experiencing non-relapse mortality (a number without dispersion). (NCT00568633)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Allo-HSCT + TLI + ATG	1
Best Standard Care	2

Overall Survival (OS)

Overall survival defined as the time interval between the date of attaining a first complete remission (CR) and the date of death from any cause. The outcome is reported as the number of participants alive (without dispersion). (NCT00568633)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Allo-HSCT + TLI + ATG	9
Best Standard Care	13

Patients Completing the Intended Therapy in Both Arms

The assessment for completion of the intended therapy (in both arms) will be reported as the percentage of participants, a number without dispersion (NCT00568633)
Timeframe: 2 years

Intervention	percentage of participants (Number)
Allo-HSCT + TLI + ATG	100
Best Standard Care	81.8

Relapse Rate

Relapse will be determined as ≥ 5% blast cells in the bone marrow, not secondary to regeneration after myelosuppressive therapy; OR emergence of extramedullary leukemia; OR the re-emergence of blasts in the peripheral blood. The outcome will be reported as the number and percentage of participants that meet these criteria (a number without dispersion). (NCT00568633)
Timeframe: 2 years

Intervention	Participants (Count of Participants)
Allo-HSCT + TLI + ATG	20
Best Standard Care	24

Transplant-related Mortality

Transplant-related mortality will be assessed as any death occurring within 6 months post-transplant, from any cause except relapse. It will be measured at 100 day and 6 months after transplant. The outcome is expressed as at the number of participants experiencing transplant-related mortality (a number without dispersion). (NCT00568633)
Timeframe: 100 days and 6 months

Intervention	Participants (Count of Participants)
	At 100 days	At 6 months
Allo-HSCT + TLI + ATG	0	1

Disease-free Survival

Number of patients who were free of disease and alive at 1 year. (NCT00609739)
Timeframe: 1 year

Intervention	Participants (Number)
Cytarabine + Mitoxantrone	0

Patients Who Relapsed

Number of patients whose disease relapsed. (NCT00609739)
Timeframe: 1 Year

Intervention	participants (Number)
Cytarabine + Mitoxantrone	1

Patients With Graft-Versus-Host-Disease

Number of patients who exhibited acute and/or chronic graft-versus-host disease. (NCT00609739)
Timeframe: Up to 30 Days Post Study Treatment

Intervention	participants (Number)
Cytarabine + Mitoxantrone	1

Patients With Regimen-Related Toxicity

Number of patients with adverse events related to treatment. (NCT00609739)
Timeframe: Up to 30 Days Post Study Treatment

Intervention	participants (Number)
Cytarabine + Mitoxantrone	0

Number of Participants Experiencing Graft Failure

graft failure = absolute neutrophil count (ANC) <5 x 10^8/L and an acellular bone marrow aspirate/biopsy (NCT00630253)
Timeframe: From Day 1 to event, assessed up to100 days

Intervention	Participants (Count of Participants)
Marrow Isolex	0
UCB Arm	0
Marrow Clinimax	0

Number of Participants Experiencing Overall Survival

"The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.~Overall survival will be defined as time from enrollment to date of death or censored at the date of last documented contact for patients still alive." (NCT00630253)
Timeframe: 1 Year

Intervention	Participants (Count of Participants)
Marrow Isolex	15
UCB Arm	8
Marrow Clinimax	5

Number of Participants With Acute Graft-Versus-Host Disease (GVHD)

Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host. (NCT00630253)
Timeframe: Day 42

Intervention	Participants (Count of Participants)
Marrow Isolex	0
UCB Arm	0
Marrow Clinimax	0

Number of Participants With Chronic Graft-Versus-Host Disease (GVHD)

Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host. (NCT00630253)
Timeframe: 1 Year

Intervention	Participants (Count of Participants)
Marrow Isolex	2
UCB Arm	0
Marrow Clinimax	0

Number of Participants With Transplant Related Deaths

In the field of transplantation, toxicity is high and all deaths without previous relapse or progression are usually considered as related to transplantation (NCT00630253)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Marrow Isolex	1
UCB Arm	0
Marrow Clinimax	1

Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib

(NCT01968057)
Timeframe: Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose

Intervention	nanograms/milliliter (ng/mL) (Geometric Mean)
Baricitinib	36.2
Baricitinib + Ciclosporin	35.8

PK: Area Under the Concentration Curve From Time Zero to Infinity [AUC (0-∞)] of Baricitinib

(NCT01968057)
Timeframe: Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose

Intervention	nanogramshour/milliliter (ngh/mL) (Geometric Mean)
Baricitinib	241
Baricitinib + Ciclosporin	311

PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib

(NCT01968057)
Timeframe: Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose

Intervention	hours (Median)
Baricitinib	1.00
Baricitinib + Ciclosporin	2.00

Number of Participants Who Achieve Complete Donor Chimerism

Complete donor chimerism (NCT00741455)
Timeframe: Post-transplant days +30, +60, +100, +180 and +365

Intervention	Participants (Count of Participants)
	Complete Chimerism 30 Days Post Transplant	Complete Chimerism 60 Days Post Transplant	Complete Chimerism 100 Days Post Transplant	Complete Chimerism 180 Days Post Transplant	Complete Chimerism 365 Days Post Transplant	Chimerism Unknown	Did not achieve complete donor chimerism
Study Treatment	2	2	3	3	4	1	2

Number of Participants With Successful Bone Marrow Engraftment

Rates of successful engraftment. (NCT00741455)
Timeframe: Within 30 days of bone marrow transplant

Intervention	Participants (Count of Participants)
	Engrafted	Engrafted 16-30 Days	Engrafted >30 Days
Study Treatment	1	15	1

Overall Survival Measured in Participants

Mortality rates in subjects after successful completion of a bone marrow transplant (NCT00741455)
Timeframe: Up to 15 Years Post-Transplant

Intervention	Participants (Count of Participants)
	Survival < 1 year post-transplant	Survival 1 to < 5 years post-transplant	Survival 5 to < 10 years post-transplant	Survival 10+ years post-transplant
Study Treatment	2	8	0	7

Number of Participants With Biopsy-proven Acute Rejection

A graft core biopsy was performed on all suspected acute rejection episodes within 48 hours. Biopsies were read by the local pathologist according to the 1997 Banff criteria. A biopsy-proven acute rejection was be defined as a biopsy graded IA, IB, IIA, IIB, or III. (NCT01276457)
Timeframe: Baseline to end of study (Month 24)

Intervention	Participants (Number)
Upper Everolimus Blood Target + Very Low Dose Cyclosporine	21
Standard Everolimus Blood Target + Low Dose Cyclosporine	21

Number of Participants Who Died, Number of Participants Who Lost Their Graft, and Number of Participants Who Died or Lost Their Graft

A participant lost his graft if he/she started dialysis and was not able to subsequently be removed from dialysis or underwent graft nephrectomy. (NCT01276457)
Timeframe: Baseline to end of study (Month 24)

Intervention	Participants (Number)
	Died	Lost graft	Died or lost graft
Standard Everolimus Blood Target + Low Dose Cyclosporine	3	15	18
Upper Everolimus Blood Target + Very Low Dose Cyclosporine	2	6	8

Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Deaths

Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect. (NCT01276457)
Timeframe: Baseline to end of study (Month 24)

Intervention	Partcipants (Number)
	AEs	Infection	Clinically significant AEs	SAEs	Died
Standard Everolimus Blood Target + Low Dose Cyclosporine	143	101	53	90	3
Upper Everolimus Blood Target + Very Low Dose Cyclosporine	142	95	58	85	2

Renal Function Assessed by Creatinine Clearance

Renal function was assessed by measuring serum creatinine and by computing creatinine clearance using the formula of Cockcroft-Gault. (NCT01276457)
Timeframe: Month 12, Month 18, and Month 24

Intervention	mL/min (Mean)
	Month 12 (n=111, 111)	Month 18 (n=108, 108)	Month 24 (n=106, 110)
Standard Everolimus Blood Target + Low Dose Cyclosporine	62.50	62.80	63.76
Upper Everolimus Blood Target + Very Low Dose Cyclosporine	61.26	60.90	61.92

Percentage of Patients With Complete Clearing of Corneal Staining at Month 12

Percentage of patients with complete clearing of corneal staining at month 12. Corneal staining is evaluated following administration of fluorescein dye into the eye. Complete clearing is defined as the absence of corneal staining. (NCT00827255)
Timeframe: Month 12

Intervention	Percentage of Patients (Number)
Patients Who Received Restasis®	33.3

Percentage of Patients With an Improvement in the Composite Symptom Score

Composite symptom score improvement is defined as a 4 or more grade decrease from baseline in composite symptom score in the study eye. The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). Each of the 5 symptoms is assessed on a scale of 0=absent to 3=severe. The composite symptom score is the sum of all 5 individual symptom scores, where 0 is no symptoms and 15 is the most severe symptoms. (NCT00884585)
Timeframe: Baseline, Month 2

Intervention	Percentage of Patients (Number)
Cyclosporine Ophthalmic Solution (COS) Followed by COS	30.3
Placebo	28.7

Percentage of Patients With an Improvement in the Punctate Corneal Staining Score

Punctate corneal staining improvement is defined as a 1 or more grade decrease from baseline in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is >2 dots but ≤ 10 dots, 2 is > 10 dots but ≤ 32 dots, 3 is > 32 dots but ≤ 100 dots (approximately), 4 is > 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is >316 dots (approximately) or ulcer/erosion. (NCT00884585)
Timeframe: Baseline, Month 2

Intervention	Percentage of Patients (Number)
Cyclosporine Ophthalmic Solution (COS) Followed by COS	42.7
Placebo	42.5

Percentage of Punctate Corneal Staining Responders

Punctate corneal staining responders defined as patients achieving a punctate corneal staining score of 0 or 1 in the study eye. Punctate corneal staining is assessed on a scale of 0 to 5 where 0 is ≤2 dots, 1 is >2 dots but ≤ 10 dots, 2 is > 10 dots but ≤ 32 dots, 3 is > 32 dots but ≤ 100 dots (approximately), 4 is > 100 dots (approximately) but ≤ 316 dots (approximately), and 5 is >316 dots (approximately) or ulcer/erosion. (NCT00884585)
Timeframe: Month 2

Intervention	Percentage of Patients (Number)
Cyclosporine Ophthalmic Solution (COS) Followed by COS	24.7
Placebo	23.0

Percentage of Treatment Responders

Treatment responders are defined as patients with a ≥ 1 grade improvement from baseline in punctate corneal staining score and a ≥ 4 grade improvement from baseline in composite symptom score in the study eye. The punctate corneal staining score is assessed on a scale of 0 to 5 (0 is ≤2 dots and 5 is >316 dots (approximately) or ulcer/erosion). The composite symptom score is based on 5 symptoms (itching, tearing, ocular discomfort, photophobia, mucous discharge). The composite symptom score (0 to 15) is the sum of 5 symptoms (each symptom is assessed on a scale of 0=absent to 3=severe). (NCT00884585)
Timeframe: Baseline, Month 2

Intervention	Percentage of Patients (Number)
Cyclosporine Ophthalmic Solution (COS) Followed by COS	21.3
Placebo	17.2

Acute Graft Versus Host Disease Among Patients Who Received Early Transplant

Acute graft versus host disease (graded II, III, or IV) among patients who received early allogeneic HCT on study. (NCT02756572)
Timeframe: At day 100

Intervention	Participants (Count of Participants)
Received Allogeneic HCT on Study	0

Demonstrate the Feasibility of Collecting Resource Utilization Data for Trial Participants

The amount of days of hospitalization (the major driver of costs within the first year) will be collected for resource utilization. (NCT02756572)
Timeframe: Within the first year of induction chemotherapy on study

Intervention	days (Median)
Treatment (Chemotherapy, HCT)	49

Event-free Survival (EFS) Among Patients Who Received Early Transplant

Event-free survival among patients who received early allogeneic HCT on study as estimated with the Kaplan-Meier method. Events included death, relapse, and grade 3-4 acute graft vs host disease. (NCT02756572)
Timeframe: Up to 100 days post-transplant

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	91

Event-free Survival (EFS) Among Patients Who Received Early Transplant

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	82

Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - AGE

Patients who receive early transplant will be compared to those that don't using the Wilcoxon rank sum test for the quantitative variable of age. (NCT02756572)
Timeframe: From time of subject's study enrollment to time of subject's feasibility success assessment (i.e. when subject received transplant within 60 days or when it was determined subject would not proceed with transplant on study)

Intervention	years (Median)
Received Allogeneic HCT on Study	55
Did Not Receive Allogeneic HCT on Study	57

Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - TREATMENT RELATED MORTALITY

"Patients who receive early transplant will be compared to those that don't using the Wilcoxon rank sum test for the quantitative variable of treatment-related mortality (TRM). This outcome measure is intended to report a predicted TRM score assessed at the time of feasibility evaluation. The TRM score is used to measure treatment-related mortality, or likelihood of death within 28 days of initiation of induction chemotherapy for patients with AML. The score is normalized from 0 to 100, so that a score of 0 demonstrates the patient has a very low likelihood of TRM and a score of 100 a very high likelihood of death. A calculation is used to predict TRM using age, performance status, if they have secondary AML, albumin, creatinine, platelet count, white blood cell count, and peripheral blood blast percentage. The higher the TRM score, the higher the risk of TRM. Calculator and table of relationship between TRM score and TRM probability found here: https://trmcalculator.fredhutch.org/." (NCT02756572)
Timeframe: From time of subject's study enrollment to time of subject's feasibility success assessment (i.e. when subject received transplant within 60 days or when it was determined subject would not proceed with transplant on study)

Intervention	units on a scale (Median)
Received Allogeneic HCT on Study	2.15
Did Not Receive Allogeneic HCT on Study	3.045

Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant

Overall survival among patients who did not receive early allogeneic HCT on study as estimated with the Kaplan-Meier method. (NCT02756572)
Timeframe: Up to 100 days after induction day 1

Intervention	Percentage of participants (Number)
Did Not Receive Allogeneic HCT on Study	75

Overall Survival (OS) Among Patients Who Did Not Receive Early Transplant

Overall survival among patients who did not receive early allogeneic HCT on study as estimated with the Kaplan-Meier method. (NCT02756572)
Timeframe: Up to 6 months after induction day 1

Intervention	Percentage of participants (Number)
Did Not Receive Allogeneic HCT on Study	62

Overall Survival (OS) Among Patients Who Received Early Transplant.

Overall survival among patients who received early allogeneic HCT on study as estimated with the Kaplan-Meier method. (NCT02756572)
Timeframe: Up to 100 days post-transplant

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	91

Overall Survival (OS) Among Patients Who Received Early Transplant.

Overall survival among patients who received early allogeneic HCT on study as estimated with the Kaplan-Meier method. (NCT02756572)
Timeframe: Up to 6 months post-transplant

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	82

Relapse-free Survival (RFS) Among Patients Who Received Early Transplant

Relapse-free survival among patients who received early allogeneic HCT on study as estimated with the Kaplan-Meier method. (NCT02756572)
Timeframe: Up to 100 days post-transplant

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	91

Relapse-free Survival (RFS) Among Patients Who Received Early Transplant

Relapse-free survival among patients who received early allogeneic HCT on study as estimated with the Kaplan-Meier method. (NCT02756572)
Timeframe: Up to 6 months post-transplant

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	82

Treatment Related Mortality Among Patients Who Received Early Transplant vs Patients Who Did Not Receive Early Transplant

Treatment related mortality calculated among patients who received early allogeneic HCT on study vs patients who did not receive early transplant on study. (NCT02756572)
Timeframe: At day 100

Intervention	Percentage of participants (Number)
Received Allogeneic HCT on Study	9
Did Not Receive Allogeneic HCT on Study	23.8

Demonstrate the Feasibility of Collecting Patient-reported Outcomes for Trial Participants

The amount of returned patient-reported outcome questionnaires will be summarized for each collection timepoint using percent collection from surviving patients for PRO timepoints. (NCT02756572)
Timeframe: Up to 12 months post-HCT

Intervention	Participants (Count of Participants)
	Enrollment PROs returned	Post G-CLAM PROs returned	Pre-HCT PROs returned	6 months post-HCT PROs returned	12 months post-HCT PROs returned
Treatment (Chemotherapy, HCT)	27	23	8	4	3

Factors That Distinguish Patients Who Received Early Transplant From Those Who Did Not - GENDER

Patients who receive early transplant will be compared to those that don't using the Fisher's exact test for the categorical variables of gender. (NCT02756572)
Timeframe: From time of subject's study enrollment to time of subject's feasibility success assessment (i.e. when subject received transplant within 60 days or when it was determined subject would not proceed with transplant on study)

Intervention	Participants (Count of Participants)
	Female	Male
Did Not Receive Allogeneic HCT on Study	10	11
Received Allogeneic HCT on Study	8	1

Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Enrollment and Incidence of Early Transplant

Success will be defined as enrollment of at least 30 patients with transplants occurring in 15 of these 30 (50%) within 60 days of enrollment or start of induction chemotherapy with G-CLAM, whichever is earlier. (NCT02756572)
Timeframe: Up to 60 days after start of chemotherapy

Intervention	Participants (Count of Participants)
	Received allogeneic HCT on study within 60 days (feasibility success)	Did not receive allogeneic HCT on study within 60 days (feasibility failure)
Treatment (Chemotherapy, HCT)	9	21

Feasibility of Early Allogeneic Hematopoietic Cell Transplant Assessed by Relapsed-free Survival 6 Months After Transplant

Success will be defined as observing a 40% of higher 6-month relapse-free survival among patients who received early transplant on study. (NCT02756572)
Timeframe: 6 months after early allogeneic HCT on study

Intervention	Participants (Count of Participants)
	No relapse within 6 months post-HCT (feasibility success)	Relapse within 6 months post-HCT (feasibility failure)
Received Early Allogeneic HCT on Study	6	2

Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 28

"Complete Remission (CR), defined as <5% blasts in bone marrow with hematologic recovery (ANC>1000/ul and platelets >100,000/ml).~CRi, defined as complete remission with insufficient hematologic recovery (ANC<1000/ul or platelets<100,000/ul).~CRp, defined as complete remission but platelets <100,000/ul. Minimal residual disease (MRD), defined as any detectable disease by flow cytometry, cytogenetics, FISH or PCR in a patient otherwise fulfilling remission criteria.~Morphologic leukemia-free state (MLFS), defined as <5% blasts in bone marrow with no hematologic recovery.~Relapse, defined as >5% blasts in bone marrow, flow cytometry, or manual differential; OR treatment for active relapsed disease." (NCT02756572)
Timeframe: Approximately 28 days after early allogeneic HCT

Intervention	Participants (Count of Participants)
	CR with MRD	CR without MRD	CRi with MRD	CRi without MRD	MLFS with MRD	MLFS without MRD	Relapse
Received Allogeneic HCT on Study	0	7	0	1	0	0	0

Response Assessments After Early Allogeneic Hematopoietic Cell Transplant, Day 84

Intervention	Participants (Count of Participants)
	CR with MRD	CR without MRD	CRi with MRD	CRi without MRD	MLFS with MRD	MLFS without MRD	Relapse
Received Allogeneic HCT on Study	0	4	0	2	0	0	2

Disease Progression - Decrease in FEV1 or Additional/Increase in Immunosuppressive Therapies

Disease progression as defined by a 20% or more decline in FEV1, or those who require an increase in immunosuppressive therapies by at least 25% or the addition of new immunosuppressive therapies. (NCT01273207)
Timeframe: 6 Months

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Participants	0

Disease Stablization - Decrease in FEV1 or Less Than 10% Increase in FEV1

Stabilization in Pulmonary Function Test (PFT) as defined by less than 10% increase in FEV1 or less than 10% decline in FEV1 (NCT01273207)
Timeframe: 6 Months

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Participants	7

Improvement in Lung Function - Increase in FEV1

Continued improvement in lung function as defined by 10% or more increase in FEV1 (NCT01273207)
Timeframe: 6 Months

Intervention	Participants (Count of Participants)
Inhaled Cyclosporine in HSCT Participants	0

Incidence of Adverse Events

Number of subjects who developed reportable AEs, assessed using adapted version of the Common Toxicity Criteria (NCT00453388)
Timeframe: Up to Day 100

Intervention	Participants (Count of Participants)
Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI De-escalation)	3
Arm III (2 vs 2.5 vs 3 Gy TBI Dose-escalation)	0

Incidence of Grades III-IV Acute GVHD

"Number of subjects who developed maximum grade acute graft-vs-host disease~aGVHD Stages~Skin:~- a maculopapular eruption involving < 25% BSA~- a maculopapular eruption involving 25 - 50% BSA~- generalized erythroderma~- generalized erythroderma with bullous formation and often with desquamation~Liver:~- bilirubin 2.0 - 3.0 mg/100 mL~- bilirubin 3 - 5.9 mg/100 mL~- bilirubin 6 - 14.9 mg/100 mL~- bilirubin > 15 mg/100 mL~Gut:~Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.~aGVHD Grades Grade III: Stage 2 - 4 gastrointestinal involvement and/or +2 to +4 liver involvement, with or without a rash Grade IV: Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death" (NCT00453388)
Timeframe: Up to Day 100

Intervention	Participants (Count of Participants)
Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI De-escalation)	1
Arm III (2 vs 2.5 vs 3 Gy TBI Dose-escalation)	0

Incidence of Transplant-related Mortality

Number of subjects who expired due to transplant-related mortality (NCT00453388)
Timeframe: Up to Day 200

Intervention	Participants (Count of Participants)
Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI De-escalation)	1
Arm III (2 vs 2.5 vs 3 Gy TBI Dose-escalation)	0

Number of Patients Who Engraft at Each Dose of TBI Used

Number of subjects who engrafted. Engraftment defined as greater than 95% donor chimerism. (NCT00453388)
Timeframe: Up to Day 200

Intervention	Participants (Count of Participants)
Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI De-escalation)	5
Arm III (2 vs 2.5 vs 3 Gy TBI Dose-escalation)	1

Change in Epidermal Thickness

Change in lesional skin epidermal thickness at week 12 compared to baseline (NCT01149759)
Timeframe: 12 weeks

Intervention	micrometer (Mean)
Cyclosporine A	79.70

SCORAD Change Score

"SCORAD (SCORing Atopic Dermatitis) is a clinical tool for assessing the severity (i.e., extent, intensity) of atopic dermatitis (AD) as objectively as possible with scores ranging from 0-100. The higher the score indicates more severe AD. For this outcome the SCORAD change score is computed as an absolute number which is comparing improvement in the SCORAD score of participants at week 12 compared to their SCORAD score at baseline." (NCT01149759)
Timeframe: 12 weeks

Intervention	Change Score (Mean)
Cyclosporine A	33.34

Immune Reconstitution Efficacy - Naive CD4 T Cells

The development of total naive CD4 T cells at one year as measured using flow cytometry (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	cells/mm3 (Median)
Cultured Thymus Tissue Implantation With Immunosuppression	156

Immune Reconstitution Efficacy - Naive CD8 T Cells

The development of total naive CD8 T cells at one year as measured using flow cytometry (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	cells/mm3 (Median)
Cultured Thymus Tissue Implantation With Immunosuppression	37

Immune Reconstitution Efficacy - Response to Mitogens

Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA). (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	counts per minute (cpm) (Median)
Cultured Thymus Tissue Implantation With Immunosuppression	139189

Immune Reconstitution Efficacy - Total CD3 T Cells

The development of total CD3 T cells at one year as measured using flow cytometry (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	cells/mm3 (Median)
Cultured Thymus Tissue Implantation With Immunosuppression	726

Immune Reconstitution Efficacy - Total CD4 T Cells

The development of total CD4 T cells at one year as measured using flow cytometry (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	cells/mm3 (Median)
Cultured Thymus Tissue Implantation With Immunosuppression	593

Immune Reconstitution Efficacy - Total CD8 T Cells

The development of total CD8 T cells at one year as measured using flow cytometry (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	cells/mm3 (Median)
Cultured Thymus Tissue Implantation With Immunosuppression	145

Survival at 1 Year Post-CTTI

Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time. (NCT00579527)
Timeframe: 1 year post-CTTI

Intervention	% of participants who survive to 1 year (Number)
Cultured Thymus Tissue With Immunosuppression	71

Survival at 2 Years Post-CTTI

Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time. (NCT00579527)
Timeframe: 2 years post-CTTI

Intervention	% of participants who survive to 2 years (Number)
Cultured Thymus Tissue Implantation With Immunosuppression	71

Number of Non-Relapse Mortalities

Number of subjects expired without disease progression/relapse. (NCT01231412)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Arm I (MMF and CSP)	12
Arm II (MMF, CSP, and Sirolimus)	4
Arm 0 (CSP and Sirolimus)	0

Number of of Participants Surviving Overall

Number of subjects surviving overall post-transplant. (NCT01231412)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Arm I (MMF and CSP)	53
Arm II (MMF, CSP, and Sirolimus)	75
Arm 0 (CSP and Sirolimus)	6

Number of Participants With Relapse/Progression

"Relapse/Progression criteria:~CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever >38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes >20%.~AML, ALL, MDS >5% blasts by morphologic or flow cytometric evaluation of the BMA or appearance of extramedullary disease CLL ≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.~NHL >25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.~MM~≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or numb" (NCT01231412)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Arm I (MMF and CSP)	16
Arm II (MMF, CSP, and Sirolimus)	16
Arm 0 (CSP and Sirolimus)	1

Number of Patients With Chronic Extensive GVHD

Number of patients who developed chronic extensive GVHD post-transplant. The diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD. (NCT01231412)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Arm I (MMF and CSP)	38
Arm II (MMF, CSP, and Sirolimus)	43
Arm 0 (CSP and Sirolimus)	3

Number of Patients With Grades II-IV Acute GVHD

"Number of patients with grades II-IV acute GVHD~aGVHD Stages~Skin:~a maculopapular eruption involving < 25% BSA~a maculopapular eruption involving 25 - 50% BSA~generalized erythroderma~generalized erythroderma w/ bullous formation and often w/ desquamation~Liver:~bilirubin 2.0 - 3.0 mg/100 mL~bilirubin 3 - 5.9 mg/100 mL~bilirubin 6 - 14.9 mg/100 mL~bilirubin > 15 mg/100 mL~Gut:~Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients w/ visible bloody diarrhea are at least stage 2 gut and grade 3 overall.~aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death" (NCT01231412)
Timeframe: At day 100 post-transplant

Intervention	Participants (Count of Participants)
Arm I (MMF and CSP)	39
Arm II (MMF, CSP, and Sirolimus)	22
Arm 0 (CSP and Sirolimus)	3

Number of Patients With Grades III-IV Acute GVHD

"Number of patients with grades III-IV acute GVHD~aGVHD Stages~Skin:~a maculopapular eruption involving < 25% BSA~a maculopapular eruption involving 25 - 50% BSA~generalized erythroderma~generalized erythroderma w/ bullous formation and often w/ desquamation~Liver:~bilirubin 2.0 - 3.0 mg/100 mL~bilirubin 3 - 5.9 mg/100 mL~bilirubin 6 - 14.9 mg/100 mL~bilirubin > 15 mg/100 mL~Gut:~Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients w/ visible bloody diarrhea are at least stage 2 gut and grade 3 overall.~aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death" (NCT01231412)
Timeframe: Up to 100 days

Intervention	Participants (Count of Participants)
Arm I (MMF and CSP)	8
Arm II (MMF, CSP, and Sirolimus)	2
Arm 0 (CSP and Sirolimus)	0

Progression-free Survival

time to disease progression or death due to any cause (NCT00003270)
Timeframe: 1 year

Intervention	% of participants (Number)
Arm 1	50

Donor (Allogeneic) Hematopoietic Engraftment

Number of patients who achieve hematopoietic engraftment - assessment of nucleated peripheral blood cells for donor (allogeneic) chimerism following this reduced-intensity HCT. (NCT01626092)
Timeframe: Day 100 Following Hematopoietic Cell Transplant (HCT)

Intervention	participants (Number)
Intent-To-Treat Patients	1

Transplant-Related Mortality

Incidence of death due to complications of HCT following this reduced-intensity conditioning regimen. (NCT01626092)
Timeframe: Day 100 following HCT

Intervention	participants (Number)
Intent-To-Treat Patients	0

Cumulative Incidence of NK Cell Reconstitution

Cumulative incidence of successful reconstitution to donor level is calculated. (NCT00553202)
Timeframe: At 5 years from HSCT date

Intervention	Percentage of participants (Number)
Treatment (Chemotherapy and Allogeneic SCT)	48.1

Overall Survival (OS)

OS - Time from HSCT until death (NCT00553202)
Timeframe: At 5 years from HSCT date

Intervention	Percentage of participants (Number)
Treatment (Chemotherapy and Allogeneic SCT)	45.9

Relapse Free Survival

Number of patients with relapsed disease within 1 Year post-transplant. Relapse is defined as the detection of > 5% blasts after a documented complete remission. (NCT00036738)
Timeframe: Assessed up to 1 year

Intervention	Participants (Count of Participants)
Treatment (Allogeneic Nonmyeloablative HSCT)	3

Transplant-related Mortality

Number of patients with TRM within 100 days post-transplant. (NCT00036738)
Timeframe: At day 100

Intervention	Participants (Count of Participants)
Treatment (Allogeneic Nonmyeloablative HSCT)	1

Transplant-related Mortality

Number of patients with TRM within one year post-transplant. (NCT00036738)
Timeframe: At 1 year

Intervention	Participants (Count of Participants)
Treatment (Allogeneic Nonmyeloablative HSCT)	3

Leukemia-free Survival

Number of patients surviving in CR up to five years post-transplant. (NCT00036738)
Timeframe: Assessed up to 5 years

Intervention	Participants (Count of Participants)
	6 Months	1 Year	2 Years	3 Years	4 Years	5 Years
Treatment (Allogeneic Nonmyeloablative HSCT)	19	17	13	11	11	10

Overall Survival

Number of patients surviving up to five years post-transplant. (NCT00036738)
Timeframe: Assessed up to 5 years

Intervention	Participants (Count of Participants)
	6 Months	1 Year	2 Years	3 Years	4 Years	5 Years
Treatment (Allogeneic Nonmyeloablative HSCT)	26	24	19	17	16	13

Neutrophil Engraftment - The Days Till ANC Recovery

The primary engraftment endpoint, neutrophil engraftment, is defined as the first of three consecutive days on which the absolute neutrophil count is > 500/µL. The duration and extent of neutrophil engraftment is the time from transplant to neutrophil engraftment. (NCT00544115)
Timeframe: Up to 180 days post transplant

Intervention	days (Median)
Regimen I	17
Regimen II	16
Regimen III	15
Regimen IV	14
Regimen V	18
Regimen VI	16

Two-year Overall Survival

Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. Participants were followed up to 2 years after transplant and Kaplan-Meier survival analysis was used to generate the two-year Overall Survival estimate presented. (NCT00544115)
Timeframe: Up to 2 years post transplant

Intervention	percentage of survival probability (Number)
Regimen I	58
Regimen II	50
Regimen III	54
Regimen IV	50
Regimen V	38
Regimen VI	50

Change in EMT Score

"Change (M12 - M3) in EMT Score. Progression in EMT score is defined as an increase by >=1 of EMT score from M3 to M12.~EMT score 0 (the best): <1 EMT score 1 (the better) : 1-10% of tubular atrophy EMT score 2 : 10-25% of tubular atrophy EMT score 3 : 25-50% of tubular atrophy EMT score 4 (the worst): >50% of tubular atrophy" (NCT01079143)
Timeframe: M3 and M12 post transplantation

Intervention	scores on a scale (Mean)
Certican EMT+	-0.3
Certican EMT-	0.9
Neoral EMT+	-0.3
Neoral EMT-	0.6

Change in Urine Protein/Creatinine Ratio (Without Imputation)

One of the factors associated with EMT progression between M3 and M12 according to univariate analysis (ITT biopsies M3 & M12). (NCT01079143)
Timeframe: Month 3 (baseline), Month 12

Intervention	mg/mmol (Mean)
Certican EMT+	44.4
Certican EMT-	3.5
Neoral EMT+	16.0
Neoral EMT-	29.8

Change From Baseline (M3) in Estimated Glomerular Filtration Rate (eGFR)

"eGFR was calculated according to the abbreviated Modification of Diet in Renal Disease (MDRD) Formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²).~LOCF = Last observation carried forward" (NCT01079143)
Timeframe: M3 (baseline) to M12 post transplantation

Intervention	mL/min/1.73m^2 (Least Squares Mean)
	without imputation	imputation by LOCF(96, 97)
Certican	6.99	5.96
Neoral	2.54	2.15

Change in Estimated Glomerular Filtration Rate (eGFR) at M12 From Baseline (M3) - ANCOVA Model

The average patient renal function was evaluated on the basis of eGFR was calculated according to the abbreviated MDRD formula and creatinine clearance according to the Cockcroft-Gault formula (mL/min/1.73m²). (NCT01079143)
Timeframe: Baseline (M3), M12

,,,

Intervention	mL/min/1.73m² (Mean)
	without imputation	imputation by LOCF (36, 60, 39, 58)
Certican EMT-	5.6	27.3
Certican EMT+	8.6	-11.9
Neoral EMT-	3.8	-4.9
Neoral EMT+	1.5	5.1

Change in Interstitial Fibrosis/Tabular Atrophy (IF/TA) Grade

Difference (M12 - M3) in IF/TA grade. IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (<25%), grade II (25-50%) and grade III (>50% of lesions). (NCT01079143)
Timeframe: M3 and M12 post transplantation

,,,

Intervention	Number of Participants (Number)
	Difference in IF/TA grade -1	Difference in IF/TA grade 0	Difference in IF/TA grade 1	Difference in IF/TA grade 2	Difference in IF/TA grade 3
Certican EMT-	1	21	18	3	NA
Certican EMT+	5	9	7	3	2
Neoral EMT-	2	33	13	5	NA
Neoral EMT+	7	9	11	5	0

Change in Percentage of Interstitial Fibrosis (IF) by Numerical Quantification

Percentage of IF measured by numerical quantification. The IF percentage was transposed in grade according to the following rule: grade 0 for an IF % ≤5%, grade I for an IF % ranging from >5% to < 25%, grade II for an IF % ranging from 25 to 50%, grade III for an IF % >50%. Interstitial graft fibrosis has been identified as the primary cause of graft loss following death with a functional graft [3-5]. (NCT01079143)
Timeframe: M3 and M12 post transplantation

,,,

Intervention	Percentage of IF (Mean)
	Percentage of IF at M3 (n=26,43,32,53)	Percentage of IF at M12 (n=24,42,32,53)	Change in Percentage of IF (n=24,42,32,53)
Certican EMT-	15.9	20.9	4.9
Certican EMT+	22.8	27.6	5.1
Neoral EMT-	17.8	20.4	2.7
Neoral EMT+	23.4	27.4	3.9

Incidence (Number) of BPAR

A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system. (NCT01079143)
Timeframe: M6 and M12 post transplantation

,,,

Intervention	Number of participants (Number)
	M6 - No	M6 - Yes	M12 - No	M12 - Yes
Certican EMT-	52	8	43	17
Certican EMT+	33	3	29	7
Neoral EMT-	59	0	56	3
Neoral EMT+	39	0	37	2

Incidence (Number) of Participants With Graft Losses

If a participant underwent a graft nephrectomy, then the day of nephrectomy was considered as the day of graft loss. (NCT01079143)
Timeframe: M6 and M12 post transplantation

,,,

Intervention	Participants (Number)
	M6 - No	M6 - Yes	M12 - No	M12 - Yes
Certican EMT-	60	0	56	4
Certican EMT+	36	0	35	1
Neoral EMT-	59	0	59	0
Neoral EMT+	39	0	38	1

Incidence (Number) of Subclinical Rejections and Borderline Lesions

"Incidence of subclinical rejections and borderline lesions with regards to histological evidence of rejection with clinical findings.~Subclinical rejections: rejection without clinical symptoms which is diagnosed by chance when a graft biopsy is performed.~Clinically suspected BPAR: rejection suspected because of the presence of clinical symptoms (fever, pain, increase of creatinine) and then confirmed by the graft biopsy.~Borderline lesions: suspicious for acute T-cell mediated rejection. This category is used when no intimal arteritis is present, but there are foci of tubulitis with minor interstitial infiltration or interstitial infiltration with mild tubulitis." (NCT01079143)
Timeframe: M3

Intervention	Participants (Number)
	Subclinical rejections-No (n=68, 84)	Subclinical rejections- Yes (n=68, 84)	Subclinical rejections- missing (n=68, 84)	Clinically suspected BPAR - No (N=68, 84)	Clinically suspected BPAR - Yes (N=68, 84)	Clinically suspected BPAR - Missing (N=68, 84)	Borderline lesions - No (n=68,84)	Borderline lesions - Yes (n=68,84)	Borderline lesions - Missing (n=68,84)
Certican	67	1	1	68	0	1	62	6	1
Neoral	84	0	1	84	0	1	71	13	1

Interstitial Fibrosis/Tabular Atrophy (IF/TA)

Incidence and severity of IF/TA according to 2005/2007 Banff classification system grades (grades l to lll). IF/TA grade was assessed during centralized reading according to the Banff 2005/2007 classification comprising grade I (<25%), grade II (25-50%) and grade III (>50% of lesions). (NCT01079143)
Timeframe: M3 and M12 post transplantation

,,,

Intervention	Number of participants (Number)
	Interstitial Fibrosis/Tubular Atrophy (IF/TA)	IF/TA grade at M3 at grade 1	IFTA grade at M3 at grade II	IF/TA grade at M3 at grade III	IF/TA grade at M12 at grade 0	IT/TA grade at M12 at grade I	IF/TA grade at M12 at grade II	IF/TA grade at M12 at grade III
Certican EMT-	38	5	0	0	20	18	5	0
Certican EMT+	13	11	2	0	9	8	6	3
Neoral EMT-	44	9	0	0	31	15	6	1
Neoral EMT+	13	17	1	1	7	15	9	1

Number of Participants With Epithelial-mesenchymal Transition (EMT) Score

"Incidence and severity of EMT score. The intensity of EMT markers expression present and detectable in the renal graft at an early stage following transplantation is known as EMT score.~EMT score 0 (the best): <1 EMT score 1 (the better): 1-10% of tubular atrophy EMT score 2: 10-25% of tubular atrophy EMT score 3: 25-50% of tubular atrophy EMT score 4 (the worst): >50% of tubular atrophy" (NCT01079143)
Timeframe: M3 and M12 post transplantation

,,,

Intervention	participants (Number)
	EMT Score 0 at M3 (n= 26,43,32, 53)	EMT Score 1 at M3 (n= 26,43,32, 53)	EMT Score 2 at M3 (n= 26,43,32, 53)	EMT Score 3 at M3 (n= 26,43,32, 53)	EMT Score 4 at M3 (n= 26,43,32, 53)	EMT Score 0 at M12 (n= 25,41,32, 53)	EMT Score 1 at M12 (n= 25,41,32, 53)	EMT Score 2 at M12 (n= 25,41,32, 53)	EMT Score 3 at M12 (n= 25,41,32, 53)	EMT Score 4 at M12 (n= 25,41,32, 53)	EMT Missing Score at M12 (n= 25,41,32, 53)
Certican EMT-	26	17	0	0	0	13	11	11	4	2	2
Certican EMT+	0	0	17	9	0	1	7	10	4	3	1
Neoral EMT-	28	25	0	0	0	19	17	12	4	1	0
Neoral EMT+	0	0	20	8	4	0	9	10	9	4	0

Number of Participants With Epithelial-mesenchymal Transition (EMT) Status

Incidence and severity of EMT status. EMT status was determined centrally using the graft biopsy taken at 3 months. The result was quickly obtained (within 7 to 15 days) and sent to the company in charge of randomization in order to allocate each patient to a treatment group and to provide the investigator with this information without confirming EMT status. (NCT01079143)
Timeframe: M3 and M12 post transplantation

,,,

Intervention	Participants (Number)
	EMT Status at M3-Negative (n=26,43,32,53)	EMT Status at M3- Positive (n=26,43,32,53)	EMT Status at M3 - Not done (n=26,43,32,53)	EMT Status at M12- Negative (n=25,41,32,53)	EMT Status at M12- Positive (n=25,41,32,53)	EMT Status at M12- Not done (n=25,41,32,53)
Certican EMT-	43	0	0	24	17	0
Certican EMT+	0	26	0	8	17	0
Neoral EMT-	53	0	0	36	17	0
Neoral EMT+	0	32	0	9	23	0

Number of Participants With Progression of Renal Fibrosis Using Numerical Quantification

Comparisons according to epithelial-mesenchymal transition (EMT) profile and immunosuppressive treatment (NCT01079143)
Timeframe: M3 to M12 post transplantation

,,,

Intervention	Participants (Number)
	Fibrosis Progression - No (n=24, 42, 31, 53)	Fibrosis progression - Yes (n=24, 42,31,43)	Fibrosis progression - Missing (n=24, 42, 31, 53)
Certican EMT-	30	12	1
Certican EMT+	18	6	2
Neoral EMT-	42	11	0
Neoral EMT+	19	12	0

Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population

"Progression of Interstitial Fibrosis/Tabular Atrophy (IF/TA) is the percentage (%) of participants with an increase >= 1 in IF/TA grade according to Banff (2005 - 2007)according to Epithelial-mesenchymal transition (EMT) profile and by treatment groups.~Grade I (the better): mild interstitial fibrosis and tubular atrophy (<25% of cortical area) Grade II : moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) Grade III (the worse) : severe interstitial fibrosis and tubular atrophy (>50% of cortical area)" (NCT01079143)
Timeframe: Month 3 (M3) and Month 12 (M12) post transplantation

Intervention	Participants (Number)
	Participants with an IF/TA grade <= II at M3	Participants with Fibrosis progression, M3 to M12
Certican EMT+	26	12
Neoral EMT+	31	16

Risk Factors of IF/TA Progression

"Composite factors regarding fibrosis progression at 12 months using a logistic regression model; the parameters initially considered concerned the demographic characteristics of both recipient and donor, transplantation characteristics, hypertension, diabetes, study treatments, immunosuppression, EMT, IF/TA, function at M3, the onset of acute rejection, the presence of anti-donor antibodies at M12, infections and BK virus viremia.~Arteriolar hyaline thickening is thickening of the walls of arterioles by the deposition of homogeneous pink hyaline material.~BPAR is biopsy proven acute rejection. TEM progression is the increase ≥ 1 of TEM score between Month 3 and Month 12" (NCT01079143)
Timeframe: M12 post transplantation

Intervention	Participants (Number)
	Donor Sex - Male	Donor Sex - Female	Donor Age - <=50 years	Donor Age - >50 years	Expanded Criteria donor: NO	Expanded Criteria Donor: Yes	Delayed graft function: No	Delayed graft function: Yes	CC at M3 <50 mL/min/1.73m^2	CC at M3 >=50 mL/min/1.73m^2 (n=67, 85)	Mesangial matrix increase at M3 - 0 (n=64, 85)	Mesangial matrix (mm) increase at M3: 1 (n=64, 85)	Mesangial matrix increase at M3: 2 (n=64, 85)	Interstitial fibrosis (ci) at M3: 0 (n=66, 85)	Interstitial fibrosis (ci) at M3: 1 (n=66, 85)	Interstitial fibrosis (ci) at M3: 2 (n=66, 85)	Arteriolar hyaline thickening (ah) at M3: 0	Arteriolar hyaline thickening (ah) at M3: 1	Arteriolar hyaline thickening (ah) at M3: 2	Arteriolar hyaline thickening (ah) at M3: 3	BPAR - No	BPAR - Yes	TEM Progression fron M3-M12: No (n=67, 83)	TEM Progression fron M3-M12: Yes (n=67, 83)	TEM Progression fron M3-M12: Missing (n=67, 83)
No- No Fibrosis Progression	48	38	48	38	63	23	76	10	35	50	84	1	0	55	27	3	56	21	8	1	79	7	57	26	3
Yes- Fibrosis Progression	45	22	28	39	40	27	52	15	40	27	59	2	3	52	14	0	36	15	10	6	55	12	26	41	0

Severity of BPAR

"A biopsy proven acute rejection (BPAR) is defined as a biopsy graded IA, IB, IIA, IIB or III as per 2005/2007 Banff histological classification system.~Biopsy graded IA: Significant interstitial infiltration (> 25% of parenchyma) and foci of moderate tubulitis (> 4 mononuclear cells/tubular cross section or group of 10 tubular cells).~Biopsy grade IB: Significant interstitial infiltration (> 25% of parenchyma) and foci of severe tubulitis (> 10 mononuclear cells/tubular cross section or group of 10 tubular cells).~Biopsy grade IIA: Mild to moderate intimal arteritis. Biopsy graded IIB: Severe intimal arteritis comprising > 25% of the lumenal area.~Biopsy graded III: Transmural (full vessel wall thickness) arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells (with accompanying lymphocytic inflammation)." (NCT01079143)
Timeframe: M6 and M12 post transplantation

,,,

Intervention	Participants (Number)
	M6: Banff type Grade IA	M6: Banff type Grade IB	M6: Banff type Grade IIA	M6: Banff type Grade IIB	M6: Banff type Grade III	M12: Banff type Grade IA	M12: Banff type Grade IB	M12: Banff type Grade IIA	M12: Banff type Grade IIB	M12: Banff type Grade III
Certican EMT-	2	4	0	1	0	7	5	1	1	0
Certican EMT+	0	0	1	0	0	2	2	1	0	0
Neoral EMT-	0	0	0	0	0	0	0	1	0	0
Neoral EMT+	0	0	0	0	0	1	0	0	0	0

Treatment Failures

A treatment failure is defined as biopsy proven acute rejection (BPAR), a graft loss, a death or a loss to follow up. It was assessed between randomization and 6 and 12 months post-transplantation. (NCT01079143)
Timeframe: M6 and M12 post transplantation

,,,

Intervention	Number of Participants (Number)
	M6: Treatment Failure- No	M6: Treatment Failure- Yes	M12: Treatment Failure- No	M12: Treatment Failure- Yes	M6: BPAR - No	M6: BPAR -Yes	M12: BPAR - No	M12: BPAR - Yes	M6: Graft Loss - No	M6: Graft Loss - Yes	M12: Graft Loss - No	M12: Graft Loss - Yes	M6: Death - No	M6: Death - Yes	M12: Death - No	M12: Death - Yes	M6: Loss to follow-up - No	M6: Loss to follow-up - Yes	M12: Loss to follow-up - No	M12: Loss to follow-up - Yes
Certican EMT-	52	8	42	18	52	8	43	17	60	0	56	4	60	0	60	0	60	0	59	1
Certican EMT+	33	3	29	7	33	3	29	7	36	0	35	1	36	0	36	0	36	0	36	0
Neoral EMT-	59	0	56	3	59	0	56	3	59	0	59	0	59	0	59	0	59	0	59	0
Neoral EMT+	39	0	36	3	39	0	37	2	39	0	38	1	39	0	39	0	39	0	39	0

Type of Biopsy Proven Acute Rejection (BPAR)

,,,

Intervention	Participants (Number)
	Cellular AR - No	Cellular AR - Yes
Certican EMT-	46	14
Certican EMT+	30	6
Neoral EMT-	58	1
Neoral EMT+	38	1

Incidence of Chronic GVHD

Analyzed using cumulative incidence estimates, treating death or rejection as competing risk events. (NCT00343785)
Timeframe: 2 years

Intervention	number participants with chronic GVHD (Number)
Patients Receive a Conditioning Regimen Comprising Cyclophosph	5

Number of Days to Neutrophil Recovery to >500/uL

First of 3 consecutive days of neutrophils >500/uL (NCT00343785)
Timeframe: 100 days post-transplant

Intervention	days (Median)
Treatment (Conditioning Regimen, Transplant, GVHD Prophylaxis)	26

Overall Survival

Number of patients alive at one year (NCT00343785)
Timeframe: From the time of enrollment until death from any cause up to one year

Intervention	Participants (Count of Participants)
Treatment (Conditioning Regimen, Transplant, GVHD Prophylaxis)	21

Number of Participants With Grade II-III and III-IV Acute GVHD and Chronic GVHD

"Number of patients who developed acute GVHD post-transplant. Grade I +1 to +2 skin rash, No gut or liver involvement Grade II +1 to +3 skin rash, +1 gastrointestinal involvement and/or +1 liver involvement Grade III +2 to +4 gastrointestinal involvement and/or +2 to +4 liver involvement with or without a rash Grade IV Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death~The diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD." (NCT00104858)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy and Rituximab Followed by HCT)	46

Number of Participants With Regimen-related Toxicity and Infections

Reported using the adapted National Cancer Institute Common Toxicity Criteria. (NCT00104858)
Timeframe: Within the first 100 days

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy and Rituximab Followed by HCT)	48

Number of Participants With Relapse/Progression

"Relapse/Progression criteria for CLL~Progressive disease:~≥1 of: Physical exam/imaging studies ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.~Relapsed disease:~Criteria of progression occurring 6 months after achievement of complete or partial remission." (NCT00104858)
Timeframe: Day 84

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy and Rituximab Followed by HCT)	1

Number of Participants With Treatment-related Mortality

Number of subjects expired without disease progression/relapse. (NCT00104858)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy and Rituximab Followed by HCT)	14

Number of Patients Achieving Complete Response and Partial Response (Overall Response Rate)

"Complete Remission (CR):~Imaging studies (Xray, CT, MRI) (nodes, liver, and spleen): Normal Peripheral blood by flow cytometry: No clonal lymphocytes Bone marrow by morphology: No nodules; or if present, nodules are free from CLL cells by immunohistochemistry Duration: ≥2 months~CR with minimal residual disease Peripheral blood or bone marrow by flow cytometry: >0 - <1 CLL cells/1000 leukocytes (0.1%)~Partial Remission (PR):~Both criteria:~Absolute lymphocyte count in peripheral blood: ≥50% decrease Physical exam/Imaging studies (nodes, liver, and/or spleen): ≥50% decrease Duration: ≥2 months" (NCT00104858)
Timeframe: Up to 1 year

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy and Rituximab Followed by HCT)	35

Overall Survival

Number of participants surviving post-transplant (NCT00104858)
Timeframe: At 18 months

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy and Rituximab Followed by HCT)	34

Donor and Host Polymorphisms of the FCgammaRIIIa Receptor and CD32 and Their Impact on Disease Response and Relapse

Number of participants without progressive disease and surviving at one year. Participants with FCgammaRIIIa receptor vs participants without FCgammaRIIIa receptor. (NCT00104858)
Timeframe: 1 Year

Intervention	Participants (Count of Participants)
	Surviving participants w/ FCgammaRIIIa receptor	Surviving participants w/o FCgammaRIIIa receptor	w/ FCgammaRIIIa receptor w/o progressive disease	w/o FCgammaRIIIa receptor w/o progressive disease
Treatment (Chemotherapy and Rituximab Followed by HCT)	2	21	2	19

Rituxan Concentration

Median rituxan level at days 60, 84, 180, and 1 year. (NCT00104858)
Timeframe: Days 60, 84, 180, and 1 year

Intervention	ug/ml (Median)
	Day 60	Day 84	Day 180	1 year
Treatment (Chemotherapy and Rituximab Followed by HCT)	109	51	1.3	.03

Disease Progression/Relapse

"CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever greater than 38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes >20%.~AML, ALL >5% marrow blasts by morphologic or flow cytometric, or appearance of extramedullary disease.~CLL ≥1 of: Physical exam/Imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.~NHL >25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.~MM~≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions." (NCT00118352)
Timeframe: Up to 5 years

Intervention	percentage of participants (Number)
Dose Level 1 (No Campath)	25

Incidence of Grade III-IV Acute GVHD

"Severity of Individual Organ Involvement~Liver:~Stage 2 - bilirubin (3-5.9mg/100ml) Stage 3 - bilirubin (6-14.9mg/100ml) Stage 4 - bilirubin > 15mg/100ml~Gut:~Diarrhea is graded stage 1 to stage 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as stage 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall~Severity of GVHD~Grade III - Stage 2 to 4 gastrointestinal involvement and/or Stage 2 to 4 liver involvement with or without a rash Grade IV - Pattern and severity of GVHD similar to grade 3 with extreme constitutional symptoms or death" (NCT00118352)
Timeframe: 100 days after transplant

Intervention	percentage of participants (Number)
Dose Level 1 (No Campath)	25

Incidence of Graft Rejection

Percentage patients that experienced graft rejection. (NCT00118352)
Timeframe: 84 days after transplant

Intervention	percentage of participants (Number)
Dose Level 1 (No Campath)	0

Incidence of High-dose Corticosteroid Utilization.

Percentage patients requiring steroids greater than 1 mg/kg. (NCT00118352)
Timeframe: 100 days after transplant

Intervention	percentage of participants (Number)
Dose Level 1 (No Campath)	83.3

Incidence of Infection

Percentage patients that experienced infection(s). (NCT00118352)
Timeframe: Up to 5 years post-transplant

Intervention	percentage of participants (Number)
Dose Level 1 (No Campath)	100

Incidence of Non-relapse Mortality

Percentage patient deaths due to non-relapse mortality (NCT00118352)
Timeframe: 100 days after transplant

Intervention	percentage of participants (Number)
Dose Level 1 (No Campath)	8.3

Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant

Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity. (NCT00118742)
Timeframe: 12 months posttransplant

Intervention	Percent change in GFR (mL/min) (Mean)
CellCept + CNI (Tacrolimus or Cyclosporine)	1.2
CellCept + Sirolimus	19.7

Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant

Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity. (NCT00118742)
Timeframe: 24 months posttransplant

Intervention	Mean percent change in GFR (mL/min) (Mean)
CellCept + CNI (Tacrolimus or Cyclosporine)	-8.6
CellCept + Sirolimus	13.5

Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant

Intervention	Percent change in GFR (mL/min) (Mean)
CellCept + CNI (Tacrolimus or Cyclosporine)	1.1
CellCept + Sirolimus	25.5

Change From Baseline in Creatinine Clearance

Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation (NCT00118742)
Timeframe: 6, 12, and 24 months posttransplantation

Intervention	Percent change in creatinine CL (mL/min) (Mean)
	6 months	12 months	24 months
CellCept + CNI (Tacrolimus or Cyclosporine)	-1.3	-3.0	-12.8
CellCept + Sirolimus	18.5	14.0	7.9

Number of Subjects Who Reported Ocular Symptoms During the Parallel-Group Phase (PGP)

Number of subjects who reported ocular symptoms of any severity during the parallel-group phase (PGP) of the study. Subjects evaluated the presence and severity of ocular symptoms in each eye. The severity of each symptom (blurring, foreign body sensation, pain, burning/stinging, tearing, and itching) were recorded on a 5-point scale (0=none, +0.5=very mild,+1=mild, +2=moderate, and +3=severe). (NCT01319773)
Timeframe: 3 Days

Intervention	Number of Subjects (Number)
Cyclosporine Formulation A	3
Cyclosporine Formulation B	1

Concentration of Cyclosporine Measured in Blood at Day 1 in the Parallel-Group Phase (PGP)

Concentration of cyclosporine measured in blood at Day 1 of the parallel-group phase (PGP). Blood samples were collected up to 3 hours post-dose and concentrations of cyclosporine were measured. (NCT01319773)
Timeframe: Day 1

Intervention	Nanogram/milliliter (ng/mL) (Number)
	Time = pre-dose	Time = 0.5 hours	Time = 1 hour	Time = 3 hours
Cyclosporine Formulation A	NA	NA	NA	NA
Cyclosporine Formulation B	NA	NA	NA	NA

Number of Eyes With Ocular Symptoms Post-Dose During the Paired-Eye Phase (PEP) at Day 1

Number of eyes with ocular symptoms of any severity, post-dose in the paired-eye phase (PEP) at Day 1. Subjects evaluated the presence and severity of ocular symptoms in each eye. The severity of each symptom (blurring, foreign body sensation, pain, burning/stinging, tearing, and itching) were recorded on a 5-point scale (0=none, +0.5=very mild, +1=mild, +2=moderate, and +3=severe). (NCT01319773)
Timeframe: Day 1

Intervention	Number of Eyes (Number)
	Blurring	Foreign Body Sensation	Pain	Burning/Stinging	Tearing	Itching
Cyclosporine 0.05%	1	0	0	2	3	0
Cyclosporine Formulation A	2	0	0	3	1	0
Cyclosporine Formulation B	1	0	1	2	2	0

Graft Survival

in cyclosporine group 84.6 +/- 5.8%; in tacrolimus group 86.2 +/- 4.1% (NCT01346397)
Timeframe: 5 years

Intervention	percentage of participants (Number)
Cyclosporine Group	84.6
Tacrolimus Group	86.2

Patient Survival

in cyclosporine group 96.4 +/- 2.8%; in tacrolimus group 96.3 +/- 3.4% (NCT01346397)
Timeframe: 5 years

Intervention	percentage of participants (Number)
Cyclosporine Group	96.4
Tacrolimus Group	96.3

Corticosteroid Usage

Number of flare-ups requiring topical steroid-use across all participants over the entire 12 month follow-up period (NCT00987467)
Timeframe: Entire follow-up period (Approximately 12 months)

Intervention	Total number of flare-up episodes (Number)
Topical Steroid Resistant/Dependant AKC	3

Ocular Symptoms and Signs Total Composite Score

Symptoms (itching, tearing, discomfort, discharge, photophobia) and signs (Bulbar conjunctival hyperemia, upper tarsal conjunctival papillae, punctate keratitis, corneal neovascularization, cicatrizing conjunctivitis, and blepharitis) evaluated on a 4 point scale of 0-3, with a minimum symptom score of 0- maximum 15, and sign score minimum 0- maximum 18. These scores are combined to yeild a total composite score of signs and symptoms of minimum 0-maximum 33. The highest score would indicate the most severe case of Atopic Keratoconjunctivitis (AKC). The composite score is reported. (NCT00987467)
Timeframe: Baseline and 8 weeks

Intervention	units on a scale (Mean)
	Baseline	8 weeks
Patients With Steroid Resistant/ Dependant AKC.	29.1	4.7

Number of Donors Discontinuing Atorvastatin Due to Toxicity

"The number of donors who prematurely discontinue atorvastatin therapy due to toxicity. Donors will be assessed for the following events:~Musculoskeletal and connective tissue disorders: grade 2-5~Hepatobiliary disorders: grade 2-5~Other unexpected events thought related to the use of atorvastatin; grade 2-5~In cases where the NCI criteria do not apply, intensity will be defined as:~Mild: awareness of symptom or sign, but easily tolerated~Moderate: discomfort is enough to cause interference with normal activities~Severe: inability to perform normal daily activities~Life threatening: immediate risk of death from the reaction as it occurred" (NCT01527045)
Timeframe: Prior to stem cell collection

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	2
Primary - Reg B (TBI Alone)	0
Adjunct	1

Number of Non-relapse Mortalities

Number of patients who died without relapsed/progressive disease. (NCT01527045)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	4
Primary - Reg B (TBI Alone)	1
Adjunct	0

Number of Patients Requiring Secondary Systemic Immunosuppressive Therapy

Number of patients requiring systemic immunosuppressive therapy other than those used for prophylaxis and initial therapy. (NCT01527045)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	23
Primary - Reg B (TBI Alone)	3
Adjunct	4

Number of Patients Surviving Overall

Number of patients surviving overall post-transplant (NCT01527045)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	21
Primary - Reg B (TBI Alone)	3
Adjunct	9

Number of Patients With Chronic Extensive GVHD

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	8
Primary - Reg B (TBI Alone)	1
Adjunct	5

Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD) Post-transplant

"Number of patients who developed acute GVHD post allogeneic transplant.~aGVHD Stages~Skin:~a maculopapular eruption involving < 25% BSA~a maculopapular eruption involving 25 - 50% BSA~generalized erythroderma~generalized erythroderma w/ bullous formation and often w/ desquamation~Liver:~bilirubin 2.0 - 3.0 mg/100 mL~bilirubin 3 - 5.9 mg/100 mL~bilirubin 6 - 14.9 mg/100 mL~bilirubin > 15 mg/100 mL~Gut:~Diarrhea is graded 1 - 4 in severity. Nausea and vomiting and/or anorexia caused by GVHD is assigned as 1 in severity. The severity of gut involvement is assigned to the most severe involvement noted. Patients with visible bloody diarrhea are at least stage 2 gut and grade 3 overall.~aGVHD Grades Grade II: Stage 1 - 2 skin w/ no gut/liver involvement Grade III: Stage 2 - 4 gut involvement and/or stage 2 - 4 liver involvement Grade IV: Pattern and severity of GVHD similar to grade 3 w/ extreme constitutional symptoms or death" (NCT01527045)
Timeframe: 100 days post-transplant

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	2
Primary - Reg B (TBI Alone)	0
Adjunct	0

Number of Patients With Grades II-IV Acute Graft-versus-host-disease (GVHD)

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	15
Primary - Reg B (TBI Alone)	2
Adjunct	6

Number of Patients With Recurrent or Progressive Malignancy

"CML New cytogenetic abnormality and/or development of accelerated phase or blast crisis. The criteria for accelerated phase will be defined as unexplained fever greater than 38.3°C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, marrow blasts and promyelocytes >20%.~AML, ALL, MDS >5% marrow blasts by morphologic or flow cytometric, or appearance of extramedullary disease.~CLL ≥1 of: Physical exam/Imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.~NHL >25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.~MM~≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ treatment; or definite increase in the size or number of plasmacytomas or lytic bone lesions." (NCT01527045)
Timeframe: 1 Year post-transplant

Intervention	Participants (Count of Participants)
Primary - Reg A (Flu/TBI)	7
Primary - Reg B (TBI Alone)	4
Adjunct	3

Engraftment

Number of subjects who engrafted post-transplant. Engraftment will be monitored in a sequential fashion. (NCT00054353)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
Related Donor	12
Unrelated Donor	4

Incidence of Acute GVHD (Grades III-IV)

Number of patients with Grade III-IV acute GVHD post-transplant. Severe GVHD will be monitored in a sequential fashion. (NCT00054353)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
Related Donor	2
Unrelated Donor	0

Incidence of Chronic (Extensive) GVHD

Number of subjects with chronic extensive GVHD post-transplant. Severe GVHD will be monitored in a sequential fashion. (NCT00054353)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
Related Donor	4
Unrelated Donor	1

Non-relapse Mortality

Early NRM will be monitored in a sequential fashion. (NCT00054353)
Timeframe: At day 100

Intervention	Participants (Count of Participants)
Related Donor	1
Unrelated Donor	1

PFS

PFS will be calculated for all patients from the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission. Progressive disease is defined as greater than 25% increase in serum or urine M proteins compared to best response status after autologous transplant and/or appearance of new lytic bone lesions or plasmocytomas. (NCT00054353)
Timeframe: At 1 year post-transplant

Intervention	Participants (Count of Participants)
Related Donor	4
Unrelated Donor	1

Relapse Rate

Number of subjects who relapsed after achieving CR post-transplant. Relapse rate will be summarized using cumulative incidence estimates. (NCT00054353)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
Related Donor	1
Unrelated Donor	1

Response Rate

Number of subjects who achieved CR post-transplant. Response rate will be summarized using cumulative incidence estimates. (NCT00054353)
Timeframe: Up to 5 years

Intervention	Participants (Count of Participants)
Related Donor	2
Unrelated Donor	1

OS

Number of subjects surviving. OS will be estimated by the method of Kaplan and Meier. Confidence intervals will be estimated. (NCT00054353)
Timeframe: At 6 months and then every year thereafter, up to 5 years

Intervention	Participants (Count of Participants)
	6 Months	1 Year	2 Years	3 Years	4 Years	5 Years
Related Donor	8	5	4	3	3	3
Unrelated Donor	3	2	0	0	0	0

Disease-free Survival-incidence of Survival Without Relapse

Sufficient evidence will be taken to be an observed rate of DFS at one year after transplant that corresponds to a one-sided 95% confidence interval with an upper limit lower than 35%. (NCT00045435)
Timeframe: By 1 year after transplant

Intervention	percentage of participants (Number)
Treatment (Nonmyeloablative Donor PBSC Transplant)	47

Incidence of Rejection

Percent patients who developed infections post-transplant. (NCT00045435)
Timeframe: By 1 year after transplant

Intervention	percentage of participants (Number)
Treatment (Nonmyeloablative Donor PBSC Transplant)	0

Incidence of Relapse

Percent patients with relapsed disease post-transplant. (NCT00045435)
Timeframe: By 1 year after transplant

Intervention	percentage of participants (Number)
Treatment (Nonmyeloablative Donor PBSC Transplant)	41.2

Nonrelapse Mortality (NRM)-Incidence of Nonrelapse Death

Defined as death without morphologic evidence of disease. Sufficient evidence will be taken to be an observed rate of NRM within 200 days of transplant that corresponds to a one-sided 80% confidence interval with a lower limit greater than 15%. (NCT00045435)
Timeframe: 200 days after transplant

Intervention	percentage of participants (Number)
Treatment (Nonmyeloablative Donor PBSC Transplant)	6

Overall Survival

Percent patients surviving. (NCT00045435)
Timeframe: By 1 year after transplant

Intervention	percentage of participants (Number)
Treatment (Nonmyeloablative Donor PBSC Transplant)	70.6

Incidence of Acute and Chronic GVHD

Percent patients with acute/chronic GVHD (NCT00045435)
Timeframe: aGVHD: 100 days after transplant; cGVHD: 1 Year after transplant.

Intervention	percentage of participants (Number)
	Grade II-IV aGVHD	cGVHD
Treatment (Nonmyeloablative Donor PBSC Transplant)	35.3	35.3

Incidence of Grade IV Acute GVHD

"Clinical Stage of acute GVHD according to Organ System~Skin:~- Maculopapular rash <25% of body surface~- Maculopapular rash 25-50% of body surface~- Maculopapular rash >50% body surface area or generalized erythroderma~- Generalized erythroderma with bullous formation and desquamation~Liver:~- Bilirubin 2-3 mg/dl~- Bilirubin 3.1-6 mg/dl~- Bilirubin 6.1-15 mg/dl~- Bilirubin >15 mg/dl~Gut:~- >500-1000 mL diarrhea per day or (nausea, anorexia or vomiting with biopsy (EGD) confirmation of upper GI GVHD~- >1000 -1500 mL diarrhea per day~- >1500 mL diarrhea per day~- >1500 mL diarrhea per day plus severe abdominal pain with or without ileus~Overall Clinical Grading of Severity of acute GVHD Grade IV: 0-4 Skin, 2-4 Liver, and/or 2-4 GI" (NCT00096161)
Timeframe: Within 100 days after the last DLI

Intervention	percentage of participants (Number)
Group 1A (Pentostatin, DLI Dose Level 1)	5
Group 1B (Pentostatin, DLI Dose Level 2)	0
Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)	0

Incidence of Infections

(NCT00096161)
Timeframe: 100 days after DLI

Intervention	percentage of participants (Number)
Group 1A (Pentostatin, DLI Dose Level 1)	80
Group 1B (Pentostatin, DLI Dose Level 2)	70
Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)	33.3

Incidence of Relapse/Progression

"CML Acquisition of a new cytogenetic abnormality and/or development of accelerated phase or blast crisis. Criteria for accelerated phase: unexplained fever >38.3° C, new clonal cytogenetic abnormalities in addition to a single Ph-positive chromosome, BM blasts and promyelocytes >20%.~AML, ALL, CMML >30% BM blasts w/ deteriorating performance status, or worsening of anemia, neutropenia, or thrombocytopenia.~CLL Progressive disease: ≥1 of: physical exam/imaging studies (nodes, liver, and/or spleen) ≥50% increase or new, circulating lymphocytes by morphology and/or flow cytometry ≥50% increase, and lymph node biopsy w/ Richter's transformation.~NHL >25% increase in the sum of the products of the perpendicular diameters of marker lesions, or the appearance of new lesions.~MM~≥100% increase of the serum myeloma protein from its lowest level, or reappearance of myeloma peaks that had disappeared w/ tx; or definite increase in the size/number of plasmacytomas or lytic bone lesions." (NCT00096161)
Timeframe: 1 year after DLI

Intervention	percentage of participants (Number)
Group 1A (Pentostatin, DLI Dose Level 1)	45
Group 1B (Pentostatin, DLI Dose Level 2)	20
Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)	33.3

Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism

"A regimen will be considered successful if 20 patients are enrolled, at least 13 demonstrate improved chimerism. If fewer than 5 patients have shown improvement in chimerism then it can be at least 75% confident that the true rate of improvement is less than 0.53. Enrollment to the regimen will stop and the next regimen will be opened. Enrollment to a regimen may also be stopped at any time it becomes impossible to achieve 5 of 10 or 13 of 20 successful improvements.~Chimerism in hematopoietic cell transplant derives from this idea of a mixed entity, referring to someone who has received a transplant of genetically different tissue. A test for chimerism after a hematopoietic cell transplant involves identifying the genetic profiles of the recipient and of the donor and then evaluating the extent of mixture in the recipient's blood cells or marrow cells." (NCT00096161)
Timeframe: From the time of enrollment maintained to day 56 after the last DLI, up to Day 112

Intervention	percentage of participants (Number)
Group 1A (Pentostatin, DLI Dose Level 1)	60
Group 1B (Pentostatin, DLI Dose Level 2)	30
Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)	33.3

Survival

Percentage patients surviving. (NCT00096161)
Timeframe: 1 year after DLI

Intervention	percentage of participants (Number)
Group 1A (Pentostatin, DLI Dose Level 1)	60
Group 1B (Pentostatin, DLI Dose Level 2)	90
Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)	66.7

Incidence of GVHD

"Percentage patients with acute or chronic GVHD.~The diagnosis of chronic GVHD requires at least one manifestation that is distinctive for chronic GVHD as opposed to acute GVHD. In all cases, infection and others causes must be ruled out in the differential diagnosis of chronic GVHD." (NCT00096161)
Timeframe: 1 year after DLI

Intervention	percentage of participants (Number)
	aGVHD	cGVHD
Group 1A (Pentostatin, DLI Dose Level 1)	20	50
Group 1B (Pentostatin, DLI Dose Level 2)	0	20
Group 2C (Pentostatin, DLI Dose Level 1, Add'l IS)	0	16.7

Hematologic Response

"Hematologic response is defined as subjects having blood counts no longer meeting the standard (Camitta) criteria for severe pancytopenia in Severe Aplastic Anemia, equivalent to 2 of the following values obtained on 2 serial blood count measurements at least one week apart at landmark time points (3, 6 and 12 months)~Absolute neutrophil count > 500/ μL~Platelet count > 20,000/ μL~Reticulocyte count > 60,000/ μL~Improvement in counts that are dependent upon exogenously administered growth factors or transfusion will not be considered as fulfilling response criteria." (NCT00260689)
Timeframe: 12 months

Intervention	Participants (Count of Participants)
Horse ATG/CsA Taper	40
Rabbit ATG/CsA	18
Alemtuzumab	2

Hematologic Response

Intervention	Participants (Count of Participants)
Horse ATG/CsA Taper	38
Rabbit ATG/CsA	20
Alemtuzumab	3

Hematologic Response

Intervention	Participants (Count of Participants)
Horse ATG/CsA Taper	41
Rabbit ATG/CsA	22
Alemtuzumab	3

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Blurred Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.7	-0.6

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Driving at Night question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.7	-0.5

Change From Baseline in Font Size

The minimum font (letter) size read correctly was assessed. Smaller font size (less points) indicates better ability. A negative change from Baseline indicates an improvement and a positive change from Baseline indicates a worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	points (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	9.0	0.0

Change From Baseline in Interblink Interval (IBI) in the Worst Eye

A device was used to assess IBI. The IBI measures the time in seconds between blinks in the worse eye. A positive number change from baseline indicates a worsening (more frequent blinks) and a negative number change from baseline (less frequent blinks) indicates an improvement. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	seconds (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	5.27	-1.16

Change From Baseline in Ocular Protection Index (OPI) 2.0 in the Worse Eye

A device was used to assess OPI 2.0. This technology measures blink and tear film break-up area. These values demonstrate the average area of tear deficiency/corneal exposure. The worse eye is defined as the worse eye at Baseline. A negative value indicates an improvement in corneal protection. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	percent of area (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.38	-0.87

The OSDI© questionnaire consists of 12 questions measuring the presence of ocular symptoms. Each of the 12 questions was assessed using a 5-point scale (where 0=none of the time and 4=all of the time). The score is converted to a 0 to 100 point score where 0 is no symptoms and 100 is most symptoms. A negative change from Baseline indicates improvement. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	45.1	-14.9

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Poor Vision question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.5	-0.5

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Reading question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.5	-0.3

Change From Baseline in Reading Rate

Reading speed was assessed as the number of words read correctly calculated as words/minute. A positive change from Baseline indicates an improvement (more words read correctly/minute) and a negative change from Baseline indicates a worsening (less words read correctly/minute). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	correct words/minute (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	146.6	-3.6

Change From Baseline in Tear Film Break Up Time (TFBUT) in the Worse Eye

TFBUT is defined as the time required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film. The worse eye is defined as the Worse Eye at Baseline. A positive number change from Baseline indicates improvement and a negative number change from Baseline indicates a worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	seconds (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	2.38	-0.31

Change From Baseline in the Central Region Staining Score With Fluorescein in the Worse Eye

Staining with fluorescein in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	2.29	-0.75

Change From Baseline in the Central Region Staining Score With Lissamine Green in the Worse Eye

Staining with lissamine green in the central region of the eye was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	0.85	-0.24

Change From Baseline in the Ocular Discomfort Scale Post Wilkins Test in the Worst Eye

Participants assessed ocular discomfort post Wilkins Rate of Reading Test using the Ora Calibra™ 5-point scale where 0=no discomfort to 4=constant discomfort. A positive number change from Baseline indicates a worsening and a negative number change from Baseline indicates an improvement. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	3.08	-0.60

Change From Baseline in the Total Conjunctival Staining Score With Fluorescein in the Worse Eye

Total conjunctival staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	4.57	-0.61

Change From Baseline in the Total Conjunctival Staining Score With Lissamine Green in the Worse Eye

Total conjunctival staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 2 regions of the conjunctiva, resulting in a maximum possible score of 8 (severe staining score of 4 in both regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	3.99	-0.18

Change From Baseline in the Total Corneal Staining Score With Fluorescein in the Worse Eye

Total corneal staining with fluorescein was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	7.05	-1.51

Change From Baseline in the Total Corneal Staining Score With Lissamine Green in the Worse Eye

Total corneal staining with lissamine green was measured in the worse eye using the Ora Calibra™ (Scale 1.0) 5-point scale where 0= none (best), no staining to 4=severe staining (worst). The sum of the total includes 3 regions of the cornea, resulting in a maximum possible score of 12 (severe staining score of 4 in all three regions). The worse eye is defined as the worst eye at Baseline. A negative change from Baseline represents a decrease in staining (improvement). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	4.00	-0.34

Change From Baseline in Time to Read Passage

The time to read passage (selected portion of text ) in seconds was assessed. A negative change from Baseline indicates an improvement (less time to read the passage). (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	seconds (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	126.0	-0.7

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Watching TV question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.8	-0.9

Change From Baseline in Words Read Incorrectly

The numbers of words read incorrectly are counted. A positive change from Baseline indicates a worsening (more words read incorrectly) and a negative change from Baseline indicates an improvement. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	incorrect words (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	16.6	-4.1

The OSDI© consists of 12 questions measuring the presence of ocular symptoms. The Working with a Computer or Bank Machine question was assessed using a 5-point scale (0=none of the time to 4=all of the time). Higher OSDI© scores are associated with greater severity. A negative number change from Baseline indicates improvement and a positive number change from Baseline indicates worsening. (NCT02554981)
Timeframe: Baseline, Month 6

Intervention	score on a scale (Mean)
	Baseline	Change from Baseline at Month 6
RESTASIS®	1.9	-0.8

Symptom Improvement of Interstitial Cystitis

Number of participants with > 30% Improved Interstitial Cystitis Symptoms Index (ICSI) which is measured on a scale from 0 - 19 where the higher numbers are worse. No additional analyses have been done. (NCT01990898)
Timeframe: 3 Months

Intervention	Participants (Number)
Treatment	9

Number of Participants With Complete Response at 3 Months.

"The primary endpoint was hematologic response at 3 months, defined as no longer meeting criteria for Severe Aplastic Anemia (SAA) defined as bone marrow cellularity of less than 30% and severe pancytopenia with at least two of the following peripheral blood count criteria: (i) absolute neutrophil count less than 0.5×109/L; (ii) absolute reticulocyte count less than 60×109/L; and (iii) platelet count less than 20×109/L.~A complete response was defined as absolute neutrophil count (ANC) above 1.0×109/L, Hgb > 10 g/dL, and platelet count > 100×109/L.~A partial response was defined as a hematologic response that was not sufficient for a complete response." (NCT00944749)
Timeframe: 3-months

Intervention	Participants (Count of Participants)
Single Arm	0

Number of Participants With Complete Response at 3 Months.

"The primary endpoint was hematologic response at 3 months, defined as no longer meeting criteria for Severe Aplastic Anemia (SAA).~A complete response was defined as absolute neutrophil count (ANC) above 1.0×109/L, Hgb > 10 g/dL, and platelet count > 100×109/L.~A partial response was defined as a hematologic response that was not sufficient for a complete response.~In subjects with a non-robust hematologic response at 3 months, improvement in one or more of the listed peripheral blood parameter (a,b,c) were recorded as a response: a) ANC - if baseline ANC below 0.5×109/L, increase in ANC by > 0.3×109/L, if baseline ANC above 0.5×109/L, any increase in ANC by > 0.5×109/L of blood; (b) platelets - if baseline platelet count < 50×109/L, any increase in platelet count by > 20×109/L of blood; c) hemoglobin - any increase in hemoglobin by 1.5 g/dl of blood in transfusion-independent patients and in absolute reticulocyte count to > 60×109/L of blood in transfusion-dependent patients." (NCT00944749)
Timeframe: 3 months

Intervention	Participants (Count of Participants)
Single Arm	2

Number of Participants With Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm

Number of Participants with Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm (NCT00713193)
Timeframe: From the start of treatment until 30 days after discharge from the last PEX procedure

Intervention	participants (Number)
CSA Arm	3
Prednisone Arm	1

Time in Days to Achieve a Clinical Response, Comparing the CSA/PEX Arm to the Steroids/PEX Arm.

Days to achieve a clinical response, defined as a normal platelet count (>150 x 109/L), normal LDH, and no new end organ injury. (NCT00713193)
Timeframe: Time to starting treatment until 6 months after the last PEX procedure

Intervention	Days (Median)
CSA Arm	5
Prednisone Arm	5

Remission Status

The number of subjects to reach either complete remission or partial remission at 12 months after randomization. (NCT01180036)
Timeframe: 12 months after randomization

Intervention	Participants (Count of Participants)
Rituximab Treatment Arm	39
Cyclosporine Treatment Arm	34

Remission Status

The number of subjects to reach the composite of maintaining complete remission or partial remission at 24 months after randomization will be the primary endpoint. (NCT01180036)
Timeframe: 24 months after randomization

Intervention	Participants (Count of Participants)
Rituximab Treatment Arm	39
Cyclosporine Treatment Arm	13

Number of Infectious Complications

The number of infections complications occurring among study participants is presented here. (NCT01921218)
Timeframe: Baseline up to Month 36

Intervention	complications (Number)
Belatacept Treatment Group	12
Control Group	18

Number of Participants With Donor-specific Antibody Formation

The number of participants in each group with donor-specific antibody formation at 36 months following randomization. (NCT01921218)
Timeframe: Month 36

Intervention	Participants (Count of Participants)
Belatacept Treatment Group	3
Control Group	4

Time to Initiation of Dialysis

Time to dialysis is measured as the time of randomization to initiation of dialysis. Participants already requiring dialysis at the time of enrollment were excluded from this endpoint analysis. (NCT01921218)
Timeframe: Up to Year 2

Intervention	months (Mean)
Belatacept Treatment Group	11.75
Control Group	10.5

Glomerular Filtration Rate (GFR)

The glomerular filtration rate (GFR) assesses kidney function. GFR uses values for serum creatinine (SCr) measured in mg/dL, age in years, blood urea nitrogen (BUN) measures in mg/dL, and serum albumin (Alb) measured in g/dL. GFR is calculated as 170 x (SCr/0.95)^(-0.999) x (Age)^(-0.176) x (0.762 if the patient is female) x (1.180 if the patient is black) x (BUN)^(-0.170) x (Alb)^(0.318). A value of 90 or above is considered normal while values between 15 and 29 indicate severely decreased kidney function and values below 15 indicate kidney failure. The GFR in participants who do not require dialysis will be followed for two years. (NCT01921218)
Timeframe: Baseline up to Month 24

Intervention	mL/min/1.73 m^2 (Mean)
	Baseline	Month 1	Month 2	Month 3	Month 6	Month 9	Month 12
Control Group	14.5	11	10.5	16.5	14.5	13.5	20

Glomerular Filtration Rate (GFR)

Intervention	mL/min/1.73 m^2 (Mean)
	Baseline	Month 1	Month 2	Month 3	Month 6	Month 9	Month 12	Month 18
Belatacept Treatment Group	14.25	14.25	19.33	16.33	14.67	14.67	13.67	7

Number of Participants With Anti-human Leukocyte Antigen (HLA) Alloantibodies

The presence of anti-HLA Class I and Class II alloantibodies is categorized as being negative (absent for both classes of alloantibodies), positive for Class I, positive for Class II, and positive for both Class I and Class II alloantibodies. (NCT01921218)
Timeframe: Baseline up to Month 36

Intervention	Participants (Count of Participants)
	Baseline - Negative	Baseline - Positive Class I	Baseline - Positive Class II	Baseline - Positive Class I and II	Month 12 - Negative	Month 12 - Positive Class I	Month 12 - Positive Class II	Month 12 - Positive Class I and II	Month 24 - Negative	Month 24 - Positive Class I	Month 24 - Positive Class II	Month 24 - Positive Class I and II	Month 36 - Negative	Month 36 - Positive Class I	Month 36 - Positive Class II	Month 36 - Positive Class I and II
Belatacept Treatment Group	6	0	0	0	4	1	0	0	1	0	2	0	1	0	2	0
Control Group	5	2	0	0	2	4	3	3	1	2	1	1	1	2	1	1

Number of Participants Who Developed Acute Graft Versus Host Disease

(NCT00255684)
Timeframe: 3 months

Intervention	participants (Number)
Conditioning Therapy Followed by TBI	0

Number of Participants Who Survived 100 Days or Longer

(NCT00255684)
Timeframe: 100 days

Intervention	participants (Number)
Conditioning Therapy Followed by TBI	13

Number of Participants With Hematological Response at 6 Months

Hematological response is defined as no longer satisfying blood count criteria for Severe Aplastic Anemia. Patients were classified as responders if they met two of the following three criteria: ANC greater than 500/ mm'; platelet count greater than 20,000/mm3; and reticulocyte count greater than 40,000/mm3 (60,000/mm3 after January 1993). (NCT00195624)
Timeframe: 6 months

Intervention	Participants (Count of Participants)
Refractory	0
Relapsed	18

Change From Baseline in Quality of Life (QOL) Related to Nail Disease

"Change from baseline in quality of life as measured at week 24 by the subject satisfaction Questionnaire question: Overall, how satisfied are you with your nails? Responses ranged from 1 (very satisfied) to 5 (very unsatisfied). A negative number changed from baseline (decrease in grade score) indicates improvement and a positive change (increase in grade score) indicates worsening." (NCT00986427)
Timeframe: Baseline, week 24

Intervention	scores on a scale (Mean)
Restasis® Arm	-1.6
Refresh® Arm	-0.9

Change From Baseline in the Physician's Global Assessment (PGA) of Target Fingernails #1 and #2

"Change from baseline in the Physician's Global Assessment (PGA) of target fingernails #1 and #2 as measured at week 24.~The PGA is a static evaluation/measure of the severity of brittle nails signs in target fingernails #1 and #2 (the 2 nails with the most severe signs of brittleness). Evaluated sings were the degree of lamellar onychoschizia, ridging, longtitudinal splitting, fragility/breakage and thickness. The PGA was scored on a 6 point scale from 0 to 5, in which 0 = none, 1 = mild, 2 = mild to moderate, 3 = moderate, 4 = moderate to severe, 5 = severe. A negative number change from baseline (decrease in grade score) indicates improvement and a positive change (increase in grade score) indicates worsening." (NCT00986427)
Timeframe: Baseline, week 24

Intervention	scores on a scale (Mean)
Restasis® Arm	-1.4
Refresh® Arm	-1.4

Growth of the Treated and Untreated Nail in the Previous 4 Weeks

Growth of the treated and untreated nail the previous 4 weeks. Nail growth was measured in millimeters. (NCT00986427)
Timeframe: Week 24

Intervention	Millimeters (mm) (Mean)
Restasis® Arm Treated Nail	3.1
Restasis® Arm Untreated Nail	2.9
Refresh® Dry Eye Treated Nail	2.9
Refresh® Dry Eye Untreated Nail	2.7

Number of Subjects Achieving Improvement in the Physician's Global Improvement Assessment (PGIA)

Number of subjects achieving improvement in the PGIA. The investigator assessed the two target fingernails with a rating of Excellent, Good, Fair, No Improvement or Worse based on the comparison between the nails at the current visit and high-resolution photographs of the nails taken at baseline. An improvement was a score of Excellent/Good/Fair vs. No Improvement/Worse. (NCT00986427)
Timeframe: Week 24

Intervention	participants (Number)
Restasis® Arm	10
Refresh® Arm	9

Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]

The area under the plasma concentration versus time curve from time 0 to infinity. AUC(0-∞) was calculated as the sum of AUC(0-t) plus the ratio of the last measurable colchicine plasma concentration to the elimination rate constant. (NCT00983931)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to colchicine dosing on Days 1 and 15, and then 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 hours after colchicine dose administration

Intervention	pg-hr/mL (Mean)
Colchicine Alone	14,996.79
Colchicine With Cyclosporine	47,312.02

Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]

The area under the plasma concentration versus time curve, from time 0 to the time of the last measurable colchicine concentration (t), as calculated by the linear trapezoidal rule. (NCT00983931)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to colchicine dosing on Days 1 and 15, and then 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 hours after colchicine dose administration

Intervention	pg-hr/mL (Mean)
Colchicine Alone	12,545.04
Colchicine With Cyclosporine	39,828.11

Maximum Plasma Concentration (Cmax)

The maximum or peak concentration that colchicine reaches in the plasma. (NCT00983931)
Timeframe: serial pharmacokinetic blood samples drawn immediately prior to colchicine dosing on Days 1 and 15, and then 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, and 96 hours after colchicine dose administration

Intervention	pg/mL (Mean)
Colchicine Alone	2,720.04
Colchicine With Cyclosporine	8,817.48

Corneal Fluorescein Staining

The mean difference in corneal staining using the adjusted CCLR global staining score before and after the environmental challenge at visits baseline and Visit 3/Day 42 when patients were subjected to a 90-minute low humidity stress. Corneal fluorescein staining was graded 0-100 in 5 zones on the cornea. The scores ranged from 0 (minimum) to 500 (maximum). A higher score indicates there was greater cornea disease induced by the low humidity stress on Day 42 (NCT02199964)
Timeframe: 6 weeks

Intervention	units on a scale (Mean)
Cyclosporin 0.05% Emulsion	21.5
Endura Refresh, Artificial Tears	29

Eye Irritation Symptoms

The mean difference in subject's scoring of eye irritation symptoms using a VAS (visual analog scale) questionnaire before and after the environmental challenge after treatment at Visit 3/Day 42 when patients were subjected to a 90-minute low humidity stress. Symptoms were graded on a 4 question VAS 0-5 for each question, with scores summed for all questions for a total score that ranges from 0 (minimum) to 20 (maximum) for the pre and post challenge questionnaires. The outcome measure is the difference in the post to pre total score ranging from -20 (maximum improvement) to 20 (maximum worsening). A minus difference indicated the subject had lower irritation symptoms following the lower humidity challenge, while a positive difference indicated the subject had greater irritation following the low humidity challenge on Day 42. (NCT02199964)
Timeframe: 6 weeks

Intervention	units on a scale (Mean)
Cyclosporin 0.05% Emulsion	1.5
Endura Refresh, Artificial Tears	1

Absolute Neutrophil Count (ANC) Engraftment

The median time in days to achieve ANC recovery defined as ANC>500uL. (NCT01434472)
Timeframe: Up to day 100

Intervention	Days (Median)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	16

Hematopoietic Toxicity

Clinical sequelae due to hematopoietic toxicity as defined by incidences of neutropenic fever and bleeding. (NCT01434472)
Timeframe: Up to day 100

Intervention	Incidences (Number)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	5

Overall Survival

(NCT01434472)
Timeframe: Up to 2 years post transplant

Intervention	Participants (Count of Participants)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	14

Platelet Engraftment

The median time in days to achieve platelet recovery as defined as platelet >20,000uL. (NCT01434472)
Timeframe: Up to day 100

Intervention	Days (Median)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	9

Progression-free Survival

Based on a one-sample chi-square test with one-sided significance level of five percent. This study will be deemed successful if the 1 year progression-free survival of this highest-risk group of patients is 54% or greater. (NCT01434472)
Timeframe: 1 year

Intervention	Participants (Count of Participants)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	11

Response Rates

Response is defined as having achieved a Partial Response or better. (NCT01434472)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	16

Treatment-related Mortality

Defined as death in the absence of progressive lymphoma that can be possibly, probably, or definitely attributed to the radioimmunotherapy. (NCT01434472)
Timeframe: Day 100

Intervention	Participants (Count of Participants)
Treatment (Radiolabeled Antibody, TBI, Allogeneic PBSCT)	1